Note: Descriptions are shown in the official language in which they were submitted.
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 A 213
NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 213
NOTE: For additional volumes, please contact the Canadian Patent Office
NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
METHODS OF DIAGNOSIS OF OVARIAN CANCER, COMPOSITIONS AND
METHODS OF SCREENING FOR MODULATORS OF OVARIAN CANCER
CROSS-REFERENCES TO RELATED APPLICATIONS.
This application is related to USSN 60/299,234, filed June 18, 2001; USSN
60/315,287, filed August 27, 2001; USSN 60/317,544, filed September 5, 2001;
USSN
60/350,666, filed November 13, 2001; and USSN 60/372,246, filed April 12,
2002, each of
which is incorporated herein by reference for all purposes.
FIELD OF THE INVENTION
The invention relates to the identification of nucleic acid and protein
expression
profiles and nucleic acids, products, and antibodies thereto that are involved
in ovarian
cancer; and to the use of such expression profiles and compositions in the
diagnosis,
prognosis, and therapy of ovarian cancer. The invention further relates to
methods for
identifying and using agents and/or targets that inhibit ovarian cancer.
BACKGROUND OF THE INVENTION
Ovarian cancer is the sixth most common cancer in women, accounting for 6% of
all
female cancers. It ranks fifth as the cause of cancer death in women. The
American Cancer
Society predicts that there will be about 23,100 new cases of ovarian cancer
in this country in
the year 2000 and about 14,000 women will die of the disease. Because many
ovarian
cancers cannot be detected early in their development, they account for a
disproportionate
number of fatal cancers, being responsible for almost half the deaths from
cancer of the
female genital tract; more deaths than any other reproductive organ cancer.
Most patients with epithelial ovarian cancer, the predominant form, are
asymptomatic
in early-stage disease and usually present with stage III or IV disease. Their
five-year
survival is less than 25%, with lower survival among African-American women.
The
minority of patients discovered with early-stage disease have a five-year
survival rate of
80%-90%. See, Parker, et. al.. (1997) "Cancer Statistics, 1997" CA Cancer J.
Clin. 47:5-27.
In the absence of a family history of ovarian cancer, lifetime risk of ovarian
cancer is
1170. Risk factors include familial cancer syndromes (risk of up to 82% by age
70 in women
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
with hereditary breast/ovarian syndrome); family history (1.4% lifetime risk
with no affected
relatives, 5% with orie affected relative, 7% with two affected relatives;
Kerlikowske, et.al.
(1992) Obstet. G~necol. 80:700-707); nulliparity; advancing age; obesity;
personal history of
breast, endometrial, or colorectal cancer; fewer pregnancies; or older age
(>35 years) at first
pregnancy. However, 95% of all ovarian cancers occur in women without risk
factors. Use
of hormonal contraceptives, oophorectomy, and tubal sterilization reduce risk
of ovarian
cancer (Kerlikowske, et. al. (1992) Obstet. Gynecol. 80:700-707; Grimes (1992)
Am J.
Obstet. Gynecol. 166:1950-1954; Hankinson, et. al. (1993) JAMA 270:2813-2818);
however,
even bilateral oophorectomy may not be completely effective in preventing
ovarian cancer.
Treatment of ovarian cancer consists largely of surgical oophorectomy, anti-
hormone
therapy, and/or chemotherapy. Although many ovarian cancer patients are
effectively
treated, the current therapies can all induce serious side effects which
diminish quality of life.
Deciding on a particular course of treatment is typically based on a variety
of prognostic
parameters and markers (Fitzgibbons, et al. (2000) Arch. Pathol. Lab. Med.
124:966-978;
Hamilton and Piccart (2000) Ann. Oncol. 11:647-663), including genetic
predisposition
markers BRCA-1 and BRCA-2 (Robson (2000) J. Clin. Oncol. 18:113sup-118sup).
The identification of novel therapeutic targets and diagnostic markers is
essential for
improving the current treatment of ovarian cancer patients. Recent advances in
molecular
medicine have increased the interest in tumor-specific cell surface antigens
that could serve
as targets for various immunotherapeutic or small molecule strategies.
Antigens suitable for
immunotherapeutic strategies should be highly expressed in cancer tissues and
ideally not
expressed in normal adult tissues. Expression in tissues that are dispensable
for life,
however, may be tolerated. Examples of such antigens include Her2/neu and the
B-cell
antigen CD20. Humanized monoclonal antibodies directed to Her2lneu
(Herceptin~/trastuzumab) are currently in use for the treatment of metastatic
breast cancer.
Ross and Fletcher (1998) Stem Cells 16:413-428. Similarly, anti-CD20
monoclonal
antibodies (Rituxin~/rituximab) are used to effectively treat non-Hodgkin's
lymphoma.
Maloney, et al. (1997) Blood 90:2188-2195; Leget and Czuczman (1998) Curr.
Opin. Oncol.
10:548-551.
Potential immunotherapeutic targets have been identified for ovarian cancer.
One
such target is polymorphic epithelial mucin (MLJC1). MUC1 is a transmembrane
protein,
present at the apical surface of glandular epithelial cells. It is often
overexpressed in ovarian
cancer, and typically exhibits an altered glycosylation pattern, resulting in
an antigenically
2
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
distinct molecule, and is in early clinical trials as a vaccine target.
Gilewski, et al. (2000)
Clin. Cancer Res. 6:1693-1701; Scholl, et al. (2000) J. Immunother. 23:570-
580. The tumor-
expressed protein is often cleaved into the circulation, where it is
detectable as the tumor
marker, CA 15-3. See, e.g., Bon, et al. (1997) Clin. Chem. 43:585-593.
However, many
patients have tumors that express neither HER2 nor MUC-1; therefore, it is
clear that other
targets need to be identified to manage localized and metastatic disease.
Mutations in both BRCAl and BRCA2 are associated with increased susceptibility
to
ovarian cancer. Mutations in BRCA1 occur in approximately 5 percent (95
percent
confidence interval, 3 to 8 percent) of women in whom ovarian cancer is
diagnosed before
the age of 70 years. See Stratton, et al. (1997) N.E.J. Med. 336:1125-1130.
And, in BRCA1
gene Garners, the risk for developing ovarian cancer is .63. See Easton (1995)
Am. J. Hum.
Genet. 56:267-xxx; and Elit (2001) Can. Fam. Physician 47:778-84.
Other biochemical markers such as CA125 have been reported to be associated
with
ovarian cancer, but they are not absolute indicators of disease. Although
roughly 85% of
women with clinically apparent ovarian cancer have increased levels of CA125,
CA125 is
also increased during the first trimester of pregnancy, during menstruation,
in the presence of
non-cancerous illnesses, and in cancers of other sites.
While industry and academia have identified novel gene sequences, there has
not been
an equal effort exerted to identify the function of these novel sequences. The
elucidation of a
role for novel proteins and compounds in disease states for identification of
therapeutic
targets and diagnostic markers is essential for improving the current
treatment of ovarian
cancer patients. Accordingly, provided herein are molecular targets for
therapeutic
intervention in ovarian and other cancers. Additionally, provided herein are
methods that can
be used in diagnosis and prognosis of ovarian cancer. Further provided are
methods that can
be used to screen candidate bioactive agents for the ability to modulate
ovarian cancer.
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
SUMMARY OF THE INVENTION
The present invention therefore provides nucleotide sequences of genes that
are up-
and down-regulated in ovarian cancer cells. Such genes are useful for
diagnostic purposes,
and also as targets for screening for therapeutic compounds that modulate
ovarian cancer,
such as hormones or antibodies. The methods of detecting nucleic acids of the
invention or
their encoded proteins can be used for many purposes, e.g., early detection of
ovarian
cancers, monitoring and early detection of relapse following treatment,
monitoring response
to therapy, selecting patients for postoperative chemotherapy or radiation
therapy, selecting
therapy, determining tumor prognosis, treatment, or response to treatment (of
primary or
metastatic tumors), and early detection of pre-cancerous lesions. Other
aspects of the
invention will become apparent to the skilled artisan by the following
description of the
invention.
In one aspect, the present invention provides a method of detecting an ovarian
cancer-
associated transcript in a cell from a patient, the method comprising
contacting a biological
sample from the patient with a polynucleotide that selectively hybridizes to a
sequence at
least 80% identical to a sequence as shown in Tables 1-26.
In one embodiment, the present invention provides a method of determining the
level
of an ovarian cancer associated transcript in a cell from a patient.
In one embodiment, the present invention provides a method of detecting an
ovarian
cancer-associated transcript in a cell from a patient, the method comprising
contacting a
biological sample from the patient with a polynucleotide that selectively
hybridizes to a
sequence at least 80% identical to a sequence as shown in Tables 1-26.
In one embodiment, the polynucleotide selectively hybridizes to a sequence at
least
95% identical to a sequence as shown in Tables 1-26.
In one embodiment, the biological sample is a tissue sample. In another
embodiment,
the biological sample comprises isolated nucleic acids, e.g., mRNA.
In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent
label.
In one embodiment, the polynucleotide is immobilized on a solid surface.
In one embodiment, the patient is undergoing a therapeutic regimen to treat
ovarian
cancer. In another embodiment, the patient is suspected of having metastatic
ovarian cancer.
In one embodiment, the patient is a human.
In one embodiment, the ovarian cancer associated transcript is mRNA.
In one embodiment, the method further comprises the step of amplifying nucleic
acids
4
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
before the step of contacting the biological sample with the polynucleotide.
In another aspect, the present invention provides a method of monitoring the
efficacy
of a therapeutic treatment of ovarian cancer, the method comprising the steps
of (i) providing
a biological sample from a patient undergoing the therapeutic treatment; and
(ii) determining
the level of an ovarian cancer-associated transcript in the biological sample
by contacting the
biological sample with a polynucleotide that selectively hybridizes to a
sequence at least 80%
identical to a sequence as shown in Tables 1-26, thereby monitoring the
efficacy of the
therapy. In a further embodiment, the patient has metastatic ovarian cancer.
In a further
embodiment, the patient has a drug resistant form of ovarian cancer.
In one embodiment, the method further comprises the step of (iii) comparing
the
level of the ovarian cancer-associated transcript to a level of the ovarian
cancer-associated
transcript in a biological sample from the patient prior to, or earlier in,
the therapeutic
treatment.
Additionally, provided herein is a method of evaluating the effect of a
candidate
ovarian cancer drug comprising administering the drug to a patient and
removing a cell
sample from the patient. The expression profile of the cell is then
determined. This method
may further comprise comparing the expression profile to an expression profile
of a healthy
individual. In a preferred embodiment, said expression profile includes a gene
of Tables 1-
26.
In one aspect, the present invention provides an isolated nucleic acid
molecule
consisting of a polynucleotide sequence as shown in Tables 1-26.
In one embodiment, an expression vector or cell comprises the isolated nucleic
acid.
In one aspect, the present invention provides an isolated polypeptide which is
encoded
by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-
26.
In another aspect, the present invention provides an antibody that
specifically binds to
an isolated polypeptide which is encoded by a nucleic acid molecule having
polynucleotide
sequence as shown in Tables 1-26.
In one embodiment, the antibody is conjugated to an effector component, e.g.,
a
fluorescent label, a radioisotope or a cytotoxic chemical.
In one embodiment, the antibody is an antibody fragment. In another
embodiment,
the antibody is humanized.
In one aspect, the present invention provides a method of detecting an ovarian
cancer
cell in a biological sample from a patient, the method comprising contacting
the biological
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
sample with an antibody as described herein.
In another aspect, the present invention provides a method of detecting
antibodies
specific to ovarian cancer in a patient, the method comprising contacting a
biological sample
from the patient with a polypeptide encoded by a nucleic acid comprising a
sequence from
Tables 1-26.
In another aspect, the present invention provides a method for identifying a
compound
that modulates an ovarian cancer-associated polypeptide, the method comprising
the steps of
(i) contacting the compound with an ovarian cancer-associated polypeptide, the
polypeptide
encoded by a polynucleotide that selectively hybridizes to a sequence at least
80% identical
to a sequence as shown in Tables 1-26; and (ii) determining the functional
effect of the
compound upon the polypeptide.
In one embodiment, the functional effect is a physical effect, an enzymatic
effect, or a
chemical effect.
In one embodiment, the polypeptide is expressed in a eukaryotic host cell or
cell
membrane. In another embodiment, the polypeptide is recombinant.
In one embodiment, the functional effect is determined by measuring ligand
binding
to the polypeptide.
In another aspect, the present invention provides a method of inhibiting
proliferation
of an ovarian cancer-associated cell to treat ovarian cancer in a patient, the
method
comprising the step of administering to the subject a therapeutically
effective amount of a
compound identified as described herein.
In one embodiment, the compound is an antibody.
In another aspect, the present invention provides a drug screening assay
comprising the steps
of: (i) administering a test compound to a mammal having ovarian cancer or to
a cell sample
isolated from; (ii) comparing the level of gene expression of a polynucleotide
that selectively
hybridizes to a sequence at least 80% identical to a sequence as shown in
Tables 1-26 in a
treated cell or mammal with the level of gene expression of the polynucleotide
in a control
cell sample or mammal, wherein a test compound that modulates the level of
expression of
the polynucleotide is a candidate for the treatment of ovarian cancer.
In one embodiment, the control is a mammal with ovarian cancer or a cell
sample that
has not been treated with the test compound. In another embodiment, the
control is a normal
cell or mammal, or is non-malignant tissue.
In one embodiment, the test compound is administered in varying amounts or
6
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
concentrations. In another embodiment, the test compound is administered for
varying time
periods. In another embodiment, the comparison can occur after addition or
removal of the
drug candidate.
In one embodiment, the levels of a plurality of polynucleotides that
selectively
hybridize to a sequence at least 80% identical to a sequence as shown in
Tables 1-26 are
individually compared to their respective levels in a control cell sample or
mammal. In a
preferred embodiment the plurality of polynucleotides is from three to ten.
In another aspect, the present invention provides a method for treating a
mammal
having ovarian cancer comprising administering a compound identified by the
assay
described herein.
In another aspect, the present invention provides a pharmaceutical composition
for treating a
mammal having ovarian cancer, the composition comprising a compound identified
by the
assay described herein and a physiologically acceptable excipient.
In one aspect, the present invention provides a method of screening drug
candidates
by providing a cell expressing a gene that is up- and down-regulated as in an
ovarian cancer.
In one embodiment, a gene is selected from Tables 1-26. The method further
includes
adding a drug candidate to the cell and determining the effect of the drug
candidate on the
expression of the expression profile gene.
In one embodiment, the method of screening drug candidates includes comparing
the
level of expression in the absence of the drug candidate to the level of
expression in the
presence of the drug candidate, wherein the concentration of the drug
candidate can vary
when present, and wherein the comparison can occur after addition or removal
of the drug
candidate. In a preferred embodiment, the cell expresses at least two
expression profile
genes. The profile genes may show an increase or decrease.
Also provided is a method of evaluating the effect of a candidate ovarian
cancer drug
comprising administering the drug to a transgenic animal expressing or over-
expressing the
ovarian cancer modulatory~protein, or an animal lacking the ovarian cancer
modulatory
protein, for example as a result of a gene knockout.
Moreover, provided herein is a biochip comprising one or more nucleic acid
segments
of Tables 1-26, wherein the biochip comprises fewer than 1000 nucleic acid
probes.
Preferably, at least two nucleic acid segments are included. More preferably,
at least three
nucleic acid segments are included.
Furthermore, a method of diagnosing a disorder associated with ovarian cancer
is
7
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
provided. The method comprises determining the expression of a gene of Tables
1-26 in a
first tissue type of a first individual, and comparing the distribution to the
expression of the
gene from a second normal tissue type from the first individual or a second
unaffected
individual. A difference in the expression indicates that the first individual
has a disorder
associated with ovarian cancer.
In a further embodiment, the biochip also includes a polynucleotide sequence
of a
gene that is not up- and down-regulated in ovarian cancer.
In one embodiment a method for screening for a bioactive agent capable of
interfering
with the binding of an ovarian cancer modulating protein (ovarian cancer
modulatory protein)
or a fragment thereof and an antibody which binds to said ovarian cancer
modulatory protein
or fragment thereof. In a preferred embodiment, the method comprises combining
an ovarian
cancer modulatory protein or fragment thereof, a candidate bioactive agent and
an antibody
which binds to said ovarian cancer modulatory protein or fragment thereof. The
method
further includes determining the binding of said ovarian cancer modulatory
protein or
fragment thereof and said antibody. Wherein there is a change in binding, an
agent is
identified as an interfering agent. The interfering agent can be an agonist or
an antagonist.
Preferably, the agent.inhibits ovarian cancer.
Also provided herein are methods of eliciting an immune response in an
individual.
In one embodiment a method provided herein comprises administering to an
individual a
composition comprising an ovarian cancer modulating protein, or a fragment
thereof. In
another embodiment, the protein is encoded by a nucleic acid selected from
those of Tables
1-26.
Further provided herein are compositions capable of eliciting an immune
response in
an individual. W one embodiment, a composition provided herein comprises an
ovarian
cancer modulating protein, preferably encoded by a nucleic acid of Table 1-26
or a fragment
thereof, and a pharmaceutically acceptable carrier. In another embodiment,
said composition
comprises a nucleic acid comprising a sequence encoding an ovarian cancer
modulating
protein, preferably selected from the nucleic acids of Tables 1-26, and a
pharmaceutically
acceptable carrier.
Also provided are methods of neutralizing the effect of an ovarian cancer
protein, or a
fragment thereof, comprising contacting an agent specific for said protein
with said protein in
an amount sufficient to effect neutralization. In another embodiment, the
protein is encoded
by a nucleic acid selected from those of Tables 1-26.
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
In another aspect of the invention, a method of treating an individual for
ovarian
cancer is provided. In one embodiment, the method comprises administering to
said
individual an inhibitor of an ovarian cancer modulating protein. In another
embodiment, the
method comprises administering to a patient having ovarian cancer an antibody
to an ovarian
cancer modulating protein conjugated to a therapeutic moiety. Such a
therapeutic moiety can
be a cytotoxic agent or a radioisotope.
9
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the objects outlined above, the present invention provides
novel
methods for diagnosis and prognosis evaluation for ovarian cancer (OC),
including metastatic
ovarian cancer, as well as methods for screening for compositions which
modulate ovarian
cancer. Also provided are methods for treating ovarian cancer and related
conditions, e.g.,
ovarian carcinoma (e.g., epithelial (including malignant serous tumors,
malignant mucinous
tumors, and malignant endometrioid tumors), germ cell (including teratomas,
choriocarcinomas, polyembryomas, embryonal carcinoma, endodermal sinus tumor,
dysgerminoma, and gonadoblastoma), and stromal carcinomas (e.g., granulosal
stromal cell
tumors)), fallopian tube carcinoma, and peritoneal carcinoma.
Tables 1-26 provide unigene cluster identification numbers for the nucleotide
sequence of genes that exhibit increased or decreased expression in ovarian
cancer samples.
Tables 1-26 also provide an exemplar accession number that provides a
nucleotide sequence
that is part of the unigene cluster.
Definitions
The term "ovarian cancer protein" or "ovarian cancer polynucleotide" or
"ovarian
cancer-associated transcript" refers to nucleic acid and polypeptide
polymorphic variants,
alleles, mutants, and interspecies homologues that: (1) have a nucleotide
sequence that has
greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%,
90%,
preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or greater
nucleotide
sequence identity, preferably over a region of over a region of at least about
25, 50, 100, 200,
500, 1000, or more nucleotides, to a nucleotide sequence of or associated with
a gene of
Tables 1-26; (2) bind to antibodies, e.g., polyclonal antibodies, raised
against an immunogen
comprising an amino acid sequence encoded by a nucleotide sequence of or
associated with a
gene of Tables 1-26, and conservatively modified variants thereof; (3)
specifically hybridize
under stringent hybridization conditions to a nucleic acid sequence, or the
complement
thereof of Tables 1-26 and conservatively modified variants thereof; or (4)
have an amino
acid sequence that has greater than about 60% amino acid sequence identity,
65%, 70%, 75%,
80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or
greater
amino sequence identity, preferably over a region of over a region of at least
about 25, 50,
100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by
a nucleotide
sequence of or associated with a gene of Tables 1-26. A polynucleotide or
polypeptide
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
sequence is typically from a mammal including, but not limited to, primate,
e.g., human;
rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. An
"ovarian
cancer polypeptide" and an "ovarian cancer polynucleotide," include both
naturally occurring
or recombinant forms.
A "full length" ovarian cancer protein or nucleic acid refers to an ovarian
cancer
polypeptide or polynucleotide sequence, or a variant thereof, that contains
all of the elements
normally contained in one or more naturally occurnng, wild type ovarian cancer
polynucleotide or polypeptide sequences. The "full length" may be prior to, or
after, various
stages of post-translation processing or splicing, including alternative
splicing.
"Biological sample" as used herein is a sample of biological tissue or fluid
that
contains nucleic acids or polypeptides, e.g., of an ovarian cancer protein,
polynucleotide or
transcript. Such samples include, but are not limited to, tissue isolated from
primates, e.g.,
humans, or rodents, e.g., mice, and rats. Biological samples may also include
sections of
tissues such as biopsy and autopsy samples, frozen sections taken for
histologic purposes,
blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological
samples also
include explants and primary and/or transformed cell cultures derived from
patient tissues. A
biological sample is typically obtained from a eukaryotic organism, most
preferably a
mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent,
e.g., guinea
pig, rat, mouse; rabbit; or a bird; reptile; or fish. Livestock and domestic
animals are of
particular interest.
"Providing a biological sample" means to obtain a biological sample for use in
methods described in this invention. Most often, this will be done by removing
a sample of
cells from an animal, but can also be accomplished by using previously
isolated cells (e.g.,
isolated by another person, at another time, and/or for another purpose), or
by performing the
methods of the invention in vivo. Archival tissues, having treatment or
outcome history, will
be particularly useful.
The terms "identical" or percent "identity," in the context of two or more
nucleic
acids or polypeptide sequences, refer to two or more sequences or subsequences
that are the
same or have a specified percentage of amino acid residues or nucleotides that
are the same
(e.g., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,
94%,
95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when
compared and
aligned for maximum correspondence over a comparison window or designated
region) as
measured using a BLAST or BLAST 2.0 sequence comparison algorithms with
default
11
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
parameters described below, or by manual alignment and visual inspection (see,
e.g., NCBI
web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are
then said to
be "substantially identical." This definition also refers to, or may be
applied to, the
compliment of a test sequence. The definition also includes sequences that
have deletions
and/or additions, as well as those that have substitutions, as well as
naturally occurring, e.g.,
polymorphic or allelic variants, and man-made variants. As described below,
the preferred
algorithms can account for gaps and the like. Preferably, identity exists over
a region that is
at least about 25 amino acids or nucleotides in length, or more preferably
over a region that is
50-100 amino acids or nucleotides in length.
For sequence comparison, typically one sequence acts as a reference sequence,
to
which test sequences are compared. When using a sequence comparison algorithm,
test and
reference sequences are entered into a computer, subsequence coordinates are
designated, if
necessary, and sequence algorithm program parameters are designated.
Preferably, default
program parameters can be used, or alternative parameters can be designated.
The sequence
comparison algorithm then calculates the percent sequence identities for the
test sequences
relative to the reference sequence, based on the program parameters.
A "comparison window", as used herein, includes reference to a segment of one
of the
number of contiguous positions selected from the group consisting typically of
from 20 to
600, usually about 50 to about 200, more usually about 100 to about 150 in
which a sequence
may be compared to a reference sequence of the same number of contiguous
positions after
the two sequences are optimally aligned. Methods of alignment of sequences for
comparison
are well-known in the art. Optimal alignment of sequences for comparison can
be conducted,
e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl.
Math.
2;482-489, by the homology alignment algorithm of Needleman and Wunsch (1970)
J. Mol.
Biol. 48:443-453, by the search for similarity method of Pearson and Lipman
(1988) Proc.
Nat'l. Acad. Sci. USA 85:2444-2448, by computerized implementations of these
algorithms
(GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package,
Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment
and
visual inspection (see, e.g., Ausubel, et al. (eds. 1995 and supplements)
Current Protocols in
Molecular Biolo~y Lippincott.
Preferred examples of algorithms that are suitable for determining percent
sequence
identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,
which are
described in Altschul, et al. (1977) Nuc. Acids Res. 25:3389-3402 and
Altschul, et al. (1990)
12
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
J. Mol. Biol. 215:403-410. BLAST and BLAST 2.0 are used, with the parameters
described
herein, to determine percent sequence identity for the nucleic acids and
proteins of the
invention. Software for performing BLAST analyses is publicly available
through the
National Center for Biotechnology Information (http://www.ncbi.nhn.nih.gov~.
This
algorithm involves first identifying high scoring sequence pairs (HSPs) by
identifying short
words of length W in the query sequence, which either match or satisfy some
positive-valued
threshold score T when aligned with a word of the same length in a database
sequence. T is
referred to as the neighborhood word score threshold (Altschul, et al.,
supra). These initial
neighborhood word hits act as seeds for initiating searches to find longer
HSPs containing
them. The word hits are extended in both directions along each sequence for as
far as the
cumulative alignment score can be increased. Cumulative scores are calculated
using, e.g.,
for nucleotide sequences, the parameters M (reward score for a pair of
matching residues;
always > 0) and N (penalty score for mismatching residues; always < 0). For
amino acid
sequences, a scoring matrix is used to calculate the cumulative score.
Extension of the word
hits in each direction are halted when: the cumulative alignment score falls
off by the
quantity X from its maximum achieved value; the cumulative score goes to zero
or below,
due to the accumulation of one or more negative-scoring residue alignments; or
the end of
either sequence is reached. The BLAST algorithm parameters W, T, and X
determine the
sensitivity and speed of the alignment. The BLASTN program (for nucleotide
sequences)
uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4
and a
comparison of both strands. For amino acid sequences, the BLASTP program uses
as
defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62
scoring matrix
(see Henikoff and Henikoff (1989) Proc. Nat'1 Acad. Sci. USA 89:10915-919)
alignments (B)
of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
The BLAST algorithm also performs a statistical analysis of the similarity
between
two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'1 Acad. Sci.
USA 90:5873-
5887). One measure of similarity provided by the BLAST algorithm is the
smallest sum
probability (P(N)), which provides an indication of the probability by which a
match between
two nucleotide or amino acid sequences would occur by chance. For example, a
nucleic acid
is considered similar to a reference sequence if the smallest sum probability
in a comparison
of the test nucleic acid to the reference nucleic acid is less than about 0.2,
more preferably
less than about 0.01, and most preferably less than about 0.001. Log values
may be large
negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.
13
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
An indication that two nucleic acid sequences or polypeptides are
substantially
identical is that the polypeptide encoded by the first nucleic acid is
immunologically cross
reactive with the antibodies raised against the polypeptide encoded by the
second nucleic
acid, as described below. Thus, a polypeptide is typically substantially
identical to a second
polypeptide, e.g., where the two peptides differ only by conservative
substitutions. Another
indication that two nucleic acid sequences are substantially identical is that
the two molecules
or their complements hybridize to each other under stringent conditions, as
described below.
Yet another indication that two nucleic acid sequences are substantially
identical is that the
same primers can be used to amplify the sequences.
A "host cell" is a naturally occurring cell or a transformed cell that
contains an
expression vector and supports the replication or expression of the expression
vector. Host
cells may be cultured cells, explants, cells in vivo, and the like. Host cells
may be
prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect,
amphibian, or
mammalian cells, such as CHO, HeLa, and the like (see, e.g., the American Type
Culture
Collection catalog or Web site, www.atcc.org).
The terms "isolated," "purified," or "biologically pure" refer to material
that is
substantially or essentially free from components that normally accompany it
as found in its
native state. Purity and homogeneity are typically determined using analytical
chemistry
techniques such as polyacrylamide gel electrophoresis or high performance
liquid
chromatography. A protein or nucleic acid that is the predominant species
present in a
preparation is substantially purified. In particular, an isolated nucleic acid
is separated from
some open reading frames that naturally flank the gene and encode proteins
other than protein
encoded by the gene. The term "purified" in some embodiments denotes that a
nucleic acid
or protein gives rise to essentially one band in an electrophoretic gel.
Preferably, it means
that the nucleic acid or protein is at least ~5% pure, more preferably at
least 95% pure, and
most preferably at least 99% pure. "Purify" or "purification" in other
embodiments means
removing at least one contaminant from the composition to be purified. In this
sense,
purification does not require that the purified compound be homogenous, e.g.,
100% pure.
The terms "polypeptide," "peptide" and "protein" are used interchangeably
herein to
refer to a polymer of amino acid residues. The terms apply to amino acid
polymers in which
one or more amino acid residue is an artificial chemical mimetic of a
corresponding naturally
occurnng amino acid, as well as to naturally occurnng amino acid polymers,
those containing
modified residues, and non-naturally occurring amino acid polymers.
14
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
The term "amino acid" refers to naturally occurring and synthetic amino acids,
as well
as amino acid analogs and amino acid mimetics that function similarly to the
naturally
occurring amino acids. Naturally occurring amino acids are those encoded by
the genetic
code, as well as those amino acids that are later modified, e.g.,
hydroxyproline, y-
S carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to
compounds that have
the same basic chemical structure as a naturally occurring amino acid, e.g.,
an a carbon that is
bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g.,
homoserine,
norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs
may have
modified R groups (e.g., norleucine) or modified peptide backbones, but retain
the same basic
chemical structure as a naturally occurring amino acid. Amino acid mimetics
refers to
chemical compounds that have a structure that is different from the general
chemical
structure of an amino acid, but that functions similarly to a naturally
occurring amino acid.
Amino acids may be referred to herein by either their commonly known three
letter
symbols or by the one-letter symbols recommended by the ICTPAC-IUB Biochemical
Nomenclature Commission. Nucleotides, likewise, may be referred to by their
commonly
accepted single-letter codes.
"Conservatively modified variants" applies to both amino acid and nucleic acid
sequences. With respect to particular nucleic acid sequences, conservatively
modified
variants refers to those nucleic acids which encode identical or essentially
identical amino
acid sequences, or where the nucleic acid does not encode an amino acid
sequence, to
essentially identical or associated, e:g., naturally contiguous, sequences.
Because of the
degeneracy of the genetic code, a large number of functionally identical
nucleic acids encode
most proteins. For instance, the codons GCA, GCC, GCG, and GCU all encode the
amino
acid alanine. Thus, at every position where an alanine is specified by a
codon, the codon can
be altered to another of the corresponding codons described without altering
the encoded
polypeptide. Such nucleic acid variations are "silent variations," which are
one species of
conservatively modified variations. Every nucleic acid sequence herein which
encodes a
polypeptide also describes silent variations of the nucleic acid. In certain
contexts each
codon in a nucleic acid (except AUG, which is ordinarily the only codon for
methionine, and
TGG, which is ordinarily the only codon for tryptophan) can be modified to
yield a
functionally identical molecule. Accordingly, a silent variation of a nucleic
acid which
encodes a polypeptide is implicit in a described sequence with respect to the
expression
product, but not necessarily with respect to actual probe sequences.
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
As to amino acid sequences, one of skill will recognize that individual
substitutions,
deletions, or additions to a nucleic acid, peptide, polypeptide, or protein
sequence which
alters, adds, or deletes a single amino acid or a small percentage of amino
acids in the
encoded sequence is a "conservatively modified variant" where the alteration
results in the
substitution of an amino acid with a chemically similar amino acid.
Conservative substitution
tables providing functionally similar amino acids are well known in the art.
Such
conservatively modified variants are in addition to and do not exclude
polymorphic variants,
interspecies homologs, and alleles of the invention. Typically conservative
substitutions for
one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid
(E); 3)
Asparagine (I~, Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I),
Leucine (L),
Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan
(W); 7) Serine
(S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton
(1984)
Proteins Freeman).
Macromolecular structures such as polypeptide structures can be described in
terms of
various levels of organization. For a general discussion of this organization,
see, e.g.,
Alberts, et al. (2001) Molecular Biology of the Cell (4th ed.) Garland Pub.;
and Cantor and
Schimmel (1980) Biophysical Chemistry Part I: The Conformation of Biological
Macromolecules Freeman. "Primary structure" refers to the amino acid sequence
of a
particular peptide. "Secondary structure" refers to locally ordered, three
dimensional
structures within a polypeptide. These structures are commonly known as
domains.
Domains are portions of a polypeptide that often form a compact unit of the
polypeptide and
are typically 25 to approximately 500 amino acids long. Typical domains are
made up of
sections of lesser organization such as stretches of (3-sheet and a-helices.
"Tertiary structure"
refers to the complete three dimensional structure of a polypeptide monomer.
"Quaternary
structure" refers to the three dimensional structure formed, usually by the
non-covalent
association of independent tertiary units. Anisotropic terms are also known as
energy terms.
"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical
equivalents
used herein means at least two nucleotides covalently linked together.
Oligonucleotides are
typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50, or more
nucleotides in length, up
to about 100 nucleotides in length. Nucleic acids and polynucleotides are a
polymers of any
length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000,
7000, 10,000,
etc. A nucleic acid of the present invention will generally contain
phosphodiester bonds,
16
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
although in some cases, nucleic acid analogs are included that may have at
least on,e different
linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-
methylphosphoroamidite linkages (see Eckstein (1992) Oli~onucleotides and
Analogues: A
Practical Approach Oxford University Press); and peptide nucleic acid
backbones and
linkages. Other analog nucleic acids include those with positive backbones;
non-ionic
backbones, and non-ribose backbones, including those described in U.S. Patent
Nos.
5,235,033 and 5,034,506, and Chapters 6 and 7 of Sanghvi and Cook (eds. 1994)
Carbohydrate Modifications in Antisense Research ASC Symposium Series 580.
Nucleic
acids containing one or more carbocyclic sugars are also included within one
definition of
nucleic acids. Modifications of the ribose-phosphate backbone may be done for
a variety of
reasons, e.g., to increase the stability and half life of such molecules in
physiological
environments or as probes on a biochip. Mixtures of naturally occurring
nucleic acids and
analogs can be made; alternatively, mixtures of different nucleic acid
analogs, and mixtures
of naturally occurring nucleic acids and analogs may be made.
A variety of references disclose such nucleic acid analogs, including, e.g.,
phosphoramidate (Beaucage, et al. (1993) Tetrahedron 49:1925-1963 and
references therein;
Letsinger (1970) J. Org. Chem. 35:3800-3803; Sprinzl, et al. (1977) Eur. J.
Biochem. 81:579-
589; Letsinger, et al. (1986) Nucl. Acids Res. 14:3487-499; Sawai, et al.
(1984) Chem. Lett.
805, Letsinger, et al. (1988) J. Am. Chem. Soc. 110:4470-4471; and Pauwels, et
al. (1986),
Chemica Scri~ta 26:141-149), phosphorothioate (Mag, et a1. (1991) Nucl. Acids
Res.
19:1437-441; and U.S. Patent No. 5,644,048), phosphorodithioate (Brill, et al.
(1989) J. Am.
Chem. Soc. 111:2321-2322), O-methylphophoroamidite linkages (see Eckstein
(1992)
Oligonucleotides and Analogues: A Practical Approach Oxford Univ. Press), and
peptide
nucleic acid backbones and linkages (see Egholm (1992) J. Am. Chem. Soc.
114:1895-897;
Meier, et al. (1992) Angew. Chem. Int. Ed. En~l. 31:1008-1010; Nielsen (1993)
Nature,
365:566-568; Carlsson, et al. (1996) Nature 380:207, each of which is
incorporated by
reference). Other analog nucleic acids include those with positive backbones
(Denpcy, et al.
(1995) Proc. Nat'1 Acad. Sci. USA 92:6097-101; non-ionic backbones (U.S.
Patent Nos.
5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi, et al.
(1991) Angew.
Chem. Intl. Ed. En 1g ish 30:423-426; Letsinger, et al. (1988) J. Am. Chem.
Soc. 110:4470-
4471; Jung, et al. (1994) Nucleoside and Nucleotide 13:1597; Chapters 2 and 3,
in Sanghvi
and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ASC
Symposium
Series SM; Mesmaeker, et al. (1994) Bioorganic and Medicinal Chem. Lett. 4:395-
398; Jeffs,
17
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
et al. (1994) J. Biomolecular NMR 34:17-xx; Horn, et al. (1996) Tetrahedron
Lett. 37:743-
xxx) and non-ribose backbones, including those described in U.S. Patent Nos.
5,235,033 and
5,034,506, and Chapters 6 and 7, in Sanghvi and Cook (eds. 1994) Carbohydrate
Modifications 'in Antisense Research ASC Symposium Series 580. Nucleic acids
containing
one or more carbocyclic sugars are also included within one definition of
nucleic acids (see
Jenkins, et al. (1995) Chem. Soc. Rev. pp 169-176). Several nucleic acid
analogs are
described in Rawls (p. 35 June 2, 1997) C&E News. Each of these references is
hereby
expressly incorporated by reference.
Particularly preferred are peptide nucleic acids (PNA) which includes peptide
nucleic
acid analogs. These backbones are substantially non-ionic under neutral
conditions, in
contrast to the highly charged phosphodiester backbone of naturally occurring
nucleic acids.
This results in two advantages. First, the PNA backbone exhibits improved
hybridization
kinetics. PNAs have larger changes in the melting temperature (Tm) for
mismatched versus
perfectly matched base pairs. DNA and RNA typically exhibit a 2-4° C
drop in Tm for an
internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-
9° C.
Similarly, due to their non-ionic nature, hybridization of the bases attached
to these
backbones is relatively insensitive to salt concentration. In addition, PNAs
are not degraded
by cellular enzymes, and thus can be more stable.
The nucleic acids may be single stranded or double stranded, as specified, or
contain
portions of both double stranded or single stranded sequence. As will be
appreciated by those
in the art, the depiction of a single strand also defines the sequence of the
complementary
strand; thus the sequences described herein also provide the complement of the
sequence.
The nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where
the
nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and
combinations
of bases, including uracil, adenine, thymine, cytosine, guanine, inosine,
xanthine
hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a
naturally
occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term
"nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and
modified
nucleosides such as amino modified nucleosides. In addition, "nucleoside"
includes non-
naturally occurnng analog structures. Thus, e.g., the individual units of a
peptide nucleic
acid, each containing a base, are referred to herein as a nucleoside.
A "label" or a "detectable moiety" is a composition detectable by
spectroscopic,
18
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
photochemical, biochemical, immunochemical, chemical, or other physical means.
For
example, useful labels include 32P, fluorescent dyes, electron-dense reagents,
enzymes (e.g.,
as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or
other entities
which can be made detectable, e.g., by incorporating a radiolabel into the
peptide or used to
S detect antibodies specifically reactive with the peptide. The labels may be
incorporated into
the ovarian cancer nucleic acids, proteins and antibodies at aaiy position.
Any method known
in the art for conjugating the antibody to the label may be employed,
including those methods
described by Hunter, et al. (1962) Nature 144:945-xxx; David, et al. (1974)
Biochemistry
13:1014-1021; Pain, et al. (1981) J. Immunol. Meth. 40:219-230; and Nygren
(1982) J.
Histochem. and C. ochem. 30_:407-412.
An "effector" or "effector moiety" or "effector component" is a molecule that
is
bound (or linked, or conjugated), either covalently, through a linker or a
chemical bond, or
non-covalently, through ionic, van der Waals, electrostatic, or hydrogen
bonds, to an
antibody. The "effector" can be a variety of molecules including, e.g.,
detection moieties
including radioactive compounds, fluorescent compounds, an enzyme or
substrate, tags such
as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a
lipase; an
antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.
A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either
covalently, through a linker or a chemical bond, or non-covalently, through
ionic, van der
Waals, electrostatic, or hydrogen bonds to a label such that the presence of
the probe may be
detected by detecting the presence of the label bound to the probe.
Alternatively, method
using high affinity interactions may achieve the same results where one of a
pair of binding
partners binds to the other, e.g., biotin, streptavidin.
As used herein a "nucleic acid probe or oligonucleotide" is a nucleic acid
capable of
binding to a target nucleic acid of complementary sequence through one or more
types of
chemical bonds, usually through complementary base pairing, usually through
hydrogen bond
formation. As used herein, a probe may include natural (e.g., A, G, C, or T)
or modified
bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may
be joined by a
linkage other than a phosphodiester bond, so long as it does not functionally
interfere with
hybridization. Thus, e.g., probes may be peptide nucleic acids in which the
constituent bases
are joined by peptide bonds rather than phosphodiester linkages. Probes may
bind target
sequences lacking complete complementarity with the probe sequence depending
upon the
19
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
stringency of the hybridization conditions. The probes are preferably directly
labeled, e.g.,
with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled
such as with
biotin to which a streptavidin complex may later bind. By assaying for the
presence or
absence of the probe, one can detect the presence or absence of the select
sequence or
subsequence. Diagnosis or prognosis may be based at the genomic level, or at
the level of
RNA or protein expression.
The term "recombinant" when used with reference, e.g., to a cell, or nucleic
acid,
protein, or vector, indicates that the cell, nucleic acid, protein or vector,
has been modified by
the introduction of a heterologous nucleic acid or protein or the alteration
of a native nucleic
acid or protein, or that the cell is derived from a cell so modified. Thus,
e.g., recombinant
cells express genes that are not found within the native (non-recombinant)
form of the cell or
express native genes that are otherwise abnormally expressed, under expressed
or not
expressed at all. By the term "recombinant nucleic acid" herein is meant
nucleic acid,
originally formed in vitro, in general, by the manipulation of nucleic acid,
e.g., using
polymerases and endonucleases, in a form not normally found in nature. In this
manner,
operably linkage of different sequences is achieved. Thus an isolated nucleic
acid, in a linear
form, or an expression vector formed in vitro by ligating DNA molecules that
are not
normally joined, are both considered recombinant for the purposes of this
invention. It is
understood that once a recombinant nucleic acid is made and reintroduced into
a host cell or
organism, it will replicate non-recombinantly, e.g., using the in vivo
cellular machinery of the
host cell rather than in vitro manipulations; however, such nucleic acids,
once produced
recombinantly, although subsequently replicated non-recombinantly, are still
considered
recombinant for the purposes of the invention. Similarly, a "recombinant
protein" is a protein
made using recombinant techniques, e.g., through the expression of a
recombinant nucleic
acid as depicted above.
The term "heterologous" when used with reference to portions of a nucleic acid
indicates that the nucleic acid comprises two or more subsequences that are
not normally
found in the same relationship to each other in nature. For instance, the
nucleic acid is
typically recombinantly produced, having two or more sequences, e.g., from
unrelated genes
arranged to make a new functional nucleic acid, e.g., a promoter from one
source and a
coding region from another source. Similarly, a heterologous protein will
often refer to two
or more subsequences that are not found in the same relationship to each other
in nature (e.g.,
a fusion protein).
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
A "promoter" is defined as an array of nucleic acid control sequences that
direct
transcription of a nucleic acid. As used herein, a promoter includes necessary
nucleic acid
sequences near the start site of transcription, such as, in the case of a
polymerise II type
promoter, a TATA element. A promoter also optionally includes distal enhancer
or repressor
elements, which can be located as much as several thousand base pairs from the
start site of
transcription. A "constitutive" promoter is a promoter that is active under
most
environmental and developmental conditions. An "inducible" promoter is a
promoter that is
active under environmental or developmental regulation. The term "operably
linked" refers
to a functional linkage between a nucleic acid expression control sequence
(such as a
promoter, or array of transcription factor binding sites) and a second nucleic
acid sequence,
e.g., wherein the expression control sequence directs transcription of the
nucleic acid
corresponding to the second sequence.
An "expression vector" is a nucleic acid construct, generated recombinantly or
synthetically, with a series of specified nucleic acid elements that permit
transcription of a
particular nucleic acid in a host cell. The expression vector can be part of a
plasmid, virus, or
nucleic acid fragment. Typically, the expression vector includes a nucleic
acid to be
transcribed operably linked to a promoter.
The phrase "selectively (or specifically) hybridizes to" refers to the
binding,
duplexing, or hybridizing of a molecule only to a particular nucleotide
sequence under
stringent hybridization conditions when that sequence is present in a complex
mixture (e.g.,
total cellular or library DNA or RNA).
The phrase "stringent hybridization conditions" refers to conditions under
which a
probe will hybridize to its target subsequence, typically in a complex mixture
of nucleic
acids, but to no other sequences. Stringent conditions are sequence-dependent
and will be
different in different circumstances. Longer sequences hybridize specifically
at higher
temperatures. An extensive guide to the hybridization of nucleic acids is
found in "Overview
of principles of hybridization and the strategy of nucleic acid assays" in
Tijssen (1993)
Hybridization with Nucleic Probes (Laboratory Techniques in Biochemistr~and
Molecular
Biolo (vol. 24) Elsevier. Generally, stringent conditions are selected to be
about 5-10° C
lower than the thermal melting point (Tm) for the specific sequence at a
defined ionic
strength pH. The Tm is the temperature (under defined ionic strength, pH, and
nucleic
concentration) at which 50% of the probes complementary to the target
hybridize to the target
21
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
sequence at equilibrium (as the target sequences are present in excess, at Tm,
SO% of the
probes are occupied at equilibrium). Stringent conditions will be those in
which the salt
concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0
M sodium ion
concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at
least about 30° C for
S short probes (e.g., 10 to 50 nucleotides) and at least about 60° C
for long probes (e.g., greater
than SO nucleotides). Stringent conditions may also be achieved with the
addition of
destabilizing agents such as formamide. For selective or specific
hybridization, a positive
signal is typically at least two times background, preferably 10 times
background
hybridization. Exemplary stringent hybridization conditions can be as
following: 50%
formamide, Sx SSC, and 1% SDS, incubating at 42° C, or, Sx SSC, 1% SDS,
incubating at
65° C, with wash in 0.2x SSC, and 0.1% SDS at 65° C. For PCR, a
temperature of about 36°
C is typical for low stringency amplification, although annealing temperatures
may vary
between about 32-48° C depending on primer length. For high stringency
PCR amplification,
a temperature of about 62° C is typical, although high stringency
annealing temperatures can
range from about SO° C to about 65° C, depending on the primer
length and specificity.
Typical cycle conditions for both high and low stringency amplifications
include a
denaturation phase of 90-95° C for 30-120 sec, an annealing phase
lasting 30-120 sec, and an
extension phase of about 72° C for 1-2 min. Protocols and guidelines
for low and high
stringency amplification reactions are available, e.g., in Innis, et al.
(1990) PCR Protocols: A
Guide to Methods and Applications Academic Press, N.Y.
Nucleic acids that do not hybridize to each other under stringent conditions
are still
substantially identical if the polypeptides which they encode are
substantially identical. This
occurs, e.g., when a copy of a nucleic acid is created using the maximum codon
degeneracy
permitted by the genetic code. In such cases, the nucleic acids typically
hybridize under
moderately stringent hybridization conditions. Exemplary "moderately stringent
hybridization conditions" include a hybridization in a buffer of 40%
formamide, 1 M NaCI,
1% SDS at 37° C, and a wash in 1X SSC at 45° C. A positive
hybridization is at least twice
background. Alternative hybridization and wash conditions can be utilized to
provide
conditions of similar stringency. Additional guidelines for determining
hybridization
parameters are provided, e.g., Ausubel, et al. (ed. 1991 and supplements)
Current Protocols in
Molecular Biolo~y Lippincott.
The phrase "functional effects" in the context of assays for testing compounds
that
22
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
modulate activity of an ovarian cancer protein includes the determination of a
parameter that
is indirectly or directly under the influence of the ovarian cancer protein or
nucleic acid, e.g.,
a functional, physical, physiological, or chemical effect, such as the ability
to decrease
ovarian cancer. It includes ligand binding activity; cell growth on soft agax;
anchorage
dependence; contact inhibition and density limitation of growth; cellular
proliferation;
cellular transformation; growth factor or serum dependence; tumor specific
marker levels;
invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and
protein
expression in cells undergoing metastasis, and other characteristics of
ovarian cancer cells.
"Functional effects" include in vitro, in vivo, and ex vivo activities.
By "determining the functional effect" is meant assaying for a compound that
increases or decreases a parameter that is indirectly or directly under the
influence of an
ovarian cancer protein sequence, e.g., functional, enzymatic, physical,
physiological, and
chemical effects. Such functional effects can be measured by any means known
to those
skilled in the art, e.g., changes in spectroscopic characteristics (e.g.,
fluorescence,
absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or
solubility
properties for the protein, measuring inducible markers or transcriptional
activation of the
ovarian cancer protein; measuring binding activity or binding assays, e.g.,
binding to
antibodies or other ligands, and measuring cellular proliferation.
Determination of the
functional effect of a compound on ovarian cancer can also be performed using
ovarian
cancer assays known to those of skill in the art such as an in vitro assays,
e.g., cell growth on
soft agar; anchorage dependence; contact inhibition and density limitation of
growth; cellular
proliferation; cellular transformation; growth factor or serum dependence;
tumor specific
marker levels; invasiveness into Matrigel; tumor growth and metastasis in
vivo; mRNA and
protein expression in cells undergoing metastasis, and other characteristics
of ovarian cancer
cells. The functional effects can be evaluated by means known to those skilled
in the art, e.g.,
microscopy for quantitative or qualitative measures of alterations in
morphological features,
measurement of changes in RNA or protein levels for ovarian cancer-associated
sequences,
measurement of RNA stability, or identification of downstream or reporter gene
expression
(CAT, luciferase, (3-gal, GFP, and the like), e.g., via chemiluminescence,
fluorescence,
colorimetric reactions, antibody binding, inducible markers, and ligand
binding assays.
"Inhibitors", "activators", and "modulators" of ovarian cancer polynucleotide
and
polypeptide sequences are used to refer to activating, inhibitory, or
modulating molecules or
compounds identified using in vitro and in vivo assays of ovarian cancer
polynucleotide and
23
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially
or totally block
activity, decrease, prevent, delay activation, inactivate, desensitize, or
down regulate the
activity or expression of ovarian cancer proteins, e.g., antagonists.
Antisense or inhibitory
nucleic acids may inhibit expression and subsequent function of the protein.
"Activators" are
compounds that increase, open, activate, facilitate, enhance activation,
sensitize, agonize, or
up regulate ovarian cancer protein activity. Inhibitors, activators, or
modulators also include
genetically modified versions of ovarian cancer proteins, e.g., versions with
altered activity,
as well as naturally occurring and synthetic ligands, antagonists, agonists,
antibodies, small
chemical molecules, and the like. Assays for inhibitors and activators
include, e.g.,
expressing the ovarian cancer,protein in vitro, in cells, or cell membranes,
applying putative
modulator compounds, and then determining the functional effects on activity,
as described
above. Activators and inhibitors of ovarian cancer can also be identified by
incubating
ovarian cancer cells with the test compound and determining increases or
decreases in the
expression of one or more ovarian cancer proteins, e.g., 1, 2, 3, 4, 5, 10,
15, 20, 25, 30, 40,
S0, or more ovarian cancer proteins, such as ovarian cancer proteins encoded
by the
sequences set out in Tables 1-26.
Samples or assays comprising ovarian cancer proteins that are treated with a
potential
activator, inhibitor, or modulator are compared to control samples without the
inhibitor,
activator, or modulator to examine the extent of inhibition. Control samples
(untreated with
inhibitors) are assigned a relative protein activity value of 100%. Inhibition
of a polypeptide
is achieved when the activity value relative to the control is about 80%,
preferably SO%, more
preferably 25% or less. Activation of an ovarian cancer polypeptide is
achieved when the
activity value relative to the control (untreated with activators) is 110%,
more preferably
1.50%, more preferably 200-500% (e.g., 2-5 fold higher relative to the
control), more
preferably 1000-3000% higher.
The phrase "changes in cell growth" refers to a change in cell growth and
proliferation characteristics in vitro or in vivo, e.g., cell viability,
formation of foci,
anchorage independence, semi-solid or soft agar growth, change in contact
inhibition or
density limitation of growth, loss of growth factor or serum requirements,
change in cell
morphology, gain or loss of immortalization, gain or loss of tumor specific
markers, ability to
form or suppress tumors when injected into suitable animal hosts, and/or
immortalization of
the cell. See, e.g., pp. 231-241 in Freshney (1994) Culture of Animal Cells: A
Manual of
Basic Technique (3d ed.) Wiley-Liss.
24
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
"Tumor cell" refers to pre-cancerous, cancerous, and normal cells in a tumor.
"Cancer cells," "transformed" cells or "transformation" in tissue culture,
refers to
spontaneous or induced phenotypic changes that do not necessarily involve the
uptake of new
genetic material. Although transformation can arise from infection with a
transforming virus
and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also
arise
spontaneously or following exposure to a carcinogen, thereby mutating an
endogenous gene.
Transformation is typically associated with phenotypic changes, such as
immortalization of
cells, aberrant growth control, non-morphological changes, and/or malignancy.
See,
Freshney (1994) Culture of Animal Cells.
"Antibody" refers to a,polypeptide comprising a framework region from an
immunoglobulin gene or fragments thereof that specifically binds and
recognizes an antigen.
The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma,
delta,
epsilon, and mu constant region genes, as well as the myriad immunoglobulin
variable region
genes. Light chains are classified as either kappa or lambda. Heavy chains are
classified as
gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin
classes, IgG,
IgM, IgA, IgD, and IgE, respectively. Typically, the antigen-binding region of
an antibody or
its functional equivalent will be most critical in specificity and affinity of
binding. See, e.g.,
Paul (ed. 1999) Fundamental Immunolo~y (4th ed.) Raven.
An exemplary immunoglobulin (antibody) structural unit comprises a tetramer.
Each
tetramer is composed of two identical pairs of polypeptide chains, each pair
having one
"light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus
of each
chain defines a variable region of about 100 to 110 or more amino acids
primarily responsible
for antigen recognition. The terms variable light chain (VL) and variable
heavy chain (VH)
refer to these light and heavy chains respectively.
Antibodies exist, e.g., as intact immunoglobulins or as a number of well-
characterized
fragments produced by digestion with various peptidases. Thus, e.g., pepsin
digests an
antibody below the disulfide linkages in the hinge region to produce F(ab)'2,
a dimer of Fab
which itself is a light chain joined to Vg-CH1 by a disulfide bond. The
F(ab)'2 may b.e
reduced under mild conditions to break the disulfide linkage in the hinge
region, thereby
converting the F(ab)'2 dimer into an Fab' monomer. The Fab' monomer is
essentially Fab
with part of the hinge region. See Paul (ed. 1999) Fundamental Immunolo~y (4th
ed.) Raven.
While variouseantibody fragments are defined in ternls of the digestion of an
intact antibody,
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
one of skill will appreciate that such fragments may be synthesized de novo
either chemically
or by using recombinant DNA methodology. Thus, the term antibody, as used
herein, also
includes antibody fragments either produced by the modification of whole
antibodies, or
those synthesized de novo using recombinant DNA methodologies (e.g., single
chain Fv) or
those identified using phage display libraries. See, e.g., McCafferty, et al.
(1990) Nature
348:552-554. '
For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal
antibodies, many techniques known in the art can be used (see, e.g., Kohler
and Milstein
(1975) Nature 256:495-497; Kozbor, et al. (1983) Immunolo~y TodaX 4:72; Cole,
et al., pp.
77-96 in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therapy
Liss; Coligan
(1991) Current Protocols in Immunolo~y Lippincott; Harlow and Lane (1988)
Antibodies: A
Laboratory Manual CSH Press; and Goding (1986) Monoclonal Antibodies:
Principles and
Practice (2d ed.) Academic Press. Techniques for the production of single
chain antibodies
(U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides
of this
invention. Transgenic mice, or other organisms, e.g., other mammals, may be
used to express
humanized antibodies. Alternatively, phage display technology can be used to
identify
antibodies and heteromeric Fab fragments that specifically bind to selected
antigens. See,
e.g., McCafferty, et al. (1990) Nature 348:552-554; and Marks, et al. (1992)
Biotechnolo~y
10:779-783.
A "chimeric antibody" is an antibody molecule in which (a) the constant
region, or a
portion thereof, is altered, replaced or exchanged so that the antigen binding
site (variable
region) is linked to a constant region of a different or altered class,
effector function and/or
species, or an entirely different molecule which confers new properties to the
chimeric
antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b)
the variable
region, or a portion thereof, is altered, replaced or exchanged with a
variable region having a
different or altered antigen specificity.
Identification of ovarian cancer-associated sequences
In one aspect, the expression levels of genes are determined in different
patient
samples for which diagnosis information is desired, to provide expression
profiles. An
expression profile of a particular sample is essentially a "fingerprint" of
the state of the
sample; while two states may have any particular gene similarly expressed, the
evaluation of
a number of genes simultaneously allows the generation of a gene expression
profile that is
26
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
characteristic of the state of the cell. That is, normal tissue (e.g., normal
ovarian or other
tissue) may be distinguished from cancerous or metastatic cancerous tissue of
the ovarian, or
ovarian cancer tissue or metastatic ovarian cancerous tissue can be compared
with tissue
samples of ovarian and other tissues from surviving cancer patients. By
comparing
S expression profiles of tissue in known different ovarian cancer states,
information regarding
which genes are important (including both up- and down-regulation of genes) in
each of these
states is obtained. Molecular profiling may distinguish subtypes of a
currently collective
disease designation, e.g., different forms of a cancer.
The identification of sequences that are differentially expressed in ovarian
cancer
versus non-ovarian cancer tissue allows the use of this information in a
number of ways. For
example, a particular treatment regime may be evaluated: does a
chemotherapeutic drug act
to down-regulate ovarian cancer, and thus tumor growth or recurrence, in a
particular patient.
Alternatively, does existing treatment induce expression of a target.
Similarly, diagnosis and
treatment outcomes may be done or confirmed by comparing patient samples with
the known
expression profiles. Metastatic tissue can also be analyzed to determine the
stage of ovarian
cancer in the tissue or origin of the primary tumor. Furthermore, these gene
expression
profiles (or individual genes) allow screening of drug candidates with an eye
to mimicking or
altering a particular expression profile; e.g., screening can be done for
drugs that suppress the
ovarian cancer expression profile. This may be done by making biochips
comprising sets of
the important ovarian cancer genes, which can then be used in these screens.
These methods
can also be based on evaluating protein expression; that is, protein
expression levels of the
ovarian cancer proteins can be evaluated for diagnostic purposes or to screen
candidate
agents. In addition, the ovarian cancer nucleic acid sequences can be
administered for gene
therapy purposes, including the administration of antisense or RNAi nucleic
acids, or the
ovarian cancer proteins (including antibodies and other modulators thereof)
administered as
therapeutic drugs.
Thus the present invention provides nucleic acid and protein sequences that
are
differentially expressed in ovarian cancer relative to normal tissues and/or
non-malignant
tissues, herein termed "ovarian cancer sequences." As outlined below, ovarian
cancer
sequences include those that are up-regulated (e.g., expressed at a higher
level) in ovarian
cancer, as well as those that are down-regulated (e.g., expressed at a lower
level). In a
preferred embodiment, the ovarian cancer sequences are from humans; however,
as will be
appreciated by those in the art, ovarian cancer sequences from other organisms
may be useful
27
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
in animal models of disease and drug evaluation; thus, other ovarian cancer
sequences are
provided, from vertebrates, including mammals, including rodents (rats, mice,
hamsters,
guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs,
cows, horses, etc.)
and pets (e.g., dogs, cats, etc.). Ovarian cancer sequences, e.g., counterpart
genes, from other
organisms may be obtained using the techniques outlined below.
Ovarian cancer sequences can include both nucleic acid and amino acid
sequences.
Ovarian cancer nucleic acid sequences are useful in a variety of applications,
including
diagnostic applications, which will detect naturally occurring nucleic acids.
Screening
applications; e.g., biochips comprising nucleic acid probes or PCR microtiter
plates with
selected probes to the ovarian cancer sequences, are also provided.
An ovarian cancer sequence can be initially identified by substantial nucleic
acid
and/or amino acid sequence homology to the ovarian cancer sequences outlined
herein. Such
homology can be based upon the overall nucleic acid or amino acid sequence,
and is
generally determined as outlined below, using either homology programs or
hybridization
1 S conditions.
For identifying ovarian cancer-associated sequences, the ovarian cancer screen
typically includes comparing genes identified in different tissues, e.g.,
normal and cancerous
tissues, or tumor tissue samples from patients who have metastatic disease vs.
non metastatic
tissue. Other suitable tissue comparisons include comparing ovarian cancer
samples with
metastatic cancer samples from other cancers, such as lung, ovarian,
gastrointestinal cancers,
etc. Samples of different stages of ovarian cancer, e.g., survivor tissue,
drug resistant states,
and tissue undergoing metastasis, are applied to biochips comprising nucleic
acid probes.
The samples are first microdissected, if applicable, and treated for the
preparation of mRNA.
Suitable biochips are commercially available, e.g., from Affymetrix. Gene
expression
profiles as described herein are generated and the data analyzed.
In one embodiment, the genes showing changes in expression as between normal
and
disease states are compared to genes expressed in other normal tissues,
preferably normal
ovarian, but also including, and not limited to, lung, heart, brain, liver,
ovarian, kidney,
muscle, colon, small intestine, large intestine, spleen, bone, and/or
placenta. In a preferred
embodiment, those genes identified during the ovarian cancer screen that are
expressed in any
significant amount in other tissues are removed from the profile, although in
some
embodiments, expression in non-essential tissues may be tolerated. That is,
when screening
for drugs, it is usually.preferable that the target be disease specific, to
minimize possible side
28
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
effects by interaction with target present in other organs.
In a preferred embodiment, ovarian cancer sequences are those that are up-
regulated
in ovarian cancer; that is, the expression of these genes is higher in the
ovarian cancer tissue
as compared to non-cancerous tissue. "Up-regulation" as used herein often
means at least
about a two-fold change, preferably at least about a three fold change, with
at least about
five-fold or higher being preferred. Other embodiments are directed to
sequences up
regulated in non-malignant conditions relative to normal.
Unigene cluster identification numbers and accession numbers herein refer to
the
GenBank sequence database and the sequences of the accession numbers are
hereby
expressly incorporated by reference. GenBank is known in the art, see, e.g.,
Benson, et al.
(1998) Nucl. Acids Res. 26:1-7; and http:/lwww.ncbi.nlm.nih.govl. Sequences
are also
available in other databases, e.g., European Molecular Biology Laboratory
(EMBL) and
DNA Database of Japan (DDBJ). In some situations, the sequences may be derived
from
assembly of available sequences or be predicted from genomic DNA using exon
prediction
algorithms, e.g., FGENESH. See Salamov and Solovyev (2000) Genome Res. 10:516-
522.
In other situations, sequences have been derived from cloning and sequencing
of isolated
nucleic acids.
In another preferred embodiment, ovarian cancer sequences are those that are
down-
regulated in ovarian cancer; that is, the expression of these genes is lower
in ovarian cancer
tissue as compared to non-cancerous tissue. "Down-regulation" as used herein
often means
at least about a two-fold change, preferably at least about a three-fold
change, with at least
about five-fold or higher being preferred.
Informatics
The ability to identify genes that are over or under expressed in ovarian
cancer can
additionally provide high-resolution, high-sensitivity datasets which can be
used in the areas
of diagnostics, therapeutics, drug development, pharmacogenetics, protein
structure,
biosensor development, and other related areas. Expression profiles can be
used in diagnostic
or prognostic evaluation of patients with ovarian cancer. Subcellular
toxicological
information can be generated to better direct drug structure and activity
correlation (see
Anderson (June 11-12, 1998) Pharmaceutical Proteomics: Targets, Mechanism, and
Function,
paper presented at the IBC Proteomics conference, Coronado, CA) or in a
biological sensor
device to predict the likely toxicological effect of chemical exposures and
likely tolerable
29
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue
from
datasets relevant to other biomolecules and bioactive agents (e.g., nucleic
acids, saccharides,
lipids, drugs, and the like).
Thus, in another embodiment, the present invention provides a database that
includes
at least one set of assay data. The data contained in the database is
acquired, e.g., using array
analysis either singly or in a library format. The database can be in a form
in which data can
be maintained and transmitted, but is preferably an electronic database, and
can be
maintained on any electronic device allowing for the storage of and access to
the database,
such as a personal computer, but is preferably distributed on a wide area
network, such as the
World Wide Web.
The focus of the present section on databases that include peptide sequence
data is for
clarity of illustration only. It will be apparent to those of skill in the art
that similar databases
can be assembled for any assay data acquired using an assay of the invention.
The compositions and methods for identifying and/or quantitating the relative
and/or
1 S absolute abundance of a variety of molecular and macromolecular species
from a biological
sample undergoing ovarian cancer, e.g., the identification of ovarian cancer-
associated
sequences described herein, provide an abundance of information which can be
correlated
with pathological conditions, predisposition to disease, drug testing,
therapeutic monitoring,
gene-disease causal linkages, identification of correlates of immunity and
physiological
status, and outcome data, among others. Although data generated from the
assays of the
invention is suited for manual review and analysis, in a preferred embodiment,
data
processing using high-speed computers is utilized.
An array of methods for indexing and retrieving biomolecular information is
known
in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a
relational database
system for storing biomolecular sequence information in a manner that allows
sequences to
be catalogued and searched according to one or more protein function
hierarchies. U.S.
Patent 5,953,727 discloses a relational database having sequence records
containing
information in a format that allows a collection of partial-length DNA
sequences to be
catalogued and searched according to association with one or more sequencing
projects for
obtaining full-length sequences from the collection of partial length
sequences. U.S. Patent
5,706,498 discloses a gene database retrieval system for making a retrieval of
a gene
sequence similar to a sequence data item in a gene database based on the
degree of similarity
between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses
a method
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
using mass spectroscopy fragmentation patterns of peptides to identify amino
acid sequences
in computer databases by comparison of predicted mass spectra with
experimentally-derived
mass spectra using a closeness-of fit measure. U.S. Patent 5,926,818 discloses
a multi-
dimensional database comprising a functionality for mufti-dimensional data
analysis
described as on-line analytical processing (OLAP), which entails the
consolidation of
projected and actual data according to more than one consolidation path or
dimension. U.S.
Patent 5,295,261 reports a hybrid database structure in which the fields of
each database
record are divided into two classes, navigational and informational data, with
navigational
fields stored in a hierarchical topological map which can be viewed as a tree
structure or as
the merger of two or more such tree structures.
Fundamentals of bioinformatics are provided, e.g., in Mount, et al. (2001)
Bioinformatics: Sequence and Genome Analysis CSH Press, NY; Durbin, et al.
(eds. 1999)
Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic
Acids
Cambridge Univ. Press; Baxevanis and Oeullette (eds. 1998) Bioinformatics: A
Practical
Guide to the Analysis of Genes and Proteins (2d ed.) Wiley-Liss; Rashidi and
Buehler (1999)
Bioinformatics: Basic Applications in Biological Science and Medicine CRC
Press; Setubal,
et al. (eds 1997) Introduction to Computational Molecular Biolo~y Brooks/Cole;
Misener and
Krawetz (eds. 2000) Bioinformatics: Methods and Protocols Humana Press;
Higgins and
Taylor (eds. 2000) Bioinformatics: Sequence, Structure, and Databanks: A
Practical
Approach Oxford Univ. Press; Brown (2001) Bioinformatics: A Biologist's Guide
to
Biocomputin~ and the Internet Eaton Pub.; Han and Kamber (2000) Data Mining:
Concepts
and Techniques Kaufinann Pub.; and Waterman (1995) Introduction to
Computational
Biolog.~ps, Sequences, and Genomes Chap and Hall.
The present invention provides a computer database comprising a computer and
software for storing in computer-retrievable form assay data records cross-
tabulated, e.g.,
with data specifying the source of the target-containing sample from which
each sequence
specificity record was obtained.
In an exemplary embodiment, at least one of the sources of target-containing
sample
is from a control tissue sample known to be free of pathological disorders. In
a variation, at
least one of the sources is a known pathological tissue specimen, e.g., a
neoplastic lesion or
another tissue specimen to be analyzed for ovarian cancer. In another
variation, assay records
cross-tabulate one or more of the following parameters for a target species in
a sample: (1) a
unique identification code, which can include, e.g., a target molecular
structure and/or
31
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
characteristic separation coordinate (e.g., electrophoretic or genomic
position coordinates);
(2) sample source; and (3) absolute andlor relative quantity of target species
present in the
sample.
The invention also provides for the storage and retrieval of a collection of
target data
in a computer data storage apparatus, which can include magnetic disks,
optical disks,
magneto-optical disks, DRAM, SRAM, SGR.AM, SDRAM, RDRAM, DDR RAM, magnetic
bubble memory devices, and other data storage devices, including CPU registers
and on-CPU
data storage arrays. Typically, the target data records are stored as a bit
pattern in an array of
magnetic domains on a magnetizable medium or as an array of charge states or
transistor gate
states, such as an array of cells in a DRAM device (e.g., each cell comprised
of a transistor
and a charge storage area, which may be on the transistor). In one embodiment,
the invention
provides such storage devices, and computer systems built therewith,
comprising a bit pattern
encoding a protein expression fingerprint record comprising unique identifiers
fox at least 10
target data records cross-tabulated with target source.
When the target is a peptide or nucleic acid, the invention preferably
provides a
method for identifying related peptide or nucleic acid sequences, comprising
performing a
computerized comparison between a peptide or nucleic acid sequence assay
record stored in
or retrieved from a computer storage device or database and at least one other
sequence. The
comparison can include a sequence analysis or comparison algorithm or computer
program
embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison
may
be of the relative amount of a peptide or nucleic acid sequence in a pool of
sequences
determined from a polypeptide or nucleic acid sample of a specimen.
The invention also preferably provides a magnetic disk, such as an IBM-
compatible
(DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g.,
Linux,
SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or
hard (fixed,
Winchester) disk drive, comprising a bit pattern encoding data from an assay
of the invention
in a file format suitable for retrieval and processing in a computerized
sequence analysis,
comparison, or relative quantitation method.
The invention also provides a network, comprising a plurality of computing
devices
linked via a data link, such as an Ethernet cable (coax or lOBaseT), telephone
line, ISDN
line, wireless network, optical fiber, or other suitable signal transmission
medium, whereby at
least one network device (e.g., computer, disk array, etc.) comprises a
pattern of magnetic
domains (e.g., magnetic disk) andlor charge domains (e.g., an array of DRAM
cells)
32
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
composing a bit pattern encoding data acquired from an assay of the invention.
The invention also provides a method for transmitting assay data that includes
generating an electronic signal on an electronic communications device, such
as a modem,
ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the
signal
includes (in native or encrypted format) a bit pattern encoding data from an
assay or a
database comprising a plurality of assay results obtained by the method of the
invention.
In a preferred embodiment, the invention provides a computer system for
comparing a
query target to a database containing an array of data structures, such as an
assay result
obtained by the method of the invention, and ranking database targets based on
the degree of
identity and gap weight to the,target data. A central processor is preferably
initialized to load
and execute the computer program for alignment and/or comparison of the assay
results.
Data for a query target is entered into the central processor via an I/O
device. Execution of
the computer program results in the central processor retrieving the assay
data from the data
file, which comprises a binary description of an assay result.
The target data or record and the computer program can be transferred to
secondary
memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or
SDRAM). Targets are ranked according to the degree of correspondence between a
selected
assay characteristic (e.g., binding to a selected affinity moiety) and the
same characteristic of
the query target and results are output via an I/O device. For example, a
central processor
can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000,
SPARC,
MIl'S 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public
domain
molecular biology software package (e.g., UWGCG Sequence Analysis Software,
Darwin); a
data file can be an optical or magnetic disk, a data server, a memory device
(e.g., DRAM,
SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device
can
be a terminal comprising a video display and a keyboard, a modem, an ISDN
terminal
adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or
other suitable I/O
device.
The invention also preferably provides the use of a computer system, e.g.,
which
typically comprises one or more of (1) a computer; (2) a stored bit pattern
encoding a
collection of peptide sequence specificity records obtained by methods of the
inventions,
which may be stored in the computer; (3) a comparison target, such as a query
target; and (4)
a program for alignment and comparison, typically with rank-ordering of
comparison results
on the basis of computed similarity values.
33
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
Characteristics of ovarian cancer-associated proteins
Ovarian cancer proteins of the present invention may be categorized as
secreted
proteins, transmembrane proteins, or intracellular proteins. In one
embodiment, the ovarian
S cancer protein is an intracellular protein. Intracellular proteins may be
found in the
cytoplasm and/or in the nucleus. Intracellular proteins are involved in all
aspects of cellular
function and replication (including, e.g., signaling pathways); aberrant
expression of such
proteins often results in unregulated or disregulated cellular processes. See,
e.g., Alberts, et
al. (eds. 1994) Molecular Biology of the Cell (3d ed.) Garland. For example,
many
intracellular proteins have enzymatic activity such as protein kinase
activity, protein
phosphatase activity, protease activity, nucleotide cyclase activity,
polymerase activity, and
the like. Intracellular proteins can also serve as docking proteins that are
involved in
organizing complexes of proteins, or targeting proteins to various subcellular
localizations,
and are often involved in maintaining the structural integrity of organelles.
An increasingly appreciated concept in characterizing proteins is the presence
in the
proteins of one or more structural motifs for which defined functions have
been attributed.
In addition to the highly conserved sequences found in the enzymatic domain of
proteins,
highly conserved sequences have been identified in proteins that are involved
in protein-
protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-
phosphorylated targets in a sequence dependent manner. PTB domains, which are
distinct
from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind
to proline-
rich targets. In addition, PH domains, tetratricopeptide repeats and WD
domains to name
only a few, have been shown to mediate protein-protein interactions. Some of
these may also
be involved in binding to phospholipids or other second messengers. As will be
appreciated
by one of ordinary skill in the art, these motifs can be identified on the
basis of amino acid
sequence; thus, an analysis of the sequence of proteins may provide insight
into both the
enzymatic potential of the molecule andlor molecules with which the protein
may associate.
One useful database is Pfam (protein families), which is a large collection of
multiple
sequence alignments and hidden Markov models covering many common protein
domains.
Versions are available via the Internet from Washington University in St.
Louis, the Sanger
Center in England, and the I~arolinska Institute in Sweden. See, e.g.,
Bateman, et al. (2000)
Nuc. Acids Res. 28:263-266; Sonnhammer, et al. (1997) Proteins 28:405-420;
Bateman, et al.
(1999) Nuc. Acids Res. 27:260-262; and Sonnhammer, et al. (1998) Nuc. Acids
Res. 26:320-
34
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
322.
In another preferred embodiment, the ovarian cancer sequences are
transmembrane
proteins. Transmembrane proteins are molecules that span a phospholipid
bilayer of a cell.
They may have an intracellular domain, an extracellular domain, or both. The
intracellular
domains of such proteins may have a number of functions including those
already described
for intracellular proteins. For example, the intracellular domain may have
enzymatic activity
and/or may serve as a binding site for additional proteins. Frequently the
intracellular
domain of transmembrane proteins serves both roles. For example certain
receptor tyrosine
kinases have both protein kinase activity and SH2 domains. In addition,
autophosphorylation
of tyrosines on the receptor molecule itself, creates binding sites for
additional SH2 domain
containing proteins.
Transmembrane proteins may contain from one to many transmembrane domains.
For example, receptor tyrosine kinases, certain cytokine receptors, receptor
guanylyl cyclases
and receptor serine/threonine protein kinases contain a single transmembrane
domain.
However, various other proteins including channels and adenylyl cyclases
contain numerous
transmembrane domains. Many important cell surface receptors such as G protein
coupled
receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as
they contain
7 membrane spanning regions. Characteristics of transmembrane domains include
approximately 17 consecutive hydrophobic amino acids that may be followed by
charged
amino acids. Therefore, upon analysis of the amino acid sequence of a
particular protein, the
localization and number of transmembrane domains within the protein may be
predicted (see,
e.g., PSORT web site http://psort.nibb.ac.jp/). Important transmembrane
protein receptors
include, but are not limited to the insulin receptor, insulin-like growth
factor receptor, human
growth hormone receptor, glucose transporters, transferrin receptor, epidermal
growth factor
receptor, low density lipoprotein receptor, epidermal growth factor receptor,
leptin receptor,
interleukin receptors, e.g., IL-1 receptor, IL-2 receptor, etc.
The extracellular domains of transmembrane proteins are diverse; however,
conserved
motifs are found repeatedly among various extracellular domains. Conserved
structure
and/or functions have been ascribed to different extracellular motifs. Many
extracellular
30. domains are involved in binding to other molecules. In one aspect,
extracellular domains are
found on receptors. Factors that bind the receptor domain include circulating
ligands, which
may be peptides, proteins, or small molecules such as adenosine and the like.
For example,
growth factors such as, EGF, FGF, and PDGF are circulating growth factors that
bind to their
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
cognate receptors to initiate a variety of cellular responses. Other factors
include cytokines,
mitogenuc factors, neurotrophic factors and the like. Extracellular domains
also bind to cell-
associated molecules, or may be processed or shed to the blood stream. In this
respect, they
can mediate cell-cell interactions. Cell-associated ligands can be tethered to
the cell, e.g., via
a glycosylphosphatidylinositol (GPl~ anchor, or may themselves be
transmembrane proteins.
Extracellular domains also associate with the extracellular matrix and
contribute to the
maintenance of the cell structure.
Ovarian cancer proteins that are transmembrane are particularly preferred in
the
present invention as they are readily accessible targets for
immunotherapeutics, as are
described herein. In addition, as outlined below, transmembrane proteins can
be also useful
in imaging modalities. Antibodies may be used to label such readily accessible
proteins in
situ. Alternatively, antibodies can also label intracellular proteins, in
which case samples are
typically permeablized to provide access to intracellular proteins. In
addition, some
membrane proteins can be processed to release a soluble protein, or to expose
a residual
fragment. Released soluble proteins may be useful diagnostic markers,
processed residual
protein fragments may be useful ovarian markers of disease.
It will also be appreciated by those in the art that a transmembrane protein
can be
made soluble by removing transmembrane sequences, e.g., through recombinant
methods.
Furthermore, transmembrane proteins that have been made soluble can be made to
be
secreted through recombinant means by adding an appropriate signal sequence.
In another embodiment, the ovarian cancer proteins are secreted proteins; the
secretion of which can'be either constitutive or regulated. These proteins may
have a signal
peptide or signal sequence that targets the molecule to the secretory pathway.
Secreted
proteins are involved in numerous physiological events; e.g., if circulating,
they often serve
to transmit signals to various other cell types. The secreted protein may
function in an
autocrine manner (acting on the cell that secreted the factor), a paracrine
manner (acting on
cells in close proximity to the cell that secreted the factor), an endocrine
manner (acting on
cells at a distance, e.g., secretion into the blood stream), or exocrine
(secretion, e.g., through a
duct or to an adjacent epithelial surface as sweat glands, sebaceous glands,
pancreatic ducts,
lacrimal glands, mammary glands, wax producing glands of the ear, etc.). Thus,
secreted
molecules often find use in modulating or altering numerous aspects of
physiology. Ovarian
cancer proteins that are secreted proteins are particularly preferred as good
diagnostic
markers, e.g., for blood, plasma, serum, or stool tests. Those which are
enzymes may be
36
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
antibody or small molecule therapeutic targets. Others may be useful as
vaccine targets, e.g.,
via CTL mechanisms, as protein or DNA vaccines.
Use of ovarian cancer nucleic acids
As described above, ovarian cancer sequence is initially identified by
substantial
nucleic acid and/or amino acid sequence homology or linkage to the ovarian
cancer
sequences outlined herein. Such homology can be based upon the overall nucleic
acid or
amino acid sequence, and is generally determined as outlined below, using
either homology
programs or hybridization conditions. Typically, linked sequences on a mRNA
are found on
the same molecule.
The ovarian cancer nucleic acid sequences of the invention, e.g., in Table 1-
26, can be
fragments of larger genes, e.g., they are nucleic acid segments. "Genes" in
this context
includes coding regions, non-coding regions, and mixtures of coding and non-
coding regions.
Accordingly, as will be appreciated by those in the art, using the sequences
provided herein,
extended sequences, in either direction, of the ovarian cancer genes can be
obtained, using
techniques well known in the art for cloning either longer sequences or the
full length
sequences; see Ausubel, et al., supra. Much can be done by informatics and
many sequences
can be clustered to include multiple sequences corresponding to a single gene,
e.g., systems
such as UniGene (see, http://www.ncbi.nlm.nih.gov/IJniGene~.
Once the ovarian cancer nucleic acid is identified, it can be cloned and, if
necessary,
its constituent parts recombined to form the entire ovarian cancer nucleic
acid coding regions
or the entire mRNA sequence. Once isolated from its natural source, e.g.,
contained within a
plasmid or other vector or excised as a linear nucleic acid segment, the
recombinant ovarian
cancer nucleic acid can be further-used as a probe to identify and isolate
other ovarian cancer
nucleic acids, e.g., extended coding regions. It can also be used as a
"precursor" nucleic acid
to make modified or variant ovarian cancer nucleic acids and proteins.
The ovarian cancer nucleic acids of the present invention are useful in
several ways.
In a first embodiment, nucleic acid probes to the ovarian cancer nucleic acids
are made and
attached to biochips to be used in screening and diagnostic methods, as
outlined below, or for
administration, e.g., for gene therapy, vaccine, RNAi, and/or antisense
applications.
Alternatively, the ovarian cancer nucleic acids that include coding regions of
ovarian cancer
proteins can be put into expression vectors for the expression of ovarian
cancer proteins,
again for screening puxposes or for administration to a patient.
37
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
In a preferred embodiment, nucleic acid probes to ovarian cancer nucleic acids
(both
the nucleic acid sequences outlined in the figures andlor the complements
thereof are made.
The nucleic acid probes attached to the biochip are designed to be
substantially
complementary to the ovarian cancer nucleic acids, e.g., the target sequence
(either the target
sequence of the sample or to other probe sequences, e.g., in sandwich assays),
such that
hybridization of the target sequence and the probes of the present invention
occurs. As
outlined below, this complementarity need not be perfect; there may be any
number of base
pair mismatches which will interfere with hybridization between the target
sequence and the
single stranded nucleic acids of the present invention. However, if the number
of mutations
is so great that no hybridization can occur under even the least stringent of
hybridization
conditions, the sequence is not a complementary target sequence. Thus, by
"substantially
complementary" herein is meant that the probes are sufficiently complementary
to the target
sequences to hybridize under normal reaction conditions, particularly high
stringency
conditions, as outlined herein.
1 S A nucleic acid probe is generally single stranded but can be partially
single and
partially double stranded. The strandedness of the probe is dictated by the
structure,
composition, and properties of the target sequence. In general, the nucleic
acid probes range
from about 8 to about 100 bases long, with from about 10 to about 80 bases
being preferred,
and from about 30 to about 50 bases being particularly preferred. That is,
generally whole
genes are not used. In some embodiments, much longer nucleic acids can be
used, up to
hundreds of bases.
In a preferred embodiment, more than one probe per sequence is used, with
either
overlapping probes or probes to different sections of the target being used.
That is, two,
three, four or more probes, with three being preferred, are used to build in a
redundancy for a
particular target. The probes can be overlapping (e.g., have some sequence in
common), or
separate. In some cases, PCR primers may be used to amplify signal for higher
sensitivity.
As will be appreciated by those in the art, nucleic acids can be attached or
immobilized to a solid support in a wide variety of ways. By "immobilized" and
grammatical
equivalents herein is meant the association or binding between the nucleic
acid probe and the
solid support is sufficient to be stable under the conditions of binding,
washing, analysis, and
removal as outlined below. The binding can typically be covalent or non-
covalent. By "non
covalent binding" and grammatical equivalents herein is meant one or more of
electrostatic,
hydrophilic, and hydrophobic interactions. Included in non-covalent binding is
the covalent
38
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
attachment of a molecule, such as, streptavidin to the support and the non-
covalent binding of
the biotinylated probe to the streptavidin. By "covalent binding" and
grammatical
equivalents herein is meant that the two moieties, the solid support and the
probe, are
attached by at least one bond, including sigma bonds, pi bonds and
coordination bonds.
Covalent bonds can be formed directly between the probe and the solid support
or can be
formed by a cross linker or by inclusion of a specific reactive group on
either the solid
support or the probe or both molecules. Immobilization may also involve a
combination of
covalent and non-covalent interactions.
In general, the probes are attached to the biochip in a wide variety of ways,
as will be
appreciated by those in the art. As described herein, the nucleic acids can
either be
synthesized first, with subsequent attachment to the biochip, or can be
directly synthesized on
the biochip.
The biochip comprises a suitable solid substrate. By "substrate" or "solid
support" or
other grammatical equivalents herein is meant a material that can be modified
to contain
1 S discrete individual sites appropriate for the attachment or association of
the nucleic acid
probes and is amenable to at least one detection method. As will be
appreciated by those in
the art, the number of possible substrates are very large, and include, but
are not limited to,
glass and modified or functionalized glass, plastics (including acrylics,
polystyrene and
copolymers of styrene and other materials, polypropylene, polyethylene,
polybutylene,
polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose,
resins, silica or silica-
based materials including silicon and modified silicon, carbon, metals,
inorganic glasses,
plastics, etc. In general, the substrates allow optical detection and do not
appreciably
fluoresce. See, e.g., W00055627 Reusable Low Fluorescent Plastic Biochip.
Generally the substrate is planar, although as will be appreciated by those in
the art,
other configurations of substrates may be used as well. For example, the
probes may be
placed on the inside surface of a tube, fox flow-through sample analysis to
minimize sample
volume. Similarly, the substrate may be flexible, such as a flexible foam,
including closed
cell foams made of particular plastics.
In a preferred embodiment, the surface of the biochip and the probe may be
derivatized with chemical functional groups for subsequent attachment of the
two. Thus, e.g.,
the biochip is derivatized with a chemical functional group including, but not
limited to,
amino groups, carboxyl groups, oxo groups and thiol groups, with amino groups
being
particularly preferred. . Using these functional groups, the probes can be
attached using
39
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
functional groups on the probes. For example, nucleic acids containing amino
groups can be
attached to surfaces comprising amino groups, e.g., using linkers as are known
in the art; e.g.,
homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce
Chemical Company
catalog, technical section on cross-linkers, pages 155-200). In addition, in
some cases,
additional linkers, such as alkyl groups (including substituted and
heteroalkyl groups) may be
used.
In this embodiment, oligonucleotides are synthesized as is known in the art,
and then
attached to the surface of the solid support. As will be appreciated by those
skilled in the art,
either the 5' or 3' terminus may be attached to the solid support, or
attachment may be via an
internal nucleoside.
In another embodiment, the immobilization to the solid support may be very
strong,
yet non-covalent. For example, biotinylated oligonucleotides can be made,
which bind to
surfaces covalently coated with streptavidin, resulting in attachment.
Alternatively, the oligonucleotides may be synthesized on the surface, as is
known in
the art. For example, photoactivation techniques utilizing photopolymerization
compounds
and techniques are used. In a preferred embodiment, the nucleic acids can be
synthesized in
situ, using well known photolithographic techniques, such as those described
in WO
95125116; WO 95!35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and
references cited
within, all of which are expressly incorporated by reference; these methods of
attachment
form the basis of the Affymetrix GeneChipTM technology.
Often, amplification-based assays are performed to measure the expression
level of
ovarian cancer-associated sequences. These assays are typically performed in
conjunction
with reverse transcription. In such assays, an ovarian cancer-associated
nucleic acid
sequence acts as a template in an amplification reaction (e.g., Polymerase
Chain Reaction, or
PCR). In a quantitative amplification, the amount of amplification product
will be
proportional to the amount of template in the original sample. Comparison to
appropriate
controls provides a measure of the amount of ovarian cancer-associated RNA.
Methods of
quantitative amplification are well known to those of skill in the art.
Detailed protocols for
quantitative PCR are available. See, e.g., Innis, et a!.(1990) PCR Protocols:
A Guide to
Methods and Applications Academic Press.
In some embodiments, a TaqMan based assay is used to measure expression.
TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5'
fluorescent
dye and a 3' quenching agent. The probe hybridizes to a PCR product, but
cannot itself be
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
extended due to a blocking agent at the 3' end. When the PCR product is
amplified in
subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq,
results in the
cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye
and the 3'
quenching agent, thereby resulting in an increase in fluorescence as a
function of
amplification (see, e.g., literature provided by Perkin-Elmer, e.g.,
www2.perkin-elmer.com).
Other suitable amplification methods include, but are not limited to, ligase
chain
reaction (LCR; see Wu and Wallace (1989) Genomics 4:560-569; Landegren, et al.
(1988)
Science 241:1077-1980; and Barringer, et al. (1990) Gene 89:117-122),
transcription
amplification (Kwoh, et al. (1989) Proc. Naf1 Acad. Sci. USA 86:1173-1177),
self sustained
sequence replication (Guatelli, et al. (1990) Proc. Nat'1 Acad. Sci. USA
87:1874-1878), dot
PCR, linker adapter PCR, etc.
Expression of ovarian cancer proteins from nucleic acids
In a preferred embodiment, ovarian cancer nucleic acids, e.g., encoding
ovarian
cancer proteins are used to make a variety of expression vectors to express
ovarian cancer
proteins which can then be used in screening assays, as described below.
Expression vectors
and recombinant DNA technology are well known and are used to express
proteins. See, e.g.,
Ausubel, supra; and Fernandez and Hoeffler (eds. 1999) Gene Expression Systems
Academic
Press. The expression vectors may be either self replicating extrachromosomal
vectors or
vectors which integrate into a host genome. Generally, these expression
vectors include
transcriptional and translational regulatory nucleic acid operably linked to
the nucleic acid
encoding the ovarian cancer protein. The term "control sequences" refers to
DNA sequences
used for the expression of an operably linked coding sequence in a particular
host organism.
Control sequences that are suitable for prokaryotes, e.g., include a promoter,
optionally an
operator sequence, and a ribosome binding site. Eukaryotic cells are known to
utilize
promoters, polyadenylation signals, and enhancers.
Nucleic acid is "operably linked" when it is placed into a functional
relationship with
another nucleic acid sequence. For example, DNA for a pre-sequence or
secretory leader is
operably linked to DNA for a polypeptide if it is expressed as a pre-protein
that participates
in the secretion of the.polypeptide; a promoter or enhancer is operably linked
to a coding
sequence if it affects the transcription of the sequence; a ribosome binding
site is operably
linked to a coding sequence if it is positioned so as to facilitate
translation; and two sequences
may be operably linked when they are physically part of the same polymer.
Generally,
41
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
"operably linked" means that the DNA sequences being linked are contiguous,
and, in the
case of a secretory leader, contiguous and in reading phase. However,
enhancers do not have
to be contiguous. Linking is typically accomplished by ligation at convenient
restriction
sites. If such sites do not exist, synthetic oligonucleotide adaptors or
linkers are used in
accordance with conventional practice. Transcriptional and translational
regulatory nucleic
acid will generally be appropriate to the host cell used to express the
ovarian cancer protein.
Numerous types of appropriate expression vectors, and suitable regulatory
sequences are
known in the art for a variety of host cells.
In general, transcriptional and translational regulatory sequences may
include, but are
not limited to, promoter sequences, ribosomal binding sites, transcriptional
start and stop
sequences, translational start and stop sequences, and enhancer or activator
sequences. In a
preferred embodiment, the regulatory sequences include a promoter and
transcriptional start
and stop sequences.
Promoter sequences typically encode constitutive or inducible promoters. The
promoters may be naturally occurring promoters or hybrid promoters. Hybrid
promoters,
which combine elements of more than one promoter, are also known in the art,
and are useful
in the present invention.
In addition, an expression vector may comprise additional elements. For
example, the
expression vector may have two replication systems, thus allowing it to be
maintained in two
organisms, e.g., in mammalian or insect cells for expression and in a
procaryotic host for
cloning and amplification. Furthermore, for integrating expression vectors,
the expression
vector contains at least one sequence homologous to the host cell genome, and
preferably two
homologous sequences which flank the expression construct. The integrating
vector may be
directed to a specific locus in the host cell by selecting the appropriate
homologous sequence
for inclusion in the vector. Constructs for integrating vectors are available.
See, e.g.,
Fernandez and Hoeffler, supra.
In addition, in a preferred embodiment, the expression vector contains a
selectable
marker gene to allow the selection of transformed host cells. Selection genes
are well known
in the art and will vary with the host cell used.
The ovarian cancer proteins of the present invention are produced by culturing
a host
cell transformed with an expression vector containing nucleic acid encoding an
ovarian
cancer protein, under the appropriate conditions to induce or cause expression
of the ovarian
cancer protein. Conditions appropriate for ovarian cancer protein expression
will vary with
42
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
the choice of the expression vector and the host cell, and will be easily
ascertained by one
skilled in the art through routine experimentation or optimization. For
example, the use of
constitutive promoters in the expression vector will require optimizing the
growth and
proliferation of the host cell, while the use of an inducible promoter
requires the appropriate
growth conditions for induction. In addition, in some embodiments, the timing
of the harvest
is important. For example, the baculovirus systems used in insect cell
expression are lytic
viruses, and thus harvest time selection can be crucial for product yield.
Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and
insect and
animal cells, including mammalian cells. Of particular interest are
Saccharomyces cerevisiae
and other yeasts, E. coli, Bacillus subtilis, Sf~ cells, C129 cells, 293
cells, Neurospora, BHI~,
CHO, COS, HeLa cells, HCTVEC (human umbilical vein endothelial cells), THP1
cells (a
macrophage cell line) and various other human cells and cell lines.
In a preferred embodiment, the ovarian cancer proteins are expressed in
mammalian
cells. Mammalian expression systems are also known in the art, and include
retroviral and
adenoviral systems. One expression vector system is a retroviral vector system
such as is
generally described in PCT/US97/01019 and PCT/US97/01048, both of which are
hereby
expressly incorporated by reference. Of particular use as mammalian promoters
are the
promoters from mammalian viral genes, since the viral genes are often highly
expressed and
have a broad host range. Examples include the SV40 early promoter, mouse
mammary tumor
virus LTR promoter, adenovirus major late promoter, herpes simplex virus
promoter, and the
CMV promoter. See, e.g., Fernandez and Hoeffler, supra. Typically,
transcription
termination and polyadenylation sequences recognized by mammalian cells are
regulatory
regions located 3' to the translation stop codon and thus, together with the
promoter elements,
flank the coding sequence. Examples of transcription terminator and
polyadenylation signals
include those derived form SV40.
The methods of introducing exogenous nucleic acid into mammalian hosts, as
well as
other hosts, is well known in the art, and will vary with the host cell used.
Techniques
include dextran-mediated transfection, calcium phosphate precipitation,
polybrene mediated
transfection, protoplast fusion, electroporation, viral infection,
encapsulation of the
30. polynucleotide(s) in liposomes, and direct microinjection of the DNA into
nuclei.
In a preferred embodiment, ovarian cancer proteins are expressed in bacterial
systems.
Bacterial expression systems are well known in the art. Promoters from
bacteriophage may
also be used and are known in the art. In addition, synthetic promoters and
hybrid promoters
43
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
are also useful; e.g., the tac promoter is a hybrid of the trp and lac
promoter sequences.
Furthermore, a bacterial promoter can include naturally occurring promoters of
non-bacterial
origin that have the ability to bind bacterial RNA polymerase and initiate
transcription. In
addition to a functioning promoter sequence, an efficient ribosome binding
site is desirable.
The expression vector may also include a signal peptide sequence that provides
for secretion
of the ovarian cancer protein in bacteria. The protein is either secreted into
the growth media
(gram-positive bacteria) or into the periplasmic space, located between the
inner and outer
membrane of the cell (gram-negative bacteria). The bacterial expression vector
may also
include a selectable marker gene to allow for the selection of bacterial
strains that have been
transformed. Suitable selection genes include genes which render the bacteria
resistant to
drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin,
and
tetracycline. Selectable markers also include biosynthetic genes, such as
those in the
histidine, tryptophan, and leucine biosynthetic pathways. These components are
assembled
into expression vectors. Expression vectors for bacteria are well known in the
art, and
include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and
Streptococcus
lividans, among others. See Fernandez and Hoeffler, supra. The bacterial
expression vectors
are transformed into bacterial host cells using techniques well known ~in the
art, such as
calcium chloride treatment, electroporation, and others.
In one embodiment, ovarian cancer proteins are produced in insect cells.
Expression
vectors for the transformation of insect cells, and in particular, baculovirus-
based expression
vectors, are well known in the art.
In a preferred embodiment, an ovarian cancer protein is produced in yeast
cells.
Yeast expression systems are well known in the art, and include expression
vectors for
Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula
polymorpha,
Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris,
Schizosaccharomyces pombe, and Yarrowia lipolytica.
The ovarian cancer protein may also be made as a fusion protein, using
techniques
well known in the art. Thus, e.g., for the creation of monoclonal antibodies,
if the desired
epitope is small, the ovarian cancer protein may be fused to a carrier protein
to form an
immunogen. Alternatively, the ovarian cancer protein may be made as a fusion
protein to
increase expression, or for other reasons. For example, when the ovarian
cancer protein is an
ovarian cancer peptide, the nucleic acid encoding the peptide may be linked to
other nucleic
acid for expression purposes.
44
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
In a preferred embodiment, the ovarian cancer protein is purified or isolated
after
expression. Ovarian cancer proteins may be isolated or purified in a variety
of ways known
to those skilled in the art depending on what other components are present in
the sample.
Standard purification methods include electrophoretic, molecular,
immunological and
chromatographic techniques, including ion exchange, hydrophobic, affinity, and
reverse-
phase HPLC chromatography, and chromatofocusing. For example, the ovarian
cancer
protein may be purified using a standard anti-ovarian cancer protein antibody
column.
Ultrafiltration and diafiltration techniques, in conjunction with protein
concentration, are also
useful. For general guidance in suitable purification techniques, see Scopes
(192) Protein
Purification Springer-Verlag.,, The degree of purification necessary will vary
depending on
the use of the ovarian cancer protein. In some instances no purification will
be necessary.
Once expressed and purified if necessary, the ovarian cancer proteins and
nucleic
acids are useful in a number of applications. They may be used as
immunoselection reagents,
as vaccine reagents, as screening agents, etc.
Variants of ovarian cancer proteins
In one embodiment, the ovarian cancer proteins are derivative or variant
ovarian
cancer proteins as compared to the wild-type sequence. That is, as outlined
more :fully below,
the derivative ovarian cancer peptide will often contain at least one amino
acid substitution,
deletion or insertion, with amino acid substitutions being particularly
preferred. The amino
acid substitution, insertion, or deletion may occur at most any residue within
the ovarian
cancer peptide.
Also included within one embodiment of ovarian cancer proteins of the present
invention are amino acid sequence variants. These variants typically fall into
one or more of
three classes: substitutional, insertional or deletional variants. These
variants ordinarily are
prepared by site specific mutagenesis of nucleotides in the DNA encoding the
ovarian cancer
protein, using cassette or PCR mutagenesis or other techniques.well known in
the art, to
produce DNA encoding the variant, and thereafter expressing the DNA in
recombinant cell
culture as outlined above. However, variant ovarian cancer protein fragments
having up to
about 100-150 residues may be prepared by in vitro synthesis using established
techniques.
Amino acid sequence variants are characterized by the predetermined nature of
the variation,
a feature that sets them apart from naturally occurring allelic or
interspecies variation of the
ovarian cancer protein. amino acid sequence. The variants typically exhibit
the same
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
qualitative biological activity as the naturally occurnng analogue, although
variants can also
be selected which have modified characteristics as will be more fully outlined
below.
While the site or region for introducing an amino acid sequence variation is
predetermined, the mutation per se need not be predetermined. For example, in
order to
optimize the performance of a mutation at a given site, random mutagenesis may
be
conducted at the target codon or region and the expressed ovarian cancer
variants screened
for the optimal combination of desired activity. Techniques for making
substitution
mutations at predetermined sites in DNA having a known sequence are well
known, e.g.,
M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done
using
assays of ovarian cancer protein activities.
Amino acid substitutions are typically of single residues; insertions usually
will be on
the order of from about 1 to 20 amino acids, although considerably larger
insertions may be
tolerated. Deletions range from about 1 to about 20 residues, although in some
cases
deletions may be much larger.
Substitutions, deletions, insertions or any combination thereof may be used to
arrive
at a final derivative. Generally these changes are done on a few amino acids
to minimize the
alteration of the molecule. However, larger changes may be tolerated in
certain
circumstances. When small alterations in the characteristics of the ovarian
cancer protein are
desired, substitutions are generally made in accordance with the amino acid
substitution
relationships provided in the definition section.
The variants typically exhibit the same qualitative biological activity and
will elicit
the same immune response as the naturally-occurring analog, although variants
also are
selected to modify the characteristics of the ovarian cancer proteins as
needed. Alternatively,
the variant may be designed such that the biological activity of the ovarian
cancer protein is
altered. For example, glycosylation sites may be altered or removed. '
Substantial changes in function or immunological identity are made by
selecting
substitutions that are less conservative than those described above. For
example,
substitutions may be made which more significantly affect: the structure of
the polypeptide
backbone in the area of the alteration, for example the alpha-helical or beta-
sheet structure;
the charge or hydrophobicity of the molecule at the target site; or the bulk
of the side chain.
The substitutions which in general are expected to produce the greatest
changes in the
polypeptide's properties are those in which (a) a hydrophilic residue, e.g.,
serine or threonine
is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine,
phenylalanine,
46
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
valine, or alanine; (b) a cysteine or proline is substituted for (or by) any
other residue; (c) a
residue having an electropositive side chain, e.g., lysine, arginine, or
histidine, is substituted
for (or by) an electronegative residue, e.g., glutamic or aspartic acid; (d) a
residue having a
bulky side chain, e.g., phenylalanine, is substituted for (or by) one not
having a side chain,
e.g., glycine; or (e) a proline residue is incorporated or substituted, which
changes the degree
of rotational freedom of the peptidyl bond.
Covalent modifications of ovarian cancer polypeptides are included within the
scope
of this invention. One type of covalent modification includes reacting
targeted amino acid
residues of an ovarian cancer polypeptide with an organic derivatizing agent
that is capable of
reacting with selected side chains or the N-or C-terminal residues of an
ovarian cancer
polypeptide. Derivatization with bifunctional agents is useful, for instance,
for crosslinking
ovarian cancer polypeptides to a water-insoluble support matrix or surface for
use in the
method for purifying anti-ovarian cancer polypeptide antibodies or screening
assays, as is
more fully described below. Commonly used crosslinking agents include, e.g.,
1,1-
bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters,
e.g., esters
with 4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters
such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such
as bis-N-
maleimido-1,8-octane and agents such as methyl-3-((p-
azidophenyl)dithio)propioimidate.
Other modifications include deamidation of glutamine and asparagine residues
to the
corresponding glutamic and aspartic acid residues, respectively, hydroxylation
of proline and
lysine, phosphorylation of hydroxyl groups of serine, threonine, or tyrosine
residues,
methylation of the amino groups of the lysine, arginine, and histidine side
chains (e.g., pp.
79-86, Creighton (1983) Proteins: Structure and Molecular Pro ep rties
Freeman), acetylation
o.f the N-terminal amine, and amidation of a C-terminal carboxyl group.
Another type of covalent modification of the ovarian cancer polypeptide
included
within the scope of this invention comprises altering the native glycosylation
pattern of the
polypeptide. "Altering the native glycosylation pattern" is intended for
purposes herein to
mean deleting one or more carbohydrate moieties found in native sequence
ovarian cancer
polypeptide, and/or adding one or more glycosylation sites that are not
present in the native
sequence ovarian cancer polypeptide. Glycosylation patterns can be altered in
many ways.
For example the use of different cell types to express ovarian cancer-
associated sequences
can result in different glycosylation patterns.
Addition of glycosylation sites to ovarian cancer polypeptides may also be
47
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
accomplished by altering the amino acid sequence thereof. The alteration may
be made, e.g.,
by the addition of, or substitution by, one or more serine or threonine
residues to the native
sequence ovarian cancer polypeptide (for O-linked glycosylation sites). The
ovarian cancer
amino acid sequence may optionally be altered through changes at the DNA
level,
particularly by mutating the DNA encoding the ovarian cancer polypeptide at
pre-selected
bases such that colons are generated that will translate into the desired
amino acids.
Another means of increasing the number of carbohydrate moieties on the ovarian
cancer polypeptide is by chemical or enzymatic coupling of glycosides to the
polypeptide.
See, e.g., WO 87105330, and pp. 259-306 in Aplin and Wriston (1981) CRC Crit.
Rev.
Biochem. CRC Press.
Removal of carbohydrate moieties present on the ovarian cancer polypeptide may
be
accomplished chemically or enzymatically or by mutational substitution of
colons encoding
for amino acid residues that serve as targets for glycosylation. Chemical
deglycosylation
techniques are applicable. See, e.g., Sojar and Bahl (1987) Arch. Biochem.
Biophys. 259:52-
IS 57; and Edge, et al. (1981) Anal. Biochem. 118:131-137. Enzymatic cleavage
of
carbohydrate moieties on polypeptides can be achieved by the use of a variety
of endo-and
exo-glycosidases. See, e.g., Thotakura, et al. (1987) Meth. Enzymol., 138:350-
359.
Another type of covalent modification of ovarian cancer comprises linking the
ovarian cancer polypeptide to one of a variety of non-proteinaceous polymers,
e.g.,
polyethylene glycol, polypropylene glycol, or polyoxyalkylene. See, e.g., U.S.
Patent Nos.
4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337.
Ovarian cancer polypeptides of the present invention may also be modified in a
way
to form chimeric molecules, e.g., comprising an ovarian cancer polypeptide
fused to another
heterologous polypeptide or amino acid sequence. In one embodiment, such a
chimeric
molecule comprises a fusion of an ovarian cancer polypeptide with a tag
polypeptide which
provides an epitope to which an anti-tag antibody can selectively bind. The
epitope tag is
generally placed at the amino-or carboxyl-terminus of the ovarian cancer
polypeptide. The
presence of such epitope-tagged forms of an ovarian cancer polypeptide can be
detected
using an antibody against the tag polypeptide. Also, provision of the epitope
tag enables the
ovarian cancer polypeptide to be readily purified by affinity purification
using an anti-tag
antibody or another type of affinity matrix that binds to the epitope tag. In
an alternative
embodiment, the chimeric molecule may comprise a fusion of an ovarian cancer
polypeptide
with an immunoglobulin or a particular region of an immunoglobulin. For a
bivalent form of
48
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
the chimeric molecule, such a fusion could be to the Fc region of an IgG
molecule.
Various tag polypeptides and their respective antibodies are well known in the
art.
Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-
gly) tags; His6
and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5
(Field, et al.
(1988) Mol. Cell. Biol. 8:2159-2165); the c-myc tag and the 8F9, 3C7, 6E10,
G4, B7, and
9E10 antibodies thereto (Evan, et al. (1985) Mol. Cell. Biol. 5:3610-3616);
and the Herpes
Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky, et al.
(1990) Protein
Engineering 3:547-553). Other tag polypeptides include, e.g., the Flag-peptide
(Hopp, et al.
(1988) BioTechnolo~y 6:1204-1210); the KT3 epitope peptide (Martin, et al.
(1992) Science
255:192-194); tubulin epitope peptide (Skinner, et al. (1991) J. Biol. Chem.
266:15163-
15166); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al. (1990)
Proc. Nat'1
Acad. Sci. USA 87:6393-6397).
Also included are other ovarian cancer proteins of the ovarian cancer family,
and
ovarian cancer proteins from other organisms, which are cloned and expressed
as outlined
below. Thus, probe or degenerate polymerase chain reaction (PCR) primer
sequences may be
used to find other related ovarian cancer proteins from humans or other
organisms. As will
be appreciated by those in the art, particularly useful probe and/or PCR
primer sequences
include the unique areas of the ovarian cancer nucleic acid sequence. As is
generally known
in the art, preferred PCR primers are from about 15 to about 35 nucleotides in
length, with
from about 20 to about 30 being preferred, and may contain inosine as needed.
The
conditions for the PCR reaction are well known in the art (e.g., Innis, PCR
Protocols, supra).
Antibodies to ovarian cancer proteins
In a preferred embodiment, when the ovarian cancer protein is to be used to
generate
antibodies, e.g., for immunotherapy or immunodiagnosis, the ovarian cancer
protein should
share at least one epitope or determinant with the full length protein. By
"epitope" or
"determinant" herein is typically meant a portion of a protein which will
generate and/or bind
an antibody or T-cell receptor in the context of MHC. Thus, in most instances,
antibodies
made to a smaller ovarian cancer protein will be able to bind to the full-
length protein,
particularly linear epitopes. In a preferred embodiment, the epitope is
unique; that is,
antibodies generated to a unique epitope show little or no cross-reactivity.
Methods of preparing polyclonal antibodies are known to the skilled artisan
(e.g.,
Coligan, supra; and Harlow and Lane, supra). Polyclonal antibodies can be
raised in a
49
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
mammal, e.g., by one or more injections of an immunizing agent and, if
desired, an adjuvant.
Typically, the immunizing agent andlor adjuvant will be injected in the mammal
by multiple
subcutaneous or intraperitoneal injections. The immunizing agent may include a
protein
encoded by a nucleic acid of the figures or fragment thereof or a fusion
protein thereof. It
may be useful to conjugate the immunizing agent to a protein known to be
immunogenic in
the mammal being immunized. Examples of such immunogenic proteins include but
are not
limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and
soybean
trypsin inhibitor. Examples of adjuvants which may be employed include
Freund's complete
adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose
dicorynomycolate). The immunization protocol may be selected by one skilled in
the art
without undue experimentation.
The antibodies may, alternatively, be monoclonal antibodies. Monoclonal
antibodies
may be prepared using hybridoma methods, such as those described by Kohler and
Milstein
(1975) Nature 256:495-497. In a hybridoma method, a mouse, hamster, or other
appropriate
16 host animal, is typically immunized with an immunizing agent to elicit
lymphocytes that
produce or are capable of producing antibodies that will specifically bind to
the immunizing
agent. Alternatively, the lymphocytes may be immunized in vitro. The
immunizing agent
will typically include a polypeptide encoded by a nucleic acid of Tables 1-26
or fragment
thereof, or a fusion protein thereof. Generally, either peripheral blood
lymphocytes ("PBLs")
are used if cells of human origin are desired, or spleen cells or lymph node
cells are used if
non-human mammalian sources are desired. The lymphocytes are then fused with
an
immortalized cell line using a suitable fusing agent, such as polyethylene
glycol, to form a
hybridoma cell (e.g., pp. 59-103 in Goding (1986) Monoclonal Antibodies:
Principles and
Practice Academic Press). Immortalized cell lines are usually transformed
mammalian cells,
particularly myeloma cells of rodent, bovine and human origin. Usually, rat or
mouse
myeloma cell lines are employed. The hybridoma cells may be cultured in a
suitable culture
medium that preferably contains one or more substances that inhibit the growth
or survival of
the unfused, immortalized cells. For example, if the parental cells lack the
enzyme
hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture
medium
for the hybridomas typically will include hypoxanthine, aminopterin, and
thymidine ("HAT
medium"), which substances prevent the growth of HGPRT-deficient cells.
In one embodiment, the antibodies are bispecific antibodies. Bispecific
antibodies are
monoclonal, preferably human or humanized, antibodies that have binding
specificities for at
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
least two different antigens ar that have binding specificities for two
epitopes on the same
antigen. In one embodiment, one of the binding specificities is for a protein
encoded~by a
nucleic acid Table 1-26 or a fragment thereof, the other one is for any other
antigen, and
preferably for a cell-surface protein or receptor or receptor subunit,
preferably one that is
tumor specific. Alternatively, tetramer-type technology may create multivalent
reagents.
In a preferred embodiment, the antibodies to ovarian cancer protein are
capable of
reducing or eliminating a biological function of an ovarian cancer protein, as
is described
below. That is, the addition of anti-ovarian cancer protein antibodies (either
polyclonal or
preferably monoclonal) to ovarian cancer tissue (or cells containing ovarian
cancer) may
reduce or eliminate the ovarian cancer. Generally, at least a 25% decrease in
activity,
growth, size or the like is preferred, with at least about 50% being
particularly preferred and
about a 95-100% decrease being especially preferred.
In a preferred embodiment the antibodies to the ovarian cancer proteins are
humanized antibodies (e.g., Xenerex Biosciences; Medarex, Inc.; Abgenix, Inc.;
Protein
Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are
chimeric
molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such
as Fv,
Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which
contain
minimal sequence derived from non-human immunoglobulin. Humanized antibodies
include
human immunoglobulins (recipient antibody) in which residues from a
complementary
determining region (CDR) of the recipient are replaced by residues from a CDR
of a non-
human species (donor antibody) such as mouse, rat or rabbit having the desired
specificity,
affinity and capacity. In some instances, Fv framework residues of the human
immunoglobulin are replaced by corresponding non-human residues. Humanized
antibodies
may also comprise residues which are found neither in the recipient antibody
nor in the
imported CDR or framework sequences. In general, a humanized antibody will
comprise
substantially all of at least one, and typically two, variable domains, in
which all or
substantially all of the CDR regions correspond to those of a non-human
immunoglobulin
and all or substantially all of the framework (FR) regions are those of a
human
immunoglobulin consensus sequence. The humanized antibody optimally also will
comprise
at least a portion of an immunoglobulin constant region (Fc), typically that
of a human
immunoglobulin. Humanization can be essentially performed following the method
of
Winter and co-workers, e.g., by substituting rodent CDRs or CDR sequences for
the
51
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
corresponding sequences of a human antibody. See, e.g., Jones, et al. (1986)
Nature 321:522-
525; Riechmann, et al. (1988) Nature 332:323-329; Presta (1992) Curr. Op.
Struct. Biol.
2:593-596; and Verhoeyen, et al. (1988) Science 239:1534-1536). Accordingly,
such
humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567),
wherein
substantially less than an intact human variable domain has been substituted
by the
corresponding sequence from a non-human species.
Human antibodies can also be produced using various techniques known in the
art,
including phage display libraries (see, e.g., Hoogenboom and Winter (1991) J.
Mol. Biol.
227:381-388; and Marks, et al. (1991) J. Mol. Biol. 222:581-597) or human
monoclonal
antibodies (see, e.g., p. 77, Cole, et al. in Reisfeld and Sell (1985)
Monoclonal Antibodies
and Cancer Therany Liss; and Boerner, et al. (1991) J. Immunol. 147:86-95).
Similarly,
human antibodies can be made by introducing of human immunoglobulin loci into
transgenic
animals, e.g., mice in which the endogenous immunoglobulin genes have been
partially or
completely inactivated. Upon challenge, human antibody production is observed,
which
closely resembles that seen in humans in all respects, including gene
rearrangement,
assembly, and antibody repertoire. See, e.g., U.S. Patent Nos. 5,545,807;
5,545,806;
5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks, et al. (1992)
Bio/Technolo~y 10:779-
783; Lonberg, et al. (1994) Nature 368:856-859; Mornson (1994) Nature 368:812-
13;
Neuberger (1996) Nature Biotechnolo~y 14:826 commenting on Fishwild, et al.
(1996)
Nature Biotechnolo~y 14:845-51; and Lonberg and Huszar (1995) Intern. Rev.
Immunol.
13:65-93.
By immunotherapy is meant treatment of ovarian cancer, e.g., with an antibody
raised
against ovarian cancer proteins. As used herein, immunotherapy can be passive
or active.
Passive immunotherapy as defined herein is the passive transfer of antibody to
a recipient
(patient). Active immunization is the induction of antibody and/or T-cell
responses in a
recipient (patient). Induction of an immune response is the result of
providing the recipient
with an antigen to which antibodies are raised. The antigen may be provided by
inj ecting a
polypeptide against which antibodies are desired to be raised into a
recipient, or contacting
the recipient with a nucleic acid capable of expressing the antigen and under
conditions for
expression of the antigen, leading to an immune response.
In a preferred embodiment the ovarian cancer proteins against which antibodies
are
raised are secreted proteins as described above. Without being bound by
theory, antibodies
used for treatment, bind and prevent the secreted protein from binding to its
receptor, thereby
52
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
inactivating the secreted ovarian cancer protein.
In another preferred embodiment, the ovarian cancer protein to which
antibodies are
raised is a transmembrane protein. Without being bound by theory, antibodies
used for
treatment, bind the extracellular domain of the ovarian cancer protein and
prevent it from
binding to other proteins, such as circulating ligands or cell-associated
molecules. The
antibody may cause down-regulation of the transmembrane ovarian cancer
protein. As will
be appreciated by one of ordinary skill in the art, the antibody may be a
competitive, non-
competitive or uncompetitive inhibitor of protein binding to the extracellular
domain of the
ovarian cancer protein. The antibody is also an antagonist of the ovarian
cancer protein.
Further, the antibody prevents activation of the transmembrane ovarian cancer
protein. In
one aspect, when the antibody prevents the binding of other molecules to the
ovarian cancer
protein, the antibody prevents growth of the cell. The antibody may also be
used to target or
sensitize the cell to cytotoxic agents, including, but not limited to TNF-a,
TNF-(3, IL-1, INF
y, and IL-2, or chemotherapeutic agents including SFU, vinblastine,
actinomycin D, cisplatin,
1 S methotrexate, and the like. In some instances the antibody belongs to a
sub-type that
activates serum complement when complexed with the transmembrane protein
thereby
mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, ovarian
cancer is
treated by administering to a patient antibodies directed against the
transmembrane ovarian
cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin
payload, or
otherwise provide means to locally ablate cells.
In another preferred embodiment, the antibody is conjugated to an effector
moiety.
The effector moiety can be any number of molecules, including labeling
moieties such as
radioactive labels or fluorescent labels, or can be a therapeutic moiety. In
one aspect the
therapeutic moiety is a small molecule that modulates the activity of the
ovarian cancer
protein. In another aspect the therapeutic moiety modulates the activity of
molecules
associated with or in close proximity to the ovarian cancer protein. The
therapeutic moiety
may inhibit enzymatic activity such as protease or collagenase or protein
kinase activity
associated with ovarian cancer.
In a preferred embodiment, the therapeutic moiety can also be a cytotoxic
agent. In
this method, targeting the cytotoxic agent to ovarian cancer tissue or cells,
results in a
reduction in the number of afflicted cells, thereby reducing symptoms
associated with ovarian
cancer. Cytotoxic agents are numerous and varied and include, but are not
limited to,
53
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins
and their
corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A
chain, abrin A
chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents
also include
radiochemicals made by conjugating radioisotopes to antibodies raised against
ovarian cancer
proteins, or binding of a radionuclide to a chelating agent that has been
covalently attached to
the antibody. Targeting the therapeutic moiety to transmembrane ovarian cancer
proteins not
only serves to increase the local concentration of therapeutic moiety in the
ovarian cancer
afflicted area, but also serves to reduce deleterious side effects that may be
associated with
the untargeted therapeutic moiety.
Tn another preferred embodiment, the ovarian cancer protein against which the
antibodies are raised is an intracellular protein. In this case, the antibody
may be conjugated
to a protein which facilitates entry into the cell. In one case, the antibody
enters the cell by
endocytosis. In another embodiment, a nucleic acid encoding the antibody is
administered to
the individual or cell. Moreover, wherein the ovarian cancer protein can be
targeted within a
cell, e.g., the nucleus, an antibody thereto contains a signal for that target
localization, e.g., a
nuclear localization signal.
The ovarian cancer antibodies of the invention specifically bind to ovarian
cancer
proteins. By "specifically bind" herein is meant that the antibodies bind to
the protein with a
I~ of at least about 0.1 mM, more usually at least about 1 pM, preferably at
least about 0.1
p,M or better, and most preferably, 0.01 p.M or better. Selectivity of binding
is also
important.
Detection of ovarian cancer sequence for diagnostic and therapeutic
applications
In one aspect, the RNA expression levels of genes are determined for different
cellular states in the ovarian cancer phenotype. Expression levels of genes in
normal tissue
(e.g., not undergoing ovarian cancer) and in ovarian cancer tissue (and in
some cases, for
varying seventies of ovarian cancer that relate to prognosis, as outlined
below, or in non-
malignant disease are evaluated to provide expression profiles. An expression
profile of a
particular cell state or point of development is essentially a "fingerprint"
of the state of the
cell. While two states may have any particular gene similarly expressed, the
evaluation of a
number of genes simultaneously allows the generation of a gene expression
profile that is
reflective of the state of the cell. By comparing expression profiles of cells
in different states,
54
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
information regarding which genes are important (including both up- and down-
regulation of
genes) in each of these states is obtained. Then, diagnosis may be performed
or confirmed to
determine whether a tissue sample has the gene expression profile of normal or
cancerous
tissue. This will provide for molecular diagnosis of related conditions.
"Differential expression," or grammatical equivalents as used herein, refers
to
qualitative or quantitative differences in the temporal and/or cellular gene
expression
patterns within and among cells and tissue. Thus, a differentially expressed
gene can
qualitatively have its expression altered, including an activation or
inactivation, in, e.g.,
normal versus ovarian cancer tissue. Genes may be turned on or turned off in a
particular
state, relative to another state thus permitting comparison of two or more
states. A
qualitatively regulated gene will exhibit an expression pattern within a state
or cell type
which is detectable by standard techniques. Some genes will be expressed in
one state or cell
type; but not in both. Alternatively, the difference in expression may be
quantitative, e.g., in
that expression is modulated, either up-regulated, resulting in an increased
amount of
transcript, or down-regulated, resulting in a decreased amount of transcript.
The degree to
which expression differs need only be large enough to quantify via standard
characterization
techniques as outlined below, such as by use of Affymetrix GeneChipTM
expression arrays.
See, e.g., Lockhart (1996) Nature Biotechnolo~y 14:1675-1680. Other techniques
include,
but are not limited to, quantitative reverse transcriptase PCR, northern
analysis, and RNase
protection. As outlined above, preferably the change in expression (e.g., up-
regulation or
down-regulation) is at least about SO%, more preferably at least about 100%,
more preferably
at least about 150%, more preferably at least about 200%, with from 300 to at
least 1000%
being especially preferred.
Evaluation may be at the gene transcript, or the protein level. The amount of
gene
expression may be monitored using nucleic acid probes to the DNA or RNA
equivalent of the
gene transcript, and the quantification of gene expression levels, or,
alternatively, the final
gene product itself (protein) can be monitored, e.g., with antibodies to the
ovarian cancer
protein and standard immunoassays (ELISAs, etc.) or other techniques,
including mass
spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins
corresponding to ovarian
cancer genes, e.g., those identified as being important in an ovarian cancer
or disease
phenotype, can be evaluated in an ovarian disease diagnostic test. In a
preferred
embodiment, gene expression monitoring is performed simultaneously on a number
of genes.
Multiple protein expression monitoring can be performed, or on an individual
basis.
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
In this embodiment, the ovarian cancer nucleic acid probes are attached to
biochips as
outlined herein for the detection and quantification of ovarian cancer
sequences in a
particular sample. The assays are further described below in the example. PCR
techniques
can be used to provide greater sensitivity.
In a preferred embodiment nucleic acids encoding the ovarian cancer protein
are
detected. Although DNA or RNA encoding the ovarian cancer protein may be
detected, of
particular interest are methods wherein an mRNA encoding an ovarian cancer
protein is
detected. Probes to detect mRNA can be a nucleotideldeoxynucleotide probe that
is
complementary to and hybridizes with the mRNA and includes, but is not limited
to,
oligonucleotides, cDNA or RNA. Probes also should contain a detectable label,
as defined
herein. In one method the mRNA is detected after immobilizing the nucleic acid
to be
examined on a solid support such as nylon membranes and hybridizing the probe
with the
sample. Following washing to remove the non-specifically bound probe, the
label is
detected. In another method detection of the mRNA is performed in situ. In
this method
permeabilized cells or tissue samples are contacted with a detectably labeled
nucleic acid
probe for sufficient time to allow the probe to hybridize with the target
mRNA. Following
washing to remove the non-specifically bound probe, the label is detected. For
example a
digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA
encoding
an ovarian cancer protein is detected by binding the digoxygenin with an anti-
digoxygenin
secondary antibody and developed with vitro blue tetrazolium and 5-bromo-4-
chloro-3-
indoyl phosphate.
In a preferred embodiment, various proteins from the three classes of proteins
as
described herein (secreted, transmembrane or intracellular proteins) are used
in diagnostic
assays. The ovarian cancer proteins, antibodies, nucleic acids, modified
proteins and cells
containing ovarian cancer sequences are used in diagnostic assays. This can be
performed on
an individual gene or corresponding polypeptide level. In a preferred
embodiment, the
expression profiles are used, preferably in conjunction with high throughput
screening
techniques to allow monitoring for expression profile genes and/or
corresponding
polypeptides.
As described and defined herein, ovarian cancer proteins, including
intracellular,
transmembrane, or secreted proteins, find use as prognostic or diagnostic
markers of ovarian
disease. Detection of these proteins in putative ovarian cancer tissue allows
for detection,
diagnosis, or prognosis of ovarian disease, and for selection of therapeutic
strategy. In one
56
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
embodiment, antibodies are used to detect ovarian cancer proteins. A preferred
method
separates proteins from a sample by electrophoresis on a gel (typically a
denaturing and
reducing protein gel, but may be another type of gel, including isoelectric
focusing gels and
the like). Following separation of proteins, the ovarian cancer protein is
detected, e.g., by
immunoblotting with antibodies raised against the ovarian cancer protein.
Methods of
immunoblotting are well known to those of ordinary skill in the art.
In another preferred method, antibodies to the ovarian cancer protein find use
in in
situ imaging techniques, e.g., in histology. See, e.g., Asai (ed. 1993)
Methods in Cell
Biology: Antibodies in Cell Biolo~y (vol. 37) Academic Press. Cells are
contacted with from
one to many antibodies to the ovarian cancer protein(s). Following washing to
remove non-
specific antibody binding, the presence of the antibody or antibodies is
detected. In one
embodiment the antibody is detected by incubating with a secondary antibody
that contains a
detectable label. In another method the primary antibody to the ovarian cancer
proteins)
contains a detectable label, e.g., an enzyme marker that can act on a
substrate. In another
preferred embodiment each one of multiple primary antibodies contains a
distinct and
detectable label. This method finds particular use in simultaneous screening
for a plurality of
ovarian cancer proteins. As will be appreciated by one of ordinary skill in
the art, many other
histological imaging techniques are also provided by the invention.
In a preferred embodiment the label is detected in a fluorometer which has the
ability
to detect and distinguish emissions of different wavelengths. In addition, a
fluorescence
activated cell sorter (FACS) can be used in the method.
In another preferred embodiment, antibodies find use in diagnosing ovarian
cancer
from blood, serum, plasma, stool, and other samples. Such samples, therefore,
are useful as
samples to be probed or tested for the presence of ovarian cancer proteins.
Antibodies can be
used to detect an ovarian cancer protein by previously described immunoassay
techniques
including ELISA, immunoblotting (western blotting), immunoprecipitation,
BIACORE
technology, and the like. Conversely, the presence of antibodies may indicate
an immune
response against an endogenous ovarian cancer protein.
In a preferred embodiment, in situ hybridization of labeled ovarian cancer
nucleic
acid probes to tissue arrays is done. For example, arrays of tissue samples,
including ovarian
cancer tissue and/or normal tissue, are made. In situ hybridization (see,
e.g., Ausubel, supra)
is then performed. When comparing the fingerprints between an individual and a
standard,
the skilled artisan can make a diagnosis, a prognosis, or a prediction based
on the findings. It
57
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
is further understood that the genes which indicate the diagnosis may differ
from those which
indicate the prognosis and molecular profiling of the condition of the cells
may lead to
distinctions between responsive or refractory conditions or may be predictive
of outcomes.
In a preferred embodiment, the ovarian cancer proteins, antibodies, nucleic
acids,
modified proteins and cells containing ovarian cancer sequences are used in
prognosis assays.
As above, gene expression profiles can be generated that correlate to ovarian
cancer, clinical,
pathological, or other information, in terms of long term prognosis. Again,
this may be done
on either a protein or gene level, with the use of a plurality of genes being
preferred. As
above, ovarian cancer probes may be attached to biochips for the detection and
quantification
of ovarian cancer sequences in a tissue or patient. The assays proceed as
outlined above. for
diagnosis. PCR method may provide more sensitive and accurate quantification.
Assays for therapeutic compounds
In a preferred embodiment members of the proteins, nucleic acids, and
antibodies as
described herein are used in drug screening assays. The ovarian cancer
proteins, antibodies,
nucleic acids, modified proteins and cells containing ovarian cancer sequences
are used in
drug screening assays or by evaluating the effect of drug candidates on a
"gene expression
profile" or expression profile of polypeptides. In a preferred embodiment, the
expression
profiles are used, preferably in conjunction with high throughput screening
techniques to
allow monitoring for expression profile genes after treatment with a candidate
agent. See,
e.g., Zlokarnik, et al. (1998) Science 279:84-88; and Heid (1996) Genome Res.
6:986-994.
In a preferred embodiment, the ovarian cancer proteins, antibodies, nucleic
acids,
modified proteins and cells containing the native or modified ovarian cancer
proteins are used
in screening assays. That is, the present invention provides novel methods for
screening for
compositions which modulate the ovarian cancer phenotype or an identified
physiological
function of an ovarian cancer protein. As above, this can be done on an
individual gene level
or by evaluating the effect of drug candidates on a "gene expression profile".
In a preferred
embodiment, the expression profiles are used, preferably in conjunction with
high throughput
screening techniques to allow monitoring for expression profile genes after
treatment with a
candidate agent. See, e.g., Zlokarnik, supra.
Having identified the differentially expressed genes herein, a variety of
assays may be
executed. In a preferred embodiment, assays may be run on an individual gene
or protein
level. That is, having identified a particular gene as up regulated in ovarian
cancer, test
58
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
compounds can be screened for the ability to modulate gene expression or for
binding to the
ovarian cancer protein. "Modulation" thus includes both an increase and a
decrease in gene
expression. The preferred amount of modulation will depend on the original
change of the
gene expression in normal versus tissue undergoing ovarian cancer, with
changes of at least
10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-
1000% or
greater. Thus, if a gene exhibits a 4-fold increase in ovarian cancer tissue
compared to
normal tissue, a decrease of about four-fold is often desired; similarly, a 10-
fold decrease in
ovarian cancer tissue compared to normal tissue often provides a target value
of a 10-fold
increase in expression to be induced by the test compound.
The amount of gene expression may be monitored using nucleic acid probes and
the
quantification of gene expression levels, or, alternatively, the gene product
itself can be
monitored, e.g., through the use of antibodies to the ovarian cancer protein
and standard
immunoassays. Proteomics and separation techniques may also allow
quantification of
expression.
In a preferred embodiment, gene expression or protein monitoring of a number
of
entities, e.g., an expression profile, is monitored simultaneously. Such
profiles will typically
involve a plurality of those entities described herein.
In this embodiment, the ovarian cancer nucleic acid probes are attached to
biochips as
outlined herein for the detection and quantification of ovarian cancer
sequences in a
particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of
microtiter plate, may
be used with dispensed primers in desired wells. A PCR reaction can then be
performed and
analyzed for each well.
Expression monitoring can be performed to identify compounds that modify the
expression of one or more ovarian cancer-associated sequences, e.g., a
polynucleotide
sequence set out inTables 1-26. Generally, in a preferred embodiment, a test
modulator is
added to the cells prior to analysis. Moreover, screens are also provided to
identify agents
that modulate ovarian cancer, modulate ovarian cancer proteins, bind to an
ovarian cancer
protein, or interfere with the binding of an ovarian cancer protein and an
antibody or other
binding partner.
The term "test compound" or "drug candidate" or "modulator" or grammatical
equivalents as used herein describes any molecule, e.g., protein,
oligopeptide, small organic
molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity
to directly or
indirectly alter the ovarian cancer phenotype or the expression of an ovarian
cancer sequence,
59
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators
alter
expression profiles, or expression profile nucleic acids or proteins provided
herein. In one
embodiment, the modulator suppresses an ovarian cancer phenotype, e.g., to a
normal or non-
malignant tissue fingerprint. In another embodiment, a modulator induced an
ovarian cancer
phenotype. Generally, a plurality of assay mixtures are run in parallel with
different agent
concentrations to obtain a differential response to the various
concentrations. Typically, one
of these concentrations serves as a negative control, e.g., at zero
concentration or below the
level of detection.
Drug candidates encompass numerous chemical classes, though typically they are
organic molecules, preferably small organic compounds having a molecular
weight of more
than 100 and less than about 2,500 daltons. Preferred small molecules are less
than 2000, or
less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise
functional
groups necessary for structural interaction with proteins, particularly
hydrogen bonding, and
typically include at least an amine, carbonyl, hydroxyl or carboxyl group,
preferably at least
two of the functional chemical groups. The candidate agents often comprise
cyclical carbon
or heterocyclic structures and/or aromatic or polyaromatic structures
substituted with one or
more of the above functional groups. Candidate agents are also found among
biomolecules
including peptides, saccharides, fatty acids, steroids, purines, pyrimidines,
derivatives,
structural analogs or combinations thereof. Particularly preferred are
peptides.
In one aspect, a modulator will neutralize the effect of an ovarian cancer
protein. By
"neutralize" is meant that activity of a protein is inhibited or blocked and
the consequent
effect on the cell.
In certain embodiments, combinatorial libraries of potential modulators will
be
screened for an ability to bind to an ovarian cancer polypeptide or to
modulate activity.
Conventionally, new chemical entities with useful properties are generated by
identifying a
chemical compound (called a "lead compound") with some desirable property or
activity,
e.g., inhibiting activity, creating variants of the lead compound, and
evaluating the property
and activity of those variant compounds. Often, high throughput screening
(HTS) methods
are employed for such an analysis.
In one preferred embodiment, high throughput screening methods involve
providing a
library containing a large number of potential therapeutic compounds
(candidate
compounds). Such "combinatorial chemical libraries" are then screened in one
or more
assays to identify those library members (particular chemical species or
subclasses) that
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
display a desired characteristic activity. The compounds thus identified can
serve as
conventional "lead compounds" or can themselves be used as potential or actual
therapeutics.
A combinatorial chemical library is a collection of diverse chemical compounds
generated by either chemical synthesis or biological synthesis by combining a
number of
chemical "building blocks" such as reagents. For example, a linear
combinatorial chemical
library, such as a polypeptide (e.g., mutein) library, is formed by combining
a set of chemical
building blocks called amino acids in every possible way for a given compound
length (e.g.,
the number of amino acids in a polypeptide compound). Millions of chemical
compounds
can be synthesized through such combinatorial mixing of chemical building
blocks. See, e.g.,
Gallop, et al. (1994) J. Med. Chem. 37:1233-1251.
Preparation and screening of combinatorial chemical libraries is well known to
those
of skill in the art. Such combinatorial chemical libraries include, but are
not limited to,
peptide libraries (see, e.g., U.S. Patent No. 5,010,175; Furka (1991) Pept.
Prot. Res. 37:487-
493; and Houghton, et al. (1991) Nature 354:84-88), peptoids (PCT Publication
No WO
91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-
oligomers (PCT
Publication WO 92/00091), benzodiazepines (U.5. Pat. No. 5,288,514),
diversomers such as
hydantoins, benzodiazepines and dipeptides (Hobbs, et al. (1993) Proc. Nat'1
Acad. Sci. USA
90:6909-913), vinylogous polypeptides (Hagihara, et al. (1992) J. Amer. Chem.
Soc.
114:6568-570), non-peptidal peptidomimetics with a Beta-D-Glucose scaffolding
(Hirschmann, et al. (1992) J. Amer. Chem. Soc. 114:9217-218), analogous
organic syntheses
of small compound libraries (Chen, et al. (1994) J. Amer. Chem. Soc. 116:2661-
662),
oligocarbamates (Cho, et al. (1993) Science 261:1303-305), and/or peptidyl
phosphonates
(Campbell, et a1.(1994) J. Org'Chem. 59:658-xxx). See, generally, Gordon, et
al. (1994) J.
Med. Chem. 37:1385-401, nucleic acid libraries (see, e.g., Stratagene, Corp.),
peptide nucleic
acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see,
e.g., Vaughn, et
a1.(1996) Nature Biotechnolo~y 14:309-314; and PCTlLTS96/14287), carbohydrate
libraries
(see, e.g., Liang, et al. (1996) Science 274:1520-1522; and U.S. Patent No.
5,593,853), and
small organic molecule libraries (see, e.g., benzodiazepines, page 33, Baum
(Jan. 18, 1993)
C&E News; isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and
metathiazanones,
U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and
5,519,134;
morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent
No.
5,288,514; and the like).
Devices for the preparation of combinatorial libraries are commercially
available.
61
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
See, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY; Symphony,
Rainin,
Woburn, MA; 433A Applied Biosystems, Foster City, CA; 9050 Plus, Millipore,
Bedford,
MA.
A number of well known robotic systems have also been developed for solution
phase
chemistries. These systems include automated workstations like the automated
synthesis
apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and
many robotic
systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, MA;
Orca,
Hewlett-Packard, Palo Alto, CA), which mimic the manual synthetic operations
performed by
a chemist. Any of the above devices are suitable for use with the present
invention. The
nature and implementation of modifications to these devices (if any) so that
they can operate
as discussed herein will be apparent to persons skilled in the relevant art.
In addition,
numerous combinatorial libraries are themselves commercially available (see,
e.g.,
ComGenex, Princeton, N.J.; Asinex, Moscow, RU; Tripos, Inc., St. Louis, MO;
ChemStar,
Ltd, Moscow, RU; 3D Pharmaceuticals, Exton, PA; Martek Biosciences, Columbia,
MD;
1 S etc.).
. The assays to identify modulators are amenable to high throughput screening.
Preferred assays thus detect enhancement or inhibition of ovarian cancer gene
transcription,
inhibition or enhancement of polypeptide expression, and inhibition or
enhancement of
polypeptide activity.
High throughput assays for the presence, absence, quantification, or other
properties
of particular nucleic acids or protein products are well known to those of
skill in the art.
Similarly, binding assays and reporter gene assays are similarly well known.
Thus, e.g., U.S.
Patent No. 5,559,410 discloses high throughput screening methods for proteins,
U.S. Patent
No. 5,585,639 discloses high throughput screening methods for nucleic acid
binding (e.g., in
arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high
throughput methods of
screening for ligand/antibody binding.
In addition, high throughput screening systems are commercially available
(see, e.g.,
Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman
Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.).
These systems
typically automate entire procedures, including all sample and reagent
pipetting, liquid
dispensing, timed incubations, and final readings of the microplate in
detectors) appropriate
for the assay. These configurable systems provide high throughput and rapid
start up as well
as a high degree of flexibility and customization. The manufacturers of such
systems provide
62
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
detailed protocols for various high throughput systems. Thus, e.g., Zymark
Corp. provides
technical bulletins describing screening systems for detecting the modulation
of gene
transcription, ligand binding, and the like.
In one embodiment, modulators are proteins, often naturally occurring proteins
or
fragments of naturally occurring proteins. Thus, e.g., cellular extracts
containing proteins, or
random or directed digests of proteinaceous cellular extracts, may be used. In
this way
libraries of proteins may be made for screening in the methods of the
invention. Particularly
preferred in this embodiment are libraries of bacterial, fungal, viral, and
mammalian proteins,
with the latter being preferred, and human proteins being especially
preferred. Particularly
useful test compound will be directed to the class of proteins to which the
target belongs, e.g.,
substrates for enzymes or ligands and receptors.
In a preferred embodiment, modulators are peptides of from about 5 to about 30
amino acids, with from about 5 to about 20 amino acids being preferred, and
from about 7 to
about 15 being particularly preferred. The peptides may be digests of
naturally occurring
proteins as is outlined above, random peptides, or "biased" random peptides.
By
"randomized" or grammatical equivalents herein is meant that each nucleic acid
and peptide
consists of essentially random nucleotides and amino acids, respectively.
Since generally
these random peptides (or nucleic acids, discussed below) are chemically
synthesized, they
may incorporate any nucleotide or amino acid at any position. The synthetic
process can be
designed to generate randomized proteins or nucleic acids, to allow the
formation of all or
most of the possible combinations over the length of the sequence, thus
forming a library of
randomized candidate bioactive proteinaceous agents.
In one embodiment, the library is fully randomized, with no sequence
preferences or
constants at any position. In a preferred embodiment, the library is biased.
That is, some
positions within the sequence are either held constant, or are selected from a
limited number
of possibilities. For example, in a preferred embodiment, the nucleotides or
amino acid
residues are randomized within a defined class, e.g., of hydrophobic amino
acids, hydrophilic
residues, sterically biased (either small or large) residues, towards the
creation of nucleic acid
binding domains, the creation of cysteines, for cross-linking, prolines for SH-
3 domains,
serines, threonines, tyrosines or histidines for phosphorylation sites, etc.,
or to purines, etc.
Modulators of ovarian cancer can also be nucleic acids, as defined above.
As described above generally for proteins, nucleic acid modulating agents may
be
naturally occurring nucleic acids, random nucleic acids, or "biased" random
nucleic acids.
63
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
For example, digests of procaryotic or eucaryotic genomes may be used as is
outlined above
for proteins.
In a preferred embodiment, the candidate compounds are organic chemical
moieties, a
wide variety of which are available in the literature.
After the candidate agent has been added and the cells allowed to incubate for
some
period of time, the sample containing a target sequence to be analyzed is
added to the
biochip. If required, the target sequence is prepared using known techniques.
.For example,
the sample may be treated to lyse the cells, using known lysis buffers,
electroporation, etc.,
with purification and/or amplification such as PCR performed as appropriate.
For example,
an in vitro transcription with labels covalently attached to the nucleotides
is performed.
Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3
or cy5.
In a preferred embodiment, the target sequence is labeled with, e.g., a
fluorescent, a
. chemiluminescent, a chemical, or a radioactive signal, to provide a means of
detecting the
target sequence's specific binding to a probe. The label also can be an
enzyme, such as,
alkaline phosphatase or horseradish peroxidase, which when provided with an
appropriate
substrate produces a product that can be detected. Alternatively, the label
can be a labeled
compound or small molecule, such as an enzyme inhibitor, that binds but is not
catalyzed or
altered by the enzyme. The label also can be a moiety or compound, such as, an
epitope tag
or biotin which specifically binds to streptavidin. For the example of biotin,
the streptavidin
is labeled as described above, thereby, providing a detectable signal for the
bound target
sequence. Unbound labeled streptavidin is typically removed prior to analysis.
As will be appreciated by those in the art, these assays can be direct
hybridization
assays or can comprise "sandwich assays", which include the use of multiple
probes, as is
generally outlined in U.S. Patent Nos. 5,681,702; 5,597,909; 5,545,730;
5,594,117;
5,591,584; 5,571,670; 5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352;
5,594,118;
5,359,100; 5,124,246; and 5,681,697, each of which is hereby incorporated by
reference. In
this embodiment, in general, the target nucleic acid is prepared as outlined
above, and then
added to the biochip comprising a plurality of nucleic acid probes, under
conditions that
allow the formation of a hybridization complex.
A variety of hybridization conditions may be used in the present invention,
including
high, moderate and low stringency conditions as outlined above. The assays are
generally
run under stringency conditions which allows formation of the label probe
hybridization
complex only in the presence of target. Stringency can be controlled by
altering a step
64
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
parameter that is a thermodynamic variable, including, but not limited to,
temperature,
formamide concentration, salt concentration, chaotropic salt concentration pH,
organic
solvent concentration, etc.
These parameters may also be used to control non-specific binding, as is
generally
outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform
certain steps at
higher stringency conditions to reduce non-specific binding.
The reactions outlined herein may be accomplished in a variety of ways.
Components
of the reaction may be added simultaneously, or sequentially, in different
orders, with
preferred embodiments outlined below. In addition, the reaction may include a
variety of
other reagents. These include salts, buffers, neutral proteins, e.g., albumin,
detergents, etc.
which may be used to facilitate optimal hybridization and detection, and/or
reduce non-
specific or background interactions. Reagents that otherwise improve the
efficiency of the
assay, such as protease inhibitors, nuclease inhibitors, anti-microbial
agents, etc., may also be
used as appropriate, depending on the sample preparation methods and purity of
the target.
The assay data are analyzed to determine the expression levels, and changes in
expression levels as between states, of individual genes, forming a gene
expression profile.
Screens are performed to identify modulators of the ovarian cancer phenotype.
In one
embodiment, screening is performed to identify modulators that can induce or
suppress a
particular expression profile, thus preferably generating the associated
phenotype. In another
embodiment, e.g., for diagnostic applications, having identified
differentially expressed genes
important in a particular state, screens can be performed to identify
modulators that alter
expression of individual genes. In an another embodiment, screening is
performed to identify
modulators that alter a biological function of the expression product of a
differentially
expressed gene. Again, having identified the importance of a gene in a
particular state,
screens are performed to identify agents that bind and/or modulate the
biological activity of
the gene product.
In addition screens can be done for genes that are induced in response to a
candidate
agent. After identifying a modulator based upon its ability to suppress an
ovarian cancer
expression pattern leading to a normal expression pattern, or to modulate a
single ovarian
cancer gene expression profile so as to mimic the expression of the gene from
normal tissue,
a screen as described above can be performed to identify genes that are
specifically
modulated in response to the agent. Comparing expression profiles between
normal tissue
and agent treated ovarian cancer tissue reveals genes that are not expressed
in normal tissue
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
or ovarian cancer tissue, but are expressed in agent treated tissue. These
agent-specific
sequences can be identified and used by methods described herein for ovarian
cancer genes or
proteins. In particular these sequences and the proteins they encode find use
in marking or
identifying agent treated cells. In addition, antibodies can be raised against
the agent induced
proteins and used to target novel therapeutics to the treated ovarian cancer
tissue sample.
Thus, in one embodiment, a test compound is administered to a population of
ovarian
cancer cells, that have an associated ovarian cancer expression profile. By
"administration"
or "contacting" herein is meant that the candidate agent is added to the cells
in such a manner
as to allow the agent to act upon the cell, whether by uptake and
intracellular action, or by
action at the cell surface. In some embodiments, nucleic acid encoding a
proteinaceous
candidate agent (e.g., a peptide) may be put into a viral construct such as an
adenoviral or
retroviral construct, and added to the cell, such that expression of the
peptide agent is
accomplished, e.g., PCT US97101019. Regulatable gene therapy systems can also
be used.
Once the test compound has been administered to the cells, the cells can be
washed if
desired and are allowed to incubate under preferably physiological conditions
for some
period of time. The cells are then harvested and a new gene expression profile
is generated,
as outlined herein.
Thus, e.g., ovarian cancer or non-malignant tissue may be screened for agents
that
modulate, e.g., induce or suppress the ovarian cancer phenotype. A change in
at least one
gene, preferably many, of the expression profile indicates that the agent has
an effect on
ovarian cancer activity. By defining such a signature for the ovarian cancer
phenotype,
screens for new drugs that alter the phenotype can be devised. With this
approach, the drug
target need not be known and need not be represented in the original
expression screening
platform, nor does the level of transcript for the target protein need to
change.
In a preferred embodiment, as outlined above, screens may be done on
individual
genes and gene products (proteins). That is, having identified a particular
differentially
expressed gene as important in a particular state, screening of modulators of
either the
expression of the gene or the gene product itself can be done. The gene
products of
differentially expressed genes are sometimes referred to herein as "ovarian
cancer proteins"
or a "ovarian cancer modulatory protein". The ovarian cancer modulatory
protein may be a
fragment, or alternatively, be the full length protein to the fragment encoded
by the nucleic
acids of the Tables. Preferably, the ovarian cancer modulatory protein is a
fragment. In a
preferred embodiment, the ovarian cancer amino acid sequence which is used to
determine
66
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
sequence identity or similarity is encoded by a nucleic acid of the Tables. In
another
embodiment, the sequences are naturally occurring allelic variants of a
protein encoded by a
nucleic acid of the Tables. In another embodiment, the sequences are sequence
variants as
further described herein.
Preferably, the ovarian cancer modulatory protein is a fragment of
approximately 14
to 24 amino acids long. More preferably the fragment is a soluble fragment.
Preferably, the
fragment includes a non-transmembrane region. In a preferred embodiment, the
fragment has
an N-terminal Cys to aid in solubility. In another embodiment, the C-terminus
of the
fragment is kept as a free acid and the N-terminus is a free amine to aid in
coupling, e.g., to
cysteine. Or, the ovarian cancer proteins are conjugated to an immunogenic
agent, e.g., to
BSA.
Measurements of ovarian cancer polypeptide activity, or of ovarian cancer or
the
ovarian cancer phenotype can be performed using a variety of assays. For
example, the
effects of the test compounds upon the function of the ovarian cancer
polypeptides can be
measured by examining parameters described above. A suitable physiological
change that
affects activity can be used to assess the influence of a test compound on the
polypeptides of
this invention. When the functional consequences are determined using intact
cells or
animals, one can also measure a variety of effects such as, in the case of
ovarian cancer
associated with tumors, tumor growth, tumor metastasis, neovascularization,
hormone
release, transcriptional changes to both known and uncharacterized genetic
markers (e.g.,
northern blots), changes in cell metabolism such as cell growth or pH changes,
and changes
in intracellular second messengers such as cGMP. In the assays of the
invention, mammalian
ovarian cancer polypeptide is typically used, e.g., mouse, preferably human.
Assays to identify compounds with modulating activity can be performed in
vitro.
For example, an ovarian cancer polypeptide is first contacted with a potential
modulator and
incubated for a suitable amount of time, e.g., from 0.5 to 4g hours. In one
embodiment, the
ovarian cancer polypeptide levels are determined in vitro by measuring the
level of protein or
mRNA. The level of protein is measured using immunoassays such as western
blotting,
ELISA and the like with an antibody that selectively binds to the ovarian
cancer polypeptide
or a fragment thereof. For measurement of mRNA, amplification, e.g., using
PCR, LCR, or
hybridization assays, e.g., northern hybridization, RNAse protection, dot
blotting, are
preferred. The level of protein or mRNA is detected using directly or
indirectly labeled
detection agents, e.g., fluorescently or radioactively labeled nucleic acids,
radioactively or
67
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
enzymatically labeled antibodies, and the like, as described herein.
Alternatively, a reporter gene system can be devised using the ovarian cancer
protein
promoter operably linked to a reporter gene such as luciferase, green
fluorescent protein,
CAT, or (3-gal. The reporter construct is typically transfected into a cell.
After treatment
with a potential modulator, the amount of reporter gene transcription,
translation, or activity
is measured according to standard techniques known to those of skill in the
art.
In a preferred embodiment, as outlined above, screens may be done on
individual
genes and gene products (proteins). That is, having identified a particular
differentially
expressed gene as important in a particular state, screening of modulators of
the expression of
the gene or the gene product itself can be done. The gene products of
differentially expressed
genes are sometimes referred to herein as "ovarian cancer proteins." The
ovarian cancer
protein may be a fragment, or alternatively, be the full length protein to a
fragment shown
herein.
In one embodiment, screening for modulators of expression of specific genes is
1 S performed. Typically, the expression of only one or a few genes are
evaluated. In another
embodiment, screens are designed to first find compounds that bind to
differentially
expressed proteins. These compounds are then evaluated for the ability to
modulate
differentially expressed activity. Moreover, once initial candidate compounds
are identified,
variants can be further screened to better evaluate structure activity
relationships.
In a preferred embodiment, binding assays are done. In general, purified or
isolated
gene product is used; that is, the gene products of one or more differentially
expressed
nucleic acids are made. For example, antibodies are generated to the protein
gene products,
and standard immunoassays are run to determine the amount of protein present.
Alternatively, cells comprising the ovarian cancer proteins can be used in the
assays.
Thus, in a preferred embodiment, the methods comprise combining an ovarian
cancer
protein and a candidate compound, and determining the binding of the compound
to the
ovarian cancer protein. Preferred embodiments utilize the human ovarian cancer
protein,
although other mammalian proteins, e.g., counterparts, may also be used, e.g.,
for the
development of animal models of human disease. In some embodiments, as
outlined herein,
variant or derivative ovarian cancer proteins may be used.
Generally, in a preferred embodiment of the methods herein, the ovarian cancer
protein or the candidate agent is non-diffusably bound to an insoluble support
having isolated
sample receiving areas (e.g., a microtiter plate, an array, etc.). The
insoluble supports may be
68
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
made of any composition to which the compositions can be bound, is readily
separated from
soluble material, and is otherwise compatible with the overall method of
screening: The
surface of such supports may be solid or porous and of any convenient shape.
Examples of
suitable insoluble supports include microtiter plates, arrays, membranes and
beads. These are
typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon
or nitrocellulose,
teflonTM, etc. Microtiter plates and arrays are especially convenient because
a large number
of assays can be carried out simultaneously, using small amounts of reagents
and samples.
The particular manner of binding of the composition is not crucial so long as
it is compatible
with the reagents and overall methods of the invention, maintains the activity
of the
composition and is non-diffusible. Preferred methods of binding include the
use of
antibodies (which do not sterically block either the ligand binding site or
activation sequence
when the protein is bound to the support), direct binding to "sticky" or ionic
supports,
chemical crosslinking, the synthesis of the protein or agent on the surface,
etc. Following
binding of the protein or agent, excess unbound material is removed by
washing. The sample
receiving areas may then be blocked through incubation with bovine serum
albumin (BSA),
casein or other innocuous protein or other moiety.
In a preferred embodiment, the ovarian cancer protein is bound to the support,
and a
test compound is added to the assay. Alternatively, the candidate agent is
bound to the
support and the ovarian cancer protein is added. Novel binding agents include
specific
antibodies, non-natural binding agents identified in screens of chemical
libraries, peptide
analogs, etc. Of particular interest are screening assays for agents that have
a low toxicity for
human cells. A wide variety of assays may be used for this purpose, including
labeled in
vitro protein-protein binding assays, electrophoretic mobility shift assays,
immunoassays for
protein binding, functional assays (phosphorylation assays, etc.) and the
like.
The determination of the binding of the test modulating compound to the
ovarian
cancer protein may be done in a number of ways. In a preferred embodiment, the
compound
is labeled, and binding determined directly, e.g., by attaching all or a
portion of the ovarian
cancer protein to a solid support, adding a labeled candidate agent (e.g., a
fluorescent label),
washing off excess reagent, and determining whether the label is present on
the solid support.
Various blocking and washing steps may be utilized as appropriate.
In some embodiments, only one of the components is labeled, e.g., the proteins
(or
proteinaceous candidate compounds) can be labeled. Alternatively, more than
one
69
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
component can be labeled with different labels, e.g., 125I for the proteins
and a fluorophor
for the compound. Proximity reagents, e.g., quenching or energy transfer
reagents are also
useful.
In one embodiment, the binding of the test compound is determined by
competitive
S binding assay. The competitor is a binding moiety known to bind to the
target molecule (e.g.,
an ovarian cancer protein), such as an antibody, peptide, binding partner,
ligand, etc. Under
certain circumstances, there may be competitive binding between the compound
and the
binding moiety, with the binding moiety displacing the compound. In one
embodiment, the
test compound is labeled. Either the compound, or the competitor, or both, is
added first to
the protein for a time sufficient to allow binding, if present. Incubations
may be performed at
a temperature which facilitates optimal activity, typically 4-40° C.
Incubation periods are
typically optimized, e.g., to facilitate rapid high throughput screening.
Typically between 0.1
and 1 hr will be sufficient. Excess reagent is generally removed or washed
away. The
second component is then added, and the presence or absence of the labeled
component is
followed, to indicate binding.
In a preferred embodiment, the competitor is added first, followed by the test
compound. Displacement of the competitor is an indication that the test
compound is binding
to the ovarian cancer protein and thus is capable of binding to, and
potentially modulating,
the activity of the ovarian cancer protein. In this embodiment, either
component can be
labeled. Thus, e.g., if the competitor is labeled, the presence of label in
the wash solution
indicates displacement by the agent. Alternatively, if the test compound is
labeled, the
presence of the label on the support indicates displacement.
In an alternative embodiment, the test compound is added first, with
incubation and
washing, followed by the competitor. The absence of binding by the competitor
may indicate
that the test compound is bound to the ovarian cancer protein with a higher
affinity. Thus, if
the test compound is labeled, the presence of the label on the support,
coupled with a lack of
competitor binding, may indicate~that the test compound is capable of binding
to the ovarian
cancer protein.
In a preferred embodiment, the methods comprise differential screening to
identity
agents that are capable of modulating the activity of the ovarian cancer
proteins. In this
embodiment, the methods comprise combining an ovarian cancer protein and a
competitor in
a first sample. A second sample comprises a test compound, an ovarian cancer
protein, and a
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
competitor. The binding of the competitor is determined for both samples, and
a change, or
difference in binding between the two samples indicates the presence of an
agent capable of
binding to the ovarian cancer protein and potentially modulating its activity.
That is, if the
binding of the competitor is different in the second sample relative to the
first sample, the
agent is capable of binding to the ovarian cancer protein.
Alternatively, differential screening is used to identify drug candidates that
bind to the
native ovarian cancer protein, but cannot bind to modified ovarian cancer
proteins. The
structure of the ovarian cancer protein may be modeled, and used in rational
drug design to
synthesize agents that interact with that site. Drug candidates that affect
the activity of an
ovarian cancer protein are also identified by screening drugs for the ability
to either enhance
or reduce the activity of the protein.
Positive controls and negative controls may be used in the assays. Preferably
control
and test samples are performed in at least triplicate to obtain statistically
significant results.
Incubation of all samples is for a time sufficient for the binding of the
agent to the protein.
Following incubation, samples are washed free of non-specifically bound
material and the
amount of bound, generally labeled agent determined. For example, where a
radiolabel is
employed, the samples may be counted in a scintillation counter to determine
the amount of
bound compound.
A variety of other reagents may be included in the screening assays. These
include
reagents like salts, neutral proteins, e.g., albumin, detergents, etc. which
may be used to
facilitate optimal protein-protein binding and/or reduce~non-specific or
background
interactions. Also reagents that otherwise improve the efficiency of the
assay, such as
protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be
used. The mixture
of components may be added in an order that provides for the requisite
binding.
In a preferred embodiment, the invention provides methods for screening for a
compound capable of modulating the activity of an ovarian cancer protein. The
methods
comprise adding a test compound, as defined above, to a cell comprising
ovarian cancer
proteins. Preferred cell types include almost any cell. The cells contain a
recombinant
nucleic acid that encodes an ovarian cancer protein. In a preferred
embodiment, a library of
candidate agents are tested on a plurality of cells.
In one aspect, the assays are evaluated in the presence or absence or previous
or
subsequent exposure of physiological signals, e.g., hormones, antibodies,
peptides, antigens,
cytokines, growth factors, action potentials, pharmacological agents including
71
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
chemotherapeutics, radiation, carcinogenics, or other cells (e.g., cell-cell
contacts). In
another example, the determinations are determined at different stages of the
cell cycle
process.
In this way, compounds that modulate ovarian cancer agents are identified.
Compounds with pharmacological activity are able to enhance or interfere with
the activity of
the ovarian cancer protein. Once identified, similar structures are evaluated
to identify
critical structural feature of the compound.
In one embodiment, a method of inhibiting ovarian cancer cell division is
provided.
The method comprises administration of an ovarian cancer inhibitor. 1n another
embodiment,
a method of inhibiting ovarian cancer is provided. The method comprises
administration of
an ovarian cancer inhibitor. In a further embodiment, methods of treating
cells or individuals
with ovarian cancer are provided. The method comprises administration of an
ovarian cancer
inhibitor.
In one embodiment, an ovarian cancer inhibitor is an antibody as discussed
above. In
1 S another embodiment, the ovarian cancer inhibitor is an antisense or RNAi
molecule.
A variety of cell viability, growth, proliferation, and metastasis assays are
known to
those of skill in the art, as described below.
Soft agar growth or colony formation in suspension
Normal cells require a solid substrate to attach and grow. When the cells are
transformed, they lose this phenotype and grow detached from the substrate.
For example,
transformed cells can grow in stirred suspension culture or suspended in semi-
solid media,
such as semi-solid or soft agar. The transformed cells, when transfected With
tumor
suppressor genes, regenerate normal phenotype and require a solid substrate to
attach and
grow. Soft agar growth or colony formation in suspension assays can be used to
identify
modulators of ovarian cancer sequences, which when expressed in host cells,
inhibit
abnormal cellular proliferation and transformation. A therapeutic compound
would reduce or
eliminate the host cells' ability to grow in stirred suspension culture or
suspended in semi=
solid media, such as semi-solid or soft.
Techniques for soft agar growth or colony formation in suspension assays are
described in Freshney (1994) Culture of Animal Cells: A Manual of Basic
Technique (3d ed.)
Wiley-Liss, herein incorporated by reference. See also, the methods section of
Garkavtsev, et
al. (1996), supra, herein incorporated by reference.
72
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
Contact inhibition and density limitation of growth
Normal cells typically grow in a flat and organized pattern in a petri dish
until they
touch other cells. When the cells touch one another, they are contact
inhibited and stop
growing. When cells are transformed, however, the cells are not contact
inhibited and
continue to grow to high densities in disorganized foci. Thus, the transformed
cells grow to a
higher saturation density than normal cells. This can be detected
morphologically by the
formation of a disoriented monolayer of cells or rounded cells in foci within
the regular
pattern of normal surrounding cells. Alternatively, labeling index with (3H)-
thymidine at
saturation density can be used,to measure density limitation of growth. See,
e.g., Freshney
(1994), supra. The transformed cells, when transfected with tumor suppressor
genes,
regenerate a normal phenotype and become contact inhibited and would grow to a
lower
density.
In this assay, labeling index with (3H)-thymidine at saturation density is a
preferred
method of measuring density limitation of growth. Transformed host cells are
transfected
with an ovarian cancer-associated sequence and are grown for 24 hr at
saturation density in
non-limiting medium conditions. The percentage of cells labeling with (3H)-
thymidine is
determined autoradiographically. See, e.g., Freshney (1994), supra.
Growth factor or serum dependence
Transformed cells typically have a lower serum dependence than their normal
counterparts. See, e.g., Temin (1966) J. Nat'1 Cancer Inst. 37:167-175; Eagle,
et al. (1970) J.
Exp. Med. 131:836-879; and Freshney, supra. This is in part due to release of
various growth
factors by the transformed cells. Growth factor or serum dependence of
transformed host
cells can be compared with that of control.
Tumor specific markers levels
Tumor cells release an increased amount of certain factors (hereinafter "tumor
specific maxkers") than their normal counterparts. For example, plasminogen
activator (PA)
is released from human glioma at a higher level than from normal brain cells
(see, e.g.,
Gullino, pp. 178-184 "Angiogenesis, tumor vascularization, and potential
interference with
tumor growth" in Mihich (ed. 1985) Biological Responses in Cancer Plenum.
Similarly,
73
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
tumor angiogenesis factor (TAF) is released at a higher level in tumor cells
than their normal
counterparts. See, e.g., Folkman (1992) Sem Cancer Biol. 3:89-96.
Various techniques which measure the release of these factors are described in
Freshney (1994), supra. Also, see, Unkeless, et al. (1974) J. Biol. Chem.
249:4295-4305;
Strickland and Beers (1976) J. Biol. Chem. 251:5694-5702; Whur, et al. (1980)
Br. J. Cancer
42:305-312; Gullino, pp. 178-184 "Angiogenesis, tumor vascularization, and
potential
interference with tumor growth" in Mihich (ed. 1985) Biological Responses in
Cancer
Plenum; and Freshney (1985) Anticancer Res. 5:111-130.
Invasiveness into Matrigel ,
The degree of invasiveness into Matrigel or some other extracellular matrix
constituent can be used as an assay to identify compounds that modulate
ovarian cancer-
associated sequences. Tumor cells exhibit a good correlation between
malignancy and
invasiveness of cells into Matrigel or some other extracellular matrix
constituent. In this
assay, tumorigenic cells are typically used as host cells. Expression of a
tumor suppressor
gene in these host cells would decrease invasiveness of the host cells.
Alternatively, the level of invasion of host cells can be measured by using
filters
coated with Matrigel or some other extracellular matrix constituent.
Penetration into the gel,
or through to the distal side of the filter, is rated as invasiveness, and
rated histologically by
number of cells and distance moved, or by pre-labeling the cells with 1251 and
counting the
radioactivity on the distal side of the filter or bottom of the dish. See,
e.g., Freshney (1984),
supra.
Tumor growth in vivo
Effects of ovarian cancer-associated sequences on cell growth can be tested in
transgenic or immune-suppressed mice. Knock-out transgenic mice can be made,
in which
the ovarian cancer gene is disrupted or in which an ovarian cancer gene is
inserted. Knock-
out transgenic mice can be made by insertion of a marker gene or other
heterologous gene
into the endogenous ovarian cancer gene site in the mouse genome via
homologous
recombination. Such mice can also be made by substituting the endogenous
ovarian cancer
gene with a mutated version of the ovarian cancer gene, or by mutating the
endogenous
ovarian cancer gene, e.g., by exposure to carcinogens.
74
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
A DNA construct is introduced into the nuclei of embryonic stem cells. Cells
containing the newly engineered genetic lesion are injected into a host mouse
embryo, which
is re-implanted into a recipient female. Some of these embryos develop into
chimeric mice
that possess germ cells partially derived from the mutant cell line. By
breeding the chimeric
mice it is possible to obtain a new line of mice containing the introduced
genetic lesion. See,
e.g., Capecchi, et al. (1989) Science 244:1288-1292. Chimeric targeted mice
can be derived
according to Hogan, et al. (1988) Manipulating the Mouse Embryo: A Laboratory
Manual
CSH Press; and Robertson (ed. 1987) Teratocarcinomas and Embryonic Stem Cells:
A
Practical Approach IRL Press, Washington, D.C.
Alternatively, various~immune-suppressed or immune-deficient host animals can
be
used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella, et
al. (1974) J.
Nat'1 Cancer Inst. 52:921-930), a SCID mouse, a thymectomized mouse, or an
irradiated
mouse (see, e.g., Bradley, et al. (1978) Br. J. Cancer 38:263-272; Selby, et
al. (1980) Br. J.
Cancer 41:52-61) can be used as a host. Transplantable tumor cells (typically
about 106
cells) injected into isogenic hosts will produce invasive tumors in a high
proportions of cases,
while normal cells of similar origin will not. In hosts which developed
invasive tumors, cells
expressing an ovarian cancer-associated sequences are injected subcutaneously.
After a
suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g.,
by volume or
by its two largest dimensions) and compared to the control. Tumors that have
statistically
significant reduction (using, e.g., Student's T test) are said to have
inhibited growth.
Polynucleotide modulators of ovarian cancer
Antisense and RNAi Polynucleotides
In certain embodiments, the activity of an ovarian cancer-associated protein
is down-
regulated, or entirely inhibited, by the use of antisense polynucleotide,
e.g., a nucleic acid
complementary to, and which can preferably hybridize specifically to, a coding
mRNA
nucleic acid sequence, e.g., an ovarian cancer protein mRNA, or a subsequence
thereof.
Binding of the antisense polynucleotide to the mRNA reduces the translation
andlor stability
of the mRNA.
In the context of this invention, antisense polynucleotides can comprise
naturally-
occurring nucleotides, or synthetic species formed from naturally-occurring
subunits or their
close homologs. Antisense polynucleotides may also have altered sugar moieties
or inter-
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
sugar linkages. Exemplary among these are the phosphorothioate and other
sulfur containing
species which are known for use in the art. Analogs are comprehended by this
invention so
long as they function effectively to hybridize with the ovarian cancer protein
mRNA. See,
e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.
Such antisense polynucleotides can readily be synthesized using recombinant
means,
or can be synthesized in vitro. Equipment for such synthesis is sold by
several vendors,
including Applied Biosystems. The preparation of other oligonucleotides such
as
phosphorothioates and alkylated derivatives is also well known to those of
skill in the art.
Antisense molecules as used herein include antisense or sense
oligonucleotides.
Sense oligonucleotides can, e;g., be employed to block transcription by
binding to the anti-
sense strand. The antisense and sense oligonucleotide comprise a single-
stranded nucleic
acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or
DNA
(antisense) sequences for ovarian cancer molecules. A preferred antisense
molecule is for an
ovarian cancer sequences in Tables 1-26, or for a ligand or activator thereof.
Antisense or
sense oligonucleotides, according to the present invention, comprise a
fragment generally at
least about 14 nucleotides, preferably from about 14 to 30 nucleotides. An
antisense or a
sense oligonucleotide can be developed based upon a cDNA sequence encoding a
given
protein. See, e.g., Stein and Cohen (1988) Cancer Res. 48:2659-2668; and van
der Krol, et
al. (1988) BioTechniques 6:958-976.
RNA interference is a mechanism to suppress gene expression in a sequence
specific
manner. See, e.g., Brumelkamp, et al. (2002) Sciencexpress (2lMarch2002);
Sharp (1999)
Genes Dev. 13:139-141; and Cathew (2001) Curr. Op. Cell Biol. 13:244-248. In
mammalian
cells, short, e.g., 21 nt, double stranded small interfering RNAs (siRNA) have
been shown to
be effective at inducing an RNAi response. See, e.g., Elbashir, et al. (2001)
Nature 411:494-
498. The mechanism may be used to down-regulate expression levels of
identified genes,
e.g., treatment of or validation of relevance to disease.
Ribozymes
In addition to antisense polynucleotides, ribozymes can be used to target and
inhibit
transcription of ovarian cancer-associated nucleotide sequences. A ribozyme is
an RNA
molecule that catalytically cleaves other RNA molecules. Different kinds of
ribozymes have
been described, including group I ribozymes, hammerhead ribozymes, hairpin
ribozymes,
RNase P, and axhead ribozymes (see, e.g., Castanotto, et al. (1994) Adv.
Pharmacol. 25: 289-
76
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
317 for a general review of the properties of different ribozymes).
The general features of hairpin ribozymes are described, e.g., in Hampel, et
al. (1990)
Nucl. Acids Res. 18:299-304; European Patent Publication No. 0 360 257; U.S.
Patent No.
5,254,678. Methods of preparing them are well known to those of skill in the
art. See, e.g.,
WO 94/26877; Ojwang, et al. (1993) Proc. Nat'1 Acad. Sci. USA 90:6340-6344;
Yamada, et
al. (1994) Hum. Gene Ther. 1:39-45; Leavitt, et al. (1995) Proc. Nat'1 Acad.
~Sci. USA
92:699-703; Leavitt, et al. (1994) Hum. Gene Ther. 5:1151-120; and Yamada, et
al. (1994)
Virolo~y 205:121-126.
Polynucleotide modulators of ovarian cancer may be introduced into a cell
containing
the target nucleotide sequence by formation of a conjugate with a ligand
binding molecule, as
described in WO 91/04753. Suitable ligand binding molecules include, but are
not limited to,
cell surface receptors, growth factors, other cytokines, or other ligands that
bind to cell
surface receptors. Preferably, conjugation of the ligand binding molecule does
not
substantially interfere with the ability of the ligand binding molecule to
bind to its
corresponding molecule or receptor, or block entry of the sense or antisense
oligonucleotide
or its conjugated version into the cell. Alternatively, a polynucleotide
modulator of ovarian
cancer may be introduced into a cell containing the target nucleic acid
sequence, e.g., by
formation of an polynucleotide-lipid complex, as described in WO 90/10448. It
is
understood that the use of antisense molecules or knock out and knock in
models may also be
used in screening assays as discussed above, in addition to methods of
treatment.
Thus, in one embodiment, methods of modulating ovarian cancer in cells or
organisms are provided. Ix~ one embodiment, the methods comprise administering
to a cell an
anti-ovarian cancer antibody that reduces or eliminates the biological
activity of an
endogenous ovarian cancer protein. Alternatively, the methods comprise
administering to a
cell or organism a recombinant nucleic acid encoding an ovarian cancer
protein. This may be
accomplished in any number of ways. In a preferred embodiment, e.g., when the
ovarian
cancer sequence is down-regulated in ovarian cancer, such state may be
reversed by
increasing the amount of ovarian cancer gene product in the cell. This can be
accomplished,
e.g., by over-expressing the endogenous ovarian cancer gene or administering a
gene
encoding the ovarian cancer sequence, using known gene-therapy techniques,
e.g.. In a
preferred embodiment, the gene therapy techniques include the incorporation of
the
exogenous gene using enhanced homologous recombination (EHR), e.g., as
described in
PCT/IJS93/03868, hereby incorporated by reference in its entirety.
Alternatively, e.g., when
77
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
the ovarian cancer sequence is up-regulated in ovarian cancer, the activity of
the endogenous
ovarian cancer gene is decreased, e.g., by the administration of an ovarian
cancer antisense or
RNAi nucleic acid.
In one embodiment, the ovarian cancer proteins of the present invention may be
used
to generate polyclonal and monoclonal antibodies to ovarian cancer proteins.
Similarly, the
ovarian cancer proteins can be coupled, using standard technology, to affinity
chromatography columns. These columns may then be used to purify ovarian
cancer
antibodies useful for production, diagnostic, or therapeutic purposes. In a
preferred
embodiment, the antibodies are generated to epitopes unique to an ovarian
cancer protein;
that is, the antibodies show little or no cross-reactivity to other proteins.
The ovarian cancer
antibodies may be coupled to standard affinity chromatography columns and used
to purify
ovarian cancer proteins. The antibodies may also be used as blocking
polypeptides, as
outlined above, since they will specifically bind to the ovarian cancer
protein.
Methods of identifying variant ovarian cancer-associated sequences
Without being bound by theory, expression of various ovarian cancer sequences
is
correlated with ovarian cancer. Accordingly, disorders based on mutant or
variant ovarian
cancer genes may be determined. In one embodiment, the invention provides
methods for
identifying cells containing variant ovarian cancer genes, e.g., determining
all or part of the
sequence of at least one endogenous ovarian cancer genes in a cell. This may
be
accomplished using any number of sequencing techniques. In a preferred
embodiment, the
invention provides methods of identifying the ovarian cancer genotype of an
individual, e.g.,
determining all or part of the sequence of at least one ovarian cancer gene of
the individual.
This is generally done in at least one tissue of the individual, and may
include the evaluation
of a number of tissues or different samples of the same tissue. The method may
include
comparing the sequence of the sequenced ovarian cancer gene to a known ovarian
cancer
gene, e.g., a wild-type gene.
The sequence of all or part of the ovarian cancer gene can then be compared to
the
sequence of a known ovarian cancer gene to determine if any differences exist.
This can be
done using any number of known homology programs, such as Bestfit, etc. In a
preferred
embodiment, the presence of a difference in the sequence between the ovarian
cancer gene of
the patient and the known ovarian cancer gene correlates with a disease state
or a propensity
for a disease state, as outlined herein.
78
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
In a preferred embodiment, the ovarian cancer genes are used as probes to
determine
the number of copies of the ovarian cancer gene in the genome.
In another preferred embodiment, the ovarian cancer genes are used as probes
to
determine the chromosomal localization of the ovarian cancer genes.
Information such as
chromosomal localization finds use in providing a diagnosis or prognosis in
particular when
chromosomal abnormalities such as translocations, and the like are identified
in the ovarian
cancer gene locus.
Administration of pharmaceutical and vaccine compositions
In one embodiment, a therapeutically effective dose of an ovarian cancer
protein or
modulator thereof, is administered to a patient. By "therapeutically effective
dose" herein is
meant a dose that produces effects for which it is administered. The exact
dose will depend
on the purpose of the treatment, and will be ascertainable by one skilled in
the art using
known techniques. See, e.g., Ansel, et al. (1999) Pharmaceutical Dosage Forms
and Drug
Deliver~ystems Lippincott; Lieberman (1992) Pharmaceutical Dosage Fornis
(vols. 1-3)
Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd (1999) The
Art,
Science and Technology of Pharmaceutical Cornpoundin~ Amer. Pharmaceutical
Assn.; and
Pickar (1999) Dosage Calculations Thomson. Adjustments for ovarian cancer
degradation,
systemic versus localized delivery, and rate of new protease synthesis, as
well as the age,
body weight, general health, sex, diet, time of administration, drug
interaction, and the
severity of the condition may be necessary, and will be ascertainable with
routine
experimentation by those skilled in the art. U.S. Patent Application No.
09/687,576, further
discloses the use of compositions and methods of diagnosis and treatment in
ovarian cancer is
hereby expressly incorporated by reference.
A "patient" for the purposes of the present invention includes both humans and
other
animals, particularly mammals. Thus the methods are applicable to both human
therapy and
veterinary applications. In the preferred embodiment the patient is a mammal,
preferably a
primate, and in the most preferred embodiment the patient is human.
The administration of the ovarian cancer proteins and modulators thereof of
the
present invention can be done in a variety of ways as discussed above,
including, but not
limited to, orally, subcutaneously, intravenously, infra-nasally,
transdermally,
intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or
intraocularly. In
some instances, e.g., in the treatment of wounds and inflammation, the ovarian
cancer
79
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
proteins and modulators may be directly applied as a solution or spray.
The pharmaceutical compositions of the present invention comprise an ovarian
cancer
protein in a form suitable for administration to a patient. In the preferred
embodiment, the
pharmaceutical compositions are in a water soluble form, such as being present
as
S pharmaceutically acceptable salts, which is meant to include both acid and
base addition
salts. "Pharmaceutically acceptable acid addition salt" refers to those salts
that retain the
biological effectiveness of the free bases and that are not biologically or
otherwise
undesirable, formed with inorganic acids such as hydrochloric acid,
hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids
such as acetic acid,
propionic acid, glycolic acid, pyruvic acid, oxalic acid, malefic acid,
malonic acid, succinic
acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid,
mandelic acid,
methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic
acid, and the like.
"Pharmaceutically acceptable base addition salts" include those derived from
inorganic bases
such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper,
manganese, aluminum salts and the like. Particularly preferred are the
ammonium,
potassium, sodium, calcium, and magnesium salts. Salts derived from
pharmaceutically
acceptable organic non-toxic bases include salts of primary, secondary, and
tertiary amines,
substituted amines including naturally occurnng substituted amines, cyclic
amines and basic
ion exchange resins, such as isopropylamine, trimethylamine, diethylamine,
triethylamine,
tripropylamine, and ethanolamine.
The pharmaceutical compositions may also include one or more of the following:
Garner proteins such as serum albumin; buffers; fillers such as
microcrystalline cellulose,
lactose, corn and other starches; binding agents; sweeteners and other
flavoring agents;
coloring agents; and polyethylene glycol.
The pharmaceutical compositions can be administered in a variety of unit
dosage
forms depending upon the method of administration. For example, unit dosage
forms
suitable for oral administration include, but are not limited to, powder,
tablets, pills, capsules,
and lozenges. It is recognized that ovarian cancer protein modulators (e.g.,
antibodies,
antisense constructs, ribozymes, small organic molecules, etc.) when
administered orally,
should be protected from digestion. This is typically accomplished either by
complexing the
molecules) with a composition to render it resistant to acidic and enzymatic
hydrolysis, or by
packaging the molecules) in an appropriately resistant Garner, such as a
liposome or a
protection burner. Means of protecting agents from digestion are well known in
the art.
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
The compositions for administration will commonly comprise an ovarian cancer
protein modulator dissolved in a pharmaceutically acceptable carrier,
preferably ari aqueous
carrier. A variety of aqueous Garners can be used, e.g., buffered saline and
the like. These
solutions are sterile and generally free of undesirable matter. These
compositions may be
sterilized by conventional, well known sterilization techniques. The
compositions may
contain pharmaceutically acceptable auxiliary substances as required to
approximate
physiological conditions such as pH adjusting and buffering agents, toxicity
adjusting agents
and the.like, e.g., sodium acetate, sodium chloride, potassium chloride,
calcium chloride,
sodium lactate and the like. The concentration of active agent in these
formulations can vary
widely, and will be selected primarily based on fluid volumes, viscosities,
body weight, and
the like in accordance with the particular mode of administration selected and
the patient's
needs. See, e.g., Remington's Pharmaceutical Science (15th ed., 1980) and
Hardman and
Limbird (eds. 2001) Goodman and Gillman: The Phannacolo~ical Basis of
Therapeutics
(10th ed.) McGraw-Hill. Thus, a typical pharmaceutical composition for
intravenous
administration would be about 0.1 to 10 mg per patient per day. Dosages from
0.1 up to
about 100 mg per patient per day may be used, particularly when the drug is
administered to a
secluded site and not into the blood stream, such as into a body cavity or
into a lumen of an
organ. Substantially higher dosages are possible in topical administration.
Actual methods
for preparing parenterally administrable compositions are readily available.
The compositions containing modulators of ovarian cancer proteins can be
administered for therapeutic or prophylactic treatments. In therapeutic
applications,
compositions are administered to a patient suffering from a disease (e.g., a
cancer) in an
amount sufficient to cure or at least partially arrest the disease and/or its
complications. An
amount adequate to accomplish this is defined as a "therapeutically effective
dose." Amounts
effective for this use will depend upon the severity of the disease and the
general state of the
patient's health. Single or multiple administrations of the compositions may
be administered
depending on the dosage and frequency as required and tolerated by the
patient. In any event,
the composition should provide a sufficient quantity of the agents of this
invention to
effectively treat the patient. An amount of modulator that is capable of
preventing or slowing
the development of cancer in a mammal is referred to as a "prophylactically
effective dose."
The particular dose required for a prophylactic treatment will depend upon the
medical
condition and history of the mammal, the particular cancer being prevented, as
well as other
factors such as age, weight, gender, administration route, efficiency, etc.
Such prophylactic
81
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
treatments may be used, e.g., in a mammal who has previously had cancer to
prevent a
recurrence of the cancer, or in a mammal who is suspected of having a
significant likelihood
of developing cancer based, e.g., in part, upon gene expression profiles.
Vaccine strategies
may be used, in either a DNA vaccine form, or protein vaccine.
It will be appreciated that the present ovarian cancer protein-modulating
compounds
can be administered alone or in combination with additional ovarian cancer
modulating
compounds or with other therapeutic agent, e.g., other anti-cancer agents or
treatments.
In numerous embodiments, one or more nucleic acids, e.g., polynucleotides
comprising nucleic acid sequences set forth in Tables 1-26, such as RNAi,
antisense
polynucleotides or ribozymes, will be introduced into cells, in vitro or in
vivo. The present
invention provides methods, reagents, vectors, and cells useful for expression
of ovarian
cancer-associated polypeptides and nucleic acids using in vitro (cell-free),
ex vivo or in vivo
(cell or organism-based) recombinant expression systems.
The particular procedure used to introduce the nucleic acids into a host cell
for
expression of a protein or nucleic acid is application specific. Many
procedures for
introducing foreign nucleotide sequences into host cells may be used. These
include the use
of calcium phosphate transfection, spheroplasts, electroporation, liposomes,
microinjection,
plasma vectors, viral vectors and any of the other well known methods for
introducing cloned
genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host
cell. See,
e.g., Berger and Kimmel (1987) Guide to Molecular Cloning Techniques from
Methods in
Enzymolo~y (vol. 152) Academic Press; Ausubel, et al. (eds. 1999 and
supplements) Current
Protocols Lippincott; and Sambrook, et al. (2001) Molecular Cloning: A
Laboratory Manual
(3d ed., Vol. 1-3) CSH Press.
In a preferred embodiment, ovarian cancer proteins and modulators are
administered
as therapeutic agents, and can be formulated as outlined above. Similarly,
ovarian cancer
genes (including both the full.-length sequence, partial sequences, or
regulatory sequences of
the ovarian cancer coding regions) can be administered in a gene therapy
application. These
ovarian cancer genes can include antisense applications, either as gene
therapy (e.g., for
incorporation into the genome) or as antisense compositions, as will be
appreciated by those
in the art.
Ovarian cancer polypeptides and polynucleotides can also be administered as
vaccine
compositions to stimulate HTL, CTL, and antibody responses.. Such vaccine
compositions
can include, e.g., lipidated peptides (see, e.g., Vitiello, et al. (1995) J.
Clin. Invest. 95:341-
82
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
349), peptide compositions encapsulated in poly(D,L-lactide-co-glycolide,
"PLG")
microspheres (see, e.g., Eldridge, et al. (1991) Molec. Immunol. 28:287-294;
Alonso, et al.
(1994) Vaccine 12:299-306; Jones, et al. (1995) Vaccine 13:675-681), peptide
compositions
contained in immune stimulating complexes (ISCOMS; see, e.g., Takahashi, et
al. (1990)
Nature 344:873-875; Hu, et al. (1998) Clin. Exp. Immunol. 113:235-243),
multiple antigen .
peptide systems (MAPS; see, e.g., Tam (1988) Proc. Nat'1 Acad. Sci. USA
85:5409-5413;
Tam (1996) J. Immunol. Methods 196:17-32), peptides formulated as multivalent
peptides;
peptides for use in ballistic delivery systems, typically crystallized
peptides, viral delivery
vectors (Perkus, et al., p. 379, in Kaufmann (ed. 1996) Concepts in Vaccine
Development de
Gruyter; Chakrabarti, et al. (1986) Nature 320:535-537; Hu, et al. (1986)
Nature 320:537-
540; Kieny, et al. (1986) AIDS Bio/Technolo~y 4:790-795; Top, et al. (1971) J.
Infect. Dis.
124:148-154; Chanda, et al. (1990) Virolo~y 175:535-547), particles of viral
or synthetic
origin (see, e.g., Kofler, et al. (1996) J. hmnunol. Methods 192:25-35;
Eldridge, et al. (1993)
Sem. Hematol. 30:16-24; Falo, et al. (1995) Nature Med. 7:649-653), adjuvants
(Warren, et
a1. (1986) Ann. Rev. Immunol. 4:369-388; Gupta, et al. (1993) Vaccine 11:293-
306),
liposomes (Reddy, et a1.(1992) J. Immunol. 148:1585-1589; Rock (1996) Immunol.
Today
17:131-137), or, naked or particle absorbed cDNA (Ulmer, et al. (1993) Science
259:1745-
1749; Robinson, et al. (1993) Vaccine 11:957-960; Shiver, et al., p. 423, in
Kaufmann (ed.
1996) Concepts in Vaccine Development de Gruyter; Cease and Berzofsky (1994)
Ann. Rev.
Immunol. 12:923-989; and Eldridge, et al. (1993) Sem. Hematol. 30:16-24).
Toxin-targeted
delivery technologies, also known as receptor mediated targeting, such as
those of Avant
Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.
Vaccine compositions often include adjuvants. Many adjuvants contain a
substance
designed to protect the antigen from rapid catabolism, such as aluminum
hydroxide or
mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella
pertussis, or
Mycobacterium tuberculosis derived proteins. Certain adjuvants are
commercially available
as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco
Laboratories, Detroit,
MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline
Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel
(alum) or
aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of
acylated
tyrosine; acylated sugars; cationically or anionically derivatized
polysaccharides;
polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil
A.
Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth
factors, may also be
83
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
used as adjuvants.
Vaccines can be administered as nucleic acid compositions wherein DNA or RNA
encoding one or more of the polypeptides, or a fragment thereof, is
administered to a patient.
See, e.g., Wolff et. al. (1990) Science 247:1465-1468; U.S. Patent Nos.
5,580,859; 5,589,466;
5,804,566; 5,739,118; 5,736,524; 5,679,647; and WO 98/04720. Examples of DNA-
based
delivery technologies include "naked DNA", facilitated (bupivicaine, polymers,
peptide-
mediated) delivery, cationic lipid complexes, and particle-mediated ("gene
gun") or pressure-
mediated delivery (see, e.g., U.S. Patent No. 5,922,687).
For therapeutic or prophylactic immunization purposes, the peptides of the
invention
can be expressed by viral or bacterial vectors. Examples of expression vectors
include
attenuated viral hosts, such as vaccinia or fowlpox. This approach involves
the use of
vaccinia virus, e.g., as a vector to express nucleotide sequences that encode
ovarian cancer
polypeptides or polypeptide fragments. Upon introduction into a host, the
recombinant
vaccinia virus expresses the immunogenic peptide, and thereby elicits an
immune response.
Vaccinia vectors and methods useful in immunization protocols are described
in, e.g., U.S.
Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG
vectors are
described in Stover, et al. (1991) Nature 351:456-460. A wide variety of other
vectors useful
for therapeutic administration or immunization e.g., adeno and adeno-
associated virus
vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax
toxin vectors, and the
like, will be apparent. See, e.g., Shata, et al. (2000) Mol. Med. Today 6:66-
71; Shedlock, et
al. (2000) J. Leukoc. Biol. 68:793-806; and Hipp, et al. (2000) In Vivo 14:571-
85.
Methods for the use of genes as DNA vaccines are well known, and include
placing
an ovarian cancer gene or portion of an ovarian cancer gene under the control
of a regulatable
promoter or a tissue-specific promoter for expression in an ovarian cancer
patient. The
ovarian cancer gene used for DNA vaccines can encode full-length ovarian
cancer proteins,
but more preferably encodes portions of the ovarian cancer proteins including
peptides
derived from the ovarian cancer protein. In one embodiment, a patient is
immunized with a
DNA vaccine comprising a plurality of nucleotide sequences derived from an
ovarian cancer
gene. For example, ovarian cancer-associated genes or sequence encoding
subfragments of an
ovarian cancer protein are introduced into expression vectors and tested for
their
immunogenicity in the context of Class I MHC and an ability to generate
cytotoxic T cell
responses. This procedure provides for production of cytotoxic T cell
responses against cells
which present antigen, including intracellular epitopes.
84
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
In a preferred embodiment, the DNA vaccines include a gene encoding an
adjuvant
molecule with the DNA vaccine. Such adjuvant molecules include cytokines that
increase
the immunogenic response to the ovarian cancer polypeptide encoded by the DNA
vaccine.
Additional or alternative adjuvants are available.
In another preferred embodiment ovarian cancer genes find use in generating
animal
models of ovarian cancer. When the ovarian cancer gene identified is repressed
or
diminished in cancer tissue, gene therapy technology, e.g., wherein antisense
RNA directed
to the ovarian cancer gene will also diminish or repress expression of the
gene. Animal
models of ovarian cancer find use in screening for modulators of an ovarian
cancer-
associated sequence or modulators of ovarian cancer. Similarly, transgenic
animal
technology including gene knockout technology, e.g., as a result of homologous
recombination with an appropriate gene targeting vector, will result in the
absence or
increased expression of the ovarian cancer protein. When desired, tissue-
specific expression
or knockout of the ovarian cancer protein may be necessary.
It is also possible that the ovarian cancer protein is overexpressed in
ovarian cancer.
As such, transgenic animals can be generated that overexpress the ovarian
cancer protein.
Depending on the desired expression level, promoters of various strengths can
be employed
to express the transgene. Also, the number of copies of the integrated
transgene can be
determined and compared for a determination of the expression level of the
transgene.
Animals generated by such methods find use as animal models of ovarian cancer
and are
additionally useful in screening for modulators to treat ovarian cancer.
Kits for Use in Diagnostic andlor Prognostic Applications
For use in diagnostic, research, and therapeutic applications suggested above,
kits are
also provided by the invention. In the diagnostic and research applications
such kits may
include any or all of the following: assay reagents, buffers, ovarian cancer-
specific nucleic
acids or antibodies, hybridization probes and/or primers, siRNA or antisense
polynucleotides,
ribozymes, dominant negative ovarian cancer polypeptides or polynucleotides,
small
molecules inhibitors of ovarian cancer-associated sequences etc. A therapeutic
product may
include sterile saline or another pharmaceutically acceptable emulsion and
suspension base.
In addition, the kits may include instructional materials containing
directions (e.g.,
protocols) for the practice of the methods of this invention. While the
instructional materials
typically comprise written or printed materials they are not limited to such.
Any medium
~5
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
capable of storing such instructions and communicating them to an end user is
contemplated
by this invention. Such media include, but are not limited to electronic
storage media (e.g.,
magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and
the like. Such
media may include addresses to Internet sites that provide such instructional
materials.
The present invention also provides for kits for screening for modulators of
ovarian
cancer-associated sequences. Such kits can be prepared from readily available
materials and
reagents. For example, such kits can comprise one or more of the following
materials: an
ovarian cancer-associated polypeptide or polynucleotide, reaction tubes, and
instructions for
testing ovarian cancer-associated activity. Optionally, the kit contains
biologically active
ovarian cancer protein. A wide variety of kits and components can be prepared
according to
the present invention, depending upon the intended user of the kit and the
particular needs of
the user. Diagnosis would typically involve evaluation of a plurality of genes
or products.
The genes will be selected based on correlations with important parameters in
disease which
may be identified in historical or outcome data.
1S
EXAMPLES
Example 1: Gene Chip Analysis
Molecular profiles of various normal and cancerous tissues were determined and
analyzed using gene chips. RNA was isolated and gene chip analysis was
performed as
described (Glynne, et al. (2000) Nature 403:672-676; Zhao, et al. (2000) Genes
Dev. 14:981-
993).
TABLE 1A lists about 1119 genes up-regulated in ovarian cancer compared to
normal adult tissues. These were selected from 59000 probesets on the
AffymetrixlEos Hu03
GeneChip array such that the ratio of "average" ovarian cancer to "average'
normal adult tissues was greater Than or equal to 5Ø The "average" ovarian
cancer level was set to
the 80th percentile value amongst various ovarian cancers. The "average"
normal adult tissue level was set to the 85th percenUle amongst various non-
malignant tissues.
3O TABLE tA: ABOUT 1119 UP-REGULATED OVARIAN CANCER GENES
Pkey: Primekey
Ex. Accn:
Exemplar
Accession
UGID: UniGeneID
rUe: UniGenetitle
ratio: ratio
tumor vs
normal
Ussues
Pkey Ex. UG Title ratio
Accn ID
423634 AW959908Hs.1690heparin-binding growth 65.7
factor binding protein
423017 AWt78761Hs.227948'serine (or cysfeine) 63.6
proteinase inhibitor,
Glade B(ovalbumi
432938 T27013Hs.3132steroidogenic acute 58.3
regulatory protein
445810 AW265700Hs.155660ESTs 35.9
431938 AA938471Hs.115242developmentally regulated32.0
GTP-binding protein
1
407112 AA070801Hs.51615"ESTs, Weakly similar 31.3
to ALU7-HUMAN ALU SUBFAM
425650 NM-001944Hs.1925desmoglein 3 (pemphigus30.0
vulgaris antigen)
402075 predicted exon 27.9
400301 X03635Hs.1657estrogenreceptorl 26.4
86
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
402639 predicted exon 25.3
421948L42583Hs.111758kerafin 6A 24.7
414540BE379050 "gb:601236655F1 NIH 24.6
MGC_44 Homo Sapiens
cDNA clon
418994AA296520Hs.89546selecfin E (endothelial24.5
adhesion molecule 1)
401575 predicted exon 23.6
457024AA397546Hs.119151ESTs 23.2
440684A1253123Hs.127356"ESTs, Highly similar 23.1
to NEST-HUMAN NESTI
[H.sapien
459006AW298631Hs.27721hypothetical protein 22.8
FLJ20353
400964 predicted exon 22.5
1 402421 predicted exon 20.9
~
437329AA811977Hs.291761ESTs 20.8
414605BE390440 "g6:60128360iF1 N1H 20.7
MGC 44 Homo sapiens
cDNA clon
411004AW813242 'gb:MR3-ST0191-020200-207-g10ST019120.4
Homosapiens
401283 predicted exon 20.3
1 440633AI140686Hs.263320ESTs 19.9
445603H08345Hs.106234ESTs 19.7
403786 predicted exon 19.7
436508AW6D4381Hs.121121ESTs 19.6
459390BE385725 "gb:601276347F1 NIH_MGC-2019.2
Homo Sapiens cDNA clon
421823N40B50Hs.28625ESTs 19.0
417366BE185289Hs.1076small proline-rich protein18.9
18 (comifin)
422525AA758797Hs.192807ESTs 18.5
458121S42416Hs.74647Human T-cell receptor 18.3
acfive alpha-chain
mRNA from JM c
430520NM_016190Hs.242057chromosome 1 open reading18.1
frame 10
25 450192AA263143Hs.24596RAD51-interacting protein18.0'
416839H94900Hs.17882ESTs 17.9
440788A1806594Hs.128577ESTs 17.9
451072AA013451Hs.117929ESTs 17.7
402203 predicted exon 17.3
417611AW993983 "gb:RC1-BN0035-130400-013-a0417.3
BN0035 Homo Sapiens
438658AI222068Hs.123571ESTs 17.3
403747 predicted exon 17.2
444958AW292643Hs.167047ESTs 17.2
404097 predicted exon 17.1
35 459375BE251770 "gb:601112470FiNIH MGC_l6HomosapienscDNAclon16.9
443198A1039813 gb:ox49dD6.x1 Soares 16.9
total-fetus Nb2HF8
9w Homo sapi
441557AW452647Hs.270482ESTs 16.9
433871W02410Hs.205555ESTs 16.8
429163AA884766 gb:am20a10.s1 Soares_NFL_T16.7
GBC S1 Homo Sapiens
cD
443406A1056238Hs.143316ESTs ' 16.7
400613 predicted exon 16.6
448372AWd45166Hs.170802ESTs 16.5
410929H47233Hs.30643ESTs 16.5
445687A1263105Hs.145597ESTs 16.1
45 422036AA302647Hs.271891ESTs 16.0
404767 predicted exon 15.9
420831AA280824Hs.190035ESTs 15.8
405196 predicted exon 15.8
452947AW130413 "gb:xf50104.x1 NCI-CGAP_Gas415.8
Homo sapiens cDNA clo
429538BE182592Hs.139322small proline-rich protein15.8
3
d35313AI769400Hs.189729ESTs 15.7
449635AI989942Hs.232150ESTs 15.6
424098AF077374Hs.139322small praline-rich protein15.4
3
411660AW855718 "gb:RCt-CT0279-070100-021-a0615.4
CT0279 Homo Sapiens
c
55 442653BE269247Hs.170226Homo Sapiens clone 2357915.4
mRNA sequence
443534A1076123 gb:oy92e04.x1 Soares 15.4
' fetal-liver_spleen_1NFLS_S1
Homo
458012At424899Hs.188211ESTs 15.3
441018A1809587Hs.148782ESTs 15.1
425972BE391563Hs.165433"ESTs, Highly similar 15.1
to T17342 hypothefical
protein DKFZ
60 418092845154Hs.106604ESTs 15.1
410909AW898161Hs.53112"ESTs, Weakly similar 15.1
to ALUB-HUMAN ALU SUBFAM
458234BE551408Hs.127196ESTs 15.0
4342D8T92641Hs.127648hypotheficalprotein 15.0
PR02176
d03177 predicted exon 15.0
6 423725AJ4D3108Hs.132127hypotheficalprotein 14.9
5 LOC57822
425090AA350552 "gb:EST57886 Infant 14.7
brain Homo Sapiens
cDNA 5' end, m8
409723AW885757Hs.257862ESTs 1d.6
423735AA330259 "gb:EST33963 Embryo,12 14.6
week II Homo Sapiens
cDNA 5'
444266AI424984Hs.125465ESTs 14.5
443341AW631480Hs.8688ESTs 14.4
457336AW969657Hs.291029ESTs 14.4
440500AA972165Hs.150308ESTs 14.4
446292AF081497Hs.279682Rh type C glycoprotein 14.3
438086AA336519Hs.301167"Homo Sapiens cDNA: 14.3
FLJ21545 fir, clone
COL06195"
75 434715BE005346Hs.116410ESTs 14.2
409387AW384900Hs.123526ESTs 14.2
409272A8014569Hs.52526KIAA0669 gene product 14.2
454913AW841462 "gb:RC6-CN0014-080300-012-80914.0
CN0014 Homo Sapiens
439846T63959Hs.228320'Homo Sapiens cDNA: 14.0
FLJ23537 fir, clone
LNG07690"
409695AA296961 "gb:EST112514 Adrenal i3.9
gland tumor Homo Sapiens
cDNA
422897AA679784Hs.4290ESTs 13.9
d04664 predicted exon 13.9
458829AI557388 "gb:PT2.1 6 G03.r tumor213.8
Homo Sapiens cDNA 3',
mRNA
407327AA487182Hs.269414ESTs 13.8
g7
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
455435AW939445 'gb:OV1-DT0072-310100-056-b0713.7
OT0072 Homo Sapiens
449327AI638743Hs.224672ESTs 13.7
411693AW857271 "gb:CMO-CT0307-210100-158-g0913.7
CT0307 Homo Sapiens
407463AJ272034 gb:Homo Sapiens mRNA 13.6
for putative capacitative
calcium c
446767AI380107Hs.158954ESTs 13.6
433040H70423Hs.300511ESTs 13.5
435209AW027809Hs.187698'ESTs, Highly similar 13.5
to cytomegaloviros partial
fusion race
441459AI919142Hs.214233ESTs 13.5
401269 predicted axon 13.4
1 438663AI199575Hs.153070ESTs 13.4
~
426698AA394104Hs.97489ESTs 13.4
423637AL137279Hs.130187Homo Sapiens mRNA; cDNA 13.2
DKFZp43401214 (from
clon
448543AW897741Hs.21380Homo Sapiens mRNA; cDNA 13.2
DKFZp586P1124 (from
clon
456714AW897265 'gb:CMO-NN0057-150400-335-a0413.2
NN0057 Homo Sapiens
1 458356A1024855Hs.131575ESTs 13.2
.
431822AA516049 "gb:ng65d01.s1 NCI CGAP_Lip213.1
Homo Sapiens cDNA clo
454822AW833793 'gb:OV4-TT0008-130100-O80-a0613.1
TT0008 Homo Sapiens
c
453358AI990738Hs.240066ESTs 13.1
435542AA687376Hs.269533ESTs 13.1
421286AA806584Hs.187895ESTs 13.0
452799AI948829Hs.213786ESTs 13.0
444355BE383686Hs.191621ESTs 13.0
444271AW452569Hs.149804ESTs 12.9
443860AW866632 'gb:OV4-SN0024-210400-181-g0412.9
SN0024 Homo Sapiens
428719AA358193Hs.193128hypothetical prgtein 12.9
FLJ10805
418282AA215535Hs.98i33ESTs 12.8
437308AA749417Hs.292353ESTs 12.7
400584 predicted axon 12.7
426306AA447310Hs.164059'Homo Sapiens cDNA FLJi333812.7
fis, clone OVARC100188
448466AI522109Hs.171066ESTs 12.7
402738 predicted axon 12.7
451531AA018311Hs.114762ESTs 12.6
435243AW292886Hs.261373adenosine A2b receptor 12.6
pseudogene
431725X65724Hs.2839Norrie disease (pseudoglioma)12.6
35425108A1000489Hs.96967ESTs 12.5
422330D30783Hs.i15263epiregulin 12.5
432949AA570749Hs.298866ESTs 12.5
417009AA19i719Hs.171872DEADIH (Asp-Glu-Ala-AspIHis)12.4
box polypeptide 8 (RNA
456378AA843387Hs.87279ESTs 12.4
40432966AA650114 "gb:ns92h09.s1 NCI-CGAP_Pr312.4
Homo Sapiens cDNA clon
440571AA904461Hs.130798ESTs 12.3
411178AW820852 'gb:RC2-ST0301-120200-011-f1212.3
ST0301 Homo Sapiens
c
445934AF131737Hs.13475hypothetical protein 12.3
433917AI809325Hs.i Human DNA sequence from 12.2
22814clone RP5-1028Di5 on
chrom
4S402018 predicted axon 12.2
424101AA335394 "gb:EST39787 Epididymus 12.2
Homo Sapiens cDNA 5'
end, mR
448533AL119710Hs.21365nucleosome assembly protein12.1
1-like 3
458154AW816379 "gb:OV4-ST0234-181199-035-g0112.1
ST0234 Homo sapiens
c
440919AW291274Hs.262826ESTs 12.0
415747AA381209 "gb:EST94257 Activated 12.0
T-cells I Homo Sapiens
cDNA 5' a
411748AW859920 "gb:OV1-CT03o4-260100-052-g0512.0
CT0364 Homo sapieos
452975M85521Hs.69469dendritic cell protein 12.0
427276AA400269Hs.49598ESTs 12.0
454315AW373564Hs.251928nuclear pore complex 12.0
interacting protein
5 450786H86632Hs.33654ESTs 12.0
J
402578 predicted axon 11.9
459591AL037185 gb:DKFZp564Ai 169 r1 11.9
564 (synonym: hibr2)
Homo sapie
433449AW772282 'gb:hn71b05.x1NCl_CGAP_KidilHomosapienscDNAc11.9
429108AA890521Hs.126035ESTs 11:8
454556AW807073 'gb:MR4-ST0062-031199-018-40611.7
ST0062 Homo Sapiens
443613A1079356 gb:oz39b09.s1 Soares 11.7
NhHMPu-St HomosapienscDNAc
400385NM Hs.283104putative capacitative 11.6
020389 calcium channel
411725AW858396 "gb:CMO-CT0341-181299-130-c0611.5
CT0341 Homo Sapiens
455174A1694575Hs.147801ESTs 11.5
65412402AW984788 "gb:RC1-HN0015-120400-021-c0711.5
HN0015 Homo Sapiens
434205AF119861Hs.283032hypothetical protein 11.5
PR02015
450496AW449251Hs.257131ESTs 11.5
411149N68715Hs.269128ESTs 11.5
414210HE383592 'gb:601297871F1 NIH MGC-1911.4
Homo sapiens cDNAclon
409994D86864Hs.57735acetyl LDL receptor; 11.3
SREC
453845AL157568 gb:DKFZp761F0816_r1761 11.3
(synonym: hamy2) Homo
sapi
404849 predicted axon 11.3
442824BE178065Hs.144081ESTs 11.3
428548AA430058Hs.98649EST 11.3
75434804AA649530 'gb:ns44f05.s1 NCI CGAP-Alvt11.3
Homo Sapiens cDNA clo
430486BE062109Hs.241551'chloride channel, calcium11.3
activated, family member
2"
400174 predicted axon 11.2
424324AA346316 'gb:EST52440 Greater 11.2
omentum tumor Homo Sapiens
cDN
447724AW298375Hs.24477ESTs 11.2
457028AW449838Hs.97562ESTs 11.2
429900AA460421Hs.30875ESTs 11.2
452240AI591147Hs.61232ESTs 11.2
458067AA393603Hs.36752"Homo Sapiens cDNA: FLJ2283411.1
fis, clone KAIA4314'
402222 predicted axon 11.1
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
446745AW118189Hs.156400ESTs 11.1
453060AW29d092Hs.21594ESTs 11.1
443482AW188093Hs.250385ESTs 11.1
436843M824588 "gb:oc83d02.s1 NCI_CGAP_GCB111.0
Homo Sapiens cDNA c
416320H47867Hs.34024ESTs 11.0
435772AA700019Hs.132992"ATP-binding cassette, 11.0
sub-family G (WHITE),
member 5 (
451542AA018365Hs.32713ESTs 11.0
408522AI541214Hs.46320"Small proline-rich protein11.0
SPRK [human, odontogenic
kera
414712N88858.compHs.77039ribosomal protein S3A 10.9
1 411940AW876686 "gb:CM4-PT0031-180200-507-e0510.9
~ PT0031 Homo Sapiens
c
408733AW264812Hs.254290ESTs 10.9
452030AL137578Hs.27607Homo Sapiens mRNA; cDNA 10.9
DKFZp56dN2464 (from
clon
458175AW296024Hs.150434ESTs . 10.9
400612 predicted exon 10.9
1 440159AI637599Hs.126127ESTs 10.8
429443A8028967Hs.202687"potassium voltage-gated10.8
channel, Shal-related
subfamily, m
416319AI815601Hs.79197"CD83 anflgen (activated10.8
B lymphocytes, immunoglobulin
s
405783 predicted exon 10.7
405708 predicted exon 10.7
433266AI863224Hs.288677"Homo sapiens cDNA FLJ1387210.6
fis, clone THYR0100132
456900AA355442Hs.i69054ESTs 10.6
432408N39127Hs.76391"myxovirus (influenza) 10.6
resistance 1, homolog
of murine (int
451702AW665452Hs.246503ESTs 10.6
418179X51630Hs.1145Wilms tumor 1 10.6
25 408987H85615 gb:yt03f11.r1 Soares 10.6
reflna N2b5HR Homo sapiens
cDNA
405285 predicted exori 10.5
419276BE165909Hs.134682"Homo Sapiens cDNA: FLJ2316110.5
fls, clone LNG09730"
407287AI678812Hs.201658"ESTs, Weakly similar 10.5
to ALU4_HUMAN ALU SUBFAM
403065 predicted exon 10.5
414195BE263293 "gb:601144881 F2 NIH 10.4
MGC 19 Homo Sapiens
cDNA clan
454258AI457286Hs.i43979"ESTs, Weakly similar 10.4
to KIAA1276 protein
[H.sapiens]"
412951BE018611Hs.251946"Homo Sapiens cDNA: FLJ2310710.4
fis, clone LNG07738"
428888AA437010Hs.266584ESTs 10.4
440834AA907027Hs.128606ESTs 10.4
437096AA744d06 "gb:ny51h02.s1 NCI_CGAP_Prl810.4
Homo Sapiens cDNA clo
400135 predicted exon 10.4
447849AI538147Hs.164277ESTs 10.3
400593 predicted exon 10.3
427469AA403084Hs.269347ESTs 10.3
402794 predicted exon 10.2
452743AW965082Hs.61455ESTs 10.2
448983AI611654Hs.224908ESTs 10.2
422696AF242524Hs.26323hypothetical nuclear 10.2
factor 588122
428949AA442153Hs.104744"ESTs, Weakly similar 10.2
io AF2088551 BM-013
[H.sapiens]
45 409191AW818390 "gb:RCt-ST0278-160200-014-41010.2
5T0278 Homo Sapiens
c
428493AK001745Hs.184628hypotheflcai protein 10.2
FLJ10883
406076AL390179Hs.137011Homo Sapiens mRNA; cDNA 10.2
DKFZp547P134 (from clone
410626BE407727 "gb:60i299771F1 NIH_MGC_2110.1
HomosapienscDNAclon
445835AW290999Hs.145534chromosome 21 open reading10.1
frame 23
452507AI904646 "gb:OV-BT065-020399-103 10.1
BT065 Homo Sapiens cDNA,
m
433297AV658581Hs.282633ESTs 10.1
426724AA383623Hs.293616ESTs 10.0
436659AI217900Hs.144464ESTs 10.0
405675 predicted exon 10.0
S 413466BE141737Hs.254105"enolase 1, (alpha)" 10.0
5
447198D61523Hs.283435ESTs 10.0
403306NM Hs.74368"transmembrane protein 10.0
006825 (63kD), endoplasmic
reticulumlGo
413544BE147225 "gb:PM2-HT0225-031299-003-f119.9
HT0225 Homo Sapiens
437094AW103746Hs.136907ESTs 9.9
401497 predicted exon 9.9
416203H27794Hs.269055ESTs 9.9
426882AA393108Hs.97365ESTs 9.9
454874AW836407 "gb:PM3-LT0031-301299-002-b099.9
LT0031 Homo Sapiens
406702220656Hs.278432"myosin, heavy polypeptide9.9
6, cardiac muscle, alpha
(cardio
65 404952 predicted exon 9.9
430691C14187Hs.103538ESTs 9.9
444518A1160278Hs.146884ESTs 9.8
416665H72974 gb:yu28a10.s1 Soaresfetal9.8
liver spleen iNFLS Homosapie
438691AA906288Hs.212184ESTs 9.8
405636 predicted exon 9.8
437242AA747538Hs.187942ESTs 9.8
425627AF019612Hs.297007ESTs 9.8
452226AA024898Hs.296002ESTs 9.8
418986A1i23555Hs.81796ESTs 9.8
75 441139AW449009Hs.126647ESTs 9.7
427244AA402400Hs.178045ESTs 9.7
423756AA828125 "gb:od71a09.s1 NCI CGAP-Ov2HomosapienscDNAclo9.7
457940AL360159Hs.30445Homo Sapiens mRNA full 9.6
length insert cDNA clone
EURO
443526AW792804Hs.134002ESTs~ 9.6
440576AW449775Hs.126008ESTs 9.6
419088AI538323Hs.77496small nuclear ribonucleoprotein9.6
polypepflde G
454707AW814989 "gb:MR1-ST0206-170400-024-g059.6
ST020fi Homo Sapiens
446252A1283125Hs.150009ESTs 9.6
434374AA631439 "gb:np86d02.s1 NCI-CGAP 9.6
Thy1 Homo Sapiens cDNA
c7
89
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
403093 predicted exon 9.6
454633AW811380 "gbaL3-ST0143-290999-019-D059.6
ST0143 Homo Sapiens
c
407291AA001464 gb:ze45b01.r1 Soares 9.5
refina N2b4HR Homo
Sapiens cDNA
455203AW865450 'gb:PM4-SN0020-010400-00&b099.5
SN0020 Homo sapiens
403647 predicted exon 9.5
401530 predicted exon 9.5
414281BE269751Hs.288995hypothefical protein 9.5
FW20813
411057AW815098 'gb:OV4-ST0212-091199-023-f109.5
ST0212 Homo sapiens
c
415953H14425Hs.27947ESTs 9.5
1 450174T82121Hs.177285ESTs 9.5
0
422949AA319435 "gb:EST21657 Adrenal 9.5
gland tumor Nomo Sapiens
cONA 5
402112856624Hs.2186eukaryotic translation 9.5
elongation factor 1
gamma
457886AA742279Hs.293346ESTs 9.4
458145At239457Hs.130794ESTs ~ 9.4
15 452332AW014859Hs.101657ESTs 9.4
~
434950AW974892 "gb:EST386997 MAGE resequences,9.3
MAGN Homo sapien
409601AF237621Hs.80828keratin 1 (epidermolytic9.3
hyperkeratosis)
419968X04430Hs.93913'iniedeukin 6 (interferon,9.3
beta 2)"
436211AIf001581Hs.80961"polymerase (DNA directed),9.3
gamma'
2,0428412AA4282d0Hs.126083ESTs 9.3
449441AI656040Hs.196532ESTs 9.3
458771AW295151Hs.163612ESTs 9.3
458543AA213403Hs.257542ESTs 9.3
414257A1828600Hs.21124"ESTs, Weakly similar 9.3
to ALUS_HUMAN ALU SUBFAM
442826A1018777Hs.131241ESTs ' 9.3
446740A1611635Hs.192605ESTs ' 9.2
408938AA059013Hs.22607ESTs 9.2
434157A1538316Hs.158451ESTs 9.2
408774AW270899Hs.254569ESTs 9.2
424268AA397653Hs.144339Human DNA sequence from9.2
clone 495010 on chromosome
415715F30364 "gb:HSPD20786 HM3 Homo 9.1
Sapiens cDNA clone
s400009
405277 predicted exan 9.1
412167AW897230 "gb;CMO-NN0057-150400-335-al9.1
l NN0057 Homo Sapiens
442771AWd09808Hs.101550ESTs 9.1
35 404898 predictedexon 9.1
401230 predicted exon 9.1
400623 predicted exan 9.1
418808AI821836Hs.10359ESTs 9.1
436396AI683487Hs.299112'Homo Sapiens cDNA FLJ 9.1
11441 fis, clone HEMBA100132
40 440466AA885871Hs.i35727ESTs 9.0
437568A1954795Hs.156135ESTs 9.0
405382 predicted exon 9.0
435673AF202961Hs.284200"Homo Sapiens uncharacterized9.0
gastric protein ZG12P
mRN
405848 predicted exon 9.0
45 437229AW976005 'gb:EST388114 MAGE resequences,9.0
MAGN Homo sapien
417728AW138437Hs.24790ICIAA1573 protein 9.0
454597AW809648 ~gb:MR4-5T0124-261099-015-d0i9.0
ST0124 Homo Sapiens
427093AA398118Hs.97579ESTs 9.0
408000L11690Hs.620bullous pemphigoid antigen9.0
1 (2301240kD)
50 440556AW206958Hs.125968ESTs 9.0
400163
predicted exon
.9
420120AL049610Hs.95243transcripfion elongation8.9
factorA (SII)-like
1
417549AA203651 gb:zx58fi0.r1 Soares 8.9
fetal liver-spleen_1NFLS
S1 Homo
406163 predicted exon 8.9
55 437918AI761449Hs.121629ESTs 8.9
449419834910Hs.119172ESTs 8.9
434683AW298724Hs.202639ESTs 8.9
418432M14156Hs.85112insulin-like growth 8.9
factor 1 (somatomedia
C)
454590AW809762Hs.222056"Homo Sapiens cDNA FLJ115728.8
fis, clone HEMBA100337
60 454574AW809109 ~gb:MR4-ST0117-070100-027-a048.8
ST0117 Homo Sapiens
c
441433AA933809Hs.42746ESTs 8.8
416858AW979294Hs.85634ESTs 8.8
421978AJ243662Hs.110196NICE-1 protein 8.8
451528AA018297Hs.35493ESTs 8.8
408751N91553Hs.258343ESTs 8.7
401862 predicted exon 8.7
417344AW997313 "gb:RC2-BN0048-250400-018-f128.7
BN0048 Homo sapiens
454455AW752710 'gb:IL3-CT0219-281099-024-A038.7
CT0219 Homo Sapiens
c
455592BE008002 "gb:QVO-BN0147-290400-214-h048.7
BN0147 Homo Sapiens
70 417650T05870Hs.100640ESTs 8.7
456309AA225A23 ~gb:nc24a12.r1 NCI_CGAP_Prt8.7
Homo Sapiens cDNA clon
432030AI908400Hs.143789ESTs 8.7
421492BE176990Hs.104916hypothetical protein 8.7
FLJ21940
402576 predicted exon 8.7
75 426874N67325Hs.247132ESTs 8.7
403334 predicted exon 8.7
408562AI436323Hs.31141"Homo sapiens mRNA for 8.7
IfIAA1568 protein,
partial cds"
439443AF086261Hs.127892ESTs 8.7
428600AW863261Hs.15036"ESTs, Highly similar 8.7
to AFi613581 HSPC095
[H.sapiens
414539BE379046 'gb:601236646F1 NIH_MGC-448.6
Homo Sapiens cDNA clon
432527AW975028Hs.102754ESTs 8.6
403273 predicted exon 8.6
452077BE144949 "gb:RC2-HT0187-041099-011-4128.6
HT0187 Homo Sapiens
444598A1288830Hs.149924ESTs 8.6
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
434066AF116649Hs.283944"Homo Sapiens PR00566 8.6
mRNA, complete cds"
429643AA455889Hs.187548ESTs 8.6
432340AA534222 gb:nj21d02.s1 NCI-CGAP-AA18.6
Homo Sapiens cDNA clon
446142AI754693Hs.145968ESTs 8.6
417412X16896Hs.82112'intedeukin 1 receptor, 8.6
type I"
416913AW934714 "gb:RC1-DT0001-031299-011-all8.5
DT0001 Homo Sapiens
451318AA029888Hs.95071ESTs 8.5
405547 predicted exon 8.5
423843AA332652 'gb:EST36627 Embryo, 8.5
8 week I Homo Sapiens
cDNA 5' en
1 454145AA046872Hs.62798ESTs 8.4
~
401200 predicted exon 8.4
404166 predicted exon 8.4
412761AW995092 "gb:OVO-BN0041-030300-145-a108.4
BN0041 Homo Sapiens
412333AW937485 'gb:OV3-DT0044-221299-045b098.4
DT0044 Homo Sapiens
15 455092BE152428 "gb:CMO-HT0323-151299-126-b048.4
HT0323 Homo Sapiens
419281N96452Hs.42189ESTs 8.4
446171A1374927 gbaa66c04.x1 Scares total-fetus8.3
Nb2HF8_9w Homo sapie
437362AL359561Hs.i6493,hypotheficalprotein DKFZp762N23168.3
402631 predicted exon 8.3
458573AV653838Hs.295131ESTs 8.3
439185AF087976Hs.233343ESTs 8.3
445881A1263029Hs.210689ESTs 8.3
449737A1668581Hs.246316ESTs 8.3
401830AJ004832Hs.5038neuropathytargetesterase8.3
25 421991NN[_014918Hs.110488KIAA0990 protein 8.3
416996W91892Hs.59609ESTs ' 8.2
443626A1540644Hs.138479"ESTs, Moderately similar8.2
to ALU7_HUMAN ALU SURF
407471D55644 gb:Human spleen PABL 8.2
(pseudoautosomal boundary-like
se
402664 predicted exon 8.2
417682W69561 gb:zd47a08.r1 Soares-fetal_heart_NbHHI9W8.2
Homo sapien
424983A1742434Hs.169911ESTs 8.2
434353AA630863Hs.131375"ESTs, Weakly similar 8.2
to ALUB-HUMAN !!!! ALU
CLAS
453448AL036710Hs.209527ESTs 8.2
455121BE156459 "gb:QVO-HT0368-040100-082-f068.2
HT0368 Homo Sapiens
35 404270 predicted exon 8.1
438297AW515196Hs.258238"ESTs, Moderately similar8.1
to ALU1 HUMAN ALU SUBF
418122842778Hs.22217ESTs 8.1
419929U90268Hs.93810cerebral cavernous malformations8.1
1
400925 predicted exon 8.1
40 403350 predicted exan 8.1
426116AA868729Hs.144694ESTs 8.1
441518AW161697Hs.294150ESTs 8.1
421888AA299780Hs.121036ESTs 8.1
402745 predicted exon 8.1
45 402071 prodicted exon 8.1
444781NM Hs.11950GPI-anchored metastasis-associated8.0
014400 protein homolog
430372AI206173Hs.211375ESTs 8.0
449867A1672379Hs.73919"clathrin, light polypepfide8.0
(Lcb)"
422174AL049325Hs.112493Nomo Sapiens mRNA; cDNA 8.0
DKFZp564D036 (from clone
413382BE090689 "gb:RCt-BT0720-280300-011-f088.0
BT0720 Homo Sapiens
c
456502A1798611Hs.157277ESTs 8,0
405336 predicted exon 8.0
405917 predicted exon 8.0
436007AI247716Hs.232168ESTs 8.0
S 439192AW970536Hs.105413ESTs 8.0
437724AW444828Hs.184323ESTs 8.0
452755AW138937Hs.213436ESTs 8.0
401781 predicted exon 7.9
406057 prodicted exon 7.9
406289AW068311Hs.82582"integrin, beta-like 7.9
1 (with EGF-like repeat
domains)"
421459AI821539Hs.97249ESTs 7.9
4482518E280486Hs.84045"Homo Sapiens cDNA FLJi 7.9
1979 fis, clone HEM88100128
429125AA446854Hs.271004ESTs 7.9
440154BE077129Hs.126119"Homo Sapiens cDNA FLJ132737.9
fis, clone OVARC100i01
65 413233AW578713Hs.47534"ESTs, Weakly similar 7.9
to ORF YKL201c [S.cerevisiae]"
438268AA782163Hs.293502ESTs 7.9
452466N84635Hs.29664Human DNA sequence from 7.9
clone 682J15 on chromosome
6
441194BE274581 "gb:601120870F1 NIH_MGC 7.9
20 Homo sapiens cDNA
clon
425292NM-005624Hs.15554537 kDa leucine-dch repeat7.9
(L88) protein
445090AW205208Hs.147293ESTs 7.9
431292AA370141Hs.251453Human DNA sequence from 7.9
clone 967N21 on chromosome
414266BE267834 "gb:601124428F1 NIH_MGC_87.8
Homo Sapiens cDNA clone
407839AA045144Hs.161566ESTs 7.8
456101AA159478 gb:zo74dO6.s1 Stralagene7.8
pancreas (937208) Homo
Sapiens
75 455853BE147225 'gb:PM2-HT0225-031299-003-f117.8
HT0225 Homo sapiens
414995C18200 gb:C18200 Human placenta7.8
cDNA (TFujiwara) Homo
sapie
447247AW369351Hs.287955"Homo Sapiens cDNA FLJ130907.8
fis, clone NT2RP3002142
416151T26661 "gb:A865C7R Infant brain,7.8
LLNL array of Dr. M.
Soares 1
446435AW206737Hs.253582ESTs 7.8
403698 prodicted exon 7.8
424914AA348410Hs.119065ESTs 7.8
409731AA125985Hs.56145'thymosin, beta, idenfified7.8
in neuroblastoma cells'
401604 predicted exon 7.8
413025AA805265Hs.291646ESTs 7.8
91
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
405896 predicted exon 7.8
454505AW801365 "gb:IL5-UM0067-240300-050-a017.7
UM0067 Homo Sapiens
448283AI340462Hs.182979ritwsomal protein L12 7.7
434098AA625499 'gb:af69g08.r1 Soares_NhHMPu_Si7.7
Homo Sapiens cDNA
431673AW971302Hs.293233ESTs 7.7
421029AW057782Hs.293053ESTs 7.7
408391AW859276 'gb:MR1-CT0352-240200-105-d027.7
CT0352 Homo Sapiens
422529AW015128Hs.256703ESTs 7.7
454389AW752571 "gb:IL3-CT0213-170100-055-F027.7
CT0213 Homo Sapiens
c
1 427821AA470158Hs.98202ESTs 7.7
~
434657AA641876Hs.191840ESTs 7.7
445628A13d4166Hs.155743ESTs 7.7
424872AA347923 "gb:EST54302 Fetal heart7.7
II Homo sapiens cDNA
5' end, m
439232Nd8590Hs.46693ESTs 7.7
1 441417AI733297Hs.144474ESTs 7.7
453596AA441838Hs.62905ESTs 7.7
430440X52599Hs.2561'nerve growth factor, 7.7
beta polypepGde"
413306AW303544Hs.118654ESTs 7.7
400968 predicted exon 7.7
446726AW300144Hs.209209'Homo Sapiens cDNA FLJ116297.7
fis, clone HEMBA100424
427504AA776743Hs.191589ESTs 7.7
405621 predicted exon 7.6
414127AI431863Hs.135270ESTs 7.6
409866AW502152 gb:Ul-HF-BROp-ajr-f 11-0-ULr17.6
NIN-MGC 52 Homo sap
446232AI281848Hs.165547ESTs 7.6
403568 predicted exon 7.6
451458A1797558Hs.270820ESTs 7.6
439157AA912737Hs.20160ESTs 7.6
401793 predicted exon 7.6
429839AI190291Hs.112143ESTs 7.6
445672A1907438Hs.282862ESTs 7.6
449444AW818436Hs.23590"salute carrier family 7.6
16 (monocarboxylic acid
transporters)
447499AW262580Hs.147674KIAA1621 protein 7.6
421773W69233Hs.112457ESTs 7.6
3 439706AW872527Hs.59761ESTs 7.5
5
432189AA527941 "gb:nh30c04.s1 NCI-CGAP-Pr37.5
Homo Sapiens cDNA clon
402050 predicted exon 7.5
429687AI675749Hs.211608nucleoporin 153kD 7.5
423193807299Hs.254837"Homo Sapiens cDNA FLJ135027.5
fis, clone PLACE1004836
40 416548H62953 gb:yr47f06.r1 Soares 7.5
fetal liver spleen iNFLS
Homo sapien
443236A1079496Hs.134169ESTs 7.5
436053A1057224Hs.15443ESTs 7.4
437191NM-006846Hs.5476"swine protease inhibitor,7.4
Kazal type, 5"
451829AW964081Hs.247377ESTs 7.4
45 443151AI827193Hs.132714ESTs 7.4
452055A1377431Hs.293772ESTs 7.4
445265A1218295Hs.144942ESTs 7.d
401032 predicted exon 7.4
448184BE541249Hs.109697ESTs 7.4
J~~414808795945 gb:ye42e02.r1SoaresfetalliverspleeniNFLSHomosapien7.4
418540AI821597Hs.90877"ESTs, Weakly similar 7.4
to ALU1 HUMAN ALU SUBFAM
410449AW748954Hs.18192SerIArg-related nuclear 7.4
matrix protein (plenty
of prolines 1
435568AA688048Hs.294080ESTs 7.4
459160A1904723 'gb:CM-BTO66-120299-092 7.4
BTO66 Homo sapiens cDNA,
J~ 419753N42531 gb:yy11c12.r1 Soares 7.4
5 melanocyte 2NbHM Homo
Sapiens cD
432383AK000144Hs.274449"Homo Sapiens cDNA FW201377.4
fis, clone COL07137"
404893 predicted exon 7.4'
425349AA425234Hs.79886ribose 5-phosphate isomerase7.4
A (ribose 5-phosphate
epimer
413864BE175582 "gb:RC5-HT0580-100500-022-C017.3
HT0580 Homo Sapiens
426871AA393041Hs.216493ESTs 7.3
415613820233 gb:yg18h11.r1 Soares 7.3
infant brain 1N18 Homo
Sapiens cDN
427025AA397589Hs.97523ESTs 7.3
444683A1375101Hs.158721"ESTs, Weakly similar 7.3
to ALU1 HUMAN ALU SUBFAM
447700AI420183Hs.171077"ESTs, Weakly similar 7.3
to similar to sednelthreonine
kinase
412740AW993984 "gb:RC1-BN0035-130400-013-a057.3
8N0035 Homo Sapiens
416642796118Hs.226313"ESTs, Weakly similar 7.3
to ALU1 FIUMAN ALU SUBFAM
416506H59879Hs.237306ESTs 7.3
426130AA853282 gb:NHTBCae04f07r1 Normal7.3
Human Trabecular Bone
Cell
407392A8032369 "gb:Homo Sapiens MIST 7.3
mRNA, partial cds."
432365AK001106Hs.274419hypothetical protein 7.3
FLJ10244
451221A1949701Hs.210589ESTs 7.3
443161A1038316 gb:ox48c08.x1 Soares 7.3
total fetus Nb2HF8 9w
Homo sapi
418186BE541042Hs.23240"Homo Sapiens cDNA FLJ134967.3
fis, clone PLACE1004471
439152H65014 gb:yu66f10.r1 Weizmann 7.2
Olfactory Epithelium
Homo sapie
75 459534BE386808Hs.147905ESTs 7.2
443326BE156494Hs.188478ESTs 7.2
417351790278Hs.15049ESTs 7.2
454182AW177335 "gb:CMi-CT0129-180899-006-b087.2
CT0129 Homo Sapiens
402298 predicted exon 7.2
458562N34128Hs.145268ESTs 7.2
407021052077 "gb:Human madnerl Uansposase7.2
gene,complete consensus
449276AW241510Hs.252713ESTs 7.2
418251AA832123Hs.177723ESTs 7.2
420788AA937957Hs.193367ESTs 7.2
92
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
401881 ~ predicted exon 7.2
456436AA251079Hs.158386ESTs 7.2
413425F20956 "gb:HSPD05390 HM3 Homo 7.2
Sapiens cDNA clone
032-X4-
448966AW372914Hs.287462"Homo Sapiens cDNA FLJ118757.2
fis, clone HEMBA100707
429340N35938Hs.199429Homo sapiens mRNA; cDNA7.2
DKFZp434M2216 (from
clon
406053 predicted exon 7.2
405851 predicted exon 7.2
431009BE149762Hs.248213"gap juncfion protein, 7.2
beta 6 (connexin 30)"
426662AA879474Hs.122710ESTs 7.2
1~ 408536AW38i532Hs.135188ESTs 7.1.
455013BE073250 "gb:MRO-BT0551-060300-102-e057.1
BT0551 Homo Sapiens
428910W03667Hs.193792ESTs 7.1
424634NM Hs.151407"cartilage intermediate7.1
003613 layer protein, nucleotide
pyrophosph
449794AW444502Hs.256982"ESTs, Highly similar 7.1
to AF1168651 hedgehog-interacting
I 423410AF058989Hs.128231"G antigen, family B,1 7.1
S (prostate associated)"
445460AI797473Hs.209468ESTs 7.1
447285A1371849Hs.200696"ATPase, Class Vl,iype 7.1
11C"
419750AL079741Hs.183114"Homo Sapiens cDNA FLJ142367.1
fis, clone NT2RP4000515
438986AF085888Hs.269307ESTs 7.1
420757X78592Hs.99915androgen receptor (dihydrotestosterone7.1
receptor, testicular
432479AL042844Hs.275675katanin p80 (WD40-containing)7.1
subunit B 1
449733874546Hs.29438"Homo Sapiens cDNA FLJ120947.1
fis, clone HEMB8100260
437846AA773866Hs.244569ESTs 7.1
454934AW846080 "gb:MR3-CT0176-081099-D02-b097.1
CT0176 Homo Sapiens
421929AA300543Hs.247360ESTs 7.1
401780 predicted exon 7.0
448106AI800470Hs.171941ESTs 7.0
448835BE277929Hs.11081"ESTs, Weakly similar 7.0
to S57447 HPBRII-7
protein [H.sap
400842 predicted exon 7.0
3 429364AA451797Hs.201202"ESTs, Moderately similar7.0
~ to Pro-Pol-dUTPase
polyprotein
454963AW847647 "gb:IL3-CT0213-280100-056-A067.0
CT0213 Homo sapiens
c
423891AK002042Hs.134795"Homo Sapiens cDNA FLJ111807.0
fis, clone PLACE1007452
407506071600 "gb:Human zinc finger 7.0
protein zfp31 (zf31)
mRNA, partial
413802AW964490Hs.32241ESTs 7.0
35 440051BE559980 "gb:601345293F1 NIH_MGC-87.0
Homo Sapiens cDNA clone
446283AI948801Hs.171073ESTs 7.0
419236AA330447Hs.135159"Homo Sapiens cDNA FLJ114817.0
fis, clone HEMBA100180
405472 predicted exan 7.0
435024AI863518Hs.127743"ESTs, Weakly similar 7.0
to V-ATPase G-subunit
like protein ~
453969AW090783Hs.301731"Homo Sapiens cDNA FLJ117387.0
fis, clone HEMBA100547
404992 predicted exon 7.0
428129AI244311Hs.26912ESTs 7.0
414315224878 "gb:HSB65D052 STRATAGENE7.0
Human skeletal muscle
cD
400491H25530Hs.50868"solute carrier family 6.9
22 (organic ca6on fransporter),
memb
45 459275AI808913Hs.118321ESTs 6.9
450853AA479629Hs.44243ESTs 6.9
457460A1143312Hs.164004ESTs 6.9
434168AI204525Hs.i ESTs 6.9
16156
445153AI214671 "gb:qm32d02.x1 NCI_CGAP-Lu56.9
Homo Sapiens cDNA clo
450028AI912012Hs.200737ESTs 6.9
414954D81402 gb:HUM162A03B Human 6.9
fetal brain (TFujiwara)
Homo sa
459478AW195566Hs.253182ESTs 6.9
426269H153D2Hs.168950Homo Sapiens mRNA; cDNA6.9
DKFZp566A1D4fi (from
clon
401050 predicted exon 6.9
447588AI394154Hs.279659"ESTs, Weakly similar 6.9
S to unknown protein
[H.sapiensJ"
449002AI620018Hs.117461ESTs 6.9
452759AW590773Hs.258996ESTs 6.9
443220885304Hs.132032"Homo Sapiens cDNA FLJ116836.9
fis, clone HEMBA100490
400749 predicted exon 6.8
406277 predicted exan 6.8
433785BE044593Hs.112704ESTs 6.8
434129A1807757Hs.221041ESTs 6.8
453369BE551550Hs.232630ESTs 6.8
411722AW875942 "gb:CM1-PT0013-131299-067-b106.8
PT0013 Homo sapiens
65 .455152AW858621 "gb:CMO-CT0342-021299-115-f046.8
CT0342 Homo Sapiens
412670AA115456 gb:zk89b05.r1 Soares~regnant_uterus6.8
NbHPU Homo sapi
419054N40340Hs.191510"ESTs, Weakly similar 6.8
to ORF2 [M.muscutusJ"
421316AA287203Hs.251397SMA5 6.8
432363AA534489 gb:nf76g11.s1 NCI_CGAP_Co36.8
Homo Sapiens cDNA clone
458603AW103046Hs.6162KIAA0771 protein 6.8
439527AW298119Hs.202536ESTs 6.8
408920AL120071Hs.48998fibronecfin leucine 6.8
rich fransmembrane
protein 2
439127AW978465Hs.292368ESTs 6.8
434890AF161345Hs.283930"Homo sapiens HSPC082 6.8
mRNA, parfial cds"
75 429413NM_014058Hs.201877DESC1 protein 6.7
407788BE514982Hs.38991S100 calcium-binding 6.7
protein A2
447252890916 gb:ynOte10.r1 Soares 6.7
adult brain N2b4HB55Y
Homo sapien
455851BE146879 "gb:OV4-HT0222-261099-014-c116.7
HT0222 Homo Sapiens
439509AF086332Hs.58314ESTs 6.7
418858AW961605Hs.21145"Homo Sapiens cDNA: 6.7
FLJ22489 fis, clone
HRC10951"
419323A1092379Hs.135275ESTs 6.7
415317243388Hs.5570hypothetical protein 6.7
FLJ10006
418654AA226334Hs.154291ESTs 6.7
407413AF067801 'gb:Homo sapiens HDCGC21P6.7
mRNA, complete cds."
93
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
439694AA843915Hs.54707ESTs 6.7
451191N67900Hs.118446ESTs 6.7
454006U12775Hs.37006agouti (mouse)-signaling6.7
protein
443657814973 gb:yf42f10.s1 Soares 6.7
fetal liver spleen 1NFLS
Homo sapien
455879BE153275 "gb:PMO-HT0335-180400-008-ei6.7
t HT0335 Homo Sapiens
451368BE242152Hs.288417protein serine ihreonine6.7
kinase CIk4
453509AL040021 gb:DKFZp434N1812-r1434 6.7
(synonym: htes3) Homo
sapie
420892AW975076Hs.172589nuclear phosphoprotein 6.7
similar to 5. cerevisiae
PWP1
423372AI246375Hs.154458ESTs 6.7
1 450316W84446Hs.17850ESTs 6.7
~
447795AW295151Hs.163612ESTs 6.7
413252BE074910 "gb:RC5-BT0580-170300-021-F126.7
BT0580 Homo Sapiens
405771 predicted exon 6.6
411483AW848115 "gb:IL3-CT0214-301299-048-C096.6
CT021d Homo Sapiens
c
15 420271AI954365Hs.42892ESTs 6.6
431948AA917706Hs.194616ESTs 6.6
409629AW449589Hs.279724ESTs 6.6
458841W28965 gb:5dd10 Human retina 6.6
cDNA randomly primed
sublibrary
416565AW000960Hs.44970ESTs 6.6
2~ 409097AA677927Hs.1d4269ESTs 6.6
441832A1018249Hs.128062ESTs 6.6
457285A1038858Hs.228780"ESTs, Highly similar 6.6
to AF1995971 A-type
potassium cha
406504 predicted exon 6.6
414606BE387771 "gb:601283251 Fi NIH_MGC-446.6
Homo Sapiens cDNA clon
452956AW003578Hs.231872ESTs 6.6
410743AA089d74Hs.272153ESTs ' 6.6
404599 predicted exon 6.6
423575C18863Hs.163443"Homo sapiens cDNA FLJ115766.6
fis, clone HEMBA100354
443027A1027847Hs.253550ESTs 6.6
30 458663AV658d44Hs.280776"Homo Sapiens cDNA FLJ136846.6
fis, clone PLACE2000021
431277AA501806Hs.249965ESTs 6.6
445232BE294357 "gb:601172878F1 N1H_MGC-176.6
Homo Sapiens cDNA clon
459170AI905518 "gb:RGBT091-210199-098 6.6
BT091 Homo Sapiens cDNA,
m
437876AA770151Hs.126424ESTs fi,6
35 406752A1285598Hs.217493annexinA2 6.6
401245 predicted exon 6.6
446102AW768067Hs.252956ESTs 6.5
446989AK001898Hs.16740hypothetical protein 6.5
FLJ11036
421160AL080215Hs.102301Homo Sapiens mRNA; cDNA 6.5
DKFZp586J0323 (from
clone
4~ 458831H71739Hs.200227ESTs 6.5
408914AW450309 gb:Ul-H-B13-akz-g-08-0-ULs16.5
NCI-CGAP-Subs Homo sa
411018AW813428 "gb:MR3-ST0192-010200-210-c056.5
ST0192 Homo sapiens
c
436562H71937Hs.169756"complement component 6.5
1, s subcomponent"
457620AA602711 "gb:np03h06.s1 NCI_CGAP_Pr26.5
Homo Sapiens cDNA clon
45 438647AA813118Hs.163230ESTs 6.5
439570T79925Hs.269165ESTs 6.5
419273BE271180Hs.293490ESTs 6.5
443745A8039610Hs.9728ALEX1 protein 6.5
431029BE392725Hs.248571Homo Sapiens PAC clone 6.5
RP5-1163J12 from 7q21.2-q31.1
458695AV660159Hs.282284ESTs 6.5
410966AW812088 "gb:RC4-ST0173-191099-032-a076.4
ST0173 Homo Sapiens
c
417135AA422067Hs.50547ESTs 6.4
416441BE407197 "gb:601301552F1 NIH_MGC-216.4
Homo Sapiens cDNA clon
413702BE170313 "gb:QV4-HT0536-040500-193-g026.4
HT0536 Homo Sapiens
55 452563AI907552 "gb:RGBT147-120499-044 6.4
BT147 Homo Sapiens cDNA,
m
408956AK001868Hs.295306"ESTs, Highly similar 6.4
to unnamed protein product
[H.sapien
406349 predicted exon 6.4
425420BE536911Hs.234545"ESTs, Weakly similar 6.4
to AF1551351 novel retinal
pigmen
459430AW662886 gb:hi82h11.x1 Soares 6.4
NFLLT_GBC-S1 Homo Sapiens
cDN
425733F13287Hs.159388Homo Sapiens clone 235786.4
mRNA sequence
458678AI306162Hs.170938"ESTs, Weakly similar 6.4
to KIAA0705 protein
[H.sapiens]"
429695AA835714Hs.293556ESTs 6.4
426872AA410446Hs.112011"ESTs, Weakly similar 6.4
to unknown [H.sapiens]"
437152AL050027 gb:Homo Sapiens mRNA; 6.4
cDNA DKFZp566C0324 (from
c
65 440517AW139632Hs.132246ESTs 6.4
450877A1799608Hs.29178ESTs 6.4
1
410664NM_006033Hs.65370"lipase, endothelial" 6.4
405793 predicted exan 6.4
418709AA227394 gb:zr17c10.r1 Stratagene6.4
NT2 neuronal precursor
937230 H
428684AA431792Hs.44784ESTs 6.4
448516AW898595 "gb:RCi-NN0073-260400-011-g096.4
NN0073 Homo Sapiens
400983 predicted exon 6.3
422365AF035537Hs.115521"REV3 (yeast homology-like,6.3
catalytic subunit of
DNA poly
425612BE004257 "gb:CMO-BN0103-180300-296-c046.3
BN0103 Homo Sapiens
75 401521 predicted exon 6.3
430290AI734110Hs.136355ESTs 6.3
414931AK000342Hs.77646Homo Sapiens mRNA; cDNA 6.3
DKFZp761 M0223 (from
clon
437939AW298600Hs.141840"ESTs, Weakly similar 6.3
to S59501 interferon
receptor JFNA
451842AI820539Hs.267087"ESTs, Moderately similar6.3
to ALU4_HUMAN ALU SURF
g0 405810 predicted exan 6.3
443747AV646352 "gb:AV646352 GLC Homc 6.3
Sapiens cDNA clone GLCAME
427287NM Hs.174188KIAA0938 protein 6.3
014903
413521BE145814 "gb:MRO-HT0208-101299-202-a046.3
HT0208 Homosapiens
429090AW820278Hs.99066ESTs 6.3
94
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
451488H22999Hs.208846ESTs 6.3
455713BE069891 "gb:QV4-BT0401-201299-064-b016.3
BT0401 Homo Sapiens
452161843077Hs.221747ESTs 6.3
428647AA830050Hs.124344ESTs 6.3
445063A1246275Hs.149196ESTs 6.3
456671ABOi1i42Hs.114293KIAA0570 gene product 6.3
401508 predicted exon 6.3
412677AW029608Hs.17384ESTs 6.3
441720AI346487Hs.28739ESTs 6.3
1 418051AW192535Hs.19479ESTs 6.3
0
438014N71183Hs.121806"Homo Sapiens cDNA FLJ119716.3
fis, clone HEMBB100120
432101A1918950Hs.11092"Homo Sapiens cDNA FLJ142906.3
fis, clone PLACE1006795
421032AW293133Hs.101340ESTs 6.3
436532AA721522 "gb:nv54h12.r1 NCI_CGAP-Ew16.3
Homo sapiens cDNA clo
1 431318AA502700Hs.293147ESTs 6.3
413470N20934 gb:yx54c1 1.s1 Soares 6.3
metanocyte 2NbHM Homo
Sapiens c
402425 predicted exon 6.3
455993BE179085 "gb:RCO-HT0613-140300-021-4066.3
HT0613 Homo Sapiens
400160 predicted exon 6.3
20 413795AL040178Hs.142003ESTs 6.2
405071 predicted exon 6.2
403741 predicted exon 6.2
432489AI804855Hs.207530ESTs 6.2
402296 predicted exan 6.2
446091AW022192Hs.200197ESTs 6.2
444788A1871122Hs.202821ESTs ' 6.2
404972 predicted exan 6.2
400227 predicted exon 8.2
433804AI936561Hs.112740ESTs 6.2
448807A1571940Hs.7549ESTs 6.2
404340 predicted exon 6.2
424632AB014523Hs.151406KIAA0623 gene product 6.2
449547H93543Hs.117963ESTs 6.2
406945KOi383Hs.203967metallothioneinlA(iunctional)6.2
3 433663AF083131Hs.229535CATX-15 protein 6.2
5
407809AW082279Hs.244106ESTs 6.2
418342BE002723Hs.293504"ESTs, Moderately similar6.2
to ALU1 HUMAN ALU SURF
438007AA133008Hs.158675ribosomal protein L14 6.2
410536N39533 gb:yv27d04.s1 Soares 6.2
fetal liver spleen
1 NFLS Homo sapie
448005AW207437Hs.170378ESTs . 6.2
414083AL121282Hs.257786ESTs 6.2
405362 predicted exon 6.2
410102AW248508Hs.279727"Homo Sapiens cDNA FLJ140356.2
fis, clone HEMBA100463
457868AW975133 "gb:EST387239 MAGE resequences,6.2
MAGN Homo sapien
45 407395AF005082 "gb:Homo sapiens skin-specific6.2
protein (xp33) mRNA,
part
443603BE502601Hs.134289"ESTs, Weakly similar 6.2
to KIAA1063 protein
(H.sapiens]"
430051AA464611Hs.52515transducin (beta)-like 6.1
2
434569AI311295Hs.58609ESTs 6.1
430481AA479678Hs.203269"ESTs, Moderately similar6.1
to ALUB_HUMAN ALU SUBF
402859 predicted exon 6.1
401260 predicted exon 6.1
406544 predicted exon 6.1
428446A1024600Hs.98612ESTs 6.1
.
412246A1160873Hs.69233"ESTs, Weakly similar 6.1
to KIAA1064 protein
[H.sapiens]"
55 400420AJ277247Hs.287369intedeukin 22 6.1
455662BE065387 "gb:RC1-BT0314-030500-016-4036.1
BT0314 Homo Sapiens
428613AB037749Hs.186928KIAA1328 protein 6.1
443267AW450630Hs.133851ESTs 6.1
433405AW157566Hs.156892ESTs 6.1
416795AI497778Hs.168053"ESTs, Highly similar 6.1
to AF2279481 HBV pX
associated p
435706W31254Hs.7045GL004 protein 6.1
450769AA057418Hs.33654ESTs 6.1
427174AA398848Hs.97541ESTs 6.1
425389AW974499Hs.192183ESTs 6.1
65 416675H73802Hs.35381ESTs 6.1
432749NM-014438Hs.278909lntedeukin-1 Superfamilye6.1
401809 predicted exon 6.1
403041 predicted exon 6.0
408523AW833259 "gb:RC2-TT0007-131099-011-c016.0
TT0007 Homo sapiens
c
70 416515N91716Hs.194140ESTs 6.0
452591BE173164Hs.1516insulin-like growth 6.0
factor-binding protein
4
437146AA730977 "gb:nw55f05.s1 NCI-CGAP_Ew16.0
Homo Sapiens cDNA clo
450094AI174947Hs.295789Homo Sapiens mRNA; cDNA6.0
DKFZp564D1164 (from
clon
402529 predicted exon 6.0
75 430706NM Hs.247816"H4 histone family, 6.0
003540 member C"
459186AI908287 "gb:RGBT168-020499-035 6.0
BT168 Homo Sapiens
cDNA, m
452158AI699120Hs.61198ESTs 6.0
411237AW833676 "gb:OV4-TTOOOB-181199-038-h04TT00086.0
Homosapiens
400441M15530Hs.99879B-cell growth factor 6.0
1 (l2kD)
439398AA284267Hs.221504ESTs .
6.0
440662H39048Hs.127432ESTs 6.0
415451H19415Hs.268720"ESTs, Moderately similar6.0
to ALUt HUMAN ALU SUBF
459587AA031956 gb:zk15e04.s1 Soares,~regnant-uterus-NbHPU6.0
Homo sapi
456072H54381 gb:yq89a03.s1 Soares 6.0
fetal liver spleen
1NFLS Homo sapie
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
409954AW512770Hs.266457ESTs 6.0
443488A1073495Hs.i "ESTs, Weakly similar 6.0
33912to methyl-CpG binding
domain-coot
430825A1734186Hs.185105ESTs 6.0
454466AA984138Hs.279895"Homo Sapiens mRNA for 6.0
KIAA1578 protein, partial
cds'
456506AA278277Hs.194212ESTs 6.0
449228AJ403107Hs.148590"ESTs, Weakly similar 6.0
to AF2088461 BM-004
(H.sapiens]
457727AW974687 "gb:EST386776 MAGE resequences,6.0
MAGM Homo sapien
442440BE464435Hs.146180"ESTs, Weakly similar 5.9
to non-receptor protein
tyrosine kina
455110BE154505 "gb:PMO-HT0343-281299-003-e065.9
HT0343 Homo Sapiens
1 402790 predicted exon 5.9
~
409982BE005839 "gb:RC2-BN0120-250400.012-f035.9
BN0120 Homo Sapiens
427635BE397988Hs.179982tumor protein p5&binding5.9
protein
408948AW296713Hs.221441ESTs 5.9
402046 predicted exon 5.9
1 416438889238Hs.34262ESTs 5.9
S
403083 predicted exon 5.9
402481 predicted exon 5.9
409867AW502161 gb:Ul-HF-BROp-ajr-g-12-0-ULr15.9
NIH_MGC-52 Homo sap
420362079734Hs.97206huntingtin interacting 5.9
protein 1
421375AA489200Hs.100595"ESTs, Moderately similar5.9
to ALU1 HUMAN ALU SUBF
437630AI252782Hs.153029ESTs 5.9
443500AV646388Hs.137071ESTs 5.9
448995A1613276Hs.5662"guanine nucleotide binding5.9
protein (G protein),
beta polyp
438214H06076Hs.26320TRABID protein 5.9
428046AW812795Hs.155381"ESTs, Moderately similar5.9
to 138022 hypothetical
protein [H
431941AK000106Ns.272227"Homo sapien's cDNA FLJ200995.9
tis, clone COL04544"
403356 predicted exon 5.9
439031AF075079 gb:Homo sapiens full 5.9
length insert cDNA YQ80A08
430032AW936136Hs.99610ESTs 5.9
423457FOB208Hs.155606paired mesoderm homeo 5.9
box 1
422158L10343Hs.112341"protease inhibitor 3, 5.9
skin-derived (SKALP)"
406592 predicted exon 5.9
418636AW749855 "gb:OV4-BT0534-281299-053-c055.8
BT0534 Homo Sapiens
429399AA452244Hs.16727ESTs 5.8
35 408590AW238162Hs.253873ESTs 5.8
422168AA586894Hs.112408S100 calcium-binding 5.8
protein A7 (psoriasin
1)
417421AL138201Hs.82120"nuclear receptor subfamily5.8
4, group A, member 2"
401129 predicted exon 5.8
434745AW974445Hs.185155"ESTs, Weakly similar 5.8
to HuEMAP [H.sapiens)"
402600 predicted exon 5.8
436185AW753380Hs.49753"Homo Sapiens mRNA for 5.8
KIAA1561 protein, partial
cds"
419519AI198719Hs.176376ESTs 5.8
452542AW812256 "gb:RCO-ST0174-191099-031-a075.8
ST0174 Homo Sapiens
c
427166AA431576Hs.155658ESTs 5.8
45 416168H23687 gb:yn72d12.r1 Soares 5.8
adult brain N2b5HB55Y
Homo sapie
431467N71831Hs.256398Homo Sapiens mRNA; cDNA 5.8
DKFZp434E0528 (from
clon
421558AB011125Hs.105749KIAA0553 protein 5.8
458055AW979121Hs.131375"ESTs, Weakly similar 5.8
to ALUB HUMAN !!!! ALU
CLAS
418345AJ001696Hs.241407'serine (orcysteine) 5.8
proteinase inhibitor,
Glade 8 (ovalbumi
426544AA492325 gb:ng81b11.siNCI-CGAP_Pr6HomosapienscDNAclone5.8
433544AI793211Hs.i65372'ESTs, Moderately similar5.8
to ALUt HUMAN ALU SUBF
442007AA301116Ns.142838"Homo Sapiens cDNA: FLJ234445.8
tis, clone HSI01343"
443422810288Hs.301529ESTs 5.8
434311BE543469Hs.266263"Homo Sapiens cDNA FLJ141155.8
tis, clone MAMMA10017
55 424966AU077312Hs.153985"solute carrier family 5.8
7 (cationic amino acid
transporter, y+
441744AA960922Hs.200938ESTs 5.8
413101BE065215 "gb:RCt-BT0314-310300-015-f015.7
BT0314 Homo Sapiens
c
445687W80382Hs.149297ESTs 5.7
441369AA931535 gb:oo56a04.s1 NCl_CGAP_Lu55.7
Homo Sapiens cDNA clon
414428BE296906Hs.182625VAMP (vesicle-associated5.7
membrane protein)-associated
pr
43.1211M86849Hs.5566"gap junction protein, 5.7
beta 2, 26kD (connexin
26)"
411541W03940 gb:za62b02.r1 Soares 5.7
fetal liver spleen 1
NFLS Homo sapien
448612AI696363Hs.171285ESTs 5.7
419118AA234223Hs.139204ESTs 5.7
65 406322 predictedexon 5.7
454690AW854639 "gb:MR1-CT0258-140100-203-4105.7
CT0258 Homo Sapiens
450313A1038989Ns.24809hypotheticalprotein FLJ108265.7
'
416292AA179233Hs.42390nasopharyngeal carcinoma5.7
susceptibility protein
449309AW589823Hs.224189ESTs 5.7
408418AW963897Hs.44743KIAA1435 protein 5.7
416100H18700Hs.268799ESTs 5.7
437845AA769578Hs.90488ESTs 5.7
443345A1052508Hs.164482"ESTs, Weakly similar 5.7
to contains similarity
to TPR domain
418407AL044818Hs.84928"nuclear Uanscription 5.7
factor Y, beta'
75 434557AW855466Hs.271866"ESTs, Weakly similar 5.7
to ALU1 HUMAN ALU SUBFAM
431688AA513906 "gb:ng67c08.s1 NCI-CGAP-Up2HomosapienscDNAclo5.7
437641AA811452Hs.291911ESTs 5.7
409319AW752736Hs.33565ESTs 5.7
403967AF030107Hs.17165regulator of G-protein 5.7
signalling 13
445189AI936450Hs.147482ESTs 5.7
414418H62943Hs.154188ESTs 5.7
446563BE326588Hs.141454ESTs 5.7
446075AWd51457Hs.279179ESTs 5.7
428068AW016437Hs.233462ESTs 5.7
96
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
438425AW292922Hs.293170ESTs 5.7
415532814780Hs.12826ESTs 5.7
441442AL043282Hs.131824ESTs 5.7
443380A1792478Hs.135377ESTs 5.7
445527W39694Hs.83286ESTs 5.7
4143768E393856Hs.669i5'ESTs, Weakly similar 5.7
to 16.7Kd protein [H.sapiens]"
457960AA771881Hs.298149ESTs 5.6
453293AA382267Hs.10653ESTs 5.6
452503AB000509Hs.29736TNF receptor-associated5.6
factor 5
1 405227 predicted exon 5.6
~
442257AW503831 gb:Ul-HF-BNO-alb-b-05-0-Ut.r15.6
NtH MGC-50 Homo sap
403403 predicted exon 5.6
454377AA076811 gb:7B03C12 Chromosome 5.6
7 Fetal Brain cDNA
Library Hom
438656H85310Hs.209456"ESTs, Weakly similar -
to NG22 [H.sapiens]" 5.6
1 419936AI792788 "gb:o191d05.y5 NCI_CGAP_KidS5.6
S Homo Sapiens cDNA clo
437267AW511443Hs.258110ESTs 5.6
430563AA481269Hs.178381ESTs 5.6
444835A1198994Hs.158479ESTs 5.6
444902AJ132099Hs.12114vanin 1 5.6
451800AW977435Hs.31890ESTs 5.6
405465 predicted exon 5.6
403891 predicted exan 5.6
425557AI694300Hs.46730ESTs 5.6
432162AA584062Hs.272798hypothetical protein 5.6
FLJ20413
450152AI138635Hs.22968ESTs 5.6
410053AW579707Ns.59332ESTs ' 5.6
d21285NM Hs.1363"cytochrome P450, subfamily5.6
000102 XVII (steroid 17-alpha-hydro
425264AA353953Hs.20369"ESTs, Weakly similar 5.6
to gonadotropin inducible
transcript
418844M62982Hs.1200arachidonate 12-lipoxygenase5.6
30 429616AI982722Hs.120845ESTs 5.6
423528AB011137Hs.129740KIAA0565 gene product 5.6
403089 predicted exon 5.6
414373AW162907Hs.75969praline-rich protein 5.6
with nuclear largeGng
signal
403687 predicted exon 5.6
35 417079U65590Hs.81134interleukin 1 receptor 5.5
antagonist
432501BE546532Hs.287329Fas binding protein 5.5
1
403691 predicted exon 5.5
409545BE296182 "gb:601177324F1 NIN-MGC_175.5
Homo Sapiens cDNA clon
435990A1015862Hs.131793ESTs 5.5
444409A1792140Hs.49265ESTs 5.5
435478AA682622 gb:zj20f09.s1 Soares 5.5
fetal liver_spleen
1NFLS S1 Homo
439981AI348408Hs.124675"ESTs, Weakly similar 5.5
to unnamed protein
product [H.sapie
433644AW342028Hs.256112ESTs 5.5
441541AA938663Hs.199828ESTs 5.5
45 400709 predicted exon 5.5
407615AW753085 'gb:PM1-CT0247-151299-005-a035.5
CT0247 Homo Sapiens
424153AA451737Hs.141496MAGE-like 2 5.5
452465AA610211Hs.342d4ESTs 5.5
406030 predicted exan 5.5
431071AA491379 'gb:aa65f05.r1 NCI_CGAP5.5
GCB1 Homo Sapiens cDNA
c1
418086AA211791Hs.269666"Homo sapiens cDNA FLJ134155.5
fis, clone PLACE1001799
453034BE246010Hs.184109ribosomal protein L37a 5.5
412953245794Hs.238809ESTs 5.5
425351A1206234Hs.155924cAMP responsive element5.5
modulator
55 406149 predictedexon 5.5
416533BE244053Hs.79362retinoblastoma-like 5.5
2 (p130)
458378A1040535Hs.150524ESTs 5.5
401213 predicted exon 5.5
405904 predicted exon 5.5
60 445132244811 gb:HSC29G031 normalized'
infant brain cDNA Homo 5.5
sapie
405138 predicted exon 5.5
442238AW135374Hs.270949ESTs 5.5
416852AF283776Hs.80285Homo Sapiens mRNA; cDNA5.5
DKFZp586C1723 (from
clon
448691AA481119Ns.283558hypothetical protein 5.5
PR01855
65 452242850956Hs.59503"ESTs, Weakly similar 5.5
to AF1573181 AD-017
protein (H.s
456994AA383623Hs.293616ESTs 5.5
440913A1267491Hs.160593ESTs 5.5
435380AA679001Hs.192221ESTs 5.5
450375AA009647Hs.8850a disinlegrin and metalloproteinase5.5
domain 12 (meltrin
alph
414035Y00630Hs.75716"serine (orcysteine) 5.4
proteinase inhibitor,
Glade B (ovalbumi
459084H01699Hs.27289CGI-125 protein 5.4
405867 predicted exon 5.4
414093BE544867 "gb:601078872F1 NIH_MGC-125.4
Homo Sapiens cDNA clon
447306Ai373163Hs.170333ESTs 5.4
75 413083BE064528 'gb:RC4-BT0311-250200-014-hD65.4
BT0311 Homo sapiens
404828 predicted exon 5.4
402543 predicted exan 5.4
421988AW450481Hs.161333ESTs 5.4
413404BE503463Hs.297431ESTs 5.4
459043A1806444Hs.208113"ESTs, Weakly similar 5.4
to N-WASP [H.sapiens]'
404410 predicted exon 5.4
430264AA470519 'gb:nc71f10.s1 NCI_CGAP_Pr15.4
Homo Sapiens cDNA clon
431499NM-001514Hs.258561general transcription 5.4
factor 118
412566AW962574 'gb:EST374647 MAGE resequences,5.d
MAGG Homo sapien
97
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
454239BE176420Hs.8177ESTs 5.4
458163AA884304Hs.131163ESTs 5.4
446205AW172662Hs.149479ESTs 5.4
455275AW977806 "gb:EST389810 MAGE resequences,5.4
MAGO Homo sapien
415579AA165232Hs.222069ESTs 5.4
423200AA323073Hs.289083ESTs 5.4
440052A1633744Hs.1956d8ESTs 5.4
424717H03754Hs.152213"wingless-type MMTV 5.d
integration site family,
member 5A"
420111AA255652 gb:zs21h11.r1 NCI CGAP 5.4
GCBt Homo Sapiens cDNA
clo
1 432140Alf000404Hs.272688hypothetical protein 5.4
~ FLJ20397
414904AA157881Hs.143056ESTs 5.4
409479BE163800Hs.1369i2ESTs 5.4
404727 predicted exon 5.4
446011AI623778Hs.145809ESTs 5.4
15 456083046922Hs.77252fragile hislidine toad 5.4
gene
424834AVf001432Hs.153408"Homo Sapiens cDNA FLJ105705.4
fis, clone NT2RP2003117
425071NM Hs.154424"deiodinase, iodothyronine,5.4
013989 type II"
426065N32049 gb:yw96g08.s1 Soares-placenta-8to9weeks-2NbHP8to9W5.4
d15602F12920Hs.165575ESTs 5.4
432839AA579465Hs.287332ESTs 5.4
416879H98899Hs.42599ESTs 5.4
456088BE177320Hs.156148"Homo Sapiens cDNA: 5.4
FLJ23082 fis, clone
LNG06451"
423175W27595Hs.18653ESTs 5.4
424585AA464840 gb:zx43h11.r1 Soares 5.3
total-fetus Nb2HF8-9w
Homo sapie
452281T93500Hs.28792"Homo sapie0s cDNA FLJ110415.3
fis, clone PLACE1004405
424323AA338791 Hs.146763nascent-polypepGde-associated5.3
complex alpha polypepfide
426701AI968103Hs.209461"Homo Sapiens cDNA FLJ128365.3
fis, clone NT2RP2003206
447645AW897321Hs.159699ESTs 5.3
402974 predicted exon 5.3
436607AW661783Hs.211061ESTs 5.3
428873AI701609Hs.98908ESTs 5.3
405454 predicted exon 5.3
431867AA523660Hs.191727ESTs 5.3
442768AL048534Hs.48458"ESTs, Weakly similar 5.3
to ALUB HUMAN ALU SUBFAM
35 424085NM-002914Hs.139226replication factor C 5.3
(activator 1) 2 (40kD)
435098AF174394Hs.177461"Homo Sapiens apoptotic-related5.3
protein PCAR mRNA,
par
421284062435Hs.103128"cholinergic receptor, 5.3
nicofinic, alpha polypeptide
6"
435711AF226667Hs.58553CTP synthase II 5.3
405292 predicted exon ~ 5.3
410123T16981Hs.21963ESTs 5.3
435435T89473Hs.192328ESTs 5.3
417071N58820Hs.275133ESTs 5.3
d38958H50167Hs.33113ESTs 5.3
457405AA504860 gb:ab03a10.s15tratagene5.3
fetal retina 937202
Homo Sapiens
45 413642BE154837 "gb:PMi-HT0345-121199-001-c0B5.3
HT0345 Homo Sapiens
433868AA612960 gb:nq38gO6.s1 NCI_CGAP_CoIO5.3
Homo sapiens cDNA clo
444461853734Hs.25978ESTs 5.3
427088AA398085Hs.142390ESTs 5.3
451307AW293207Hs.211516ESTs 5.3
403831 predicted exon 5.3
402892 predicted exon 5.3
433420AI674093Hs.293961ESTs 5.3
455759BE080469 "gb:OVt-BT0630-280200-086-d065.3
BT0630 Homo Sapiens
411379A1816344Hs.12554"ESTs, Weakly similar 5.3
to Nucleosome Assembly
Protein 1-
55 428483AI908539Hs.184592ICIAA0344 gene product 5.3
429208AA447990Hs.190478ESTs 5.3
447572A1631546Hs.159732ESTs 5.3
434896AW022054Hs.136591ESTs 5.3
417616807728Hs.268668ESTs 5.3
411805AW864183 "gb:PMO-SN0014-260400-002-d025.3
SN0014 Homo Sapiens
419000T79855Hs.268592ESTs 5.3
413488BE144017Hs.184693"Uanscdption elongation5.3
factor B (SIII), polypeptide
1 (15k
400975 predicted exan 5.3
407453AJ132087 gb:Homo Sapiens mRNA 5.3
for axonemal dynein
heavy chain (
65 430757AI458623 "gbak04g09.x1 NCI CGAP_Lu245.3
Homo Sapiens cDNA clo
417793AW405434Hs.82575small nuclear ribonucleoprotein5.2
polypeptide B"
401877A8011094Hs.129892ItIAA0522 protein 5.2
457122A1026157Hs.33728"ESTs, Weakly similar 5.2 ,
to ALUi HUMAN ALU SUBFAM
410706A1732404Hs.68846ESTs 5.2
435807A1033299Hs.113614ESTs 5.2
d28398AI249368Hs.98558ESTs 5.2
401088 predicted exon 5.2
414501N43991Hs.171984ESTs 5.2
419083AI479560Hs.98613"Homo Sapiens cDNA FLJ122925.2
fis, clone MAMMA10018
75 421107AA283822Hs.55606"ESTs, Weakly similar 5.2
to ZN91 HUMAN ZINC
FINGER P
411489AW848346 "gb:IL3-CT0214-150200-076-F035.2
CT0214 Homo Sapiens
c
419249X14767Hs.89768"gamma-aminobutyric 5.2
acid (GABA) A receptor,
beta 1"
430082AW514083Hs.190135ESTs 5.2
425698NM Hs.159241polycysGc kidney disease5.2
016112 2-like 1
8~ 451686AA059246Hs.110293ESTs 5.2
453867AI929383Hs.108196HSPC037 protein 5.2
419985H66373Hs.15973"ESTs, Highly similar 5.2
to bA393J16.3 [H.sapiens]"
426650AA382814 "gb:EST96097 Tests I 5.2
Homo Sapiens cDNA 5'
end, mRNA
424115AA335497Hs.293965ESTs 5.2
98
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
405576 predicted exon 5.2
409584AA076010 gb:zm89f12.s1 SUatagene5.2
ovarian cancer (937219)
Homo so
454423AW603985Hs.179662nucleosome assembly 5.2
protein 1-like 1
417173061397Hs.81424ubiquifin-like 1 (sentrin)5.2
439155H81076Hs.269001ESTs 5.2
432267AK000872Hs.274227"Homo Sapiens cDNA FLJ100105.2
fis, clone HEMBA100030
459024AA020799Hs.179825RAN binding protein 5.2
2-like 1
404088 predicted exon 5.2
403525 predicted exon 5.2
l 445882AI948717Hs.225155"ESTs, Weakly similar 5.2
0 to PSF_HUMAN PTB-ASSOCIATE
448257AW772070Hs.253146ESTs 5.2
410500809442 gb:yf26c09.r1 Snares 5.2
fetal liver spleen
1 NFLS Homo sapien
456084AAi55859Hs.79708ESTs 5.2
410523BE143839 "gb:MRO-HT0164-151299-012-d035.2
HT0164 Homo Sapiens
I 434623A8023163Hs.4014KIAA0946 protein; Hunfingtin5.2
S interacfing protein
H
454484AW795196Hs.215857ring finger protein 5.2
1d
402131 predicted exon 5.2
438913AI380429Hs.172445ESTs 5.2
402628 predicted exon 5.1
415973824707Hs.260201ESTs 5.1
455640BE064059 "gb:qV3-BT0296-010300-111-e045.1
BT0296 Homo Sapiens
442750A1016803Hs.131096ESTs 5.1
404638 predicted exon 5.1
431117AF003522Hs.250500delta (Drosophila)-like5.1
1
428619ALi35623Hs.193914KIAA0575 gene product 5.1
439519AA837118Hs.118366ESTs 5.1
427335AA448542Hs.251677G antigen 7B 5.1
416450AA180467Hs.142556ESTs 5.1
440676AW613524Hs.279570ESTs 5.1
414584BE409585 "gb:601301836F1 NIH 5.1
MGC_2l Homo Sapiens
cDNA clon
443175N57863 gb:yv60c02.s1 Snares 5.1
fetal liver spleen
1 NFLS Homo sapie
408968AI652236Hs.49376hypotheficalprotein 5.1
FLJ20644
415654AW968363 "gb:EST380439 MAGE resequences,5.1
MAGJ Homo Sapiens
440559AW629054Hs.125976"ESTs, Weakly similar 5.1
to metalloproteaseldisintegrinicystei
35 421236AI287622Hs.15i956ESTs 5.1
416258N45661Hs.275131ESTs 5.1
405982 predicted exon 5.1
406589 predicted exon 5.1
412458AW953229Hs.169142ESTs 5.1
435693A1033134Hs.119887ESTs 5.1
449182AW292381Hs.224i50ESTs 5.1
403963 predicted exon 5.1
440630AI733112Hs.176101ESTs 5.1
415412F08049Hs.52132ESTs 5.1
45 442832AW206560Hs.253569ESTs 5.1
445359A1808725Hs.147783ESTs 5.1
412088A1689496Hs.108932ESTs 5.1
428785AIOi5953Hs.i25265ESTs 5.1
430163X66610Hs.234748"enolase alpha, lung-specific"5.1
455441AW945964 "gb:OVO-ET0001-050500-228-e095.1
ET0001 Homo Sapiens
c
400304AF005082Hs.113261"Homo Sapiens skin-specific5.1
protein (xp33) mRNA,
partial
403944 predicted exon 5.1
457069BE159191Hs.i "ESTs, Weakly similar 5.1
14318 to ORF1 [H.sapiens]"
414125BE253197 "g6:601116804F1 NIN_MGC_165.1
Homo Sapiens cDNA clon
SS 448566AW291319Hs.i94574ESTs 5.1
457948A1498640Hs.159354ESTs 5.1
438240N92638Hs.124004ESTs 5.1
404070 predicted exon 5.1
402709 predicted exon 5.1
416425BE077308 "gb:RC1-BTO606-060200-012-h125.0
BTO606 Homo Sapiens
40.7173T64349 gb:yc10d08.s1 Stratagene5.0
lung (937210) Homo
sapiens cDN
452502AI904296 "gb:PM-BT046-220199-2865.0
1 BT046 Homo Sapiens
cDNA
446657AI335191Hs.260702"ESTs, Moderately similar5.0
to ALU7-HUMAN ALU SUBF
459124AW301478Hs.299178ESTs 5.0
65 409940BE548143 "gb:601073109F1 NIH 5.0
MGC_12 Homo Sapiens
cONA clon
443547AW271273Hs.23767"Homo Sapiens cDNA FLJ126665.0
fis, clone NT2RM400225
447452BE618258Hs.102480ESTs 5.0
414327SE408145Hs.185254"ESTs, Moderately similar5.0
to NAG1 protein [R.norvegicus]
416155AI807264Hs.205442"ESTs, Weakly similar 5.0
to AF1176101 inner
centromere pro
408081AW451597Hs.167409ESTs 5.0
426834A1091533Hs.135167ESTs 5.0
433368AW877277 "gb:MR4-PT0051-150200-001-d035.0
PT0051 Homo Sapiens
433098AW190593Hs.151143ESTs 5.0
439721W92142Hs.271963"ESTs, Weakly similar 5.0
to ALU5_HUMAN ALU SUBFAM
75 441818AI630451Hs.7976KIAA0332 protein 5.0
458804AL157625 gb:DKFZp761L2016-r1 5.0
761 (synonym: hamy2)
Homo sapi
411905BE265067 "gb:601193893F1 NIH_MGC_75.0
Homo Sapiens cDNA clone
434248AA628151Hs.187783ESTs 5.0
423967AW296756Hs.11641"Homo Sapiens cDNA: 5.0
FLJ21432 fis, clone
COL04219"
g0 456212N51636 gb:yy87bOt.s1 Snares-mulfiple-sclerosis-2NbHMSPHomo5.0
442914AW188551Hs.99519"Homo Sapiens cDNA Fl,l140075.0
fis, clone Y79AA1002407
436084AK000185 "gb:Homo Sapiens cDNA 5.0
FLJ20178 fis, clone
COL09990"
449252AW594482Hs.253315ESTs 5.0
454653AW812227 'gb:RC2-ST0173-201099-011-g095.0
ST0173 Homo Sapiens
c
99
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
414699AI815523Hs.76930"synuclein, alpha (non A4
component of amyloid precursor)
5.0
443335T89697Hs.16645ESTs 5.0
448419AL080072Hs.2iHomo Sapiens mRNA; cDNA
195 DVfFZp564M0616 (from clop
5.0
425574AA359663 "gb:EST68717 Fetai lung
II Homo Sapiens cDNA 5'
end, m8 5.0
d35174AA687378Hs.194624ESTs 5.0
429548AW138872Ns.135288ESTs 5.0
450613A1702055 "gbaq20g10.x1 NCI_CGAP-Ut1
Homo sapiens cDNA clop
5.0
400432AX01580Hs.287767Sequence 8 from Patent W09950285
5.0
9
421751AW813731Hs.i59153ESTs 5.0
10405800 predicted exon 5.0
429430AI381837Hs.155335ESTs 5.0
439518W76326 gb:zd60d04.r1 Soares fetal
hear~NbHHI9W Homo sapien
5.0
430884AF053748Hs.248114glial cell derived neurotrophic
factor 5.0
452741BE392914Hs.30503"Homo Sapiens cDNA FLJ11344
fis, clone PLACE1010870
5.0
I 441001AW137017Hs.126373Human DNA sequence from
S clone RP5-1184F4 on chromos
5.0
438490AW593272Hs.26261ESTs 5.0
408170AW204516Hs.31835ESTs 5.0
449104808702 gb:yf24cO6.r1 Soares fetal
liver spleen 1NFLS Homo
sapien 5.0
ZO TABLE 1B:
Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers
Pkey CAT Accession
Number
4076151005404AW753085 AW753082 AW054744 AW753107 AW753087
1
4083911055687_1AW859276 AW85927d AW 190959 T91463
d085231063925AW833259 AW833273 AW206846
1
4089141089828AW450309
-1
3 408987109306' H85615 H86300 H86263 H86282 AA059278 H86304
0 1
4091911107176AW818390 AW818237 AW858911 AW858977 BE072544 W26498
1
4095451138823BE296182 AW629821
1
409584114165AA076010 AA076009 A1094314
1
409695114876AA296961 AA296889 AA076945 AA077528 AA077497
1
4098661156522AW502152 H41202 H29772
1
4098671156530AW502161 AW502587 AW502345
1
4099401160994BE548143 AW511659
1
40998211650221BE005839BE005619AW516815
4105001206323809442 AW846115 AW846108 AW751967 AW846083 AW846087
1 AW846090
40 410523_ BE143839 AW752787 AW752795 BE143584 N71805
1207041
1
4105361207322_1N39533 AW753094 AW753093
4106261212621_-iBE407727
4109661228071AW812088 AW812105 AW812082
1
4110041228975AW813242 BE146089 AW813195 AW813173 AW813206 BE145953
1 BE146212 AW813196 AW854582 AW813241 BE061582
45 4110181229132AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
1
4110571230493AW8f5098 BE154843 BE154831
1
4111781234752_1AW820852 AW820773 AW821088
4112371236377-1AW833676 AW833814 AW833798 AW833677 AW833449 AW833630
AW833626 AW833444 AW833366 AW833791 AW833659 AW833432
AW833534 AW833556 AW833553
4114831247172-1AW848115 AW848127 AW887028 AW887117
0
4114891247360AW848346 AW848760 AW848340 AW848818 AW849043 AW849061
1
4115411249044W03940 T98335 AW850705
1
4116601253078AW855718 AW855740 AW855748
1
4116931254206AW857271 AW857308 AW857296 AW857258
1
5 4117221254914_1AW875942 AW858234 AW875938 AW875941 AW858235 AW875958
5
4117251255047_1AW858396 AW858505 AW858476 AW861971 AW858556 AW86190B
AW858514 AW858601 AW861909 AW858434 AW858400 AW858405
AW858393
4117481256178AW859920 BE079582 AW997112
1
4118051259273AW864183AW864181AW864135AW864i98
1
60 411905_ BE265067 BE264978 AW875420
1265181
1
4119401266262-1AW876686 AW876717 AW877215 AW876691 AW876722 AW877218
AW876694 AW876725
4121671280605AW897230 AW897252 AW897244 AW897231 AW897263
1
4123331289037AW937485 AW937589 AW937658 AW937654 AW937492
1
4124021292917AW984788 AW984816 AW984811 AW984807 AW984819 AW984790
1 AW984782 AW984784 AW984780 AW984814 AW984795 AW984793
65 _ AW984789 AW984823 AW948021 AW984802 AW984800 AW984799
AW984825 AW984792 AW984821 AW984820 AW984808 AW984809
AW984812 AW984801 AW984813 AW984778 AW984804 AW984798
AW948017 AW984827
4125661306469AW962574 BE073261
1
412670131990AA115456 AW978117 AA814593
1
4127401324538AW993984 AW994001 AW994002
1
70 4127611325424AW995092 AW995095 AW995103
1
4130831348639BE064528 BE064589 BE064561
1
4131011349154BE065215 BE155544 BE155541 BE155540 BE155542 BE155543
1
4132521355877BE074910 BE074913 BE074911 BE074903 8E074892 BE074935
1
4133821365954BE090689 BE090685 BE090697 BE090680 BE090691 BE090696
1 BE090698 BE090686
75 413425136885F20956 AA12937d AA133740 AW819878
1
4134701371604N20934 BE141875 BE141877
1
4135211374612_1BE145814 BE145830 BE145884 BE145823 BE145905 BE145883
BE145833 BE145889 BE145834
4135441375671BE147225 BE147205 BE147234
1
4136421381386BE154837 BE154879 BE154850 BE154877 BE154835 BE154849
1 BE154902 BE154905 BE154867 BE154901 BE154904 8E154899
$0 4137021383899BE170313 BE158339 BE158290
1
4138641395788BE175582 BE175514 BE175505 BE175591 BE175530
1
4140931416417-1BE544867 BE247720
4141251419230BE253197 BE259456 BE254462
1
4141951424854-8E263293.
3
100
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4142101426051BE383592 BE261671
1
4142661430984BE267834 BE514180 BE514096
1
414315143512-1224878 AA494098 F13654 AA494040 AA143127
4145391460320BE379046 BE395459
1
414540_ BE379050
1460324--1
4145841464068BE409585
-1
4146051465790BE390440
-1
4146061465801BE387771 BE387954 BE389705
1
4148081492624T95945 898276 BE539541
1
1 4149541509857D81402 C15494 D61078 D61313 D80399 D81520
0 1
4149951511736C18200 D78681 T82025
1
4156131540602820233 F12901 T74740
1
415654154135_1AW968363 AA465492 834539 AA165411
4157151548818F30364 F36559 T15435
1
15 415747155189AA381209 AA381245 AA167683
1
4161511573926T26661 244135 H23016
1
4161681574545H23687 H46460 H40239
1
416425159388-1BE077308 AL043350 AW962170 AA180251 AA325287
4164411 BE407197 AA182474 AA180369 BE275628 BE276131
159480
20 416548- H62953 N76608 N72413
1600181
1
4166651607797_1H72974 W28967
416913163001AW934714 BE161007 BE162500 AW749902 AW749864 BE162498
1 BE161005 AA190449 AW513465 BE161006 BE162499
417344166827_1AW997313 AA195805
417549168700AA203651 889136
1
417611168900-1AW993983 AW994798 AW993990 AW993999 AW993989 AA204755
4176821692759W69561 808486 887183
1
418636177402AW749855 AA225995 AW750208 AW750206
1
418709178363_1AA227394 AA641866 AW750732
419753187763N42531 W25700 AA249574 AA569553
1
3 419936_ A1792788 BE142230 AA252019
0 189181
1
420111190755AA255652 AA280911 AW967920 AA262684
1
422949223184AA319435 N56456 AA319377 AW961532 Td8452 AA894424
1
423735231498AA330259 AA661806 AA502431 AW974633 AA649496
1
423756231725AA828125 AA834883 AA330555
1
3 423843232510AA332652 AA331633 AW999369 AW902993 BE170475 AA378845
1 AW964175 A1475221
424101235398AA335394 AA335535 AA335244 AW966148
1
424324238127_1AA346316 BE160193 AA338802 AW954536
424585241151AA464840 AA343628
1
424872244505AA347923 AA347928 AW961769
1
40 425090246649AA350552 821667 AW953258
1
425574253317AA359663 AA359654 AW963124
1
425612253969BE004257 AW811190 AA360576 BE172402 BE181703
1
426065260276N32049 834821 878237
1
426130261414AA853282 BE255688 AA370481
1
45 426544- AA492325 AA503675 AA381181
268987
1
4266502702831AA382814AA4024i1AA412355
429163300543AA884766 AW974271 AA592975 AA447312
1
430264315008AA470519 BE303010 BE302954 BE384120
1
430757322947AId58623 AA639708 AA485409 822065 AA485570
1
50 431071327550AA491379 H86020 AW969148
1
431688336609_1AA513906 AA847734 AI35704d
431822338082AA516049 AW004922
1
432189342819AA527941 A1810608 A1620190 AA635266
1
432340345248AA534222 AA632632 T81234
1
55 432363345469AA534489 AW970240 AW970323
1
432966356839-1AA650114 AW974148 AA572946
433368364276AW877277 AW811294
1
433449366532AW772282 AA592974
1
433868375629AA612960 A1934769 T12348
1
60 434098380006AA625499 AA625269 AA625184
1
434374384889_1AA631439 A1086355 A1082577
434804393481AA649530 AA659316 Hfi4973
1
434950396061AW974892 AA654375
1
435478406683AA682622 BE141696
1
65 43608441437 AK000185 AW841262
1
436532421802AA721522 AW975443 T93070
1
436843427748AA824588 AA732269 AW977146
1
437096433006AA744406 AA745347 AA745535
1
43714643371 AA730977 A1261584 AA334473 243283 AW875861 AW938044
1 BE150701 AW936262 AA306862 BE565575 BE567380 AA728920
AA167612
70 _ AI239729 AI251752 AA485791 BE568425 AW962958
43715243386 AL050027 BE089051
1
437229434947_1AW976005 AW419264 AA747275 AA810377
43903146798 AF075079 H48601 H48795
1
43915246920 H65014 AF086007 H65015
1
75 43951847334 W76326 AF086341 W72300
1
44005148426 BE559980 BE397203 BE268207 BE559764 BE267725 BE513654
2 BE267742 BE268219 BE267665 BE561356
44119451193 BE274581 BE275382 AA703515 BE166690
1
441369515636AA931535 A1458601 244913
1
44225753699 AW503831 AW503317 BE565665
1
443161561305A1038316 AI344631 AI261653
1
443175561882N57863 A1038952 W90167 N64103
1
443198562655A1039813 A1684642 240121 A1951414 BE501049
1
443534572957_1A1076123 A1244834 A1695239
443613575391A1079356 W23287
1
101
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
443657 576685-1 814973 814967 A1081006
443747 57918 1 AV646352 AV652121 AV652008
443860 583216_1 AW866632 A1089351 D61942 _
445132 63111 1 244811 813709 AV652749 AW814906 AA084016
445153 631644-1 A1214671 245244 H24136 825934
445232 633433-1 BE294357 N36568 A1217006
446171 664826_1 A1374927 A1278380 A1301383
447252 714160-1 890916 AL120023 818429 242095 A1369730 890824
448516 766241 1 AW898595 AW898588 AW898590 AW898663 AW898592 A1525093
1 ~ 449104 798149-1 808702 809864 AI630313
450613 840016_1 A1702055 889204 886260
452077 897051 1 BE144949 BE144991 BE144990 A1832199
452502 919733-1 A1904296 BE007223 830687
452507 919998-1 A1904646 BE179494 BE179421
1 ~ 452542 921410_1 AW812256 AW812257 A1906423 A1906422
452563 922265-1 A1907552 003707 002870
452947 939810_1 AW130413 A1932362
453509 969632-1 AL040021 AL040037
453845 983027--1 AL157568
454182 10495691 AW177335AW177352AW177340AW177378AW177339AW177388AW177393
454377 114761 1 AA0768i1 AW814764
454389 115682_1 AW752571 AW847602 AA077979
454455 1206965 1 AW752710 BE180336 BE180186
454505 1219564 1 AW801365 AW801435 AW801372
25 454556 1223878_1 AW807073 AW807055 AW807067 AW807276 AW807030 AW807363
AW845892 AW807091 AW807275 AW807284 AW807287 AW845B91
AW807195 AW807271
454574 1225636 1 AW809109 AW809112 AW809122 AW809126 AW809128 AW809133
AW809131 AW809113 AW809111 AW809132
454597 1226059_1 AW809648 AW809704 AW809643 AW809653 AW809709 AW809949
AW809939 AW810010 AW809705 AW809950 AW809822 AW809667
AW810093 AW810076 AW809673 AW810349 AW809895
454633 1227504_1 AW811380 AW811385
454653 1228081 1 AW812227 AW812294 AW812092
454690 1229106 1 AW854639 AW854719 AW854718 BE145880 AW854692 BE145866
AW816154 AW854698 AW854654 AW813335 AW854699
454707 1230250_1 AW814989 AW814852 AW814808
454822 1236369 1 AW833793 AW833799 AW833346 AW833371 AW833795 AW833562
AW833667 AW833377
3 5 454874 1238494 1 AW836407 BE175600 BE175579
454913 1242238 1 AW841462 BE156657 BE156668 BE092475
454934 1245577_1 AW846080 AW846074 AW846118 AW846130
454963 1246752-1 AW847647 AW847659 AW847656 AW847653 AW847717 AW847786
455013 1248899_1 BE073250 BE073378 BE073379 AW850533 AW850529
455092 12529711 BE152428AW855572AW855607
455110 1253955 1 BE154505 BE154462 BEi54454 BE154460 BE154489 BE154496
AW856909 BEi54497 BE154565 BE154572 BE154500 BE154472
455121 1254339-i BE156459 BE156469 BE156468 AW857d47
455152 1255227 1 AW858621 AW937120
455203 1259973 1 AW865450 AW865119 AW865452 AW865461 AW865325 AW865114
AW865116 AW865321 AW865590 AW865390
45 455275 1272255 1 AW977806 AW887923 AW886321
455435 1290546 1 AW939445 AW939465 AW939604 AW939531 AW939530 AW939993
455441 1291505_1 AW945964 AW946020 AW946034 AW946027 AW946041 AW946044
AW946033 AW946024 AW946021 AW946029 AW946015 AW946016
AW946039 AW946045 AW946028 AW946036
455592 1335196_1 BE008002 BE007997 BE007998 BE008000
455640 1348141 1 BE064059 BE063903 BE063838 BE063863 BE064056 BE063974
BE063904 BE063898 BE063896 BE063906 BE063980
455662 1349206 1 BE065387 BE065310 BE065391
455713 1352512_1 BE069891 BE158893 BE069898 BE158900
455759 1359316 1 BE080469 BE080474 BE080477 BE080546 BE080545
455851 1375451 1 BE146879 BE146914 BE146918
5 455853 1375671 1 BE147225 BE147205 BE147234
455879 1380017_1 BE153275 BE153189 BE153329 BE153022 BE153030 BE152974
455993 1398665 1 BE179085 BE179084 BE179086 BE179264
456072 1470256 1 H54381 H54463 BE393262
456101 151654_1 AA159478 AW901089 AA160437 AW593155
456212 1655565 1 N51636 T51874 T51829
456309 177026_1 AA225423 AA225369 BE144153 AW801549
456714 221500_1 AW897265 AW897274 AL119504 AW897275 AW897270 AW897312 AW897318
AW897317 AA317240 AW961361 T06241 AA326794
AL138130 AW407975 AW999277
457405 333127_1 AA504860 AA504911
65 457620 371514 1 AA602711 BE078290
457727 393566_1 AW974687 AA649656 AA652145
457868 426095 1 AW975133 AA7299d3 AA805813
458154 491768_1 AW816379 AA888282 AA879046 AA879195
458804 75803 1 AL157625 N72696 BE622492
458829 773443 1 A1557388 BE158936
458841 784186 1 W28965 W28971
459160 920051 1 A1904723 A1904725 A1904729 A1904722 A1904758 A1904736
459170 920646 1 A1905518 A1905516 A1905457 A1905515 AW176013 AW176037
,75 459186 922888-1 AI906287 BE064074 BE068820 BE068823 BE068822 BE068826
TABLE 1C: '
Pkey: Unique number corresponding to an Eos probeset
Ref: Sequence source. The 7 digit numbers in this column are Genbank
Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled
"The DNA sequence of
human chromosome 22" Dunham, et al. (1999) Nature 402:489-095
$o SUand: Indicates DNA strand from which exons were predicted
Nt_position: Indicates nucleotide positions of predicted exons
1
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
Pkey Ref StrandN~posi6on
4005849887612Minus18398-18573
4005939887642Minus25013-25127 -
4006129929646Minus151513-151662
4006139664507Plus 92278-92472
4006237228177Plus 74195-74335,74653-74827
4007097249204Plus 153075-154680
4007497331445Minus9162-9293
4008421927148Plus 90462-90673
1 4009257651921Plus 38183-38391,43900-44086
0
4009647139719Minus155282-155403
4009687923967Plus 19938-20043
4009757139779Minus108473-108847
4009838081198Plus 107903-108832
15 4010328117525Minus68451-68555
4010508117628Minus78449-79425
4010888492704Plus 194659-195179
4011298699792Minus62022-62242,62326-62451,62543-62710,63072-63167
4012009743387Minus111586-111806 114791-114916,115419-115583,116351-
116446,116847-116907,122653-123067,124982-125407
4012139858408Plus 96243-98380,98489-98619
4012309929527Minus33835-34006,34539-34592,36461-36745,48925-09098,52604-52758
4012454827300Minus59373-59531
4012608076883Minus86008-86355
4012698954206Plus 2259-2591
4012639800093Minus47256-47456.,
4014977381770Plus 92607-92813
4015087534110Minus110779-110983
4015217705251Plus 9127-9234
4015307770649Plus 41468-42406
3 4015757229804Minus76253-76364
0
4016047689963Minus119835-120185
4017807249190Minus28397-28617,28920-29045,29135-29296,29411-29567,29705-
29787,30224-30573
4017817249190Minus83215-83435,83531-83656,83740-83901,84237-84393,84955-
85037,86290-86814
4017937263888Minus102945-103083
3 4018097342191Minus107548-108298
S
4018627770606Minus55839-55993,59145-59293
4018818122429Minus148470-148651,153418-153618,154282-154438
4020187528100Plus 168728-168659
4020468072415Plus 166394-166556,168167-168395
40 4020508076908Minus130105-130227
4020718117361Plus 85924-86039
4020758117407Plus 121907-122035,122804-122921,124019-124161,124455-
124610,125672-126076
4021317704961Minus33114-33209,33496-33678
4022038576119Minus8124-8285
45 4022229958106Plus 3261-3834,3939-4269
4022966598824Plus 22587-23723
4022986598824Plus 36758-37953
4024219796341Minus46609-46662,46758-46811,86293-86346,89776-
89829,9004&90101,102817-102924
4024259796347Minus50224-50395
4024819797406Plus 87891-88991
0
4025297630937Minus165-917
4025439838066Minus89684-90893
4025767230225Minus1867-2247
4025789684928Plus 66350-66496
5 4026289931216Plus 31753-31966
5
4026319931231Minus115658-116580
4026399958129Minus20167-22383
4026648077024Plus 70318-70846
4027098901246Minus56847-57055
60 4027387331557Minus8725-8859
4027459212200Minus76516-76690
4027904835258Minus147744-147861
4027946136940Minus131034-131794
4028006010175Plus 43921-44049,46181-46273
4028599588237Minus69821-75323
4028928086844Minus194384-194645
4029749663349Plus 124035-124321
4030413171152Plus 70527-71019
4030658954197Minus71615-71773,73930-74144
70 4030838954241Plus 163070-163351
4030898954241Plus 171964-172239
4030938954241Plus 177083-177373,177464-177751
4031779838213Minus142560-142726
4032738018055Plus 133809-134099
4033348568877.Minus137205-137350
4033508569775Minus135374-135523
4033568569930Plus 92839-93036
4034039436460Plus 21240-21399
4035257960440Plus 152431-153243
g 4035688101145Minus85509-85658
0
4036478699843Minus35849-36204
4036877367384Plus 9009-9534
4036917387384Minus88280-88463
4036984263532Plus 10464-10907
103
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4037417630932Minus2833-3468
4037477658395Minus20493-20621
4037868083636Minus73028-73217
4038317249249Minus61468-61575
4038917331467Minus191508-193220
4039447711864Minus129213-129415
4039638568150Plus149466-149665
4040702996642Plus7210-7414,1004&10195
4040889958257Plus184131-184295
1 4040977770701Plus55512-55781
0
4041667596822Plus86147-86509
4042709828129Minus3649-3750,4161-4306,5962-6049,6849-6965
4043407630856Plus10898-11506
4044107342122Plus49052-49176,56177-56273,59384-59488
15 4045998705107Plus110443-110733
4046389796751Minus99433-99528,100035-100161
4046649797142Minus104257-105215
4047278081050Plus115534-115747
4047677882827Minus23244-23759
20 4048286580415Minus26291-27253
4048497706886Plus144843-144964,149846-150121
4048936850447Plus65083-65223
4048987331420Minus177015-177328
4049527382669Minus136326-136618
4049723213020Plus48711-49524,,
4049924662677Minus106104-106199,111659-111781
4050717708797Minus11115-11552
4051388576241Plus90303-90516
4051967230083Minus135716-135851
3 4052276731245Minus22550-22802
0
40527739110473Plus23471-23572
4052856139075Minus55744-55903,57080-57170,61478-61560
4052923845420Plus33227-33442
4053366094635Plus33267-33563
3 4053622337862Minus105008-105142,105980-106091,140445-140556,142519-142641
4053826552767Plus31923-32311
4054547656675Plus133807-134053
4054657767904Plus8935-9073,12242-12367,13364-13506,14965-15493
4054728439781Plus106297-106447,108462-108596
40 4055471054740Plus124361-124520,124914-125050
4055764003382Plus84000-85009
4056215523811Plus59362-59607
4056365123990Plus56384-56587
4056754557087Plus70304-70630
45 4057084156182Plus55030-55604
4057717018349Plus91191-91254,91510-91589
4057835738434Minus27238-27865
4057931405887Minus89197-89453
4058002791346Plus19271-19813
5 4058104938307Minus64543-64966
0
4058487651809Minus28135-28244
4058516164995Minus26407-27151
4058676758731Minus74553-75173
4058966758795Plus57311-57874
.5 40590477051111Minus16375-16584
5
4059177712162Minus106829-107213
4059828247790Minus36028-36408
4060308312328Minus~ 96123-96547
4060536758997Plus30921-31532
60 4060576691254Minus20830-21222
4061497144791Minus44464-45164
4061637158901Plus66690-66835
4062775686030Minus4759-5490
4063229212102Minus130230-130418
65 4063499256007Minus21251-21526
4065047711360Minus107068-107277
4065447711508Plus46576-46757
4065898224211Plus38806-38989
4065924567182I~lus352560-352963
TABLE 2A lists about 187 genes up-regulated in ovarian cancer compared to
normal adult tissues that are likely to be exlracellular or cell-surface
proteins. These were selected
as for Table 1A, except that the ratio was greater than or equal to 2.5, and
the predicted protein contained a PFAM domain that is indicative of
extracellular localizafion (e.g., 1g,
,7$ fi3, egf, 71m domains).
TABLE 2A: ABOUT 187 UP-REGULATED OVARIAN CANCER GENES ENCODING
EXTRACELLULARICELL SURFACE PROTEINS
Pkey: Primekey
Ex.Accn: ExempIarAccession
UG ID: UniGene ID
g0 Title: UnigeneTiBe
PFAM domains ,
ratio: tumor vs. normal tissues
104
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
Pkey Ex. UG Tifle PFAM domain ratio
Accn ID
No.
423017AW178761Hs.227948serine (or cysteine)serpin 63.6
proteinase inhibito
431938AA938471Hs.115242developmentally SCP 32.0
regulated GTP-bindi
425650NM Hs.1925desmoglein 3 (pemphiguscadherin 30.0
001944 vulgarts ant
418994AA296520Hs.89546selecfln E (endothelialEGF;IecGn c;sushi24.5
adhesion molec
452947AW130413 gb:xf50f04.x1 alpha-amylase 15.8
NCI-CGAP_Gas4
Hom
418092845154Hs.106604ESTs pkinase;Acflvin 15.1
recp
431725X65724Hs.2839Norrie disease Cys-knot 12.6
(pseudoglioma)
422330D30783Hs.115263epiregulin EGF 12.5
1~ 446745AW1i8189Hs.156400ESTs vwa 11.1
416319AI815601Hs.79197CD83 anflgen (activatedig 10.8
B lymphocyt
432408N39127Hs.76391myxovirus (influenza)ion trans;K tetra10.6
resistance 1,
ho
405285 predicted exon A2M;A2M-N 10.5
405636 predicted exon EGF;IdI_recep~a;ldl-recepLb9.8
I 403093 predicted exon fn3 9.6
S
446740AI611635Hs.192605ESTs RYDR ITPR 9.2
405547 predicted exon ABC-tran;ABC_membrane8.5
412333AW937485 gb:OV3-DTOOd4-221299-045-b0971m 1 8.4
DT
404270 predicted exon SCP 8.1
402745 predicted exon EGF;IdI_recept-b;thyroglobulin-18.1
452755AW138937Hs.213436ESTs cystafln 8.0
421459A1821539Hs.97249ESTs , 7.9
disintegrin;Repralysin
416151T26661 gb:AB65C7R Infantlaminin-G;EGF 7.8
brain, LLNL area
446232AI281848Hs.165547ESTs 71m 7.6
3
431009BE149762Hs.248213gap junctionprotein_ 7.2
beta 6 (connexin connexin
424634NM Hs.151407cartilage intermediateig;tsp-1 7.1
003613 layer protein,
n
400749 predicted exon fn3;ldl_recept_a;ldl_recept_b6.8
419054N40340Hs.191510ESTs, Weakly similarioig;SPRY 6.8
ORF2 [M.m
459170AI905518 gb:RGBT091-210199-098ABC tran;ABC_membrane6.6
BT091 Ho
416441BE407197 gb:601301552F1 SDF 6.4
NIH_MGC_21 Hom
410664NM-006033Hs.65370lipase, endothelialRibosomal-L22 6.4
402425 predicted exon ion traps 6.3
415451H19415Hs.268720ESTs, Moderately Ephrin 6.0
similar to ALUt
H
403083 predicted exon fn3 5.9
35 448995AI613276Hs.5662guanine nucleofldeSDF 5.9
binding protein
(G
418345AJ001696Hs.241407serine (or cysteine)serpin 5.8
proteinase inhibilo
424966AU077312Hs.153985solute carrter aa~ermeases 5.8
family 7 (cationic
amino
431211M86849Hs.5566gap juncflon protein,connexin 5.7
beta 2, 26kD
(co
430563AA481269Hs.1783B1ESTs ABC tran;ABC_membrane5.6
40 450152AI138635Hs.22968ESTs ig;pkinase 5.6
418844M62982Hs.1200arachidonate 12-lipoxygenaseIipoxygenase;PLAT5.6
403089 predicted exon fn3 5.6
d03687 predicted exon isp-i;Reprolysin5.6
403691 predicted exon isp-l;Reproiysin5.5
45 414035Y00630Hs.75716sedne (or cysteine)serpin 5.4
proteinase inhibilo
421284U62435Hs.103128cholinergic receptor,neur-chap 5.3
nicotinic, alpha
p
435435T89473Hs.192328ESTs Iipase;PLAT 5.3
457122A1026157Hs.33728ESTs, Weakly similarIipoxygenase;PLAT5.2
to ALU1 HUM
419249X14767Hs.89768gamma-aminobutyricneur-chap 5.2
acid (GAGA) A
425698NM Hs.159241polycysflc kidneyion inns 5.2
016112 disease 2-like
1
431117AF003522Hs.250500delta (Drosophila)-likeEGF;DSL 5.1
1
457948AI498640Hs.159354ESTs G-alpha;arf 5.1
435174AA687378Hs.194624ESTs SPRY 5.0
408170AW204516Hs.31835ESTs arf;ras 5.0
434351AW974991Hs.191852ESTs,WeaklysimilartoALUiarf;ras 4.9
HUM
430708U78308Hs.278485olfactory receptor,7trr~1 4.8
family 1, subfamily
d22597BE245909Hs.118634ATP-binding cassette,ABC tran;ABC-membrane4.8
sub-family B
(M
405545 predicted exon ABC-tran;ABC_membrane4.8
426471M22440Hs.170009transforming growthEGF 4.7
factor, alpha
409632W74001Hs.55279sertne (orcysteine)serpin 4.7
proteinase inhibito
420206M91463Hs.95958solute carrter sugar_tr 4.6
family 2 (facilitated
gluc
415138C18356Hs.78045tissue factor Kunitz-BPTI;G-gamma4.6
pathway inhibitor
2
424402M63108Hs.1769luteinizing hormonelchodogonadotrop7tm 1 4.5
436480AJ271643Hs.87469putaflve acid-sensingASC 4.5
ion channel
65 430226BE245562Hs.2551adrenergic, beta-2-,7tm_1 4.4
receptor, surface
436126AW449757Hs.163036ESTs SNF 4.4
406812AF000575Hs.67846leukocyte immunoglobulin-likeig 4.4
recep
409385AA071267 gb:zm61g01.r1 TIMP 4.3
Stratagene fibroblast
(
449184AW296295Hs.196491ESTs TNFR 4.3
c6
410555U92649Hs.64311a disintegrtn - 4.3
and metalloproteinasedisinlegrin;Reprolysin
do
422389AF240635Hs.115897protocadhertn cadhedn 4.3
12 .
405281 predicted exon A2M;A2M-N 4.3
413548BE147555Hs.288541Homo sapiens mRNAEGF;IdI-recept 4.3
for KIAA1558 a;ldl_recept-b
449535W15267Hs.23672low density lipoproteinIdl recept_a;EGF;IdI_recepf_b4.3
receptor-relate
425864U56420Hs.159903olfactory receptor,7trr~1 4.3
family 5, subfamily
410611AW954134Hs.20924KIAA1628 protein Peptidase-S9 4.2
430686NM Hs.2633desmoglein 1 cadherin;Cadherin-C4.1
001942 term
418693At750878Hs.87409thrombospondin vwc;TSPN 4.0
1
445924AI264671Hs.164166ESTs sugar-tr 3.9
g0 457148AF091035Hs.184627KIAA0118 protein arf;ras 3.9
428568AC004755Hs.184922one cut domain, E1-E2 ATPase 3.9
family member
3
412170D16532Hs.73729very low density EGF;IdI recept_a;ldl_recept3.8
lipoprotein receptorb
442566837337Hs.12111ESTs ' ank;death;RHD;TIG3.8
403763 predicted exon 7tm-1 3.8
105
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
403074 predicted exon fn3 3.8
413605BE152644 gb:CMi-HT0329-250200-128-f09alpha-amylase 3.8
HT
442295AI827248Hs.224398Homo Sapiens cDNACollagen;COLFI 3.7
FLJ11469 fis,
c
403661 predicted exon 7tm_3;ANF_receptor3.7
407305AA715284 gb:nv35f03.r1 pkinase;Sema;Plexin_repeat;TIG3.7
NCI CGAP_Br5
Hom
457353X65633Hs.248144melanocortin 2 7tm_1 3.7
receptor (adrenocortic
431176A1026984Hs.293662ESTs laminin_EGF;laminin_B3.6
436233AI742878Hs.124116ESTs 1g 3.6
431808M30703Hs.270833amphiregulin (schwannoma-derivedEGF 3.6
g
445798NM Hs.13321rearranged L-myc zf C2H2 3.6
012421 fusion sequence
400380NM Hs.283079G protein-coupled7tm_1 3.6
018485 receptor C5L2
453893NM Hs.36451glutamate receptor,lig chap 3.5
000835 ionotropic, N-met
409402AF208234Hs.695cystafin B (stefincystafin 3.5
B)
421166AA305407Hs.102308potassium inwardly-rectifyingIRK 3.5
channe
1 445575225368Hs.172004fifin fn3 3.5
5
428957NM_003881Hs.194679WNT1 inducible tsp_l;vwc;IGFBP 3.5
signaling pathway
p
403909NM_016255Hs.95260Homo Sapiens mRNA;Na H Exchanger 3.5
cDNA DKFZp
403077 predicted exon fn3 3.5
455612BE042896Hs.274848ESTs ABC Van;ABC_membrane3.5
424091AF235097Hs.139263calcium channel, ion traps 3.5
voltage-dependent,
a
403956W28077Hs.79389net (chicken)-likecadherin;Cadherin_C3.4
2 ierm
457470A8040973Hs.272385G protein-coupled7tm_1 3.4
receptor 72
401522N47812Hs.81360CGI-35 protein disintegrin;Reprolysin3.4
404886 predicted exon ion traps 3.4
437692AA176959Hs,172004fifin fi3 3.4
407944834008Hs.239727desmocollin 2 cadherin 3.d
407393AB038237 gb:Homo Sapiens 71m 1 3.3
mRNA for G protei
436936AL134451Hs.i97478ESTs EGF;laminin_G 3.3
423309BE006775Hs.126782sushi-repeat proteinsushi;HYR 3.3
402172 predicted exon 1g 3.3
447420AI378628 gbac72g07.x1 Soares_NhHMPu_S1ank;pkinase;death3.3
H
438901AF085834Hs.29036ESTs sushi 3.3
424362AL137646Hs.146001Homo Sapiens mRNA;trypsin;sushi;CUB3.3
cDNA DKFZp
430453BE387060Hs.3903Cdc42 effector fn3 3.3
protein 4; binder
of Rh
416631H69466 gb:yr88f07.r1 Idl recept-a;MACPF3.3
Soaresfetalliverspleen
453174AI633529Hs.135238ESTs 77m_1 3.3
433848AF095719Hs.93764car6oxypepfidase Zn carbOpept;Propep_M143.2
A3
408546W49512Hs.46348bradykinin receptor77m 1 3.2
B1
423573AA328504 gb:EST31993 Embryo,1271m 1 ' 3.2
week I Hom
458662AI823410Hs.i69149karyopherin alpha7Un_3;ANF receptor3.2
1 (imporlin alpha
5
433430AI863735Hs.186755ESTs thyroglobulin_1;IGFBP3.2
438850833727Hs.24688EST ank;pkinase;death3.2
420783A1659838Hs.99923lecfin, galactoside-binding,Gal-bind tecfin 3.2
soluble, 7
409968056102Hs.57699adhesion glycoprotein1g 3.1
430630AW269920Hs.2621cystatin A (stefin, 3.1
A) 7tm_3;ANF receptor
420737L08096Hs.99B99tumornecrosisfactor(ligand)superfaTNF 3.1
422279H69644Hs.114231Gtype leclin-likelectin c 3.1
receptor-2
400289X07820Hs.2258matrix metalloproteinasehemopexin;Pepiidase_M103.1
10 (stromely
412597AU077051Hs.74561alpha-2-macroglobulinA2M;A2M N 3.1
5 453420AJ003459. gb:AJ003459 SelectedIRK 3.1
0 chromosome 2
404243 predicted exon zf-C3HC4;SPRY;zf-B3.1
box
449987AW079749Hs.184719ESTs, Weakly similarABC han;ABC_membrane3.1
to AF116721 1
422471AA311027Hs.271894ESTs 1g 3.0
400464 predicted exon Peptidase_S9 3.0
SS 458713BE044496Hs.282707ESTs EGF 3.0
421340F07783Hs.1369decay accelerafingsushi 3.0
factor for complem
449523NM_000579Hs.54443chemokine (GC 71m_1 3.0
motif) receptor
5
400704 predicted exon lig chan;ANF 3.0
receptor
416239AL03B450Hs.48948ESTs E1-E2 ATPase;Hydrolase3.0
60 433664AW292176Hs.245834ESTs Ricin_B lecfin 3.0
423994X01057Hs.1724interleukin 2 rtm 2.9
receptor, alpha
447726AL137638Hs.19368Homo Sapiens mRNA;vwa 2.9
cDNA DKFZp
425483AF231022Hs.301273Homo Sapiens protocadherinEGF;cadhedn;laminin2.9
Fat 2 (FA G
423513AF035960Hs.129719transglutaminase Transglut_core;Transglutamin_N2.9
5
65 d01537 predicted exon ig;pkinase;LRRNT;LRRCT2.9
405790 predicted exon Sema;Plexin repeat;TIG2.9
422669H12402Hs.119122ribosomal proteinarf;ras;Ribosomal_S172.9
Ll3a
d30793M83181Hs.2479405-hydroxytryptamine71rr~1 2.9
(serotonin) recep
403411 predicted exon ABC Uan;ABC membrane2.8
70 428188M98447Hs.22transglutaminase Transglutamin_N;Transglut_core2.8
1 (K polypepfide
ep
414482S57498Hs.76252 7trr~1 2.8
endothelin receptor
type A
427223BE208189Hs.174031cytochrome c oxidaseCOX6B 2.8
subunit Vlb
404187 predicted exon 1g 2.8
443537D13305Hs.203cholecystokinin 7trn-1 2.8
B receptor
75 428701NM_013276Hs.190207carbohydrate kinase-
likevwa;integrin_A;P2X_receptor2.7
411213AA676939Hs.69285neuropilin 1 CUB;MAM;FS F8 2.7
type C
453999BE328153Hs.240087ESTs kazal 2.7
401244 predicted exon vwa;vwd;TIL 2.7
458930NM Hs.24640sema domain, immunoglobulinSema 2.7
003612 domai
g0 434411AA632649Hs.201372ESTs . sushi 2.7
400421AF263537Hs.287370fibroblastgrowthfactor23FGF 2.7
448999AF179274Hs.22791transmembrane kazal 2.7
protein with
EGF-like
417350050928Hs.82001polycysfic kidneyion traps 2.6
disease 2 (autosoma
419452033635Hs.90572, PTK7 protein pkinase;ig 2.6
tyrosine kinase
7
106
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
401657 prodicted exon 71m 1 2.6
456711AA033699Hs.83938 ESTs, Moderatelysushi;trypsin;CUB2.6
similar to MASP-2
432042AW971345Hs.292715 ESTs sugar-U 2.6
433138AB029496Hs.59729 semaphodn sem2 ig;Sema 2.6
452530AI905518gb:RGBT091-210199-098 ABC Uan;ABC-membrane2.6
BT091 Ho
426418M90464Hs.169825 collagen, typeCollagen;C4 2.6
IV, alpha 5 (Alport
syn
403796 predicted exon cadherin 2.6
431728NM Hs.268107 multimedn EGF;CIq 2.6
007351
441595AW206035Hs.192123 ESTs sugar-U 2.6
1 445537AJ245671Hs.12844 EGF-like-domain,EGF;MAM 2.6
~ multiple 6
447197836075gb:yh88b01.s1 Soaves SDF 2.5
placenta Nb2H
428765X54150Hs.i93122 FcfragmentoflgA,receptorfor1g 2.5
450245AA007536Hs.271767 ESTs, Moderately1g 2.5
similar to ALU1 N
416429H54658Hs.268942 ESTs E1-E2 ATPase;Hydrolase2.5
I 417067AJ001417Hs.81086 solute comer sugar-U 2.5
S family 22 (extraneurona
433182A8039920Hs.127821 BWRT protein ion traps 2.5
403092 predicted exon fi3 2.5
406850AI624300Hs.172928 collagen, typevwc;Collagen;COLFI2.5
I, alpha 1
438698AW297855Hs.125815 ESTs Iipoxygenase;PLAT2.5
d56815NM-013348Hs.144011 potassium inwardly-rectifyingIRK 2.5
channe
7ABLE
28:
Pkey:ue identifier number
Uniq Eos
probeset
CAT number
number:
Gene
cluster
Accession:Genbank
accession
numbers
s
Pkey CAT Accession
Number
d09385112523AA071267 T65940 T64515
1 AA071334
4123331289037AW937485 AW937589 AW937658
1 AW937654 AW937492
4136051379792_1BE152644 BE152712 BE752668BE152816 BE152656BE152715
BE152659 BE152810 BE152811BE152643 BE152660BE152662
BE152706
BE152669 BE152661 BE152672BE152767 BE152714BE152665
BE152653 BE152716 BE152651BE152677 BE152708BE152679
BE152652
BE152771 BE152775 BE152666BE152676 BE152667BE152808
BE152768 BE152813 BE152664BE152681 BE152814BE152711
BE152709
BE152707 BE152815 BE152678BE152682 BEi52778BE152762
BE152673 BE152782 BE152671BE152760 BE152780BE152776
BE152809
BE152781 BE152774 BE152763
BE152769
3 4161511573926T26661 244135 H23016
1
416441159480BE407197 AA182474 AA180369
1 BE275628 BE276131
4166311605019H69466 H93884 N59684
1
423573229714AA328504 AA327783 AW962370
1
447197711623836075 AI366546 836167
1
447420721207A1378628 N32350 H85772
1
452530920646A1905518 A1905516 A1905457
1 A1905515 AW176013 AW176037
452947939810AW130413 AI932362
1
453420966433AJ003459 AJ003461
1
459170920646A1905518 A1905516 A1905457
1 A1905515 AW176013 AW176037
45 _
TABLE
2C:
Pkey:
Unique
number
corresponding
to
an
Eos
probeset
Ref: . "Dunham ublicationDNA sequence
Sequence 1. et aL" entitledof
source. refers to "The
The the p
7
digit
numbers
in
this
column
are
Genbank
Identifier
(GI)
numbers
hum an 22" Dunham, et al. (1999)
chromosomeNature 402:489-095
SUand: nd from which exons were
Indicates predicted
DNA
stra
Nt~osition: Indicates
nucleotide
positions
of
predicted
exons
Pkey Ref Strand Nt_position
4004649929670Plus 22074-22214
4007048118864Minus 63110-63241
4007497331445Minus 9162-9293
4012444827300Minus 55359-56376
4015377960358Minus 186786-187029,190607-190779,198218-198348
4016579100664Minus 7312-8163
4021728575911Minus 143378-143671
4024259796347Minus 50224-50395
4027459212200Minus 76516-76690
4030748954241Plus 143375-143561
4030778954241Plus 146923-147222,147326-147628
65 4030838954241Plus 163070-163351
4030898954241Plus 171964-172239
4030928954241Plus 174720-175016,175104-175406,175508-175813
4030938954241Plus 177083-177373,177464-177751
4034119438635Minus 104247-104420
70 4036618705027Minus 30268-30482
4036877387384Plus 9009-9534
4036917387384Minus 88280-88463
4037637229888Minus 43575-43887
4037968099896Minus 75073-77664
75 4041874481839Plus 7644-7991
4042435672609Plus 74695-75123
4042709828129Minus 3649-3750,4161-4306,5962-6049,6849-6965
d048864884062Plus 30058-30596
4052816139075Minus 34202-34351,35194-35336,45412-45475,d5731-05958,47296-
47457,49549-09658,49790-49904,50231-50342, 53583-
53667,54111-
54279
4052856139075Minus 55744-55903,57080-57170,61478-61560
4055451054740Plus 118677-118807,119091-119296,121626-121823
4055471054740Plus 124361-124520,124914-125050
4056365123990Plus 56384-56587
1~7
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
405790 1203968 Plus 136364-136509,136579-136699,136805-136941
TABLE 3A lists about 1643 genes up-regulated in ovarian cancer compared to
normal ovaries. These were selected as for Table 1A, except that the ratio was
greater than or
equal to 15, and the denominator was the arithmefic mean value for various non-
malignant ovary specimens obtained.
TABLE 3A: ABOUT 1643 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL OVARY
Pkey:
Primekey
Ex.Accn:ExempIarAccession
UG niGene
ID: ID
U
Title:
Unigene
Title
PFAMmains
do
rafio:
tumor
vs.
normal
tissues
PkeyEx. 0G Title rafio
Accn ID
No.
420859AW468397Hs.1000005100 calcium-binding 219.9
protein A8 (calgranulin
A)
422166W72424Hs.112405S100 calcium-binding 180.2
protein A9 (calgranulin
B)
422158L10343Hs.112341protease inhibitor 165.0
3, skin-derived (SKALP)
424799BE550723Hs.153179fatty acid binding 161.5
protein 5 (psoriasis-associated)
442402NM_000954Hs.8272prosiagiandin D2 synthase150.2
(21kD, brain)
408522AI541214Hs.46320Small praline-rich 149.5
protein SPRK [human,
odontogenic k
431369BE184455Hs.251754secretory leukocyte 144.9
protease inhibitor
(aniileukoprotein
430520NM-016190Hs.242057chromosome 1 open reading.
frame 10 136.6
428471X57348Hs.184510strafifin 129.5
421978AJ243662Hs.110196NICE-1 protei0 108.7
437191NM_006846Hs.5476serine protease inhibitor,106.2
Kazal type, 5
407788BE514982Hs.38991S100 calcium-binding 105.5
protein A2
441565AW953575Ns.169902solute carrier family 103.6
2 (facilitated glucose
transporter),
431211M86849Hs.5566gap junction protein, 102.1
beta 2, 26kD (connexin
26)
419329AY007220Hs.288998S100-Type calcium binding95.3
protein A14
430572033114Hs.245188tissue inhibitor of 87.0
metalloproteinase
3 (Sorsby fundus d
417079065590Hs.81134interleukin 1 receptor86.1
antagonist
412636NM_004415Hs.74316desmoplakin (DPI, DPII)85.0
417515L24203Hs.82237ataxia-telangiectasia 84.8
group D-associated
protein
426295AW367283Hs.75839zinc fingerprotein6(CMPX1)84.5
452669AA216363Hs.262958ESTs, Weakly similar 84.4
to allemafively spliced
product a
406711N25514Hs.77385myosin, light polypepfide83.8
6, alkali, smooth
muscle and n
406712M31212Hs.77385myosin, light polypeptide81.0
6, alkali, smooth
muscle and n
432680T47364Hs.278613interferon, alpha-inducible81.0
protein 27
416889AW250318Hs.80395mat, T-cell differenfialion77.8
protein
409453AI885516Hs.95612ESTs 75.3
424670W61215Hs.116651epithelial V-like anfigen67.5
1
417130AW276858Hs.81256S100 calcium-binding 67.0
protein A4 (calcium
protein, calv
423634AW959908Hs.1690heparin-binding growth65.7
factor binding protein
442379NM_004613Hs.8265transglutaminase 2 64.7
(C polypeptide, protein-glutamine-g
456898NM Hs.155597Dcomponentofcomplement(adipsin)64.6
001928
423017AW178761Hs.227948sedne (or cysteine) 63.6
proteinase inhibitor,
Glade B (ovalbu
447990BE048821Hs.20144small inducible cytokine60.7
subfamily A (Cys-Cys),
memb
424362AL137646Hs.146001Homo sapiens mRNA; 60.3
cDNA DKFZp586F0824
(from
414438AI879277Hs.76136thioredoxin 59.9
420136AW801090Hs.195851acfin, alpha 2, smooth58.9
muscle, aorta
433336AF017986Hs.31386ESTs, Highly similar 58.8
to JE0174 friuled
protein-2 [H.sa
403741 predicted exon 57.0
430637BE160081Hs.256290S100 calcium-binding 56.1
protein A11 (calgiuarin)
424098AF077374Hs.139322small proline-rich 55.8
protein 3
441591AF055992Hs.183Duffy blood group 55.6
426521AF161445Hs.170219hypothetical protein 55.5
406713002629Hs.77385myosin, IigM pclypepfide55.3
6, alkali, smooth
muscle and n
406725D51245Hs.288061actin, beta 54.1
422168AA586894Hs.1124085100 calcium-binding 54.1
protein A7 (psoriasin
1 )
406755N80129Hs.94360metalloihionein 1L 54.0
425593AA278921Hs.1908proteoglycan 1, secretory53.3
granule
442257AW503831 gb:Ul-HF-BNO-alb-b-OS-0-ULr153.1
N!H-MGC-50 Homo
421957AW068637Hs.109857hypoihefical protein 52.3
DKFZp434H0820
447526AL048753Hs.340small inducible cytokine51.2
A2 (monocyte chemotacfic
pro
406722H27498Hs.283305Homo sapiens SNC73 51.0
protein (SNC73) mRNA,
comple
427223BE208189Hs.174031cytochrome c oxidase 51.0
subunit Vlb
414420AA043424Hs.76095immediate early response50.9
3
417259AW903838Hs.81800chondroifin sulfate 50.3
proteoglycan 2 (versican)
414191AW250089Hs.75807PDZ and LIM domain 49.5
1 (elfin)
436906H95990Hs.181244major histocompatibility49.0
complex, class I,
A
408000L11690Hs.620bullous pemphigoid 49.0
antigen 1 (2301240kD)
414035Y00630Hs.75716serine (or cysteine) 48.8
proteinase inhibitor,
Glade B (ovalbu
432706NM Hs.286124CD24 anfigen (small 48.8
013230 cell lung caroinoma
cluster 4 antig
421948L42583Hs.111758kerafin 6A 48.7
414662AL036058Hs.76807major histocompatibilily48.5
complex, class II,
DR alpha
425071NM-013989Hs.154424deiodinase, iodothyronine,48.5
type II
404767 predicted exon 48.4
418327070370Hs.84136paired-like homeodomain48.2
transcripfion factor
1
436729BE621807Hs.3337transmembrane 4 superfamily47.7
member 1
414183AW957446Hs.30i711ESTs 47.2
400163 predicted exon 47.0
433423BE407127Hs.8997heat shock 70kD protein46.9
1A
423457F08208Hs.155606paired mesoderm homeo 46.6
box 1
108
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
414085AA114016Hs.75746aldehyde dehydrogenase46.0
6
423189M59371 Hs.171596EphA2 45.6
438240N92638 Hs.124004ESTs 45.5
417366BE185289Hs.1076small praline-rich 45.3
protein 1B (comifin)
412774AA120B65Hs.23136ESTs 45.1
407242M18728 gb:Human nonspecific 44.8
crossreacting antigen
mRNA, ca
431292AA370141Hs.251453Human DNA sequence 44.8
from clone 967N21
on chromos
403695 predicted exon 43.5
417365D506B3 Hs.82028Uansforming growth 43.4
factor, beta receptor
II (70-80kD)
1 432331W37862 Hs.274368Homo Sapiens mRNA; 43.4
~ cDNA DKFZp58611524
(from c
424479AF064238Hs.149098smoothelin 43.3
444726NM-006147Hs.11801interferon regulatory 43.2
factor 6
432314AA533447Hs.285173ESTs 43.2
429500X78565 Hs.289114hexabrachion (tenascin43.1
C,cytotacfin)
1 441406245957 Hs.7837Homo Sapiens cDNA FLJ 42.7
S 10457 fis, clone NT2RP1001
412969AI373162Hs.75103tyrosine 3-monooxygenaselUyptophan42.6
5-monooxygenas
423720AL044191Hs.23388Homo Sapiens cDNA: 42.5
FLJ21310 fis, clone
COL02160
400111 predicted exon 42.4
407207T03651 Hs.179661tubulin, beta polypepfide42.4
417164AA338283Hs.81361heterogeneous nuclear 42.2
ribonucleoprotein
AIB
424971AA479005Hs.154036tumor suppressing subtransferable41.9
candidate 3
439394AA149250Hs.56105ESTs, Weakly similar 41.9
to WDNM RAT WDNM1
PROT
406657AI678644Hs.277477major histocompatibility41.8
complex, class I,
C
451092AI207256Hs.13766Homo Sapiens mRNA for 41.6
FLJ00074 protein,
partial cds
25 412596AA161219Hs.799diphtheria toxin receptor41.6
(heparin-binding epidermal
gro
422103AA984330Hs.111676protein kinase H11; 41.5
small stress protein-like
protein HS
428785A1015953Hs.125265ESTs 41.3
450988BE618571Hs.429ATP synthase, H+transporting,41.0
mitochondria) FO camp
414622AI752666Hs.76669nicofinamide N-methylUansferase40.8
405022 predicted exon 40.8
408221AA912183Hs.47447ESTs 40.8
446500078093 Hs.15154sushi-repeat-containing40.7
protein, X chromosome
421416BE302950Hs.104125adenylyl cyclase-associated40.6
protein
412247AF022375Hs.73793vascular endothelial 40.5
growth factor
35 410541AA065003Hs.64179hypothetical protein 40.5
406658AI920965Hs.77961major histocompafibility40.0
complex, class I,
B
420225AW243046Hs.94789ESTs 40.0
406825A1982529Hs.84298CD74 antigen (invariant39.4
polypeptide of major
histocom
443623AA345519Hs.9641complement component 39.4
1, q subcomponent,
alpha poly
40 404201AF059566Hs.103983solute cartier family 39.3
5 (sodium iodide symporter),
mem
405138 predicted exon 39.1
408733AW264812Hs.254290ESTs 39.0
414044BE614194Hs.75721profilin 1 38.9
430152A8001325Hs.234642aquaporin 3 38.8
45 428121AB006622Hs.182536Homo Sapiens cDNA: 38.8
FLJ21370 fis, clone
COL03092
434311BE543469Hs.266263Homo Sapiens cDNA FLJ1411538.7
fis, clone MAMMA10
406140 predicted exon 38.5
432918AF077200Hs.279813hypotheficalprolein 38.4
420107AL043980Hs.7886pellino (Drosophila) 38.4
homolog 1
5~ 427693BE546832Hs.180370cofilin 1 (non-muscle)38.1
448835BE277929Hs.11081ESTs, Weakly similar 38.1
to S57447 HPBRII-7
protein [H.
432374W68815 Hs.301885Homo Sapiens cDNA FLJ1134637.9
fis, clone PLACE1010
428383BE616599Hs.184029hypothefical protein 37.7
DKFZp761A052
436258AW867491Hs.107125ESTs, Weakly similar 37.7
to S57447 HPBRII-7
protein [H.
55 420798W93774 Hs.99936keratin 10 (epidertnolyfic37.7
hypedceratosis; keralosis
palm
400327M18679 Hs.247942Human variant 5S rRNA-like37.6
gene and ORF, complete
401781 predicted exon 37.6
448257AW772070Hs.253146ESTs 37.3
428415AA337211Hs.184222Down syndrome crifical37.2
region gene 1
424206NM-003734Hs.198241amine oxidase, copper 37.2
, containing 3 (vascular
adhesion p
406812AF000575Hs.67846leukocyte immunoglobulin-like37.2
receptor, subfamily
8 (
425882083115 Hs.161002absentin melanoma 1 37.2
432501BE546532Hs.287329Fas binding protein 37.1
1
421786AI188653Hs.2i351ESTs 37.1
65 427981BE275986Hs.181311asparaginyl-tRNA synthetase37.0
410143AA188169Hs.288819Homo Sapiens cDNA: 36.8
FLJ21022 fis, clone
CAE06383
451328AW853606Hs.109012ESTs 36.7
414135NM 004419Hs.2128dual specificity phosphatase36.7
5
414602AW630088Hs.76550Homo sapiens mRNA; 36.7
cDNA DKFZp564B1264
(from
401785 predicted exon 36.5
411469T09997 Hs.70327cysteine-rich protein 36.2
2
419693AA133749Hs.92323FXYD domain-containing36.1
ion Uansport regulator
3
417039AA302180Hs.80986ATP synthase, H+Uansporfing,36.1
mitochonddal FO comp
406718AA505525Hs.169476glyceraldehyde-3-phosphate36.0
dehydrogenase
75 402543 predicted exon 36.0
408669AI493591Hs.78146plateleUendothelial 35.9
cell adhesion molecule
(CD31 anfig
414987AA524394Hs.165544ESTs 35.9
445810AW265700Hs.155660ESTs ' 35.9
406653AA574074Hs.77961major histocompafibility35.7
complex, class I,
B
g0 407498028131 gb:Human HMGI-C chimedc35.6
transcript mRNA, parfial
412524AA417813Hs.11177ESTs 35.5
401521 predicted exon 35.4
408948AW296713Hs.221441ESTs 35.1
406728AI986345Hs.183704ubiquitin C 34.9
109
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
440669AI206964 gb:qr30g06.x1 NCI CGAP34.8
GC6 Homo Sapiens cDNA
422658AF231981Hs.250175homolog of yeast long 34.8
chain polyunsaturated
fatty acid
452924AW5B0939Hs.97199complement component 34.7
C1q receptor
428600AW863261Hs.15036ESTs, Highly similario34.7
AF1613581 HSPC095
[H.sapi
409828AW501137 gb:Ul-HF-BPOp-ait-e-12-0-ULr134.5
NIH MGC 51 Homo
459390BE385725 gb:601276347F1 NIH 34.5
MGC_20 Homo Sapiens
cDNA
445055BE512856Hs.109051glycoprotein, synaptic34.3
2
411789AF245505Hs.72157Homo Sapiens adlican 34.3
mRNA, complete cds
410626BE407727 gb:601299771F1 NIH_MGC-2134.2
Homo Sapiens cDNA
1 410706A1732404Hs.68846ESTs 34.2
0
419273BE271180Hs.293490ESTs 34.2
d07839AA045144Hs.161566ESTs 34.0
444286A1625304Hs.190312ESTs 34.0
449226AB002365Hs.23311KIAA0367 protein 34.0
1 414290A1568801Hs.71721ESTs 33.9
401245 predicted exon 33.9
425222M85430Hs.155191villin 2 (ezrin) 33.8
409950842678Hs.301669KIAA0564 protein 33.8
437201F29279Hs.177486amyloid beta (A4) precursor33.7
protein (protease
nexin-II,
406566AF088886Hs.11590cathepsin F 33.7
405071 predicted axon 33.7
455426AW937792 gb:OV3-DT0045-140200-082-b0733.6
DT0045 Homo sapi
415160T82802 gb:yd38a04.r1 Soares 33.5
fetal liver spleen
1NFLS Homo s
424995245023 gb:HSC2FA041 normalized33.5
infant brain cDNA
Homo s
453870AW385001Hs.8042Homo Sapiens cDNA: 33.5
FLJ23173 fis, clone
LNG10019
433470AW960564Hs.3337transmembrane 4 superfamily33.4
member 1
428188M98447Hs.22 iransglutaminase 1 33.3
(K polypepfide epidermal
type I, pro
417409BE272506Hs.82109syndecan 1 33.3
425389AW974499Hs.192183ESTs 33.3
30 434658AI624436Hs.194488ESTs 33.2
456562AA306049Hs.102669DKFZP4340125 protein 33.1
447111A1017574Hs.17409cysteine-rich protein 33.0
1 (intestinal)
432360BE045243Hs.274416NADH dehydrogenase 32.9
(ubiquinone) 1 alpha
subcomple
424125M31669Hs.1735inhibin, beta B (activin32.7
AB beta polypeptide)
3 419968X04430Hs.93913interleukin 6 (interferon,32.7
5 beta 2)
429415NM Hs.202097procollagen Gendopeptidase32.6
002593 enhancer
451541BE279383Hs.26557plakophilin 3 32.6
424499N90344Hs.149436kinesin family member 32.4
~ 58
402144 predicted axon 32.4
40 422511AU076442Hs.117938collagen, type XVII, 32.4
alpha 1
400231 predicted axon 32.3
437712X04588Hs.85844neurotrophic tyrosine 32.3
kinase, receptor,
type 1
417433BE270266Hs.82i285T4 oncofetal trophoblast32.2
glycoprotein
419659A8023206Hs.92186Lemon coiled-coil protein32.0
45 428582BE336699Hs.185055GENE protein 32.0
421401AW410478Hs.104019Uansforming, acidic 32.0
coiled-coil containing
protein 3
414064BE245289Hs.16165expressed in activated32.0
TILAK lymphocytes
431938AA938471Hs.115242developmentally regulated32.0
GTP-binding protein
1
411930F06485 gb:HSC19G051 normalized31.9
infant brain cDNA
Homo s
428150AW950547Hs.182684cytochrome c oxidase ~
subunit Vlla polypeptide31.8
2 (liver)
401887 predicted axon 31.8
412570AA033517Hs.74047electron-Uansfer-fiavoprotein,31.7
beta polypeptide
422738X80915Hs.1573growth differentiation31.6
factor 5 (cartilage-derived
morph
453092X64838Hs.31638restin (Reed-Steinberg31.5
cell-expressed intermediate
filam
5 413924AL119964Hs.75616KIAA0018 gene product 31.4
S
420231806866Hs.19813ESTs 31.3
434715BE005346Hs.116410ESTs 31.3
422831802504 gb:yeB6fO6.r1 Soares 31.2
fetal liver spleen
1 NFLS Homo so
416854H40164Hs.80296Purkinje cell protein 31.2
4
422976AU076657Hs.1600sec61 homolog 31.1
4263568E536836 gb:601064837F1 NIH_MGC_1031.0
Homo Sapiens cDNA
433935AF112208Hs.44163l3kDadifferenfiation-associated30.8
protein
430040AW503115Hs.227823pM5 protein 30.8
406340AA299679Hs.180370cofilin 1 (non-muscle)30.8
65 426050AF017307Hs.166096E74-like factor 3 (ets30.7
domain Uanscription
factor, epith
425105BE280066Hs.24956hypothetical protein 30.7
FLJ22056
402066 predicted axon 30.7
429538BE182592Hs.139322small proline-rich 30.6
protein 3
418371M13560Hs.84298CD74 antigen (invariant30.4
polypeptide of major
histocom
70 421251228913Hs.102948enigma (LIM domain 30.3
protein)
456084AA155B59Hs.79708ESTs 30.3
402023 predicted axon . 30.3
404356 predicted axon 30.2
415973824707Hs.260201ESTs 30.2
75 445983A1269107Hs.132219ESTs 30.1
450440A8024334Hs.25001tyrosine 3-monooxygenaseltryptophan30.1
5-monooxygenas
458789AL157468Hs.20157Homo Sapiens cDNA FLJ2084830.1
fis, clone ADKA01732
400842 predicted axon 30.1
406828AA419202Hs.84298CD74 antigen (invariant30.0
polypeptide of major
histocom
g0 423267AL137416Hs.126177Homo Sapiens mRNA; 30.0
cDNA DKFZp4340192
(from c
451383AW239364Hs.20242hypothetical protein 30.0
FLJ12788
437042AK000702Hs.5420hypothetical protein 30.0
FW20695
459399BE407712 gb:601299745F1 NIH 30.0
MGC_21 Homo Sapiens
cDNA
425650NM-001944Hs.1925desmoglein 3 (pemphigus30.0
vulgads antigen)
110
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
416511NM-006762Hs.79356Lysosomal-associated 29.9
multispanning membrane
protein
431009BE149762Hs.248213gap junction protein, 29.7
beta 6 (connexin 30)
436651BE045962Hs.275998ESTs 29.6
419766BE243101Hs.22391chromosome 20open reading29.5
frame 3
420747BE294407Hs.99910phosphofructokinase, 29.5
platelet
436895AF037335Hs.5338carbonic anhydrase 29.5
XII
412765AK000620Hs.74571ADP-ribosyialion factor29.4
1
419223X60111Hs.1244CD9 antigen(p24) 29.4
413796AW408094Hs.75545intedeukin 4 receptor 29.4
1~ 447795AW295151Hs.163612ESTs 29.4
431 M57399Hs.44 pleiofrophin (heparin 29.4
1 binding growth factor
03 8, neurite g
415314N88802Hs.5422glycoprotein M68 29.3
428411AW291464Hs.10338ESTs 29.3
430580AA806105Hs.140immunoglobulin heavy 29.3
constant gamma 3 (Gm
marker)
15 430451AA836472Hs.249982cathepsin B 29.2
453949AU077146Hs.36927heatshock105kD 29.2
413859AW992356Hs.8364pymvate dehydrogenase 29.2
kinase, isoenzyme
4
407845AL036518Hs.118598ESTs 29.1
453500A1478427Hs.43125ESTs 29.1
456054BE313241 gb:601151545F1 NIN-MGC_1929.0
Homo Sapiens cDNA
453467AI535997Hs.30089ESTs 29.0
411794AL118577Hs.75658phosphorylase, glycogen;28.9
brain
421773W69233Hs.112457ESTs 28.9
423621BE002904 gb:OV4-BN0090-070400-163-c0728.8
BN0090 Hamo sapi
25 408935BE539706Hs.285363ESTs 28.8
450847NM Hs.25590stanniocalcin 1 28.8
003155
431243U46455Hs.252189syndecan 4 (amphiglycan,28.7
ryudocan)
423225AA852604Hs.125359Thy-1 cell surface 28.7
antigen
433469F12741 gb:HSC3DG061 normalized28.7
infant brain cDNA
Homo
30 405783 predicted exon 28.7
417308H60720Hs.81892KIAA0i01 gene product 28.7
400749 predicted exon 28.7
413442BE140643 gb:RCO-HT0015-310599-01628.6
HT0015 Homo Sapiens
c
404828 predicted exon 28.6
3 407453AJ132087 gb:Homo Sapiens mRNA 28.6
for axonemal dynein
heavy ch
418529AW005695Hs.250897TRK-fused gene (NOTE: 28.6
non-standard symbol
and nam
413787Ai352558Hs.75544tyrosine 3-monooxygenaseltryptophan28.5
5-monooxygenas
450690AA296696Hs.25334FXYD domain-containing28.5
ion fransport regulator
5
402430 predicted exon 28.4
40 413929BE501689Hs.75617collagen, type IV, 28.2
alpha 2
423803NM_005709Hs.132945PDZ-73 protein 28.2
406086 predicted exon 28.2
416585X54162Hs.79386leiomodin 1 (smooth 28.2
muscle)
417055N39489Hs.7258Homo sapiens cDNA: 28.1
FL,122021 fis, clone
HEP08253
45 449184AW296295Hs.196491ESTs 28.1
446542NM-004281Hs.15259BCL2-associated athanogene28.1
3
412793AW997986 gb:RC1-BN0056-230200-021-e1128.0
BN0056 Homo sapie
452818W21909Hs.8372ubiquinol-cytochrome 28.0
c reductase (6.4kD)
subunit
402869 predicted exon 27.9
4361310AA353044Hs.5321ARP3 (actin-related 27.9
protein 3, yeast)
homolog
402075 predicted exon 27.9
410480897457Hs.63984cadhedn 13, H-cadherin27.8
(heart)
406690M29540Hs.220529carcinoembryonic antigen-related27.8
cell adhesion molecul
439766AB033492Hs.301241Homo sapiens mRNA; 27.7
cDNA DKFZp586A0424
(from
55 424482BE268621Hs.149155voltage-dependent anion27.6
channel 1
420737L08096Hs.99899tumor necrosis factor 27.6
(ligand) superfamily,
member 7
414663BE396326 gb:601289258F1 NIH 27.6
MGC_8 Homo Sapiens
cDNA c
409703NM-006187Hs.560092'-5'oligoadenylate 27.6
synthetase 3
446108AL036596Hs.102773ESTs 27.5
60 428144BE269243Hs.182625VAMP (vesicle-associated27.5
membrane protein)-associate
445688AI248205'Hs.153244ESTs 27.5
405411 predicted exon 27.5
410275U85658Hs.61796franscription factor 27.5
AP-2 gamma (activating
enhancer-b
424675NM Hs.151641glycoprotein A repetitions27.3
005512 predominant
65 450455AL117424Hs.25035chloddeintracellularchannel427.3
414855AA156986Hs.104640HIV-1 inducer of short27.2
franscripts binding
protein
433578BE336886Hs.3416adipose differentiation-related27.2
protein
401994 predicted exon 27.2
445033AV652402Hs.155145ESTs 27.2
7~ 402277 predicted exon 27.1
428106BE620016Hs.182470PTDO10 protein 27.1
448625AW970786Hs.178470Homo Sapiens cDNA: 27.1
FLJ22662 fis, clone
HS108080
422587AI879352Hs.118625hexokinase 1 27.0
457204BE264152Hs.221994ESTs 27.0
75 444094A1695764Hs.202394ESTs 27.0
414053BE391635Hs.75725fransgelin 2 26.9
430511BE018156Hs.2575calpain 1, (mull) large26.9
subunit
434039L32977Hs.3712ubiquinot-cytochrome 26.9
c reductase, Rieske
iron-sulfur po
424939AK000059Hs.153881Homo Sapiens NY-REN-6226.9
antigen mRNA, partial
cds
414539BE379046 gb:601236646F1 NIH_MGC-4426.9
Homo Sapiens cDNA
404675 predicted exon 26.8
401597AA172106Hs.110950Rag C protein 26.8
401405 predicted exon 26.8
411541W03940 gb:za62b02.r1 Soares 26.8
fetal liver spleen
1 NFLS Homo sa
111
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
412025AI827451Hs.24143ESTs 26.7
414276BE297862 gb:601174780F1 NIH 26.7
MGC_17 Homo sapiens
cDNA
444065AW449415Hs.10260Homo Sapiens cDNA FLJ7134126.7
fis, clone PLACE1010
447981853772Hs.8929hypothetical protein 26.7
FLJ11362
410677NM Hs.65424tetranecfin (plasminogen-binding26.5
003278 protein)
400982 predicted exon 26.5
452933AW391423Hs.288555Homo Sapiens cDNA: 26.5
FLJ22425 fis, clone
HRC08686
407233X16354Hs.50964carcinoembryonic anfigen-related26.4
cell adhesion molecul
430127AA219498Hs.233952proteasome (prosome, 26.3
macropain) subunit,
alpha type 7
1 448218A1188489 gb:qd09b12.x1 Soares~lacenta26.3
~ 8to9weeks_2NbHP8to
413511A1627178Hs.75412Arginine-rich protein 26.2
459511AI142379 gb:qg6dc01.r1 Soares 26.2
tesfis-NHT Homo Sapiens
cDNA
4106688E379794Hs.65403hypothetical protein 26.2
458662AI823410Hs.169149karyopherin alpha 1 26.2
(imporiin alpha 5)
15 451219AA054209Hs.167904ESTs 26.2
448939BE267795Hs.22595hypotheficalprotein 26.2
FLJ10637
400800Y10262Hs.46925eyes absent (Drosophila)26.2
homolog 3
446342BE298665Hs.14846Homo Sapiens mRNA; 26.2
cDNA DKFZp564D016
(from c
421177AW070211Hs.102415Homo Sapiens mRNA; 26.1
cDNA DKFZp586N0121
(from
433848AF095719Hs.93764carboxypepfidase A3 26.1
448497BE613269Hs.21893ESTs, Weakly similar 26.1
to glycerol 3-phosphate
pertnease
415279F04237Hs.1447glial fibdllary acidic26.0
protein
419323A1092379Hs.135275ESTs 26.0
430265L36033Hs.237356stromal cell-derived 25.9
factor 1
25 437679NM Hs.5753inositol(myo):~(or4)-monophosphatase225.9
014214
425535AB007937Hs.158287KIAA0468 gene product 25.8
412923AA179922Hs.75056adaptor-related protein25.8
complex 3, delta 1
subunit
447980AI703397Hs.202355ESTs 25.8 ,
419118AA234223Hs.139204ESTs 25.8
421224AW402154Hs.125812ESTs 25.8
414890BE281095Hs.77573uridine phosphorylase 25.8
447330BE279949Hs.18141ladinin 1 25.7
405610 predicted exon 25.7
447604AW089933Hs.293674ESTs 25.7
3 445677H96577Hs.6838ras homolog gene family,25.7
member E
456088BE177320Hs.156148Homo Sapiens cDNA: 25.7
FLJ23082 fis, clone
LNG06451
417120N79687Hs.46616ESTs 25.6
405194 predicted exon 25.6
410687U24389Hs.65436lysyl oxidase-like 25.6
1
421888AA299780Hs.121036ESTs 25.6
420459AF016045Hs.97905ovo (Drosophila) homolog-like25.5
1
416323N72630Hs.33981Homo sapiens genomic 25.5
. DNA, chromosome 21q,
section
446292AF081497Hs.279682Rh type G glycoprotein25.5
416274AW160404Hs.79126guanine nucteofide 25.5
binding protein 10
45 430028BE564110Hs.227750NADH dehydrogenase 25.5
(ubiquinone) 1 beta
subcomplex
438450A1050866Hs.65853nodal, mouse, homolog 25.5
400215 predicted exon 25.4
430014H59354Hs.182485acfinin, alpha 4 25.4
453582AW854339Hs.33476hypothefical protein 25.4
FLJi1937
405867 predicted exon 25.4
459170AI905518 gb;RGBT091-210199-098 25.4
8T091 Homo Sapiens
cDNA
407944834008Hs.239727desmocollin 2 25.4
415748090086Hs.979pyruvate dehydrogenase25.3
(lipoamide)beta
423287H38340 gb:yp70h07.r1 Soares 25.3
adult brain N2b4HB55Y
Homo s
55 450944AA554989Hs.209061sudD (suppressor of 25.3
bimD6, Aspergillus
nidulans) homo
432906BE265489Hs.3123lethal giant larvae 25.3
(Drosophila) homolog
2
400104 predicted exon 25.3
449019AI949095Hs.67776ESTs, Weakly similar 25.3
to ALU7-HUMAN ALU
SUBFA
406897M57417 gb:Homo Sapiens mucin 25.3
(mucin) mRNA, partial
cds.
402639 predicted exon 25.3
447147AA910353Hs.292815ESTs 25.3
453379AA035261Hs.61753ESTs 25.3
414217AI309298Hs.279898Homo Sapiens cDNA: 25.3
FLJ23165 fis, clone
LNG09846
430223NM Hs.235935nephroblastoma overexpressed25.3
002514 gene
65 406685M18728 gb:Human nonspecific 25.3
crossreacting antigen
mRNA, co
444747AW450407Hs.257291ESTs, Weakly similar 25.2
to PSSS_HUMAN PROSTASIN
417883822519Hs.23398ESTs 25.2
430235BE268048Hs.236494RAB10, member RAS oncogene25.2
family
d59001AI761313Hs.204605ESTs 25.2
434368AW519020Hs.212640Homo Sapiens cDNA FLJ1326525.2
fis, clone OVARC1000
415917143912 gb:HSCIOAi 1 t normalized25.2
infant brain cDNA
Homo
444409AI792140Hs.49265ESTs 25.2
428578BE391797Hs.82148hypothetical protein 25.1
433417AA587773Hs.136494ESTs 25.1
75 426372BE304680Hs.169531DEADIH (Asp-Glu-Ala-AspIHis)25.1
box polypepfide 21
402131 predicted exon 25.1
450545AW135582Hs.201767ESTs 25.0
434162A1221214Hs.116136ESTs 25.0
406571 predicted exon 24.9
427600AW630918Hs.179774proteasome (prosome, 24.9
macropain) activator
subunit 2 (P
409402AF208234Hs.695cystatin B (stefin 24.9
B)
400135 predicted exon 24.9
426403AI393048Hs.239894leucine rich repeat 24.9
(in FLII) interacting
protein 1
403223 predicted exon 24.8
112
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
435236T03890Hs.157208ESTs,HighlysimilartoArxhomeoprotein[M.musculu24.8
457439AW410408Hs.271167L-pipecolic acid oxidase24.8
448667278394Hs.d896Homo Sapiens cDNA: 24.8
FLJ22046 fis, clone
HEP09276
440605240094Hs.185698ESTs 24.8
426724AA383623Hs.293616ESTs 24.8
403359
predicted exon
4.7
442826AIOi8777Hs.131241ESTs 24.7
411503AW190338Hs.28029purinergic receptor 24.6
P2X, ligand-gated
ion channel, 4
414540BE379050 gb:601236655F1 NIH 24.6
MGC 44 Homo Sapiens
cDNA
1 421595AB014520Hs.105958Homo Sapiens cDNA: 24.5
~ FLJ22735 fis, clone
HUV00180
438802AA825976Hs.136954ESTs 24.5
400491H25530Hs.50868solute carrier family 24.5
22 (organic cotton
transporter), me
418994AA296520Hs.89546selectin E (endothelial24.5
adhesion molecule
1)
426383BE537380 gb:601064570F1 NIH-MGC_1024.4
Homo Sapiens cDNA
1 418408AA219321Hs.173294ESTs 24.4
416186W87575Hs.269177ESTs 24.4
416908AA333990Hs.80424coagulafion factor 24.4
XII1, A1 polypepfide
453857AL080235Hs.35861DKFZP586E1621 protein 24.4
439706AW872527Hs.5976tESTs 24.4
441619NM-014056Hs.7917DKFZP564K247 protein 24.4
417198F11533Hs.81634ATP synthase, H+Uansporiing,24.3
mitochondrial FO comp
433662W07162Hs.150826CATX-8 protein 24.3
453986M13232Hs.36989coagulafion factor 24.3
VII (serum prothrombin
conversion a
457123AA770021Hs.16332ESTs 24.3
25 433864AA931550Hs.192785ESTs 24.3
409865AW502208 gb:Ul-HF-BROp-aju-e-09-0-ULr124.3
NIH MGC 52Hom
448175BE296174Hs.225160Homo Sapiens cDNA FLJ1310224.3
fis, clone NT2RP3002
406277 predicted exon 24.3
451957AI796320Hs.10299Homo Sapiens cDNA FLJ1354524.3
fis, clone PLACE1006
3 408802AL048269Hs.288544Homo Sapiens cDNA: 24.2
~ FLJ20882 fis, clone
ADKA0320
401757 predicted exon 24.2
444751AI207d06Hs.11866hypotheficalprotein 24.2
PR01197
408647AW245831 gb:2822937.5prime NIH 24.2
MGC 7 Homo Sapiens
cDNA
418870AF147204Hs.89d14chemokine (GX-C motif),24.2
receptor 4 (fusin)
35 436913AA789074Hs.187478ESTs 24.2
434745AW974445Hs.185155ESTs, Weakly similar 24.2
to HuEMAP [H.sapiens]
451743AW074266Hs.23071ESTs 24.2
421853AL117472Hs.108924DKFZP586P1422 protein 24.2
407926AW956382Hs.59771ESTs 24.1
413973BE279858Hs.128417Homo Sapiens cDNA FLJ1400924.1
fis, clone Y79AA1002
439078AF085936 gb:Homo Sapiens full 24.1
length insert cDNA
clone YR58F
401913 predicted exon 24.1
435138BE314734 gb:601152976F1 NIH_MGC_1924.1
Homo Sapiens cDNA
405311 predicted exon 24.0
4$ 413127BE066529Hs.83484SRY (sex determining 24.0
region Y)-box 4
430793M83181Hs.2479d05-hydroxytryptamine 24.0
(serotonin) receptor
1A
434445AI349306Hs.11782ESTs 24.0
418166AI754416Hs.260024Cdc42 effector protein24.0
3
431971BE274907Hs.77385myosin, light polypeptide23.9
6, alkali, smooth
muscle and n
401167 predicted exon 23.9
454163AW175997 gb:QVO-BT0078-190899-005-E0223.9
BT0078 Homo sapi
403306NM Hs.74368Uansmembrane protein 23.9
006825 (63kD), endoplasmic
reticuluml
410627AA181339Hs.929myosin, heavy polypeptide23.9
7, cardiac muscle,
beta
450796NM Hs.25482envoplakin 23.8
001988
55 442199BE277633Hs.286027etoposide-induced mRNA23.8
402699 predicted exon 23.8
426143BE379836Hs.167106proteasome (prosome, 23.8
macropain) subunit,
alpha type, 3
437592NM Hs.5710cellular repressor 23.8
003851- ofEtA-sfimulatedgenes
433598AI762836Hs.271433ESTs, Moderately similar23.8
to ALU2-HUMAN ALU
SU
401088 predicted exon 23.8
445924AI264671Hs.164166ESTs 23.8
420902AA742277 gb:ny28e09.s1 NCI CGAP_GCBi23.8
Homo Sapiens cDN
426369AF134157Hs.169487Kreisler (mouse) maf 23.8
related leucine zipper
homolog
458698AW452189Hs.257528ESTs 23.7
65 422048NM Hs.288126spondin 2, extracellular23.7
012445 matrix protein
413460Rfi1610Hs.21527ESTs, Weakly similar 23.6
to KIAA0918 protein
[H.sapiens
401575 predicted exon 23.6
431822AA516049 gb:ng65d01.s1 NCI-CLAP-Lip223.6
Homo sapiens cDNA
427276AA400269Hs.49598ESTs 23.6
417069AA442192Hs.81097cytochrome c oxidase 23.5
subunit Vlll
400161 predicted exon 23.5
417190NM Hs.815482,4-dienoyl CoA reductase23.5
001359 1, mitochondrial
443667AI129066Hs.135457ESTs 23.5
413544BE147225 gb:PM2-HT0225-031299-003-f1123.5
HT0225 Homo sapie
75 400685 predicted exon 23.5
422090W05345Hs.293884ESTs 23.4
432517AF275816Hs.283096PR domain containing 23.4
9
405307
predicted exon 23.4
416328H48389Hs.268886ESTs 23.4
go 427174AA398848Hs.97541ESTs 23.4
426148AI751071Hs.i67135Homo Sapiens cDNA FLJ1072823.3
fis, clone NT2RP3001
452544AW851888 gb:OVO-CT0225-131099-034-40523.3
CT0225 Homo sapie
404890 predicted exon 23.3
408725AA131539Hs.15669ESTs 23.3
113
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
428362AA426555Hs.169333ESTs 23.3
425349AA425234Hs.79886ribose 5-phosphate 23.3
isomerase A (ribose
5-phosphate ep
422440NM Hs.116724aldo-keto reductase 23.3
004812 family 1, member 811
(aldose redu
410962BE273749Hs.752FK506-binding protein 23.2
1A (l2kD)
411796AA807197Hs.6918ESTs 23.2
458954AW379075Hs.141742Homo Sapiens cDNA FLJ1221123.2
fis, clone MAMMA10
408896AI6104d7Hs.48778niban protein 23.2
457024AA397546Hs.119151ESTs 23.2
414591A1888490Hs.55902ESTs 23.2
1 437846AA773866Hs.244569ESTs 23.2
~
401220 predicted exon 23.1
421747AI816224Hs.107747DKFZP566C243 protein 23.1
452950AA428123Hs.7745l7kD fetal brain protein23.1
414327BE408145Hs.185254ESTs, Moderately similar23.1
to NAG1 protein [R.norvegic
1 405256 predicted exon 23.1
452416AA026115Hs.114777ESTs 23.1
440684A1253123Hs.127356ESTs, Highly similar 23.1
to NEST_HUMAN NESTI
[H.sap
445603H08345Hs.106234ESTs 23.1
436306AA805939Hs.117927ESTs 23.1
20 434867AF159442Hs.103382phospholipid scramblase23.0
3
404727 predicted exon 23.0
407317AI20d033Hs.271461ESTs, Weakly similar 23.0
to ALUS_HUMAN ALU
SUBFA
405580 predicted exon 23.0
437898W81260Hs.43410ESTs 22.9
25 448781AW243419Hs.254048ESTs , 22.9
457297AW968188Hs.290999ESTs 22.9
405545 predicted exon 22.9
431562A1884334Hs.11637ESTs 22.9
440703AL137663Hs.7378Homo sapiens mRNA; 22.9
cDNA DKFZp434G227
(from c
30 439848AW979249 gb:EST391359 MAGE resequences,22.9
MAGP Homo sap
418149AA811473Hs.291877ESTs 22.9
439332AW842747Hs.293314ESTs, Highly similar 22.8
to unnamed protein
product [H.sa
401566 predicted exon 22.8
425078NM Hs.154437phosphodiesterase 2A, 22.8
002599 cGMP-stimulated
35 406684X16354Hs.50964caroinoembryonic antigen-related22.8
cell adhesion molecul
421651AW860612Hs.283586ESTs 22.8
421064A1245432Hs.101382tumor necrosis factor,22.8
alpha-induced protein
2
441249AA971585Hs.166250ESTs 22.8
457624AA809159Hs.287581Homo Sapiens cDNA FLJ1354422.8
fis, clone PLACE1006
4~ 407395AF005082 gb:Homo Sapiens skin-specific22.8
protein (xp33) mRNA,
p
459006AW298631Hs.2772thypothetical protein 22.8
FLJ20353
436827H72187Hs.5322guanine nucleotide 22.7
binding protein (G
protein), gamma
418174120688Hs.83656Rho GDP dissociation 22.7
inhibitor (GDI) beta
418307U70867Hs.83974solute carrier family 22.7
21 (prostaglandin
transporter), mem
45 456035N54956Hs.271726ESTs 22.7
457867AA045767Hs.5300bladdercancerassociated22.7
protein
440401A1126341Hs.143887ESTs 22.7
400126 predicted exon 22.7
414931AK000342Hs.77646Homo Sapiens mRNA; 22.7
cDNA DKFZp761 M0223
(from
406719A1832962Hs.169476glyceraldehyde-3-phosphate22.6
dehydrogenase
439675W95357Hs.138860Rho GTPase activating 22.6
protein 1
456058N94587Hs.55063ESTs 22.6
441926A1015051Hs.130953ESTs 22.6
428423AU076517Hs.184276solute carrier family 22.6
9 (sodiumlhydrogen
exchanger), is
55 438516BE561958Hs.285823immunoglobulin heavy 22.6
constant mu
420674NM Hs.1327butyrylcholinesterase 22.6
000055
422160AW582898 gb:ia07e04.y1 Human 22.5
Pancreatic Islets
Homo Sapiens c
412408D51103Hs.73851ATP synthase, H+transporting,22.5
mitochondria) FO camp
400964 predicted exon 22.5
434360AW015415Hs.127780ESTs 22.5
427977AW630727Hs.181307H3 histone, family 22.4
3A
450339A1693281Hs.54547ESTs 22.4
424059AW451266Hs.107418ESTs 22.4
414626BE410589 gb:601303308F1 NIH_MGC-2122.4
Homo sapiens cDNA
65 401991 predicted exon 22.4
419741NM Hs.93002ubiqui6n comer protein22.3
007019 E2-C
457952U25750Hs.210783Human chromosome 17q2122.3
mRNA clone 1046:1-1
422597BE245909Hs.118634ATP-binding cassette, 22.3
sub-family 8 (MDR1TAP),
mem
429504X99133Hs.204238lipocalin 2 (oncogene 22.3
24p3)
447306AI373163Hs.170333ESTs 22.3
424966AU077312Hs.t solute comer family 22.3
539857 (cationic amino
acid transporter,
422739H20106Hs.119591adaptor-related protein22.2
complex 2, sigma 1
subunit
432504AL121015Hs.277704oxygen regulated protein(150kD)22.2
423804AW403448Hs.1706interferon-stimulated 22.2
transcripUon factor
3, gamma (48k
75 404683AI924294Hs.173259uncharacterized bone 22.2
marrow protein BM033
441624AF220191Hs.179666uncharacterized hypothalamus22.2
protein HSMNP1
425751T19239Hs.1940crystallin, alpha B 22.2
452976844214Hs.101189ESTs 22.2
414642AA150350 gb:z103h01.r1 Soares~regnant-uterus22.2
NbHPU Homo
437452AL390127Hs.7104Homo Sapiens mRNA; 22.2
cDNA DKFZp761 P06121
(from
417426NM_002291Hs.82124laminin, beta 1 22.2
414774X02419Hs.77274plasminogen activator,22.1
urokinase
424631AA688021Hs.179808ESTs 22.1
413967AW204431Hs.117853ESTs 22.1
114
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
400174 predicted exon 22.1
431837T79326Hs.298262ESTs, Weakly similar 22.1
to dJ88J8.1 (H.sapiensJ
401628 predicted exon 22.1
418374AJ011916Hs.84359hypotheficalprotein 22.0
429297X82494Hs.198862fibulin 2 22.0
403508 predicted exon 22.0
432638A1017717Hs.126525chromosome 21 open 22.0
reading frame 15
407382AA503620 gb:ne49bOB.s1 NCI CGAP22.0
Co3 Homo Sapiens cDNA
411492T46848Hs.70337immunoglobulin superfamily,22.0
member 4
1 420185AL044056Hs.158047ESTs 22.0
0
409545BE296182 gb:601177324F1 NIH_MGC_1722.0
Homo Sapiens cDNA
426662AA879474Hs.122710ESTs 22.0
424247X14008Hs.234734lysozyme (renal amyloidosis)22.0
443062N77999Hs.8963Homo Sapiens mRNA full21.9
length insert cDNA
clone EU
1 422447AA310711Hs.12d340ESTs 21.9
421574AJ000152Hs.105924defensin,beta 2 21.9
435302A1076259Hs.190337ESTs 21.9
414527BE241739Hs.76359catalase 21.9
441436AW137772Hs.185980ESTs 21.9
454178AW177274 gb:CM2-CT0128-230899-005-a0221.8
CT0128 Homo sapie
448838BE614761 gb:601281335F1 NIH 21.8
MGC_39 Homo sapiens
cDNA
427889AI400968Hs.181046dual specificity phosphatase21.8
3 (vaccinia virus
phosphat
441114AA917466Hs.126600ESTs 21.8
451831NM_00167dHs.460aclivafing iranscripfion21.8
factor 3 ~
405600 predicted exon 21.8
446981AI6527d3Hs.197497ESTs 21.8
432839AA579465Hs.287332ESTs 21.8
405208 predicted exon 21.8
435025T08990Hs.4742anchor attachment protein21.7
1 (Gaa1 p, yeast)
homolog
413976BE295452Hs.75655procollagen-proline, 21.7
2-oxoglutarate 4-dioxygenase
(pro
423515AA327017Hs.162204ESTs 21.7
452329N36626Hs.29106mitogen-activated protein21.7
kinase phosphatase
x
423050AA320946 gb:EST23529 Adipose 21.7
tissue, brown Homo
Sapiens cD
413679BE156765 gb:RC1-HT0370-120100-012~c0921.7
HT0370 Homo sapie
35 442166AW845280Hs.204723ESTs 21.6
445585AI243836Hs.1d7066ESTs 21.6
406160 predicted exon 21.6
433025AA374743Hs.279920tyrosine 3-monooxygenase/tryptophan21.6
' 5-monooxygenas
446598AW250546 gb:2821774.5prime NIH_MGC21.6
7 Homo Sapiens cDNA
434493AA635305Hs.121574ESTs 21.6
429582A1569068Hs.22247ESTs 21.6
403796 predicted exon 21.6
405028 predicted exon 21.6
426597AA382250Hs.145601ESTs 21.6
45 437308AA749417Hs.292353ESTs 21.6
447384AI377221Hs.40528ESTs 21.6
429060AW139155Hs.194995hypothefical protein 21.6
DKFZp43400320
437068AA743643Hs.291427ESTs 21.6
418509A8028624Hs.85539ATP synthase, H+transporfing,21.5
mitochondria) FO comp
432999BE29d029Hs.279903Ras homolog enriched 21.5
in brain 2
407663NM_016429Hs.37482C0PZ2 for nonclathrin 21.5
coat protein zeta-COP
446627AI973016Hs.15725hypothefical protein 21.5
S8BI48
413605BE152644 gb:CM1-HT0329-250200-128-f0921.5
HT0329 Homo sapie
427286AW732802Hs.2132epidermal growth factor21.5
receptor pathway substrate
8
55 405226 predicted exon 21.4
402570 predicted exon 21.4
457960AA771881Hs.298149ESTs 21.4
400684 predicted exon 21.4
425943H46986Hs.31861ESTs 21.4
60 434240AF119912Hs.25B119hypothefical protein 21.4
PR03073
448376AI494332Hs.196963ESTs 21.4
408089H59799Hs.42644thioredoxin-like 21.4
400304AF005082Hs.113261Homo Sapiens skin-specific21.4
protein (xp33) mRNA,
part
412652AI801777Hs.6774ESTs 21.4
65 428373A1751656Hs.183986poliovirus receptor-related21.3
2 (herpesvirus entry
mediato
416138C18946Hs.79026myeloidleukemiafactor221.3
425184BE278288Hs.155048Lutheran blood group 21.3
(Auberger b antigen
included)
411028AW813703 gb:RC3-ST0197-130100-014-h0921.3
ST0197 Homo sapien
417438243989Hs.821d1Human clone 23612 mRNA21.3
sequence
70 417534NM Hs.82251myosin IC 21.3
004998
427767AI879283Hs.180714cytochrome c oxidase 21.2
subunit Vla polypepiide
1
433300AA582307 gb:nn49d09.s1 NCI-CGAP-Kid621.2
Homo Sapiens cDNA
452061A1074259Hs.469succinate dehydrogenase21.2
complex, subunit A,
flavoprot
411939AI365585Hs.i46246ESTs 21.2
75 435060A1422719Hs.233349ESTs, Weakly similar 21.2
to fork head like
protein [H.sapie
432412AI470549Hs.162201ESTs 21.2
407491S82769 gb:GABAA receptor gamma21.2
3 subunit [human,
fetal bra
418960NM Hs.89525hepatoma-derfved growth21.1
004494 factor (high-mobility
group p
426254BE018103Hs.168541Homo Sapiens mRNA full21.1
length insert cDNA
clone EU
458188AW297226Hs.137840ESTs, Moderately similar21.1
to SIXt HUMAN HOMEOB
406215 predicted exon 21.1
425461AK000602Hs.157938hypotheficalprotein 21.1
FLJ20595
448296BE622756Hs.10949Homo Sapiens cDNA FLJ1416221.1
fis, clone NT2RM4002
409415A4579258Hs.6083Homo sapiens cDNA: 21.1
FLJ21028 fis, clone
CAE07155
115
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
408546W49512Hs.46348bradykinin receptor 21.1
Bt
450008H52970Hs.36688WAP four-disulfide core21.1
domain 1
430998AFi28847Hs.204038indolelhylamine N-methyltransferase21.1
438901AF085834Hs.29036ESTs 21.1
440500AA972165Hs.150308ESTs 21.1
413101BE065215 gb:RC1-BT0314-310300-015-f0121.1
BT0314 Homo sapie
447452BE618258Hs.102480ESTs 21.1
412446AI7680i5Hs.92127ESTs 21.1
418975T75496Hs.296980ESTs 21.0
1 454961AW847807 gb:IL3-CT0213-190200-040-E1221.0
~ CT0213 Homo sapien
401072 predicted exon 21.0
401204 predicted exon 21.0
433626AF078859Hs.86347hypothetical protein 21.0
418047837633Hs.4847ESTs 21.0
1 443380AI792478Hs.135377ESTs 21.0
427424AA402453Hs.113011ESTs 21.0
433412AV653729Hs.8185CGI-44 protein; sulfide21.0
dehydrogenase like
(yeast)
422599BE387202Hs.118638non-metaslatic cells 20.9
1, protein (NM23A)
expressed in
435656893409Hs.120759ESTs 20.9
413745AW247252Hs.75514nucleoside phosphorylase20.9
418874T60872 gb:yb72h11.s1 Stratagene20.9
ovary (937217) Homo
sapien
452574AF127481Hs.35093lymphoid blast crisis 20.9
oncogene '
400332S66407Hs.248032FLT4 20.9
402421 predicted exon 20.9
25 427138N77624Hs.173717phosphatidic acid phosphatase20.9
type 2B
432038AA524746Hs.162110ESTs 20.8
423711AF059194Hs.131953v-maf musculoaponeurofic20.8
fibrosarcoma (avian)
oncoge
402297 predicted exon 20.8
405133 predicted exon 20.8
436661AI125270Hs.128069ESTs, Weakly similar 20.8
to similar to collagen
[C.elegans]
437836BE269291Hs.292458ESTs 20.8
437329AA811977Hs.291761ESTs 20.8
445830H10451Hs.42656Homo Sapiens cDNA FLJ1266720.8
fis, clone NT2RM4002
406824AW515961Hs.84298CD74 antigen (invariant20.7
polypeptide of major
histocom
35 421271AW170057Hs.133179ESTs 20.7
400256
predicted exon
0.7
414028AA782576Hs.4944Homo Sapiens cDNA FLJ1278320.7
fis, clone NT2RP2001
456728AL120077Hs.122967ketch (Drosophila)-like20.7
2 (Mayven)
417707AL035786Hs.82425actin related protein 20.7
213 complex, subunit
5 (16 kD)
438713H16902Hs.6749ESTs 20.7
450306ALO80080Hs.24766DKFZP564E1962 protein 20.7
438898AI819863Hs.106243ESTs 20.7
403273 predicted exon 20.7
414605BE390440 gb:601283601F1 NIH_MGC-4420.7
Homo Sapiens cDNA
45 401283 predicted exon 20.7
403703 predicted exon 20.6
416969A1815443Hs.283404organic cation transporter20.6
442400AW381148Hs.3593ESTs 20.6
4475638E536115Hs.160983ESTs 20.5
419754H52299Hs.75243bromodomain-containing 20.5
2
408204AA454501Hs.43666protein tyrosine phosphatase20.5
type IVA, member 3
450507AW295603Hs.250891ESTs 20.5
429612AF062649Hs.252587pituitary tumor-transforming20.5
1
413758BEi62391 gb:PM2-HT0451-090100-002-f0420.5
HT0451 Homo sapie
55 432140AK000404Hs.272688hypothetical protein 20.5
FLJ20397
400642 predicted exon 20.4
431582F07136Hs.261828G protein-coupled receptor20.4
kinase 7
442724AA355525Hs.159604cysteinyl-iRNA synthetase20.4
417861AA334551Hs.82767sperm specific antigen 20.4
2
402948 predicted exon 20.4
411004AW813242 gb:MR3-ST0191-020200-207-g1020.4
ST0191 Homo sapie
435478AA682622 gb:zj20t09.s1 Soares 20.4
fetal liver_spleen
1NFLS Si Ho
447955BE544271Hs.288390Homo Sapiens cDNA: FLJ2279520.3
fis, clone KAIA2543
433592NM Hs.3436deleted in oral cancer 20.3
004642 (mouse, homology 1
420865N73241Hs.100001solute cartier family 20.3
17 (sodium phosphate),
memt~er 1
449482AI784266Hs.28774ESTs 20.3
400807 predicted exon 20.3
419942025138Hs.93841potassium large conductance20.3
calcium-activated channel
420783AI659838Hs.99923lecfin, galactoside-binding,20.3
soluble, 7 (galectin
7)
402986BE244588Hs.6456chaperonin containing 20.3
TCP1, subunit 2 (beta)
451375. A1792066Hs.283902Homo Sapiens 8AC clone 20.3
RP11-d81J13 from 2
453586AA248089Hs.50841ESTs, Weakly similar 20.3
to tuftelin [M.musculus]
433090AI720050Hs.145362immortalization-upregulated20.3
protein
425053AF046024Hs.154320ubiquifin-acfivafing 20.3
enzyme E1 C (homologous
to yeast
75 412802041518Hs.74602aquapodn 1 (channel-forming20.3
integral protein, 28kD)
409738BE222975Hs.56205insulin induced gene 20.3
1
428245AF151048Hs.183180hypothefical protein 20.2
412582BE270631Hs.74077proteasome (prosome, 20.2
macropain) subunit,
alpha type, 6
406207 predicted exon 20.2
400931 predicted exon 20.2
410709AL122109Hs.65735Homo Sapiens mRNA; cDNA20.2
DKFZp434M1827 (from
428436NM-001955Hs.2271endothelin 1 20.2
446918AL135125Hs.13913KIAA1577 protein 20.2
417821BE245149Hs.82643protein tyrosine kinase20.2
9
116
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
429113D28235Hs.196384prostaglandin-endoperoxide20.2
synthase 2 (prostaglandin
G
414511AAi48725Hs.12969hypothetical protein 20.2
451546AF051782Hs.26584Homo Sapiens clone 20.1
CDABP0038 mRNA sequence
441899AI372588Hs.8022TU3A protein 20.1
425811AL039104Hs.159557karyophedn alpha 2 20.1
(RAG cohort 1, importin
alpha 1)
411014AW816072 gb:MR3-ST0220-070100-021-h0720.1
ST0220 Homo sapie
451400BE160479 gb:QV1-HT0413-210200-081-g0520.1
HT0413 Homo sapi
459247N46243Hs.110373ESTs 20.1
441633AW958544Hs.112242ESTs 20.1
1 427466AA523543Hs.7678cellular retinoic acid-binding20.0
~ protein 1
406893M22406 gb:Human intestinal 20.0
mucin mRNA, partial
cds, clone SM
406268 predicted exon 20.0
403348 predicted exon 20.0
400970 predicted exon 20.0
15 414045NM-002951Hs.75722ribophorin II 20.0
427169AA398823Hs.97549EST 20.0
405586 predicted exon 20.0
445834AI913290Hs.145532ESTs, Weakly similar 20.0
to Gag polyprotein
[M.musculus
422525AA75B797Hs.192807ESTs 20.0
425383D83407Hs.156007Down syndrome critical20.0
region gene 1-like
1
454590AW809762Hs.222056Homo sapiens cDNA FLJ1157220.0
fis, clone HEMBA100
411529AA430348Hs.288837Homo Sapiens cDNA FLJ1292720.0
fis, clone NT2RP2004
425397J04088Hs.i56346topoisomerase (DNA) 20.0
II alpha (170kD)
403234 predicted exoh 19.9
427267At201185Hs.119164ESTs 19.9
400203 predicted exon
19.9
449296AL137257Hs.23458Homo Sapiens mRNA; 19.9
cDNA DKFZp43401613
(from
406704M21665Hs.929myosin, heavy polypepfide19.9
7, cardiac muscle,
beta
423083AA321774Hs.10941ESTs, Weakly similar 19.9
to IPP1 HUMAN PROTEIN
PH
422112BE540240Hs.111783Lsm1 protein 19.9
413282BE078159 gb:CMO-BT0615-140200-175-e0619.9
BT0615 Homo sapie
453702AA037637Hs.42128ESTs 19.9
403065 predicted exon 19.9
440633AI140686Hs.263320ESTs 19.9
35 456994AA383623Hs.293616ESTs 19.9
458260841782Hs.22279ESTs 19.9
452388BE019696Hs.29287retinoblastoma-binding19.9
protein 8
422278AF072873Hs.114218fiizzled (Drosophila) 19.9
homolog 6
441989AA306207Hs.286241Homo Sapiens cDNA: 19.9
FLJ22698 fis, clone
HSIi 2044
418758AW959311Hs.87019ESTs 19.9
406646M33600Hs.180255major histocompatibility19.8
complex, class II,
DR beta 1
d33053BE301909Hs.279952glutathione S-transferase19.8
subunit 13 homolog
414194BE175494Hs.75811N-acylsphingosine amidohydrolase19.8
(acid ceramidase)
452321AW844498Hs.289052Homo Sapiens LENG8 19.8
mRNA, variant C, partial
sequen
45 449713AW027025Hs.239262ESTs 19.8
458827AW970786Hs.178470Homo Sapiens cDNA: 19.8
FLJ22662 fis, clone
HS108080
414092214244Hs.75752cytochromecoxidasesubunitVllb19.8
441730AI243276Hs.149017ESTs 19.8
420701N42919Hs.88630ESTs, Weakly similar 19.8
to AC0072281 831665
2 [H.sap
403642 predicted exon 19.8
d08987H85615 gb:yt03f11.r1 Soares 19.8
retina N2b5HR Homo
sapiens cD
446712AW204789Hs.209828ESTs 19.8
403286 predicted exon 19.8
434439A1022360Hs.190583ESTs 19.8
55 404067 predicted exon 19.7
455694BE067300 gb:PM2-BT0349-161299-001-h1019.7
BT0349 Homo sapie
403287 predicted exon 19.7
434633AI189587Hs.120915ESTs 19.7
408199AA132637Hs.15396ESTs 19.7
420080M94065Hs.94925dihydroorotate dehydrogenase19.7
408852AW291435Hs.254961ESTs 19.7
403786 predicted exon 19.7
416839H94900Hs.17882ESTs 19.7
434385AA631946Hs.259580ESTs 19.7
65 446645A1343645Hs.156108ESTs 19.7
425612BE004257 gb:CMO-BN0103-180300-296-c0419.7
8N0103 Homo sapi
402520 predicted exon 19.6
436098820597Hs.9739ESTs 19.6
438974AF089816Hs.6454chromosome 19 open 19.6
reading frame 3
7~ 447751AA339541Hs.24956hypothetical protein 19.6
FLJ22056
451310AW250651Hs.26213ESTs, Moderately similar19.6
to dJ447F3.3 [H.sapiens]
435961BE293127Hs.283722GTTt protein 19.6
452937BE410390Hs.288940five-span transmembrane19.6
protein M83
404850 prodicted exon 19.6
75 438360H74149Hs.288193hypothetical protein 19.6
FLJ10375
436508AW604381Hs.121121ESTs 19.6
4304868E062109Hs.241551chloride channel, calcium19.6
acfivated, family
member 2
407824AA147884Hs.9812ESTs 19.6
406388 predicted exon 19.6
$0 430204AA618335Hs.146137ESTs, Weakly similar 19.5
to putative [C.elegans]
457560AI801934Hs.163909ESTs 19.5
429521BE048708Hs.50949ESTs 19.5
429758AW137722Hs.246804ESTs 19.5
441473AA934995Hs.184846ESTs, Weakly similar 19.5
to 8288301 [H.sapiens]
.
117
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
411724AA770559Hs.71618polymerase (RNA) II 19.5
(DNA directed) polypeptide
L (7.
450453AA009883Hs.50186ESTs 19.5
419687A1638859Hs.227699ESTs, Weakly similar 19.5
to Yhr217cp [S.cerevisiae]
442162AW294966Hs.150849ESTs 19.5
435056AW023337Hs.5422glycoprotein M6B 19.5
417412X16896Hs.82112intedeukin 1 receptor,19.5
type I
413825BE299181Hs.75564CD151 antigen 19.4
422687AW068823Hs.119206insulin-like growth 19.4
factor binding protein
7
435551AF212365Hs.5470IL-178 receptor 19.4
1 440069BE617892Hs.6895acfin related protein 19.4
~ 213 complex, subunit
3 (21 kD)
432277AI669790Hs.161825ESTs 19.4
428044AA093322Hs.182225RNA binding motif protein19.4
3
456064AA256213Hs.72010ESTs 19.4
424897D63216Hs.153684fizzled-related protein19.4
15 424673AA345051Hs.294092ESTs 19.4
403852 predicted exon 19.3
405699 predicted exon 19.3
433096AU076803Hs,282975carboxylesterase 2 19.3
(intestine, liver)
400344NM-012368Hs.258574olfactory receptor, 19.3
. family 2, subfamily
C, member 1
20 417501AL041219Hs.82222sema domain, immunoglobulin19.3
domain (1g), short
basic
400449 predicted exon 19.3
453801ALi34751Hs.23450mRNAforFLJ00023 protein19.3
435849BE305242Hs.112442ESTs, Weakly similar 19.3
to CLDE HUMAN CLAUDIN-
454181AW177377 gb:CM4-CT0129-190899-007-e0919.3
CT0129 Homo sapie
25 414807AI738616Hs.77348hydroxyprostaglandin 19.3
dehydrogenase 15-(NAD)
406326 predicted exon 19.3
421921H83363Hs.109571translocase of inner 19.3
mitochondrial membrane
10 (yeast)
416700AW498958Hs.79572cathepsin D (lysosomal19.2
aspartyl protease)
458857AI627342Hs.224601ESTs 19.2
405501 predicted exon 19.2
416601808652Hs.20205hemoglobin, beta pseudogene19.2
1
426600NM Hs.171014VGF nerve growth factor19.2
003378 inducible
425590AI954686Hs.158321beaded filament structural19.2
protein 2, phakinin
428151AA422028 gb:zv26g06.r1 Soares-NhNMPu-S119.2
Homo sapiens cDN
35 426420BE383808Hs.169829KIAA1180 protein 19.2
414428BE296906Hs.182625VAMP (vesicle.associaled19.2
membrane protein)-associate
404601 predicted exon 19.2
403861 predicted exon _
19.2
448363BE174595Hs.3666-pyruvoyltetrahydropterin19.2
synthase
40 406655M21533Hs.181244ma]or hislocompatibility19.1
complex, class I,
A
435372AA809591Hs.106486ESTs, Highly similar 19.1
to CIKG HUMAN VOLTAGE-G
413154BE067870 gb:RCO-BT0362-021299-031-b0619.1
BT0362 Homo sapie
443021AA368546Hs.8904Ig superfamily protein19.1
412975T70956Hs.75106clusterin (complement 19.1
lysis inhibitor, 5P-40,40,
sulfated
45 412633AF001691Hs.74304pedplakin 19.1
402071 predicted exon 19.1
410387AI277367Hs.47094ESTs 19.1
423961D13666Hs.136348osteoblast specific 19.1
factor 2 (fasciclin
I-like)
407032U73799 gb:Human dynactin mRNA,19.0
partial cds.
404034 predicted exon 19.0
456534X91195Hs.100623phospholipase C,beta 19.0
3,neighborpseudogene
446599297832Hs.15476differentially expressed19.0
in FDCP (mouse homology
6
426410BE298446Hs.180372BCL2-like 1 19.0
419618AA528295 gb:nh26e06.s1 NCI_CGAP_Pr319.0
Homo Sapiens cDNA
c
457632AW292151Hs.112689ESTs 19.0
S
417138AA193646Hs.65771Homo Sapiens chromosome19.0
19, BAC CIT-HSPC_204F
417933X02308Hs.82962thymidylate synthetase19.0
458808AW134832Hs.246295ESTs 19.0
415860D56051Hs.78888diazepam binding inhibitor18.9
(GABA receptor modulator
440919AW291274Hs.262826ESTs 18.9
423725AJ403108Hs.132127hypotheficalprotein 18.9
LOC57822
401747 predicted exon 18.9
454209AW179083 gb:MR4-ST0065-270899-006-A0718.8
ST0065 Homo sapi
417661T84155Hs.15464Homo Sapiens cDNA: 18.8
FLJ21351 fis, clone
COL02762
65 426499C14937Hs.11169Gene 331Mig-6 18.8
404240 predicted exon 18.8
439718AA307634Hs.6650vacuolar protein sorting18.8
458 (yeast homology
401789 predicted exon 18.8
456952AW445081Hs.301469ESTs 18.8
439739A1199391Hs.124464ESTs 18.8
437974T74445Hs.5957Homo sapiens clone 18.8
24416 mRNA sequence
427490295152Hs.178695mitogen-acfivated protein18.8
kinase 13
443482AW188093Hs.250385ESTs 18.8
411420BE390652 gb:601286820F1 NIH 18.8
MGC-44 Homo Sapiens
cDNA
75 435196F35675Hs.188128ESTs, Moderately similar18.8
1o ALUB HUMAN !!!!
ALU
417022NM-014737Hs.80905Ras associafion (RaIGDSIAF-6)18.8
domain family 2
413531AL036958Hs.75416DAZ associated protein18.7
2
428981BE313077Hs.93135ESTs 18.7
421598AW630942Hs.106061RD RNA-binding protein18.7
443907AU076484Hs.9963TYRO protein tyrosine 18.7
kinase binding protein
406754AA477223Hs.75922brain protein 13 18.7
400661 predicted exon ~ 18.7
442638A1088742Hs.134713ESTs 18.7
434169AA883752Hs.179724ESTs 18.7
llg
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
424126AA335635Hs.96917ESTs 18.7
408473BE259039Hs.129953Ewing sarcoma breakpoint18.7
region 1
401962 predicted exon 18.7
447326AW002252Hs.201395ESTs 18.7
459053AI807052Hs.210361ESTs 18.7
403362 predicted exon 18.7
427697T18997Hs.180372BCL2-like 1 18.7
402061H83363Hs.109571Uanslocase of inner 18.7
mitochondrial membrane
10 (yeast)
433785BE044593Hs.112704ESTs 18.7
1 405423 predicted exon 18.6
~
429259AA420450Hs.292911ESTs 18.6
444071A1627808Hs.110524ESTs 18.6
410512AA085603Hs.250570ESTs 18.6
440376A1024452Hs.236816ESTs 18.6
15 457353X65633Hs.24814dmelanocortin 2 receptor18.6
(adrenocorticotropic
hormone)
432749NM-014438Hs.278909Interleukin-1 Superfamily18.6
a .
415602F12920Hs.165575ESTs 18.6
407891AA486620Hs.41135endomucin-2 18.6
455910243712 gb:HSC1JA121 normalized18.6
infant brain cDNA
Homo s
426716NM Hs.171921sema domain, immunoglobulin18.6
006379 domain (1g), short
basic
444246H93281Hs.10710hypotheflcalprotein 18.6
FLJ20417
428125AA393071Hs.182579leucine aminopeptidase18.6
406457 predicted exon 18.5
446625AI333070Hs.156141ESTs 18.5
423334AK000906Hs.127273hypotheUcalprotein 18.5
FLJ10044
423103AA322029 gb:EST24685'Cerebellum18.5
II Homo Sapiens cDNA
5' en
443549T89608Hs.16601ESTs 18.5
419299A1311085Hs.62406Homo Sapiens cDNA: 18.5
FLJ22573 fls, clone
H5102387
411942AW877015 gb:QV2-PT0010-250300-096-f1218.5
PT0010 Homo sapien
3 442440BE464435Hs.146180ESTs, Weakly similar 18.5
0 to non-receptor protein
tyrosine k
454574AW809109 gb:MR4-ST0117-070100-027-a0418.5
ST0117 Homo sapie
454377AA076811 gb:7B03C12 Chromosome 18.5
7 Feiai Brain cDNA
Library
422365AF035537Hs.i REV3 (yeast homology-like,18.5
15521 catalytic subunit
of DNA p
421733AL119671Hs.1420fibroblast growth factor18.5
receptor 3 (achondroplasia,
tha
35 420603A8042636Hs.4775junctophilin 3 18.4
401373 predicted exon 18.4
402292 predicted exon 18.4
444118AA458542Hs.10326coatomer protein complex,18.4
subunit epsilon
408310AW179023 gb:PM3-ST0036-170899-001-e0818.4
ST0036 Homo sapie
411236AW833752 gb:QVd-TT0008-130100-077-b0718.4
TT0008 Homo sapie
431405AI470895Hs.252574ritwsomal protein LlOa18.4
441408AI733249Hs.i26897ESTs 18.4
453994BE180964Hs.165590ribosomal protein S13 18.4
444518AI160278Hs.146884ESTs 18.4
45 402407 predicted exon 18.4
404270 predicted exon 18.4
409103AF251237Hs.112208RAGE-1 protein 18.4
415198AW009480Hs.943natural killer cell 18.3
Uanscript 4
430771BE387244Hs.2664flavin containing monooxygenase18.3
4
S 432636AA340864Hs.278562claudin 7 18.3
o
433504NM Hs.3363KIAA0214 gene product 18.3
014874
415606W70022 gb:zd51e10.r1 Soares 18.3
fetal heart-NbHH19W
Homo so
401401BE047878Hs.99093Homo Sapiens chromosome18.3
19, cosmid 828379
420758AW297536Hs.33053ESTs 18.3
55 457520AA553495Hs.162264ESTs 18.3
432323AK001409Hs.274356hypotheGcalprotein 18.3
FLJ10547
404750 predicted exon 18.3
450645AL117441Hs.25264DKFZP434N126 protein 18.3
.
445160AI299144Hs.150797ESTs 18.3
418461BE242781Hs.288037Homo Sapiens cDNA FLJ1299918.3
fis, clone NT2RP3000
40.1809 predicted exon 18.3
458121S42416Hs.74647Human T-cell receptor 18.3
active alpha~chain
mRNA from
435106AA100847Hs.193380ESTs, Highly similar 18.3
to AF1746001 F-box
protein Fbx
448398AW444655Hs.170838ESTs 18.3
65 428145BE243327Hs.182626chromosome 22 open 18.2
reading frame 5
445302AK001537Hs.12488hypotheflcal protein 18.2
FLJ10675
407352H47860 gb:yp76h12.r1 Soares 18.2
fetal liver spleen
1 NFLS Homo s
413190AA151802Hs.40368adaplor-related protein18.2
complex 1, sigma 2
subunit
436371AI821912Hs.113912ESTs 18.2
400965 predicted exon 18.2
433427AI816449Hs.171889cholinephosphotransferase18.2
1
427504AA776743Hs.191589ESTs 18.2
426759A1590401Hs.21213ESTs 18.2
423792AW135866Hs.245854ESTs 18.2
75 406826AW516005Hs.84298CD74 anflgen (invariant18.1
polypeptide of major
histocom
406659AA663985Hs.277477major histocompatibility18.1
complex, class I,
C
437453AI761350Hs.181391hypothetical protein 18.1
DKFZp761G2113 ~
409276AW372097Hs.278429hepatocellular carcinoma-associated18.1
antigen 59
449628AI697676Hs.197713ESTs 18.1
421043BE379455Hs.89072ESTs 18.1
442344A1022925Hs.301212ESTs 18.1
448744AL135424Hs.9469phosphoinositol 3-phosphate18.1
binding protein-1
416062AA724811Hs.74427p53-induced protein 18.1
414500W24087Hs.76285DKFZP5648167 protein 18.1
119
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
427272NM Hs.17d140ATP citrate lyase 18.1
001096
403964 predicted exon 18.1
433217AB040914Hs.278628KIAA1481 protein 18.1
427902AI809202Hs.208343ESTs, Weakly similar 18.1
to cerebroside sulfoUansferase
[H
449586AI863918Hs.195078ESTs 18.1
430826U10061Hs.248019POU domain, class 4, 18.1
Uanscription factor
3
414195BE263293 gb:601144881F2 NIH 18.1
MGC_19 Homo Sapiens
cDNA
416305AU076628Hs.79187coxsackie virus and 18.1
adenovirus receptor
411088BE247593Hs.145053ESTs 18.1
419407AW410377Hs.41502Homo Sapiens cDNA: 16.1
FLJ21276 fis, clone
COL01829
407938AA905097Hs.85050phospholamban 18.1
449360AI640623Hs.252720ESTs 18.1
d17286AA122237Hs.81874microsomal glutathione18.0
S-Uansferase 2
405515 predicted exon 18.0
439319AW016401Hs.233476ESTs 18.0
419387BE379356Hs.90107cell membrane glycoprotein,110000M(r)18.0
(surface antig
414015AA34098Hs.756937 18.0
prolylcarboxypeptidase
(angiotensinase C)
447778BE620592Hs.71190ESTs 18.0
435523T62849Hs.11090high affinity immunoglobulin18.0
epsilon receptor beta
sub
429230AF088991Hs.198274NADH dehydrogenase 18.0
(ubiquinone) 1 beta
sutxomplex
457822AA970001Hs.150319ESTs 18.0
442424AI342715Hs.129569ESTs, Moderately similar18.0
to 834087 hypothetical
prote
418394AF132818Hs.84728Kroppel-like factor 18.0
5 (intestinal)
413477AI815825Hs.48756ESTs, Moderately similar18.0
to neuronal-STOP protein
[M
405277 predicted exon 18.0
450192AA263143Hs.24596RAD51-interaEting protein18.0
442191W95186Hs.8136endothelial PAS domain18.0
protein 1
429490AI971131Hs.293684ESTs, Weakly similar 18.0
to alternatively spliced
product a
406744AA554082Hs.279860hypothetical protein 17.9
FLJ20030
425205NM_005854Hs.155106receptor (calcitonin) 17.9
activity modifying
protein 2
414387AL043148Hs.186257ESTs 17.9
411811AW864370 gb:PM4-SN0016-100500-004-h0917.9
SN0016 Homo sapie
433882U90441Hs.3622procollagen-proline, 17.9
2-oxoglutarate 4-dioxygenase
(pro
414333BE274897 gb:601122959F1 NIH_MGC_2017.9
Homo Sapiens cDNA
403747 predicted exon 17.9
435542AA687376Hs.269533ESTs 17.9
403093 predicted exon 17.9
412088AI689496Hs.108932ESTs 17.9
450506NM Hs.418fibroblast activation 17.9
004460 protein, alpha
404763 predicted exon 17.9
454633AW811380 gb:IL3-5T0143-290999-019-D0517.9
ST0143 Homo sapien
440788AI806594Hs.128577ESTs 17.9
411800N39342Hs.5184TH1 drosophila homolog17.9
441361BE263308Hs.7797TERFi (TRFt)-interacting17.8
nuclearfactor2
422033AW245805Hs.110903claudin 5 (Uansmembrane17.8
protein deleted in
velocardiof
d05333 predicted exon 17.8
408297817710Hs.113314ESTs 17.8
403036 predicted exon 17.8
417924AU077231Hs.82932cyclin Di (PRAD1: parathyroid17.8
adenomatosis 1)
417091AA193283Hs.291990ESTs 17.8
440789AB007857Hs.7416KIAA0397 gene product 17.8
438397AA806478Hs.123206ESTs 17.8
435948AA702675Hs.114135ESTs 17.8
450273AW296454Hs.24743hypothetical protein 17.8
FLJ20171
435969W85773Hs.191386ESTs 17.8
427031AA397601Hs.125147ESTs 17.8
454505AW801365 gb:IL5-UM0067-240300-050-a0117.8
UM0067 Homo sapi
403447 predicted exon 17.8
433297AV658581Hs.282633ESTs 17.8
443326BE156494Hs.188478ESTs t7.8
448283AI340462Hs.182979ribosomal protein L12 17.8
458067AA393603Hs.36752Homo Sapiens cDNA: 17.8
FLJ22834 fis, clone
KAIA4314
452359BE167229Hs.29206Homo Sapiens clone 17.8
24659 mRNA sequence
434098AA625499 gb:af69g08.r1 Soares_NhHMPu_S117.8
Homo Sapiens cDN
450911AA011586Hs.272097ESTs 17.7
410342831350Hs.743Fc fragment of IgE, 17.7
high affinity I, receptor
far; gamma
407082247055 gb:Human partial cDNA 17.7
sequence, famesyl
pyrophosph
415271X94232Hs.78335microtubule-associated17.7
protein, RP/EB family,
member
417413AA197072Hs.86092Human DNA sequence 17.7
from clone RP11-243Ji
6 on chr
408937AA210734Hs.291386ESTs 17.7
433459AA593498 gb:nn27b05.s1 NCI_CGAP-Gas117.7
Homo Sapiens cDNA
459536AI254723Hs.145496ESTs 17.7
428500AI815395Hs.184641delta-6 fatty acid 17.7
desaturase
433463841963Hs.4197ESTs 17.7
406537 predicted exon 17.7
410003AA079487 gb:zm97f08.s1 SUatagene17.7
colon HT29 (937221)
Homo
440857AA907808Hs.135556ESTs 17.7
451072AA013451Hs.117929ESTs 17.7
418693AI750878Hs.87409ihrombospondin 1 17.7
443624BE616129Hs.9651related RAS viral (r-ras)17.6
oncogene homolog
422626AA344932Hs.118786metallothionein 2A 17.6
410756AB037820Hs.66159KIAA1399 protein 17.6
436621AI266254Hs.132929ESTs 17.6
453317NM-002277Hs.41696keratin, hair, acidic,l17.6
120
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
456828AFt56889Hs.1d8427LIM homeobox protein 17.6
3
421486AWd08800Hs.104859hypothetical protein 17.6
DKFZp762E1312
428834AW899713Hs.10338ESTs 17.6
451419836309Hs.174369EST 17.6
448413A1745379Hs.42911ESTs 17.6
424323AA338791Hs.146763nascent-polypepflde-associated17.6
complex alpha polypept
423943AF163570Hs.135756polymerase (DNA-directed)17.6
kappa
439423BE536678Hs.147099ESTs 17.6
434025AFt Hs.216381Homo Sapiens clone 17.6
14264 HH409 unknown mRNA
1 408246N55669Hs.43946L13 protein 17.6
0
441579AW468847Hs.12719dESTs 17.5
420667NM_0i4183Hs.104002HSPC162protein 17.5
453680AL079647Hs.14485ESTs 17.5
400202 prodicted exon 17.5
15410768AF038185Hs.66187Homo Sapiens clone 17.5
23700 mRNA sequence
409932AI376750Hs.57600adaptor-related protein17.5
complex 1, sigma 1
subunit
425563AF084199Hs.299837ESTs 17.5
440475A1807671Hs.128343ESTs 17.5
452767AW014195Hs.61472ESTs, Weakly similar 17.5
to unknown [S.cerevisiae]
20410570AI133096Hs.64593ATP synthase, H+transporflng,17.4
mitochonddai F1F0,
su
419600AA448958Hs.91481NEU1 protein 17.4
419588AI347205Hs.91375Human clone 23614 mRNA17.4
sequence
428975NM Hs.194694mitogen-acflvated protein17.4
004672 kinase kinase kinase
6
448928AI350260Hs.5384Homo Sapiens cDNA FLJ1174317.4
fis, clone HEMBA100
403924 predicted exon 17.4
419889AA251600 gb:zs10d12.r1~NCl CGAP-GCBs17.4
HomosapienscDNA
405023AW408800Hs.104859hypothetical protein 17.4
DKFZp762E1312
426065N32049 gb:yw96g08.s1 Soares-placenta17.4
8to9weeks 2NbHP8to
453199A1336266Hs.301854Homo Sapiens PR00412 17.4
mRNA, complete cds
455132AW857955 gb:PMO-CT0325-151299-002-A1217.4
CT0325 Homo sapi
442932AA457211Hs.8858bromodomainadjacenttozincfingerdomain,lA17.4
432065AA401039Hs.2903protein phosphatase 17.3
4 (formerly X), catalyflc
subunit
444652BE513613Hs.11538acfln related protein 17.3
213 complex, subunit
1A (41 kD)
417935853697Hs.170044_ 17.3
ESTs
35430050AA430993Hs.227913AP15-like 1 17.3
446272BE268912Hs.14601hematopoieflc cell-specific17.3
Lyn substrate 1
425996W67330Hs.81256S100 calcium-binding 17.3
protein A4 (calcium
protein, calv
416964D87467Hs.80620guanine nucleotide 17.3
exchange factor for
Rapl; M-Ras-re
437418AI478954Hs.59459ESTs 17.3
447255A1884908Hs.158607ESTs 17.3
402203 predicted exon 17.3
417611AW993983 gb:RC1-BN0035-130400-013-a0417.3
BN0035 Homo sapie
426560AA381661Hs.119878ESTs 17.3
446163AA026880Hs.25252Homo Sapiens cDNA FLJ 17.3
13603 fis, clone PLACE1010
45445017AI205493Hs.176860ESTs 17.3
438658A1222068Hs.123571ESTs ' 17.3
442238AW135374Hs.270949ESTs 17.3
443195BE148235Hs.193063Homo Sapiens cDNA FLJ1420117.3
fis, clone NT2RP3002
442609AL020996Hs.8518selenoprolein N 17.2
50416591AA091976Hs.79387proleasome (prosome, 17.2
macropain) 26S subunit,
ATPase
403674 predicted exon 17.2
430514AA318501Hs.241587megakaryocyte-enhanced17.2
gene transcript 1
protein
411696AW857404 gb:CM3-CT0313-291199-046-c1117.2
CT0313 Homo sapie
434560813052Hs.3964Homo Sapiens clone 17.2
' 24877 mRNA sequence
S 422627BE336857Hs.118787transforming growth 17.2
factor, beta-induced,
68kD
414364D38521Hs.75935KIAA0077 protein 17.2
409119AA531133Hs.4253G protein-coupled receptor17.2
44
425640034051Hs.299204ESTs, Highly similar 17.2
to CDSS_HUMAN CYCLIN-DE
436044BE247571Hs.15627Nit protein 2 17.2
401657 predicted exon 17.2
449763A1822t12Hs.118241ESTs 17.2
409601AF237621Hs.80828kera8n t (epidermolytic17.2
hyperkeralosis)
449636AI656608Hs.281328ESTs 17.2
444958AW292643Hs.167047ESTs 17.2
65429978AA249027Hs.24t507ribosomal protein S6 17.2
453043AW136440Hs.224277ESTs 17.2
458640AI284935 gb:qk55g09.x1 NCI CGAP-Co817.1
Homo Sapiens cDNA
456329T41418 gb:phlh3-1911TV Outward17.1
Alu-primed hncDNA
librar
414839X63692Hs.77462DNA (cytosine-5-)-methyltransferase17.1
1
403662 predicted exan 17.1
411651AW855392 gb:CM3-CT0275-191099-024-e1217.1
CT0275 Homo sapie
404097 predicted exon 17.1
447252890916 gb:yn01e10.r1 Soares 17.1
adult brain N2b4HB55Y
Homo s
430024AI808780Hs.227730integrin, alpha 6 17.1
75412828AL133396Hs.74621prion protein (p27-30)17.1
(Creutzfeld-Jakob
disease, Gerst
444558AW18t975Hs.165892ESTs 17.1
420869X58964Hs.123638regulatory factorX,1(influencesHLAclassllexpressi17.1
448812H30775Hs.22140BM88 anflgen 17.0
431777AA570296Hs.105470found in inflammatory 17.0
zone 1
422007AI739435Hs.39168ESTs 17.0
403051 predicted exon 17.0
402427 predicted exon 17.0
417408F17211Hs.86092.Human DNA sequence 17.0
from clone RP11-243J16
on chr
450598AF151076Hs.25199hypotheflcalprotein 17.0
121
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
421121AA459028Hs.86228TRIAD3 protein 17.0
458488AL040565Hs.209544ESTs 17.0
417158AW965223Hs.110062ESTs, Weakly similar 17.0
to ACR3_HUMAN 30 KD
ADIP
439318AW837046Hs.6527G protein-coupled receptor17.0
56
428758AA433988Hs.98502Homo Sapiens cDNA FLJ1430317.0
fis, clone PLACE2000
447572AI631546Hs.159732ESTs 17.0
434434AA633516Hs.157201ESTs 17.0
409994D86B64Hs.57735acetyl LDL receptor, 17.0
SREC
408927AW295650Hs.255453ESTs 17.0
1 439093AA534163Hs.5476serine protease inhibitor,17.0
~ Kazal type, 5
454-066AA984138Hs.279895Homo Sapiens mRNA for 17.0
KIAA1578 protein,
partial cd
426996AW968934Hs.173108Homo Sapiens cDNA: 17.0
FLJ21897 fis, clone
HEP03447,
436659AI217900Hs.144464ESTs 17.0
422731AL138411 gb:DKFZp434A1229 r143417.0
(synonym: htes3) Homo
s
1 429294AA095971Hs.198793KIAA0750 gene product 17.0
432847BE266941Hs.279554proteasome (prosome, 16.9
macropain) 26S subunit,
non-AT
416977AW130242Hs.293476ESTs 16.9
406827AA971409Hs.84298CD74 anfigen (invariant16.9
polypepfide of major
histocom
453758083527 gb:HSU83527 Human fetal16.9
brain (M.Lovetl) Homo
sap
431314AI732204Hs.105423ESTs 16.9
423185BE299590Hs.125078omithine decarboxylase16.9
antizyme 1
435086AW975243Hs.122596ESTs 16.9
447383N24231 gb:yx22a11.ri Soares 16.9
melanocyte 2NbHM Homo
sapie
456251813326Hs.21303ESTs 16.9
456327H68741Hs.38774ESTs 16.9
450594N31036 gb:yx51g04.r1~Soares 16.9
melanocyte 2NbHM Homo
sapie
428177AA423967Hs.178113ESTs, Moderately similar16.9
to kinesin like protein
9 [M.m
453250AI346520Hs.121619chromosome 11 open 16.9
reading Frame 15
418294AF061739Hs.83954protein associated 16.9
with PRK1
446546BE167687Hs.156628ESTs 16.9
421100AW351839Hs.124660Homo Sapiens cDNA: 16.9
FLJ21763 fis, clone
COLF6967
455993BE179085 gb:RCO-HT0613-140300-021-40616.9
HT0613 Homo sapie
459375BE251770 gb:601112470F1 NIH 16.9
MGC_16 Homo Sapiens
cDNA
454803AW860148 gb:RCO-CT0379-290100-032-b1016.9
CT0379 Homo sapie
35 445474AI240014Hs.259558ESTs 16.9
443198A1039B13 gb:ox49dO6.x1 Soares 16.9
total-fetus-Nb2HF8-9w
Homo
441557AW452647Hs.270482ESTs 16.9
420206M91463Hs.95958solute carrier family 16.9
2 (facilitated glucose
transporter),
442202BE272862Hs.106534Homo sapiens cDNA: 16.9
FLJ22625 fis, clone
HSI06009
416913AW934714 gb:RCt-DT0001-031299-011-al16.9
l DT0001 Homo sapie
419355AA428520Hs.90061progesterone binding 16.9
protein
452975M85521Hs.69469dendritic cell protein16.9
432525AI796096Hs.109414ESTs 16.8
453718AL119317Hs.120360phospholipase A2, group16.8
VI (cytosolic, calcium-indepe
45 437270818087Hs.11282ESTs, Weakly similar 16.8
to cleft lip and palate
transmemb
408007AW135965Hs.246783ESTs 16.8
450954A1904740Hs.25691receptor (calcitonin) 16.8
activity modifying
protein 3
402958 predicted exon 16.8
445656W22050Hs.21299ESTs, Weakly similar 16.8
to AFi 518401 CGI-82
protein [H
410684AA088500Hs.170298ESTs 16.8
437669A1358105Hs.123164ESTs, Weakly similar 16.8
to match to ESTs AA667999
[H.
447869AW139113Hs.164307ESTs 16.8
458025AI275406 gb:q163c10.x1 Soares_NhHMPu_S116.8
Homo Sapiens cDN
445614AV660763Hs.110675apolipoprotein GIV 16.8
55 454610AW8i0224 gb:MR4-ST0125-021199-017-e07ST012516.8
Homosapie
449303AK001495Hs.23467hypothetical protein 16.8
FLJ10633
422105AI929700Hs.111680endosulfine alpha 16.8
444788AI871122Hs.202821ESTs 16.8
414057AI815559Hs.75730signal recognition 16.8
particle receptor
('docking protein')
408822AW500715Hs.57079Homo Sapiens cDNA FLJ1326716.8
fis, clone OVARC1000
433379AA586368Hs.190232ESTs 16.8
441552AA937975 gb:oc08ei2.s1 NCI-CGAP-GCB116.8
HomosapienscDN
403582 predicted exon 16.8
433871W02410Hs.205555ESTs 16.8
65 439509AF086332Hs.58314ESTs 16.8
431639AK000680Hs.266175phosphoprotein associated16.8
with GEMS
430129BE301708Hs.233955hypotheficalprotein 16.8
FLJ20401
401465 predicted exon 16.8
448913AA194d22Hs.22564myosin VI 16.8
70 410261AF145713Hs.61490schwannomin interacting16.8
protein 1
421199BE244219Hs.102497paxillin 16.7
450489AI697990Hs.224375ESTs 16.7
410186AW602528 gb:RC5-BT0562-260100-011-A0216.7
BT0562 Homo sapi
447224BE617125 gb:601441664F1 NIH_MGC_6516.7
Homo Sapiens cDNA
75 403010 predicted exon 16.7
404881 predicted exon 16.7
445572AI243445Hs.189654ESTs 16.7
419440A8020689Hs.90419KIAA0882 protein 16.7
443406A1056238Hs.143316ESTs 16.7
457901AW207023Hs.250497ESTs, Highly similar 16.7
to dJ745C22.1 [H.sapiensj
448364T08958Hs.16561HSPC141 protein 16.6
407239AA076350Hs.67846leukocyte immunoglobulin-like16.6
receptor, subfamily
B (
401847 predicted exon 16.6
429523AK000788Hs.205280Homo Sapiens cDNA FLJ2078116.6
fis, clone COLOd235
1
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
432845AI989751Hs.150378ESTs 16.6
400246 predicted exon 16.6
404971 predicted exon 16.6
422954AW998605Hs.32399ESTs, Weakly similar 16.6
to Similar to Ena-VASP
like prat
415042NM Hs.77837UDP-glucose pyrophosphorylase16.6
006759 2
432201AI5386i3Hs.135657ESTs 16.6
456993AL134577Hs.200302ESTs 16.6
456525AW468397Hs.100000S100 calcium-binding 16.6
protein A8 (calgranulin
A)
444060AA340277Hs.10248Homo Sapiens cDNA FLJ2016716.6
fis, clone COL09512
1 428928BE409838Hs.194657cadhe~n 1, type 1, E-cadherin16.6
~ (epithelial)
448199AI953278Hs.170557ESTs 16.6
443422810288Hs.301529ESTs 16.6
401117 predicted exon 16.6
400613 predicted exon 16.6
15 431214AA294921Hs.250811v-rat simian leukemia 16.6
viral oncogene homolog
B (ras re
431649AL133077Hs.266746Homo Sapiens cDNA: FLJ2261516.5
fis, clone HSI05118
421335X99977Hs.103505ARS component B 16.5
427154AL137262Hs.288991Homo sapiens cDNA: FLJ2252316.5
fis, clone HRC12507
401010 predicted exon 16.5
436678BE512828Hs.5273NADH dehydrogenase (ubiquinone)16.5
Fe-S protein 3 (30k
401589 predicted exon 16.5
402538 predicted exon 16.5
430478NM Hs.241535TNF-inducible protein 16.5
014349 CG12-1
437623D63880Hs.5719chromosome condensation-related16.5
SMGassociated pro
25 401244 predicted exon 16.5
415167AA160784Hs.26410ESTs ' 16.5
438291BE514605Hs.289092Homo Sapiens cDNA: FLJ2238016.5
fis, clone HRC07453,
405183 predicted exon 16.5
436480AJ271643Hs.87469putative acid-sensing 16.5
ion channel
30 456691A1023428Hs.205696ESTs 16.5
418332834976Hs.78293ESTs 16.5
446052AA358760 gb:EST67699 Fetal lung 16.5
II Homo Sapiens cDNA
5' end
444859AW449137Hs.157487ESTs 16.5
437192AW975786Hs.75355ubiquitin-conjugating 16.5
enzyme E2N (homclogous
to yea
35 400891 predicted exon 16.5
448372AW445166Hs.170802ESTs 16.5
425798AA364002 gb:EST74529 Pineal gland16.5
II Homo Sapiens cDNA
5' en
459253AL157476Hs.32913Homo Sapiens mRNA; cDNA16.5
DKFZp761 C082 (from
c
420746AWi95932Hs.197488ESTs 16.4
414717BE271039Hs.77060proteasome (prosome, 16.4
macropain) subunit,
beta type, 6
400727 predicted exon 16.4
422691NM_003365Hs.119251ubiquinol-cytochrome 16.4
c reductase core protein
I
405639 predicted exon 16.4
414444BE298594 gb:601119754F1 NIH MGC_1716.4
Homo Sapiens cDNA
45 456146AL034349Hs.79005protein tyrosine phosphatase,16.4
receptor type, K
414610BE388044 gb:601283747Fi NIH MGC_4416.4
Homo Sapiens cDNA
414267AL078459Hs.289109dimethylarginine dimethylaminohydrolase16.4
1
401268 predicted exon 16.4
403613 predicted exon 16.4
50 4142038E262170 gb:601150419F1 NIH MGC 16.4
19 Homo Sapiens cDNA
454315AW373564Hs.251928nuclear pore complex 16.4
interacfing protein
452114N22687Hs.8236ESTs 16.4
404638. predicted exon 16.4
404600 predicted exon 16.3
55 448855AF070574Hs.22316Homo Sapiens clone 2481916.3
mRNA sequence
406629AW277078Hs.181165eukaryotic translation 16.3
elongation factor 1
alpha 1
450957BE515202Hs.21497Homo Sapiens mRNA for 16.3
FLJ00042 protein, partial
cds
449966H60542Hs.37848ESTs 16.3
402585 predicted exon 16.3
436008A1078428Hs.58785ESTs 16.3
40.1492 predicted exan 16.3
412288NM_003005Hs.73800selecfin P (granule 16.3
membrane protein 140kD,
antigen C
405088 predicted exon 16.3
' 437345BE259522Hs.5556NADH dehydrogenase (ubiquinone)16.3
1, alphalbeta subco
65 4322808E440142Hs.2943signal recognifion particle16.3
l9kD
419596BE379320Hs.91448MKP-1 like protein tyrosine16.3
phosphatase
428801AW277121Hs.254881ESTs 16.3
431394AK000692Hs.252351HERV-H LTR-associating 16.3
2
452998BE019681Hs.6019Homo Sapiens cDNA: FLJ2128816.3
fis, clone COL01927
439938AI147392Hs.124607ESTs 16.3
418844M62982Hs.1200arachidonate 12-lipoxygenase16.3
.446081AA972412Hs.13755f-box and WD-40 domain 16.3
protein 2
443534A1076123 gb:oy92e04.x1 Soares-fetal16.3
liver-spleen 1NFLS
Si H
459510AA076706 gb:7B01802 Chromosome 16.3
7 Fetal Brain cDNA
Library
75 450517AI523755Hs.59236ESTs, Weakly similar 16.3
to 835049 ankyrin 1,
erythrocyte
451936AI354355Hs.16697down-regulator of transcripfion16.3
1, TBP-binding (negativ
454478AW805749 gb:OVi-UM0105-180400-162-f1016.2
UM0105 Homo sap
407214AA412048Hs.279574CGI-39 protein; cell 16.2
death-regulatory protein
GRIM19
406580 predicted exon 16.2
409452BE336714Hs.289271cytochrome c-1 16.2
416841N33878Hs.249495heterogeneous nuclearribonucleoprotein16.2
A1
458710AV660856 gb:AV660856 GLC Homo 16.2
Sapiens cDNA clone
GLCG
450657AK001579Hs.25277hypotheficalprotein 16.2
FLJ21065
- , predicted exon 16.2
404230
123
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
439471W69839Hs.58033ESTs 16.2
400848 predicted exon 16.2
428797AA496205Hs.193700Homo Sapiens mRNA; 16.2
cDNA DKFZp58610324
(from c
416272AA178882 gb:zp38b09.r1 Stratagene16.2
muscle 937209 Homo
Sapiens
444465AI206592Hs.143843ESTs 16.2
431257AF039597 gb:Homo Sapiens Ku86 16.2
autoanfigen related
protein 1 (K
447775BE179318 gb:RCt-HT0615-290300-021-g0516.2
HT0615 Homo sapie
403833 predicted exon 16.2
444140AV648089Hs.282383ESTs 16.2
l0 446102AW168067Hs.252956ESTs 16.2
416475T70298 gb:yd26g02.siSoaresfetalliverspleenlNFLSHomos16.2
d30783AW971248Hs.291289ESTs, Weakly similar 16.2
to ALU1 FIUMAN ALU
SUBFA
414070AW963783 gb:EST375856 MAGE resequences,16.2
MAGH Homo sap
444283AI138971Hs.154636ESTs 16.2
1 405599X92715Hs.3057zincfingerprotein 74(Cos52)16.2
409427AW389668 gb:RC2-ST0168-071299-013-f0616.2
ST0168 Homo sapien
409417AA156247Hs.295908ESTs, Weakly similar 16.2
to ALU7-HUMAN ALU
SUBFA
435380AAfi79001Hs.192221ESTs 16.2
406752A1285598Hs.217493annexin A2 16.2
2~ 406096F12200Hs.5811chromosome 21 open 16.2
reading frame 59
417551AI816291Hs.82273hypotheticalprotein 16.2
441252AW360901Hs.183047ESTs, Weakly similar 16.2
to unnamed protein
product [H.s
419608AL037237Hs.91586transmembrane 9 supeAamily16.1
member 1
438894AI630819Hs.300431ESTs ~ 16.1
25 451287AK002158Hs.26194hypothefical protein 16.1
FLJ11296
412499AW956916Hs.11238KIAA0622 protein; Drosophila16.1
mulfiple asters' (Mast
433355AI808235 gb:wf44e01.x1 Soares 16.1
NFL-T-GBC S1 Homo
sapien
416818AI986408Hs.204766ESTs, Weakly similar 16.1
to 848013 proline-rich
proleogly
438765A1031888Hs.132594ESTs 16.1
424470BE244261Hs.5615nuclear RNA exportfactorl16.1
416194H27114Hs.301212ESTs 16.1
446702844518Hs.143496ESTs 16.1
414222AL135173Hs.878sorbitoldehydrogenase 16.1
443122A1806656Hs.209022ESTs, Weakly similar 1fi.1
to Pro-Pol-dUTPase
polyprotein
35 448648BE614345Hs.159089ESTs 16.1
456394W28506 gb:48f1 Human retina 16.1
cDNA randomly primed
sublibra
445887AI263105Hs.145597ESTs 16.1
412332AW937661Hs.288324Homo Sapiens cDNA FLJ1328316.1
fis, clone OVARC1001
403912 predicted exon 16.1
4~ 441446866269Hs.28714ESTs 16.1
403153 predicted exan 16.0
444907AW772596Hs.148586ESTs 16.0
421946899629Hs.109773hypotheticalprotein 16.0
FLJ20625
437513AW410681Hs.5648proteasome (prosome, 16.D
macropain) 26S subunit,
non-AT
45 407752AA573581Hs.13328ESTs 16.0
447953A1804218Hs.209614Homo Sapiens cDNA: 16.0
FLJ22343 fis, clone
HRC06043
425708AK001342Hs.14570Homo sapiens cDNA: 16.0
FLJ22530 fis, clone
HRC12866
421449AA713491Hs.291501ESTs 16.0
418323NM Hs.1162major histocompatibility16.0
002118 complex, class II,
DM beta
447787BE620108 gb:601483015F1 NIH_MGC_6916.0
Homo Sapiens cDNA
422716AI702835Hs.124475ESTs 16.0
443958BE241880Hs.10029cathepsin C 16.0
417908AA207221 gb:zq55h04.s1 Stratagene16.0
neuroepithelium (937231)
Ho
438542AA810131Hs.123317ESTs 16.0
55 400288X06256Hs.149609integrin, alpha 5 (fibronecfin16.0
receptor, alpha polypeptid
456825H67220Hs.146406ni~ilase 1 16.0
431360NM Hs.251680loricrin 16.0
000427
414266BE267834 gb:601124428F1 NIH-MGC-816.0
Homo Sapiens cDNA
c
440571AA904461Hs.130798ESTs 16.0
426075AW513691Hs.270149ESTs 16.0
413488BE144017Hs.i84693transcdpficn elongafion16.0
factor B (SIII), polypeptide
1 (1
446767AI380107Hs.158954ESTs 16.0
418008W56044Hs.211556Homo Sapiens cDNA: 16.0
FLJ23378 fis, clone
HEP16248
404239 predicted exon 16.0
65 458401AW236939Hs.172154ESTs 16.D
412955BE241849Hs.75082ras homolog gene family,15.9
member G (rho G)
423072AI792946Hs.123116solute comer family 15.9
12 (sodiumlpotassiumlchloride
iron
444954AW247076Hs.12163eukaryotic translation15.9
initiation factor
2, subunit 2 (beta
449023AI623261Hs.248875ESTs 15.9
435729BE048886Hs.275017EST 15.9
438575BE304709Hs.146550myosin, heavy polypepfide15.9
9, non-muscle
413047H02209 gb:yj38c09.r1 5oares 15.9
placenta Nb2HP Homo
Sapiens cD
425997AK000086Hs.165948hypotheGcalprotein 15.9
FLJ20079
446663AW614370Hs.254620ESTs 15.9
75 448564AL044962Hs.21453Homo Sapiens mRNA for 15.9
inositol 1,4,5-trisphosphate
3
455640BE064059 gb:OV3-BT0296-010300-111-e0415.9
BT0296 Homo sapie
404345AA730407Hs.159156protocadherin 11 15.9
418512AWd98974Hs.89981diacylglycerol kinase,15.9
zeta (104kD)
411551AW851309 gb:IL3-CT0220-170200-067-C1115.9
CT0220 Homo sapien
g 446726AW300144Hs.209209Homo Sapiens cDNA FLJ 15.9
0 11629 fis, clone HEMBA100
410748BE383816Hs.136005ESTs, Highly similar 15.9
to bG115G20.2 [H.sapiens]
449618A1076459Hs.i4366Homo sapiens cDNA FLJ1281915.9
fis, clone NT2RP2002
429697AW296451Hs.24605ESTs 15.9
424012AW368377Hs.137569tumor protein 63 kDa 15.9
with strong homology
to p53
124
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
403151 predicted exon 15.8
452363AI582743Hs.94953ESTs, Highly similar 15.8
to C10C_HUMAN COMPLEME
425971AF135024Hs.165296kallikrein 13 15.8
432626X75363Hs.250770kallikrein 15 15.8
431972AI805145Hs.191711ESTs 15.8
400269 predicted exon 15.8
404703AI904493Hs.99890polymerase (DNA directed),15.8
delta 1, catalytic
subunit (1
449335AW150717Hs.296176STAT induced STAT inhibitor15.8
3
4i NM Hs.85146v-els avian erythroblastosis15.8
8443005239 virus E26 oncogene
homolo
1 445773H73456Hs.13299Homo Sapiens mRNA; 15.8
~ cDNA DKFZp761 M0111
(from
433782AF090945 gb:Homo Sapiens clone 15.8
H00670
406473 predicted exon 15.8
420831AA280824Hs.190035ESTs 15.8
402939 predicted exon 15.8
I 405196 predicted exon 15.8
S
452947AW130413 gb:xf50f04.x1 NCI CGAP_Gas415.8
Homo Sapiens cDNA
414170AA335996Hs.3743matrix metalloproteinase15.8
24 (membrane-inserted)
437133A8018319Hs.5460KIAA0776 protein 15.8
458356A1024855Hs.131575ESTs 15.8
407857A1928445Hs.92254hypothetical protein 15.8
FLJ20163
405687 predicted exon 15.8
415189L34657Hs.78146plateletlendothelial 15.8
cell adhesion molecule
(C031 antig
408662AW247699Hs.105897ESTs 15.7
448338AI492857 gbah72hO8.x1 Soares_NhHMPu_St15.7
HomosapienscDN
25 402694 predicted exon 15.7
430224AW675175 hypothetical protein 15.7
Hs.235975DKFZp434D0412
458792N56666 gb:yw75e02.r1 Soares-placenta-Sto9weeks_2NbHP8to15.7
402944 predicted exon 15.7
422675BE018517Hs.119140eukaryotic franslation15.7
initiation factor
5A
3 408661AW247625 gb:2820094.5prime NIH_MGC-715.7
0 Homo sapiens cDNA
423238AA323569Hs.280482ESTs 15.7
421517AB018352Hs.105399KIAA0809 protein 15.7
429865AB023217Hs.225968KIAA1000 protein 15.7
440815AW071945Hs.7436putative acyltransferase15.7
35 400634 predictedexon 15.7
451034AL050341Hs.25846zinc metalloproteinase,15.7
STE24 (yeast, homology
457571AI375726Hs.279918hypotheticalprotein 15.7
450105BE281124Hs.288013similar to yeast BETS 15.7
(S. cerevisiae)
407464AJ276396 gb:Homo Sapiens mRNA 15.7
for mafrix exfracellular
phosp
4o 439465AF086285 gb:Homo Sapiens full 15.7
length insert cDNA
clone ZD47B
451837T92157Hs.16970ESTs 15.7
435313AI769400Hs.189729ESTs 15.7
402738 predicted exon 15.7
432966AA650114 gb:ns92h09.s1 NCI_CGAP_Pr315.7
Homo Sapiens cDNA
c
45 457666AWd70302Hs.129663ESTs 15.7
401269 predicted exon 15.7
427509M62505Hs.2161complement component 15.7
5 receptor 1 (C5a
ligand)
418846AI821602Hs.115127ESTs 15.6
448891AI587332Hs.209115ESTs 15.6
445930AF055009Hs.13456Homo Sapiens clone 15.6
24747 mRNA sequence
421254AK001724Hs.102950coat protein gamma-cop15.6
447073AW204821Hs.157726ESTs 15.6
445438AB014578Hs.12707KIAA0678 protein 15.6
432126AA865239Hs.55144ESTs 15.6
55 424091AF235097Hs.139263calcium channel, voltage-dependent,15.6
alpha lFsubunit
440832A1057548Hs.128224ESTs 15.6
449228AJ403107Hs.148590ESTs, Weakly similar 15.6
to AF2088461 BM-004
[H.sapie
434253AI393345Hs.116215ESTs 15.6
459270AL039604 gb:DKFZp434E2211 r1 15.6
434 (synonym: htes3)
Homo s
454425AW300927Hs.27192hypothetical protein 15.6
4J1057820.2
412055AA099907Hs.271806ESTs 15.6
400837 predicted exon 15.6
458866BE616694Hs.288042Homo Sapiens cDNA FLJ1429915.6
fis, clone PLACE1010
417124BE122762Hs.25338ESTs 15.6
65 414376BE393856Hs.66915ESTs, Weakly similar 15.6
to 16.7K4 protein
[H.sapiens]
418636AW749855 gb:OV4-BT0534-281299-053~c0515.6
BT0534 Homo sapie
454128AL031259Hs.41639programmed cell death 15.6
2
441074AW500001Hs.4783Homo Sapiens cDNA: 15.6
FLJ22035 fis, clone
HEP08838
451742T77609Hs.117970ankyrin 2, neuronal 15.6
403687 predicted exon 15.6
431838A1097229Hs.217484ESTs 15.6
402855 predicted exon 15.6
449635AI989942Hs.232150ESTs 15.6
434392AW983709Hs.268051ESTs 15.6
75 444301AK000136Hs.10760hypothetical protein 15.6
FLJ20129
414973C19089 gb:C19089 Human placenta15.5
cDNA (TFujiwara) Homo
428374AW405156Hs.183994protein phosphatase 15.5
1, catalytic subunit,
alpha isoform '
415745AI301107Hs.150790ESTs 15.5
432532AW058459Hs.162246ESTs 15.5
417112AA193439 gb:zr41609.s1 Soares 15.5
NhHMPu-S1 HomosapienscDN
418101AL047476Hs.98485gap junction protein, 15.5
beta 4 (connexin 30.3)
453110AW384928Hs.225160Homo Sapiens cDNA FLJ1310215.5
fis, clone NT2RP3002
458606AJ239397 gb:AJ239397 Uni-ZAP 15.5
XR retinal pigment
epithelium H
436989AA741028Hs.256155ESTs 15.5
125
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
407396AF011757 gb:Homo Sapiens RAGE 15.5
binding protein (P12)
mRNA,
449684AI659166Hs.207144ESTs 15.5
454666AW812994 gb:RC3-ST0186-230300-019-g0215.5
ST0186 Homo sapien
430492015197Hs.300803Human histo-blood group15.5
ABO protein mRNA,
partial
439460AA836220Hs.13774ESTs 15.5
449231BE410360 gb:601302340F1 NIH_MGC_2115.5
Homo Sapiens cDNA
453060AW294092Hs.21594ESTs 15.5
416961BE391476Hs.80617ribosomal protein S16 15.5
439988AA860119Hs.255976ESTs 15.5
1 400917 predicted exon 15.5
~
424585AA464840 gb:zx43h11.r1 Snares 15.5
total_fetus_Nb2HF8
9w Homo
431029BE392725Hs.248571Homo Sapiens PAC clone15.5
RP5-1163J12 from 7q21.2-q3
441680AW444598Hs.7940RAP1, GTP-GDP dissociation15.5
stimulator 1
437830AB020658Hs.5867KIAA0851 protein 15.5
15 409479BE163800Hs.136912ESTs 15.5
409885AW503068 gb:Ul-HF-BPOp-aje-g-10-0-Ul.rt15.4
NIH MGC_51 Homo
459090AA443323Hs.107812ESTs, Weakly similar 15.4
to SPOP [H.sapiens]
429324AA488101Hs.199245inactivation escape 15.4
1
403766 predicted exon 15.4
20 413970059309Hs.75653fumarate hydratase 15.4
4566748E266120Hs.269358ESTs 15.4
417931W95642Hs.82961trefoil factor 3 (intestinal)15.4
430125046418Hs.233950serine protease inhibitor,15.4
Kunitz type 1
452154AW953265Hs.271277hypothetical protein 15.4
from EUROIMAGE 363668
422984W28614Hs.75984chorionic somatomammotropin15.4
hormone 2
408649BE242232Hs.26045' 15.4
protein tyrosine phosphatase,
receptor type, A
417497AW402482Hs.82212CD53 antigen 15.4
404666 predicted exon 15.4
456847AI360456Hs.37776ESTs 15.4
30 426995AA400646Hs.221988ESTs 15.4
445350AF052112Hs.12540lysophospholipase I 15.4
450214BE439763Hs.227571regulator of G-protein15.4
signalling 4
449733874546Hs.29438Homo Sapiens cDNA FLJ1209415.4
fis, clone HEMB8100
411660AW855718 gb:RCi-CT0279-070100-021-a0615.4
CT0279 Homo sapie
3 442653BE269247Hs.170226Homo sapiens clone 15.4
23579 mRNA sequence
447552AI394i25Hs.160413ESTs 15.4
448712W01046Hs.181634Homo Sapiens cDNA: 15.4
FLJ23602 fis, clone
LNG15735
420180A1004035Hs.25191ESTs 15.4
440099AL080058Hs.6909DKFZP564G202 protein 15.4
427550BE24281Hs.179606nuclear RNA helicase, 15.4
B DECD variant of DEAD
box fam
432894AW167668Hs.279772brain specific protein15.3
412113AW161274Hs.74427p53-induced protein 15.3
431614A1189827 gb:qd19d07.x1 Snares_placenta_8to9weeks_2NbHP8to15.3
445870AW410053Hs.13406syntaxin 18 15.3
45 424347AA723883Hs.145513Homo Sapiens mRNA; 15.3
cDNA DKFZp434L0435
(from
425132AW250114 gb:2821134.5prime NIH 15.3
MGC-7 Homo Sapiens
cDNA
439756AL359651Hs.283852Homo Sapiens mRNA full15.3
length insert cDNA
clone EU
432946060899Hs.279854mannosidase, alpha, 15.3
class 28, member 1
406130 predicted exon 15.3
5 453359AA448787Hs.24872ESTs, Weakly similar 15.3
0 to aortic carboxypeptidase-like
p
405491 predicted exon 15.3
436481AA379597Hs.5199HSPC150 protein similar15.3
to ubiquilin-conjugating
enzy
446826AK000626Hs.16230hypothetical protein 15.3
FLJ20619
441211AW946155Hs.7750hypothetical protein 15.3
AL133206
55 418711AW247977Hs.87595translocase of inner 15.3
mitochondria) membrane
22 (yeast)
457301AA469146 gb:nc67e03.s1 NCI CGAP_Pr115.3
Homo Sapiens cDNA
c
449999AI679421Hs.231098ESTs, Highly similar 15.3
to ALU4_HUMAN ALU
SUBFA
439090H65724Hs.271663ESTs 15.3
416586D44643Hs.14144secreted modular calcium-binding15.3
protein 1
411940AW876686 gb:CM4-PT0031-180200-507-e0515.3
PT0031 Homo sapie
407639AW205369Hs.252936ESTs 15.3
458012A1424899Hs.18B211ESTs 15.3
426490NM_001621Hs.170087arylhydrocarbon receptor15.3
408741M73720Hs.646carboxypeptidase A3 15.3
(mast cell)
6S 437371AK000868Hs.5570hypothelicalprotein 15.3
FLJ10006
437134AA349944Hs.42915ARP2 (actin-related 15.3
protein 2, yeast)
homolog
441890AI809547Hs.128075ESTs 15.3
409442AA3i0162Hs.169248cytochromec 15.3
407078226256 gb:H.sapiens isoform 15.2
t gene for L-type
calcium channe
70 436553AW407157Hs.181125immunoglobulin lambda 15.2
locus
443177BE268461Hs.202benzodiazapine receptor15.2
(peripheral)
448771BE315511Hs.296244SNARE protein 15.2
436837A1968248Hs.187869ESTs 15.2
423623AB011117Hs.129943KIAA0545 protein 15.2
75 422651NM_015670Hs.118926DKFZP586K0919 protein 15.2
403221AL134878Hs.119500karyophedn alpha 4 15.2
(importin alpha 3)
431620AA126109Hs.2649812'-5'oligoadenylale 15.2
symthetase 2
404794NM_000078Hs.89538cholesteryl ester transfer15.2
protein, plasma
412944AA384110Hs.197143ESTs 15.2
450817N71597Hs.29698ESTs 15.2
418666AF001434Hs.155119EH domain containing 15.2
1
451636AW173270Hs.140444ESTs 15.2
426302AA459085Hs.275163non-metastatic cells 15.2
2, protein (NM23B)
expressed in
454485AW795322 gb:PMO-UM0018-120400.002-h0115.2
UM0018 Homo sap
126
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
440617AA894880Hs.181181ESTs 15.2
449718AA459480Hs.23956hypotheficalprotein 15.2
FLJ20502
405227 predicted exon 15.2
431006BE152871 gb:CM1-HT0333-101299-064-d1215.2
HT0333 Homo sapi
443476AW068594Hs.133878ESTs, Weakly similar 15.2
toAF1518891 CGI-131
protein
438828AL134275Hs.6434hypotheficalprotein 15.2
DKFZp761F2014
407634AW016569Hs.301280ESTs, Highly similar 15.2
to AF241831 1 intracellular
hyalu
436857AA732647 gb:nz89d01.s1 NCI 15.2
CGAP-GCB1 HomosapienscDN
431526Y10129Hs.258742myosin-binding protein15.1
C, cardiac
1 447386NM_006289Hs.18420KIAA1027 protein 15.1
~
436573AA723297Hs.127138ESTs 15.1
432858BE618609Hs.279591Homo sapiens clone 15.1
25056 mRNA sequence
437352AL353957Hs.284181hypothetical protein 15.1
DKFZp434P0531
413209AW083791Hs.21263Homo Sapiens cDNA 15.1
FLJ13152 fis, clone
NT2RP3003
I 407376AA993138Hs.1422fi7ESTs, Weakiy similar 15.1
S to ALUF_HUMAN !!!!
ALU CL
430475BE387420Hs.241531pefiin 15.1
446764AW291276Hs.285532ESTs 15.1
425868. A8017548Hs.160100Homo Sapiens gene 15.1
for Sepiapterin Reductase,
parfial c
453464AI884911Hs.32989receptor (calcitonin)15.1
activity modifying
protein 1
447246AW449032Hs.170257ESTs 15.1
401780 predicted exon 15.1
434063AA018893Hs.3727unr-interacting protein15.1
416114AI695549Hs.183868glucuronidase,beta 15.1
441018A18095B7Hs.148782ESTs 15.1
25 425972BE391563Hs.165433ESTs, Highly s]milar 15.1
to T17342 hypothefical
protein D
426062N57014Hs.44013ESTs 15.1
451234AI914901Hs.24052ESTs 15.1
429565A8020719Hs.207802KIAA0912 protein 15.1
418092845154Hs.106604ESTs 15.1
30 424550A1650541Hs.115298ESTs 15.1
425023AW956889Hs.154210endothelial differentiation,15.1
sphingolipid G-protein-coup
445213AW204314Hs.170784ESTs . 15.1
418102858958Hs.26608ESTs 15.0
450082AI908894Hs.245B93ESTs 15.0
3 446749NM_016069Hs.16089CGI-136 protein 15.0
S
406124 predicted exon 15.0
457408AL137507Hs.255348Homo Sapiens mRNA; 15.0
cDNA DKFZp761 P211
(from c
410051025773Hs.218182ESTs, Weakly similar 15.0
to dJ1042K10.2 [H.sapiens]
440965AI523646Hs.i69859ESTs . 15.0
440190AW752597 gb:IL3-CT0214-161299-045-BO615.0
CT0214 Homo sapien
417437052682Hs.82132interferon regulatory15.0
factor 4
454249AW249008 gb:2821048.5prime 15.0
NIH MGC-7 Homo Sapiens
cDNA
432276AF163302Hs.274255somatostafin receptor-interacting15.0
protein
401116 predicted exon 15.0
45 423960AA164516Hs.136309CGI-61 protein 15.0
451661AB020650Hs.26777KIAA0843 protein 15.0
450983AA305384Hs.25740ER01 (S. cerevisiae)-like15.0
446187AK001241Hs.14229hypotheficalprotein 15.0
FLJ10379
404122 predicted exon 15.0
50 411299BE409857Hs.69499hypothefical protein 15.0
403077 predicted exon 15.0
438000A1825880Hs.5985non-kinase Cdc42 effector15.0
protein SPEC2
447118A8014599Hs.17411KIAA0699 protein 15.0
417878090916Hs.82845Human clone 23815 15.0
mRNA sequence
55 444079H09048Hs.23606ESTs 15.0
458234BE551408Hs.127196ESTs 15.0
434208T92641Hs.127648hypothefical protein 15.0
PR02176
423136AW375506Hs.124147ESTs 15.0
403177 predicted exon 15.0
448699A1857269Hs.227351ESTs 15.0
425248AW957442Hs.252766ESTs 15.0
429430AI381837Hs.155335ESTs 15.0
TABLE 38:
65 Pkey: Unique Eos probeset idenfifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers
PkeyCAT Accession
Number
4083101051011AW179023 AW179010
1
4086471071855AW245831 AW273207
1
4086611073036AW247625 AW249214
1
408987109306 H85615 H86300 H86263 H86282AA059278 H86304
1
4094271129667AW389668 AW389657 AW609198 AW389649
1
75 4095451138823BE296182 AW629821
1
4098281155571AW501137 AW501295 AW501212
1
4098651156518AW502208 AW502366 AW502148
1
4098851157385AW503068 AW503789
1
410003116761 AA079487 AA128547 AA128291 AA079587 AA079600
1
g 4101861182096_1AW602528 BE073859 238412
0
4106261212621BE407727
-1
4110041228975AW813242 8E14fi089 AW813195 AW813173 AW813206 BE145953
t BE146212 AW813196 AW8545B2 AW813241 BE061582
4110141229091AW816072 AW813375 AW813385 AW813372 AW813436 AW816148
1 AW813475 AW816107 AW813398 AW813479 AW814475 AW813317
4110281229404-1AW813703 AW813839
1~7
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4112361236374AW833752 AW833633 AW833776 AW833719
1 AW833362 AW833749
4114201245222BE390652
-1
4115411249044W03940 T98335 AW850705
1
d115511249196AW851309 AW850888 AW851419 AW851d12
1 AW851299
4116511252835AW855392 AW855559 AW855423
1
4116601253078AW855718 AW855740 AW855748
1
4116961254304AW857404AW857401 BE144856
1
4118111259427AW864370 AW864319 AW864504
1
4119301266070F06485 AW876454
1
1 4119401266262_1AW876686 AW876717 AW877215 AW876691
~ AW876722 AW877218 AW876694 AW876725
4119421266449AW877015 AW877133 AW876978 AW877071
1 AW876988 AW877069 AW877063 AW877013
4127931327636AW997986
-1
4130471346806H02209 BE062154 BE062032
1
4131011349154BE065215 BE155544 BE155541 BE155540
1 BE155542 BE155543
1 4131541351077_1BE067870 BE067866 BE165133 BE165334
BE165329 BE165332
4132821358147_1BE078159 BE078276 BE078163 BE078277
BE078279 BE078158
4134421370508_1BE140643 BE140645 BE140644 BE140657
BE140660 8E140659 BE140661
4135441375671BE147225 BE147205 BE147234
1
4136051379792BE152644 BE152712 BE152668 BE152659 BE152656 BE152660
1 BE152810 BE152811 BE152816 BE152643 BE152715 BE152662
BE152706
_ BE152669 BE152661 BE152672 BE152653 BE152714 BE152708
BE152716 BE152651 BE152767 BE152677 BE152665 BE152679
BE152652
BE152771 BE152775 BE152666 BE152768 BE152667 BE152814
8E152813 BE15266d BE152676 BE152681 8E152808 BE152711
BE152709
BE152707 8E152815 BE152678 BE152673 BE152778 BE152780
BE152782 BE152671 BE152682 BE152760 BE152762 BE152776
BE152809
BEt52781 BE152774 BE152763 BE152769
4136791382784BE156765 BE156770 BE156767 BE156769 BE156836 BE156792
1 BE156B03 BE156802 BE156847 BE156853 BE156834 BE156779
BE156780
_ BE156789 BE156833 BE156844 BE156831 BE156793 BE156852
BE156849 BE156797 BE156784 BE156801
BE156843
4137581386900BE162391
-1
414070141442AW963783 F36521 F30667 AW753177 AW753195
1 AW853065 AA135150 AA375028
4141951424854BE263293
-3
4142031425510BE262170 BE382553 BE261026 BE273627
2
3 4142661430984_1BE267834 BE514180 BE514096
0
4142761432115BE297862
-1
4143331436492-1BE274897 BE408199 BE274723
4144441446827BE298594
-1
4145391460320BE379046 BE395459
1
35 4145401460324BE379050
-1
4146051465790BE390440
-1
4146101466027_1BE388044 8E391117 BE391530
4146261467232_1BE410589 BE390949 BE408297 BE389529
414642146960AA150350 AA361174 AW959038
1
4146631472628BE396326
-1
4149731510755C19089 C18814 C16621
1
4151601525766T82802 D78670 808505
1
4156061540470W70022 835201 F12763 T74725 H63485
1 245782 H61126
4159171561575243912 H09194
1
45 416272158407AA178882 AA179898 AA178897
1
4164751596398T70298 H58072 802750
1
416913163001AW934714 BE161007 BE162500 AW749902 65 BE161006 BE162d99
1 AW749864 BE162498 BE161005 AA190449
AW5134
417112165068AA193439 AA193537 AW814128
1
417611168900AW993983 AW994798 AW993990 AW993999
1 AW993989 AA204755
417908170764_1AA207221 BE538271
418636177402AW749855 AA225995 AW750208 AW750206
1
4188741799516T60872 T60906
1
d19618186533AA528295 AW971284 AA247945
1
419889188798AA251600 AA279607
1
5 420902197525AA742277 AW976493 AA281585
S 1
422160212412_1AW582898 AA305114
422731220507_1AL138411 AL138412 AA315B60
422831221879_1802504 AA317715 AW961465 AF121172
423050224288AA320946 H92114 BE144449 BE144438
1
423103225019-1AA322029 BE315237
423287226793H38340 H39081 AA324112
1
423621230314BE002904 H64880 AA328679
1
424585241151AA464840 AA343628
1
424995245794245023 AA349514
1
65 425132247059-1AW250114 243124 AA431 d21 A1879054
AA351616 AA351035 AL048999
425612253969BE004257 AW811190 AA360576 BE172402
1 BE181703
425798256586AA364002 A1522307
1
426065260276N32049 834821 878237
1
426356265381BE536836 AA376153
1
426383266126BE537380 BE255215
1
428151287658AA422028 W79191
1
431006326833BE152871 BE152870 AA490552
1
43125733049 AF039597 BE243938
1
431614335668A1189827 AW860554 AW860552 AA508543
1
75 431822338082AA516049 AW004922
1
432966356839AA650114 AW974148 AA572946
1
433300362452AA582307 BE273018
1
433355364004A1808235 A102d295 AA584528
1
433459366899AA593498 AW749647 AW749630
1
433469367263F12741 T75155 AA594014
1
43378237414_1AF090945 AW996754 A1064870
434098380006_1AA625499 AA625269 AA625184
435138401159_1BE314734 AA666393
435478406683_1AA682622 BEid1696
12~
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
436857428068AA732647 BE008970 BE009028
1
43907846841AF085936 N64070 H64017
1
43946547272AF086285 W69587 W69421
1
439848477806AW979249 D63277 AA846968
1
440190_ AW752597 AW848781 AW849062 AW848490 AW752699 AW752604
488021_1AW752700
440669499661AI206964 AI350890 AA902772 AI768881
1
441552520138AA937975 F11215 BE005635
1
44225753699_1AW503831 AW503317 BE565665
443198562655A1039813 AI684642 240121 AI951414 BE501049
1
1 443534572957A1076123 A1244834 A1695239
~ 1
44605265988_1AA358760 AA158850 AW062737 AW062738 AV656291
44659868463_1AW250546 BE257108 BE251006 BE255957 BE250926 BE513012
AV659318
44722471279BE617125
-1
447252714160890916 AL120023 818429 242095 A1369730 890824
1
1 44738371990N24231 BE617964 N36313
1
44777573665-1BE179318 BE620044
44778773719BE620108 BE312062 AW896316 BE262546
1
44821875525_1A1188d89 BE622201
448338758968A1492857 AW070478 A1885157
1
44883878409BE614761 AA263136 W00335 W00327
4
44923180303BE410360 AA442408AA315540
1
45059483962-1N31036 N42915 F07753 AA010329
451400868459BE160479 BE160478 BE0692i1 AW861059 A1793147
1
452544921467AW851888 AW851889 AW852147
1
25 452947_ AW130413 AI932362
939810_1
453758980026083527 AL120938 083522
1
4541631048369AW175997 AW176000 AW175999 AW175994 AW176004 AW175989
1
45417810494581AW177274AW177249AW177223AW177216AW177233
4541811049567AW177377 AW177357 AW177359 AW177385 AW177358 AW177395
1 AW177394 AW177396 AW177383 AW177333 AWi77384 AWi77382
_ . .AW177360 AW177356
4542091051071AW179083 AW179085 AW179087 AW179081 AW179084 AW179086
1 AW179082 AW801493 AW801658 AW801714
4542491073933AW249008 BE295653 BE296765
1
454377114761AA076811 AW814764
1
4544781214744AW805749 AW805872 AW79d466 AW798102 AW796921 AW794538
1 AW794380
3 454485_ AW795322 AW795308 AW795311 AW795310 AW795314 AW795321
S 1215381
1
4545051219564AW801365 AW801435 AW801372
1
4545741225636AW809109 AW809112 AW809122 AW809126 AW809128 AW809133
1 AW809131 AW809113 AW809111 AW809132
4546101226543AW810224 AW810337 AW810295 AW810333 AW810335 AW810296
1 AW816053
4546331227504AW811380 AW811385
1
4546661228600AW812994 AW812723 AW812930
1
4548031235520AW860148 AW862380 AW821887 AW821863 AW821870 AW821894
1 AW862351 AW862378
4549611246745AW847807 AW847935 AW847636
1
4551321254686_1AW857955 AW861636 AW857967 AW857958 AW8579d3 AW857945
AW857963 AW857968 AW857959 AW857961 AW857956 BE072135
AW857972 BE072137 AW857952 AW857935 AW857940 AW857944
AW857947 AW857934
45 4554261289303_1AW937792 BE072250 BE072251 BE072264
4556401348141BE064059 BE063903 BE063838 BE063863 BE064056 BE063974
1 BE063904 BE063898 BE063896 BE063906 BE063980
4556941350650BE067300 BE067293 BE067279
1
4559101382504243712 BE156729 BE156538 BE156731 BE156673 BE156539
1 BE156674 BE156430 BE156672 BE156675 BE156432 BE156541
4559931398665BE179085 BE179084 BE179086 BE179264
1
5 456054_ BE313241 BE3831d8
0 1452761
1
4563291789807T41418 T41320T41379
1
4563941843275W28506
-2
457301314434AA469146 AA469396AA469218 AA469395
1
45802546409A1275406 L23206
1
5 45860665568AJ239397 AV655764
S 1
458640670076A1284935 AWd09822 BE408182
1
45871069727_1AV660856 BE167375
456792748294N56666 A1460076
1
459170920646A1905518 A1905516 A1905457 A1905515 AW176013 AW176037
1
459270969232AL039604 AL039497
1
TABLE
3C:
Pkey: ue
Uniq number
corresponding
to
an
Eos
probeset
Ref: The 7 digit numbers in this column aro Genbank Identifier
Sequence (GI) numbers. "Dunham I. et al." refers to the publication
source. entitled "The DNA sequence of
human
chromosome
22"
Dunham,
et
al.
(1999)
Nature
402:489-495
,
Strand:
Indicates
DNA
strand
from
which
exons
were
predicted
Nt_position:
Indicates
nucleotide
positions
of
predicted
exons
Pkey Ref Strand Nt
position
4004499887692_
Minus 50889-51188
4006139864507Plus 92278-92472
4006348567750Minus 101102-101223,101886-102018
4006428117693Plus 10475-10845
4006618118474Plus 84912-85187
75 4006848118768Plus 58189-58323
4006858118768Minus 72969-73050,73713-73800
4007276705887Plus 106175-107016
4007497331445Minus 9162-9293
4008078567878Plus 69375-70295
4008379188531Plus 144778-144838,145582-145670,146656-146751,147255-
147419,147682-147807
4008421927148Plus 90462-90673
4008481927148Plus 107149-107339,110873-111171
4008919958279Minus 140073-140427
4009177283186Minus 173258-173631
129
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4009317651921Minus142145-142353,144311-144721
4009647139719Minus155282-155403
4009657770576Minus173043-173564
4009707960452Minus92744-92895
4009828078794Minus119245-119471
4010108117391Minus83967-84180
4010723687273Plus 64370-64524
4010888492704Plus 194659-195179
4011169966559Plus 123579-124447
1 4011178570083Minus28948-29204
0
4011679438381Plus 18944-19176
4012049743388Minus33694-33872
4012209929324Minus48079-48279
4012444827300Minus55359-56376
1 4012454827300Minus59373-59531
4012689797154Plus 152272-152483,157312-157418,156025-158205,158838-
156974,160716-160952
4012698954206Plus 2259-2591
4012839800093Minus47256-47456
4013737248205Minus84211-84336
4014057768126Minus69276-69452,69548-69958
4014656682292Plus 25676-25800
4014927341778Plus 171020-171282,171858-172241
4015217705251Plus 9127-9234
4015668469090Minus96277-96420;96979-97160
~
25 4015757229804Minus76253-76364
4015899966292Plus 135969-136263
4016288575954Minus210617-210796 -
4016579100664Minus7312-8163
4017479789672Minus118596-118816,119119-119244,119609-119761,120422-
120990,130161-130381,130468-130593,131097-131258,131866-
3 131932,132451-132575,133580-134011
0
4017577239630Plus 88641-86751
4017807249190Minus28397-28617,28920-29045,29135-29296,29411-29567,29705-
29787,30224-30573
4017817249190Minus83215-83435,83531-83656,83740-83901,84237-84393,84955-
85037,86290-86814
4017857249190Minus165776-165996,166189-166314,166408-166569,167112-
167268,167387-167469,168634-168942
4017897249213Minus70399-70629,70941-71055
4018097342191Minus107548-108298
4018477139731Plus 85447-85593
4018877229981Plus 93973-94120
4019139369520Minus33753-33904
40 4019623176728Minus71433-71648,76711-76833,78677-78845,79585-79763,82349-
82485
4019914156128Plus 2398-2513
4019944153858Minus42904-43124,43211-43336,44607-44763,45199-05281,46337-46732
4020237528158Minus132872-133040
4020666649269Plus 135543-136031
45 4020718117361Plus 85924-86039
4020758117407Plus 121907-122035,122804-122921,124019-124161,124455-
124610,125672-126076
4021317704961Minus33114-33209,33496-33678
4021447242326Plus 115425-115977
4022038576119Minus8124-8285
50 4022772894631Plus 16980-17152,17933-16018,18170-18306
4022922447220Plus 33880-34029,34176-34336,34953-35103
4022976598824Plus 35279-35405,35573-35659
4024073962498Minus115812-116187
4024219796341Minus46609-46662,46758-46811,86293-86346,89776-89829,90048-
90101,102817-102924
5 4024279796372Plus 16266-16431
5
4024309796372Minus62382-62552
4025207596899Minus171761-171996
4025389801137Minus96314-96539
4025439838066Minus89684-90893
60 4025709884747Minus12649-12866
4025859908890Minus174893-175050,183210-183435
4026399958129Minus20167-22383
4026948569867Plus 2218-2440
4026998570304Minus182773-182883,184551-184732
65 4027387331557Minus8725-8859
4028559662953Minus59763-59909
4028696434643Minus138639-139335
4029399187334Minus18329-18535
4029449368423Plus 110411-110716,111173-111640
70 4029489368458Minus143456-143626,143808-143935
4029589368493Plus 13324-13507
4030103132346Plus 78365-79052
4030363132360Plus 66545-66712
4030514827080Minus5269-5411
7S 4030658954197Minus71615-71773,73930-74144
4030778954241Plus 146923-147222,147326-147628
4030938954241Plus 177083-177373,177464-177751
4031517407965Minus14055-14264
4031539799871Minus42232-43389
g 4031779838213Minus142560-142726
0
4032237630969Plus 81529-81692
4032347637801Plus 180641-180822
4032738018055Plus 133809-134099
4032868080320Plus 118369-118872
130
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4032878080320Minus126097-126411
4033487239527Plus 13809-13968
4033598570207Minus108939-109229
4033628571772Plus 64099-64260
4034479837821Minus159072-159387
4035087630896Plus 5570-5719
4035828101186Plus 18308-18458
4036138493504Plus 81290-81465
4036428699671Plus 7062-7311
1 4036625823349Plus 58627-59062,59222-59548
~
4036747321642Plus 104988-105623,107394-107590
403687738738dPlus 9009-9534
4036953046276Plus 168272-168514
4037034966380Plus 83681-84042
1 4037417630932Minus2833-3468
4037477658395Minus20493-20621
4037667229888Plus 136283-136830
4037868083636Minus73028-73217
4037968099896Minus75073-77664
403833887461Plus 13522-13664
d038527708872Minus124007-124202
4038617708966Plus 58363-58649
4039127710730Minus72000-72290,72431-72700,72929-73199
4039247711688Minus89369-89592
25 4039647596976Plus 178174-178300
-
4040348567760Minus44635-47010
'
4040673282162Plus 1415-2071
4040977770701Plus 55512-55781
4041229796270Plus 90540-92977
4042307981448Minus92934-93093
4042395002624Plus 94841-95095
4042405002624Minus116132-116407,116653-116922
4042709626129Minus3649-3750,4161-4306,5962-6049,6849-6965
4043567630858Minus126433-126623
3 4046008705107Plus 118354-118444,118649-118792
5
4046018705107Plus 128449-128693,129085-129249,130525-130733
4046389796751Minus99433-99528,100035-100161
4046667272179Minus18677-18993
4046759797204Minus48532-48645,49808-49975,51088-51369,54944-55063
40 4047278081050Plus 115534-115747
4047507596836Plus 181879-182198
4047637882612Plus 50981-51392
4047677882827Minus23244-23759
4048286580415Minus26291-27253
45 4048505420148Minus35145-35413,40635-41062
4048815931510Minus36360-36608
4048907329390Plus 101280-101408
4049713212939Minus74585-75532
4050227330304Plus 217163-217439
5 4050287533974Minus110588-110847,110933-111115
0
4050717708797Minus11115-11552
4050888072518Minus115690-117621
4051338516055Minus28127-28288
4051388576241Plus 90303-90516
5 4051837209940Plus 12335-12653
5
4051947230072Plus 190465-190645,193346-193610
4051967230083Minus135716-135851
4052087230142Plus 8068-8214
4052267248966Plus 53547-54128
4052276731245Minus22550-22802
4052567329310Plus 26070-26309
4052773980473Plus 23471-23572
4053073638954Plus 39195-39429
4053113638954Plus 46313-46496
65 4053333165399Plus 149905-150215
4054113451356Minus17503-17778,18021-18290
4054234753276Plus 6162-6983
4054915801645Plus 81857-82045
4055019211311Minus49085-49400,49565-49679,50117-50262
4055159454624Plus 37329-37469
4055451054740Plus 118677-118807,119091-119296,121626-121823
4055804512267Plus 169232-169647
4055865002511Plus 38810-39017
4056005923640Plus 26662-27225
7 4056105757553Minus71907-72080
5
4056395091650Plus 211184-211350
4056876249668Minus54787-54891,55844-55917
4056994165331Plus 100727-100859
4057835138434Minus27238-27885
4058676758731Minus74553-75173
4060867107817Plus 9418-9573
4061249149714Minus1331-1774
4061309161404Minus32394-32498
4061409168231Minus49887-50219
131
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
406160 7144945Plus55498-56268
406207 5923650Minus162607-162800
406215 7342161Plus310-432
406268 6682695Minus6605-7072
406277 5686030Minus4759-5490
406326 9212385Plus84508-84655
406388 9256205Plus85153-85277
406457 9755793Plus44966-45406
406473 9795566Minus109669-109931
4065377711478Plus32904-33017
d06571 7711622Minus65634-65912,66116-66596
406580 7711838Minus96654-97640
TABLE 4A lists about 131 genes up-regulated in ovarian cancer compared to
normal ovaries that are likely to be extracellular or cell-surface proteins.
These were selected as for
Table 3A, except that the ratio was greater than or equal to 10, and the
predicted protein contained a PFAM domain that is indicitive of extracellular
localization.
TABLE
4A:
ABOUT131
UP-REGULATED
GENES
ENCODING
EXTRACELLULARICELL
SURFACE
PROTEINS,
OVARIAN
CANCER
VERSUS
NORMAL
OVARY
Pkey:
Primekey
Ex. Exemplar
Accn:Accession
UG
ID:
UniGene
ID
Title:
Unigene
Title
PFAM
domains
ratio:
tumor
vs.
normal
ovary
2
j
Pkey Ex. UG Title PFAM ratio
Accn ID
403077 predicted exon fn3 15.0
426535AU077012Hs.288582ESTs, Weakly similarKunitz_BPTI 14.9
to ubiquitous
TP
403089 predicted exon fi3 14.9
3~ 457148AF091035Hs.184627KIAA0118protein arf;ras 14.8
431176A1026984Hs.293662ESTs laminin EGF;laminin14.8
B;
434293NM Hs.3796Eph86 fn3;pkinase;EPH_Ibd14.8
004445
408482NM Hs.45743adenosine A2b receptor7tm_1 14.6
000676
428695AI355647Hs.189999purinergic receptor7tm 1 14.5
(family A group
5)
35 426125X87241Hs.166994FAT tumor suppressorEGF 14.4
(Drosophila) ho
423732AF058056Hs.132183solute carver familysugar-tr;MCT 14.3
16 (monocarboxy
422125NM-003459Hs.111967solute carver familyCation efflux 14.2
30 (zinc transporfe~
407483NM_012368 (NONE) 7tm 1 14.2
'
446689AW594695Hs.167046ESTs 7tm 1 14.1
410184AW503667Hs.59545ring finger proteinzf-C3HC4;SPRY;zf-B14.0
15 box
423217NM Hs.1640collagen, type fn3;vwa 14.0
000094 VII, alpha 1 (epidermoly
405448A10i5709Hs.172089Homo sapiens mRNA;trypsin;sushi;CUB14.0
cDNA DKFZpS
450684AA872605Hs.25333intedeukin 1 receptor,1g 14.0
type II
406692L36607 gb:Homo sapiens 1g 13.9
(clone 22) pregnancy
45 425549U64863Hs.158297programmed cell 1g 13.8
death 1
452755AW138937Hs.213436ESTs cystatin 13.8
427637AK000816Hs.179986flotillin 1 Band 7 13.7
424591855704Hs.150968hypocretin (orexin)7tm 1 13.7
receptor 1
405024 predicted exon TGF-beta;TGFb_propeptide13.7
405285 predicted exon A2M;A2M-N 13.7
412116AW402i66Hs.784Epstein-Barrvims 7tm_i 13.7
induced gene 2
(lym
420256U84722Hs.76206cadherin 5, type cadherin;Cadherin_C13.6
2, VE-cadherin Term
(vascu
420511AF052692Hs.98485gapjunc6on protein,connexin 13.5
beta 4 (connexin
3
448638817122Hs.21639nuclear protein, 1g 13.4
marker far differon6at
55 431117AF003522Hs.250500delta (Drosophila)-likeEGF;DSL 13.4
1
439285AL133916Hs.298998ESTs ig;pkinase;LRRNT;LRRGT13.4
424283AA338246Hs.301678ESTs E1-E2_ATPase;Hydrolase13.3
436233Ah42878Hs.124116ESTs 1g 13.3
443859NM Hs.9914follista6n kazal 13.2
013409
410016AA297977Hs.57907small inducible IL8 13.2
cytokine subfamily
A,(
414020NM-002984Hs.75703small inducible IL8 13.2
cytokine A4 (homologo
400242 predicted exon Ephrin 13.0
429057AF156557Hs.194816stomatin-like proteinBand 7;SCP2 12.9
1
438294AI693753Hs.143004ESTs E1-E2_ATPase;Hydrclase12.9
65 458493AV649408Hs.282418ESTs RYDR_ITPR 12.8
444181A8033063Hs.10491KIAA1237 protein fi3;ig;PH;RhoGEF12.8
422357AF016272Hs.115418cadherin 16, KSP-cadherincadherin 12.7
409632W74001Hs.55279sedne (or cysteine)serpin 12.7
proteinase inhibitor
407000U12139 gb:Human alphat(XI)TSPN;CoIlagen;COLFI12.6
collagen (COL1
70 417064W02903Hs.15440ESTs lectin c 12.6
439389AA318940Hs.56004ESTs hemopexin;Peptidase-M1012.6
407786AA687538Hs.38972tetraspan 1 transmembrane4 12.5
410498AA355749 gb:EST64459 Jurkataa~ermeases 12.5
T-cells VI Homo
422487AJ010901Hs.198267mucin 4, tracheobronchialvwd 12.5
75 422330D30783Hs.115263epiregulin EGF 12.5
402425 predicted exon ion_trans 12.4
414875H42679Hs.77522major histocompatibilily1g 12.2
complex, clas
424239M67439Hs.143526dopamine receptor 7tm 1 12.2
D5
442622NM-000435Hs.8546Notch (Drosophila)EGF;ank;notch 12.2
homolog 3
405368 predicted exon 7tm 1 12.2
402406 predicted exon Gal-bind IecGn 12.1
426514BE616633Hs.301122bone morphogeneticTGF-beta;TGFb_propepGde12.1
protein 7 (osteoge
406811U82979Hs.67846leukocyte immunoglobulin-like1g 12.0
recepto
416441BE407197 gb:601301552F1 SDF 12.0
NIH_MGC-21 Homo
132
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
433221AB040917Hs.97860KIAAi484protein fi3;ig;LRRCT 11.9
442915AA852875Hs.8850a disintegrin and disintegrin;Reprolysin;11.9
metalloproleinase
dom
423613AF036035Hs.129910hyaluronoglucosaminidaseig;Sema;AcetylUansf11.9
3
411213AA676939Hs.69285neuropilin 1 CUB;MAM;F5 F8_type11.9
C
S 425483AF231022Hs.301273Homo sapiens protocadherin_ 11.8
Fat2 (FA EGF;cadherin;laminin-G
421258AA286731 gb:zs53dO8.r1 NCI 7trrL3 11.8
CGAP-GCB1 Hom
423795AW849759 gb:IL3-CT021fi-240200-077-C04arf;ras 11.7
CTO
422424AI186431Hs.116577prostate differentiationTGF-beta 11.7
factor
443296AI765286 gb:wi73b05.x1 NCI 1g 11.7
CGAP_Kidl2 Ho
1 448999AF179274Hs.22791transmembrane proteinkazal 11.7
~ with EGF-like
414878AA341040Hs.77541ADP-ribosylalion arf;ras 11:5
factor 5
429344894036Hs.199538inhibin, beta C TGF-beta 11.5
402114 predicted exon laminin-EGF;laminin-G11.5
419216AU076718Hs.164021small inducible IL8 11.5
cytokine subfamily
B (
~
1 430263D12614Hs.36lyphotoxin alpha TNF 11.4
S (TNF superfamily,
m
400464 predicted exon Peptidase-S9 11.4
456841AA875863Hs.152345poliovirus receptor-related1g 11.4
1 (herpesvir
409420215008Hs.54451laminin, gamma laminin-EGF;laminin-B11.4
2 (nicein (100kD),
kal
418043AW377752Hs.83341H.sapiens mRNA fn3;ig;pkinase 11.3
for tyrosine kinase
re
426523S68616Hs.170222solute carver familyNa H Exchanger 11.3
9 (sodiumlhydrog
446051BE048061Hs.153315ESTs Reprolysin;disintegrin11.3
439710AF086543 gb:Homo sapiens Xlink 11.3
full length insert
cDN
416602NM Hs.79389net (chicken)-likevwc;TSPN 11.3
006159 2
418299AA279530Hs.83968inlegrin, beta integrin-B 11.3
2 (anfigen CD18
(p95), 1y
ZS 425721AC002115Hs.159309uroplakin 1A, Uansmembrane4;COX6B;Ets11.2
409757NM Hs.123114cystatin SN cystatin 11.2
001898
430630AW269920Hs.2621cystatin A (stefin7tm-3;ANF receptor11.2
A)
429630M85289Hs.211573heparan sulfate laminin-EGF,ig;ldf_recept-a11.1
proteoglycan 2
(perleca
427289A1097346Hs.174203solute cartierfamilySDF 11.1
1 (glutamatelneutr
3~ 401248AB028989Hs.88500mitogen-activated vwa;vwd;TIL 11.1
protein kinase
8 tote
412627BE391959Hs.74276chloride intracellularchannellG-patch;ig;MutS11.1
C
420104U09825Hs.1287zinc fingerprotein173zf-C3HC4;SPRY;zf-B11.1
box
405275AB028989Hs.88500mitogen-activated vwa;vwd;TIL 11.1
protein kinase
8 tote
425864U56420Hs.159903olfactory receptor,7tm 1 11.1
family 5, subfamily
3S 446745AW118189Hs.156400ESTs vwa 11.1
441834AL138034Hs.7979KIAA0736 gene productsugar_tr 11.0
450986BE241845Hs.25744Novel human gene PH;RhoGAP;GaI-bind11.0
mapping to chomos lectin
416118N52773Hs.167721ESTs hemopexin;Peptidase_M1011.0
443071AL080021Hs.8986complement componentClq;Collagen 10.9
1, q subcompo
431247AL021578Hs.278489matrilin 4 EGF;vwa 10.9
431449M55994Hs.256278tumor necrosis TNFF~c6 10.9
factor receptor
superfam
457044S73899Hs.2i31arginine vasopressin7tm_1 10.9
receptor 1A
416319AI815601Hs.79197CD83 antigen (activatedtg 10.8
B lymphocyte
402172 predicted exon 1g 10.7
4S 424218AF031824Hs.143212cystatin F (leukocystafin)cystatin 10.6
409208Y00093Hs.51077integrin, alpha vwa 10.6
X (antigen CD11
C (p15
426330M77235Hs.169331sodium channel, ion lrans;l4 10.6
voltage-gated,
type V,
439758AA845235Hs.124470ESTs transmembrane4 10.6
412429AV650262Hs.75765GR02oncogene IL8 10.6
S~ 449987AW079749Hs.184719ESTs,WeaklysimilartoAF11672111ABC-
tran;ABC_membrane10.6
432408N39127Hs.76391myxovirus (influenza)ion trans;K-tetra10.6
resistance 1,
hom
406672M26041Hs.198253major histocompafibilityig;MHC_II_alpha10.5
complex, clas
419749X73608Hs.93029sparclosteonectin,kazal;thyroglobulirLl10:5
cwcv and kazal-like
419086NM Hs.89591Kallmann syndrome fn3;wap 10.5
000216 t sequence
S 425009X58288Hs.154151protein tyrosine fi3;ig;Y~hosphalase;MAM10.5
S phosphatase, receptor
t
423869BE409301Hs.134012C1q-related factorGTP_EFTU;EFG_C 10.4
430209AF177941Hs.235368Pro-(alpha)3(u) Collagen;COLFI;TSPN10.4
collagen
400834 predicted exon IRK 10.4
442941AU076728Hs.8867cysteine-~ch, angiogenicCys knot;tsp_l;vwc;IGFBP10.4
inducer, 61
403691 predicted exon tsp-l;Reprolysin;10.4
430776AJOt Hs.247905potassium voltage~gatedion traps 10.3
1021 channel, subfa
432342AL036128Hs.274404plasminogen activator,EGF;fnl;kringle;irypsin10.3
tissue
413731BE243845Hs.75511connecfive tissue Cys knot;lsp-l;vwc10.3
growth factor
423309BE006775Hs.126782sushi-repeat proteinsushi;HYR 10.3
6S 431728NM-007351Hs.268107mulfimerin EGF;CIq 10.3
450245AA007536Hs.271767ESTs, Moderately 1g 10.2
similar to ALU1
HU
446983AA157484Hs.97199complement componentClqreceptorEGF;XIink 10.2
414320U13616Hs.75893ankyrin 3, node death;ank;ZU5 10.1
of Ranvier (ankyrin
G)
400253 predicted exon 7tm-1 10.0
406694M94891Hs.225932pregnancy specific1g 10.0
beta-1-glycoprolein
418793AW382987Hs.88474prostaglandin-endoperoxideEGF 10.0
synthase 1
410664NM Hs.65370lipase, endothelialRibosomal_L22 10.0
006033
427274NM_005211Hs.174142colony sfimulatingpkinase;ig 10.0
factor t receptor,
fo
7S TABLE 4B:
Pkey: Unique Eos probeset idenfifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers
Pkey CAT Number Accession
410498 120611 1 AA355749 AA085520 AW966333 AA340319 BE170936
416441 159480 1 BE407197 AA182474 AAi 80369 BE275628 BE276131
421258 200725 1 AA286731 AA287621 AW188228AW137774
423795 232093_1 AW849759 AW849758 T89549 AA331069
133
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
439710 AF086543 W96291 W96225
47550
1
443296 AI765286AW297086BE568658
56539-2
TABLE 4C:
Pkey: Uniquecorresponding to an Eos probeset
number
Ref: Sequence. The 7 digit numbers in this column are Genbank Identifier
source (GI) numbers. Dunham I. et al." refers to the publication
entitled "The DNA sequence of
human chromosome
22" Ounham,
et al.
(1999)
Nature
402:489-495
Strand:
Indicates
DNA strand
from which
exons
were predicted
Nt_position:nucleotide positions of predicted exons
Indicates
l
0
Pkey Ref Strand Nt_position
d00464 Plus 22074-22214
9929670
400834 Plus 121963-122288
8705192
402114 Plus 71578-71715
8318586
1 402172 Minus 143378-143671
8575911
402406 Plus 10872-11123,12932-13048
3970929
402425 Minus 50224-50395
9796347
403077 Plus 146923-147222,147326-147628
8954241
403089 Plus 171964-172239
8954241
403691 Minus 88280-88463
7387384
405024 Plus 88500-88697
7107727
405285 Minus 55744-55903,57080-57170,61478-61560
6139075
405368 Plus 46055-47188
2104517
TABLE 5A lists gbout 685 genes down-regulated in ovarian cancer compared to
normal ovaries. These were selected as for Table 3A, except that the numerator
and
denominator were switched, and the ratio was greater than or equal to 3.0
(1.e. 3-fold down-regulated in tumor vs. normal ovary).
TABLE
5A:
68S
DOWN-REGULATED
GENES,
OVARIAN
CANCER
VERSUS
NORMAL
OVARY
Pkey:
Primekey
Ex. Exemplar
Accn:Accession
UG
ID:
UniGene
ID
Title:
UniGene
Title
ratio:
ration
normal
ovary
vs
tumor
3
5
PkeyEx. UG Title ratio
Accn ID
421013M62397Hs.1345mutated in colorectal 14.8
cancers
439360AA448488Hs.55346ESTs, Weakly similar 12.8
to Zi41 HUMAN ZINC FINGE
407644D168i5Hs.37288nuclear receptor subfamily12.6
1, group D, member 2
40 424851AA676441Hs.119059ESTs 11.6
455056AW853057 gb:RC1-CT0249-170200-025-h0411.5
CT0249 Homo sapie
420727H75701Hs.99886complement component 11.3
4-binding protein, beta
451617C01056Hs.168000ESTs 10.0
'
401308 predicted exon 9.9
45 440987AA911705Hs.130229ESTs 9.7
409725T40760Hs.90459EST 9.7
415752BE314524Hs.78776putative transmembrane 9.7
protein
437690AA804362Hs.180544ESTs 9.6
437787A1908263Hs.29i625ESTs 9.5
459054AW798466Hs.823962',5'-oligoadenylate 9.2
synthetase 1
435330816769Hs.185689ESTs 9.2
436642AA724430Hs.127960ESTs 9.1
453752AL120800 gb:DKFZp762E152-rt 762 9.1
(synonym: hmel2) Homo
so
451683AI808964Hs.207673ESTs 9.1
5 d01464AF039241Hs.9028histone deacetylase 5 9.0
5
436812AW298067 gb:Ul-H-BWO-ajp-g-09-0-Ul.si8.7
NCI CGAP_Sub6 Hom
410758BE535988 gb:601062418F1 NIH-MGC-108.7
Homo sapiens cDNA
412637AA115097Hs.261313ESTs 8.4
419166AA234638Hs.293584ESTs 8.3
423739AA398155Hs.97600ESTs 8.1
413813M96956Hs.75561teratocarcinoma-delved 8.1
growth factor 1
416211814625 gb:yg45c03.r1 Soares 8.0
infant brain 1 NIB Homo
Sapiens
443131A1033833Hs.132689ESTs 7.9
415Bfi6T10115Hs.92423KIAA1566 protein 7.9
65 410130AI912097Hs.163208ESTs 7.9
439426A113i502Hs.f43135ESTs, Weaktysimilarto 7.8
FAFY-HUMAN PROBABLE
408141069205Hs.45152ESTs, Moderately similar7.7
to neurogenic basic-helix-loop
419015T79262Hs.14463ESTs 7.6
441573BE563966Hs.6529ESTs 7.5
419386AA236867Hs.143868ESTs 7.5
430562D78260Hs.285097ESTs 7.5
434738AA836265 gb:od17e02.s1 NCI_CGAP_GCB17.4
Homosapiens cDNA
403283 predicted exon 7.4
415861Zd3123Hs.144513ESTs 7.4
75 412732AW993300 gb:RC2-BN0033-180200-015-g067.4
BN0033 Homo sapie
441247AW118681Hs.128051ESTs 7.4
442865N57659Hs.114541ESTs, Weakly similario 7.3
neuronal thread protein
AD7C-
409699BE154650 gb:PM3-HT0344-071299-003c087.3
HT0344 Homo sapie
420352BE258835 gb:601117374F1 NIH MGC_167.3
Homo Sapiens cDNA
421418AA806639' gb:ob88g05.s1 NCI-CGAP_GCB17.2
Homo Sapiens cDN
413597AW302885Hs.117183ESTs 7.2
454102AW752363 gb:RCO-CT0201-270999-011-f037.1
CT0201 Homo sapien
445487AI806287Hs.201217ESTs 7.1
457604A1004397Hs.130558ESTs, Weakly similar 7.1
to similar to 0-sialoglycoprotein
134
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
400942 predicted exon 6.9
407596886913 gb:yq30f05.r1 Soares 6.9
fetal liver spleen 1NFLS
Homo so
422046AI638562 gbas50at0.x1 NCI-CGAF-Ut16.9
Homo Sapiens cDNA c
441284AA927676Hs.196542ESTs 6.9
446224AW450551Hs.13308ESTs 6.9
424943AU077260Hs.153924death-associated protein6.9
kinase 1
453967AW009077Hs.232947ESTs 6.9
448683AA167642Hs.14632ESTs 6.8
431877AA521204Hs.105507ESTs 6.8
1 411337AW837349 gb:QV2-LT0038-270300-108-4126.8
0 LT0038 Homo sapie
410596AA374186 gb:EST86290 HSC172 cells6.8
I Homo Sapiens cDNA
5' a
417762AA205976 gb:zq48a10.r1 Stratagene6.7
hNT neuron (937233)
Homo
406364 predicted exon 6.7
452238F01811Hs.187931ESTs, Moderately similar6.7
to S22703 voltage-gated
pota
15 415288815794Hs.141027ESTs, Weakly similar 6.7
to ALUi HUMAN ALU SUBFA
407437AF220264 gb:Homo Sapiens MOST-1 6.7
mRNA, complete cds.
439126AF085984 gb:Homo Sapiens full 6.6
length insert cDNA clone
YT99F
452453AI9D2519 gb:OV-BT009-101198-051 6.6
BT009 Homo Sapiens cDNA
431800AW452768Hs.162045ESTs 6.5
426380AI291267Hs.149990ESTs, Weakly similar 6.5
to unnamed protein product
[H.sa
449529AI990559Hs.232033ESTs 6.4
437755AW204256Hs.291887ESTs 6.4
448307AI480289Hs.211026ESTs 6.4
439586AA922936Hs.110039ESTs 6.4
420051N35696Hs.44745ESTs 6.4
425806AI522299Hs.173369ESTs ~ 6.4
433923A1823453Hs.146625ESTs 6.4
408159H63977Hs.118526ESTs 6.3
434844AF157116Hs.301355hypothetical protein 6.3
LOC56757
3 430197AA468888Hs.187697ESTs, Weakly similar 6.3
~ to ALU5_HUMAN ALU SUBFA
440332AI218517Hs.188051ESTs 6.3
450061A1797034Hs.201115ESTs 6.3
454994AW850176 gb:IL3-CT0219-271099-022-H046.3
CT0219 Homo sapien
402105 predicted exon 6.3
3 409090W56067Hs.103105ESTs 6.2
405752 predicted exon 6.2
408074820723Hs.124764ESTs 6.2
459200Y09306Hs.30148homeodomain-interacting 6.1
protein kinase 3
416310T81421Hs.221396ESTs 6.1
421976AL138443Hs.23450mRNA for FLJ00023 protein6.1
429755NM_001364Hs.215839discs, large (Drosophila)6.0
homolog 2 (chapsyn-110)
448732BE614063 gb:601503993F1 NIN-MGC-716.0
Homo sapiens cDNA
453909AW004045Hs.203365ESTs 6.0
431178AA493884Hs.218008Homo Sapiens cDNA: FLJ214406.0
tis, clone COL04389
45 449671AW959755Hs.288896Homo sapiens cDNA FLJ129776.0
fis, clone NT2RP20062
421349W01715Hs.102958ESTs, Weakly similar 6.0
to Lpg6p [S.cerevisiae)
453282AK000043Hs.32922hypothetical protein 5.9
FLJ20036
420618AA278781Hs.280698ESTs 5.9
412480~E142364 gb:CMO-HT0143-270999-062-4125.9
HT0143 Homo sapi
449858AW205979Hs.196065ESTs 5.9
429884AL049925Hs.225984DKFZP547G0910 protein 5.9
416453H56968Hs.114593ESTs 5.9
459497AA825742Hs.87517ESTs 5.9
433773AA759293Hs.112692ESTs 5.9
55 458942AA009647Hs.8850a disintegrin and metalloproteinase5.9
domain 12 (meltrin a
436054A1076262Hs.119813ESTs 5.9
410495N95428 gb:zb80d09.s1 Soares 5.8
senescent fibroblasts_NbHSF
H
403277 predicted exon 5.8
444302AI140115Hs.225130ESTs 5.8
439834A1754576Hs.124523ESTs 5.8
404020 predicted exon 5.8
454338AW381251Hs.1050pleckstdn homology, Sec75.7
and coiledlcoil domains
1(cy
430922AW373747Hs.183337ESTs 5.7
420269N55394Hs.963988-oxoguanine DNA glycosylase5.7
65 428498AA429575Hs.243032ESTs 5.7
445597H65649 gb:yr72d10.r1 Soares 5.7
fetal liver spleen 1NFLS
Homo so
411543AW85i248 gb:IL3-CT0220-160200-066-F015.7
CT0220 Homo sapien
408354A1382803Hs.159235ESTs 5.7
444431AW513324Hs.42280ESTs 5.7
406605 predicted exon 5.7
405541AF039241Hs.9028histone deacetylase 5 5.6
458090A1282149Hs.56213ESTs, Highly similar 5.6
to FXD3_HUMAN FORKHEAD
454529245439Hs.270425ESTs 5.6
445632A1261545 gb:qz30a07.x1 NCI-CGAP-Kidt5.6
1 Homo sapiens cDNA
75 441223AI475067Hs.132499ESTs 5.6
432552A1537170Hs.173725ESTs, Weakly similar 5.6
to ALUB-HUMAN ALU SUBFA
443650AI698330Hs.151444ESTs 5.6
403714 predicted exon 5.6
444165AL137443Hs.10441hypotheticalprotein FLJ112365.6
458914BE327696Hs.280922ESTs 5.6
420620AA278807Hs.173343ESTs 5.5
458228AA934995Hs.184846ESTs,WeaklysimilartoR288301[H.sapiens[5.5
448067868568Hs.183373src homology 3 domain-containing5.5
protein HIP-55
427000AI187420Hs.145221ESTs 5.5
135
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
452351AA025647 gb:ze85d01.r1 Soares 5.5
fetal heart_NbHHI9W
Homo sa
459359N99545 gb:za40a05.r1 Soares 5.5
fetal liver spleen 1
NFLS Homo sa
408385AF055634Hs.44553unc5(C.elegans homolog)c5.5
450938AW753734Hs.277215ESTs 5.5
431888H99557Hs.2864early endosome antigen 5.4
1, 162kD
459418W96550Hs.26418ESTs 5.4
416718883017Hs.204828ESTs 5.4
413236H16442Hs.127376KIAA0266 gene product 5.4
439063AF085922Hs.113968ESTs 5.4
1 446361A1291234Hs.282241ESTs 5.4
~
458253AW296952Hs.196802ESTs ' 5.4
433682AA642418Hs.17381ESTs 5.4
455790BE090690 gb:RC1-BT0720-280300-011-g025.4
BT0720 Homo sapie
445755AW294870Hs.223672ESTs 5.3
1 436513AJ278110Hs.125507DEAD-box protein 5.3
416671N94087Hs.26073ESTs, Moderately similar5.3
to HG14-HUMAN NONHIS
440231AW015420Hs.163323ESTs 5.3
429866AA460104Hs.99540ESTs 5.3
437779AA345232Hs.21227ESTs 5.3
2~ 424029AB014594Hs.i37579KIAA0694 gene product 5.3
425614A1334963Hs.156256ESTs 5.3
430653AW902062Hs.30280ESTs 5.2
d08855T83061Hs.279604desmin 5.2
410454AW749041 gb:RC3-BT0319-100100-012-c055.2
BT0319 Homo sapie
438116AI904105Hs.122016ESTs 5.2
409138W73159Hs.58290ESTs ' 5.2
423047NM Hs.123064H1 histone family, member5.2
005323 T (testis-specific)
440212AW300959Hs.126216ESTs, Weakly similar 5.2
to good similarity to
E. coli hypo
404108 predicted exon 5.2
3 456253T12198 gb:A588F Heart Homo Sapiens5.2
0 cDNA clone A588, mRN
409365AA702376Hs.226440Homo Sapiens clone 248815.1
mRNA sequence
444013T08531Hs.44404hypothetical protein 5.1
PR01488
454071A1041793Hs.42502ESTs 5.1
419761M17373Hs.93177interferon,beta l,fibroblast5.1
35 451250AA491275Hs.236940Homo Sapiens cDNA FLJ125425.1
fis, clone NT2RM4000
405290 predicted exon 5.1
454487AW796342. gb:PM2-UM0027-230200-002-h025.1
UM0027 Homo sap
444131AI80660UHs.207119EST, Weakly similar to 5.1
intrinsic factor-B12
receptor pr
441679BE502267Hs.65996ESTs 5.1
450077AA523752Hs.120855ESTs 5.1
421209AJ010230Hs.102576retfinger protein-like 5.1
1 anGsense
445140AI650599Hs.i97913ESTs 5.1
421126M74587Hs.102122insulin-like growth factor5.1
binding protein 1
447037AI357568Hs.157612ESTs 5.f
45 407168845175 gb:yg40f01.si Soares 5.0
infant brain 1 NIB Homo
Sapiens
436196AK001084 gb:Homo sapiens cDNA 5.0
FLJ10222 fis, clone
HEMBBi
442772AW503680Hs.300513ESTs, Weakly similar 5.0
to T15B7.2 (C.elegansj
444138AI701572Hs.151153ESTs 5.0
458589AV654623Hs.288141Homo Sapiens cDNA FLJ130165.0
fis, clone NT2RP30006
S 451640AA195601Hs.26771Human DNA sequence from 5.0
o clone 747H23 on chromos
441318A1078234Hs.176130ESTs 5.0
407490S79281 gb:pancreaGc ribonuclease4.9
[human, mRNA Recombinan
438224AA933999 gb:on91f04.s1 Soares 4.9
NFL-T-GBC_S1 Homo Sapiens
451638AW798466Hs.823962',5'-oligoadenylate 4.9
synthetase 1
5 457356AA489621Hs.191670ESTs 4.9
5
430679844428Hs.22801ESTs 4.9
445747A1820863Hs.145328ESTs, Weakly similar 4.9
to ALU1 HUMAN ALU SUBFA
409036T88693Hs.226410ESTs 4.9
433382T64293Hs.291453ESTs 4.9
401287 predicted exon 4.9
424188AW954552Hs.142634zinc finger protein 4.9
404868 predicted exon 4.9
410152AW593104Hs.23681ESTs 4.9
444997A1204451Hs.146196ESTs 4.9
65 4310758E267477 gb:601189542F2 NIH MGC-74.8
Homo Sapiens cDNA c1
429033NM-007374Hs.194756sine oculis homeobox 4.8
(Drosophila) homolog
6
414337BE386606 gb:601273980F1 NIH MGC d.8
20 Homo Sapiens cDNA
410336BE391510Hs.18498Homo sapiens cDNA FLJ122774.8
fis, clone MAMMA10
445283AW515763Hs.246872ESTs 4.8
434792AA649253Hs.132458ESTs 4.8
433403AF040247 gb:Homo Sapiens erythroid4.8
differentiation-related
factor
454940AW846202 gb:OVO-CT0179-011299-061-f104.8
CT0179 Homo sapie
455534AW991925 gb:PM3-BN0011-130100-002-b074.8
BN0011 Homo sapi
416437N48990Hs.37204ESTs 4.8
7S 433767AA609245 gb:af13a11.s1 Soares 4.8
tests NHT Homo Sapiens
cDNA
434977AI734233Hs.226142ESTs, Weakly similar 4.8
to ALU7-HUMAN ALU SUBFA
416192NM Hs.998peroxisome proliferative4.8
005036 activated receptor,
alpha
459218AA812633Ns.10845ESTs 4.8
402109 predicted exon 4.8
0 444490Ai151080Hs.146830ESTs 4.8
432632AW973801Hs.134656ESTs 4.8
438683AA813982Hs.291842ESTs 4.8
404044 predicted exon 4.8
449862AI672277Hs.199475ESTs 4.8
136
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
419002T78625Hs.268594ESTs 4.7
425582AL157686Hs.293737ESTs 4.7
416086H18252Hs.227263ESTs 4.7
441133AA918191Hs.194457ESTs 4.7
446323A1288274Hs.149868ESTs .
4.7
440347A1125590Hs.142864ESTs 4.7
439481AF086294Hs.125844ESTs 4.6
456388W28557 gb:48d8 Human refina 4.6
cDNA randomly primed
sublibra
441864834177Hs.181315ESTs, Moderately similar4.6
to ALU4-HUMAN ALU SU
1 445910893483Hs.260273ESTs 4.6
~
403531 predicted exon 4.6
429773AI332482Hs.218791proteoglycan 4, (megakaryocyte4.6
sfimulating factor,
arfic
422563BE299342Hs.19348Homo sapiens cDNA FLJ131194.6
fis, clone NT2RP30026
422890243784Hs.78713solu(e comer family 25 4.6
(mitochonddal carrfer;
phospha
1 453663AL048807Hs.180714cytochrome c oxidase 4.6
S subunit Vla polypeptide
1
447839N72050Hs.164144ESTs 4.5
415612F12893Hs.13301ESTs 4.5
433371T25451 gb:PTH1188 HTGDL1 Homo 4.5
Sapiens cDNA 5'13' simila
410667AW936099 gb:OVO-DT0020-210100-095-d044.5
DT0020 Homo sapie
410890AW809575 gb:MR4-ST0121-060200-002-a124.5
ST0121 Homo sapie
404451 predicted exon 4.5
441705A1087052Hs.55993ESTs 4.5
439597W79579Hs.58552ESTs 4.5
407825NM Hs.d0202lymphoid-restricted membrane4.5
006152 protein
25 423073BE252922Hs.123119MAD (mothers against 4.5
decapentaplegic, Drosophila)
ho
456278BE300369Hs.42643ESTs, Weakly similar 4.5
to KIAA1016 protein
[H.sapiens
424719H90452 gb:yv01c03.r1 Soares 4.5
fetal liver spleen 1
NFLS Homo so
439542AW297571Hs.17646ESTs 4.5
444433AV649844Hs.282436ESTs 4.5
3~ 438831BE263273Hs.301128ESTs 4.5
410065AW812744 gb:RC3-ST0186-181099-012-c094.5
ST0186 Homo sapien
453895AA039843Hs.61948ESTs 4.5
458250AI807339Hs.152174ESTs, Weakly similar 4.5
to 2140 HUMAN ZINC FINGE
423403AA325483 gb:EST28475 Cerebellum 4.5
II Homo sapiens cDNA
5' en
3 454679AW813110 gb:CM4-5T0189-051099-021-f054.5
ST0189 Homo sapien
445368AI221631Hs.166788ESTs 4.5
401004 predicted exon 4.5
425837AF007567Hs.159609insulin receptor substrate4.5
4
420497AW206285Hs.253548ESTs 4.5
449438AA927317Hs.176719ESTs 4.5
429409AI694817Hs.155980ESTs 4.5
447959A1452784Hs.270270ESTs 4.4
407340AA810168Hs.232119ESTs d.4
424326NM Hs.145296disintegrin protease 4.4
014479
45 443479AF027219Hs.9443zinc finger protein 202 4.4
443246T75157Hs.285516ESTs, Weakly similar 4.4
to hypothetical protein
[H.sapien
414475BE302955Hs.119598ribosomal protein L3 4.4
432075AW972934 gb:EST385030 MAGE resequences,4.4
MAGM Homo sap
417906824769Hs.23725ESTs 4.4
406518W28077Hs.79389nel (chicken)-like 2 4.4
441460AI962478Hs.226804ESTs, Moderately similar4.4
to ALUC_HUMAN !!!! ALU
450549T49427Hs.181244major hisiocompatibility4.4
complex, class I, A
426528AA380828 gb:EST93827 Activated 4.4
T-cells VII Homo Sapiens
cDN
430535AW968485 gb:EST380561 MAGE resequences,4.4
MAGJ Homo sapi
55 408479BE047329Hs.144483ESTs 4.3
448636AI557139Hs.129179Homo Sapiens cDNA FLJ135814.3
fis, clone PLACE10090
411280N50617 gb:yy89h02.r1 Soares-multiple-sclerosis-2NbHMSP4.3
H
440790AW593050Hs.128580ESTs 4.3
458301AF003834 gb:AF003834 Clontech 4.3
HI1149x Homo sapiens
cDNA
6~ 442277AW448914Hs.202391ESTs 4.3
449463AI657038Hs.196109ESTs 4.3
433426H69125Hs.133525ESTs 4.3
410782AW504860Hs.288836Homo Sapiens cDNA FW 4.3
12673 fis, clone NT2RM4002
423040AA320749Hs.209464KIAA1604 protein 4.3
65 432430AW079984Hs.262480ESTs 4.3
432072N62937Hs.269109ESTs 4.3
452213AL110237Hs.28425Homo Sapiens mRNA; cDNA 4.3
DKFZp566D224 (from c
403635 predicted exon 4.3
441919AI553802Hs.128121ESTs 4.3
416717H79559Hs.297726ESTs 4.3
430995NM_005092Hs.248197tumor necros!s factor 4.2
(ligand) superfamily,
member 18
429269AA449013Hs.99203ESTs 4.2
415840815955Hs.21758ESTs 4.2
451300AA017066Hs.237686EST 4.2
75 445366A1221511Hs.298662ESTs 4.2
424194BE245833Hs.169854hypolheficalprotein SP1924.2
459105NM Hs.28423upstream binding protein4.2
014517 1 (LBP-ia)
455387BE069037 gb:OV3-BT0379-161299-040-e124.2
BT0379 Homo sapie
410507AA355288Hs.271408ESTs d.2
go 453823AL137967 gb:DKFZp761D2315_r1 761 4.2
(synonym:hamy2) Homo
450966AA017245Hs.32794ESTs 4.2
432694AW991585Hs.276755ESTs, Weakly similar 4.2
to F53B1.2 (C.elegans]
455108AW856866 gb:RCO-CT0299-291199-031-G024.2
CT0299 Homo sapie
443609AV650231Hs.282941ESTs 4.2
137
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
427469AA403084Hs.269347ESTs 4.2
417178N51636 gb:yy87bOt.s1 Soares multiple4.2
sclerosis 2NbHMSP H
439751AA196090Hs.50794Homo Sapiens mRNA full 4.2
length insert cDNA clone
EU
431982AW419296Hs.105754ESTs 4.1
442641AI890955Hs.262983ESTs 4.1
422128AW881145 gb:QVO-OT0033-010400-182-a074.1
OT0033 Homo sapie
449156AF103907Hs.171353prostate cancer anfigen 4.1
3
419668A1033098Hs.132777ESTs 4.1
418236AW994005Hs.172572hypothefical protein FLJ200934.1
1 432663AI984317Hs.122589ESTs 4.1
~
448313BE622486Hs.121688Homo Sapiens cDNA FLJ134634.1
fis, clone PLACE10034
411279AW884776 gb:QV4-OT0067-010300-121-d014.1
OT0067 Homo sapie
440652AI216751Hs.143977ESTs 4.1
416608811499Hs.189716ESTs 4.1
15 420405AA743396Hs.189023ESTs 4.1
405717 predicted exon 4.1
435267N23797Hs.110114ESTs ' 4.1
412228AW503785Hs.73792complement component (3d/Epstein4.1
Bamviros) recepto
403560AI929721Hs.5120dynein, cytoplasmic, light4.1
polypepfide
2o d49162AI632740Hs.10476ESTs 4.1
459157AI904385 gb:CM-BT054-080399-054 4.1
BT054 Homo sapiens cDN
432474AA584042 gb:nn65e09.s1 NCI CGAP_Lar14.1
Homo Sapiens cDNA
455388AW936234 gb:QVO-DT0020-090200-106-g054.0
DT0020 Homo sapie
426456AA580748Hs.130658ESTs 4.0
438597AA811662Hs.171497ESTs 4.0
437934AW880871Hs.77496small nuclear ribonucleoprotein4.0
polypeptide G
459385BE380047 gb:601159362F2 NIH MGC_534.0
Homo Sapiens cDNA
436404AW968556Hs.137240Homo Sapiens mRNA for 4.0
partial 3'UTR, sequence
2
457740AW500458 gb:Ul-HF-BNO-akb-d-07-0-ULr14.0
NIH_MGC_50 Homo
3 437385AA757055Hs.164060ESTs , 4.0
~
444530AV650124Hs.282435ESTs d.0
408066AA046914 gb:zf47h10.r1 Soares retina4.0
N2b4HR Homo Sapiens cD
411256AW834039 gb:QVO-TT0010-091199-053-e094.0
TT0010 Homo sapie
433582BE548749Hs.148016ESTs 4.0
3 438637BE500941Hs.126730ESTs, Weakly similar to 4.0
KIAA1214 protein [H.sapiens
414571BE410746Hs.22868protein tyrosine phosphatase,4.0
non-receptor type 11
446190AI279299Hs.256564ESTs 4.0
443542AI927065Ns.146040ESTs d.0
430444AW296421Hs.121035ESTs 4.0
454573BE146471 gb:QVO-HT0216-011199-043-c094.0
HT0216 Homo sapie
409846AW501748 gb:Ul-HF-BROp-ajm-b-12-0-ULr14.0
NIH MGC 52 Hom
. AI751357Hs.288741Homo Sapiens cDNA: FLJ222564.0
456141 fis, clone HRC02860
456140AA169515Hs.6006ESTs 4.0
441685A1459261Hs.144481ESTs 4.0
45 416677T83470 gb:yd46g06.r1 Soares fetal4.0
liver spleen 1 NFLS Homo
s
401740 predicted exon 4.0
420122AA255714Hs.284153Fanconi anemia, complementation4.0
group A
442594AW272467Hs.254655Unfified 3.9
426294AA374185 gb:EST86289 HSC172 cells 3.9
1 Homo Sapiens cDNA 5'
a
411922AW876260 gb:PM4-PT0019-131299-006-E043.9
PT0019 Homo sapie
452320AA042873Hs.160412ESTs 3.9
431644AW972822Hs.169248cytochrome c 3.9
409892AW956113 gb:EST368183 MAGE resequences,3.9
MAGD Homo sap
418132T92670Hs.117421ESTs 3.9
55 414372AA143654 gb:zo65a02.r1 Stratagene 3.9
pancreas (937208) Homo
sap
400196 predicted exon 3.9
416900M59964Hs.1048KIT ligand 3.9
445444AA380876Hs.270pleckstrin homology, Sec73.9
and coiledlcoil domains,
bind
435957N39015Hs.190368ESTs 3.9
60 442299AW467791Hs.155561ESTs 3.9
419499AA808136Hs.177698ESTs 3.9
438403AA806607Hs.292206ESTs 3.9
449386AA001308Hs.193213ESTs 3.9
443283BE568610 gb:601342622F1 NIH-MGC 3.9
53 Homo Sapiens cDNA
65 406481 predicted exon 3.9
453530AW021633 gb:df26c02.y1 Morton Fetal3.9
Cochlea Homo Sapiens
cDN
415558AA885143Hs.125719ESTs 3.9
41687dH98752Hs.42568ESTs 3.9
454885AW836922 gb:OV1-LT0036-150200-074-h063.9
LT0036 Homo sapie
419896299362 gb:HSZ99362 DKFZphamyl 3.9
Homo Sapiens cDNA clon
440962AI989961Hs.233477ESTs, Moderately similar 3.9
to A Chain A, Secypa
Compl
419401AW804663 gb:OV4-UM0094-160300-135-d063.9
UM0094 Homo sap
406562 predicted exon 3.8
405690BE409855Hs.808heterogeneous nuclear 3.8
ribonucleoprotein F
75 435282AA677428Hs.189731ESTs 3.8
402451 predicted exon 3.8
d51577N69101Hs.32703ESTs 3.8
457141AA521410Hs.41371ESTs 3.8
407817H92553Hs.40400ESTs 3.8
8~ 412613AA653507Hs.285711Homo sapiens cDNA FLJ130893.8
fis, clone NT2RP30021
418355L42563Hs.1165ATPase, N+IK+transporfing,3.8
nongastric, alpha polypep
446357AW161533Hs.300866ESTs 3.8
407448AJ001865 gb:Homo Sapiens mRNA, 3.8
parfial cDNA sequence
for h
456383AI148037 gb:qg61e01.r1 Soares-tesfis-NHT3.8
Nomo Sapiens cDNA
138
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
444651W58469Hs.103120ESTs 3.8
455067AW854538 gb:RC3-CT0255-200100-024-b023.8
CT0255 Homo sapie
442657BE502631Hs.130645ESTs 3.8
429142AA835639Ns.104972ESTs 3.8
429274A1379772Hs.99206ESTs 3.8
437774AW978199Hs.291648ESTs 3.8
427737AA435988Hs.178066ESTs, Weakly similar 3.8
to AF068289 5 HDCME31
P [H.s
405671 prodicted exan 3.8
413627BE182082Hs.246973ESTs 3.8
1 438658837529Hs.269924ESTs 3.8
~
416612H70565 gb:yr97c04.r1 Soares 3.8
fetal liver spleen 1
NFLS Homo so
423045AW967472Hs.301511ESTs, Highly similar 3.8
to KPT2-HUMAN SERINEITHR
453361AA035197Hs.107375ESTs 3.7
437243AA747549Hs.259122ESTs 3.7
15 437987AW450202Hs.122963ESTs 3.7
408781BE148621Hs.254602ESTs 3.7
455895BE154837 gb:PMi-HT0345-121199-001-c083.7
HT0345 Homo sapie
431492AW612343 gb:hg97c10.x1 NCI-CGAP-Kidl13.7
Homo Sapiens cDN
413247AW963969 gb:EST376042 MAGE resequences,3.7
MAGH Homc sap
422866NM Hs.121502mannosyl (alpha-1,6-)-glycoprotein3.7
002410 beta-1,&N-acetyl-g
d31828AA572994 gb:nm33f12.s1 NCI-CGAP-Lip23.7
Homo Sapiens cDNA
438872864197Hs.23589ESTs 3.7
438673A1824717Hs.123443ESTs 3.7
416624H69044 gb:yr77h05.s1SoaresfetalliverspleenlNFLSHomosa3.7
401963 predicted exon 3.7
402867 predicted exon 3.7
408315AW179148 gb:MR4-ST0067-200899-002-B073.7
ST0067 Homo sapie
418320D86981Hs.84084amyloid beta precursor 3.7
protein (cytoplasmic
tail)-bindin
447199AI939421Hs.160900ESTs ~ 3.7
422590AA312758Hs.193945Homo Sapiens cDNA FLJ139623.7
fis, clone Y79AA10012
451996AW514021Hs.245510ESTs 3.7
412463AW953444Hs.78672iaminin, alpha 4 3.7
440928AL046575Hs.130198ESTs 3.7
441951W31002Hs.128195ESTs 3.7
35 440705AA904244Hs.153205ESTs 3.7
434231AF119901Hs.250568hypothetical protein 3.7
PR02831
411039AL135674Hs.163348ESTs 3.7
413137BE066915 gb:PMO-BT0340-231199-001-b073.7
BT0340 Homo sapie
417970AA309234Hs.57760Homo Sapiens cDNA: FLJ231193.7
tis, clone LNG07978
439786AV652707Hs.33756Homo Sapiens mRNA full 3.7
length insert cDNA clone
EU
459595AL040421 gb:DKFZp43480714_r1434 3.7
(synonym: htes3) Hamo
s
443601A1078554Hs.15682ESTs 3.7
404041 predicted exon 3.6
406122 predicted exon 3.6
45 404582 predicted exon 3.6
455786BE090077 gb:RC6-BT0710-300300.021-F023.6
BT0710 Homo sapie
411899AA370573 gb:EST82238 Prostate 3.6
gland I Homo Sapiens
cDNA 5' a
426758AL036430Hs.197772ESTs 3.6
421776AW301994Hs.108183candidate tumor suppressor3.6
p33 ING1 homolog
50 430169AA468531Hs.189047ESTs 3.6
407695AI808007Hs.66450ESTs 3.6
454564AW807573 gb:MR1-ST0088-021299-004-g013.6
ST0088 Homo sapie
425902X52509Hs.161640tyrosine aminotransferase3,6
439328W07411Hs.118212ESTs, Moderately similar3.6
to ALU3_HUMAN ALU SU
55 429066AA868555Hs.178222ESTs 3.6
428690AI948490Hs.98765ESTs 3.6
437302AA837146Hs.180275ESTs 3.6
443973A1580083Hs.176154ESTs 3.6
453993AW615224Hs.252839ESTs 3.6
413623AA825721Hs.246973ESTs 3.6
409196NM_001874Hs.169765carboxypeptidase M 3.6
424916AW867440Hs.23096ESTs 3.6
424769H06469Hs.142653ret finger protein 3.6
400080 predicted exan 3.6
65 421521AI638760Hs.161795ESTs 3.6
405549 predicted exon 3.6
446114A1275715Hs.145926ESTs 3.6
441392AW451831Hs.222119ESTs, Weakly similar 3.6
to K1 CGLHUMAN KERATIN,
T
424025A1701852Hs.301296ESTs 3.5
448527A1525606 gb:PTl.3-03 G05.r tumort3.5
Homo Sapiens cDNA 5',
m8
437063AA351109Hs.5437Tax1 (human T-cell leukemia3.5
virus type I) binding
prot
449880AI673006Hs.231948ESTs, Weakly similar 3.5
to ALUB-HUMAN !!!! ALU
CL
449311A1657014 gbat49a12.x1 NCI_CGAP-GC63.5
Homo Sapiens cDNA c
442999AW662889Hs.132395ESTs 3.5
75 416238W90448 gb:zh78cO8.s1 Soaros 3.5
fetal liver-spleen 1NFLS
S1 H
423209BE278528Hs.106823H.sapiens gene from PAC 3.5
42616, similar to syntaxin
7
409854AW501833 gb:Ul-HF-BROp-ajo-d-01-0-ULr13.5
NIH_MGC_52 Hom
414941C14865Hs.182159ESTs 3.5
456337AW751661Hs.65919ESTs 3.5
415296F05086 gb:HSC01A011 normalized 3.5
infant brain cDNA Homo
s
423338AB007961Hs.127338KIAA0492 protein 3.5
415618F12954 gb:HSC3GG091 normalized 3.5
infant brain cDNA Homo
s
405583 predicted exon 3.5
435601AF217509Hs.283077centrosomal P4.1-associated3.5
protein; uncharacterized
bo
139
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
450867AA011454Hs.245122ESTs 3.5
431339AA506294Hs.257266ESTs 3.5
441969A1733386Hs.129194ESTs, Weakly similar 3.5
to ALU1 HUMAN ALU SUBFA
431343AW970603Hs.300941Homo Sapiens cDNA FLJ116613.5
fis, clone HEMBA100
434317AI674095Hs.116323ESTs 3.5
414741851321Hs.25780Homo Sapiens cDNA FLJ122523.5
fis, clone MAMMA10
439707AW297702Hs.102915ESTs 3.5
443178AI631241Hs.47312ESTs 3.5
400397AJ270770Hs.154485transcription factor 3.5
7-like 2 (T-cell specific,
HMG-box)
455887BE154173 gb:PMi-HT0340-201299-004-f123.5
HT0340 Homo sapie
434362W27081Hs.295446ESTs 3.5
409211AA078835 gb:zm94h04.s1 Stratagene3.5
colon HT29 (937221)
Homo
414390BE281040 gb:601156234F1 NIH_MGC_213.5
Homo sapiens cDNA
457142AI924353Hs.290969EST 3.5
423006U29700Hs.123014anG-Mullerian hormone 3.5
receptor, type II
453363AI989776Hs.232623ESTs 3.5
418913BE046745 gb:hn39bO6.x1 NCI_CGAP-RDF23.4
Homo Sapiens cDN
440016AW118114Hs.137057ESTs 3.4
405096 predicted exon 3.4
435072AW592176Hs.116932ESTs 3.4
436535L09078 gb:Homo Sapiens mRNA 3.4
fragment
424001W67883Hs.137476KIAA1051 protein 3.4
428361NM_015905Hs.183858transcripfional intermediary3.4
factor 1
410587AA370706Hs.11252ESTs, Weakly similar 3.4
to Weak similarity with
the Ysy6
454543AW806895 gb:QV4-5T0923-160400-172-c063.4
ST0023 Homo sapien
419515S81944Hs.90791gamma-aminobutyric acid 3.4
(GAGA) A receptor, alpha
6
410280AA083558Hs.261286ESTs 3.4
425714AW963278 gb:EST375351 MAGE resequences,3.4
MAGH Homo sap
416895AW961600 gb:EST373672 MAGE resequences,3.4
MAGG Homo sap
427935AW503687Hs.119424ESTs, Weakly similar 3.4
to unnamed protein product
[H.sa
4116738E064863 gb:RC1-BT0313-110300-015-f063.4
BT0313 Homo sapien
453339AW992599Hs.252797ESTs 3.4
424696BE439547Hs.151903Homo Sapiens clone 247063.4
mRNA sequence
436242AK002187 gb:Homo Sapiens cDNA 3.4
FLJ11325 fis, clone
PLACE10
35 442837A1022082Hs.50492ESTs 3.4
452807AA028933Hs.i62434ESTs 3.4
418110843523Hs.217754Homo Sapiens cDNA: FLJ222023.4
fis, clone HRC01333
433936AI208072Hs.123459ESTs 3.4
458177A1744995Hs.267072ESTs, Moderately similar3.4
to ALU4_HUMAN ALU SU
40 401896 predicted exon 3.4
406237 predicted exan 3.4
457688AL110157Hs.3843Homo Sapiens mRNA; cDNA 3.4
DKFZp586F2224 (from
45691AAW363582Hs.75323prohibitin 3.4
421916834441Hs.101007Homo sapiens cDNA: FLJ235463.4
fis, clone LNG08361
45 419321Nd8146Hs.269069ESTs 3.4
447876AV654978Hs.19904cystathionase (cystathionine3.4
gamma-lyase)
406197 predicted exan 3.4
443005A1027184Hs.200918ESTs 3.4
450078A1681743 gbax38g10.xi NCI-CGAP_Lu243.4
Homo Sapiens cDNA
50 431301AA502384Hs.151529ESTs 3.4
430202T85775 gb:yd60g02.r1 Soares 3.4
fetal liver spleen 1
NFLS Homo s
428559H24338Hs.27041ESTs 3.4
455731BE072188 gb:OV4-BT0536-211299-055-b093.4
BT0536 Homo sapie
420735AW297440Hs.88653ESTs 3.4
55 430881NM_000809Hs.248112gamma-aminobutyric acid 3.3
(GAGA) A receptor, alpha
4
405836 predicted exon 3.3
449178AI633748Hs.197597ESTs 3.3
453265U61232Hs.32675tubulin-specific chaperone3.3
a
430700AA768902Hs.247812H2A histone family, member3.3
K, pseudogene
60 424496AI733451Hs.129212ESTs 3.3
446963A1862668Hs.176333ESTs 3.3
422879AI241409Hs.188092ESTs 3.3
419831AW448930Hs.5415ESTs 3.3
449570AA001793 gb:zh86cO6.r1 Soares 3.3
fetal liver-spleen_1NFLS_S1
H
65 406255 predicted exon 3.3
41231qAW936903 gb:RC1-DT0029-030200-012-d023.3
DT0029 Homo sapie
401350 predicted exon 3.3
''
439098AF085955 gb:Homo Sapiens full 3.3
length insert cDNA clone
YR86G
450589AI701505Hs.202526ESTs 3.3
70 430749AJ242956Hs.25960v-myc avian myelocytomatosis3.3
viral related oncogene,
n
430689AI695595Hs.293219ESTs 3.3
454753AW819212 gb:CM1-ST0283-071299-061-c073.3
ST0283 Homo sapie
444479AA194980Hs.30818Homo Sapiens cDNA FLJ13fi813.3
fis, clone PLACE20000
413516BE145907 gb:MRO-HT0208-221299-204-e123.3
HT0208 Homo sapie
75 425541AA359119 gb:EST68172 Fetal lung 3.3
II Homo Sapiens cDNA
5' end,
457107AA418246Hs.185796ESTs, Weakly similar 3.3
to b3418.1 [H.sapiens]
421480NM-016158Hs.104671erythrocyte transmembrane3.3
protein
444289BE267060Hs.7fi391myxovirus (influenza) 3.3
resistance 1, homolog
of murine
417725825257Hs.21503ESTs 3.3
453631AL046418 gb:DKFZp434N247_r1434 3.3
(synonym: htes3) Homo
so
450692H50603Hs.94037hypolheficalprotein FLJ230533.3
413357W47611 gb:zc35e06.r1 Soares 3.3
senescent_fibroblasts_NbHSF
H
415327H22769Hs.1861membrane protein, palmitoylated3.3
1 (55kD)
457569AW970021Hs.291120. ESTs, Weakly similar ~
to ALUB-HUMAN ALU SUBFA 3.3
140
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
448601861666Hs.293690ESTs 3.3
436526AW993633Hs.287681Homo Sapiens cDNA: FLJ216853.3
fis, clone COL09372
440589BE397763Hs.194478Homo Sapiens mRNA; cDNA 3.3
DKFZp43401572 (from
418768T39310Hs.1139cold shock domain protein3.3
A
426768AW303337Hs.270411ESTs 3.3
400394AF040257Hs.283818Nomo Sapiens TNF receptor3.3
homolog mRNA, parfial
cd
433565AA599763Hs.112520ESTs 3.3
424093AA335025 gb:EST39621 Epididymus 3.3
Homo sapiens cDNA 5'
end,
.
449552AA001742Hs.83722ESTs 3.3
1 431892A4521315Hs.194424ESTs 3.3
~
d05512 predicted exon 3.3
446990AI354717Hs.223908ESTs 3.3
457729A1821863Hs.293467ESTs, Weakly similar 3.2
to ALU7-HUMAN ALU SUBFA
417333AL157545Hs.42179bromodomain and PHD finger3.2
conta!ning, 3
1 456420AW401361Hs.91773protein phosphatase 2 3.2
S (formerly 2A), catalyfic
subunit,
403497 predicted exon 3.2
427145852635Hs.25935ESTs 3.2
406454 predicted exon 3.2
441033BE562555 gb:601335867F1 NIH-MGC-443.2
Homo Sapiens cDNA
408444AW661839Hs.253204ESTs 3.2
434739AA804487Hs.144130ESTs 3.2
437060AA745591Hs.292063ESTs 3.2
423092BE274837Hs.123637putative homeodomain 3.2
transcripfion factor
424695U58331Hs.151899sarcoglyca~, delta (35kD3.2
dysUophin-associated
glycopr
443362A1053464Hs.166505ESTs 3.2
437500AL390150 gb:Homo Sapiens mRNA; 3.2
cDNA DKFZp547L156 (from
425458H89317Hs.182889ESTs 3.2
439171AA831133Hs.294128ESTs 3.2
407647AW860158 gb:RCO-CT0379-290100-032-b043.2
CT0379 Homo sapie
435608AW183971Hs.250896ESTs 3.2
426743AA383833Hs.245022ESTs 3.2
457525AW973800 gb:EST385901 MAGE resequences,3.2
MAGM Homo sap
413800AI129238Hs.192235ESTs 3.2
414193BE260069 gb:601150964F1 NIH MGC 3.2
19 Homo Sapiens cDNA
3 455565BE000537 gb:RC3-BN0072-240200-011-d073.2
BN0072 Homo sapie
410061T91029Hs.15069ESTs 3.2
450666T99968Hs.18799ESTs 3.2
458529AV652120Hs.213232ESTs 3.2
424751AA769482Hs.296320ESTs 3.2
4~ 442225A1306597Hs.129192ESTs 3.2
410990AW812929 gb:RC3-ST0186-250200-018-c053.2
ST0186 Homo sapien
435644AA700867Hs.269659ESTs 3.2
405347 predicted exon 3.2
441202AI632143Hs.135853ESTs 3.2
45 446694AV659942Hs.258132ESTs 3.2
454652AW812088 gb:RC4-ST0173-191099-032-a073.2
ST0173 Homo sapien
418985A1042330Hs.87128ESTs, Weakly similar 3.2
to similar to YBS4 YEAST
[C.el
430118AI377255Hs.183287ESTs 3.2
430691C14187Hs.103538ESTs 3.2
416313H47206Hs.194109ESTs, Weakly similar 3.2
to ALUB-HUMAN !!!! ALU
CL
446122AI362790Hs.181801ESTs 3.2
453725W28543 gb:48c5 Human retina 3.2
cDNA randomly primed
sublibra
453954AW118336Hs.75251DEADIH (Asp-Glu-Ala-AspIHis)3.2
box binding protein
1
428166AA423849Hs.79530M5-14 protein 3.2
55 447506878778Hs.29808Homo Sapiens cDNA: FLJ211223.2
fis, clone CAS059i7
401871 predicted exon 3.2
442160AI337127Hs.156325ESTs 3.2
404708 predicted exon 3.1
412588AW993055Hs.44024ESTs 3.1
431976AA719001Hs.291065ESTs 3.1
408884AW891024Hs.281172ESTs 3.1
433811AW975015Hs.123138ESTs 3.1
431691AI208511Hs.292510ESTs 3.1
418719AW975590Hs.161707ESTs 3.1
65 431740N75450Hs.183412ESTs, Moderately similar3.1
to AF11672167 PR01777
(H
435699AI911488Hs.213724ESTs 3.1
459344AW499533Hs.257976ESTs 3.1
431729AW004714Hs.162033ESTs 3.i
436771AW975687Hs.292979ESTs 3.1
434480AW956268Hs.59395Homo Sapiens clone IMAGE:1125743.1
mRNA sequence
459547AI400579Hs.225186EST 3.1
427962AA946582Hs.133546Homo Sapiens cDNA: FLJ211203.1
fis, clone CAS05691
403743 predicted exon 3.1
4135608E148411 gb:MRO-HT0241-131299-002-f043.1
HT0241 Homo sapie
75 454372H96643Hs.283565FOS-like anfigen-1 3.1
450018AA4216d2Hs.24309hypotheticalprotein FLJ111063.1
428839A1767756Hs.82302ESTs 3.1
407110AA018042Hs.95078ESTs 3.1
436133T77531Hs.191124ESTs 3.1
g0 418872894785Hs.270263ESTs 3.1
404418 predicted exon 3.1
446877AI559472Hs.270720ESTs 3.1
429053AA443967Hs.194114ESTs 3.1
425189H16622 gb:ym26c07.r1 Soares 3.1
infant brain 1NIB Homo
Sapiens
141
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
404134 predicted exon 3.1
441404AI638880Hs.126895 ESTs 3.1
40007fi predicted exon 3.1
411876AW961336Hs.69705 ESTs, Weakly similar3.1
1o KIAA0443 [H.sapiens)
451048AA013349Hs.60602 ESTs 3.1
447021A1356564Hs.161406 ESTs 3.1
404083 predicted exan 3.0
415833H05175Hs.107510 ESTs 3.0
402142 predicted exon 3.0
1 415820853720Hs.189745 ESTs 3.0
~
441140AW016534Hs.226994 ESTs 3.0
449376AA001278Hs.59905 ESTs 3.0
457593A1738815Hs.117323 ESTs 3.0
411542AW850767gb:IL3-CT0220-031199-025-A053.0
CT0220 Homo sapien
1 403375 predicted exon 3.0
S
449561A1022240Hs.17924 ESTs 3.0
406241 predicted exon 3.0
d20306AA258318Hs.219226 ESTs 3.0
413161BE068130gb:CM2-BT0368-171299-056-a013.0
BT0368 Homo sapie
2~ 448221BE622615gb:601440775T1 NIH MGC-72 3.0
Homo Sapiens cDNA
415920245684gb:HSCZRDi 21 normalized 3.0
infant brain cDNA Homo
459135AI902802gb:RG8T015-31129&026 8T015 3.0
Homo Sapiens cDNA
425357AA355842. gb:EST64303 Jurkat T-cells3.0
VI Homo Sapiens cDNA 5'
454724AA091228gb:cchn2152.seq.F Human 3.0
fetal heart, Lambda ZAP
Ex
25 429395AK002071Hs.201624 hypotheticalprotein3.0
FLJ11209
427607AA406119Hs.270479 ESTs 3.0
443598AW499970Hs.14822 ESTs 3.0
437948AA772920gb:ae73c09.s1 Stratagene 3.0
schizo brain 811 Homo sapien
418105AW937488Hs.178000 ESTs 3.0
426763AL042262Hs.172101 Numan DNA sequence3.0
from clone RP1-202121 on
chro
403473 predicted exon 3.0
427501AI369280Hs.131743 ESTs 3.0
453246NM Hs.32539 KIAA1264 protein 3.0
000933
404587M99587Hs.104134 homeo box (H6 3.0
family) 1
35 433964AW241987Hs.197025 ESTs 3.0
453472AL037925gb:DKFZp564M037 r1564 (synonym:3.0
hfbr2) Homo sa
433183AF231338Hs.222024 transcription 3.0
factor BMAL2
435899W89093Hs.189914 ESTs 3.0
425626A1537536Hs.173519 ESTs 3.0
4~ 428931AA994979Hs.98967 ATPase, H(+)-transporting,3.0
lysosomal, noncatalytic
acc
426593AW958560gb:EST370630 MAGE resequences,3.0
MAGE Homo sapi
431899AA521381Hs.18772fi ESTs 3.0
d22406AF025441Hs.116206 Opa-interacting 3.0
protein 5
448178AI479482Hs.170789 ESTs 3.0
45 404227 predicted exon 3.0
440575AA889870Hs.126006 ESTs 3.0
431198AL047634Hs.231913 ESTs 3.0
434221AF119885Hs.283040 hypothetical protein3.0
PR02543
459459AA460445gb:zx66h11.r1 Soares total_fetus-Nb2HF83.0
9w Homo
50
TABLE
58:
Pkey:
Unique
Eos
probeset
identifier
number
CAT
number:
Gene
cluster
number
Accession:Genbank
accession
numbers
55
Pkey CAT Accession
Number
4075961003489886913 886901 N25352 801370
1 H43764 AW044451 W21298
4076471007366AW860158 AW862385 AW860159
1 AW86238fi AW862341 AW821869
AW821893 AW062660 AW062656
408066103649AA046914 AA057231 H38371
1
4083151051132AW179148AW179150
1
409211_ AA078835 AA079319 AA078816
110906AA079026 AA122167AA111933
1 AA068989 AA084691 AA068999
AA069038 AA069225 AA650522
4096991149033BE154650 BE154785 AW468343
1 BE154816 BE154667
4098461156150AW50174B AW502972 AW502513
1
4098541156229AW501833 AW502145 AW502581
1
65 4098921157859AW956113 AW503580
1
41006511742581AW812744AW581974AW8i2725
4104541204154AW749041 BE066025 N85202
1
4104951205826N95428 W24040 AW751366 H81987
1
410596121053AA374186 AW963684 AA086107
1 A1491986
4106671214679AW936099 AW936243 AW936097
1 BE162104 BE162109 AW794263
4107581219899_1BE535988 AW801777
4108901226008AW809575 BE090626 BE090617
1 AW936551 AW93fi552 AW936530
AW936550 AW936481
4109901228649AW812929 AW812779 AW813088
1
4112561236790AW834039 AW834040 AW834047
1 AW845410 HE003128 AW852479
75 411279- AW884776 AW935737 AW835261 AW835240 AW835258
1237516AW835247 AW835246 AW835263
1
4112801237585N50617 N47321 854159 AW860545
1 AW835317
4113371239217AW837349 AW837355 AW882717
1
4115421249095AW850767 AW8511 BO AW851359AW851108
1 AW851223 AW851360 AW851222
4115431249127AW851248 AW851425 AW850805
1 AW851021 AW850905
411673_ BE064863 BE153698 AW856751
1253737_1BE153820 BE064737 BE153fi74
BE064730 BE065062 BE153536
AW856622 BE155079 BE064651
BE153665 BE064650 BE064691
411899126497_1AA370573 BE160501 BE160500
BE160498 8E160502 BE160497
N72424 AA09fi462
4119221265825AW876260 AW876269 AW876340 AW876171 AW876421 AW876227
1 AW876146 AW876323 AW876320 AW876243
4123191288602AW936903 AW936907 AW936908
1 AW936914
142
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
412480129929BE142364 BE142341 AA112025
1
4127321323951AW993300 N23107 822345
1
4131371350383BE066915 BE066942
1
4131611351262BE068130 BE068135 BE068134 BE068183 BE068184 BE068094
1
413247135544_1AW963969 AW963971 AA127651 AA376726
4133571364165_1W47611 BE087851
4135161374595BE145907 BE145796 BE145803 BE145851 BE145923 BE145812
1 BE145809 BE145852 BE145856
4135601376621BE148411 BE148415 H59098
1
4141931424706=BE260069
2
1 4143371436706BE386606 BE275195 BE274984
~ 1
414372143909_1AA143654 AW753140 AA213770 AW970865 AA569075 AA492132
4143901441570BE281040
-1
4152961533528_1F05086 F05091 817158
4156181540651F12954 H10624 811948 R56523T75190
1
1 4159201561733245684 H09361 853285
1
4162111578993_1814625 817952 H29120 814650
4162381580451W90448 H30749
1
4166121603885H70565 N77403 H67949
1
4166241604694_1H69044T47567 H75691 T50292
4166771608621T83470 T84283 H74054
1
416895162874AW961600 AA190217 AA321260
1
4171781655565N51636 T51874 T51829
1
417762169750AA205976 AA205930
1
418913180520BE046745 A1074878 A1817476 AW572513 AA447586 H28330
1 AA232486 AA365704 BE271167
419401184454AW804663 AW805017 AA236969
1
4198961886662299362 299363
1
420352192979BE258835 AW968316 AA258918 AW843305 814744 A1580388
1 BE071923 836280
421418202288_1AA806639 AA291008 AA836274 AW978806
422046210744-1A1638562 T16929 H13401 F07773 855836
3 422128211994AW881145 AA4907i8 M85637 AA304575 T06067 AA331991
~ 1
423403227942-1AA325483 AW962169 AW962660
424093235233AA335025 AA335496 AW966145
1
424719242889-1H90452 AA345767 AW964302 H90399
425189247825_1H16622 817322 AA351959
3 425357250578AA355842
5 -1
425541252945AA359119 AW963014 D79884
1
425714255333AW963278 AA362266 AA362267
1
426294263994-1AA374185 AW956180 H38344
426528268722-1AA380828 AW963760 AA380805 AA380830
426593269748AW95B560 AA382199 AW444933
1
430202314322T85775 AW968345 AA468998
1
430535319643AW968485 AW968670 AA480922 BE350425
1
431075327638BE267477 AA491488 AW836723
1
431492333930AW612343 AA922558 AA505925 AA927038 AW972537 AI693564
1
45 431828_ AA572994 AA516249 AA702595
338201
1
432075341066AW972934 AA525260 AA525266 AA835021 BE000149 BE000148
1
432474348197_1AA5B4042 AW973273 AA548798
433371364430T25451 AA585296 AA585305
1
43340336534 AF040247
-1
433767374014-1AA609245 AA724581 AW241989 A1377274 T47300
434738392562_1AA836265 AA648266 AW974440
43619641562_1AK001084 AA078092 AA829049
43624241641_1AK002187 866351
436812427323AW298067 AA731645 AA810101 AW194180 A1690673 AW978773
1
5 43750043772-1AL390150 AW959182 AA358923
5
437948445966AA772920 D59870 D61151 AI591331
1
438224452656_1AA933999 AA781181
43853545946 L09078 L03145 L09094 L09098 L03165 L09102
1
43909846859 AF085955 H69158 H69081
1
60 43912646887_1AF085984 H95905 H95906
.44103350807 BE562555
-1
44328356492_-1BE568610
445597644513-1H65649 AW753545 AI244270
445832651925A1261545 N59134 AW875371 AW875247
1
65 44822175534 BE622615
-1
448527766707A1525606 BE549857
1
44873277773 BE614063
-1
449311804513_1A1657014 AW594035 A1657036 A1638390
44957081018 AA001793 AA001871
1
450078823882-1AI681743 AW897287 AW897205 AW897284
45235191233 AA025647 845716 AW753786
1
452453918300_1A1902519 A1902518 A1902516
453472968371AL037925 AL037931 AL037957
1
45353097021 AW021633 AA036730 A1866854
1
75 453631975024-1AL046418 N52738 833640
453725978760_1W28543 AL119531
453752979899-1AL120800 BE378580
453623982526AL137967 BE064160 BE064186
1
4541021011603AW752363 BE147120 N22640
1
4544871216101AW796342 AW796356 BE161430
1
4545431223775-1AW806895 AW866476 AW866465 AW866535 AW866623
4545641224407AW807573 AW807566 AW807572
1
4545731225624_1BE146471 AW833743 AW833609 AW821469 AW821488 AW821541
AW821531 AW821513 AW821549 AW821384 AW821625 AW821577
AW821547 AW834577
143
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
454652 1228071 1 AW812088 AW812105 AW812082
454679 1228929 1 AW813110 AW813113
454724 123128 1 AA091228 H71860 H71073
454753 1233576_1 AW819212 AW819170 BE158474 AW819172 AW819213 AW819200
AW819256 AW819254 AW819178 AW819214 AW819215 AW819233
AW819171
454885 1238874 1 AW836922 AW876719 AW876688 AW8369i9 AW836997 AW836908
AW836912 AW836993
454940 1245640_1 AW846202 AW846i74 AW846532 AW846181 AW846458 AW846206
AW846432 AW846553 AW846533 AW846197 AW846198 AW846189
AW846469 AW846530 AW846560 AW846536 AW846472 AW846470 AW846466 AW846192
AW846479 AW846260 AW846204 AW846139
AW846187 AW846353 AW846462 AW846151 AW846549 AW846538 AW846527 AW846567
AW846531
1 ~ 454994 1248637-1 AW850176 AW850513 AW850412 AW850451
455056 1250934 1 AW853057 AW853039 AW853042 AW853050 AW853114 AW853105
AW853102 AW853111 AW853121 AW853109 AW853126
455067 1252050 1 AW854538 AW854418 AW854412
455108 1253916_1 AW856866 AW856858 AW8568S6
455387 1287871 1 BE069037 AW936025 BE069178 AW936034
15 455388 1287904_1 AW936234 AW936074 AW936181 AW936179 AW936217 AW936077
AW936227 AW936191
455534 1322942_1 AW99i925AW991919
455565 1329591 1 BE000537 BEt80584 BE180540 BE180542 BE180546
455731 1353872_1 BE072188 BE072299 BE072269 BE072317 BE072238
455786 1365510 1 BE090077 BE090079
455790 1365950 1 BE090690 8E090688 BE090681 BE090693 BE090675
455887 1380836 1 BE154173 BE154098 BE154096
455895 1381386 1 BE154837 8E154879 BE154850 BE154877 BE154835 BEi54849
BEi54902 BE154905 BE154867 BE154901 BE154904 BE154899
456253 1699178 1 T12198 T19684 T11583 815526 815585 845876 815562
456383 184252-1 A1148037 AA287178 AA236756
25 456388 1842839 -1 W28557
457525 351732_1 AW973800 AA557589 AA559886
457740 39528_1 AW500458 AW160900 AF161362 AF150327 AW578393 AW360921 AW360920
AW360902 AW360890 AW732529
458301 543058 1 AF003834 W36292
459135 918516 1 A1902802 A1902783 A1902800
459157 919804-2 A1904385 AI904382
TABLE 5C:
Pkey: Unique number corresponding to an Eos probeset
Ref: Sequence source. The 7 digit numbers in this column are Genbank
Identifier (GI) numbers. "Dunham I. et al." refers to fhe publication entitled
"The DNA sequence of
35 human chromosome 22" Dunham, et al. X1999) Nature 402:489-495
Strand: Indicates DNA strand from which exons were predicted
Nt_position: Indicates nucleotide positions of predicted exons
Pkey Ref Strand Nt-position
4o d00942 7656749 Minus 91593-91757,92720-92843,93962-94079,94824-94997
401004 7229982 Plus 62580-62772
401287 9801612 Minus 42287-42431
d01308 9212516 Plus 169019-169649
401350 9931226 Plus 14471-14623
45 401740 2982169 Plus 148357-148484,148591-148690
401871 8079355 Minus 58158-59585
401896 8569194 Plus 115129-115294
401963 3126783 Plus 51382-51521
402105 8131588 Minus 22856-24055
402109 8131678 Minus 171722-171859,173197-173303
402142 7704985 Minus 29932-30698
402451 9796677 Minus 48137-48343
402867 5596716 Plus 52806-53106,53500-53818
403277 8072597 Minus 27494-27642
5 403283 8076905 Minus 71124-71996
403375 9255944 Minus 92554-92795
403473 9945095 Minus 54241-54437
403497 6067111 Plus 7221-7441
403531 8076842 Minus 75903-76134
403635 6862664 Minus 157028-157145,161725-161900
403714 7210030 Minus 145556-145873
403743 7652003 Minus 136463-136646
404020 8655966 Minus 174449-174663
404041 8886967 Minus 1334-1503,2483-2565,5230-5337,19656-19804
65 404044 9558573 Minus 225757-225939
404083 9944029 Minus 16650-17082
404108 8247074 Minus 63603-64942
404134 6981900 Minus 40633-40911
404227 7838233 Minus 93110-93259
404418 7382420 Minus 153339-153481,155099-155294
404451 7638438 Minus 105191-105622
404582 9739220 Plus 53230-53424
404708 9800828 Plus 77522-77658
404868 9454593 Plus 39954-40430
75 405096 8072599 Plus 140844-140897,148510-148581
405290 3900849 Minus 79582-79765
405347 2979602 Minus 977-1116
405512 9454624 Plus 17802-17966,18573-18697
405549 1552494 Plus 10878-11048
405583 4512287 Plus 56211-56353
405671 2565031 Plus 25805-26923
405717 9588573 Plus 11275-11973
405752 9212305 Plus 91392-91528
405836 5686282 Minus 5031-5217
144
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
406122 9144087Minus30940-31386
406197 7289992Minus47520-47961
406237 7417725Plus 30032-30501
406241 7417725Minus34951-35752
406255 7417729Plus 2959-3200
406364 9256114Minus50715-50833
406454 9588380Minus91746-91958
406481 9864741Minus91439-91579
406562 7711584Plus 37316-37426
1 ~ 4066058272666Minus23275-23493,23723-23903
TABLE 6A lists about 68 genes highly down-regulated in ovarian cancer compared
to normal ovaries. These were selected as for Table 5A, except the 'average"
ovarian cancer
level was set to the maximum value amongst various ovarian cancers and the
"average" normal ovary level was set to the minimum value from various non-
malignant ovary
15 specimens, and the ratio was greater than or equal to 2.5 (i.e. 2.5-fold
down-regulated in the highest tumor vs. the lowest normal ovary). This has the
overall effect of increasing
stringency, and reducing the number of false-positives.
TABLE
6A:
ABOUT
68
HIGHLY
DOWN-REGULATED
GENES,
OVARIAN
CANCER
VERSUS
NORMAL
OVARY
Pkey:
Primekey
Ex.Accn:
ExempIarAccession
UG
1D:
UniGene
tD
Titre:
UniGene
Titre
ratio: vs.
ration tumor
of
normal
ovary
25 Pkey Ex. UG Title , ratio
Accn ID
424851AA676441Hs.119059ESTs 7.9
437690AA804362Hs.180544ESTs 4.7
433682AA642418Hs.17381ESTs 4.1
407437AF220264 gb:Homo sapiens MOST-1 mRNA,4.1
complete cds.
30 437787AI908263Hs.291625ESTs 4.0
453262AK000043Hs.32922hypothetical protein FLJ200364.0
440987AA911705Hs.130229ESTs 3.8
443131A1033833Hs.132689ESTs 3.8
431075BE267477 gb:601189542F2 NIH_MGC 7 3.6
Homo Sapiens cDNA clo
3 412637AA115097Hs.261313ESTs 3.6
408141U69205Hs.45152ESTs, Moderately similar 3.5
to neurogenic basic-helix-loop
420122AA255714Hs.284153Fanconi anemia, complementation3.5
group A
430653AW902062Hs.30280ESTs 3.4
401308 predicted exon 3.4
4~ 410758BE535988 gb:601062418F1 NIH MGC 10 3.4
Homo Sapiens cDNA c
421418AA806639 gb:ob88g05.s1 NCI-CGAP-GCB13.4
Homo Sapiens cDNA
450061AI797034Hs.201115ESTs 3.3
409725T40760Hs.90459EST 3.3
434738AA836265 gb:od17e02.s1 NCI_CGAP_GCBt3.3
Homo Sapiens cDNA
45 431644AW972822Hs.169248cytochrome c 3.3
450938AW753734Hs.277215ESTs 3.2
420497AW206285Hs.253548ESTs 3.2
439426A1131502Hs.143135ESTs, Weakly similar to 3.2
FAFY-HUMAN PROBABLE C
407596886913 gb:yq30t05.r1 Soares fetal 3.2
liver spleen iNFLS Homo
sap
448683AA167642Hs.14632ESTs 3.2
431982AW419296Hs.105754ESTs 3.1
452320AA042873Hs.160412ESTs 3.1
419401AW804663 gb:OV4-UM009d-160300-135-d063.1
UM0094 Homo sapim
402105 predicted exon 3.1
5 444997AI204451Hs.146196ESTs 3.1
5
403283 predicted exon 3.0
455388AW936234 gb:OVO-DT0020-090200-106-g053.0
DT0020 Homo sapie
428559H24338Hs.27041ESTs 2.9
419002T78625Hs.268594ESTs 2.9
404868 predicted exon 2.9
~
409090W56067Hs.103105ESTs 2.9
406605 predicted exon 2.9
441202AI632143Hs.135853ESTs 2.8
422046A1638562 gb:ls50at0.x1 NCI CGAP-Ut1 2.8
Homo Sapiens cDNA c7
65 442865N57659Hs.114541ESTs, Weakly similar to 2.8
neuronal thread protein
AD7c-N
444431AW513324Hs.42280ESTs 2.8
426294AA374185 gb:EST86289.HSC172 cells 2.8
~ I Homo Sapiens cDNA 5'
en
412480BE142364 gb:CMO-HT0143-270999-062-d122.8
HT0143 Homo sapie
449858AW205979Hs.196065ESTs 2.8
401464AF039241Hs.9028histone deacetylase 5 2.7
439126AF085984 gb:Homo Sapiens full length2.7
insert cDNA clone YT99F0
403277 predicted exon 2.7
450078AI681743 gbax38g10.x1 NCI GGAP-Lu24 2.7
Homo Sapiens cDNA
458090AI282149Hs.56213ESTs, Highly similar to 2.7
FXD3_HUMAN FORKHEAD D
75 420620AA278807Hs.173343ESTs 2.7
459054AW79B466Hs.823962',5'-oligoadenylate synthetase2.6
1
421379Y15221Hs.103982small inducible cytokine 2.6
subfamily B (Cys-X-Cys),
mem
454338AW381251Hs.1050pleckstrin homology, Sec7 2.6
and coiledicoil domains
1 (cyt
454529245439Hs.270425ESTs 2.6
446877A1559472Hs.270720ESTs 2.6
412588AW993055Hs.44024ESTs 2.6
449862A1672277Hs.199475ESTs 2.6
446694AV659942Hs.258132ESTs " 2.6
424029A8014594Hs.137579KIAA0694 gene product 2.6
.
145
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
454102AW752363gb:RCO-CT0201-270999-011-f03 CT0201
Homosapien 2.6
430922AW373747Hs.183337 ESTs 2.6
420289N55394Hs.96398 8-oxoguanine DNA glycosylase
2.6
410495N95428gb:zbBOd09.s1 Soares senescent fibroblasts-NbHSF
Ho 2.5
412319AW936903gb:RCi-DT0029-030200-012-d02 DT0029
Homo sapien 2.5
409699BE154650gb:PM3-HT0344-071299-003-c08 HT0344
Homo sapien 2.5
445832AI261545gb:qz30a07.x1 NCI CGAP_Kidl1 Homo
sapiens cDNA 2.5
429755NM Hs.215839 discs, large (Drosophila)
001364homolog 2 (chapsyn-110) 2.5
445755AW294870Hs.223672 ESTs 2.5
1
O
TABLE
6B:
Pkey: ue
Uniq Eos
probeset
idenfifier
number
CAT
number:
Gene
cluster
number
Accession:Genbank
accession
numbers
1
s
Pkey CAT Accession
Number
4075961003489886913 886901 H25352 801370 H43764
1 AW044451 W21298
4096991149033BE154650 BE154785 AW468343 BE154816
1 BE154667
4104951205826N95428 W24040 AW751366 H81987
1
4107581219899BE535988 AW801777
1
4123191288602AW936903 AW936907 AW936908 AW936914
1
412480129929BE142364 BE142341 AA112025
1
419401184454-1AW804663 AW805017 AA236969
421418202288AA806639 AA291008 AA836274 AW978806
1
422046_ AI638562 T16929 H13401 F07773 855836
210744_1
d26294263994-1AA374185 AW956180 H38344
431075327638BE267477 AA491488 AW836723
1
434738392562AA836265 AA648266 AW974440
1
439126d6887 AF085984 H95905 H95906
1
445832651925A1261545 N59134 AW875371 AW875247
1
450078823882AI681743 AW897287 AW897205 AW897284
1
4541021011603AW752363 BE147120 N22640
1
4553881287904_1AW936234 AW936074 AW936181 AW936179
AW936217 AW936077 AW936227 AW936191
3S TABLE6C:
Pkey: Unique number corresponding
to an Eos probeset
Ref: Sequence source. The 7 digit
numbers in this column are Genbank
Identifier (GI) numbers. "Dunham
I. et al." refers to the publication
entitled "The DNA
sequence of human chromosome 22" Dunham,
et al. (1999) Nature 402:489-495
Strand: Indicates DNA strand from
which exons were predicted
4o Nt-position: Indicates nucleofide
positions of predicted exons
401308 9212516 Plus 169019-169649
d02105 8131588 Minus 22856-24055
403277 8072597 Minus 27494-27642
45 403283 8076905 Minus 71124-71996
d04868 9454593 Plus 39954-40430
406605 8272666 Minus 23275-23493,23723-23903
Table 7A lists about 770 genes up-regulated
in ovarian cancer compared to normal
adult tissues. These were selected
from 35403 probesets on the AffymetrixlEos-Hu01
GeneChip array such that the ratio
of "average' ovarian cancer to "average'
normal adult tissues was greater
than or equal to 2.5. The "average"
ovarian cancer level was set to
the 2nd highest amongst various ovarian
cancers. The 'average" normal adult
fissue level was set to the 7th highest
amongst various non-malignant tissues.
In order to remove
gene-specific background levels of
non-specific hybridization, the 15th
peroentile value amongst the non-malignant
tissues was subtracted from both
the numerator and the
denominator before the ratio was evaluated.
55
TABLE 7A: ABOUT 770 UP-REGULATED GENES,ISSUES
OVARIAN CANCER VERSUS NORMAL ADULT
T
Pkey: Primekey
Ex.Accn: ExempIarAccession
UG ID: UniGene ID
60 Title: UniGene Tifie
ra8o: ration tumor vs. normal tissues
Pkey Ex. Accn UG ID Title ratio
109680 F09255 Hs.4993 ESTs 23.2
65 119743 W70242 Hs.58086 ESTs 22.0
132528 AA283006 Hs.50758 chromosome-associated22.0
polypeptide C
129571 X51630 Hs.1145 Wilmstumorl 20.0
102151 017280 Hs.3132 sleroidogenic 19.6
acute regulatory protein
130941 D49394 Hs.2142 5-hydroxytrypiamine17.5
(serotonin) receptor 3A
132624 AA164819 Hs.53631 ESTs 15.9
102610 065011 Hs.30743 preferenfially15.4
expressed anfigenin melanoma
101249 L33881 Hs.1904 protein kinase 14.5
C; iota
122802 AA460530 Hs.256579 ESTs 14.5
135242 M74093 Hs.9700 cyclin E1 13.8
75 101804 M86699 Hs.169840 TTK protein 12.2
kinase
123005 AA479726 Hs.105577 ESTs 12.0
114965 AA250737 Hs.72472 ESTs 11.5
115536 AA347193 Hs.62i80 ESTs 11.4
132191 AA449431 Hs.158688 KIAA0741 10.9
gene product
g0 121853 AA425887 Hs.98502 ESTs 10.9
115881 AA435577 Hs.184942 G protein-ccupled10.8
receptor 64
119780 W72967 Hs.191381 ESTs; Weakly 10.5
similar to hypothetical protein
104301 D45332 Hs.6783 ESTs 10.3
132632 N59764 Hs.5398 guanine-monophosphale10.1
synthetase
146
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
105298AA233459Hs.26369ESTs 9.7
108857AA133250Hs.62180ESTs 9.1
113168T53592Hs.161586EST . 9.0
115892AA435946Hs.50831ESTs 8.9
125666AA199856Hs.118811ESTs 8.9
102200021551Hs.157205branched chain aminotransferase8.8
1; cytosolic
108055AA043562Hs.62637ESTs 8.6
132572AA448297Hs.237825signal recognifion 8.6
parficle 72kD
115909AA436666Hs.59761ESTs 8.5
1 109166AA179845Hs.73625RAB6 interacfing; kinesin-like8.3
~ (rabkinesin6)
121779AA422036Hs.98367ESTs 8.3
102915X07820Hs.2258matrix metalloproteinase8.0
10 (stromelysin 2)
105317AA233926Hs.23635ESTs 7.8
125250W87465Hs.222926ESTs; Weakly similar 7.8
to D2092.2 [C.elegans]
1 126960AA317900Hs.161756ESTs 7.8
122969AA478539Hs.104336ESTs 7.7
130376840873Hs.155174KIAA0432 gene product 7.7
123339AA504253Hs.101515ESTs 7.7
134972M19720Hs.169252Human L-myc protein 7.6
gene; complete cds
111234N69287Hs.21943ESTs; Weakly similar 7.5
to ORF YGL221c [S.cerevi
123689AA609556Hs.256562ESTs 7.5
123494AA599786Hs.112110ESTs 7.4
131985AA434329Hs.36563ESTs 7.4
106738AA470145Hs.25130ESTs 7.4
25 108768AA127741Hs.61345ESTs 7.3
106474AA450212Hs.42484Homo sapiens mRNA; 7.2
cDNA DKFZp564C053
(from cI
123308AA496211Hs.103538ESTs 7.2
106124AA423987Hs.7567ESTs 7.2
111345N89820Hs.14559ESTs 7.1
105200AA195399Hs.24641ESTs 7.1
116416AA609219Hs.39982ESTs 7.1
118846N80567Hs.50895ESTs 7.1
133434AA278852Hs.250786ESTs 7.1
120472AA251875Hs.104472ESTs; Weakly similar 6.9
to Gag-Pol polyprotein
[
3 115291AA279943Hs.122579ESTs 6.9
J
111185N67551Hs.12844EGF-like-domain; multiple6.9
6
108778AA128548Hs.90847general transcripfion 6.9
factor IIIC; polypeptid
132939076189Hs.61152exostoses (multiple)-like6.9
2
134520N21407Hs.257325ESTs 6.9
40 114724AA131701Hs.256287ESTs; Highly similar 6.8
to SPERM SURFACE PROTEIN
116296AA489033Hs.62601Homo sapiens mRNA; 6.8
cDNA DKFZp586K1318
(from c
102136015552Hs.85769acidic 82 kDa protein fi.7
mRNA
132725L41887Hs.184167splicing factor; argininelserine-rich6.5
7 (35kD
109648F04600Hs.7154ESTs 6.4
45 116401AA599963Hs.59698ESTs 6.4
127563A1367707Hs.150587ESTs 6.4
104252AF002246Hs.210863cell adhesion molecule6.4
with homology to L1CAM
120438AA243441Hs.99488ESTs; Weakly similar 6.2
to ORF YKR074w [S.cerevi
131978D80008Hs.36232KIAA0186 gene product 6.2
134621L02547Hs.172865cleavage sfimulation 6.2
factor, 3' pre-RNA;
subu
120571AA280738Hs.128679ESTs 6.2
102627066561Hs.158174zinc finger protein 6.1
184 (Kruppel-like)
100661HG2874-HT3018 Ribosomal Protein L39 6.1
Homolog
118204N59859Hs.48443ESTs 6.0
55 131386AA096412Hs.173135dual-specificity tyrosine-(Y)-phosphorylafion6.0
129097S50223 HKR-T7=Kruppel-like 5.9
zinc finger protein
[puma
131228AA279157Hs.2d485chondroitin sulfate 5.9
proteoglycan 6 (bamacan)
106369AA443828Hs.25324ESTs 5.9
108255AA063157Hs.172608ESTs 5.8
125370AA256743Hs.151791KIAA0092 gene product 5.8
130010N52966Hs.142838ESTs 5.8
131945M87339Hs.35120replicafion factor 5.7
C (acfivator 1) 4
(37kD)
116238AA479362Hs.47144DKFZP586N0819 protein 5.7
102221024576 LIM domain only 4 5.6
65 130757800641Hs.18925ESTs; Weakly similar 5.6
to cDNA EST yk339a7.5
co
131278081523Hs.25195endometrial bleeding 5.6
associated factor
(left-
101383M14113Hs.79345coagulationfactorVlllc;procoagulantcompon5.5
131836AA610086Hs.32990DKFZP566F084 protein 5.5
129628026727Hs.1174cyclin-dependent kinase5.5
inhibitor 2A (melanom
70 106523AA453441Hs.31511ESTs 5.5
111772828287Hs.237146ESTs 5.5
101255L34600Hs.149894mitochondrial iranslational5.5
inifiation factor
106895AA489665Hs.25245ESTs 5.5
104943AA065217Hs.169674ESTs 5.5
7S 129229AA211941Hs.109643polyadenylate binding 5.4
protein-interacting
pro
102305033286Hs.90073chromosome segregation5.4
1 (yeast homology-like
106553AA454967Hs.5887ESTs; Highly similar 5.4
to RNA binding motif
pro
112305854822Hs.26244ESTs 5.3
123972C14782Hs.70337immunoglobulin superfamily;5.3
member 4
102676072514Hs.12045putafive protein 5.3
106459AA449741Hs.4029glioma-amplified sequence-415.2
107865AA025104Hs.61252ESTs 5.2
121121AA399371Hs.189095ESTs; Weakly similar 5.2
to zinc finger protein
S
127162N76398Hs.21187ESTs 5.2
147
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
131646AA171895Hs.30057Homo Sapiens clone 5.2
24749 and 24750 mRNA
segue
121770AA421714Hs.11469KIAA0896 protein 5.2
122512AA4493t1Hs.98658budding uninhibited 5.1
by benzimidazcles
t (yeas
105870AA399623Hs.23505ESTs 5.1
100341D63506Hs.8813syntaxin binding protein5.1
3
116848H65187Hs.39001ESTs 5.1
120821AA347419Hs.96870Homo Sapiens mRNA full5.1
length insert cDNA
clo
130690AA084286Hs.139033paternally expressed 5.1
gene 3
122661AA454936Hs.245541ESTs 5.1
1 123169AA488892Hs.104472ESTs; Weakly similar 5.1
~ to Gag-Pol pclyprotetn
[
108810AA130596Hs.71331ESTs; Weakly similar 5.0
to POTENT HEAT-STABLE
PR
110799N26101Hs.7838Human ring zinc-finger5.0
protein (ZNF127-Xp)
ge
120619AA284372Hs.111471ESTs 5.0
122792AA460225Hs.99519ESTs 5.0
15 129912AA047344Hs.107213ESTs; Highly similar 5.0
tc NY-REN-6 antigen
[H.s
102823090914Hs.5057carboxypepfidase D 4.9
129890M13699Hs.i ceruloplasmin (ferroxidase)4.9
11461
101084L05425 Homo sapiens autoanfigen4.9
mRNA; complete cds
134859D87716Hs.90315KIAA0007 protein 4.9
115955AA446121Hs.44198Homo sapiens BAC clone4.9
RG054D04 from 7q31
105516AA257971Hs.21214ESTs 4.9
114932AA242751Hs.16218KIAA0903 protein 4.9
106672AA461300Hs.30643ESTs 4.8
106126AA424006Hs.22972ESTs; Moderately similar4.8
to H5AR [M.musculusj
110695H93463Hs.124777ESTs 4.8
102025003911Hs.78934mutS (E. coli) homolog4.8
2 (colon cancer; nonpo
133282052960Hs.250855SRB7 (suppressor of 4.8
RNA polymerase B;
yeast)
119708W67810Hs.57904mago-nashi (Drosophila)4.7
homolog; proliferafio
120695AA291468 ESTs 4.7
30 128651AA446990Hs.103135ESTs 4.7
103152X66533Hs.77890guanylate cyclase 1; 4.7
soluble; beta 3
108699AA12i514Hs.70832ESTs 4.7
115094AA255921Hs.88095ESTs 4.7
121429AA406293Hs.193498ESTs 4.7
35 123203AA489671Hs.89709glutamate-cysteine 4.7
ligase (gamma-glutamylcyst
126802AA947601Hs.97056ESTs 4.7
130527C17384Hs.184227F-box protein 21 4.7
134470X54942Hs.83758CDC28 protein kinase 4.7
2
100449D87470Hs.75400KIAA0280 protein 4.7
4~ 110970N51374Hs.96870Homo Sapiens mRNA full4.7
length insert cDNA
clo
115901AA436403Hs.86909ESTs; Moderately similar4.7
to Frizzled-6 [H.sap
109799F10770Hs.180378Homo Sapiens clone 4.6
669 unknown mRNA;
complete
116195AA465148Hs.72402ESTs 4.6
132122065092Hs.40403CbpIp300-interacting 4.6
transacfivator; with
Glu
45 108990AA152296Hs.72045ESTs 4.6
109055AA160529Hs.48524ESTs 4.6
115937AA443269Hs.30991KIAA0957 protein 4.6
133520X74331Hs.745t9primase; polypepfide 4.6
2A (58kD)
131200AA609427Hs.210706ESTs; Moderately similar4.6
to !!1l ALU SUBFAMIL
121369AA405657Hs.128791Human DNA sequence 4.5
from clone 967N21
on chrom
132880AAd44369Hs.177537ESTs 4.5
127386A1457411Hs.106728ESTs 4.5
120067W93592Hs.47343ESTs 4.5
122986AA479063Hs.102947ESTs 4.5
55 135286AA401269Hs.97849ESTs 4.5
130155L33404Hs.151254kallikrein 7 (chymotrypfic;4.5
stratum comeum)
106103AA421104Hs.12094ESTs 4.5
102654068494Hs.24385Human hbc647 mRNA sequence4.4
107876AA025315Hs.61184Novel human gene mapping4.4
to chomosome X
109454AA232255Hs.46912ESTs 4.4
125960D63307Hs.145968ESTs 4.4
126892AIt60190Hs.76127hect (homologous to 4.4
the E6-AP (UBE3A)
carboxy
100269D38550Hs.1189E2F Uanscripfion factor4.4
3
134161097188Hs.79440IGF-II mRNA-binding 4.3
protein 3
65 100502HG1491i-HT1496 Adrenal-Specific Protein4.3
Pg2
105542AA261858Hs.8241ESTs; Weakly similar 4.3
to heat shack protein
hs
109787F10610Hs.34853inhibitor of DNA binding4.3
4; dominant negative
110759N21671Hs.19025ESTs 4.3
129970AA478975Hs.200434ESTs 4.3
134666AA482319Hs.8752putafive type II membrane4.3
protein
117693N40939Hs.44162ESTs; Weakly similar 4.3
to cDNA EST yk342h12.5
c
111008N53388Hs.7222ESTs 4.3
120977AA398155Hs.97600ESTs 4.2
105808AA393808Hs.21490KIAA0438 gene product 4.2
75 121381AA405747Hs.97865ESTs; Weakly similar 4.2
to WASP-family protein
[
100893HG4557-HT4962 Small Nuclear tZbonucleoprotein4.2
U1, tsnrp
107176AA621762Hs.7576ESTs 4.2
118976N93629Hs.93391ESTs 4.2
130703N63295Hs.18103ESTs 4.2
106540AA454607Hs.38114ESTs; Weakly similar 4.2
to coded for by C.
elega
119367T78324Hs.90905ESTs 4.2
133633D21262Hs.75337nucleolar phosphoprotein4.2
p130
105520AA258068Hs.33085WD repeat domain 3 4.2
114264240074Hs.27595ESTs 4.1
148
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
131046X02530Hs.2248IP10;'small inducible 4.1
cytokine subfamily
B (
105220AA210695Hs.i7212'ESTs 4.1
103111X63187Hs.2719epididymis-specific; 4.1
whey-acidic protein
type
125640837700Hs.208261ESTs 4.1
110561H59617Hs.5199ESTs; Weakly similar 4.1
to UBIQUITIN-CONJUGATING
118092N54915Hs.82719Homo sapiens mRNA; 4.1
cDNA DKFZp586F1822
(from c
134891F03517Hs.90787ESTs 4.1
112364859312Hs.197642ESTs; Weakly similar 4.1
to DNA-DIRECTED RNA
POLY
120699AA291716Hs.97258ESTs 4.1
1 106272AA432074Hs.32538ESTs 4.1
~
112041843300Hs.22929ESTs 4.1
131689AA599653Hs.30696iranscdption factor-like4.1
5 (basic helix-loop
116134AA460246Hs.50441ESTs; Highly similario4.1
CGI-04 protein [H.sap
107638AA009528Hs.42743ESTs; Weakly similar 4.0
to predicted using
Genef
15 131941D62657Hs.35086ubiquitin-specific 4.0
protease 1
106154AA425304Hs.6994ESTs 4.0
105546AA262032Hs.26089ESTs; Weakly similar 4.0
to 62D9.a [D.melanogaste
106319AA436606Hs.7392ESTs; Weakly similar 4.0
to Gu protein (H.sapiens
121816AA424814Hs.187509ESTs 4.0
122851AA463627Hs.99598ESTs 4.0
123337AA504153Hs.132797ESTs; Weakly similar 4.0
to ORF YGL050w [S.cerev!
128643N40212Hs.102958ESTs 4.0
129011S72869Hs.107932DNA segment; single d.0
copy; probe pH4 (transfor
130895AA609828Hs.21015ESTs; Highly similar 4.0
to tetracycline transpor
25 132323AA436102Hs.256559ESTs 4.0
134255J05032Hs.80758asparfyl-tRNA synthetase4.0
102827091327Hs.6456chaperonin containing 4.0
TCPt; subunit 2 (beta)
102123014518Hs.1594centromere prole!n 4.0
A (l7kD)
102813090651Hs.151461embryonic ectoderm 3.9
development protein
113970W86748Hs.8109ESTs 3.9
107145AA621108Hs.173001ESTs 3.9
114212239338Hs.21201DKFZP566B0846 protein 3.9
106614AA458934Hs.179912ESTs 3.9
132742AA490862Hs.55901ESTs; Weakly similar 3.9
to C43H8.1 (C.elegans]
35 120948AA397822Hs.104650ESTs; Highly similar 3.9
to similar to mago
nosh!
129337863542Hs.110488KIAA0990 prote!n 3.9
103835AA172215Hs.93748ESTs;ModeratelysimilartoTRANSCRIPTiONFAC3.9
133330042360Hs.71119Putative prostate cancertumorsuppressor3.9
133928N34096Hs.7766ubiquiGn-conjugating 3.9
enzyme E2E 1 (homologou
4~ 133640D83004Hs.75355ubiquitin-conjugating 3.9
enzyme E2N (homologous
133350AA135468Hs.71573ESTs 3.9
115623AA401475Hs.39733postsynaptic protein 3.9
CRIPT
101973S82597Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypeptid3.9
102669071207Hs.29279eyes absent (Drosoph!la)3.9
homolog 2
45 134248AA292677Hs.80624ESTs 3.9
102380040434Hs.155981mesothelin 3.9
116157AA461063Hs.44298ESTs; Highly similar 3.8
to HSPC011 [H.sapiens]
106691AA463453Hs.23259ESTs; Weakly similar 3.8
to ACTIN; CYTOPLASMIC
2
115844AA430124Hs.234607ESTs 3.8
107159AA621340Hs.10600ESTs; Weakly similar 3.8
to ORF YKR081c [S.cerevi
106498AA452141Hs.7171ESTs 3.8
134405J04177Hs.82772collagen; type XI; 3.8
alpha 1
106260AA431448Hs.5250ESTs; Weakly similar 3.8
to BACR37P7.g [D.melanog
109864H02554Hs.30323ESTs 3.8
55 124648N91948Hs.125034ESTs 3.8
134719L07515Hs.89232chromobox homolog 5 3.8
(Drosophila HP1 alpha)
113702T97307Hs.161720ESTs; Moderately similar3.8
to !!!! ALU SUBFAMIL
128639N91246Hs.102897ESTs 3.8
111299N73808Hs.24936ESTs 3.7
60 129351AA167268Hs.62349Human ras inhibitor 3.7
mRNA; 3' end
119741W70205Hs.43670kinesin family member 3.7
3A
105012AA116036Hs.9329chromosome 20 open 3.7
reading frame 1
128734AA343629Hs.104570kallikrein 8 (neuropsinlovasin)3.7
130567L07493Hs.1608replication protein 3.7
A3 (l4kD)
65 114253239909Hs.14831ESTs 3.7
103169X68560Hs.44450Sp3transcriplionfaclor3.7
111269N70711Hs.18885ESTs; Highly similar 3.7
to CGI-116 protein
[H.sa
112876T03488Hs.4842ESTs 3.7
118261N62780Hs.94122ESTs 3.7
70 130385AA126474Hs.155223stann!ocalcin 2 3.7
129300C20976Hs.110165ESTs; Highly similar 3.7
to ribosomal protein
L26
134388M15841Hs.82575small nuclear ribonucleoprotein3.7
polypeptide B
106968AA504631Hs.26813ESTs; Weakly similar 3.7
to hypothetical 43.2
kDa
100906HG4716-HT5158 Guanosine 5'-Monophosphate3.7
Synthase
75 100418D86978Hs.84790KIAA0225 protein 3.7
101484M24594Hs.20315interferon-induced 3.7
protein 56
102547057911Hs.46638chromosome 11 open 3.7
reading frame 8
103587229083Hs.821285T4 oncofetal irophoblast3.7
glycoprotein
130600AA478601Hs.258737ESTs 3.7
128733AA328993Hs.104558ESTs 3.7
134375AA412720Hs.82389ESTs; Highly similar 3.7
to CGI-118 prote!n
(H.sa
134098X06323Hs.79086ribosomal protein; 3.6
mitochondrial; L3
101188L20320Hs.184298cyclin-dependent kinase3.6
7 (homolog of Xenopus
132149T10822Hs.4095ESTs 3.6
149
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
116200AA465358Hs.118793ESTs; Highly similar 3.6
to p621 [H.sapiensj
121920AA428300Hs.161841ESTs 3.6
128609AA234365Hs.102456survival of motor neuron3.6
protein interacfing
101078L04510Hs.792ADP-ribosylafion factor3.6
domain protein 1;
64k
108693AA121289Hs.49597ESTs; Highly similar 3.6
to refinoic acid-induced
109139AA176121Hs.59757zinc finger protein 3.6
281
111870837778Hs.18685ESTs; Weakly similar 3.6
to hypothetical protein
113848W60080Hs.27099DKFZP564J0863 protein 3.6
127947AI432475Hs.146327ESTs 3.6
128056A1379480Hs.125449ESTs; Weakly similar 3.6
to MaxiK channel beta
2
129914022377Hs.13321rearranged L-myc fusion3.6
sequence
132148AA283988Hs.4094ESTs 3.6
134644S83308Hs.87224SRY (sex-determining 3.6
region Y)-box 5
115047AA252627Hs.22554homeo box B5 3.6
102398042359 Human N33 protein form3.6
1 (N33) gene, exon
1 a
127479AA513722Hs.179729collagen; type X; alpha3.6
1 (Schmid melaphyseal
105545AA262030Hs.5152ESTs; Weakly similar 3.6
to katanin p80 subunit
(
101483M24486Hs.76768procollagen-proline; 3.6
2-oxoglutarate 4-dioxyge
105709AA291268Hs.26761DKFZP586L0724 protein 3.6
122636AA454103Hs.110031ESTs 3.6
124792844357Hs.132784ESTs; Weakly similar 3.6
to cDNA EST EMBL:T01421
103621247727Hs.150675polymerase (RNA) II 3.5
(DNA directed) polypepfid
105427AA251330Hs.28248ESTs 3.5
121553AA412488Hs.48820ESTs ' 3.5
115167AA258421Hs.43728hypotheticalprotein 3.5
134570066615Hs.172280SWIISNF related; matrix3.5
associated; actin
dep
110787N24716Hs.12244ESTs; Weakly similar 3.5
to C44B9.1 [C.elegans]
131621077665Hs.139120ribonuclease P (30kD) 3.5
132813N72116Hs.57435solute carver family 3.5
11 (proton-coupled
diva
116370AA521256Hs.236204ESTs; Moderately similario3.5
NUCLEAR PORE COMP
131965W90146Hs.35962ESTs 3.5
115221AA262942Hs.79741ESTs 3.5
116093AA456020Hs.50848ESTs; Weakly similar 3.5
to KIAA0862 protein
[H.s
123507AA600176Hs.112345ESTs 3.5
129801F11087Hs.239666ESTs 3.5
115084AA255566Hs.42484Homo sapiens mRNA; 3.5
cDNA DKFZp564C053
(from c7
123442AA598803Hs.111496ESTs 3.5
115061AA253217Hs.41271ESTs 3.5
100146D13645Hs.2471KIAA0020 gene product 3.5
115140AA258030Hs.55356ESTs; Weakly similar 3.5
to supported by GENSCAN
115360AA281950Hs.5057carboxypeptidase D 3.5
130261D83767Hs.153678reproducfion 8 3.4
100824HG4058-HT4328 Oncogene Aml1-Evi-1, 3.4
Fusion Activated
102287031814Hs.3352histone deacetylase 3.4
2
102788086602Hs.74407nucleolar protein p40 3.4
118836N79820Hs.50854ESTs 3.4
102423044754Hs.179312small nuclear RNA activating3.4
complex; polypep
106300AA435840Hs.19114high-mobility group 3.4
(nonhistone chromosomal)
106156AA425354Hs.4210ESTs 3.4
106483AA451676Hs.30299IGF-II mRNA-binding 3.4
protein 2
107868AA025234Hs.61260ESTs 3.4
108187AA056538Hs.27842ESTs; Weakly similar 3.4
to similar to 1-acyl-gly
116123AA459282Hs,43756ESTs 3.4
119501W37721Hs.151363ESTs 3.4
5 129121AA127459Hs.108788ESTs; Weakly similar 3.4
5 to zeste [D.melanogaster
131638D87120Ns.29882predicted osteoblast 3.4
protein
132962N34893Hs.6153ESTs; Highly similar 3.4
to CGI-48 protein
[H.sap
133767D63875Hs.173288KIAA0155 gene product 3.4
111823835253Hs.24944ESTs 3.4
134372D63877Hs.82324KIAA0157 protein 3.4
130938AA013250Hs.21398ESTs; Moderately similar3.4
to PUTATIVE GLUCOSAM
115169AA258427Hs.58427ESTs 3.4
123978C20653Hs.170278ESTs 3.4
108807AA129968Hs.49376ESTs; Weakly similar 3.4
to PROTEIN PHOSPHATASE
P
132581842266Hs.52256ESTs; Weakly similar 3.4
to beta-TrCP protein
E3R
134654W23625Hs.8739ESTs; Weakly similar 3.4
to ORF YGR200c [S.cerevi
105730AA292701Hs.5364DKFZP5641052 protein 3.4
111295N73275Hs.21275ESTs; Weakly similar 3.3
to ubiquifin-con]ugafing
102009002680Hs.82643protein tyrosine kinase3.3
9
114161238904Hs.22385ESTs; Weakly similar 3.3
1o KIAA0970 protein
[H.s
130604X03635Hs.1657estrogen receptorl 3.3
100103AF007875Hs.5085dolichyl-phosphate 3.3
mannosyltransferase
polyps
121748AA421171Hs.234545ESTs 3.3
106698AA463745Hs.29403ESTs; Weakly similar 3.3
to PROBABLE ATP-DEPENDEN
134353S77154Hs.82120nuclear receptor subfamily3.3
4; group A; member
134154AA211320Hs.79404neuron-specific protein3.3
133142F03321Hs.65874ESTs 3.3
124461N50641Hs.80285Homo sapiens mRNA; 3.3
cDNA DKFZp586C1723
(from c
104903AA055534Hs.124134ESTs 3.3
106772AA478106Hs.12692ESTs; Weakly similar 3.3
to protein phosphatase-1
109704F09687Hs.12876ESTs 3.3
111131N64267Hs.10177ESTs 3.3
115019AA251906Hs.48473ESTs 3.3
116019AA450312Hs.237480Homo sapiens mRNA; 3.3
cDNA DKFZp434E102
(from c7
150
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
118528N67889Hs.49397ESTs 3.3
124027F03625Hs.107537ESTs 3.3
131699868657Hs.90421ESTs; Moderately similar3.3
to !!!! ALU SUBFAMIL
111044N55443Hs.23625ESTs 3.3
103768AA089997Hs.180320ESTs; Weakly similar 3.3
to GOLGI 4-TRANSMEMBRANE
131882N49091Hs.3385ESTs; Highly similar 3.3
to CGI-134 protein
[H.sa
123673AA609471Hs.112712ESTs 3.3
132936AB002305Hs.6111KIAA0307 gene product 3.3
103023X53793Hs.117950multifunctional polypeptide3.3
similar to SAICAR
1 120572AA280794Hs.258787ESTs 3.3
~
132384AA479933Hs.46967Human DNA sequence 3.3
from clone 167A19
on chrom
105658AA282914Hs.10176ESTs 3.2
105086AA147719Hs.159441ESTs 3.2
118695N71781Hs.50081Homo sapiens mRNA full3.2
length insert cDNA
clo
1 112092844538Hs.140889ESTs 3.2
125154W38419Hs.24936ESTs 3.2
108040AA041551Hs.48644ESTs 3.2
133453M68941Hs.73826proteintyrosine phosphatase;non-receptoriy3.2
124006D60302Hs.108977ESTs 3,2
116083AA455653Hs.44581ESTs; Weakly similar 3.2
to HEAT SHOCK 70 KD
PROT
106753AA476944Hs.7331ESTs 3.2
102621066075Hs.50924GATA-binding protein 3.2
6
103330X85373Hs.77496small nuclear ribonucleoprotein3.2
polypeptide G
128926AA481403Hs.107213ESTs; Highly similar 3.2
to NY-REN-6 antigen
[H.s
25 101167L15309Hs.193677zinc fingerprotein 3.2
141 (clone pHZ-44)
104055AA393755Hs.117211ESTs; Highly s!milarto3,2
CGI-62 protein [H.sap
112917T10196Hs.4263ESTs; Weakly similar 3.2
to (prediction
120358AA213459Hs.100932franscdptionfactor17 3.2
121857AA426017Hs.62694ESTs; Highly similar 3.2
to DNA-REPAIR PROTEIN
CO
122124AA434257Hs.186679ESTs; Moderately similar3.2
to !!!! ALU SUBFAMIL
132231H99131Hs.42635ESTs 3.2
134272X76040Hs.223014protease; serine;15 3.2
115860AA431719Hs.61809ESTs 3.2
115278AA279757Hs.67466ESTs; Weakly similar 3.2
to BACN32Gi 1.d [D.melano
35 134125838102Hs.50421KIAA0203 gene product 3.2
129160AA131252Hs.109007ESTs 3.2
121710AA419011Hs.96744DKFZP586D0823 protein 3.2
102242027185Hs.32943retinoic acid receptorresponder(tazarotene3.2
'
104956AA074880Hs.120975ESTs; Weakly similar 3.2
to hypothetical protein
113047T25867Hs.7549ESTs 3.2
115017AA251880Hs.179982tumor protein p53-binding3.2
protein
133780Mi4219Hs.76152decorin 3.1
129453AA421213Hs.111632Lsm3 protein 3.1
130353X86018Hs.172210MUF1 protein 3.1
45 106036AA412505Hs.10653ESTs 3.1
102234026312Hs.8123chromobox homolog 3 3.1
(Drosophila HP1 gamma)
106133AA424346Hs.107573sialyltransferase 3.1
116803H47357 ESTs; Moderately similar3.1
to weak similarity
t
106721AA465194Hs.6670ESTs 3.1
107115AA610108Hs.27693ESTs; Highly similar 3.1
to CGI-124 protein
(H.sa
133228N90029Hs.6831Homo sapiens clone 3.1
1400 unknown protein
mRNA;
104733AA019498Hs.23071ESTs 3.1
103879AA228148Hs.50252ESTs; Weakly s!milar 3.1
to putative (C.elegans]
103038X54941Hs.77550CDC28 protein kinase 3.1
1
5 135154AA126433Hs.173242sorting nexin 4 3.1
S
114860AA235112Hs.106227ESTs; Moderately similar3.1
to similar to mudne
102437046569Hs.22i986aquaporin 5 3.1
100352Dfi4159 Homo sapiens mRNA for 3.1
3-7 gene product,
parti
103631248570 H.sapiens Spl7 gene 3.1
104238AB002364Hs.27916a disintegrin-like 3.1
and melalloprotease
(repro
108613AA100967Hs.69165ESTs 3.1
115915AA436884Hs.48926ESTs 3.1
120640AA286945Hs.163933ESTs 3.1
124068H03099Hs.101619ESTs 3.1
65 130375091931Hs.155172adaplor-related protein3.1
complex 3; beta 1
sub
131632AA443671Hs.29826ESTs 3.1
131523H88801Hs.201676M phase phosphoprotein3.1
t0 (U3 small nucleolar
115827AA427890Hs.44426ESTs; Weakly similar 3.1
to PHOSPHOLIPID HYDROPER
108828AA131584Hs.7i435DKFZP56400463 protein 3.1
112198849483Hs.22159ESTs; Weakly similar 3.1
to ZINC FINGER PROTEIN
H
123960AA621785Hs.170008methylmalonate-semialdehyde3.1
dehydrogenase
131538229331Hs.28505ubiquitin~on]ugating 3.1
enzyme E2H (homologous
105616AA280670Hs.24968ESTs 3.1
101228L27706Hs.82916chaperonin containing 3.1
TCP1; subunit 6A (zeta
75 100280D42085Hs.i55314KIAA0095 gene product 3.1
132744X54326Hs.55921glutamyl-prolyl-tRNA 3.1
synthetase
103105X61970Hs.76913proteasome (prosome; 3.1
macropain) subunit;
alph
106984AA521201Hs.7129ESTs 3.1
105127AA15B132Hs.11817ESTs; Weakly similar 3.1
to contains similarity
t
102302033052Hs.69171protein kinase C-like 3.1
2
117708N45114Hs.46476ESTs 3.1
111314N74574Hs.33922H.sapiens novel gene 3.0
from PAC 117P20; chromos
132902AA490969Hs.i6B147ESTs 3.0
130356X84373Hs.155017nuclearreceptorinteracting3.0
protein 1
151
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
128420A1088155Hs.14146ESTs; Weakly similar 3.0
to unknown [H.sapiens]
108746AA126974Hs.43388ESTs 3.0
127236A1341818Hs.98658budding uninhibited 3.0
by benzimidazoles
1 (yeas
114208239301Hs.7859ESTs 3.0
107071AA609053Hs.35198ESTs 3.0
104957AA074919Hs.10026ESTs; Weakly similar 3.0
to ORF YJL063c [S.cerevi
124073H05394Hs.127376KIAA0266 gene product 3.0
130869AA128100Hs.2057uddine monophosphate 3.0
synthetase (orotate
pho
101232L28997Hs.242894ADP-ribosylafion factor-like3.0
1
1 104276CD2193Hs.85222ESTs; Weakly similar 3.0
~ to 827090-2 [H.sapiensj
126160N90960Hs.247277ESTs; Weakly similar 3.0
to transformafion-relate
128584M11433Hs.101850refinol-binding protein3.0
1; cellular
100405D86425Hs.82733nidogen 2 3.0
101335L49054 Homo sapiens t(3;5)(q25.i;p34)3.0
fusion gene NP
I5 108761AA127514Hs.61603ESTs 3.0
111346N89829Hs.13259ESTs 3.0
114988AA251089Hs.94576ESTs; Weakly similar 3.0
to phosducin; retinal
[H
f AA449338H~.48589ESTs; Weakly similar 3.0
16008 to finger protein
HZF6;
116545D20313Hs.74899ESTs 3.0
117873N49967Hs.46624ESTs 3.0
121463AA411745Hs.239681ESTs; Weakly similar 3.0
to KIAA0554 protein
[H.s
128625AA242816Hs.102652ESTs; Weakly similar 3.0
to KIAA0437 [H.sapiensj
131185M25753Hs.23960cyclin B1 3.0
134380D38073Hs.t79565minichromosome maintenance3.0
deficient (S. cere
25 105740AA293206Hs.10852ESTs .s 3.0
130919AA2917i0Hs.2f276collagen; type IV; 3.0
alpha 3 (Goodpasture
antig
134423W96151Hs.83006ESTs; Highly similar 3.0
to CGI-139 protein
[H.sa
104896AA054228Hs.23165ESTs 3.0
134407X72964Hs.82794caltracfin (20kD calcium-binding3.U
protein)
106378AA445994Hs.21331ESTs 3.0
112283853545Hs.20952Homo sapiens clone 3.0
24411 mRNA sequence
f090f8AA156960Hs.i14992ESTs 3.0
114239239742Hs.222478ESTs 3.0
114969AA250775Hs.87747ESTs 3.0
3 116408AA608752Hs.71969Homo sapiens mRNA; 3.0
S cDNA DKFZp564P0823
(from c
115286AA279803Hs.82204ESTs 2.9
105809AA393827Hs.20104ESTs 2.9
113811W44928Hs.4878ESTs 2.9
107248D59894Hs.34782ESTs 2.9
134489U0928dHs.112378LIM and senescent cell2.9
antigen-like domains
1
134064D87685Hs.78893KIAA0244 protein 2.9
127370A1024352Hs.70337immunog!obulin superfamily;2.9
member 4
113277T65797Hs.11774protein (pepfidyl-prolyl2.9
cisltrans isomerase)
132783N74897Hs.5683DEADIH (Asp-Glu-Ala-AspIHis)2.9
box polypeptide
45 109010AA156460Hs.44229dual specificity phosphatase2.9
12
130095F01831Hs.14838ESTs 2.9
106618AA459249Hs.8715ESTs; Weakly similar 2.9
to Similarity with
snail
103427X97303 H.sapiens mRNA for 2.9
Ptg-12 protein
133980D00760Hs.181309proteasome (prosome; 2.9
macropain) subunit;
alph
111353N90430Hs.6616ESTs 2.9
105344AA235303Hs.8645ESTs 2.9
134498M63180Hs.84131threonyl-tRNA synthetase2.9
117910N50828Hs.12940zinc-fingers and homeoboxes2.9
1
118903N90774Hs.132207ESTs; Moderately similar2.9
to !!!! ALU SUBFAMIL
55 121713AA419198Hs.105577ESTs 2.9
129080H19307Hs.108507ESTs 2.9
129404AA172056Hs.111128ESTs 2.9
129457X55330Hs.207776asparfylglucosaminidase2.9
130352D87450Hs.154978KIAA0261 protein 2.9
133415X69699Hs.73149paired box gene B 2.9
120649AA287115Hs.99697ESTs 2.9
131257AA256042Hs.24908ESTs 2.9
134480AA024664Hs.83916NADN dehydrogenase 2.9
(ubiquinone) 1 alpha
subco
116734F13789Hs.93796DKFZP586D2223 protein 2.9
65 105028AA126719Hs.25282ESTs 2.9
114986AA251010Hs.87807ESTs 2.9
105651AA282481Hs.18439ESTs 2.9
101714M68874' Human phosphafidylcholine2.9
2-acylhydrelase (cP
123398AA521265Hs.105514ESTs 2.9
70 106007AA411462Hs.t ESTs; Weakly similar 2.9
1042 to veli i [H.sapiens]
109450AA232183Hs.173042ESTs; Weakly similar 2.9
to !!!! ALU SUBFAMILY
J
104685AA010530Hs.9599Human BAC clone GS025M022.9
from 7q21-q22
108677AA115629Hs.118531ESTs 2.9
116028AA452112Hs.42644thioredoxin-like 2.9
75 105404AA243303Hs.21187ESTs 2.9
132365AA598694Hs.46541Homo sapiens PAC clone2.9
DJ0894A10 from 7q32-q3
f W52480Hs.56148ESTs; Moderately similar2.9
19638 to NY-REN-58 anfigen
124637N8071 Hs.75798Human DNA sequence 2.9
fi , from clone 1183121
on chro
130588AA287735Hs.16411Human DNA sequence 2.9
from clone 1189824
on chro
105640AA281623Hs.7525ESTs; Weakly similar 2.9
io KIAA0742 protein
[H.s
131818239297Hs.3281neuronal pentraxin 2.9
II
119298T23820Hs.155478cyclin T2 2.9
128742D00763Hs.251531proteasome (prosome; 2.9
macropain) subunit;
alph
115089AA255876Hs.86919ESTs; Weakly similar 2.9
to !!!! ALU SUBFAMILY
J
152
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
100468D89289Hs.118722fucosyltransferase 8 2.8
(alpha (1;6) fucosyltran
132920L06133Hs.606ATPase; Cu++transporiing;2.8
alpha polypeptide
113490T88700Hs.173374ESTs 2.8
133451Y00764Hs.73818ubiquinol-cytochrome 2.8
c reductase hinge protei
128770H98645Hs.143460protein kinase C; nu 2.8
129122N62515Hs.108790ESTs 2.8
104827AA035630Hs.8551PRP41STKIWD splicing 2.8
factor
111348N90041Hs.9585ESTs 2.8
130987845698Hs.21893ESTs; Weakly similar 2.8
to cAMP inducible 2
prot
1 102139015932Hs.2128dual specificity phosphatase2.B
~ 5
114902AA236359Hs.39504ESTs 2.8
106094AA419461Hs.18127ESTs 2.8
126438N93125Hs.137300ESTs 2.8
107129AA620553Hs.4756flap sUucture-specific 2.8
endonuclease 1
15 104491N71513Hs.39328ESTs 2.8
105043AA132239Hs.11810ESTs; Weakly similar 2.8
to CD4.2 [C.elegans]
106855AA486182Hs.17975ESTs 2.8w
109695F09530Hs.180591ESTs; Weakly similar 2.8
to RO6F6.5b [C.elegans]
120455AA251083Hs.104347ESTs 2.8
130861N23393Hs.20509ESTs 2.8
131649AA481254Hs.30120ESTs 2.8
128517AA280617Hs.100861ESTs; Weakly similar 2.8
to p60 katanin [H.sapien
100486HGi Ras-Like Protein Tc4 2.8
112-HT1112
116729F13700Hs.1 ribonuclease P; 40kD 2.8
1 subunit
5823
101851M94250Hs.82045midkine (neurite growth-promoflng2.8
factor 2)
115465AA286941Hs.43691ESTs 2.8
100137D13627Hs.15071chaperonin containing 2.8
TCP1; subunit 8 (theta)
125837H05323Hs.146401endothelial monocyte-activating2.8
polypeptide
131562090551Hs.28777H2A histone family; 2.8
member L
3 129445AA306121Hs.111515ESTs; Weakly similar 2.8
~ to predicted using
Genef
129239D31544Hs.109701ESTs; Moderately similar2.8
to weak similarity
t
106507AA452584Hs.91585protein phosphatase 2.8
1; regulatory (inhibitor)
101664M60752Hs.121017H2A histone family; 2.8
member A
129426AA412087Hs.168272EST; Highly similar 2.8
to protein inhibitor
of a
35 103437X98260Hs.82254M-phase phosphoprotein 2.8
11
129821F11019Hs.12696cortacGn SH3 domain-binding2.8
protein
130160239228Hs.151344UDP-Gal:betaGIcNAc beta2.8
1;3-galactosyltransfe
104257AF006265Hs.9222estrogen receptor-binding2.8
fragment-associated
116204AA465701Hs.108646ESTs 2.8
125914AA262925Hs.180034cleavage stimulation 2.8
factor; 3' pre-RNA;
subu
131510AA207114Hs.27842ESTs; Weakly similar 2.8
to similar to i-acyl-gly
106291AA435551Hs.30824ESTs 2.8
122761AA459296Hs.105039ESTs; Weakly similar 2.8
to !!!! ALU SUBFAMILY
J
107056AA600310Hs.18720programmed cell death 2.8
8 (apoptosis-inducing
f
45 108535AA084505Hs.226440Homo sapiens clone 248812.8
mRNA sequence
116226AA478729Hs.76450ESTs 2.8
120266AA173939Hs.193902ESTs; Weakly similar 2.8
to inner centromere
prot
128654H20689Hs.103180actin-like 6 2.8
116726F13681Hs.42309ESTs 2.7
132640033821 Tax1 (human T-cell leukemia2.7
virus type I) bin
133273AA147725Hs.69469dendriflc cell protein 2.7
108846AA132983Hs.44155DKFZP586G1517 protein 2.7
105621AA280865Hs.6375Homo Sapiens mRNA; cDNA2.7
DKFZp564K0222 (from
c
129164AA282183Hs.109045ESTs 2.7
133618078524Hs.75251DEADIH (Asp-Glu-Ala-AspIHis)2.7
box binding prot
120521AA258785Hs.107476ATP synthase; H+transporting;2.7
milochondrial
116429AA609710Hs.82837Human chromosome 3p21.12.7
gene sequence
110984N52006Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypepfld2.7
100372D79997Hs.184339KIAA0175 gene product 2.7
()~125134W19228Hs.100748ESTs 2.7
129254AA453624Hs.1098deoxynucleotidylUansferase;2.7
terminal ~
102339037022Hs.95577cyclin-dependent kinase2.7
4
106589AA456646Hs.28661ESTs 2.7
119118844122Hs.42743ESTs; Weakly similar 2.7
to predicted using
Genef
65 105973AA406320Hs.21201DKFZP566B0846 protein 2.7
106317AA436568Hs.172140ESTs 2.7
115551AA365527Hs.177861ESTs; Highly similar 2.7
to CGI-110 protein
[H.sa
103789AA096178Hs.70337immunoglobulin superfamily;2.7
member 4
105079AA743190Hs.12677ESTs; Highly similar 2.7
to CGI-147 protein
(H.sa
109299AA205649Hs.86371zinc finger protein 2.7
254
122089AA432136Hs.98682ESTs 2.7
129108L20321Hs.1087serinelthreonine kinase2.7
2
129385D82675Hs.110950Homo Sapiens clone 250072.7
mRNA sequence
131412034044Hs.124027SELENOPHOSPHATE SYNTHETASE2.7
; Human selenium d
75 104052AA393164Hs.97644mammaglobin 2 2.7
116254AA481146Hs.41086ESTs; Weakly similar 2.7
to OXYSTEROL-BINDING
PRO
106878AA488872Hs.12314Homo Sapiens mRNA; cDNA2.7
DKFZp586C1019 (from
c
114652AA101416Hs.107149ESTs; Weakly similar 2.7
to PTB-ASSOCIATED SPLICI
106831AA482014Hs.29463centrin; EF-hand protein;2.7
3 (CDC31 yeast homo
101445M21259Hs.1066small nuclear ribonucleoprotein2.7
polypepflde E
124428N36881Hs.82202ribosomal protein L17 2.7
114471AA028074Hs.103387ESTs 2.7
102051007550Hs.1197heat shock lOkD protein2.7
1 (chaperonin 10)
106916AA490814Hs.24170ESTs; Weakly similar 2.7
to ribosomal S1 protein
153
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
116142AA460649Hs.39457ESTs 2.7
109912H05509Hs.24639ESTs 2.7
103193X70476Hs.75724coatomer protein complex;2.7
subunit beta 2 (bet
102046007151Hs.182215ADP-ribosylation factor-like2.7
3
104567864534Hs.101469ESTs 2.7
112996T23539Hs.7165zincfingerprofein 259 2.7
118138N57773Hs.93560ESTs; Weakly similar 2.7
to Ug [R.norvegicus]
123095AA485724Hs.192119ESTs 2.7
124315H94892Hs.6906v-rat simian leukemia 2.7
viral oncogene homolog
1 124447N48000Hs.140945Homo Sapiens mRNA; 2.7
~ cDNA DKFZp586L141
(from c7
132834H77546Hs.57898ESTs; Highly similar 2.7
to NY-REN-49 antigen
[H.
107529Y12065Hs.5092nucleolar protein (KKEID2.7
repeaf) '
130648AA075427Hs.17296ESTs; Weakly similar 2.7
to (prediction
106685AA461551Hs.16251ESTs; Highly similar 2.6
to 73 kDA subunit
of cle
15 133848AA093287Hs.76728ESTs 2.6
134880AA092376Hs.9060615 kDa selenoprotein 2.6
128871AA400271Hs.106778Homo Sapiens mRNA for 2.6
putative Ca2~-Uansport
106846AA485223Hs.34892ESTs 2.6
119892W84548Hs.94896ESTs 2.6
132309AA460917Hs.2780jun D proto-oncogene 2.6
132923021858Hs.60679TATA box binding protein2.6
(TBP)-associated fac
114365241688Hs.i8653ESTs 2.6
114162238909Hs.22265ESTs 2.6
133370AA156897Hs.72157DKFZP56411922 protein 2.6
25 106818AA480890Hs.3542ESTs 2.6
133501W16684Hs.74284ESTs; Moderately similar2.6
to Similar 1o S.cere
100530HG1869-HT1904 Male Enhanced Antigen 2.6
130553AAd30032Hs.252587pituitary tumor-Uansforming2.6
1
108917AA137078Hs.173648ESTs 2.6
122249AA436679Hs.258543ESTs; Highly similar 2.6
to CGI-07 protein
[H.sap
119598W45531Hs.94642ESTs 2.6
119902W84865Hs.40094Human DNA sequence 2.6
from clone 167A19
on chrom
133272AA465016Hs.69423kallikrein 10 2.6
132575AA045365Hs.5188ESTs; Weakly similar 2.6
to 60S RIBOSOMAL PROTEIN
35 130459AA460264Hs.155983KIAA0677 gene product 2.6
133083N70633Hs.6456chaperonin containing 2.6
TCP1; subunit 2 (beta)
131130T19399Hs.23255nucleoporin 155kD 2.6
112043843317Hs.26312glioma amplified on 2.6
chromosome 1 protein
(feu
116146AA460701Hs.193200ESTs 2.6
4~ 122378AA446100Hs.103617ESTs 2.6
103134X65724Hs.2839Norrie disease (pseudoglioma)2.6
133395AA491296Hs.72805ESTs 2.6
115652AA405098Hs.38178ESTs 2.6
104975AA086071Hs.50758chromosomo-associated 2.6
polypeptide C
4S 134691M59979Hs.88474prostaglandin-endoperoxide2.6
synthase 1 (prosta
112869T03313Hs.4747dyskeratosis congenita2.6
1; dyskerin
100092AF000231Hs.75618RAB11A; member RAS 2.6
oncogene family
102635066838Hs.79378cyclin A1 2.6
104490N71503Hs.43087ESTs; Weakly similar 2.6
to dysfedin [H.sapiensJ
106813AA479922Hs.181022ESTs 2.6
106872AA487907Hs.18282ESTs; Highly similar 2.6
to unknown [H.sapiens]
107022AA599041Hs.28866programmed cell death 2.6
10
107113AA610073Hs.23900ESTs; Weakly similar 2.6
to oligophrenin-1
like p
113281T66300Hs.112356Homo Sapiens mRNA for 2.6
IipoylUansferase;
comp
115586AA399218Hs.92423ESTs 2.6
S
115779AA424183Hs.70945ESTs 2.6
122895AA469946Hs.105325ESTs 2.6
124726815740Hs.104576carbohydrate (keratan 2.6
sulfate Gal-6) sulfolra
129775894659Hs.12420ESTs 2.6
131991AA251909Hs.36708budding uninhibited 2.6
by benzimidazoles
1 (yeas
132518D57975Hs.5064ESTs 2.6
134612AA451712Hs.171581ESTs; Highly similar 2.6
to ubiquitin Gterminal
130313AA620323Hs.154320ubiquitin-activating 2.6
enzyme E1C (homologous
t
131971870167Hs.3611ESTs 2.6
65 133175AA134767Hs.66666ESTs 2.6
102083010323Hs.75117intedeukin enhancer 2.6
binding factor 2;
45kD
125670A1432621Hs.82685CD47 antigen (Rh-related2.6
antigen;integ~n-as
121822AA425107Hs.97016ESTs; Moderately similar2.6
to SH3 domain-bindin
106719AA465171Hs.236844ESTs 2.6
70 130029AA236412Hs.236510ESTs; Moderately similar2.6
to PFT27 [M.musculus
124328H97781Hs.14415ESTs; Highly similar 2.6
to CGI-108 protein
[H.sa
105387AA236951Hs.108636chromosome 1 open reading2.6
frame 9
103073X59417Hs.74077proteasome (prosome; 2.6
macropain) subunit;
alph
116294AA489000Hs.93748ESTs; Moderately similar2.6
to TRANSCRIPTION FAC
75 135339D59269Hs.127842Homo Sapiens mRNA full2.6
length insert cDNA
clo
125390H95094Hs.75187Uanslocase of outer 2.6
mitochondria) membrane
2
102504052077Hs.247948Human mariner) transposase2.6
gene; complete con
131076H44386Hs.22666ESTs 2.6
114096238342Hs.27007chromosome condensation)-like2.6
120402AA234339Hs.50282GTP-binding protein 2.6
raga
102125014550Hs.107573sialylUansferase 2.6
134653AA452818Hs.87385ESTs 2.6
101959S80343Hs.180B32arginyl-tRNA synthetase2.6
116766H13260Hs.95097ESTs 2.6
154
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
104954AA074514Hs.26213ESTs; Weakly similar 2.5
to protein [H.sapiens]
108771AA127924Hs.71034ESTs 2.5
116439AA610068Hs.43913PIBFt gene product 2.5
133859086782Hs.17876126S proteasome-associated2.5
padl homolog
132792AA401903Hs.242985hemoglobin; gamma G 2.5
129620AA010686Hs.239720ESTs; Weakly similar 2.5
to KIAA0691 protein
[H.s
120296AA191353Hs.22385ESTs; Weakly similar 2.5
to KIAA0970 protein
[H.s
115615AA401186Hs.48617ESTs 2.5
102983X17620Hs.118638non-metastatic cells 2.5
1; protein (NM23A)
expre
1 106288AA435536Hs.24336ESTs 2.5
~
107444W28391Hs.5181proliferafion-associated2.5
2G4; 38kD
104525816007Hs.75355ubiquifin-conjugafing 2.5
enzyme E2N (homologous
128917AA204876Hs.206097oncogene TC21 2.5
102299032907Hs.15554537 kDa leucine-rich 2.5
repeat (L88) protein
I 115363AA282071Hs.152759aclivalor of S phase 2.5
S kinase
130399AA449417Hs.155356Homo Sapiens mRNA for 2.5
putafive glucosyllransf
130752D50927Hs.18895tousled-like kinase 2.5
~ 1
132724AA417962Hs.55498geranylgeranyl diphosphate2.5
synlhase 1
106743AA476352Hs.21938ESTs; Weakly similar 2.5
to KIAA0704 protein
[H.s
128949AA190993Hs.8850a disintegrin and metalloproteinase2.5
domain 12
125685A1040346Hs.4943hepatocellularcaroinoma2.5
associated protein;
105826AA398243Hs.21806ESTs; Moderately similar2.5
to similar to NEDD-4
110841N31610Hs.18645ESTs; Weakly similar 2.5
to partial CDS (C.elegan
111987842036Hs.6763KIAA0942 protein 2.5
132669AA188378Hs.54602ESTs; Weekly similar 2.5
to 60S RIBOSOMAL PROTEIN
100398D84557Hs.155462minichromosome maintenance,
deficient (miss; S 2.5
130800AA223386Hs.19574ESTs; Weakly similar 2.5
to katanin p80 subunit
[
114481AA033562Hs.15i572ESTs 2.5
113404T82323Hs.70337immunoglobulin superfamily;2.5
member 4
100260D38491Hs.174i35KIAA0117 protein 2.5
103563122534Hs.150402activin A receptor; 2.5
type I
104573868952Hs.29780ESTs 2.5
105025AA126336Hs.22744ESTs; Weakly similar 2.5
to ZINC FINGER PROTEIN
1
105524AA258158Hs.22153ESTs; Weakly similar 2.5
to KIAA0352 [H.sapiens]
3 106157AA425367Hs.32094ESTs 2.5
S
107243D59489Hs.34727ESTs 2.5
109920H05733Hs.30558ESTs 2.5
109981H09552Hs.26090ESTs; Weakly similar 2.5
to T20B12.1 [C.elegans]
114518AA046407Hs.106469suppressor of varl 2.5
(S.cerevisiae) 3-like
1
40 114768AA149007Hs.182339Ets homologous factor 2.5
118906N91000Hs.94433ESTs 2.5
119025N98926Hs.55209ESTs; Weakly similar 2.5
to DMR-N9 PROTEIN
[H.sap
131712N29502Hs.30991KIAA0957 protein 2.5
132233X04706Hs.93574homeo box D3 2.5
45 132740AA227751Hs.55896ESTs 2.5
115239AA278650Hs.73291ESTs; Weakly similar 2.5
to similar to the
beta t
128820F10338Hs.106309Friend of GATA2 2.5
124049F10523Hs.74519pdmase; polypepfide 2.5
2A (58kD)
128781X85372Hs.105465small nuclear ribonucleoprotein2.5
polypepfide F
121361AA405494Hs.183052ESTs 2.5
134133X93920Hs.180383dual specificity phosphatase2.5
6
102502051678Hs.78050small acidic protein 2.5
115875AA433943Hs.43946ESTs; Weakly similar 2.5
to Weak similarity
to Ye
132874AA425776Hs.58609ESTs 2.5
55 109646F04543Hs.5028DKFZP56400423 protein 2.5
111197N68093Hs.22909ESTs 2.5
102968X16396Hs.154672methylene tetrahydrofolate2.5
dehydrogenase (NAD
124911888992Hs.123645ESTs 2.5
106628AA459657Hs.12311Homo Sapiens clone 2.5
23570 mRNA sequence
60 116988H82527 ys69e12.s1 Soares refina2.5
N2b4HR Homo Sapiens
131075Y00757Hs.2265secretory granule; 2.5
neuroendocdne protein
1 (
133578X78627Hs.75066franslin 2.5
100420D86983Hs.118893p53-responsive gene 2.5
2
130743W87710Hs.18724Homo Sapiens mRNA; 2.5
cDNA DKFZp564F093
(from c1
65 122465AA448164Hs.99153ESTs; Highly similar 2.5
to CGI-73 protein
[H.sap
115117AA256492Hs.49007poly(A) polymerase 2.5
124582N68477Hs.108408ESTs; Highly similar 2.5
to CGI-78 protein
[H.sap
104771AA025911Hs.24994ESTs; Highly similar 2.5
to CGI-53 protein
[H.sap
108059AA043944Hs.62663ESTs 2.5
105628AA281251Hs.35696ESTs; Weakly similar 2.5
to putafive zinc finger
109261AA195255Hs.61779ESTs 2.5
119789W73140Hs.50915kallikrein 5 2.5
130512AA045304Hs.181271ESTs; Highly similar 2.5
to CGI-120 protein
[H.sa
134402025165Hs.82712fragile X mental rotardafion;2.5
autosomal homol
75 104769AA025887Hs.114774ESTs; Weakly similar 2.5
to !!!! ALU SUBFAMILY
J
125787, Hs.29403ESTs; Weakly similar 2.5
AA744748 to PROBABLE ATP-DEPENDEN
131775AA459555Hs.31921KIAA0648 protein 2.5
TABLE 7B:
Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers
155
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
Pkey CAT Number Accession
101335 d6413-1 L49054 N874d7 AA248791 AA452193 A1015525 AI762070 AA781526
AW183498 AA625682 AI268713 AA400391 A1193725 AW590304
W56360 AA936067 AI990398 AA406183 AA628888 AA844206 AA621117 A1141092 AI808150
BE379750 AI351482 AAA93527 AA405119
AA400562 AW368723 AA463811 AW242927 850034 W56334 F21257 AA164314 BE074125
AA470924 AI307439 W16738 AA026647
T35999 T19178 AA164313 AI74d010 A1015466 A1014921
100906 4312-1 AU076916 BE298110 AW239395 AW672700 NM 003875 U10860 AW651755
BE297958 C03806 AI795876 AA644165 T36030 AW392852
AA446421 AW881866 AI469428 BE548103 T96204 894457 N78225 Ai564549 AW004984
AW780d23 AW675448 AW087890 AA971d54
AA305698 AA879433 AA535069 AI394371 AA928053 AI378367 N59764 AI364000 AI431285
T81090 AW674657 AW674987 AA897396
AW673d12 BE063175 AW674408 A1202011800723 AI753769 AI460161 AW079585 AW275744
AI873729 D25791 BE537646 T81139
Roo722
102221 3861_1 NM-006769 U24576 AWi61961 AW160473 AW160465 AW160472 AW161069
AI824831 AW162635 AI990356 AW162477 AW162571
AI520836 AW162352 AW162351 AW162752 AI962216 AI537346 AA853902 H17667 BE045346
BE559802 BE255391 AA985217 AA235051
AI129757 AW366451 T34489 D56106 D56351 AI936579 AW023219 AW889335 AW889120
AW889232 AW889175 BE093702 AW889349
AA147546 AI952998 AA912579 AI143356 AW902211 864717 AW157236 AI815242 D45274
AW263991 AA442920 AA129965 AL035713
AI923255 AI9d9082 AI142826 A1684160 AI701987 AI678954 AI827349 BE463635
AW628092 AW302281 AA493203 BE348856 BE536419
AW193969 AW673561 AW592609 AI224044 H43943 AA091912 849632 848353 AI568409
848256 AI198046 H27986 H43899 AI678759
AI680310 AI624220 H17052 AA156410 N56062 AI699430 AA664529 T09406 T10459
AA627506 AI379584 N83831 N88633 AW022651
AA971281 AA2d8036 A1039197 AI914689 AA973825 AL047305 AA129966 AI798369
AW264348 AI445879 AI658759 N67924 AI933507
AI216121 AI33317d T10972 AI375028 AI186756 AI273778 AA610487 AI7979d6 AA853903
AA903939 AI338587 AI278494 AW627595
AA904019
101714 30725_1 M68874 AL022147 M72393 AL049797 BE439441 T27650 AI766240
AW150345 AW778943 AI627464 BE439479 AA587049 AI277900
AI984983 AI630935
116803 55078 4 H47357 W33034 H55976 H55975 867830 AA527091 F24d82 AW841585
R6651d
116988 185904-1 AW953679 AW953680 AA244436 H82527 AA361046 AA244483 H82526
~J~ 132640 179_1 AW162087 AA224538 AA471218 AA088655 AA375275 8E440052
AF090891 AA324435 AF063549 A1110675 AA322223 AW953306
AA233590 AW949864 AW949859 AA383721 AA081878 U33821 NM 006024 AA350900
AA081588 AI148087 AF268075 AA088185
AI142478 AA081824 AI887930 AA070570 BE1852d8 AI459825 BE257794 AA420459
AA420859 AA777997 AA081219 AW815721
AW854758 AA157932 BE018208 AW378974 AL041212 AI247564 AW581897 A1002897
BE5432d2 AI811690 AW852076 AW852270
AA360969 AA094943 AA090680 AW601554 AA099673 AA662226 AA356814 AA330174
AA187544 C02751 AA315460 BE168358
AW080447 AI813764 AI624222 AW156901 AI954032 AW473780 AI861975 AA173643
AW511541 AI951492 BE301686 AA669760
BE182212 AA081009 T69431 AI186207 AA604124 AA7073d6 AA173953 A1016700 AI125916
AA358962 AI673719 T90593 T90497 T10776
AW513002 AW30d292 AA724885 AW474759 AI811621 AW068925 AA666305 AI580161
Ai128023 AW471151 AA5348d9 AA666358
A1078833 AI139223 AI244874 AI381658 AW263441 AI432440 AW802882 N66401 AA224251
AI167469 AI141060 AA099214 AI537130
AL120428 AA948655 D531 1 0 AA076099 AA938617 AA826543 AI357914 AA56509B
AA807994 AI2888t 2 AA632832 AA157933 AA639802
3 5 AA634268 AA282337 AA551431 AA557374 AA256923 AA872943 AA009665 H89626
AA810386 T92925 T36145 AA632190 AA130436
AI686635 AA130437 AW392904 AW392839 AW392848 AW392836 AA729737 AA070450
AW392890 WOd825 AA771848 AA084634
AA481985 AI263840 AI801006 AA235380 AI954229 AI559330 AI208724 AA887638 T25894
AA041269 Wd4443 AI581770 W46171
AA878485 W46535 AA197336 AA894945 AA394224 AI76683d AI582590 A1033007 AA481889
AW190598 AW392855 827279 AA398137
AI248407 AI241386 AI991753 AI826585 AA865699 A1096806 AI833030 AA041279
AW888745 AI703279 N70572 AI912553 BE549931
AI240422 AW376187 AW591692 AA975905 AW61 4967 AA009666 W44332 AA664659 T06561
BE468150 AI650695 AA587920 AI473310
A1032991 AA256499 AW104241 BE163782 AI984973 BE163613 AI263906 AA628191
AA282072 BE163769 BE163775 AI492939 AI473315
D56907 AA587930 H89480 AI362373 AA59B483 D56595 AI167590 C16223 AI935415
D62555 D62884 D63130 AI760286 AI650286
AW173598 AI499145 AI122566 AW903d08 AI810569 AA854936 BE049510 D62065 D61900
D62101 827475 AI469835 AI669086 N80399
N48922 N487d6 AA481381 822858 H13912 AC004549 AW602500 AW768788
45 103427 43892_1 BE514383 AA071273 AW247987 AW673286 8E312102 AW749824
BE071985 AW577383 BE071945 BE072005 AW577355 BE071965
AW239231 BE072000 BE071960 AW577360 AW749830 AW373020 X97303 AW999522 BE000192
BE562219 BE266655 BE264970
103631 152_34 864730 AF214731 T19173 BE258318 AF161446 BE542228 8E383856
BE206748 BE543260 AA640735 AA788907 BE251313 BE221852
AW855357 AA224407 AW855346 BE150454 AW070651 BE326867 AW051698 AI829278
AI470927 AW855345 AI804942 AI971004
BE046620 AI863664 AA808492 AI915971 BE046949 AW590711 AI468066 BE409685
AA332653 BE385394 AA852623 BE255591
BE254968 AA211871 BE255493 BE257727 BE255389 BE257491 BE262528 BE261296
BE313277 BE261714 BE314316 228434 AA315545
BE008562 BE012093 BE161393 T31969 AA305848 AW955238 BE619156 AI191748 AA323396
AW361760 AA216118 BE264939 AA325954
AW580281 AA302597 AW888908 AW888893 BE312970 AA134402 H52679 AA478191 T3d090
AW961505 224771 AA179552 857244
BE315207 AW583121 AI372747 T33143 AW377460 T33141 814922 AW352414 H93249
AWd05576 T33102 889545 N46625 H08434
BE165062 AW367891 H93121 H47325 T30931 AW402852 H47410 220368 T18928 T30758
H93254 AW389725 896628 AI372407 888995
S S AI815980 AW157278 AW607664 AWi 63288 AA133492 AA099328 AA157348 AI816063
AW449556 AAi 57252 AW608980 H66576
AW821127 T32030 AW856058 AA032188 242120 Ri 8582 AW402392 BE408021 AA280989
AA039427 AA035354 AW328008 T94186
897481 AA181444 AA774697 BE613141 AW630221 H13066 AI124578 AW754481 BE262112
AW839942 H60108 AW36d002 AW363800
BE547161 BE082634 AA642471 BE619719 8E082719 W28879 AW794944 C01685 AI291127
AW166099 AI936102 AI478929 870284
AA872914 W31065 N54216 AI568741 H56262 NM_017425 248570 A1831777 T75007
AA354867 AA427988 AI922844 AA733170
AW821145 BE081547 AW881571 AW881573 AW055249 AA204724 Aid17415 AI127303
AI355013 A1039527 AW593259 AA576745
AI457317 AW593236 H93126 BE396072 AL134941 AW629175 AI424011 AA115732 AA179986
AI334944 AW367922 AW152304 AA806752
AI312418 AW935023 BE301136 AA032258 AI829922 AI372406 BE177074 AW513743
AI151526 AA975643 AA478034 AI814920 AW080063
A1032624 BE177107 AA319768 AW935098 A1017620 AA974477 D51441 C14225 AL043583
D80145 AI690771 AW009711 AW881570
AI220431 N51090 Ai 143003 AA96i480 AA039351 A1094885 A1096520 AA179553
AA593974 AI373929 AA677252 AA687374 AA886867
6S AA312863 AI150654 AI138450 AA133209 H99368 A1565632 AW070496 AI539748
H59455 A1811537 H52680 T74907 AI499657 896670
AA854796 AA427863 AA224345 AA889899 AI347782 AA931056 A1076059 AI360841
AI797975 AI36226B AI200968 BE350785 897433
N98499 AA134403 AA035355 AW263162 AI369607 D80144 AI376627 AI520801 AA365942
AI707705 AI123495 T33101 H08716 AA804238
AA922201 AA723522 AW183592 AI445884 F34614 AW022342 AA363998 AA568793 AA152475
D31233 AA852622 AA099862 AI129147
AA922699 AA782664 T33142 T30009 T32913 AI676138 AI914657 N34899 AI372746
AI265911 AI352444 AA4d3158 AA910603 AI420273
AA86B050 A1277700 C14224 AW082087 841447 238385 AI911845 AI961888 891976
FOd560 AA661955 AI857675 AA369666 AA424207
N79953 AA382958 AA894626 AI884964 AA846989 AA215454 AI742580 AI339437 AI806879
A1091373 AA782558 A1026868 AW590904
AW204599 BE348235 A1819318 AA122324 AA939221 AW139711 AA131608 AW613548
AA122286 AI309179 AA437247 AW339322
A1671306 AW439848 AA131701 A1078075 N64624 AA812881 A1140547
129097 25953_1 BE243933 AA355449 T29766 F08396 N83324 NM 006963 S50223
A1207648 AA258092 AA113952 AI311718 AI128612 AW607449 M77172
75 AI951311 X52346 AA903307 AI569810 N55421 W77876 837223 883788 AA031666
H47092 AA133451 AA311095 AA906963 HB7667
N56058 AA393593 W24864 Hi0710 F06925 F07239 AW3861d0 AA325018 AA235950
AW373176 N57158 AA258093 N39467 821609
BE089979 834173 AW889005 AA745644 AI693852 AA424914 AA744771 W72632 AI291213
AA524318 AI472134 AI911230 AA528418
AA115745 AA775720 AI671134 AA975044 AW29B117 AA321015 N26288 AW952194 AI743379
AI204233 AI801026 AA830690 A1146980
AW104611 AI338576 821507 AI367623 BE244484 AI269308 AA031667 AI884346 AA731989
AA988943 AA235951 AA807887 AA642645
AI246489 N29739 AI216718 AI383349 A1038618 AI351476 AA806031 AI914178 H10711
A1095573 H89220 AW470854 AA729015 883353
AA782239 834295 H87165 AW419059 AI653689 240349 H8911 d AW07d506 AA397785
AA888377 AI911228 F03193 AI468783 AA702615
AI830829 AA748323 837224 AA424915 AA731647 H47183
120695 9683-3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691
AI927301 AI740458 AI796100 AI935603 AW052210 AA970201
AI633384 AA425910 A1017004 AI241295 AA402816 AA291468
156
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
10035237786_1AL133887
D64159
AF112218
AI766633
AL039303
AL133888
BE620604
AW976259
AW262792
AW591383
AI365413
N36652
AA807027
AI472041 BE620065
10108413883_1AW409934 AA316055 BE621134 AA171883
AW245855 BE27249d L05425 BE250310
AU077157
AW163245
AW161434
AW250083
NM BE394454 AA126101 AA581348
013285 AA303227 AA058438 AA126544
BE311494
AA858436
AA308223
AW362598
AA373618
AL135350
AW996947
AA403201
AA446682
W79685
AW246249
AW577783
AW002316
AA320025
AW753913
AI798554
AW070650
BE250413
AW250835
BE076336
AI925558
AI907634
AW804193
AW804270
AA902387
AW804232
AW804255
AW607751
AI909114
AW157242
AA93d590
AI628921
AI470650
AW409935
AW172793
AA401208
AW162279
AA888018
BE206452
AI826742
AA857353
AA48361d
AA126418
AA722289
AA780182
AW768894
AW183614
AW156969
AI244063
AA863491
AI376281
AA582490
AA846248
AI47d094
AW246802
AA446557
AA126000
AI699045
AI702310
AI253092
AA171554
AA831455
AW118384
AI954511
AI760439
AI867001
AA493881
W81287
AA515590
AA659297
AA635139
AA659293
AA766044
AA196109
N32569
AI907635
10050226409_1015979X17544 W52755 NM 003836T49116 AA333753 BE262238
212172 AW370136 BE262564BE313737 H38153 AW583056
828890
BE259532
D16897
AA885610
AA911293
AA319627
894472
829022
AA443405
896397
W04904
W01746
W01204
N74203
N58621
AA701996 11577 AA575957 Al l 49135
AW418723 AW573058 AA772985 AI188918
N53220 AI372065
AA602813
AA576129
AA593786
AA9
AA575838
W60010
A1004576
AI131265
AA3198d5
T50070
AI335742
AA2352d5
W32706
AA447372
896355
N59573
AA904616
AI291224
I BE467454
S T49117
AI268620
AA928248
AA4d9494
AA318817
T49929
894473
H38154
A1076649
AW935307
AW605112
AW935433
AW935342 A1184857 AA319871 T29465
AW935310 C21134 219785 AA329107
AW935345 T52079
AI298308
AW935395
AW93538d
AW935346
C06234
AI951555
T49928
AA371745
AA369296
AA346673
882547
T50006
102398entrez_042359
042359
Tablests in ovarian cancer compared
8A about to normal adult fissues.
li 54 These were selected
genes from 35403 probesels
up-regulated on the AffymefrixlEos-Hu01
GeneChiparray e
such ratio
that of
th "average"
ovarian
cancer
to
"average"
normal
adult
tissues
was
greater
than
or
equal
to
4Ø
The
"average"
ovarian
cancer
level
was
set
to
the ous 4th highest amongst various
3rd ovarian non-malignant fissues.
highest cancers. In order to remove
amongst The
vari "average"
normal
adult
tissue
level
was
set
to
the
gene-specific malignant tissues was subfracted
background from both the numerator
levels and the
of
non-specific
hybridization,
the
15th
percentile
value
amongst
the
non-
denominator was
before evaluated.
the
ratio
TABLE
8A:
ABOUT
54
UP-REGULATED
GENES,
OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES
Pkey:
Primekey
Ex.Accn:ExempIarAccession
UG
ID:
UniGene
ID
Tifie:
UniGene
Title
ratio:
ration
tumor
vs.
normal
tissues
Pkey Ex. UG Tifie ratio
Accn ID
130941D49394Hs.21425-hydroxytryptamine 12.1
(serotonin) receptor
3A
101249L33881Hs.1904protein kinase C; iota11.8
132528AA283006Hs.50758chromosome-associated 11.5
polypepfide C
102610U650T1Hs.30743preferenfially expressed11.0
anfigen in melanoma
115536AA347193Hs.62180ESTs 10.0
129571X51630Hs.1145Wilmstumorl 9.3
105298AA233459Hs.26369ESTs 7.8
121779AA422036Hs.98367ESTs 7.3
104301Dd5332Hs.6783ESTs 6.9
132191AA449431Hs.158688KIAA0741 gene product 6.7
102136015552Hs.85769acidic 82 kDa protein 6.6
mRNA
101804M86699Hs.169840TTK protein kinase 6.5
132572AA448297Hs.237825signal recognition 5.9
particle 72kD
106738AA470145Hs.25130ESTs 5.8
108857AA133250Hs.62180ESTs 5.8
115291AA279943Hs.122579ESTs 5.8
132632N59764Hs.5398guanine-monophosphate 5.8
synthetase
116401AA599963Hs.59698ESTs 5.7
132725L41887Hs.184167splicing factor, argininelsedne-rich5.7
7 (35kD
129097S50223 HKR-T1=Kruppel-like 5.6
zinc finger protein
(puma
134520N21407Hs.257325ESTs 5.5 ,
108778AA128548Hs.90847general transcription 5.4
factor IIIC; polypepfid
131228AA279157Hs.24485chondroifin sulfate 5.2
proteoglycan 6 (bamacan)
116238AA479362Hs.47144DKFZP586N0819 protein 5.2
108055AA043562Hs.62637ESTs 5.1
132939076189Hs.61152exostoses (mulfiple)-like5.1
2
115909AA436666Hs.59761ESTs 5.0
120438AA243441Hs.99488ESTs; Weakly similar 5.0
to ORF YKR074w [S.cerevi
123494AA599786Hs.112110ESTs 5.0
109648F04600Hs.7154ESTs 4.9
132624AA164819Hs.53631ESTs 4.9
111234N69287Hs.21943ESTs; Weakly similar 4.9
to ORF YGL221c [S.cerevi
135242M74093Hs.9700cyclin E1 4.9
123005AA479726Hs.105577ESTs 4.8
116296AA489033Hs.62601Homo sapiens mRNA; 4.7
cDNA DKFZp586K1318
(from c
100661HG287d-HT3018 Ribosomal Protein L39 4.6
Homolog
111345N89820Hs.14559ESTs 4.6
102627066561Hs.158174zinc finger protein 4.5
184 (Kruppel-like)
106459AA449741Hs.4029glioma-amplified sequence-414.5
102305033286Hs.90073chromosome segregafion4.5
1 (yeast homology-like
129229AA211941Hs.109643polyadenylate binding 4.5
protein-interacfing
pro
130376840873Hs.155174KIAA0432 gene product 4.4
120619AA284372Hs.111471ESTs 4.4
122802AA460530Hs.256579ESTs 4.4
116416AA609219Hs.39982ESTs 4.3
~f0115094AA255921Hs.88095ESTs 4.2
126802AA947601Hs.97056ESTs 4.2
126892A1160190Hs.76127heot(homologoustothe 4.2
E6-AP (UBE3A)carboxy
105516AA257971Hs.21214ESTs 4.1
131985AA434329Hs.36563ESTs 4.t
157
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
114965 AA250737 Hs.72472 ESTs 4.0
120821 AA347dt9 Hs.96870 Homo sapiens mRNAfull length insertcDNAclo 4.0
134621 L025d7 Hs.172865 cleavage stimulation factor, 3' pre-RNA; subu 4.0
134161 097188 Hs.79440 IGF-II mRNA-binding protein 3 4.0
TABLE 8B:
Pkey: Unique Eos probeset identifier number
CAT number. Gene cluster number
1 O Accession: Genbank accession numbers
Pkey CAT Number Accession
101249 2520 1 L18964 NM X02740 L33881 AA095249 BE080871 AWfi05320 M85571
AA179776 AA160650 AW117327 BE467131 AW088338 AW937631
AW087514 AI480090 AI873147 157875 AI217d04 AA827196 AI279471 AA9fi9093
AA815168 AA988896 AI754623 128044 AW950302
AW950294 A1032193 AI953696 AI6305B3 AA062633 BE541355 AA180493 AW015748
AA255651
15 100661 23182 1 BE623001 L05096 AA383604 AW966416 N53295 AA460213 AW571519
AA603655
116401 95855_1 AW893940 AW978851 AA034240 AI686323 AI767653 AA829515 AA053933
AA737691 W92607 AW261869 AA835698 AA447216 A1623248
221891 AA835700 AA599963 120152 AA533167
116416 373989_1 AW753676 811789 AW001886 AA609219 AW780420 A1860557 AI280331
AI33d300 AI288870 AAfi69343 N29918 BE537790 AA934687
H79075 N42970 863752
132191 54683-4 AA507576 A1610269 A1380079 840309 A1203932 A1342128 A1342578
843110 AW583269 A1375234 A1092708 852802 A1028462 A1016062
AI189144 A1016691 W45515 AA551452 AA44943t 110046 AA42d059 N62822 AWt97701
AA465242 AI418989 AI942433 AI891115 BE302316
AI743979 AI283341 AW340338 AA774643 AW104778 A1078020 N21d87 H97562 AA970063
BE327945 F03880 F03885 AA970699 AI29846B
AI380330 AI247787 AA770467 AI200154 A1089863 A1089890 AI695738 W88524 AI471010
AA700191 AA778937 BE440182 879225 AA338236
AA548984 AA907692 N21250 AW904736 AI90933T AA987772 AW959228 A1149372 N29644
At0399fi7 AA677529 AI694291885811 N28fi72
AA465598 AA321185 AW130492 AI824479 AI682992
130941 2774_1 NM 000869 D49394 8E252349 AW249320 AW249140 AW250535 S82612
AJ003079 AJ005205 AW178407 AA811360 AW976407 AW976408
AW248903 AA731733 AA804189 AA703169 AI435492 A1076288 AA912176 AW248713
AA743457 808170 C06167 802351
1 15909 47548_1 AW872527 AA4538fi3 AA442475 AF086541 AA36580t AI692575
AW131631 AA732993 W96131 AA436666 AA453779 AA365504 AW959717
AA975337 AA365503 AI632902 AA659686 AA665087 C00396 AA988869
108778 18565_1 AF133123 NM 012086 AA128292 S81493 AL137453 BE614053 AA307628
BE009521 BE085659 BE085542 8E085598 AL120654 813165
AA429306 813465 855236 AW99d182 W00838 AW994417 AW994404 AW994426 AW994321
AA516147 AA345603 AW953009 BE315104
AI126654 AA626457 AA291327 H67983 H66271 H67976 AW270955 AA758221 A1023487
AI921811 AI953370 AF085850 870992 N25129
AW295143 AI433661 AW608361 AA873402 AI217453 AI953358 AA262143 AA928495
AI475268 AI167211 AW385961 AA259045 AI762630
AA428238 A1001932 AI735550 AI951370 AA766807 S81492 AA918976 A1040967 870939
AA4690fi5 170340 AA477fii5 AAd78070 AI0177d3
3 S AI608833 AI635824 AI186039 AA741312 A1040184 H67656 AA258221 AA731316
AI381293 AW298d73 855237 837375 AI768014 AA128548
AI206773 AI879827 864193
102136 17647_1 AA300576 015552 NM 014597 AA223318 AA171806 BE269461 AW578439
AW604388 AW953513 AA772816 AW604383 AW577851
BE169672 AW117711 AW366303 AW366302 AW366308 AW366304 AW366300 AI908432
AW591937 AI358420 AW272622 C75067 AI926471
AW002266 BEO6d947 BE064722 110372 AW838681 AI811119 AW262098 AA588547 AI916666
AI440083 A1078150 F24260 AA512919
40 A1953413 A1064798 AI420425 AAt9t324 BE503222 AI632721 AA180035 AA558329
W44843 110610 W38442 8E542869 A1125024 BE2795fi6
AW747936 AI589491 AA559096 A1090265 AA548959 AA223220 AW515936 AW368395
AW368407 BE540776 A1039762 AI584020 AA171691
108857 61 1 AK001468 AA190315 AA374980 AW961179 AA307782 AA315295 AA347194
AW953073 AW368190 AW368192 AA280772 AA251247 N85676
AI215522 Ai216389 N87835 812261 R57094 AI660045 AA347193 816712 AW1 1 9006
N55905 N87768 AW900167 AI341261 AI818674 D20285
A1475165 AA300756 840626 AI122827 AA133250 AI952488 AA970372 AA889845 AW069517
AI524385 AA190314 AI673359 AA971105
45 AI351088 AI872789 AI91905fi AI611216 AK001 472 BE568761 AA581004
102305 18424_1 AL043202 033286 NM_001316 AF053641 AL048759 N99830 AA263091
AW408174 N90467 884306 AA317882 BE613644 AA307378 110722
AA207207 AA315560 AA113938 AW386317 AW386316 L44546 AW386335 AA243317 AA7t3588
AA192541 AA649035 BE300737 AW752491
AW902334 AW993922 BE003403 AA251521 AA382754 AA339152 AA382619 H58600 H67810
170379 182109 D81644 D60375 H59003
8E075732 AA471242 H17790 F11801 184903 878076 BE614356 816380 816395 AA876127
W95535 AA1fi4768 AI279876 H02142 C18698
o AA365866 AW954410 AI539769 139128 ALt21103 AAt92466 AA213367 A1963800
BE090601220096 BE566508 A1969470 BE044090 165536
AA837311 AA075484 AA075621 AA778294 AA587266 169722 AA446118 X85624 AI334209
AI587101 AI281280 AA568602 AA946837 C75603
AA236997 AA459274 AI150191 AA165156 AI198839 AA789258 AI139373 AA236574
AI127770 AA678954 A1140786 AA113939 AI187231
AI754062 AI753243 AA934719 AW439362 H02038 C17463 A1400951 AA227539 N66040
889384 AA872668 AI3d4110 W95d20 AA164700
C05669 BE094097 AI826398 H58956 117222 AW139044 AI271344 116445 842323 C75565
AA165228 A1025443 AA165229 C21496 AI826239
55 AI868711 AA582354 AA524392 801549 801641221083 AA5284fi3 139127 AA989472
F09450 AA084485 BE004378 AW97d353 AA137250
AI27840fi AW609291 AA137249 AA142866 AA639198 AW609271 AW149760 At025112
AA236620 AA937248 090736 AW005487 AW67d427
BE397971 AW609285 165602 199684 197378 AW609366 185647 AI572235 199083
AA199583 AW303874 135523 AA586445 239669
AA459503 N95643 AW821210 AW813461 AW582064 AW609293 AW609320 AW609270 AW582085
AW582071 AW609318 AW813451
AW813456 AW582079 AW609276 AW609280 AW609290 AW582101 AW582102 AW609263
AW609317 AW60925fi AWfi09305 AW582063
F06655 AW605343 AA446d26 BE090595 AW969578 179852 A1082505 N63239 AI973168
A1086182 AA846711 AI874213 AA730605 AI927257
AA912624 D60376 110180 AA705847 A1018123 AA493197 167083 877739 AA953087
800885 AI370606 801642 AA862914 N57843
AW023353 H77d83 H68082 842337 H58601 197267
109648 708849 1 H17800 AI362549 AI671064 123526 F03426 F04694 F04600 AI635856
238715 F02039 AW022635
132528 11027 8 178736 AA284422 AA283006
65 101804 26687-1 M86699 NM 003318 AL133475 AA122377 121415 857092 AA8065fi9
AA811904 BE538323 841558 AA421620 AI337292 AA470077
AW795371 AA543024 AI677941 AI472200 AI215042 AA732384 AA837143 AA804229
AI907533 AI742701 AA121159 AI973225 AI620839
132572 31281 1 AI929659 AA227827 AF069765 AW408768 NM 006947 AF077019 AA220974
H07969 C14621 D52294 BE512960 BE614138 BE258539
BE251981 AA355433 AA481126 AW403053 BE542282 AI929818 AL120605 AW753079
AW391834 BE018603 BE395262 W21406 AW663259
AW975690 W93905 W96519 AI863832 AA443177 AA730942 199558 186581 W19444 N55583
AI701020 AI928986 AI857864 AI590849
AW081819 AA714970 AI122630 W04887 AW662427 AA602680 W93645 AA582946 AW008812
AA311187 AAd63631 AI421918 AI400518
AI92id04 AA143770 AA587675 BE302192 AASS3080 A1493386 AW327435 AW340871
Ati43616 AA68723i AA21896i AI362249 AI378345
N74716 AW969249 AA468581 AA516399 AI274726 A11312d4 AI572604 AI929236 AW327971
865637 N90309 H07877 W96486 AI358806
190801 AI383246 AI740957 186758 AI471248 AI864233 AA910590 A1079094 AW805781
AA709025 AW 196707 AW327436 AI903790
AI873956 199348 A1924643 AW 103910 A1802993 A1080390199098 Dt 9794 AW327972
A1935904 AI288575 AW360875 AA779784 N93574
75 AW769295 W32639 AA363094 N89012 W39751 AI29i329 A129i371 AA829411 AI985219
AI422775 AA918940 AA363108 AA192633
AF086131 AA373679 AAi 65043 AA355705 AI243507 A1027796 AA573461 AA757260
AI370979 AA574149 AA558276 N70650 AI478948
835393 AA448435 AA334fi59 AW879356 AA436527 AW972044 W25165 AA521219 A1094141
AI302096 AW578551 AW578534 AW390535
Al 1 31472 N50381 AA736938 A1089112 AA863053 A1359793 AA962268127353 D82590
AAdd8297 A1277168 A1368457 AA872737 AA330346
AA308346 AA3d2341 AA355159T85701 BE162893 199703
131985 113870_1 AA503020 A1858190 A1fi86571 AW615203 AW073686 AW172459
A1828762 AW150534 A1859795 AA411046 A1539195 AA404609 A1638559
AA434329 AA171844 A1684143 AA953518 AW470i O8 A1870700 AA706376 A1539668
AI683712 AA075579 AI682137 AA291512 AA55443i
H51315 AA404225 AA075632 AA172293 H51911
132624 42095_1 AA326108 W74020 AW61269B AI750909 AA487800 AJ270695 AA044941
H20708 AA296750 AA018401 AA378581 AW964159 AA018887
868533 AA525338 AA526640 H84308 AA278942 AA164818 AA847110182335 N25519
AA021474 N31381 N36297 AA838191 AA318932
15~
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
AA961206 N41430 N41439 AW630477 W37595 BE394538 AA365256 N47771 N34873
AA988105 A1242138 AW1d8523 A1978761 N50882
AA527448 AW086200 AI750910 N50868 AA709437 N519d6 AI222179 AA732883 H96742
AW615360 N53720 W37490 887362 AA613273
H98999 AI469022 AI368442 AI460122 N20486 N24087 AA164819 N24878 AW471270
AW590458 868240 AA594434 N20400 AI419626
AW500664 A1033658 AA593215 AA907408 AA713508 AI422627 H85551 AA923571 D62680
AW627456 H96206 AA016289 AA485896 N25691
132632 4312-1 AU076916 BE298110 AW239395 AW672700 NM 003875 010860 AW651755
BE297958 C03806 AI795876 AA644165 T36030 AW392852
AA446d21 AW881866 AId69428 BE5d8103 T96204 R94d57 N78225 AI564549 AW004984
AW780d23 AW6754d8 AW087890 AA97145d
AA305698 AA879433 AA535069 A1394371 AA928053 A1378367 N59764 AI364000 A1431285
T81090 AW674657 AW674987 AA897396
AW673412 BE063175 AW674408 AI202011800723 AI753769 AI460161 AW079585 AW275744
AI873729 D25791 BE537646 TSi 139 800722
102610 9336_1 065011 NM 006115 AW182053 BE383930 BE407839 BE409930 BE408826
AW370292 AA312859 AA136204 AW365852 AW365735
1 ~ BE622732 AW939295 AA781195 A1017284 AW375329 AW375366 AW178384 AW178333
AW17&424 AW365726 AF025440 AW172852
AI570998 AW117792 AI885499 BEd65516 BE207d27 AW130942 AW513316 AW770892
BE207426 AW173563 AW168292 AW173565
A1810101 AI744983 AI861974 BE207d04 AI744982 AI613210 AW591505 AW169285
AI521444 AI7450d4 AI62790d AI690634 AI289305
AA861253 AI612799 BE207425 AI149694 AA902662 A1082d68 A1014752 AA613844
AA725693 AA136089 AI290092 AA565489 AI689083
AI859014 AW051225 AA665758 AA49699i AA564738 T19d28 AI567170 AWi66726 AW084200
AW188723 AA617626 AI918664 AW381473
I S AW381543 AA598817 AW088942 AW050423 AI362502 A1680308 AI687500 BE327836
D20455 BE410282 BE25d766 BE256014 AA357423
BE618208 AA489577 AW182114 BE379147
102627 25245-1 AL021918 AA160639 066561 AA321623 052098 AL119d53 AA455712
N80080 N46550 W07223 N75923 W05057 AI811577 AA455657
AI275d09 AI139i21 A1927568 AI927562 AI139471 AA160473 N78795 AI719983 AI718928
AA723097 AI335776 N39140 N59184 AI587600
AI864812 AA732097 N74667 AA832398 H89600 D19825 AI554833
132725 29101 1 NA~.006276 NM 006276 L41887 L22253 BE379909 BE567870 BE274265
BE539518 AW239523 AW239271 A1093618 BE504485 AA580279
AA494481 BEd40161 AW780428 BE543960 D55986 AA852399 AI630020 W77996 AA278193
810505 A1963201 A113933fi BE174301
AA662222 AA664912 AA244152 AW611553 BE503285 AA211023 AA383016 AI698174
AW195381 AA948229 AI768495 AI690437 N30025
AI718952 AI953572 BE464509 AA777315 AI337221 AW070910 AI9538d8 AW674561 H54177
AW510890 AW078699 AI436178 AA630759
BE50207d AA278769 AI499038 AW469072 AA778071 AW236753 AI933033 AI690458
AI276691 AW768235 AI952118 AA425156 AA610579
W73953 AA244153 W86Q34 AI948872 AI952678 AW087811 AI333591 AI8698B3 AI926911
W48865 AL048024 AA214485 AI972522 AI151368
W48738 AA214467 AA334640 AI678170 AA927525 AA581588 W96283 AA365470 AI471919
AW611488 AA211834 AI365198 AI69B365
AW002238 AA507624 W96150 AA446490 AL048025 AA852400 AA362221 A1338376 835083
AA290812 810397 AA975988 AW236462 243032
H16969 F13487 D19858 AA452207 BE085942 AA344396 AW949533 AA279472 AW902d06
AW070440 BE395195 H00835 AA300750
AA729303 AA420591 AA385025 AAd20542 869155 AA420592 AA2817d7 N88502 AI458206
AI700996 AW418607 AW341202 A1825692
W00640 AA214405 AA044744 AI950617 BE467493 AW474113 AA446310 BE328705 AI911573
AW243968 AI628622 AW173020 AW079958
AI140387 AW051969 AW299438 AI127170 AW769164 AI422d35 AI307116 BE549519
AI371116 AA281748 AA701073 AA679948 BE551197
N503d5 AW338776 BE326601 AI142892 AW470687 A1989568 AA911241 AW294822 AI17d414
AA804366 A1004725 AW27199d AI559313
AI270102 A1351542 AW768904 AA765964 AI961708 A1149231 AA995907 A1094280
AI185753 H01219 AW768846 AA747500 AA970106
AI601238 AA513452 AW612802 BE075163 839171 Ai565328 AI375559 F10356 AA284625 8
E241509 AI702889 AWi 93010 AA649847
3 5 AW439150 AA721407 AA810333 AA706384 A1049887 BE569015 BE622280 BE566618
AW967342 869269
111234 83711_2 AA902656 AI185915 843705 H15150 H09794 AA832464 AI697438
AI354538 AI436354 AA948272 AA928143 A1091263 841658 AI352580
A1122948 AA946670 AI340088 AI275007 N70255 AA721176 AI934162 AA827098 AA935934
AA827088 Ai081207 AA992399 AW130757
AI805667 AA035556 AI379266 AI093901 A1095234 AA909079 AA516079 AI572357
AA205969 A1432383 AA905290 AW628920 AW182996
AI266084 N49879 AW024457 AI2d6246 AI934031 AI369270 A1003836 AA010063 AA494361
Ai284151 AI919536 N34884 N69287 AW510465
AI358609 AW08142i AA706205 A1085317 AI140633 AI347104 AA602547 AI686707
AA872686 AA69d028 A1094546 240832 AI382838
AA610132 AA50i433 H84120 AI140722 AW674839 BE503822 AW663895 BE327472 AW393494
AI340087 W04189 AW393499 H56506
BE089878 BE301950 A1025d75 AA724446 BE275324 H152i0 AW957667
134161 16074_1 AA634543 AI682259 AF117108 BE396917 NM 006547 097188 076705
SE560799 BE396918 BE269531 BE560268 BE560346 AA836048
AL023775 BE545535 AA427803 C18804 D58801 AA303353 046218 BE539704 AA187966
AA252545 AA261821 D63197 AI824109 A1088047
AI424833 AI807368 AI250857 AA741476 AI146832 AA169615 AI809821 AI274288 AW
136704 AI206172 AA917039 AA243584 AI808611
AW674709 AA935733 AW450092 AA905172 AA471196 AA302256 AW673348 AI352044
AW511295 AA247134 W81035 AA722962 AW662471
R64d32 AW044616 A1086619 AW628546 AW043682 AA425750 AI743038 AI368723 AA187143
AI376987 AI803976 AI275537 AW471358
AW104877 AA195464 W81072 AW197351 AA932674 AI393d20 AI434998 863822 AW085083
A1240272 W87006 AA011347 H58428 AI497895
823223
132939 11857_1 AB009284 AF000416 AA022636 BE082610 AW367997 AA491di 0 AA337477
AA336421 W38526 AA625283 AA773685 AA490078 T6613d
AA847838 AA022647 AW054726 AI9i8001 AA431966 AI263596 AI804298 AW469314 076189
AA779001 AA625945 AL042357 AI674730
AA410350 AK001450 AV654353 AA058443 D81618 AA853665 W31930 AA3344d5 AW955767
N47777 AA883784 AA428916 AI652062
AA329703 AI417923 AI435031 AA708791 AI989636 AI220345 AI239913 AI220102
AI435875 A1076731 AI377049 A1039173 AW972638 N90076
AW263652 BE440048 BE440013 AA577463 A103B77d AW204992 AA846580 AA501952
AA342058 AA508525 D61670 W31725 AI689499
AI955969 AA526628 AI282717 T66198
111345 6692_1 AW263155 AA314512 AW408152 AA360413 BE206274 AK001402 AA307665
AW954678 W39078 AW369236 AW369115 AW369096
AW753235 AW369072 AW361194 AW369125 AW364187 H94225 T79502 AA131908 BE071359
AW368503 AW801517 AW801322 AI674163
AA861077 AI738568 AI830199 AW118577 AI478895 AI688497 H92996 AW083479 AW970625
AW613124 AI632234 AI654210 AI696847
AI923423 AA131909 AA806630 AA806158 AW592520 896509 AA813923 AA502823 AW467889
AA960972 AA994566 AI280346 AA884588
AA653563 AI200023 N89820 AW768792 C00145 896554 T79416
104301 145380_1 AA768491 AA476251 AA809748 AI186268 AA621244 AI379029 8E550341
AA651915 AI216376 A1215585 AI471780 AA772159 AWi81980
AI151169 AA759270 AI675769 A1018776 AA757335 AA148511 AI13B378 AA504167
AI420617 AW261930 AW872797 N51769 AW614403
AI860533 AW573108 N64830 AI693732 AI436159 SE501089 AI436163 AA971485 AI269364
AI935358 AI222050 AW303978 AW573247
AI871154 T16758 AI765893 AW969016 AA744720 BE094085 AA743769 AI476407 AA156619
Ai768535 881435 D45332 N75682 N51177
65 AW207d06 AA425184 820997 AA504168 Zd3298
134520 13358_3 BE091005 BE541579 AW387738 AW386083 H13769 AW377820 AW369180
AW753239 AW672695 BE379572 AW021732 AW891450
AW891416 BE091358 N50375 BE091354 BE091365 BE09136t BE091363 BE091350 AA353863
AA845510 N21407AW770981 AI361577
AA526557 AA525443 AW893622 AA630898 AI418983 BE172016 AA550754 AA66d574 C16147
AA355902 AW958586 N51590 C20995
BE544186 AI337578 AA090549 AI807374 AW450654 BE067578 AA446781 AA447058 T10807
AA4570B2 AI267703 AI880220 BE568979
70 AW380506 BE150744 AW380468 AW380546 BE150713 D60029 H88099 BE546301
BE150731 AW368467 BE091348
135242 5782_1 A1583187 M73812 AW339829 M74093 BE252510 BE252518 BE536901040788
W95578 BE018493 BE5d4205 N83637 A1671049 AWd39693
AW300786 AW374970 AA592960 AI215885 AI215884 BE302101 AI186210 AW771831 T54213
AW452924 AA834019 W95471 AA628312
AW304866 AA570076 AI559873 T54121
134621 ~ 27351_1 AA037145 L02547 NM-001324 AW411516 AA314711 AA143605 BE394455
AA325731 AA093227 AA083307 BE299438 BE295669 AA370886
75 AA338272 AA166862 BE304837 BE298306 860507 AW238966 N72750 AW505406
AW994153 AA309742 AA309929 BE090721 AW904189
AW90d214 AA363564 894127 AA352101 828249 AA206337 AW577208 AA385473 AA355463
AA400696 AA075587 W72815 AA554033
AA075530 AA620555 AA554034 T2780d AW950014 AI570740 AI268538 AA704423 AW411517
AI278646 AW339924 A1668917 AI796034
AA994601 894082 AW027137 AA400652 AW299746 W72816 AA988494 AA146582 AW087489
AA992763 AW516454 AA992759 AW270d44
g O AA227188 AI208929 AA167720 A1052527 AA865660 AA569368 AI888464 AI670003
AA827620 AA507543 AI888385 888418 AW959083
,. A1341077 AI825719 BE552285 AA738076 AW085903 828242
126802 116467_4 AW805510 AW805503 AW805500 AW805819 AW517040 AW473670 AW516701
T301d1 AA894497 BE349504 AI272007 AI98527d BE501962
AW102975 AI801727 AW197918 T24046 AA947601 AW900958
126892 38252-1 AF121856 BE242657 083194 AA226732 All fi0190 AA948725 A1079958
AW513369 W394d3 AW408479 W06854 AA094683 AI985095
AA316647 H96313 N78438 881582 H95034 879674 AA488552 W25292 W31697 W19918
T30640 808686 H78637 AA165100141909
159
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
' AA165080 834212 AA150886 T82168 N77082 W56864 819848 AA888217 AA314539
AW750293 N62714 858039 AA845453 N63268 W03474
N41923 AI264123 AI808533 AA824288 AW198143 N99916 AA902465 AA775397 AA772387
AI567675 AA227473 A1082614 858334 N78878
834329 AW438902 AA164685 AA558790 AI590102 AA863422 BE002625 AA934039 AI298102
W15351 H93997 AA725325.~E180993 W05350
AI510771 W06941 AA48841 d 879863 N91264 876884 AA312948 T71267 AW959659
A1086695 N90421 AI278098 AA164538 AI300271
AA85d381881331 AA7D0449 H06174 AW518427 AA876634 AA150778 N32393 H78585 T85364
BE002808 AW663196 N90337 BE252097
T71401 H06438 N40268 N31015 877046 T99588 T85462 W25298 T59815 H09416 T85403
W32150 N79109 878812
105298 8689-1 BE387790 BE276849 BE246825 BE246900 AA380487 AA332996 AW408727
AK000294 AI636887 AW197272 AW590657 AW594006 AI768979
AI751632 AA580098 AA313261 AA300475 AA133237 AA233499 BE242126 BE242597
BE242254 AA314374 AW961210 AW939345 AA173535
AA305779 899373 AA128304 AA447246 AA476365 T34973 BE264878 N25149 224939
BE263038 AA128317 246082 H23504 AW378551
AA088533 AA442625 H15235 H79172 AA344697 AA344742 AL040280 BE173256 BE173129
T59749 AA088410 BE242311 AA173576
AA455337 AA129715 AA582953 AW612637 AA917038 AW340019 AW006315 AW593024 H05915
AW294592 AI146814 AW195659 AW440271
AI209090 AI288689 H98630 H15174 AI214454 AI569471 AA085808 AW188361 AI751631
AW440477 AW300860 AA516088 AI365108
AI305805 AI264064 AI246276 AA442611 AA807059 AA233459 AA875987 AI374653
AA972665 AA947515 AA436867 AI216423 AI657181
AI680306 AA436854 AI537153 AA883723 228659 AA705973 240741 AAd63884 AI216025
AI564986 AA476316 AI432566 AI571662 AA447126
AW293675 AI675617 AW009004 H23498
120438 166102-1 AW015242 AA831493 AI292346 A1076966 AI191561 AA243441 AI183309
AA252613 A1038422 AI306531 AW051480 AI348605 AA195119
AI817119 A1091896 AA738d40 AA1950i3 AA976687 AA459659 AI246250 BE219252
AI703457 AA243291 AA243d01 AA989100 AA931640
AA459782
105516 9334_1 AK001269 AL354613 AA147472 AA490803 BE207628 AW816113 AA085574
AW503392 AA299910 AW750305 BE079539 BE079484
BE512838 AK001593 AW968772 AW967440 AW206280 AA251270 AI627886 AA303599
AA147473 BE206616 AA490611 AA715039
AW590866 AW590447 AI864512 AA204731 AA894490 BE001136 AA612785 AA237035
AA149960 244257 812986 AA448446 AI734041
AA422167 BE220551 866041 832927 832942 AA258773 AW386142 853730 N54624
AW880296 AA253485 AW95d441 H98989 AW614348
AI654838 AA779793 AW237213 N66635 A1186812 AA947479 BE158011 AI859480 AW805579
N52010 AA806305 AI628445 AW270990
AA778165 AA149949 A1650728 AA7491D8 AA687257 AI261661 AA747442 AA481351
AA206339 AA903407 AW473306 AI688930 AA262281
AA448310 AA748820 AI347430 BE465692 832839 AW510564 AA436408 AA257971 AA253362
AA938330 AA513150 AA976840 AA687117
AI281547 AA046243 832825 AI631554 AW139818 AI244536 852946 AW235443 840183
AA299909 AA811958 AI302918 240213 BE158047
BE158060 AA767245 AW748159 AW500735 AA094074
129097 25953_1 8E243933 AA355449 T29766 F08396 N83324 NM 006963 S50223
AI207648 AA258092 AA113952 AI311718 A1128612 AW607449 M77172
AI951311 X52346 AA903307 AI569810 N55421 W77876 837223 883788 AA031666 H47092
AA133451 AA311095 AA906963 H87667 N56058
3 0 AA393593 W24864 H10710 F06925 F07239 AW386140 AA325018 AA235950 AW373176
N57158 AA258093 N39467 821609 BE089979
R3d173 AW889005 AA74564d AI693852 AA424914 AA744771 W72632 AI291213 AA524318
AI472134 AI911230 AA528418 AA115745
AA775720 AI671134 AA975044 AW298117 AA321015 N26288 AW952194 AI743379 AI204233
AI801026 AA830690 AI146980 AW104611
AI338576 821507 AI367623 BE244484 AI269308 AA031667 AI884346 AA731989 AA988943
AA235951 AA807887 AA642645 AI246489
' N29739 AI216718 AI383349 A1038618 AI351476 AAB06031 AI914178 H10711 A1095573
H89220 AW470854 AA729015 883353 AA782239
3 5 834295 H87165 AW419059 AI653689 240349 H89114 AW074506 AA397785 AA888377
AI911228 F03193 AI468783 AA702615 AI830829
AA748323 837224 AA424915 AA731647 H47183
120619 169895 1 AW965339 AL045632 AA333229 A1806195 AA284372 AA206108 AA682533
AW44951 d AA804785 A1215473 A1357263 A16512D8 A1651753
129229 20927_1 AF013758 NM_006451 AI538709 AA209236 AA300293 AA367274 AA126598
AA324825 AW955225 F11436 AW3747d0 AW37d714 AW374774
AW751514 W74780 AI909015 AW997079 AW997067 AW379344 AW363397 W38589 AA043823
BE169280 AI909016 AW994851 AI740638
40 AW148560 AW368339 AI858333 AA314718 AW954872 AW468734 AI681980 AW519045
AW055171 AA579286 AW069164 AW615004
AA3d5052 AI446735 AI142106 AA662683 AW002813 AI418280 AW613203 AI613333
AI354d80 AI929755 AI1d6977 W74674 AW799610
AI798529 AI589422 AA043957 AI223043 AA157016 AId46759 D56729 AI587d71 F30716
AA812125 AI537301 AA653347 D11966 AI434383
AA598533 AI287254 AW139140 AW051033 AA601911 A1702506 AA737460 T30221 AI129081
N90213 AA805225 AI798518 BE001071 T10841
W20199 AW664594 AW195667 D60123 D61496 AW468018 AI720097 N90553 AA829375
AW513266 H92758 AA585324 014767 AI922391
45 D60124 D60666 AW071558 BE044120 AA728821 AA211941
120821 19274_2 Y19062 NM 014393 AW296801 AK001576 AL079288 W16667 245664
Ai768561 AL079286 812736 AW080147 AW136530 AI202958
AW241579 821013 AA347419 AI929333 AWi96689 A1040867 F13437 AA918240 AI869798
Ai365176 AW440030 AW440072 N80892
AW242030 244807 812417 AA436784 AA442041 AA046503 AL157526 AI929265 AA055542
AA045462 AA683542 N51374 AW193508
AI873524 AW473151 AW004719 AI810504 AI581093 AA493977 Zd0600 F04553 846130
F09321
S 0 106459 3897-1 AA789081 AW408328 NM 006530 U61384 AA449641 AW138216
AA448598 AJ245746 AI365301 N4d728 AA255743 AA360783 BE550380
AW593925 AI962309 AA322097 AW964625 AI695988 AW672827 BE543256 AK001413
AW603395 AA651700 AA449053 AA465540
AW083185 T62128 278373 AW673713 AWd68061 BE350755 AW673958 AW675504 AA995709
AW574841 AA835883 AI248439 AA548364
T62072 N33193 AA814046 AI376210 A1340020 AA449766 AA703407 AA427613 A1470108
AI298757 AA507602 AI658941 AA449478
AA633165 AA449741 AA831821 AA903673 AA682588 AW673075
s 5 115094 190995_1 AA255920 A1817197 AA255921 AI612925 AW874669 AA493440
129571 1726_1 X51630 M80232 X61631 S75264 AA172249 AA134066 AAi 30278 AA130187
AA130291 AA031554 AI246677 221455 AI745434 AW273544
AW088613 AW471307 AI745483 AI399854 AI683952 AA031555 AA298075 AI935945 T29809
AA172099 AA356120
121779 287665 1 AW513143 AA422036 AI821669 AW514232 AA477828 AW772009 AW439799
AW08988d
106738 174703_1 AW149266 849246 AW237401 AA938113 AW665871 AI969698 AI950812
AW874276 AI571939 AA1d1222 AI869822 AWi 04061 AI569994
60 AW972559 AA506012 AI553704 AA470145 AI332421 AA218990 AW131361 AI709076
AW392488 AW392477 AI970981 AW392476 D61949
H44981 BE172698
123005 75629-1 AW369771 AW748174 AA290801 AA419198 AA044331 AA127909 AW995442
A1480343 AA044582 AW956159 AA373451 AAi 27965
AL134913 AW994956 BE62231d BE006298 8E006312 BE006305 BE006317 BE006303
AA043906 AA234175 AA479726
108055 100690-1 AJ404672 AJ289819 AW976000 AA043561 AW450885 AW452879 AA043562
AA788832 A1564338 A1564330 A1368875 AA643607 AA994375
65 AA810342 AI367704
115291 22325_1 BE545072 AI540751 AA301103 AI916675 N85422 BE563965 AA327978
AI816094 AK001515 BE501319 AA279943 BE138895 AA343765
AW963051 AW082308 AI823992 AI653752 AI589007 AI816135 AI566535 BE501307
AW272765 AW242239 AA766315 A1014927 AA578848
AI354483 A1476548 A1038579 AA973322 AA992180 AW472921 BE504789 AI392988
AA506076 AA769228 AI370562 AL137710 BE005656
AW965920
70 130376 24827_ 4 840873
115536 61 1 AK001468 AA190315 AA374980 AW961179 AA307782 AA315295 AA347194
AW953073 AW368190 AW368192 AA280772 AA251247 N85676
Ai215522 AI216389 N87835 812261 857094 A1660045 AA3d7193 816712 AW119006
N55905 N87768 AW900167 AI341261 AI818674 D20285
AI475165 AA300756 840626 AI122827 AA133250 AI952488 AA970372 AA889845 AW069517
AI524385 AA190314 AI673359 AA971105
AI351088 AI872789 AI919056 AI611216 AK001472 BE568761 AA581004
75 114965 153955_1 A1133881 AA165164 AI826437 AI972791 AA165165 BE219575
AI73258fi A1821571 AA250737 AW136875 AI984273 AI249271
131228 8262_1 AW207469 AL079814 AA354351 AF020043 AW291396 BE550484 NM 005445
BE046917 AW594249 AI651554 AI631515 AW771344
AI969758 AI699982 AA247175 AI244676 D44780 AW593978 AI638479 AI373676 AW089547
AL121432 AA554698 A1016991 A1087260
AW449939 AF067163 W40482 AW316558 AI537184 AW381979 W40150 AI810562 AA573151
AI630288 AI675561 AI674420 AW840733
AW022653 AA114219 AJ005015 AL046587 AA878141 AW271896 AW085287 AA150465
BE536295 AA463d12 BE093222 AA213739
g 0 AA485586 AI825913 AA706307 AI337348 831995 AI819641832095 AW976653
AA742375 AA142957 AI808214 AWd68303 AI205987
AI206347 AI769095 BE501640 AA113866 A1093931 AI752855 AA612743 AA463411
AA279157 AI123791 AA213570 AI207305 AW627814
831945 832040
116238 10772-1 AV660717 NM 015437 AL050285 895774 A1867094 AA443833 A1367670
AA609046 A1440298 A1613139 A1291826 AW028954 A1123242
A1824715 AW079750 AA479362 AW 150151 AI952267 AA814094 AI168431 AI566595
AI521422 AI920793 AW051241 N70051 AI689429
160
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
AI783813 AI769315 AI743691 A1915645 AA479473 C21435 N50944 N50902 AW978102
H23837 BE087538 AA316516
122802 287993_1 AI687303 AW571681 AI554465 AI684252 AI581056 AA604098 AI628160
AI859843 AA424021 AA460530 BE042778 AW273200 AW273223
AW167288 AW083347 AI654306 AW517496 AW104706 AW273214 BE139512 AW189487
AW130822 AW167419 AI28948frAW150010
H88004 AI743745 AW088710
123494 21202-1 AW179019 AW179011 AF135160 Ntvi_014050 AF078860 BE018005
AK000285 AF151038 BE245156 AW179007 AA345114 BE619758
BE619209 W25509 AA314339 AA336674 AA337956 AW954843 AW390412 N46796 AA316235
AA314286 815686 BE535633 N57134 N46483
AW368462 AA923517 AA665223 AI418513 AA837523 AI359320 AI309273 AI522278 N40939
AA904977 AA938272 N30240 AA887965
AI671972 A1028109 AA094652 AA883262 AA887781 AI744447 AW592944 A1077790
AW8608B3 AWi48667 N89861 AA557195 AI191824
AI433166 AI719760 AA453089 AA630656 AA300976 AA639620 AW675033 AA284393
AW886987 AI476335 AI332939 BE301513 AA452920
1 ~ AW674302 AI925483 AW170412 AI698717 AI375985 BE220535 AI688151 AW514809
AW062346 AA599786 BE350848 AI560848 A1023075
AA864875 AA166871 AI807947 AW514579 AI978602 AI860340 AA830886 AI374788
AI283592 AA683152 AA743159 AI379932 AI432056
AI128904 AW150433 N38909
116296 11967-2 AW149502 243342 AW002826 AL049382 AA442545 AW9714718E220243
AW968952 AA043607 AW299245 AA659892 A1038768 H26330
BE463534 AI628252 AA836139 AI27729t AA489033 AA741239 AI209064 AI300253
AI275761239417 C01835
Table 9A lists about 382 genes up-regulated in ovarian cancer compared to
normal ovaries. These were selected from 35403 probesets on the AfiymetrixlEos-
Hu01 GeneChip
array such that the ratio of"average" ovarian cancer to "average" normal adult
ovaries was greater than or equal to 10. The "average" ovarian cancer level
was set to the 2nd
2o highest amongst various ovarian cancers. The "average" normal adult ovaries
level was set to the arithmetic mean amongst various non-malignant ovaries. In
order to remove
gene-specific background levels of non-specific hybridization, the.l5th
percenUle value amongst the non-malignant tissues (see Table 7A) was
subfracted from both the
numerator and the denominator before the ratio was evaluated.
TABLE
9A:
3B2
UP-REGULATED
GENES,
OVARIAN
CANCER
VERSUS
NORMAL
OVARY
Pkey:mekey
Pri
Ex.Accn:ExempIarAccession 3
UG
1D:
UniGene
ID
Tifie:
UniGene
title
ratio:
ratio
tumor
vs.
normal
tissues
PkeyEx. UG Title ratio
Acon ID
134454L33930Hs.173996CD24 antigen (small 86.2
cell lung carcinoma
clust
102927X12876Hs.65114keratin 18 84.7
115909AA436666Hs.59761ESTs 72.3
123169AA488892Hs.104472ESTs; Weakly similar 66.8
to Gag-Pol polyprotein
[
35 115674AA406542Hs.71520ESTs 65.4
102193020758Hs.313secreted phosphoprotein63.1
1 (osteoponfin; bone
101839M93036Hs.692membrane component; 56.8
chromosomal 4; surface
ma
115221AA262942Hs.79741ESTs 56.1
108059AA043944Hs.62663ESTs 52.3
121853AA425887Hs.98502ESTs 47.8
133504W95070Hs.74316desmoplakin (DPI; DPII)47.0
103546214244Hs.75752cytochrome c oxidase 46.5
subunit Vllb
100147D13666Hs.136348osteoblast specific 45.5
factor 2 (fasciclin
I-lik
102979X17042Hs.1908proteoglycan l;secretory44.6
granule
45 130967AA134138Hs.182579Homo sapiens leucine 44.5
aminopepfidase mRNA;
cam
102009002680Hs.82643protein tyrosine kinase40.4
9
126960AA317900Hs.161756ESTs 39.6
103111X63187Hs.2719epididymis-specific; 39.1
whey-acidic protein
type
133829AA453783Hs.76550Homo Sapiens mRNA; 39.0
cDNA DKFZp564B1264
(from c
50 t N68921Hs.34806ESTs; Weakly similar 38.9
t to neogenin [H.sapiens]
1223
102803089916Hs.26126claudin 10 38.8
104943AA065217Hs.169674ESTs 38.7
106605AA457718Hs.21103Homo Sapiens mRNA; 38.4
cDNA DKFZp564B076
(from c1
120655AA287347Hs.238205ESTs 38.1
55 102968X16396Hs.154672methylene tetrahydrofolate36.3
dehydrogenase (NAD
104052AA393164Hs.97644mammaglobin 2 36.0
109166AA179845Hs.73625RAB6 interacting; kinesin-like35.9
(rabkinesin6)
101332L47276 Homo Sapiens (cell 35.0
line HL-6) alpha topoisome
106167AA425906Hs.7956ESTs 34.5
60 101042J05428Hs.10319UDP glycosylUansferase34.3
2 family; polypepfide
125852H09290Hs.76550Homo sapiens mRNA; 33.7
cDNA DKFZp564B1264
(from c
101201L22524Hs.2256matrix metalloproteinase32.3
7 (matrilysin; uteri
126410851912Hs.12409somatostatin 32.1
134326016306Hs.81800chondroitin sulfate 32.0
proteoglycan 2 (versican)
65 125739AA428557Hs.92137v-myc avian myelocytomatosis31.6
viral oncogene h
132254L20826Hs.430plastin 1 (I isofortn)31.4
112610879392Hs.23643ESTs 30.9
101441M21005Hs.100000S100 calcium-binding 30.6
protein AS (calgranulin
116345AA496981Hs.199067HER3 receptor tyrosine30.1
kinase (c~rbB3; ERBB3
108860AAi33334Hs.129911ESTs 29.8
133859086782Hs.17876126S proteasome-associated29.2
pads homolog
107295T34527Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypepfid28.9
106210AA42B239Hs.10338ESTs 28.9
134711X04011Hs.88974cytochrome 1r245; beta28.0
polypepfide (chronic
g
75 125769AI382972Hs.821285T4 oncofetal Uophoblast27.5
glycoprotein
107222D51235Hs.82689tumorrejecfion anfigen(gp96)27.4
1
102260028386Hs.159557karyopherin alpha 2 26.9
(RAG cohort 1; imporGn
a
134691M59979Hs.88474prostaglandin-endoperoxide26.8
synthase 1 (prosta
105588AA279215Hs.10867ESTs 26.3
130718N70196Hs.18376ESTs 26.3
111185N67551Hs.12844EGF-like-domain; mulfiple25.6
6
131965W90146Hs.35962ESTs 25.6
132903AA235404Hs.5985Homo Sapiens clone 25.6
25186 mRNA sequence
114359241589Hs.153483ESTs; Moderately similar25.5
to Hi chloride chann
161
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
101185L19872Hs.170087arylhydrocarbon receptor25.2
128742000763Hs.251531proteasome (prosome; 25.1
macropain) subunit;
alph
116724F13665Hs.65641ESTs 24.9
111929840057Hs.112360prominin (mouse)-like24.9
1
102915X07820Hs.2258mafrix metalloproteinase24.8
10 (sfromelysin 2)
131210AA430047Hs,24248ESTs 24.7
101714M68874 Human phospha6dylcholine24.6
2-acylhydrolase (cP
100154014657Hs.81892KIAA0101 gene product24.6
134656X14787Hs.87409thrombospondin 1 24.3
100294049396Hs.75454antioxidant protein 23.9
1
104080AA402971Hs.57771kallikrein 11 23.7
107056AA600310Hs.18720programmed cell death23.7
8 (apoptosis-inducing
f
115697AA411502Hs.63325ESTs; Weakly similar 23.7
to airway trypsin-like
p
130350002020Hs.239138pre-B-cell colony-enhancing23.7
factor
1 105870AA399623Hs.23505ESTs 23.6
S
118528N67889Hs.49397ESTs 23.4
105309AA233790Hs.4104ESTs; Weakly similar 23.2
to cDNA EST yk386g7.5
co
109680F09255Fis.4993ESTs 23.2
131501AA121127Hs.181307H3 histone; family 23.2
3A
100824HG4058-HT4328 Oncogene Aml1-Evi-1, 23.1
Fusion Activated
111890838678Hs.12365ESTs 23.0
101543M31166Hs.2050pentaxin-related gene;22.8
rapidly induced by
IL-
102095011313Hs.75760sterol carrier protein22.8
2
114988AA251089Hs.94576ESTs; Weakly similar 22.8
to phosducin; retinal
[H
25 120695AA291468 ESTs 22.8
130941049394Hs.21425-hydroxytryptamine 22.8
(serotonin) receptor
3A
106654AA460449Hs.3784ESTs; Highly similar 22.7
to phosphoserine
aminofr
109141AA176428Hs.193380ESTs 22.6
102345037283Hs.58882Microfibril-associated22.6
glycoprotein-2
115652AA405098Hs.38178ESTs 22.4
100103AF007875Hs.5085dolichyl-phosphate 22.3
mannosyltransferase
polype
105463AA253370Hs.32646ESTs 22.2
132624AA164819Hs.53631ESTs 22.2
119743W70242Hs.58086ESTs 22.0
35 132528AA283006Hs.50758chromosome-associated22.0
polypeplide C
107174AA62i714Hs.25338ESTs 21.8
134495063477Hs.84087KIAA0143 protein 21.6
131985AA434329Hs.36563ESTs 21.5
105832AA398346Hs.21898ESTs 21.2
40 126160N90960Hs.247277ESTs; Weakly similar 21.2
to transformation-relate
114846AA234929Hs.44343ESTs 20.9
109703F09684Hs.24792ESTs; Weakly similar 20,9
to ORF YOR283w (S.cerevi
135154AA126433Hs.173242sorting nexin 4 20.8
131185M25753Hs.23960cyclin B1 20.7
45 105616AA280670Hs.24968ESTs 20.5
131148C00038Hs.23579ESTs 20.2
129337863542Hs.110488KIAA0990 protein 20.2
133640083004Hs.75355ubiquitin-conjugating20.1
enzyme E2N (homologous
127479AA513722Hs.179729collagen; type X; 19.9
alpha 1 (Schmid metaphyseal
133711J04130Hs.75703small inducible cytokine19.8
A4 (homologous 1o
mo
131818239297Hs.3281neuronal penfraxin 19.7
II
125303239821Hs.107295ESTs 19.6
109112AA169379Hs.72865ESTs 19.5
105376AA236559Hs.8768ESTs; Weakly similar 19.2
to !!!! ALU SUBFAMILY
SO
55 103605235402Hs.194657cadherin 1; E-cadherin19.1
(epithelial)
100661HG2874-HT3018 Ribosomal Protein 19.1
L39 Homolog
129571X51630Hs.1145Wilms tumor 1 19.0
115239AA278650Hs.73291ESTs; Weakly similar 18.9
to similar to the
beta t
131562090551Hs.28777H2A histone family; 18.9
member L
131272AAd23884Hs.139033paternally expressed 18.9
gene 3
130343AA490262Hs.15485ESTs; Weakly similar 18.8
to APICAL-LIKE PROTEIN
[
103245X76648Hs.28988glutaredoxin (thiolfransferase)18.7
101809M86849 Homo Sapiens connexin18.6
26 (GJB2) mRNA, complet
105344AA235303Hs.8645ESTs 18.4
65 135225AA455988Hs.9667butyrobetaine (gamma);18.4
2-oxoglutarate dioxyge
116786H25836Hs.83429tumor necrosis factor18.3
(Iigand) superfamily;
m
131510AA207114Hs.27842ESTs; Weakly similar 18.2
to similar to 1-acyl-g!y
124059F13673H5.99769ESTs 18.0
103352X89398Hs.78853uracil-DNA glycosylase17.9
70 132742AA490862~H5.55901ESTs; Weakly similar 17.9
to C43H8.1 [C.elegans]
135242M74093Hs.9700cyclin E1 17.9
123494AA599786Hs.112110ESTs 17.8
129168T90621Hs.109052chromosome 14 open 17.7
reading frame 2
128517AA2806i7Hs.100861ESTs; Weakly similar 17.6
to p60 katanin [H.sapien
75 130160239228Hs.151344UDP-Gal:betaGIcNAc 17.6
beta 1;3-galactosylfransfe
103448X99133Hs.204238tipocatin 2 (oncogene17.5
24p3)
119708W67810Hs.57904mago-nashi (Drosophila)17.5
homolog; proliferatio
122946AA477445Hs.105341ESTs 17.5
125819AA044840Hs.251871CTP synthase 17.5
131689AA599653Hs.30696franscripGon factor-like17.5
5 (basic helix-loop
115061AA253217Hs.41271ESTs 17.3
113702T97307Hs.161720ESTs; Moderately similar17.3
to !!!! ALU SUBFAMIL
115291AA279943Hs.122579ESTs 17.3
102567059863Hs.146847TRAF family member-associated17.2
NFKB activator
162
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
129229AA211941Hs.109643polyadenylate binding 17.2
protein-interacting
pro
129351AA167268Hs.62349Human ras inhibitor 17.2
mRNA; 3' end
110769N22222 yw34bO6.s1 Morton Fetal17.1
Cochlea Homo Sapiens
113182T55234Hs.9676Human DNA sequence 17.0
from clone 30M3 on
chromos
115892AA435946Hs.50831ESTs 17.0
123114AA486407Hs.105235ESTs; Moderately similar17.0
to KIAA0454 protein
123442AA598803Hs.111496ESTs 17.0
123339AA504253Hs.101515ESTs 16.9
123689AA609556Hs.256562ESTs 16.9
1 131941D62657Hs.35086ubiquitin-specific 16.8
~ protease 1
120649AA287115Hs.99697ESTs 16.8
102139U15932Hs.2128dual specificity phosphatase16.8
5
115522AA331393Hs.47378ESTs 16.7
135243AA215333Hs.97101putative G protein-coupled16.6
receptor
15 131257AA25fi042Hs.2d908ESTs 16.5
109508AA233892Hs.55902ESTs; Weakly similar 16.3
to !!!! ALU SUBFAMILY
SX
132701AA279359Hs.55220BCL2-associated athanogene16.3
2
134449L3d155Hs.83450laminin; alpha 3 (nicein16.3
(150kD); kalinin (16
126180818070Hs.37i2ubiquinol-cytochrome 16.3
c reductase; Rieske
iron
20 106124AA423987Hs.7567ESTs 16.2
115363AA282071Hs.152759ac8vatorofS phase kinase16.2
117588N34895Hs.446d8ESTs 16.1
131245AA620599Hs.24766DKFZP564E1962 protein 16.1
101674M61916Hs.82124laminin; beta 1 16.0
25 126819AA305536Hs.161d89ESTs 16.0
134039S78569Hs.78fi72laminin; alpha 4 16.0
130648AA075427Hs.17296ESTs; Weakly similar 15.9
to /prediction
102823U90914Hs.5057carboxypeptidase D 15.8
128470AA447504Hs.100261Homo Sapiens mRNA; 15.8
cDNA OKFZp5648222
(from c7
30 115844AA430124Hs.234607ESTs 15.7
132543AA417152Hs.5101protein regulator of 15.7
cytokinesis 1
130155L33404Hs.151254kallikrein 7 (chymotryptic;15.7
sfratum comeum)
101008J04162Hs.763Fc fragment of IgG; 15.7
low affinity Illa;
recept
120472AA251875Hs.104472ESTs; Weakly similar 15.6
to Gag-Poi polyprotein
[
35 116844H64938Hs.38331ESTs 15.6
106753AA476944Hs.7331ESTs 15.6
114767AA148885Hs.1544d3minichromosome maintenance15.5
deficient (S. cere
114768AAt49007Hs.182339Ets homologous factor 15.5
127370A1024352Hs.70337immunoglobulin superfamily;15.5
member 4
101507M27492Hs.82112intedeukin 1 receptor,15.4
type I
102519U52969Hs.80296Purkinje cell protein 15.4
4
102610U65011Hs.30743preferen8ally expressed15.4
antigen in melanoma
1112d4N69556Hs.24724MFH-amplified sequences15.4
with leucine-rich
tan
120404AA234921Hs.96427KIAA1013 protein 15.3
45 130455X17059Hs.155956N-acetylfransferase 15.2
1 (arylamine N-acetylfran
129519AA298786Hs.112242ESTs 15.1
106553AA454967Hs.5887ESTs; Highly similar 15.0
to RNA binding mofif
pro
109502AA233837Hs.44755ESTs; Weakly similar 14.9
to membrane glycoprotein
115967AAdd6887Hs.42911ESTs 14.9
104636AA004415Hs.106106ESTs 14.9
134133X93920Hs.180383dual specificity phosphatase14.9
6
134444X04470Hs.251754secretory leukocyte 1d.8
protease inhibitor
(anti)
132998Y00062Hs.170121protein tyrosine phosphatase;1d.8
receptor type;
131997D82399Hs.136644Homo Sapiens clone 14.6
23714 mRNA sequence
134056827358Hs.7886ESTs; Weakly similar 14.6
S to Pelle associated
prot"
101249L33881Hs.1904protein kinase C; iota14.5
105298AA233459Hs.26369ESTs 14.5
107119AA620307Hs.27379ESTs 14.5
115839AA429038Hs.40541ESTs 14.5
122802AA460530Hs.256579ESTs 14.5
129896AA043021Hs.13225UDP-Gal:betaGIcNAc 14.3
beta 1;4-galactosyltransf
130269AA284694Hs.168352nucleoporin-like protein14.3
1
134374D62633Hs.8236ESTs 14.3
106370AA443841Hs.18676sprouty (Drosophila) 14.2
homolog 2
65 130919AA291710Hs.21276collagen; type 1V; 14.1
alpha 3 (Goodpasiure
antig
132923U21858Hs.60679TATA box binding protein14.1
(TBP)-associated fac
107968AA034020Hs.61539ESTs 14.1
125390H95094Hs.75187franslocase of outer 14.1
mitochondria) membrane
2
107148AA621131Hs.5889ESTs; Weakly similar 14.1
to W01A11.2 gene product
110788N24730Hs.15420ESTs 14.0
109481AA233342H5.90fi80ESTs; Weakly similar 13.9
to WD40 protein Ciao
1 [
105646AA282147Hs.5888ESTs 13.9
106030AA412251Hs.12802development and differentiation13.8
enhancing fac
132618AA253330Hs.5344adaptor-related protein13.7
complex 1; gamma 1
su
75 133230S82240Hs.6838ras homolog gene family;13.7
member E
124803845480Hs.164866cyclin K 13.6
121381AA405747Hs.97865ESTs; Weakly similar 13.6
to WASP-family protein
[
105200AA195399Hs.24641ESTs 13.5
105627AA281245Hs.23317ESTs 13.5
114986AA251010Hs.87807ESTs 13.5
118036N52844Hs.196008ESTs 13.5
134672N79749Hs.87627ESTs; Weakly similar 13.5
to cDNA EST EM8L:T005d2
110915N46252Hs.29724ESTs 13.3
- N51919Hs.47368ESTs 13.3
117984
163
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
132550AA029597Hs.170195bone morphogenetic 13.3
protein 7 (osteogenic
prot
124315H94892Hs.6906v-rat simian leukemia13.2
viral oncogene homolog
102547057911Hs.46638chromosome 11 open 13.2
reading frame 9
125134W19228Hs.100748ESTs 13.2
111806833468Hs.24651ESTs 13.1
106983AA521195Hs.10887similar to lysosome-associated13.0
membrane glyco
106498AA452141Hs.7171ESTs 13.0
110787N24716Hs.1224dESTs; Weakly similar 13.0
to C44B9.1 [C.elegans]
122860AA464414Hs.112159ESTs 13.0
131535AA504642Hs.28436ESTs; Weakly similar 13.0
to coded for by C.
elega
116188AA464728Hs.184598ESTs 13.0
107243D59489Hs.34727ESTs 12.9
129300C20976Hs.110165ESTs; Highly similar 12.9
to ribosomal protein
L26
134487838185Hs.83954Homo Sapiens unknown 12.8
mRNA
1 102348037519Ns.87539aldehyde dehydrogenase12.8
5 8
131839H80622Hs.33010KIAA0633 protein 12.8
119620W47620Hs.560092'-5'oligoadenylate 12.8
synlhetase 3
120802AA343533Hs.128777ESTs; Weakly similar 12.7
to predicted using
Genef
102250028014Hs.74122caspase 4; apoptosis-related12.7
cysteine proteas
105539AA258873Hs.25242ESTs 12.7
114965AA250737Hs.72472ESTs 12.7
118001N52151Hs.d7447ESTs , 12.7
100448D87469Hs.57652EGF-Like-domain; multiple12.6
2
130920D50975Hs.75525calreticulin ' 12.6
131075Y00757Hs.2265secretory granule; 12.6
neuroendocrine protein
1 (
105496AA256323Hs.25264DKFZP434N126 protein 12.5
109235AA193592Hs.42300ESTs; Weakly similar 12.5
to !!!! ALU SUBFAMILY
SO
118215N62195Hs.779103-hydroxy-3-methylglutaryl-Coenzyme12.5
A synihas
134388M15841Hs.82575small nuclear ribonucleoprotein12.5
polypeptide 8
3 106897AA489790Hs.167496RAN binding protein 12.4
0 6
133050S67325Hs.63788propionyl Coenzyme 12.4
A carboxylase; beta
polype
109683F09308Hs.27607ESTs 12.3
121d63AA411745Hs.239681ESTs; Weakly similar 12.3
to KIAA0554 protein
[H.s
102876X03663Hs.174142colony stimulating 12.2
factor 1 receptor;
farmed
3 101804M86699Hs.169840TTK protein kinase 12.2
5
129017H13108Hs.107968ESTs 12.1
105812AA394126Hs.20814ESTs; Highly similar 12.1
to CGI-27 protein
(H.sap
106459AA449741Hs.4029glioma-amplified sequence-4112.0
107059AA608545Hs.23044RAD51 (S. cerevisiae)12.0
homolog (E colt RecA
ho
4~ 107080AA609210Hs.19221ESTs 12.0
110799N26101Hs.7838Human ring zinc-finger12.0
protein (ZNF127-Xp)
ge
112253851818Hs.104222Homo Sapiens mRNA; 12.0
cDNA DKFZp566L034
(from c1
116760H11054Hs.155342protein kinase C; 12.0
delta
120314AA194166Hs.221040KIAA1038 protein 12.0
45 123005AA479726Hs.105577ESTs 12.0
132572AA448297Hs.237825signal recognition 12.0
particle 72kD
110561H59617Hs.5199ESTs; Weakly similar 12.0
to UBIQUITIN-CONJUGATING
101923S75256 HNL=neuirophil lipocalin11.9
[human, ovarian cane
134992H05625Hs.92414ESTs 11.8
50 105516AA257971Hs.21214ESTs 11.8
105248AA226968Hs.22826ESTs 11.7
109130AA172040Hs.20161ESTs; Weakly similar 11.7
to IgE receptor beta
sub
115955AA4d6121Hs.44198Homo Sapiens BAC clone11.7
RG054D04 from 7q31
116135AA460314Hs.94179ESTs 11.7
5 116284AA487252Hs.237809ESTs; Weakly similar 11.7
S to hypothetical protein
132384AA479933Hs.46967Human DNA sequence 11.7
from clone 167A19
on chrom
134753Y09216Hs.173135dual-specificity tyrosine-(Y)-phosphorylation11.7
125136W31479Hs.129051ESTs 11.7
133928N34096Hs.7766ubiquitin-conjugating11.6
enzyme E2E 1 (homologou
117395N26330Hs.93701ESTs 11.5
127007AA299360 ESTi 1857 Uterus tumor11.5
I Homo Sapiens cDNA
5'
130567L07493Hs.1608replication protein 11.5
A3 (l4kD)
135073AA452000Hs.94030Homo Sapiens mRNA; 11.5
cDNA DKFZp586E1624
(from c
115140AA258030Hs.55356ESTs; Weakly similar 11.4
to supported by GENSCAN
65 115536AA347193Hs.62180ESTs 11.4
133240D31161Hs.68613ESTs 11.3
106521AA453431Hs.14732malic enzyme 1; NADP(+)-dependent;11.3
cytosolic
107674AA011027Hs.41143KIAA0581 protein 11.3
114149238814Hs.27196ESTs 11.3
132478H20906Hs.49500KIAA0746 protein 11.2
104252AF0022d6Hs.210863cell adhesion molecule11.2
with homology 1o
L1 CAM
102436046499Hs.790microsomal glutathione11.2
S-transferase 1
106726AA465339Hs.7141ESTs 11.2
100116D00654Hs.77443actin; gamma 2; smooth11.2
muscle; enteric
75 110970N51374Hs.96870Homo Sapiens mRNA 11.2
full length insert
cDNA clo
130417058522Hs.155485huntingtin-interacting11.2
protein 2
132906AA1d2857Hs.234896ESTs; Highly similar 11.2
to geminin [H.sapiens]
107853AA024427Hs.59d61DKFZP434C245 protein 11.2
103467Y00451Hs.78712aminolevulinate; delta-;11.1
synthase 1
100438D87448Hs.91417topoisomerase (DNA) 11.1
II binding protein
102654068494Hs.24385Human hbc647 mRNA 11.1
sequence
103172X68742Hs.116774integrin; alpha 1 11.1
106856AA486183Hs.15839ESTs; Weakly similar 11.1
to similar 1o oxysterol-
.
108255AA063157Hs.172608ESTs 11.1
164
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
124308H93575Hs.227146Homo Sapiens mRNA; 11.1
cDNA DKFZp564J142
(from c1
129057X62466Hs.214742CDW52 antigen (CAMPATH-111.1
antigen)
128845AA455658Hs.10649basement membrane-induced11.1
gene
129025AA420992Hs.103441ESTs; Weakly similar 11.0
to tesficular tekfin
B1-
107638AA009528Hs.42743ESTs; Weakly similar 11.0
to predicted using
Genef
134480AA024664Hs.83916NADH dehydrogenase 11.0
(ubiquinone) 1 alpha
subco
115262AA279112Hs.88594ESTs 11.0
102580060808Hs.152981CDP-diacylglycerol 10.9
synthase (phosphatidate
cy
106614AA458934Hs.179912ESTs 10.9
107115AA610108Hs.27693ESTs; Highly similar 10.9
to CGI-124 protein
[H.sa
115764AA421562Hs.91011anterior gradient 2 10.9
(Xenepus laevis) homolog
121770AA421714Hs.11469KIAA0896 protein 10.9
132191AA449431Hs.158688KIAA0741 gene product 10.9
133214Y10659Hs.250911interleukin 13 receptor;10.9
alpha 1
1 133914N32811Hs.77542ESTs 10.8
~
101973S82597Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypeptid10.8
102669071207Hs.29279eyes absent (Drosophila)10.8
homolog 2
104147AA451992Hs.226799ESTs; Highly similar 10.8
to HSPC039 protein
[H.sa
106474AA450212Hs.42484Homo Sapiens mRNA; 10.8
cDNA DKFZp564C053
(from c1
115881AA435577Hs.184942G protein-coupled receptor10.8
64
129950M31516Hs.1369decay accelerafingfactorforcomplement(CD510.8
132783N74897Hs.5683DEADIH (Asp-Glu-Ala-AspIHis)10.8
box polypepttde
133784AA214305Hs.76173ESTs 10.8
134248AA292677Hs.80624ESTs 10.8
25 105565AA278302Hs.18349ESTs; Weakly imilar 10.8
to partial CDS [C.elegan
127999AA837495Hs.69851ESTs; Weakly similar 10.8
to Wiskott-Aldrich
syndr
108040AA041551Hs.48644ESTs 10.7
130367238501Hs.8768ESTs; Weakly similar 10.7
to !!!! ALU SUBFAMILY
SO
108539AA084677Hs.54558ESTs; Weakly similar 10.7
to protein B [H.sapiens]
3 111345N89820Hs.14559ESTs 10.7
0
115583AA398913Hs.45231LDOCt protein 10.7
128965T17440Hs.107418ESTs 10.7
101396M15796Hs.78996proliferating cell 10.6
nuclear anfigen
132164084573Hs.41270proccllagen-lysine; 10.6
2-oxoglutarate 5-dioxygen
35 101275L37936Hs.3273Ts franslafion elongation10.6
factor; mitochondri
104660AA007160Hs.14846Homo Sapiens mRNA; 10.6
cDNA DKFZp564D016
(from c1
108609AA100694Hs.69499Human DNA sequence 10.6
from BAC 15E1 on chromosom
112041843300Hs.22929ESTs 10.6
114208239301Hs.7859ESTs 10.6
118537N67974Hs.75431fibrinogen; gamma polypeptide10.6
106919AA490885Hs.21766ESTs 10.6
115984AA447687Hs.91109ESTs 10.6
105538AA258860Hs.32597ring finger protein 10.6
(C3H2C3 type) 6
102200021551Hs.157205branched chain aminofransferase10.5
1; cytosolic
45 116710F10577Hs.70312ESTs 10.5
119780W72967Hs.191381ESTs; Weakly similar 10.5
to hypothetical protein
112996T23539Hs.7165zinc finger protein 10.5
259
103029X54489Hs.789GR01 oncogene (melanoma10.5
growth stimulating
ac
101255L34600Hs.149894mitochondrial iranslational10.4
inifiafion factor
107032AA599472Hs.247309succinate-CoA ligase; 10.4
GDP-forming; beta
subun
125617AI287461Hs.164950ESTs 10.4
131475239053Hs.27263ESTs 10.4
132073N67408Hs.38516ESTs 10.4
101469M22877Hs.169248Human somafic cytochrome10.3
c (HCS) gene; comple
102437046569Hs.221986aquapodn 5 10.3
104301D45332Hs.6783ESTs 10.3
127236AI341818Hs.98658budding uninhibited 10.3
by benzimidazoles
1 (yeas
101465M226t2Hs.241395protease; serine; t 10.3
(trypsin 1)
113805W42957Hs.250617ESTs 10.2
133536Y00264Hs.177486amyloid beta (A4) precursor10.2
protein (protease
109799F10770Hs.180378Homo Sapiens clone 10.2
669 unknown mRNA;
complete
113523T90037Hs.16686ESTs 10.2
116195AA465148Hs.72402ESTs 10.2
134542X57025Hs.85112insulin-like growth 10.2
factor 1 (somatomedin
C)
65 125298239255Hs.235350YD019 protein 10.2
119367T78324Hs.90905ESTs 10.2
134470X54942Hs.83758CDC28 protein kinase 10.2
2
134288AA430008Hs.8117ESTs 10.1
105127AA158132Hs.11817ESTs; Weakly similar 10.1
to contains similarity
t
110627H70485Hs.35225ESTs; Weakly similar 10.1
to MBNL protein [H.sapie
115188AA261819Hs.88367ESTs 10.1
132632N59764Hs.5398guanine-monophosphate 10.1
synthetase
124049F10523Hs.74519primase; polypepfide 10.1
2A (58kD)
100079AB002365Hs.23311KIAA0367 protein 10.0
75 113987W87494Hs.9641ESTs; Moderately similar10.0
to COMPLEMENT C10
SU
117280N22107Hs.i72241ESTs 10.0
TABLE 9B:
Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers
Pkey CAT Number Accession
100661 23182-1 BE623001 L05096 AA383604 AW966416 N53295 AA460213 AW571519
AA603655
165
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
101332 25130-1 J04088 NM 001067 AF071747 AJ011741 N85424 AL042d07
AA218572 BE296748 BE083981 AL040877 AW499918 AW675045
H17813
BE081283 AA670403 AW504327 BE094229 AA104024 AI471482
AI970337 AA737616 AI827d44 AW003286 AI742333 AI344044
AI765634 AI948838 AW235336 AW172827 AA095289 BE046383
AI734240 W16699 AI660329 AI289433 AA933778 AW469242
AA468838
AA806983 AA625873 W78031 BE206301 AA550803 AI743147
AI990075 AA948274 AA129533 AI635399 AA605313 AI624669
AW594319
AI221834 AI337434 AA307706 BE550282 AI760467 AI630636
AI221521 AW674314 AW078889 AI933732 AI6B6969 A1186928
AW074595
AI127486 AL079644 AI910815 H17814 AA310903 AW137854
T19279 AA026682 AA306035 AW383390 AW383389 AW383422
AW383427
AW383395 H09977 AA306247 AA352501 AW403639 F05421
AA224473 AA305321 H93904 AA089612 AW391543 AW402915
AW173382
AW402701 AW403113 894438 N73126 H93466 AA090928 AA095051
T29025 AW951071 L47277 L47276 AI375913 BE384156
W24652
AA7d6288 AA568223 BE090591 H93033 N57027 AA504348
AA327653 AW959913 N53767 AA843715 AI453437 AW263710
A1076594
1 ~ AA583483 AW873194 AW575166 AI128799 AI803319 AL042776
AW074313 A1887722 A1032284 AA447521 AI123B85 N29334
AI354911
AW090687 AA236763 AAd35535 AA236910 AA047124 AA236734
AW514610 H93467 AA962007 AI446783 AA127259 AI613495
AI686720 AI587374 AA936731 AA702d53 AI859757 AA216786
AI251819 AI469227 AA806022 A1092324 N71868 AA968782
AA236919
AA809450 AA227220 AA765284 AI192007 AA768810 AA805794
AA729280 AA806238 AW768817 N71879 A1050686 AA505822
AA66897d AI688160 BE045915 AW466315 AA731314 AA649568
AA834316 AW591901 AW063876 AW294770 AI300266 A1336094
15 AI560380 AA721755 H09978 D20305 D29155 AW821790 BE150864
F01675 AI457474 AW466316 AA550969 AA630788
100824 5_36 A1393237 AI521317 AI761348 AF025841 D43968 AW994987
L34598 AF025841 D89789 D89788 D89790 AW998932 AI971742
AI310238
X90976 AW139668 AW674280 AI365552 AA877d52 AV657554
C75229 AA376077 AI798056 AW609213 W25586 H30149
BE075089
BE075190 AW580858 H99598 AA425238 AA133916 AW363478
BE158121 BE158127 AW467960 BE158135 BE158126 BE158145
N92860 AA847246 AI961688 AI361423 AA878154 AA043767
AI863712 AI559226 AW339007 AI371266 AI368901 AA046624
AA134739
AW449154 AA130232 AI458720 AA962511 AI700627 870437
AW004008 AA045229 AI671572 H99599 AA043768 AI685454
AI871685
N29937 X90977 AA524240 AI142114 AI825750 AI567805
AI631365 AI347893 AA134740 F20669 AA046107 AW793216
AW963298
AW959380 AA363265 AI784593 AI268201 869451 AV657618
AI695588
101714 30725_1 M68874 AL022147 M72393 AL049797 BE439441 T27650 AI766240
AW150345 AW7789d3 AI627464 BE439479 AA587049 AI277900
AI984983 AI630935
101809 32963-1 M868d9 AA31528Q NM 004004 AA3i5269 BE142653 AA461d00
AW802042 BE152893 AW383155 AA490688 AW117930 AW384563
AW384544 AW384566 AW378307 AW378323 AW839085 AA257102
AW378317 AW276060 AW271245 AW378298 AW384497 AI59811
d
AW26d544 A1018136 AW021810 AA961504 AW086214 AW771d89
AW192483 AI290266 AW192488 AW384490 AW007451 AW890895
AA554460 AA613715 AW020066 AI783695 AI589498 AI917637
AW264471 AW384491 AI816732 AW368530 AW368521 AW368463
AA461087 AI341438 AI970613 AIOd0737 AI418d00 AA947181
AA962716 AI280695 AW769275 AW023591 AI160977 AA055d00
N71882
AA490466 AW243772 AW316636 A1076554 AW511702 N69323
H88912 AA257017 AI952506 H88913 AI912481 AA600714
BE465701
N64149 C00523 N64240 AA677120
101923 30543_1 X99133 X83006 W38398 AA401137 AA298242 AA366738 AA308126
AW583781 AA298668 AW845024 BE140204 AW845005 U47734
AA837575 NM 005564 AA329732 AA421943 BE171567 S75256
AI750047 AI762213 AA100735 AW612993 AI474120 AW062884
AI940001 AW062852 AW062899 BE182639 AW778875 AA528093
AW517424 AI939989 AA076188 BE182636 AA169569 AA167d39
35 AI283967 AA167783 AA076140 AI749649 AA166792 AI70B618
AA400973 AA514773 AA514789 AA164458 AA167440 AA07d845
AA421944 AA514874 AA079557 AA102361 AA587027 AA642930
AA878029 AA164459 AW176400 AW475086 AA857522 AA148193
AA838234 AA593897 AI284506 AW193324 AA148194 AW583341
AI669077 AW264913 AA074902 AI680515 AA169874 AA169614
AA079651 AW591737 AW190644 AA076565 AA662747 AA075896
AA535642 N27757 AI306666 AA074727 N79823 AA524360
AI826800
AA173827 BE140374 BE004062 AW265060 BE184103 A1199258
AA857853 AA299459 AA837890 AI626104 AA503624 BE183618
BE183717 AA573267 AI833071 AW270590 AA506601 BE004010
AA837854 AI675895 AI810491 AI184883 AW664712 AA076046
AA515574 AW352267 AI797418 AA772395 AI74919d AI559933
AA502597 AA321220 AI866124 AI695633 AA494293 AW085635
AA165649 AA165663
127007 19921_1 AB037771 BE005079 AA394189 AW959650 AA299360 AA398081
W37627 AW750817 AW630138 AI522058 BE326323 AA374890
AW418534 AW997510 AW995214 AW959649 AA504426 D79223
D79621 AI276062 AI973155 AA653470 AA337887 AI382521
AW084427
45 D57078 W37628 AI610506 230230 AI567034 AA766091 H25097
H25078 AW991507 AA319736
110769 229824_1BE000831 AA541787 AW173038 AA327931 AW117510 AW664665
A1066624 AI478955 AI863075 A1073744 AA490170 Rd6651
A1075653
F02865 N22222 AW972956
120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA4287718E280542
AW194691 AI927301 AI7d0458 AI796100 AI935603 AW052210
AA970201 AI633384 AA425910 A1017004 AI241295 AA402816
AA291468
O
Table 10A lists about 733 genes up-regulated in ovarian cancer compared to
normal adult fissues. These were selected from 59680 probesets on the
AffymetrixlEos-Hb03
GeneChip array such that the rafio of "average" ovarian cancer to 'average"
normal adult fissues was greater than or equal 1o 3Ø The "average" ovarian
cancer level was set to
the about the 80th percenfile amongst various ovarian cancers. The 'average"
normal adult tissue level was set to the 90th percentile value amongst various
non-malignant
5 5 tissues. In order to remove gene-specific background levels of non-
specific hybridization, the 15th percenfile value amongst the non-malignant
tissues was subtracted from both
the numerator and the denominator before the rafio was evaluated.
TABLE 10A:
ABOUT
733 UP-REGULATED
GENES,
OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES
Pkey: Primekey
Ex.Accn:
ExempIarAccession
UG ID:
UniGene
ID
Title:
UniGene
title
ratio:
ratio
tumor
vs normal
tissues
65 Pkey Ex. UG Tifie ratio
Accn ID
432938 Hs.3132steroidogenic acute 56.1
T27013 regulatory protein
418179 Hs.11d5Wilms tumor 1 33.5
X51630
400292 Hs.72472BMPR-Ib; bone morphogenetic30.0
AA250737 protein receptor
452838 Hs.30743Preferenfially expressed29.5
U65011 antigen in melanoma
415511 Hs.182362ESTs 28.1
AI732617
422956 Hs.122579ESTs 28.1
BE545072
410929 Hs.30643ESTs 27.4
H47233
400289 Hs.2258Matrix Metalloproteinase25.2
X07820 10 (Stromolysin 2)
449034 Hs.277523gbas41a09.x1 NCI CGAP 23.7
AI624049 Ut1 Homo sapiens cDNA
75 427585 Hs.179729collagen; type X; alpha22.7
D31152 1 (Schmid metaphyseal
428392 Hs.2265secretary granule, 21.9
Hf0233 neuroendocrine protein
1
448243 Hs.77496ESTs 21.3
AW369771
430691 Hs.103538ESTs 21.2
C14187
444783 Hs.62180ESTs 20.8
AK001468
407638 Hs.288693EST 20.1
AJ404672
423739 Hs.97600ESTs 19.7
AA398155
436982 Hs.5378spondin 1, (f spondin)19.0
A8018305 extracellular maUix
p
451110 Hs.301584ESTs 18.8
AI955040
426427 Hs.1698d0. TTK protein kinase 18.7
MB6699
166
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
428227AA321649Hs.2248INTERFERON-GAMMA INDUCED18.3
419854AW664873Hs.87836Homo Sapiens PAC clone 18.3
RP5-1087M19 from 7q11.
439706AW872527Hs.59761ESTs 18.3
428579NM Hs.184942G protein-coupled receptor17.4
005756 64
410247AF181721Hs.61345RU2S 17.0
428153AW513143Hs.98367hypothetical protein 16.9
FLJ22252 similar to
SRY-
415076NM_000857Hs.77890guanylate cyclase 1, 16.6
soluble, beta 3
416209AA236776Hs.79078MAD2 (mitotic arrest 16.6
deficient, yeast, homolo
424905NM Hs.153704NIMA (never in mitosis 16.2
002497 gene a)-related kinase
1 423685BE350494Hs.49753Homo sapiens mRNA far 15.9
~ KIAA1561 protein, parti
428187A1687303Hs.285529ESTs 15.9
438817A1023799Hs.i63242ESTs 15.9
424906A1566086Hs.153716Homo Sapiens mRNA for 15.9
Hmob33 protein, 3'
untr
407721Y12735Hs.38018dual-specificity tyrosine-(Y)-phosphorylatlon15.7
15 412723AA648459Hs.179912ESTs 15.3
424717H03754Hs.i wingless-type MMTV integrafion15.2
52213site family, m
443646A1085198Hs.298699ESTs 15.1
424345AK001380Hs.i45479Homo Sapiens cDNA FLJ1051814.8
fis, clone NT2RP20
428976AL037824Hs.194695ras homolog gene family,14.6
member I
418738AW388633Hs.6682solute carrier family 14.3
7, member 11
428479Y00272Hs.184572cell division cycle 14.2
2, Gi to S and G2 to
M
436209AW850417Hs.254020ESTs, Moderately similar14.1
to unnamed protein
p
427356AW023482Hs.97849ESTs 13.9
418601AA279490Hs.86368calmegin 13.8
25 416661AA634543Hs.79440IGF-II mRN9-binding 13.7
protein 3
428532AF157326Hs.184786TBP-interacting protein13.6
402408 0 13.6
447350A1375572Hs.172634ESTs; HER4(c-erb-84) 13.4
451807W52854Hs.27099DKFZP564J0863 protein 13.4
423575C18863Hs.163443ESTs 13.2
443211A1128388Hs.143655ESTs 13.2
d37872AK002015Hs.5887RNA binding motif protein13.0
7
451659BE379761Hs.14248ESTs, Weakly similar 12.7
to ALU8 HUMAN ALU SUBFAM
452904AL157581Hs.30957Homo Sapiens mRNA; cDNA12.7
DKFZp434E0626 (from
c
3 442655AW027457Hs.30323ESTs 12.5
S
452096BE394901Hs.226785ESTs 12.4
414972BE263782Hs.77695KIAA0008 gene product 12.3
d35039AW043921Hs.130526ESTs 12.3
447033A1357412Hs.157601EST-notin UniGene 12.3
433764AW753676Hs.39982ESTs 12.2
442611BE077155Hs.177537ESTs 12.0
408562A1436323Hs.31141Homo sapiens mRNA for 11.9
KIAA1568 protein, parti
427344NM Hs.21425-hydroxytryptamine 11.8
000869 (serotonin) receptor
3A
421478AI683243Hs.97258ESTs 11.8
45 426635BE395109Hs.129327ESTs 11.8
415989A1267700Hs.t11128ESTs 11.7
433159AB035898Hs.150587kinesin-like protein 11.5
2
452249BE394412Hs.61252ESTs 11.4
418506AA084248Hs.85339G proteincoupled receptor11.3
39
442353BE379594Hs.49136ESTs 11.3
0
447700A1420183Hs.171077ESTs, Weakly similar 11.3
to similar to serinelthr
450480X82125Hs.25040zinc finger protein 11.3
239
425176AW015644Hs.301430ESTs, Moderately similar11.2
to TEF1 HUMAN TRANSC
435496AW840171Hs.265398ESTs, Weakly similar 11.2
to Uansformafion-relate
SS 433133AB027249Hs.104741PDZ-binding kinase; 11.1
T-cell originated protein
445258AI635931Hs.147613ESTs 11.1
432677NM Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polypeptid11.0
004482
429782NM_005754Hs.220689Ras-GTPase-activating 10.9
protein SH3-domain-bind
404567 0 10.8
423811AW299598Hs.50895homeo box C4 10.7
452891N75582Hs.212875ESTs, Weakly similar 10.6
to KIAA0357 [H.sapiens]
441627AA947552Hs.58086ESTs 10.3
443555N71710Hs.21398ESTs, Moderately similar10.3
to GNPI_HUMAN GLUCOS
412140AA219691Hs.73625RAB6 interacting, kinesin-like10.2
(rabkinesin6)
6S 427469AA403084Hs.269347ESTs 10.1
415227AW821113Hs.72402ESTs 10.1
445413AA151342Hs.12677CGI-147 protein 10.0
425734AF056209Hs.159396peptidylglycine alpha-amidafing10.0
monooxygenase
421451AA291377Hs.50831ESTs 10.0
410044BE566742Hs.58169highly expressed in 9.8
cancer, rich in leucine
h
d27878005766Hs.181022CGI-07 protein 9.7
d08460AA054726Hs.285574ESTs 9.7
422972N59319Hs.145404ESTs 9.7
443715AI583187Hs.9700cyclin E1 9.7
75 440901AA909358Hs.128612ESTs 9.6
453160AI263307Hs.146228ESTs 9.6
415211R64730.compHs.155986ESTs; Highly similar 9.5
to SPERM SURFACE PROTEIN
425282AW163518Hs.155485hunfingtin interacting 9.5
protein 2
400250 0 9.5
410568AW162948Hs.64542pre-mRNA cleavage factor9.3
Im (68kD)
442957AI949952Hs.49397ESTs 9.3
453922AF053306Hs.36708budding uninhibited 9.3
by benzimidazoles 1
(yeas
434401AI864131Hs.71119Pulafive prostate cancer9.2
tumor suppressor
453628AW243307Hs.170187. ESTs 9.1
167
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
452055AI377431Hs.293772ESTs 9.1
424086A1351010Hs.102267lysyl oxidase 9.1
442875BE623003Hs.23625Homo sapiens clone 9.1
TCCCTA00142 mRNA sequence
416208AW291168Hs.41295ESTs 9.0
407168845175Hs.117183gb:yg40tO1.slSoaresinfantbrainiNIBHomos9.0
445537AJ245671Hs.12844EGF-like-domain; mulfiple8.9
6
409269AA576953Hs.22972Homo Sapiens cDNA FLJ133528.9
fis, clone OVARC10
433527AW235613Hs.133020ESTs 8.9
409928AL137163Hs.57549hypothetical protein 8.8
dJ47384
1 423020AA383092Hs.1608replication protein 8.7
~ A3 (l4kD)
425665AK001050Hs.159066ESTs 8.6
443204AW205878Hs.29643Homo Sapiens cDNA FLJ131038.6
fis, clone NT2RP30
449433AL672096Hs.9012ESTs 8.6
453878AW964440Hs.19025ESTs 8.6
15 450505NM-004572Hs.25051plakophilin 2 8.6
407001U12471Hs.247954Human thrombospondin-18.5
gene, partial cds
414315224878 gb:HSB65D052 STRATAGENE8.5
Human skeletal muscle
425492AL021918Hs.158i74zinc finger protein 8.5
184 (Kroppel-like)
435181AA669339Hs.28838KIAA1571 protein 8.5
436396AI683487Hs.299112Homo Sapiens cDNA FLJ11d418.5
fis, clone HEMBA10
418384AW149266Hs.25130ESTs 8.4
453370AI470523Hs.182356ESTs, Moderately similar8.4
to translation iniG
409041A8033025Hs.50081KIAA1199 protein 6.4
447078AW885727Hs.301570ESTs ' 8.4
448674W31178Hs.15d140ESTs _s 8.3
433393AF038564Hs.98074atrophin-1 interacting8.3
protein 4
433496AF064254Hs.49765VERY-LONG-CHAIN ACYL-COA8.3
SYNTHETASE
421155H87879Hs.102267lysyl oxidase 8.2
438394BE379623Hs.27693CGI-124 protein 8.2
400298AA032279Hs.61635STEAP1 8.1
409092A1735283Hs.172608ESTs 8.1
440250AA876179Hs.134650ESTs 8.1
409143AW025980Hs.138965ESTs 8.1
407771AL138272Hs.62713ESTs 8.1
35 419088AI538323Hs.77496ESTs 8.1
431725X65724Hs.2839Norrie disease (pseudoglioma)7.9
431750AA514986Hs.283705ESTs 7.9
435635AF220050Hs.181385uncharacterized hematopoiefic7.9
stemiprogenitor
441826AW503603Hs.129915phosphotriesterase 7.9
related
417728AW138437Hs.24790KIAA1573 protein 7.8
418845AA852985Hs.89232chromobox homolog 5 7.8
(Drosophila HPi alpha)
421039NM_003478Hs.101299cullin 5 7.8
446999AA151520Hs.279525hypothetical protein 7.8
PR02605
429609AF002246Hs.210863cell adhesion molecule7.8
with homology to L1
CAM
45 415139AW975942Hs.48524ESTs 7.7
450192AA263143Hs.24596RAD51-interacting protein7.7
423992AW898292Hs.137206Homo Sapiens mRNA; 7.7
cDNA DKFZp564N1663
(from c
436211AK001581Hs.80961polymerase (DNA directed),7.7
gamma
450101AV649989Hs.24385Human hbc647 mRNA sequence7.5
426921AA037145Hs.172865cleavage stimulafion 7.5
0 factor, 3' pre-RNA,
subu
433330AW207084Hs.132816ESTs 7.5
439759AL359055Hs.67709Homo Sapiens mRNA full7.5
length insert cDNA
clo
427660A1741320Hs.114121Homo sapiens cDNA: 7.5
FLJ23228 fis, clone
CAE066
422095AI868872Hs.288966ceruloplasmin (feroxidase)7.5
55 436476AA326108Hs.53631ESTs 7.5
412170D16532Ns.73729very low density lipoprotein7.4
receptor
428954AF100781Hs.194678WNT1 inducible signaling7.4
pathway protein 3
450221AA328102Hs.24641cytoskeleton associated7.4
protein 2
439262AA832333Hs.124399ESTs 7.4
435420A1928513Hs.59203ESTs 7.3
422892AA988176Hs.121553hypotheficalprotein 7.3
FLJ20641
457030A1301740Hs.173381dihydropyrimidinase-like7.3
2
411571AA122393Hs.70811hypotheficalprotein 7.2
FLJ20516
409916BE313625Hs.57435solute carcierfamily 7.2
11 (proton-coupled
diva
65 418007M13509Hs.83169Matrix metalloprotease7.2
1 (intersfitial collag
420900AL045633Hs.44269ESTs 7.2
424001W67883Hs.137476KIAA1051 protein 7.2
400301X03635Hs.1657Estrogenreceptort 7.1
400238 0 7.1
70 413573AI733859Hs.149089ESTs 7.1
428071AF212848Hs.182339transcription factor 7.1
ESE-3B
447164AF026941Hs.17518Homo Sapiens cig5 mRNA,7.1
partial sequence
453062AW207538Hs.61603ESTs 7.1
456965AW131888Hs.172792ESTs, Weakly similar 7.1
to hypothetical protein
442500AI819068Hs.209122ESTs 7.1
-046142AI754693Hs.145968ESTs 7.0
417791AW965339Hs.111471ESTs 7.0
418524AA300576Hs.85769acidic 82 kDa protein 7.0
mRNA
451797AW663858Hs.56120ESTs 7.0
8~ 452909NM Hs.30985pannexin 1 7.0
015368
453616NM Hs.33846dynein, axonemal, light7.0
003462 intermediate polypept
436281AW411194Hs.120051ESTs 7.0
449897AW819642Hs.24135transmembrane protein 6.9
vezafin; hypothetical
p
414142AW368397Hs.150042. ESTs 6.9
168
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
448776BE302464Hs.30057fransporter similar 6.9
to yeast MRS2
419423D26488Hs.90315KIAA0007 protein 6.9
420908AL049974Hs.100261Homo Sapiens mRNA; 6.8
cDNA DKFZp564B222
(from c1
452971AI873878Hs.91789ESTs 6.8
413597AW302885Hs.117183ESTs 6.8
415138C18356Hs.78045fissue factor pathway 6.8
inhibitor 2 TFPI2
437478AL390172Hs.118811ESTs 6.7
425292NM Hs.15554537 kDa leucine-rich 6.7
005824 repeat (L88) protein
421184NM-003616Hs.102456survival of motor neuron6.7
protein interacfing
1 410227AB009284Hs.61152exostoses (multiple)-like6.6
~ 2
446608N75217Hs.257846ESTs 6.6
438167828363Hs.24286ESTs 6.6
445459A1478629Hs.158465ESTs 6.6
452291AF015592Hs.28853CDC7 (cell division 6.6
cycle 7, 5. cerevisiae,
h
15 410011AB020641Hs.57856PFTAIRE protein kinase6.6
1
410292AA843087Hs.124194ESTs 6.5
415716N59294Hs.301141Homo Sapiens cDNA FLJ116896.5
fis, clone HEMBA10
424770AA425562 gb:zw46e05.r1 Soares 6.5
total-fetus_Nb2HF8-9w
Ho
438122AI620270Hs.129837ESTs 6.5
439820AL360204Hs.283853HomosapiensmRNAfuIIlengthinsertcDNAclo6.5
444743AA045648Hs.11817nudix (nucleoside diphosphate6.5
linked moiety X
450638AK001826Hs.25245hypothetical protein 6.5
FLJ11269
418203X54942Hs.83758CDC28 protein kinase 6.5
2
439901N73885Hs.124169ESTs 6.5
428758AA433988Hs.98502Homo Sapiens cDNA FLJ 6.4
14303 fis, clone PLACE20
404552 0 6.4
404599 0 6.4
419503AA243642Hs.137422ESTs 6.4
420149AA255920Hs.88095ESTs 6.4
440411N30256Hs.156971ESTs, Weakly similar 6.4
to Weak similarity
with
449108AI1406B3Hs.98328ESTs 6.4
452097AB002364Hs.27916ADAM-TS3 ; a disintegrin-like6.4
and metallopr
453619H87648Hs.33922H.sapiens novel gene 6.4
from PAC 117P20, chromos
410273BE326877Hs.281523ESTs 6.3
35 434486AA678816Hs.117142ESTs 6.3
454036AA374756Hs.93560ESTs, Weakly similar 6.3
to unnamed protein
produ
403381 0 6.2
421308AA687322Hs.192843ESTs 6.2
419346A1830417 gb:wh94d12.x1 NCI CGAP_CLL16.2
Homo Sapiens cDNA
446140AA356170Hs.26750Homo sapiens cDNA: 6.2
FLJ21908 fis, clone
HEP038
453047AW023798Hs.286025ESTs 6.2
442573H93366Hs.7567Branched chain aminotransferase6.1
1, cytosolic,
d10102AW248508Hs.279727ESTs; 6.1
410004AI298027Hs.299115ESTs 6.1
45 413335A1613318Hs.48442ESTs 6.1
424945AI221919Hs.173438hypotheficalprotein 6.1
FLJ10582
427510247542Hs.179312small nuclear RNA acfivafing6.1
complex, polypep
451229AW967707Hs.48473ESTs 6.1
452641AW952893Hs.237825signal recognifion 6.1
particle 72kD
433172A8037841Hs.102652hypothetical protein 6.1
ASH1
425465L18964Hs.1904protein kinase C; iota6.1
437117AL049256Hs.122593ESTs 6.0
423440825234Hs.i43434contacfin 1 6.0
430510AW162916Hs.241576hypothetical protein 6.0
PR02577
55 433252A8040957Hs.151343KIAAi524pratein 6.0
434699AA643687Hs.149425Homo Sapiens cDNA FLJ119806.0
fis, clone HEMBB10
436954AA740151Hs.130425ESTs 5.9
436032AA150797Hs.109276latexin protein 5.9
424590AW966399Hs.46821hypothetical protein 5.9
FLJ20086
444078BE246919Hs.10290U5 snRNP-specific 40 5.9
kDa protein (hPrpB-bindi
418379AA218940Hs.137516fidgefin-like 1 5.9
438081H49546Hs.298964ESTs 5.8
443270NM Hs.9192Homer, neuronal immediate5.8
004272 early gene,18
450459AI697193Hs.299254ESTs 5.8
65 433612AF078164Hs.61188Homo Sapiens Ku70-binding5.8
protein (KUB3) mRNA
449048245051Hs.22920similar to S68401 (cattle)5.8
glucose induced ge
417251AW015242Hs.99488ESTs; Weakly similar 5.7
to ORF YKR074w [S.cerevi
429181AW979104Hs.294009ESTs 5.7
454933BE141714 gb:OVO-HT0101-061099-032-c045.7
HT0101 Homo sapi
70 456553AA721325Hs.189058ESTs, Weakly similar 5.7
to cAMP-regulated
guanin
430371D87466Hs.240112KIAA0276 protein 5.7
425371D49441Hs.155981mesothelin 5.7
424513BE385864Hs.149894mitochondrial franslational5.6
inifiafion factor
432015AL157504Hs.159115ESTs 5.6
75 438109A1076621Hs.71367ESTs, Moderately similar5.6
to ALU7-HUMAN ALU
SU
407137197307Hs.199067v-erb-b2 avian erythroblastic5.6
leukemia viral
407945X69208Hs.606ATPase, Cu++Uansporfing,5.6
alpha polypeptide
416565AW000960Hs.44970ESTs 5.6
417830AW504786Hs.132808epithelial cell fransforming5.5
sequence 2 oncog
419752AA249573Hs.152618ESTs 5.5
~
422093AF151852Hs.111449CGI-94 protein 5.5
424583AF017445Hs.150926fucose-1-phosphate 5.5
guanylylUansferase
430388AA356923Hs.240770nuclear cap binding 5.5
protein subunit 2,
20kD
452534AW083022Hs.149425. Homo Sapiens cDNA 5.5
FL,l11980 fis, clone
HEMBB10
169
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
453279AW893940Hs.59698ESTs 5.5
424188AW954552Hs.142634zinc finger protein 5.5
453884AA355925Hs.36232KIAA0186 gene product 5.5
424641AB001106Hs.151413glia maturation factor,5.5
beta
444478W07318Hs.240M-phase phosphoprotein5.5
1
427975AI536065Hs.122460ESTs 5.5
424620AA101043Hs.151254kallikrein 7 (chymotryptic;5.5
sfratum comeum)
442914AW188551Hs.99519Homo sapiens cDNA FLJ140075.5
tis, clone Y79AA10
417995AW974175Hs.188751ESTs 5.4
1 418946AI798841Hs.132103ESTs 5.4
0
419963AA743276Hs.301052ESTs 5.4
420362U79734Hs.97206huntingtin interacting5.4
protein 1
422670AA371612Hs.115351ESTs 5.4
432837AA310693Hs.279512HSPC072 protein 5.4
15 447020T27308Hs.16986hypothetical protein 5.4
FLJ11046
458027L49054Hs.85195ESTs, Highly similar 5.4
to t(3;5)(q25.1;p34)
fus
425217AU076696Hs.155174CDCS (cell division 5.4
cycle 5, S. pombe,
homolo
422938NM Hs.1594cenfromere protein 5.4
001809 A (l7kD)
450434AA166950Hs.i ESTs, Weakly similar 5.4
8645 to partial GDS [C.elegan
20 438279AA805166Hs.165165ESTs, Moderately similar5.4
to ALUB-HUMAN ALU
5U
413384NM_000401Hs.75334exostoses (multiple) 5.3
2
420328Y19062Hs.96870staufen (Drosophila, 5.3
RNA-binding protein)
hom
436586A1308862Hs.167028ESTs 5.3
435793AB037734Hs.4993ESTs ' 5.3
422306BE044325Hs.227280Homo Sapiens mRNA for 5.3
Lsm5 protein
425154NM Hs.154850collagen, type IX, 5.2
001851 alpha 1
453293AA382267Hs.10653ESTs 5.2
429944813949Hs.226440Homo Sapiens clone 5.2
24881 mRNA sequence
434891AA814309Hs.123583ESTs 5.2
30 415263AP,948033Hs.130853ESTs 5.2
409506NM-006153Hs.54589NCK adaptor protein 5.2
1
412848AA121514Hs.70832ESTs 5.2
421246AW582962Hs.300961ESTs, Highly similar 5.2
to AF1518051 CGI-47
pro
431548AI834273Hs.9711Homo Sapiens cDNA FLJ 5.2
13018 fis, clone NT2RP30
35 412719AW016610Hs.129911ESTs 5.2
411945AL033527Hs.92137v-myc avian myelocytomatosis5.1
viral oncogene h
424078AB006625Hs.139033paternally expressed 5.1
gene 3
433558AA833757Hs.201769ESTs 5.1
434265AA846811Hs.130554Homo Sapiens cDNA: 5.1
FLJ23089 fis, clone
LNG070
40 453911AW503857Hs.4007Sarcolemmal-associated5.1
protein
415539AI733881Hs.72472BMPR-Ib; bone morphogenetic5.1
protein receptor
442717888362Hs.180591ESTs, Weakly similar 5.1
to R06F6.5b [C.elegans]
432358A1093491Hs.72830ESTs 5.0
409731AA125985Hs.56145thymosin, beta, identified5.0
in neuroblastoma c
45 419699AA248998Hs.31246ESTs 5.0
420313AB023230Hs.96427KIAA1013 protein 5.0
422505AL120862Hs.124165ESTs; (HSA)PAP protein5.0
(programmed cell deat
425733F13287Hs.159388Homo Sapiens clone 5.0
23578 mRNA sequence
434160BE551196Hs.114275ESTs 5.0
50 435094A1560129Hs.277523EST 5.0
436612AW298067 gb:Ul-H-BWO-ajp-g-09-0-ULs15.0
NCI-CGAP-Sub6 Ho
432415T16971Hs.289014ESTs 4.9
406117 0 4.9
438018AK001160Hs.5999hypothetical protein 4.9
FLJ10298
447505AL049266Hs.18724Homo Sapiens mRNA; 4.9
S cDNA DKFZp564F093
(from c1
448621A1097144Hs.5250ESTs, Weakly similar 4.9
to BACR37P7.g (D.melanog
453001AW131636Hs.191260ESTs 4.9
410561BE540255Hs.6994Homo sapiens cDNA: 4.9
FW22044 fis, clone
HEP091
418811AK001407Hs.88663hypothetical protein 4.9
FLJ10545
60 436754A1061288Hs.133437ESTs, Moderately similar4.8
to gonadofropin indu
d37212AI765021Hs.210775ESTs 4.8
447312AI434345Hs.36908activating Uanscription4.8
factor 1
409732NM-016122Hs.56148NY-REN-58 antigen 4.8
434690AI867679Hs.148410ESTs 4.8
65 444172BE147740Hs.104558ESTs 4.8
424539L02911Hs.150402activin A receptor, 4.8
type I
418677583308Hs.87224SRY (sex determining 4.8
region Y)-box 5
406076AL390179Hs.137011Homo Sapiens mRNA; 4.8
cDNA DKFZp547P134
(from c1
420179N74530Hs.21168ESTs 4.7
70 450375AA009647Hs.8850a disintegrin and metalloproteinase4.7
domain 12
419247S65791Hs.89764fragile X mental retardation4.7
1
420850BE139590Hs.122406ESTs 4.7
425420BE536911Hs.234545ESTs 4.7
428664AK001666Hs.189095similar to SALL1 (sat 4.7
(Drosophila)-like
75 419131AA406293Hs.301622ESTs 4.7
422278AF072873Hs.114218ESTs 4.7
d51684AF216751Hs.26813CDA14 4.6
400296AA305627Hs.139336ATP-binding cassette; 4.6
sub-family C (CFTRIMRP)
408425AW058674Hs.44787Homo Sapiens mRNA; 4.6
cDNA DKFZp43400227
(from c
417168AL133117Hs.81376Homo Sapiens mRNA; 4.6
cDNA DKFZp586L1121
(from c
429486AF155827Hs.203963hypothetical protein 4.6
FLJ10339
442917AA314907Hs.85950ESTs 4.6
443268A1800271Hs.129445hypotheticalprotein 4.6
FLJ12496
452795AW392555Hs.18878hypothetical protein 4.6
FLJ21620
170
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
457300AW297436Hs.158849Homo Sapiens cDNA: FLJ216634.6
its, clone COL088
d59551AI472808 gbaj70e07.x1 Soares 4.6
NSF_F8-9W-OT-PA_P_S1
Ham
421977W94197Hs.110165ribosomal protein L26 4.6
homolog
429441AJ224172Hs.204096lipophilin B (uteroglobin4.6
family member), pro
449722BE280074Hs.23960cyclin 81 4.6
431689AA305688Hs.267695UDP-Gal:betaGIcNAc beta4.5
1,3-galactosyltransfe
425178H16097Hs.161027ESTs 4.5
429597NM Hs.2442a disintegrtn and metalloproteinase4.5
003816 domain 9
436556AI364997Hs.7572ESTs 4.5
10400534 0 4.5
417845AL117461Hs.82719Homo Sapiens mRNA; cDNA4.5
DKFZp586F1822 (from
c
423123NM-012247Hs.124027SELENOPHOSPHATE SYNTHETASE4.5
; Human selenium d
448305AA625207Hs.264915Homo Sapiens cDNA FLJ129084.5
fis, clone NT2RP20
441006AW605267Hs.7627CGI-60 protein 4.5
1 414569AF109298Hs.118258Prostate cancer associated4.5
S protein 1
447924AI817226Hs.170337ESTs 4.5
d25506NM Hs.158205basic leucine zipper 4.5
003666 nuclear factor 1 (JEM-1)
411630042349Hs.71119Putative prostate cancer4.4
tumor suppressor
432842AW674093Hs.279525hypothetical protein 4.4
PR02605
413472BE242870Hs.75379solute carrier family 4.4
1 (glial high affinity
414699A1815523Hs.76930synuclein, alpha (non 4.4
A4 component of amyloid
412733AA984472Hs.74554KIAA0080 protein 4.4
419790079250Hs.93201glycerol-3-phosphate 4.4
dehydrogenase 2(mitocho
433377A1752713Hs.43845ESTs 4.4
449535W15267Hs.23672low density lipoprotein4.4
receptor-related prot
453900AW003582Hs.226414ESTs, Weakly similar 4.4
to ALUS HUMAN ALU SUBFAM
443861864512Hs.237146Homo Sapiens cDNA FLJ 4.4
14234 fis, clone NT2RP40
423025AA831267Hs.12244Homo sapiens cDNA: FLJ235814.4
fis, clone LNG136
408621AI970672Hs.d6638chromosome 11 open reading4.3
frame 8; fetal br
30416241N52639Hs.32683ESTs 4.3
432005AA524190Hs.120777ESTs, Weakly similar 4.3
to ELL?-HUMAN RNA POLYME
435532AW291488Hs.117305ESTs 4.3
451813NM Hs.27182phospholipase A2-activating4.3
016117 protein
454193BE141183 gb:MRO-HT0071-191199-001-b044.3
HT0071 Homo sapi
35418478038945Hs.1174cyclin-dependent kinase4.3
inhibitor 2A (melanom
406069 0 4.3
419465AW500239Hs.21187Homo Sapiens cDNA: FLJ230684.3
fis, clone LNG055
418413895735Hs.117753ESTs, Weakly similar 4.3
to antigen of the monocl
452028AK001859Ns.27595hypothetical protein 4.3
FLJ10997
418693AI750878Ns.87409thrombospondin 1 4.3
410361BE391804Hs.62661guanylate binding protein4.2
1, interferon-induc
409763AL043212 gb:DKFZp434H0623 r1434 4.2
(synonym: htes3) Homo
455601AI368680Hs.81658Y (sex determining 4.2
region Y)-box 2, partial
408908BE296227Hs.48915sedneithreonine kinase 4.2
15
45413582AW295647Hs.71331Homo Sapiens cDNA: FW219714.2
fis, clone HEP057
423248AA380177Hs.i25845dbulose-5-phosphate-3-epimerase4.2
425024839235Hs.12407ESTs 4.2
447153AA805202Hs.173912eukaryotic translation 4.2
inifiafion factor 4A,
447406BE618060Hs.282882ESTs 4.2
449347AV649748Hs.295901ESTs 4.2
d14279AW021691Hs.3804DKFZP564C1940 protein 4.2
428856AA436735Hs.183171Homo Sapiens cDNA: FLJ220024.2
fis, clone HEPO66
d07872AB039723Hs.40735frizzled (Drosophila) 4.2
homolog 3
421502AF111856Hs.105039solute carrier family 4.2
34 (sodium phosphate),
SS436406AW105723Hs.t25346ESTs 4.2
438209AL120659Hs.6111KIAA0307 gene product 4.2
443653AA137043Hs.9663programmed cell death 4.1
6-interacting protein
454556AW807073 gb:MR4-ST0062-031199-018-d064.1
ST0062 Homo sapi
424834AK001432Hs.153408Homo Sapiens cDNA FLJ105704.1
fis, clone NT2RP20
412593Y07558Hs.74088early growth response 4.1
3
416566NM-003914Hs.79378cyclin A1 4.1
426342AF093419Hs.169378mulUple PDZ domain proteind.t
428417AK001699Hs.184227F-box only protein 21 4.1
429317AA831552Hs.268016solute carrier family 4.1
5 (inositol transporter
6S446880AI811807Hs.108646Homo Sapiens cDNA FLJ125344.1
fis, clone NT2RM40
422988AW673847Ns.97321ESTs 4.0
d34657AA641876Hs.191840ESTs 4.0
412494AL133900Hs.792ADP-rtbosylafion factor4.0
domain protein 1, 64k
443271BE568568Hs.195704ESTs 4.0
421437AW821252Hs.104336ESTs 4.0
401644 0 4.0
405095 0 4.0
418417877182 gb:yi65e02.r1 Soares 4.0
placenta Nb2HP Homo
sapi
420807AA280627Hs.57846ESTs 4.0
75429529AA454190Hs.193811ESTs, Moderately similar4.0
to reduced expressio
457726AI217477Hs.194591ESTs 4.0
431130NM_006103Hs.2719epididymis-specific; 4.0
whey-acidic protein
type
453403BE466639Hs.61779Homo Sapiens cDNA FLJ1359i4.0
fis, clone PLACE10
442768AL048534Hs.48458ESTs, Weakly similar 4.0
to ALUB HUMAN ALU SUBFAM
413430822479Hs.24650Homo Sapiens cDNA FLJ130474.0
fis, clone NT2RP30
424081NM Hs.139120dbonuclease P (30kD) 4.0
006413
425692D90041Hs.155956NAT1; arylamine N-acetyltransferase4.0
407792A10777t5Hs.39384putative secreted ligand4.0
homologous to fjxl
408353BE439838Hs.44298hypothefical protein 4.0
171
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
421175Ai879099Hs.102397GIOT-3 for gonadoUopin 3.9
inducible transcripfi
420324AF163474Hs.96744DKFZP586D0823 protein, 3.9
Prostate androgen-regu
417531NM Hs.1087serinelthreonine kinase3.9
003157 2
458924BE242158Hs.24427DKFZP56601646 protein 3.9
400195 0 3.9
401480 0 3.9
410360AW663690 gb:hj21g03.x1 NCI_CGAP-U83.9
Homo Sapiens cDNA
410908AA121686Hs.10592ESTs 3.9
420159AI572490Hs.99785ESTs 3.9
422805AA436989Hs.121017H2A histone family; 3.9
member A
' 424639A1917494Hs.131329ESTs 3.9
428555NM-002214Hs.184908integrin, beta 8 3.9
431699NM Hs.267831Homo Sapiens cDNA FLJ129523.9
001173 fis, clone NT2RP20
433703AA210863Hs.3532nemo-like kinase 3.9
1 437144ALOd9466Hs.7859ESTs 3.9
Jr
452728AI915676Hs.239708ESTs 3.9
430447W17064Hs.241451SWIISNF related, matrix3.9
associated, actin dep
440594AW445167Hs.126036ESTs 3.9
408938AA059013Hs.22607ESTs 3.9
427051BE178110Hs.173374ESTs 3.9
447568AF155655Hs.18885CGI-116 protein 3.9
457211AW972565Hs.32399ESTs, Weakly similar 3.9
to Similar to Ena-VASP
I
443475A1066470Hs.134482ESTs 3.9
433447029195Hs.3281neuronal pehtraxin II 3.9
428093AW594506Hs.104830ESTs 3.8
437938AI950087 ESTs; Weakly similar 3.8
to Gag-Pol polyprotein
[
408829NM Hs.48384heparan sulfate (glucosamine)3.8
006042 3-0-sulfotransf
429250H56585Hs.198308iryptophan rich basic 3.8
protein
441859AW194364Hs.128022ESTs, Weakly similar 3.8
to FIG1 MOUSE FIG-1
PROT
437700AA766060Hs.122848ESTs 3.8
439560BE565647Hs.74899hypothetical protein 3.8
FLJ12820
409564AA045857Hs.54943fracture callus 1 (rat)3.8
homolog
429474AA453441Hs.31511ESTs 3.8
431965BE175190 gb:OV2-HT0577-010500-165-g043.8
HT0577 Homo sapi
454018AW016892Hs.241652ESTs 3.8
426320W47595Hs.169300transforming growth 3.8
factor, beta 2
439635AA477288Hs.94891Homo sapiens cDNA: FLJ227293.8
fis, clone HSI156
417517AF001176Hs.82238POP4 (processing of 3.8
precursor , S. cerevisiae
446402AI681145Hs.160724ESTs 3.8
450236AW162998Hs.24684KIAA1376 protein 3.8
410804064820Hs.66521Machado-Joseph disease 3.8
(spinocerebellar ataxi
400268 0 3.8
418217AI9101i47Hs.13442ESTs 3.8
421928AFOi3758Hs.109643poiyadenylate binding 3.8
protein-interacting
pro
45 417300AI765227Hs.55610solute carrier family 3.8
30 (zinc transporter),.
414136AA812d34Hs.178227ESTs 3.8
453945NM-005171Hs.36908acfivating transcription3.7
factor 1
400240 0 3.7
407877AW016811Hs.234478Homo sapiens cDNA: FLJ226483.7
fis, clone HSI073
450581AF081513Hs.25195endometdal bleeding 3.7
associated factor (left-
418223NM_014733Hs.83790KIAA0305 gene product 3.7
411704AI499220Hs.71573hypothetical protein 3.7
FLJ10074
432712AB016247Hs.288031sterol-C5-desaturase 3.7
(fungal ERG3, delta-5-de
422809AK001379Hs.121028hypothetical protein 3.7
FLJ10549
5 402820 0 3.7
5
408090BE173621Hs.292478ESTs 3.7
416421AA734006Hs.79306eukaryotic translation 3.7
initiation factor 4E
418282AA215535Hs.98133ESTs 3.7
418454AA315308 gb:EST187095 Colon carcinoma3.7
(HCC) cell line
418668AW407987Hs.87150Human clone A9A2BR11 3.7
(CAC)nl(GTG)n repeat-con
422290AA495854Hs.48827hypothetical protein 3.7
FLJ12085
432824AK001783Hs.279012hypotheficalprotein 3.7
FLJ10921
439907AA853978Hs.124577ESTs 3.7
447479AB037834Hs.18685Homo Sapiens mRNA for 3.7
KIAA1413 protein, parti
65 451073AI758905Hs.206063ESTs 3.7
450377AB033091Hs.24936ESTs 3.7
414343AL036166Hs.75914coated vesicle membrane3.7
protein
448807AI571940Hs.7549ESTs 3.7
442821BE391929Hs.8752Putative type II membrane3.7
protein
426300015979Hs.169228delta-like homolog (Drosophila)3.7
418068AW971155Hs.293902ESTs, Weakly similar 3.7
to prolyl 4-hydroxylase
411263BE297802Hs.69360kinesin-like 6 (mitofic3.7
centromere-associated
443054AI745185Hs.8939yes-associated protein 3.7
65 kDa
421154AA284333Hs.287631Homo Sapiens cDNA FLJ142693.7
fis, clone PLACE10
75 411402BE297855Hs.69855NRAS-related gene 3.7
450447AF212223Hs.25010hypotheficalprotein 3.6
P15-2
414706AW340125Hs.76989KIAA0097 gene product 3.6
434228242047Hs.283978ESTs; KIAA0738 gene 3.6
product
434164AW207019Hs.148135ESTs 3.6
409533AW969543Hs.21291mitogen-acfivated protein3.6
kinase kinase kings
402222. ~ 0 3.6
404915 0 3.6
404996 0 3.6
411560AW851186 gb:IL3-CT0220-150200-071-H053.6
CT0220 Homo sapi
172
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
419750AL079741Hs.183114Homo Sapiens cDNA FLJ142363.6
tis, clone NT2RP40
426010AA136563Hs.1975Homo Sapiens cDNA: FLJ210073.6
tis, clone CAE038
427038NM Hs.173288KIAA0155 gene product 3.6
014633
439255BE164500 gb:RC4-HT0469-230300-014-e103.6
HT0469 Homo sapi
458242BE299588Hs.28465Homo sapiens cDNA: FLJ218693.6
tis, clone HEP024
415115AA214228Hs.121751hypothefical protein 3.6
453468W00712Hs.32990DKFZP566F084 protein 3.6
441205AW137827Hs.176904ESTs 3.6
452693T79153Hs.48589zinc finger protein 3.6
228 .
1 417389BE260964Hs.82045Midkine (neurite growth-promoting3.6
~ factor 2)
448105AW591433Hs.170675ESTs, Weakly similar 3.6
to TMS2_HUMAN TRANSMEMBR
451522BE565817Hs.26498hypothetical protein 3.6
FLJ21657
440048AA897461Hs.158469ESTs, Weakly similar 3.5
to envelope protein
[H.s
419359AL043202Hs.90013chromosome segregation 3.5
1 (yeast homology-like
15 452030AL137578Hs.27607Homo Sapiens mRNA; cDNA3.5
DKFZp564N2464 (from
c
400666 0 3.5
422646H87863Hs.151380ESTs 3.5
407846AA426202Hs.40403Cbp/p300.interacting 3.5
Uansactivator, with
Glu
408730AV660717Hs.47144DKFZP586N0819 protein 3.5
401517 0 3.5
413775AW409934Hs.75528nucleolar GTPase 3.5
417177NM-004458Hs.81452fatty-acid-Coenzyme 3.5
A ligase, long-chain
4
427943AW959075 gb:EST371145 MAGE resequences,3.5
MAGE Homo sapi
439107AL046134Hs.27895ESTs 3.5
447268A1370413Hs.36563Homo Sapiens cDNA: FLJ224i83.5
tis, clone HRC085
412604AW978324Hs.47144DKFZP586N0819 protein 3.5
427134AA398409Hs.173561EST 3.5
430273A1311127Hs.125522ESTs 3.5
436671AW131159Hs.146151ESTs 3.5
3 433037NM Hs.279938HSPCO61 protein 3.5
~ 014158
453745AA952989Hs.63908Homo Sapiens HSPC316 3.5
mRNA, partial cds
400531AF151064Hs.36069hypothetical protein 3.5
433345AI681545Hs.152982EST cluster (not in 3.4
UniGene)
406400AA343629Hs.104570kallikrein 8 (neuropsinlovasin)3.4
35 407596886913 gb:yq30f05.r1 Soaresfetal3.4
liver spleen 1NFL5
453779N35187Hs.43388ESTs 3.4
444858AI199738Hs.208275ESTs, Weakly similar 3.4
to unnamed protein
produ
447688N87079Hs.19236NADH dehydrogenase (ubiquinone)3.4
1 beta subcom
424856AA347746Hs.9521ESTs, Weakly similar 3.4
to KIAA1015 protein
(H.s
407864AF069291Hs.d0539chromosome 8 open reading3.4
frame 1
404108 0 3.4
403729 0 3.4
404232 0 3.4
423687AA329633Hs.133011ESTs, Highly similar 3.4
to 2117 HUMAN ZINC
FINGE
45 428372AK000684Hs.183887hypothetical protein 3.4
FLJ22104
439741BE379646Hs.6904Homo Sapiens mRNA full 3.4
length insert cDNA
clo
441447AA934077Hs.126980ESTs 3.4
448358844433Hs.106614Human DNA sequence from3.4
clone RP4-534K7 on
ch
450926AI744361Hs.205591ESTs, Weakly similar 3.4
to zinc finger protein
P
458477NM Hs.10712phosphatase and lensin 3.4
000314 homolog (mutated in
mu
d21379Y15221Hs.103982small inducible cytokine3.4
subfamily 8 (Cys-X-C
452822X85689Hs.288617Homo Sapiens cDNA: FLJ226213.4
fis, clone HSI056
441111AI806867Hs.126594ESTs 3.4
447519046258Hs.23448ESTs 3.4
S 446913AA430650Hs.16529Uansmembrane 4 superfamily3.4
member (tetraspan
449581AI989517Hs.181605ESTs 3.4
456132BE219771Hs.237146Homo Sapiens cDNA FLJ142343.4
fis, clone NT2RP40
448186AA262105Hs.4094Homo Sapiens cDNA FLJ 3.4
14208 tis, clone NT2RP30
422611AA158177Hs.118722fucosylUansferase 8 3.4
(alpha (1,6) fucosyltran
'
441433AA933809Hs.42746ESTs 3.4
417837AL079905Hs.1103Uansforming growth factor,3.4
beta 1
450516AA902656Hs.21943NIF3 (Ngg1 interacting 3.4
factor 3, S.pombe homo
407796AA195509Hs.272239lymphocyte activation-associated3.3
protein
419200AW966405Hs.288856prefoldin 5 3.3
65 423161AL049227Hs.124776Homo Sapiens mRNA; cDNA3.3
DKFZp564N1116 (from
c
445679AI343868Hs.58800Homo Sapiens cDNA FLJ124883.3
tis, clone NT2RM20
435014BE560898Hs.10026ribosomal protein L17 3.3
isolog
446619AU076643Hs.313secroted phosphoprotein3.3
1 (osteopontin, bone
439110AA332365Hs.165539ESTs 3.3
429830A1537278Hs.225841DKFZP434D193 protein 3.3
428943AW086180Hs.37636ESTs, Weakly similar 3.3
to KIAA1392 protein
[H.s
445817NM Hs.13340histone acetylUansferase3.3
003642 1
408805H69912Hs.48269vaccinia related kinase3.3
1
441134W29092Hs.7678cellular retinoic acid-binding3.3
protein 1
75 408532AI453137Hs.63176ESTs 3.3
409517X90780Hs.54668troponin I, cardiac 3.3
414304AI621276Hs.165998DKFZP564M2423 protein 3.3
436427A1344378Hs.143399ESTs 3.3
d36662A1582393Hs.126695ESTs 3.3
440304BE159984Hs.125395ESTs 3.3
447385F12863 gb:HSC3FE081 normalized3.3
infant brain cDNA Hom
451177AI969116Hs.13034ESTs 3.3
428949AA442153Hs.104744ESTs, Weakly similar 3.3
to AF2088551 BM-013
[H.
d51743AW074266Hs.23071ESTs 3.3
173
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
421515Y11339Hs.105352GaINAc alpha-2, 6-sialylUansferase3.3
I, long f
446351AW444551Hs.258532ESTs 3.3
435102AW899053Hs.76917F-box only protein 8 3.3
418216AA662240Hs.283099AF15q14 protein 3.3
401508 0 3.3
437108AA434054Hs.80624Homo Sapiens cDNA: FLJ234423.3
fis, clone HS1009
416530062801Hs.79361kallikrein 6 (neurosin,3.3
zyme)
443171BE281128Hs.9030TONDU 3.3
458627AW088642Hs.97984ESTs; Weakly similar 3.3
to WASP-family protein
[
1 412078X69699Hs.73149paired box gene 8 3.3
~
414080AA735257Hs.47783ESTs, Weakly similar 3.3
to T12540 hypothetical
p
401197 0 3.3
422134AW179019Hs.112110ESTs 3.3
409044A1129586Hs.33033ESTs 3.3
15 416198H27332Hs.99598ESTs 3.2
436481AA379597Hs.5199HSPC150 protein similar3.2
to ubiquifin-conjugal
436525AA721428Hs.26145Homo sapiens cDNA FLJ141273.2
fis, clone MAMMA10
409142AL136877Hs.50758chromosome-associated 3.2
polypepfide C
428819AL135623Hs.193914KIAA0575 gene product 3.2
20 428728NM Hs.i ESTs; Weakly similar 3.2
01662591381 to hypothefical protein
421261AA600853Hs.98133ESTs 3.2
446219A1287344Hs.149827ESTs 3.2
457574H88717Hs.27774ESTs, Highly similar 3.2
to AF1613491 HSPC086
[H
409172299399Hs.118145ESTs 3.2
419388T67012Hs.75323prohibifin _~ 3.2
434187AA627098Hs.99103ESTs, Weakly similar 3.2
to 138428 T-complex
prot
445060AA830811Hs.88808ESTs 3.2
448254A1829900Hs.22929ESTs 3.2
452943BE247449Hs.31082hypothefical protein 3.2
FLJ10525
411393AW797437Hs.69771B-factor, properdin 3.2
453775NM_002916Hs.35120replicafion factor C 3.2
(activator 1) 4 (37kD)
408418AW963897Hs.44743KIAA1435 protein 3.2
442025AW887434Hs.11810ESTs, Weakly similar 3.2
to CD4.2 [C.elegans]
417006AW673606Hs.80758aspartyl-tRNAsynthetase3.2
35 407881AW072003Hs.40968heparin sulfate (glucosamine)3.2
3-0-sulfotransf
444755AA431791Hs.183001ESTs 3.2
402829 0 3.2
451593AF151879Iis.26706CGI-121 protein 3.2
419926AW900992Hs.93796DKFZP586D2223 protein 3.2
4~ 434551BE387162Hs.280858ESTs,HighlysimilartoXPB3.2
HUMAN DNA-REPAIR
445929A1089660Hs.7838makorin, ring finger 3.2
protein,1
409365AA702376Hs.226440Homo Sapiens clone 248813.2
mRNA sequence
418836AI655499Hs.161712ESTs 3.2
441020W79283Hs.35962ESTs 3.1
45 422363T55979Hs.115474replicafion factor C 3.1
(acfivator 1) 3 (38kD)
413010AA393273Hs.75133Uanscription factor 3.1
6-like 1 (mitochondria)
452092BE245374Hs.27842hypothetical protein 3.1
FLJ11210
410486AW235094Hs.193424ESTs, Weakly similar 3.1
to KIAA1064 protein
[H.s
434540NM Hs.5184TH1 drosophila homolog 3.1
016045
50 409178BE393948Hs.50915kallikrein 5 3.1
439480AL038511Hs.125316ESTs 3.1
417848AA206581Hs.39457ESTs 3.1
446293A1420213Hs.149722ESTs 3.1
408108A1580492Hs.42743hypothetical protein 3.1
55 415947004045Hs.78934mutS (E. coli) homolog 3.1
2 (colon cancer, nonpo
410519AW612264Hs.131705ESTs 3.1
421987A113316iHs.286131CGI-101 protein 3.1
440046AW402306Hs.6877hypothetical protein 3.1
FLJ10483
453931AL121278Hs.25144ESTs 3.1
454423AW603985Hs.i79662nucleosome assembly 3~1
protein 1-like 1
459069F13036Hs.27373Homo Sapiens mRNA; cDNA3.1
DKFZp56401763 (from
c
418735N48769Hs.44609ESTs , 3.1
414245BE148072Hs.75850WAS protein family, 3.1
member 1
410909AW898161Hs.53112ESTs, Weakly similar 3.1
to ALUB HUMAN ALU SUBFAM
434926BE543269Hs.50252Homo sapiens HSPC283 3.1
mRNA, partial cds
409239AA740875Hs.44307ESTs 3.1
429017AA463605Hs.238995ESTs 3.1
447072D61594Hs.17279tyrosylprotein sulfotransferase3.1
1
426514BE616633Hs.301122bone morphogenefic protein3.1
7 (osteogenic prot
448133AA723157Hs.73769folate receptor 1 (adult)3.1
418792AB037805Hs.88442KIAA1384 protein 3.1
427528AU077143Hs.179565minichromosome maintenance3.1
deficient (S. cere
402077 0 3.1
440671AW297920Hs.130054ESTs 3.1
419890X17360Hs.278255homeo box D4 3.1
406687M31126Hs.272620pregnancy specific beta-1-glycoprotein3.1
9
409151AA306105Hs.50785SEC22, vesicle Uafficking3.1
protein (S. cerevi
431221AA449015Hs.286145SRB7 (suppressor of 3.1
RNA polymerise B; yeast)
443584A1807036Hs.101619ESTs 3.1
g0 445525BE149866Hs.14831ESTs 3.1
410441BE298210 gb:601118016F1 NIH_MGC-173.1
Homo Sapiens cDNA c
422634NM_016010Hs.118821CGI-62 protein 3.0
420022AA256253Hs.120B17ESTs 3.0
453912AL121031Hs.32556_ KIAA0379 protein 3.0
174
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
456844AI264155Hs.152981CDP-diacylglycerol synihase
(phosphafidate cy 3.0
414941C14865Hs.182159ESTs 3.0
407807AL031427Hs.40094Human DNA sequence from
clone 167A19 on chrom
3.0
414725AA769791Hs.120355Homo Sapiens cDNA FLJ13148
fis, clone NT2RP30 3.0
444420AI148157Hs.146766ESTs 3.0
431742NM-016652Hs.268281CGI-201 protein 3.0
412519AA196241Hs.73980froponin T7, skeletal,
slow 3.0
418348AI537167Hs.96322Homo Sapiens cDNA: FLJ23560
fis, clone LNG098 3.0
444261AA298958Hs.10724MDS023 protein 3.0
1 457465AW301344Hs.195969ESTs 3.0
~
443933At091631Hs.135501Homo Sapiens two pore potassium
channel KT3.3 3.0
442150AI368158Hs.128864ESTs 3.0
414883AA926960Hs.77550CDC28 protein kinase 1
3.0
442879AF032922Hs.8813syntaxin binding protein
3 3.0
1 437949078519Hs.41654ESTs 3.0
403515 0 3.0
403864 0 3.0
407785AW207285Hs.98279ESTs 3.0
426199AA371865Hs.97090ESTs 3.0
426324AW291787Hs.200933ESTs 3.0
427738NM-000318Hs.180612peroxisomal membrane protein
3 (35kD, Zellweg 3.0
427837087309Hs.180941vacuolar protein sorting
41 (yeast homology 3.0
439430AF124250Hs.6564breast cancer anti-esfrogen
resistance 3 3.0
442039AW276240Hs.128352ESTs, Weakly similar to
p80 [R.norvegicus] 3.0
446978NM-001938Hs.16697down-regulator offranscripfionl,TBP-bindin
3.0
452431088879Hs.29499 toll-like receptor 3
3.0
452841T17431Hs.65412DEADIH (Asp-Glu-Ala-AspIHis)
box polypeplide 3.0
432114AL036021Hs.225597ESTs 3.0
445640AW969626Hs.31704ESTs, Weakly similar to
KIAA0227 [H.sapiens] 3.0
30 442607AA507576Hs.288361KIAA0741geneproduct 3.0
453920AI133148Hs.36602I factor (complement) 3.0
430000AW205931Hs.99598ESTs 3.0
429164AI688663Hs.116586ESTs 3.0
453331AI240665Hs.8895ESTs 3.0
35 448663BE614599Hs.106823H.sapiens gene from PAC
42616, similar to syn
3.0
425776025128Hs.159499parathyroid hormone receptor2
3.0
401714 0 3.0
400903 0 3.0
428428AL037544Hs.184298cyclin~dependent kinase
7 (homolog of Xenopus
3.0
443761AI525743Hs.160603ESTs 3.0
451640AA195601Hs.26771Human DNA sequence from
clone 747H23 on chrom
3.0
442580AI733682Hs.130239ESTs 3.0
TABLE t08:
45 Pkey: Unique Eos probeset idenfifier number
CAT number. Gene cluster number
Accession: Genbank accession numbers
Pkey CAT Accession
Number
4075961003489886913 886901 H25352 801370 H43764 AW044451 W21298
1
409763115392_1AL043212 AA077575 AA077655 819502 BE545457 AI638421
814093
4103601197225AW663690
-2
410441120358-1BE298210 A1672315 AW086489 BE298417 AA455921 AA902537
BE327124 814963 AA085210 AW274273 A1333584 A1369742
A1039658
AI885095 AI476470 AI287650 AI885299 AI985381 AW592624
AW340136 AI266556 AA456390 AI310815 AA484951
4115601249443AW851186 AW996967 BE143456
1
414315143512224878 AA494098 F13654 AA494040 AA143127
1
4184171750818877182 877197 880484
1
418454175699AA315308 AA223392 BE538098 BE087173
1
419346184129A1830417 AA236612
1
424770243504AA425562 A1880208 AA346fi46 N22655 AW811775 AW811786
1
427943284802AW959075 W06838 AA417863
1
43196533959 BE175190 BE003348
2
436812427323AW298067 AA731645 AA810101 AW194180 A1690673 AW978773
1
43793844573 AI950087 N70208 897040 N36809 AI308119 AW967677 N35320
2 AI251473 H59397 AW971573 897278 W01059 AW967671 AA908598
6S _ AA251875 AI820501 AI820532 W87891 T85904 071456 T82391
BE328571 T75102 834725 AA884922 BE328517 A1219788
AA884444
N92578 F13493 AA927794 AI560251 AW874068 AL134043
AW235363 AA663345 AW008282 AA488964 AA2831 d4 AI890387
AI9503d4
AI741346 AI689062 AA282915 AW102898 AI872193 AI763273
AW173586 AW150329 A1653832 AI762688 AA988777 AA488892
AI356394
AW103813 AI539642 AA642789 AA856975 AW505512 AI961530
AW629970 BE612881 AW276997 AW513601 AW512843 AA044209
AW856538 AA180009 AA337499 AW961101 AA251669 AA251874
AI819225 AW205862 AI683338 AI858509 AW276905 AI633006
AA972584
7o AA908741 AW072629 AW513996 AA293273 AA969759 N75628
N22388 H84729 H60052 T92487 A1022058 AA780419 AA551005
W80701
AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802
866056 A1002839 867840 AA300207 AW959581 T63226 F04005
439255470321BE164500 AA832198 BE164502
1
447385719912_1F12863 A1377223 T75099
4541931050256BE141183 AW178167 AW178162 AW178166 AW178172 AW845893
1 AW178159 AW178222 AW178213 AW178215 AW178090 AW178091
75 _ AW178161 AW178207 AW178210 AW178214 AW178212 BE140918
BE140917 AW178135 AW178205 AW178209 AW178223 AW178220
AW178206 AW178203 AW178165 AW178168 AW178160 AW178136
AW845878 AW178131 AW178138 AW178105 AW845894 AW178129
AW845810 AW845828 AW178216 AW178112 AW178211 AW178224
BE140915 AW178221 AW178130 AW178134 AW178096 AW178108
AW178133 AW178164 AW178218 AW178171 AW178157 AW178158
AW178103 BE141189 AW178170 AW845816 BE141586 AW178156
AW178104 AW178163 AW178093 AW178208 AW178137 AW178140
AW178219 BE141592 AW845901 BE141580 AW178155 BEi41598
BE140957
4545561223878_1AW807073 AW807055 AW807067 AW807276 AW807030 AW807363
AW845892 AW807091 AW807275 AW807284 AW807287 AW845891
AW807195 AW807271
4549331245515-1BE141714 AW845993 AW845989
175
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
TABLE 10C:
Pkey: Unique number corresponding to an Eos probeset
Ref: Sequence source. The 7 digit numbers in this column are Genbank IdenUfier
(GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA
sequence of
human chromosome 22" Dunham, et al. (1999) Nature 402:489-095
Strand: Indicates DNA strand from which exons were predicted
Nt-position: Indicates nucleotide positions of predicted exons
Pkey Ref StrandNt~osition
4005346981826Minus278637-279292
1 4006668118496Plus 17982-18115,20297-20456
~
4009032911732Plus 59112-59228
4011979719705Plus 176341-176452
4014807321503Plus 166120-166347,166451-166557,169651-169832
4015087534110Minus110779-110983
1 4015177677912Plus 29278-29770
4016448576138Plus 82655-83959
4017146715702Plus 96484-96681
4020778117414Plus 65014-65195
4022229958106Plus 3261-3834,3939-4269
4024089796239Minus110326-110491
4028206456853Minus82274-82443
4028298918414Plus 101532-101852,102006-102263
4033819438267Minus26009-26178
4035157656757Minus173358-179553
25 4037297543752Minus37662-37909..,
4038647709019Minus51753-51890,79290-79445
4041088247074Minus6360&64942
4042328218045Minus71800-71956
4045527243881Plus 19854-20010
4045677249169Minus101320-101501
4045998705107Plus 110443-110733
4049157341766Minus100915-101087
4049966007890Plus 37999-38145,38652-38998,39727-39672,40557-40674,42351-42450
4050958072599Plus 138877-139066
3 4060699117732Plus 68880-69374
S
4061179142932Plus 54304-54584
Table 11A lists about 222 genes up-regulated in ovarian cancer compared to
normal adult tissues that are likely to encode extracellular or cell-surface
proteins. These were
selected as for Table 10A, except that the ratio was greater than or equal to
2.0, and the predicted protein contained a structural domain that is
indicative of extracellular
localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane
domains). Predicted protein domains are noted.
TABLE 11A: ABOUT 222 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELL SURFACE
PROTEINS, OVARIAN CANCER VERSUS NORMAL ADULT TISSUES
Pkey:
Primekey
45 Ex. Exemplar
Accn:Accession
UG
ID:
UniGene
ID
Title:
UniGene
title
PFAM protein
domains: siroctural
predicted domains
ratio:
ratio
tumor
vs
normal
tissue
5o
PkeyEx. UG Title PFAM domainsratio
Accn (D
400292AA250737Hs.72472BMPR-Ib; bone pkinase,Activin30.0
morphogenetic recp
pro
400289X07820Hs.2258Matrix MetalloproteinaseSS,hemopexin,Peptidas25.2
10 (Strom
427585031152Hs.179729collagen; type C1q Collagen22.7
X; alpha 1 ~
(Schmid m
436982AB018305Hs.5378spondin 1, (f tsp- 19.0
spondin) extracellular1
m
428579NM-005756Hs.184942G protein-coupledTM 17.4
receptor 64
443646A1085198Hs.298699ESTs TSPN,vwc,tsp_1,EGF15.1
436209AW850417Hs.254020ESTs, ModeratelyTM 14.1
similar to
unname
418601AA279490Hs.86368calmegin SS,calreticulin13.8
428532AF157326Hs.184786TBP-interactingTM 13.6
protein
427344NM Hs.21425-hydroxytryptamineTM,neur_chan11.8
000869 (serotonin)
rec
432677NM-004482Hs.278611UDP-N-acetyl-alpha-D-gataclosaminTM,Glycos-
transf_2,Ri11.0
404567NM_015902Hs.278428progestin inducedTM,HECT,zf-UBR110.8
protein (0D5)
445537AJ245671Hs.12844EGF-like-domain;SS,MAM,EGF 8.9
mulUple 6
65 409928AL137163Hs.57549hypothetical TM,MSP_domain8.8
protein 4J47384
407001012471Hs.247954Human thrombospondin-1TSPN,vwc,tsp-1,EGF8.5
gene, par
453370AI470523Hs.182356ESTs, ModeratelyABC_tran,ABC8.4
similar to membr
translat
400298AA032279Hs.61635STEAP1 TM 8.1
431725X65724Hs.2839Norrie disease SS,Cys knot 7.9
(pseudoglioma)
70 429609AF002246Hs.210863cell adhesion TM,fn3,ig 7.8
molecule with
homolo
412170016532Hs.73729very low densityTM,IdI_recept_a,Idl_rec7.4
lipoprotein
recepto
428954AF100781Hs.194678WNT1 inducible SS,IGFBP,Cys7.4
signaling pathwayknot,tsp
418007M13509Hs.83169Matrix metalloproteaseSS,hemopexin,Peptidas7.2
1 (interstitia
424001W67883Hs.137476ItIAA1051 proteinPep-M12B_propep,Rep7.2
75 456965AW131888Hs.172792ESTs, Weakly TM 7.1
similar to
hypothelica
446142AI754693Hs.145968ESTs Cadherin_C 7.0
term,cadhe
415138C18356Hs.78045tissue factor Kunitz_BPTI,G-gamma6.8
pathway inhibitor
2 TFP
438167828363Hs.24286ESTs 7tm 1 6.6
452097AB002364Hs.27916ADAM-TS3 ; a Pep-M12B-prapep,Rep6.4
disintegrin-like
and
go 449048245051Hs.22920similar to 568401SS 5.8
(caUle) glucose
in
425371049441Hs.155981mesothelin SS 5.7
407945X69208Hs.606ATPase, Cu++transporUng,alphaTM,E1-E2_ATPase,Hy5.6
p
424620AA101043Ns.151254kallikrein 7 SS,trypsin 5.5
(chymotryptic;
stratum c
420362079734Hs.97206hunting8n interactingTM,ENTH,I_LWEO. 5.4
protein 1
176
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
413384NM Hs.75334exostoses (mulfiple)TM 5.3
000401 2
425154NM Hs.154850collagen, type Coltagen,TSPN5.2
001851 lX, alpha 1
411945AL033527Hs.92137v-myc avian TGF-bela,TGFb,~ropep5.1
myelocytomatosis
viral
415539AI733881Hs.72472BMPR-Ib; bone pkinase,Activin5.1
morphogenefic recp
pro
436018AK001160Hs.5999hypothefical TM 4.9
protein FLJ10298
424539L02911Hs.150402acfivin A receptor,Acfivin recp,pkinase4.8
type I
450375AA009647Hs.8850a disintegrin disintegrin,Reprolysin,P4.7
and metalloproteinase
d
451684AF216751Hs.26813CDA74 TM 4.6
400296AA305627Hs.139336ATP-binding TM,A8C_tran,ABC_m4.6
cassette; sub-family
C
1 429597NM-003816Hs.2442a disintegrin TM 4.5
~ and metalloproleinase
d
400534AP000541 predicted exonsTM,KRAB,zf-C2H24.5
425506NM Hs.158205basic leucine TM,Folate 4.5
003666 zipper nuclear carrier
factor 1
413472BE242870Hs.75379solute carrier TM,SDF 4.4
family 1 (glial
high off
449535W15267Hs.23672towdensilylipoproteinreceptor-velaSS,tdl-recept4.4
b,ldl-rece
15 452028AK001859Hs.27595hypothefical Zn carbOpept,Propep-M4.3
protein FLJ10997
418693AI750878Hs.87409lhrombospondin EGF,TSPN,tsp-l,isp_3,4.3
1
410361BE391804Hs.62661guanylate bindingTM,GBP 4.2
protein 1,
interfer
407872AB039723Hs.40735fizzled (Drosophila)FrizzIed,Fz,7tm4.2
homolog 3 2
421502AF111856Hs.105039solute carrier TM,Na Pi_cotrans4.2
family 34 (sodium
pho
412494AL133900Hs.792ADP-ribosylafionarf,zf B 4.0
factor domain box,zf C3HC4
pro
405095NM-014479Hs.145296disintegrin Reprolysin,disintegrin4.0
protease
431130NM Hs.2719epididymis-specific;SS,wap 4.0
006103 whey-acidic
pro
407792A1077715Hs.39384putafive secretedSS 4.0
ligand homologous
408829NM Hs.48384heparan sulfateTM 3.8
006042 (glucosamine)
3-0-s
25 450581AF081513Hs.25195endomeUial.bleedingSS,TGF-beta,TGFb-pro3.7
associated
fact
432712AB016247Hs.288031sterol-C5-desaturaseTM,Sterol_desat3.7
(fungal ERG3,
450447AF212223Hs.25010hypothetical TM,ANF-receptor,guan3.6
protein Pi5-2
414706AW340125Hs.76989KIAA0097 gene TM 3.6
product
417389BE260964Hs.82045Midkine (neuriteTM,PTN MK 3.6
growth-promofing
400666X07820Hs.2258Matrix MetalloproteinaseSS,hemopexin,Peptidas3.5
10 (Strom
406400AA343629Hs.104570kallikrein 8 SS,trypsin 3.4
(neuropsinlovasin)
407864AF069291Hs.40539chromosome 8 TM,FHA,BRCT 3.4
open reading
frame 1
452822X85689Hs.288617Homo sapiens EGF,fn3,pkinase3.4
cDNA: FLJ22621
fis,
446913AA430650Hs.16529transmembrane TM,transmembrane43.4
4 superfamily
memb
3 422611AA158fHs.118722fucosyltransferaseSS 3.4
S 77 8 (alpha (1,6)
fuc
423161AL049227Hs.124776Homo Sapiens cadherin,Cadherin-C3.3
mRNA; cDNA to
DKFZ
435102AW899053Hs.76917F-box only proteinTM,Sec7 3.3
8
416530062801Hs.79361kallikrein 6 SS,TM,trypsin3.3
(neurosin,
zyme)
401197 predicted exonsarf,Ets 3.3
40 436525AA721428Hs.26145Homo Sapiens TM 3.2
cDNA FLJ 14127
fis,
4529438E247449Hs.31082hypothefical TM 3.2
protein FW10525
411393AW797437Hs.69771B-factor, properdinSS,sushi,trypsin,vwa,fib3.2
407881AW072003Hs.40968heparan sulfateSS 3.2
(glucosamine)
3-0-s
418836A1655499Hs.161712ESTs pkinase,Activin3.2
recp
409178BE393948Hs.50915kallikrein 5 SS,Irypsin 3.1
421987AL133161Hs.286131CGI-101 proteinTM 3.1
447072D61594Hs.17279tyrosylprotein 5S 3.1
sulfotransferase
1
426514BE616633Hs.301122bone morphogeneticSS,TGFb_propeptide,T3.1
protein 7 (osteo
448133AA723157Hs.73769folate receptorTM 3.1
1 (adult)
406687M31126Hs.272620pregnancy specificSS,Pepfidase3.1
beta-1-glycoprotMlO,hem
456844A1264155Hs.152981CDP-diacylglycerolTM,Cytidylyltrans3.0
synthase (phosp'
414725AA769791Hs.120355Homo Sapiens SPRY,7tm_1 3.0
cDNA FLJ13148
fis,
407785AW207285Hs.98279ESTs Sema,ig 3.0
427738NM Hs.180612peroxisomal TM,zf-C3HC4 3.0
000318 membrane protein
3 (35
55 452431088879Hs.29499toll-like receptorTM,TIR,LRRCT3.0
3
453920AI133148Hs.36602I factor (complement)Idl recept_a,trypsin,SRC3.0
453331AI240665Hs.8895ESTs disintegrin,Reprolysin,P3.0
425776025128Hs.159499parathyroid TM,7Un 2 3.0
hormone receptor
2
428428AL037544Hs.184298cyclin-dependentTM,pkinase 3.0
kinase 7 (homolog
6fl407910AA650274Hs.41296fibronecfin TM,LRRCT,LRRNT,LR2.9
leucine rich
iransmembra
408380AF123050Hs.44532diubiquifin TM,ubiquifin,7tmL3,AN2.9
407783AW996872Hs.172028a disintegrin disintegrin,Reprolysin2.9
and metalloproteinase
d
420757X78592Hs.99915androgen receptorTM,Androgen-recep,ho2.9
(dihydrotestostero
424406D54120Hs.146409wingless-type cadherin,Cadherin_C2.9
MMTV integrationto ~
sit
65 428549AA430064Hs.220929ESTs, Moderatelyarf 2.9
similar to
ARF-fa
419452033635Hs.90572PTK7 protein TM,pkinase,ig2.9
tyrosine kinase
7
452281T93500Hs.28792ESTs TGFb-propepfide,TGF-2.9
420440NM Hs.97644mammaglobin SS,Uteroglobin2.9
002407 2
418848AI820961Hs.193465ESTs pkinase,Acfivin2.9
recp
421991NM Hs.110488KIAA0990 proteinSS 2.9
014918
433190M26901Hs.3210renin SS,asp 2.9
424538NM Hs.150390zinc finger TM 2.8
005095 protein 262
433002AF048730Hs.279906cyclin T1 SS 2.8
444342NM Hs.10887similar to lysosome-associatedTM,Lamp 2.8
014398 mem
75 430598AK001y64Hs.247112hypothefical TM 2.8
protein FLJ10902
428450NM Ns.184339KIAA0175 gene TM,pkinase,KA12.8
014791 product
450171AL133661Hs.24583hypothetical TM 2.8
protein DKFZp434C03
423554M90516Hs.i674glutamine-fructose-6-phosphatetranTM,GATase-2,SIS2.6
430016NM-004736Hs.227656xenotropic and TM 2.8
polytropic
retrovirus
417866AW067903Hs.82772collagen, type Collagen,COLFI,TSPN2.8
XI, alpha 1
424894H83520Hs.153678reproducfion SS,UBX 2.8
8
430651AA961694Hs.105187kinesin proteinSS 2.7
9 gene
414853031116Hs.77501sarcoglycan, TM 2.7
beta (43kD
dystrophin-
448595AB014544Hs.21572KIAA0644 gene TM,LRRCT,LRR2.7
product
177
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
452835AK001269Hs.30738ESTs TM 2.7
403019AA834626Hs.66718RAD54 (S.cerevisiae)-likeSS,Anfi-proliferat2.7
420281AI623693Hs.191533ESTs Cafion efflux2.7
434815AF155582Hs.46744corel UDP-galactose:N-acetylgalactSS 2.6
432201AI538613Hs.135657TMPRSS3a mRNA Uefoil,trypsin2.6
for serine
protea
430450823553Hs.241489hypotheficalproteinSS 2.6
448402BE244226Hs.21094RA818, member ras,arf 2.6
RAS oncogene
tam
421802BE261458Hs.108408CGI-78 protein TM 2.6
452355N54926Hs.29202G protein-coupledTM,7tm 1 2.6
receptor 34
1 417742864719 gb:EST22d11 ank,death,RHD,TIG2.6
~ WATMi Homo
sapie
451346NM_006338Hs.26312glioma amplifiedTM,ig,LRR,LRRNT,LR2.6
on chromosome
1
433147AF091434Hs.43080platelet delvedTM,PDGF,CUB 2.6
growth factor
C
420079NM-014051Hs.94896PTDOtt protein SS,TM, 2.6
419918X80700Hs.93728pre-B~cell leukemiahomeobox,ig,Acyltransf2.5
Uanscripfion
fac
15 432350NM_005865Hs.274407protease, serine,16SS 2.5
(thymus)
406671AA129547Hs.285754met proto-oncogenepkinase,Sema,Plexin2.5
(hepatocyte re
gro
417412X16896Hs.82112interleukin SS,TIR,ig 2.5
1 receptor,
type I
422530AW972300Hs.118110bone marrow TM 2.5
sUcmal cell
anfigen 2
433929AI375499Hs.27379ESTs EGF,IdI_recept-a,ldl_re2.5
443562AF118838Hs.9599solute carrier TM,mito carr2.5
family 25,
member 13
414386X00442Hs.75990haptoglobin sushi,trypsin2.5
417576AA339449Hs.82285phosphoribosylglycinamideAIRS,formyt_Uansf,GA2.5
formylU
449207AL044222Hs.23255nucleoporin TM 2.5
155kD
416107AA173846Hs.79015antigen ide~fifiedTM,ig 2.4
by monoclonal
ant
25 421750AK000768Hs.107872hypotheficalproteinTM,PH 2.4
FLJ20761
d14812X72755Hs.77367monokine inducedSS,ILB 2.4
by gamma interfe
406137842764Hs.3248mutS (E. colt) TM,MutS C,MutS_N,P2.4
homolog 6
450710AW953381Hs.18627ESTs, Weakly TM 2.4
similar to
601447 GP
430291AV660345Hs.23812fiCGl-49 protein TM 2.4
30 425184BE278288Hs.155048Lutheran blood ig 2.4
group (Auberger
b a
451418BE387790Hs.26369ESTs TM 2.4
412277BE277592Hs.73799guanine nucleotideTM,G-alpha 2.4
binding protein
(
4137198E439580Hs.75498small inducibleSS,ILB 2.4
cytokine subfamily
A
451806NM Hs.27076RNA 3'-terminalTM,RCT 2.3
003729 phosphate cyclase
35 416224NM_002902Hs.79088reticulocalbin SS,efhand 2.3
2, EF-hand
calcium bi
452268NM_003512Hs.28777H2A histone histone,Calc_CGRP_IA42.3
family, member
L
451668243948Hs.26789ASPIC (acidic SS,TM, 2.3
secreted protein
in ca
400880M84349Hs.119663CD59 anfigen SS,UPAR LY6 2.3
421340F07783Hs.1369decay acceleratingSS,sushi 2.3
factor for
comple
443986AI381750Hs.283437HTGN29 protein TM 2.3
443037AW500305Hs.8906syntaxin 7 TM,Syntaxin 2.3.-
440516S42303Hs.i61cadherin 2, HNH,cadherin,Cadherin2.3
type 1, N-cadherin
(near
404877AI394145Hs.18048melanoma anfigenTM,MAGE 2.3
MAGE-10
440704M69241Hs.162insulin-like SS,thyroglobulin-1,IGF2.3
growth factor
binding pr
437952D63209Hs.5944solute comer TM 2.3
family 11 (proton~coup
418624AI734080Hs.104211ESTs Sema,ig 2.2
410434AF051152Hs.63668toll-like receptorSS,TIR,LRRCT,LRR2.2
2
424687J05070Hs.151738matrix metalloproteinaseSS,fn2,hemopexin,Pepti2.2
9 (gelatins
431457NM Hs.256297integrin, alphaTM,FG-GAP,vwa2.2
012211 11
407907AI752235Hs.41270procollagen-lysine,SS,Lysyl_hydro2.2
2-oxoglutarate
5
400898AF220030Hs.125300Homo Sapiens SPRY,7tm-1 2.2
tripartite
motif protein
400303AA242758Hs.79136Human breast SS,TM, 2.2
cancer, estrogen
regal
411789AF245505Hs.72157Homo sapiens ig,LRRCT 2.2
mRNA; cDNA
OKFZ
414809AI434699Hs.77356Uansferrin receptorTM,PA,Ribosomal_S22.2
(p90, CD71)
55 401131NM_001651Hs.298023Homo Sapiens TM,MIP 2.2
aquapodn 5
(AOP5),
400277Y00281Hs.2280Human mRNA for TM 2.1
ribophorin
I
409317U20165Hs.53250bone morphogeneticTM,pkinase 2.1
protein recepto
409956AW103364Hs.727H.sapiens activinTGF-beta,TGFb-propep2.1
beta-A subunit
(ex
451253H48299Hs.26126claudin 10 TM,PMP22 2.1
Claudin
60 429638AI916662Hs.211577Kinecfin 1 (kinesin_ 2.1
receptor) TM
409267NM-012453Hs.52515Uansducin (beta)-likeTM,WD40 2.1
2
418414J04977Hs.84981X-ray repair SS 2.1
complementing
defectiv
449057AB037784Hs.22941ESTs TM 2.1
417666AI345001Hs.82380menage a trots zf C3HC4 2.1
1 (CAK assembly
fac
65 428485NM_002950Hs.2280ri6ophorin I TM 2.1
445798NM Hs.13321rearranged L-mycTM,zf C2H2 2.1
012421 fusion sequence
430057AWd50303Hs.2534bone morphogeneticTM,Acfivin 2.1
protein receptorecp,pkina
425189H16fi22 gb:ym26c07.r1 RasGEF,PH,fibrinogen_2.1
Soares infant
brain 1
413063AL035737Hs.75184chifinase 3-likeSS,Glyco-hydro-182.1
1 (cartilage
glycopro
421343BE246444Hs.283fi85hypothetical . TM 2.1
protein FLJ20396
425627AF019612Hs.297007ESTs TM,Peptidase2.1
M50
426261AW242243Hs.168670peroxisomal Ei-E2_ATPase,Cafion-2.1
famesylated
protein
431638NM-000916Hs.2820oxytocin receptorTM,7tm-1 2.1
456546AI690321Hs.203845ESTs, Weakly TM 2.1
similar to
TWIK-vela
421685AF189723Hs.106778calcium UansportATPaseTM,Et-E2_ATPase,Hy2.1
ATP2C1
424099AF071202Hs.139336ATP-binding TM,ABC_Uan,ABC-m2.1
cassette; sub-family
C
424800AL035588Hs.153203MyoD family TM 2.1
inhibitor
410007AW950887Hs.57813zinc ribbon TFIIS 2.1
domain containing,1
436135D85390Hs.5057carboxypepfidaseSS,Zn carbOpept2.1
D
d20633NM Hs.99526odorant-bindingTM,lipocalin2.1
014581 protein 2B
420162BE378432Hs.95577cyclin-dependentkinase4pkinase,ank,ArfGap,PH2.1
4261568E244537Hs.167382naUiurefic pepfideTM,ANF recepior,guan2.0
receptor A/guany
442711AF151073Hs.8645hypothetical TM 2.0
protein
411872AW327356Hs.90918. chromosome TM 2.0
11 open reading
Uame
17g
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
427801 AW979155Hs.234433hypothefical TM,Aa_Uans 2.0
protein PR01068
430268 AK000737Hs.237480hypotheficalproteinTM 2.0
FLJ20730
431183 NM Hs.250696KDEL (Lys-Asp-Glu-Leu)TM,ER_lumen 2.0
006855 endoplas recept,l
431846 HE019924Hs.271580Uroplakin 1B TM,transmembrane42.0
$ 404210 002478Hs.100469Human AF-6 mRNATM,RA,DIL,PDZ,FHA2.0
4356d0 AF220053Hs.54960uncharactedzedhematopoieficstemlTM,SET,zf-CXXC,PHD2.0
447906 AL050062Hs.19999DKFZP566K023 SS 2.0
protein
412666 AL080116Hs.74420origin recognifionTM 2.0
complex, subunit
417181 L10i23~Hs.1071surfactant proteinTM 2.0
A binding protein
1 423945 AA410943Hs.72472BMPR-Ib; bone TM,pkinase,Acfivin_rec2.0
~ morphogenefic
pro
411773 NM Hs.72026protease, serine,SS,trypsin 2.0
006799 21 (tesfisin)
448350 L14561Hs.785d6Homo Sapiens TM,E1-E2 2.0
clone 24411 ATPase,Hy
mRNA s
401093 AI955244Hs.121520HYPOTHETICAL TM,LRRCT 2.0
16.4 kDa PROTE
415664 NM_004939Hs.78580DEADIH (Asp-Glu-Ala-AspIHis)DEAD,helicase_C,SPRY2.0
bo
1$ 448165 NM_005591Hs.202379meiotic recombinafionDNA_repair,Glyco_tran2.0
(S. cerevisiae
416391 AI878927Hs.79284mesoderm specificTM,abhydrolase2.0
transcript
(mouse
422926 NM_016102Hs.121748ring finger SPRY,zf C3HC4,zf2.0
protein 16 B_
446849 AU076617Hs.16251cleavage and TM 2.0
polyadenylafion
specif
427617 D42063Hs.179825RAN binding TM,Ran BPl,zf2.0
protein 2-like RanBP
1
411678 AI90711dHs.71d65squalene epoxidaseTM,Monooxygenase2.0
432554 A1479813Hs.278411NCK-associated TM 2.0
protein 1
TABLE 11B:
Pkey: Unique
Eos probeset
idenUfier
number
2$ CAT number. _s
Gene cluster
number
Accession:
Genbank
accession
numbers
Pkey CAT Accession
Number
417742 1696262_1864719
244680
812451
425189 247825_1H16622
817322
AA351959
TABLE 11C:
Pkey: Unique n Eos probeset
number
corresponding
to a
Ref: Sequence GI) numbers.
source. "Dunham
The 7 digit I. et al."
numbers refers to
in this the publication
column enfitled
are Genbank "The DNA
Identifier sequence
( of
3 human chromosome et al. (1999)
$ 22" Dunham, Nature 402:489-495
Strand: exons were predicted
Indicates
DNA strand
from which
Nt_position:eotide
Indicates positions
nucl of
predicted
exons
Pkey Ref StrandNt_position
40 400534 6981826Minus278637-279292
401197 9719705Plus 176341-176452
4$ Table 12A lists about 57 genes up-regulated in ovarian cancer compared to
normal adult tissues that are likely to encode either enzymes or proteins
amenable to modulation by
small molecules. These were selected as for Table 10A, except that the ratio
was greater than or equal to 2.0, and the predicted protein contained a
structural domain that is
indicative of enzymatic function or of being modulated by small molecules
(e.g., pkinase, peptidase, isomerase, iransporters). Predicted protein domains
are noted.
TABLE 12A: ABOUT 57 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELL SURFACE
PROTEINS, OVARIAN CANCER VERSUS NORMAL ADULT TISSUES
Pkey:
Primekey
$~ Ex.Accn:ExempIarAccession
UG
7D:
UniGene
ID
Tifie:Gene
Uni fifie
PFAM mains: ains
do predicted
structural
dom
rafio:
ratio
tumor
vs.
normal
$
Pkey Ex. UG Tifie PFAM domains ratio
Accn ID
400292AA250737Hs.72472BMPR-Ib; bone pkinase,Acfivin30.0
morphogenefic recp
pro
400289X07820Hs.2258Matrix MetalloproteinaseSS, ,Peptidase_M1025.2 '
10 (Strom
426427M86699Hs.169840TTK protein pkinase 18.7
kinase
60 424905NM Hs.153704NIMA (never pkinase 16.2
002497 in mitosis
gene a)-vela
433159A8035898Hs.150587kinesin-like kinesin 11.5
protein 2
453370AI470523Hs.182356ESTs, ModeratelyABC trap 8.4
similar to
translat
418007M13509Hs.83169Matrix metalloproteaseSS, ,Peptidase_M107.2
1 (intersfifia
425465L18964Ns.1904protein kinase Ski Sno,pkinase_C6.1
C; iota
6$ 409506NM_006153Ns.54589NCKadaptorproteiniSH2,SH3 5.2
415539AI733881Hs.72472BMPR-Ib; bone pkinase,Acfivin5.1
morphogenefic recp
pro
424539L02911Hs.150402acfivin A receptor,Acfivin recp,pkinase4.8
type I
400296AA305627Hs.139336ATP-binding TM,ABC_tran 4.6
cassette; sub-family
C
431699NM_001173Hs.267831Homo Sapiens RhoGAP,FF,ras3.9
cDNA FLJi2952
fis,
439560BE565647Hs.74899hypothetical C2,PI-PLGY,PI-PLGX3.8
protein FLJ12820
450447AF212223Hs.25010hypothetical ANF_receptor,pkinase3.6
protein P15-2
400666X07820Hs.2258Matrix MetalloproteinaseSS, ,Pepfidase_M103.5
10 (Strom
452822X85689Hs.288617Homo Sapiens EGF,fn3,pkinase3.4
cDNA: FW22621
fis,
416530062801Ns.79361kallikrein 6 SS,TM,trypsin3.3
(neurosin,
zyme)
7$ 411393AW797437Hs.69771B-factor, properdinSS,sushi,irypsin,vwa,fn3,3.2
444755AA431791Hs.183001ESTs AAA 3.2
418836A1655499Hs.161712ESTs pkinase,Activin3.2
recp
d09178BE393948Hs.50915kallikrein 5 SS,trypsin 3.1
406687M31126Hs.272620pregnancy specificSS,Pepfidase 3.1
beta-1-glycoprotMi 0, ,1g
453920AI133148Hs.36602I factor (complement)Idl recept_a,trypsin,SRCR3.0
404653AA923729Hs.263220 pkinase 2.9
419452033635Hs.90572PTK7 protein TM,pkinase,ig2.9
tyrosine kinase
7
418848AI820961Hs.193465ESTs pkinase,Acfivin2.9
recp
428450NM Hs.184339fUAA0175 gene TM,pkinase,KAi2.8
014791 product
179
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
401323AL158037 predicted exon lactamase-B 2.7
444798BE242144Hs.12013ATP-binding 5H3,pkinase 2.7
cassette, sub-family,ABC-Uan
E
432201AI538613Hs.135657TMPRSS3a mRNA Uefoil,irypsin2.6
for serine
protea
448402BE244226Hs.21094RA818, member ras,arf 2.6
RAS oncogene
tam
406671AA1295d7Hs.285754met proto-oncogenepkinase,Sema 2.5
(hepatocyte
gro
453448AL036710Hs.209527ESTs CNH,pkinase 2.5
414386X00442Hs.75990haptogtobin sushi,trypsin2.5
421270H56037Hs.108146ESTs RhoGAP 2.4
.
414695BE439915Hs.76913proteasome (prosome,proteasome 2.4
macropain)
su
10431341AA307211Hs.251531proteasome (prosome,proteasome 2.4
macropain)
su
424085NM_002914Hs.i39226replication AAA,Viral 2.2
factor C (activatorhelicaset
1) 2 (4
424687J05070Hs.151738maUix metalloproteinaseSS,fn2, ,Peptidase-M102.2
9 (gelatins
416517AA775987Hs.79357proteasome (prosome,AAA 2.2
macropain)
26
417601NM Hs.82292KIAA0215 gene PHD 2.1
014735 product
15400509M97639Hs.155585receptor tyrosinepro-isomerase2.1
kinase-like
orphan
430057AW450303Hs.2534bane morphogenelicActivin recp,pkinase2.1
protein recepto
421841AA908197Hs.108850KIAA0936 proteinTPR,pkinase 2.1
453078AF053551Hs.31584metaxin 2 pro-isomerase2.1
424099AF071202Hs.139336ATP-binding TM,ABC-Iran 2.1
cassette; sub-family
C
20411190AA306342Hs.69171. pkinase,pkinase-C,HRi2.1
protein kinase
Glike 2
407740AA295547Hs.62666ESTs p450 2.1
420162BE378432Hs.95577cyclin-dependentpkinase,ank,ArfGap2.1
kinase 4 ,ras
420490H69894Hs.193041ESTs Pl3Ka,Pl3_P14-kinase2.1
426156BE244537Hs.167382naUiureticpeP6dereceptorAlguanyTM,ANF-
receptor,pkinase2.0
25423945AA410943Hs.72472BMPR-Ib; bone TM,pkinase,AcUvin2.0
morphogenetic recp
pro
411773NM Hs.72026protease, sedne,SS,irypsin 2.0
006799 21 (testisin)
447298BE617527Hs.180450ribosomal proteinPI3Ka, PI4_kinase2.0
S24
427617D42063Hs.179825RAN binding TPR,pro isomerase2.0
protein 2-like
1
453546AF042385Hs.33251peptidylprolyl pro-isomerase,rrm2.0
isomerase E
(cycloph
30
TABLE2C:
1
Pkey: an Eos probeset
Unique
numt~er
corresponding
1o
Ref:
Sequence
source.
The
7
digit
numbers
in
this
column
are
Genbank
Identifier
(GI)
numbers.
"Dunham
I.
et
al."
refers
to
the
publication
entitled
"The
DNA
sequence
of
human
chromosome
22"
Dunham,
et
al.
(1999)
Nature
402:489-495
35SUand:Indicates h exons were
DNA predicted
strand
from
whic
N~position:
Indicates
nucleotide
positions
of
predicted
exons
Pkey Ref StrandN(_.position
4013239212516,Plus213509-214450
40
Table 13A lists about 1086 genes up-regulated in ovarian cancer compared to
normal ovaries. These were selected as far Table 1 OA, except that the ratio
was greater than or
equal to 10, and the denominator was the median value for various non-
malignant ovary specimens.
4S TABLE 13A: About 1086 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL
OVARY
Pkey:
Primekey
Ex. Exemplay
Accn:Accession
UG
ID:
UniGene
ID
Title:
UniGeneUUe
50 ratio: al
ration ovary
tumor
vs.
norm
PkeyEx. UG Title ratio
Accn ID
439706AW872527Hs.59761ESTs 109.2
446619AU076643Hs.313secreted phosphaprotein107.8
1 (osteopontin, bone
55 422095AI868872Hs.288966ceruloplasmin (ferroxidase)104.4
447111A1017574Hs.17409cysteine-rich protein 88.3
1 (intestinal)
431130NM Hs.2719epididymis-specific; 82.8
006103 whey-acidic protein
type
431369BE184455Hs.251754secretory leukocyte 81.9
protease inhibitor
(antil
413859AW992356Hs.8364ESTs 73.9
60 446291BE397753Hs.14623interferon, gamma-inducible72.7
protein 30
426050AF017307Hs.166096E74-like factor 3 (ets68.1
domain Uanscription
f
411469T09997Hs.70327cysteine-rich protein 66.6
2
429504X99133Hs.204238lipocalin 2 (oncogene 65.7
24p3)
416971834657Hs.80658uncoupling protein 64.9
2 (mitochondrial,
proton c
65 450273AW296454Hs.24743hypothetical protein 62.5
FLJ20171
446441AK001782Hs.15093hypothetical protein 60.7
428758AA433988Hs.98502Homo Sapiens cDNA FLJ1430359.7
Us, clone PLACE20
441406245957Hs.7837Homo Sapiens cDNA FLJ1045757.8
Us, clone NT2RP10
441859AW194364Hs.128022ESTs, Weakly similar 56.7
to FIG1 MOUSE FIG-1
PROT
70 448406AW772298Hs.21103Homo sapiens mRNA; 55.7
cDNA DKFZp5648076
414602AW630088Hs.76550Homo Sapiens mRNA; 55.2
cDNA DKFZp564B1264
418068AW971155Hs.293902ESTs, Weakly similar 54.8
to prolyl d-hydroxylase
428330L22524Hs.2256maUix metalloproteinase53.4
7 (matrilysin, uteri
412636NM Hs.743i6desmoplakin (DPI, DPII)51.4
004415
75 430634AI860651Hs.26685ESTs 50.7
439318AW837046Hs.6527G protein-coupled receptor50.7
56
417259AW903838Hs.81800chondroi8n sulfate 50.6
proteoglycan 2 (versican)
407786AA687538Hs.38972teUaspan 1 50.4
426836N41720Hs.172684vesicle-assxiated membrane49.7
protein 8 (endobr
80 417308H60720Hs.81892KIAA0101 gene product 48.9
436876AI124756Hs.5337isociUate dehydrogenase48.4
2 (NADP+), mitochond
439180AI393742Hs.199067v-erb-b2 avian erythroblastic47.1
leukemia viral
428289M26301Hs.2253complement component 46.3
2
405484 0 46.1
180
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
425371D49441Hs.155981mesothelin 45.7
403912 0 45.0
443021AA368546Hs.8904Ig superfamily protein44.6
427697T18997Hs.180372BCL2-like 1 44.3
S 428227AA321649Hs.2248INTERFERON-GAMMA INDUCED44.0
PROTEIN
404678 0 43.9
400289X07820Hs.2258MaUix Metalloproteinase43.8
10 (SUcmolysin 2)
451035AU076785Hs.430plasfin 1 (I isoform) 43.8
440848BE314650Hs.7476ATPase, H+Uansporfing,42.8
lysosomal (vacuolar
1 436278BE396290Hs.5097synaptogyrin 2 42.4
~
413936AF113676Hs.75621serine (or cysteine) 42.1
proteinase inhibitor,
c7
420859AW468397Hs.100000S100 calcium-binding 42.1
protein A8 (calgranulin
428411AW291464Hs.10338ESTs 41.8
422166W72424Hs.112405S100 calcium-binding 41.5
protein A9 (calgranulin
15 412477AA150864Hs.790microsomal glutathione40.7
5-Uansferase 1
417130AW276858Hs.81256S100 calcium-binding 40.1
protein A4 (calcium
prot
424673AA345051Hs.294092ESTs 39.8
416530U62801Hs.79361kallikrein 6 (neurosin,39.7
zyme)
443162T49951Hs.9029ESTs; Highly similar 39.5
to KERATIN; TYPE I
CYTO
413719BE439580Hs.75498small inducible cytokine39.3
subfamily A (Cys-Cys
424687J05070Hs.151738matrix metalloproteinase38.9
9 (gelafinase B, 92k
413063AL035737Hs.75184chifinase 3-like 1 38.5
(cartilage glycoprotein-39
429441AJ224172Hs.204096lipophilin B (uteroglobin38.1
family member), pro
418526BE019020Hs.85838solute comer family 37.9
16 (monocarboxylic
acid
415511AI732617Hs.182362ESTs , 37.7
409453AI8855i6Hs.95612ESTs 37.7
445537AJ245671Hs.12844EGF-like-domain; mulfiple37.3
6
442432BE093589Hs.38178Homo Sapiens cDNA: 37.3
FLJ23468 fis, clone
HSIi i6
408243Y00787Hs.624interleukin 8 37.3
419092J05581Hs.89603mucin 1, Uansmembrane 36.7
444172BE147740Hs.104558ESTs 36.0
412115AK001763Hs.73239hypothetical protein 35.8
FLJ10901
420440NM Hs.97644mammaglobin 2 35.7
002407
414386X00442Hs.75990haptoglobin 35.3
35 423225AA852604Hs.125359Thy-1 cell surface 35.1
anfigen
440596H13032Hs.103378ESTs, Weakly similar 35.0
to DRR1 [H.sapiens]
413278BE563085Hs.833interferon-sfimulated 34.9
protein,15 kDa
418506AA084248Hs.85339G protein-coupled receptor34.8
39
445919T53519Hs.290357ESTs 34.7
416854H40164Hs.80296Purkinje cell protein 34.4
4
414186U33446Hs.75799protease, serine, 8 34.2
(prostasin)
434371AA631362 gb:np86b01.s1 NCI-CGAP_Thyi33.9
Homo Sapiens cDNA
421937AI878857Hs.109706HN1 protein 33.9
449722BE280074Hs.23960cyclin 81 33.8
45 400965 0 33.7
452203X57522Hs.158164ATP-binding cassette, 33.5
sub-family B (MDR/TAP),
411945AL033527Hs.92137v-myc avian myelocytomatosis33:5
viral oncogene h
425811AL039104Hs.159557karyopherin alpha 2 33.4
(RAG cohort 1, importin
a
408901AK001330Hs.48855hypotheiicai protein 33.3
FLJ10468
438461AW075485Hs.286049phosphoserine aminotransferase33.3
422963M79141Hs.13234ESTs 33.3
426158NM Hs.199067v-erb-b2 avian erythroblastic33.2
001982 leukemia viral
431836AF178532Hs.271411beta-site APP-cleaving32.8
enzyme 2
421502AF111856Hs.105039solute comer family 32.5
34 (sodium phosphate),
431211M86849Hs.5566Homo Sapiens connexin 32.5
5 26 (GJB2) mRNA, complet
436552NM Hs.5216HSPC028 protein 32.5
014038
442533AA161224Hs.8372ubiquinol-cytochrome 32.5
c reductase (6.4kD)
subu
406400AA343fi29Hs.104570kallikrein 8 (neuropsinlovasin)32.4
450353A1244661Hs.103296ESTs 32.4
422158L10343Hs.112341protease inhibitor 32.4
3, skin-derived (SKALP)
433412AV653729Hs.8185CGI-44 protein; sulfide32.3
dehydrogenase like
(y
441020W79283Hs.35962ESTs 32.2
432201A1538613Hs.135657TMPRSS3a mRNA for serine32.0
protease (ECHOS1)
(T
424125M31669Hs.1735inhibin, beta B (acfivin31.9
AB beta polypeptide)
65 453309At791809Hs.32949defensin, beta 1 31.8
408380AF123050Hs.44532diubiquitin 31.7
419329AY007220Hs.2889985100-type calcium binding31.6
protein A14
409231AA446644Hs.692GA733-2; epithelial 31.6
glycoprotein (EGP)
(KSA)
423961D13666Hs.136348Homo Sapiens mRNA for 31.2
osteoblast specific
fac
413840AI301558Hs.290801ESTs 30.8
440943AW082298Hs.146161ESTs, Weakly similar 30.8
to KIAA0859 protein
[H.s
419239AA468183Hs.184598Homo Sapiens cDNA: 30.4
FLJ23241 fis, clone
COL013
410132NM Hs.58882Microfibril-associated30.2
003480 glycoprotein-2
418203X54942Hs.83758CDC28 protein kinase 30.1
2
75 412719AW016610Hs.129911ESTs 30.0
407862BE548267Hs.50724Homo Sapiens cDNA FLJ1093430.0
fis, clone OVARC10
431563A1027643Hs.120912ESTs 29.9
431743AW972642Hs.293055ESTs a 29.8
443295A1049783Hs.241284ESTs 29.7
8~ 413745AW247252Hs.75514nucleosidephosphorylase29.7
441028AI333660Hs.17558ESTs 29.6
442315AA173992Hs.7956ESTs 29.6
452838U65011Hs.30743Preferentially expressed29.5
anfigen in melanoma
428479Y00272Hs.184572cell division cycle 29.5
2, Gt to S and G2
to M
181
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
432280BE440142Hs.2943signal recognifion 29.4
parficle l9kD
420158AI791905Hs.95549hypotheficalprotein 29.3
445033AV652402Hs.155145ESTs 29.2
452367071207Hs.29279eyes absent (Drosophila)29.1
homolog 2
432706NM-013230Hs.286124CD24 29.0
422163AF027208Hs.297332prominin (mouse)-like 28.7
1
447035NM Hs.17144shortrohain dehydrogenaselreductase28.6
004753 1
443958BE241880Hs.10029cathepsin C 28.2
422956BE545072Hs.122579ESTs 28.1
1 450377AB033091Hs.24936ESTs 28.0
~
447471AF039843Hs.18676sprouty (Drosophila) 28.0
homolog 2
444725AW952022Hs.234174Homo sapiens cDNA FLJi38i927.8
fis, clone THYR010
430250NM Hs.283021chloddeinfracellularchannel527.7
016929
416305AU076628Hs.79187coxsackie virus and 27.6
adenovirus receptor
15 418174L20688Hs.83656Rho GDP dissociafion 27.5
inhibitor (GDI) beta
417233W25005Hs.24395small inducibie cytokine27.4
subfamily B (Cys-X-C
417866AW067903Hs.82772collagen, type XI, 27.3
alpha 1
427344NM-000869Hs.2i425-hydroxytryptamine 27.2
(serotonin) receptor
3A
442993BE0i8682Hs.44343ESTs 27.2
407137T97307Hs.199067v-erb-b2 avian erythroblasfic27.0
leukemia viral
419356AI656166Hs.7331ESTs 27.0
433662W07162Hs.150826CATX-8 protein 26.7
422576BE548555Hs.118554CGI-83 protein 26.4
423271W47225Hs.126256intedeukin 1, beta 26.3
25 443715AI583187Hs.9700cyclin E1 26.1
420186NM Hs.95697liver-specific bHLH-Zip26.0
015925 franscription factor
419551AW582256Hs.91011anterior gradient 2 25.9
(Xenepus laevis) homolog
443672AA323362Hs.9667butyrobetaine (gamma),25.8
2-oxoglutarate dioxyge
416889AW250318Hs.80395mat, T-cell dif(erenfiafion25.3
protein
3 408474AA188823Hs.83196Homo sapiens cDNA: 25.3
0 FLJ23597 fis, clone
LNG152
411825AK000334Hs.72289hypothetical protein 25.3
FLJ20327
400881 0 25.2
440594AW445167Hs.126036ESTs 25.1
414586AA306160Hs.76506lymphocyte cytosolic 25.1
protein 1 (L-plastin)
3 411925AW014588Hs.72925chromosome 11 open 25.1
reading frame 13
417869BE076254Hs.82793proteasome (prosome, 25.0
macropain) subunit,
beta
433447029195Hs.3281neuronal penfraxin 25.0
II
450858C18458Hs.25597elongation of very 24.8
long chain fatty acids
(FE
410619BE512730Hs.65114keratin 18 24.8
434094AA305599Hs.238205hypothefical protein 24.6
PR02013
421924BE514514Hs.109606coronin, actin-binding24.6
protein,1A
446859A1494299Hs.i6297COX17 (yeast) homolog,24.5
cytochrome c oxidase
a
421451AA291377Hs.50831ESTs 24.3
433929A1375499Hs.27379ESTs 24.3
4S 438930AW843633Hs.81256S100 calcium-binding 24.2
protein A4 (calcium
prot
444212AW503976Hs.106d9basement membrane-induced24.2
gene
441633AW958544Hs.t12242ESTs 24.2
441134W29092Hs.7678cellular refinoic acid-binding24.2
protein 1
417715AW969587Hs.86366ESTs 24.1
409361NM Hs.54416sine oculis homeobox 24.1
005982 (Drosophila) homolog
1
416984H38765Hs.80706diaphorase (NADHINADPH)24.1
(cytochrome b-5 reduc
430125046418Hs.233950serine protease inhibitor,23.9
Kunitz type 1
434078AW880709Hs.283683EST 23.8
~
408669A1493591Hs.78146plateleUendothelial 23.8
cell adhesion molecule
(
5 439413A1598252Hs.37810ESTs 23.7
S
449034AI624049Hs.277523gbas41a09.x1 NCI_CGAP 23.7
Ut1 Homo~apienscDNA
420344BE463721Hs.97101Putafive G protein-coupled23.6
receptor GPCR150
431243046455Hs.252189syndecan 4(amphiglycan,ryudocan)23.6
417515L24203Hs.82237ataxia-telangiectasia 23.5
group D-associated
prat
60 451267A1033894Hs.117865solute carver family 23.4
17 (anionlsugar franspo
450101AV649989Hs.24385Human hbc647 mRNA sequence23.4
419693AA133749Hs.92323FXYD domain-containing23.4
ion fransport regulato
431103M57399Hs.44 pleiotrophin (heparin 23.4
binding growth factor
8
451110AI955040Hs.301584ESTs 23.3
6$ 426295AW367283Hs.75839zinc finger protein 23.2
6 (CMPX1)
448517AA0B2750Hs.42194hypothetical protein 23.1
FLJ22649 similar to
sign
424670W61215Hs.116651epithelial V-like anfigen23.1
1
417847AI521558Hs.288312Homo Sapiens cDNA: 23.1
FLJ22316 fis, clone
HRC052
449027AJ271216Hs.22880dipeptidylpepfidaselll23.1
424969AW950928Hs.153998creative kinase, mitochondrial23.1
1 (ubiquitous)
433159A8035898Hs.150587kinesin-like protein 23.0
2
411393AW797437Hs.69771B-factor, properdin 23.0
434815AF155582Hs.46744corel UDP-galactose:N-acetylgalactosamine-alp22.8
427585D31152Hs.179729ccllagen; type X; alpha22.7
1 (Schmid metaphyseal
75 445721H92136Hs.13144HSPC160 protein 22.6
448258BE386983Hs.85015ESTs,WeaklysimilartoA4P_HUMANINTESTINAL22.6
456844AI264155Hs.152981CDP-diacylglycerol 22.6
synthase (phosphafidate
cy
452698NM Hs.301921ESTs 22.5
001295
418693A1750878Hs.87409ihrombospondin 1 22.4
8~ 414880AW247305Hs.119140eukaryofic franslafion22.4
inifiafion factor
5A
401519 0 22.3
402496 0 22.3
420324AF163474Hs.96744DKFZP586D0823 protein,22.3
Prostate androgen-regu
403022 0 22.2
182
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
434042AI589941Hs.8254hypothetical protein 22.1
PR00899
419080AW150835Hs.18878hypothetical protein 22.1
FL121620
406545A8018249Hs.10458small inducible cytokine22.1
subfamily A (Cys-Cys
447362AW176120Hs.9061ESTs 22.0
429547AW009166Hs.99376ESTs 22.0
427954J03060Hs.247551metaxin 1 22.0
423161AL049227Hs.124776Homo Sapiens mRNA; 22.0
cDNA DKFZp564Ni 1
i6 (from c
428392H10233Hs.2265secretary granule, 21.9
neuroendocrine protein
1 (
444107T46839Hs.10319UDP glycosylUansferase21.7
2 family, polypeptide
l 414421.A1521130Hs.55567ESTs, Weakly similar 21.5
0 to LAK-4p [H.sapiens]
412589828660Hs.24305ESTs 21.5
446525AW967069Hs.211556Homo Sapiens cDNA: 21.5
FLJ23378 fis, clone
HEP162
416847L43821Hs.80261enhancer of filamentation21.5
1 (cas-like docking
436972AA284679Hs.25640claudin 3 21.5
15 428698AA852773Hs.297939ESTs; Weakly similar 21.5
to neogenin [H.sapiens]
421340F07783Hs.1369decay acceleratingfactorforcomplement(CD521.4
413966AA133935Hs.173704ESTs 21.4
448243AW369771Hs.77496ESTs 21.3
421928AF013758Hs.109643polyadenylate binding 21.3
protein-interacting
pro
403399 0 21.3
435793A8037734Hs.4993ESTs 21.3
432629AW860548Hs.280658ESTs 21.2
449057AB037784Hs.22941ESTs 21.2
437575AW954355Hs.36529ESTs 21.2
401131 0 21.0
407207T03651Hs.179661tubulin, beta~polypeplide20.8
444783AK001468Hs.62180ESTs 20.8
426230AA367019Hs.241395protease, serine,1 20.6
(trypsin 1)
447343AA256641Hs.23689dESTs; Nighty similar 20.7
to LOW-DENSITY LIPOPROTE
409041AB033025Hs.50081KIAA1199 protein 20.6
421305BE397354Hs.289721diptheda toxin resistance20.6
protein required f
411704AI499220Hs.71573hypotheticalprotein 20.5
FLJ10074
417018M16038Hs.80887v-yes-1 Yamaguchi sarcoma20.5
viral related oncog
432827268128Hs.3109Rho GTPase activating 20.4
protein 4
35 410174AA306007Hs.59461DKFZP434C245protein 20.4
425184BE278288Hs.155048Lutheran blood group 20.4
(Auberger b antigen
incl
452322BE566343Hs.28988glutaredoxin (thiolUansferase)20.3
447526AL048753Hs.340small inducible cytokine20.2
A2 (monocyte chemota
447335BE617695Hs.286192protein phosphatase 20.2
1, regulatory (inhibitor)
424867A1024860Hs.153591Not56 (D. melanogaster)-like20.1
protein
410275U85658Hs.61796transcription factor 20.1
AP-2 gamma (activating
a
429083Y09397Hs.227817BCL2-related protein 20.0
A1
410173AA706017Hs.119944ESTs 19.8
433047M86135Hs.279946methionine-tRNA synthetase19.8
45 419088AI538323Hs.77496ESTs 19.7
403381 0 19.6
409162H25530Hs.50868solute carrfer family 19.5
22 (organic canon
Uan
426150NM Hs.167218Bares-like homeobox 19.4
003658 2
449292AI990292Hs.225457ESTs 19.4
425207A8014551Hs.155120rhohac guanine nucleotide19.4
0 exchange factor (G
419950AK001645Hs.93871hypothetical protein 19.3
FLJ10783
436481AA379597Hs.5199HSPC150 protein similar19.3
to ubiquitin-conjugat
445930AF055009Hs.13456Homo sapiens clone 19.2
24747 mRNA sequence
446608N75217Hs.257846ESTs 19.1
5 425222M85430Hs.155191villin 2 (ezrin) 19.1
5
428309M97815Hs.183650cellular retinoic acid-binding19.1
protein 2
420005AW271106Hs.133294ESTs 19.1
436982AB018305Hs.5378spondin 1, (f spondin)19.0
extracellular matrix
p
407142AA412535Hs.55235sphingomyelin phosphodiesterase19.0
2, neufral me
430122NM Hs.233765TCF3 (E2A) fusion partner18.9
013342 (in childhood Leuke
446293AI420213Hs.149722ESTs 18.9
444825AW167613Hs.248mitogen-activated protein18.9
kinase kinase kings
407634AW016569Hs.301280UDP-GIcNAc:betaGal 18.9
beta-1,3-N-acetylglucosami
445200AA084460Hs.12409somatostatin 18.9
6S 418917X02994Hs.1217adenosine deaminase 18.8
435777AW419202Hs.286192protein phosphatase 18.8
1, regulatory (inhibitor)
431049AA846576Hs.103267hypothetical protein 18.7
FLJ22548 similar to
gene
426427M86699Hs.169840TTK protein kinase 18.7
436281AW411194Hs.120051ESTs 18.6
425907AA365752Hs.155965ESTs 18.6
459720 ESTs 18.6
421242AW161386Hs.13561ESTs, Weakly similar 18.5
to dJ37E16.5 [H.sapiens]
457715AA642402Hs.59142ESTs 18.5
451668243948Hs.26789ASPIC (acidic secreted18.4
protein in cartilage)A
75 437142AI791617Hs.145068ESTs 18.4
418588BE387040Hs.182476ESTs, Weakly similar 18.3
to similar to alphalbeta
433068NM Hs.288215sialylUansferase 18.3
006456
419854AW664873Hs.87836Homo Sapiens PAC clone18.3
RP5-1087M19 from 7q11.
444726NM Hs.11801interferon regulatory 18.3
006147 factor 6
423011NM Hs.299847ESTs, Highly similar 18.2
000683 to A2AD HUMAN ALPHA-2G2
451428AW083334Hs.11067ESTs, Weakly similar 18.2
to K02E10.2 [C.elegans]
424865AF011333Hs.153563lymphocyte antigen 18.2
75
418742AW451197Hs.113418ESTs 18.1
446627A1973016Hs.15725ESTs; hypotheticalprotein18.1
S88148
1~3
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
424885Af333771Hs.82204ESTs 18.1
402926 0 18.0
405452 0 18.0
428641AA431367Hs.234546GMPR2 for guanosine 18.0
monophosphate reductase
t
454390AB020713Hs.56966KIAA0906 protein 18.0
441784A1522132Hs.28700ESTs 18.0
418758AW959311Hs.87019ESTs 17.9
406621A1970672Hs.46638chromosome 1 t open 17.9
reading frame 8; fetal
6r
426201AW182614Hs.i28499ESTs 17.8
1 410442X73424Hs.63788propionyl Coenzyme A 17.8
~ carboxylase, beta polype
456423AW748920 gb:CM2-BT0306-171199-034-g0217.8
BT0306 Homo sapi
422867L32137Hs.i584cartilage oligomertc 17.8
matrix protein
448110AA626937Hs.181551ESTs 17.7
421750AK000768Hs.107872hypotheticalprotein 17.7
FLJ20761
1 405224 0 17.7
447630AI660149Hs.44865lymphoid enhancer-binding17.7
factor 1
407663NM Hs.37482COPZ2 for nonclathrin 17.7
016429 coat protein zeta-COP
427490295152Hs.178695mitogen-activated protein17.6
kinase 13
414812X72755Hs.77367monokine induced by 17.6
gamma interferon
427691AW194426Hs.20726ESTs 17.6
420650AA455706Hs.44581heat shock protein hsp70-related17.5
protein
439841AF038961Hs.6710mannose-P-dolichol utilization17.5
defect 1
425810A1923627Hs.31903ESTs 17.5
425397J04088Hs.156346topoisomerase (DNA) 17.5
II alpha (170kD)
456098AW747800Hs.55016hypothetical~rotein 17.4
FLJ21935
428579Nt~005756Hs.184942G protein-coupled receptor17.4
64
410361BE391804Hs.62661guanylate binding protein17.4
1, interferon-induc
442402NM Hs.8272prostaglandin D2synthase17.4
000954 (2lkD, brain)
411734AW374954Hs.71779Homo Sapiens DNA from 17.3
chromosome 19, cosmid
F
405295 0 17.3
408340AB037762Hs.44268myelin gene expression 17.3
factor 2
456068AI677897Hs.76640RGC32 protein 17.3
448571AA486794Hs.66915ESTs, Weakly similar 17.2
~ to 16.7K4 protein [H.sap
441829AL117482Hs.7978DKFZP434C131 protein 17.2
35 418004037519Hs.87539aldehyde dehydrogenase 17.2
8
412078X69699Hs.73149paired box gene 8 17.2
414658X58528Hs.76781ATP-binding cassette, 17.1
sub-family D (ALD),
mem
418478038945Hs.1174cyclin-dependentkinaseinhibitor2A(melanom17.0
426805AB032945Hs.172506myosin VB 17.0
410247AF181721Hs.61345RU2S 17.0
434516AA807814Hs.70582ESTs, Moderately similar16.9
to AF1440561 apoplo
428153AW513143Hs.98367hypothetical protein 16.9
FLJ22252 similar to
SRY-
417793AW405434Hs.82575small nuclear ribonucleoprotein16.9
polypeptide 8
454163AW175997 gb:OVO-BT0078-190899-D05-E0216.9
8TOD78 Homo sapi
4S 415402AA164687Hs.297889ESTs 16.9
420309AW043637Hs.21766ESTs 16.9
419201M22324Hs.1239alanyl (membrane) aminopeptidase16.9
(aminopeptid
444391AL137597Hs.11114hypotheticalprotein 16.9
dJ1181N3.1
457705AW974668 gb:EST386757 MAGE resequences,16.8
MAGM Homo sapi
412723AA648459Hs.179912ESTs 16.8
435774888066Hs.4992tumor suppressing subtransferable16.8
candidate 1
408753AI337192Hs.47438SH3 domain binding glutamic16.8
acid-rich protein
447783AF054178Hs.19561NADH dehydrogenase (ubiquinone)16.8
1 alpha subco
418085840328Hs.258822ESTs 16.7
~
5 452472AW957300Hs.294142ESTs, Weakly similar 16.7
5 to SP49 HUMAN SPLICEOSOM
409112BE243971Hs.50649quinone oxidoreductase 16.7
homolog
410250A1082777Hs.61384KIAA1445 protein 16.7
446219A1287344Hs.149827ESTs 16.6
428928BE409838Hs.194657cadhedn 1, type 1, E-cadherin16.6
(epithelial)
425812AA364128Hs.245633ESTs 16.6
411742AW247593Hs.71819eukaryotic Uanslation 16.6
initiation factor 4E
b
415076NM Hs.77890guanylate cyctase 1, 16.6
OOD857 soluble, beta 3
416209AA236776Hs.79078MAD2 (mitotic arrest 16.6
deficient, yeast, homolo
'
440667BE076969Hs.7337hypothetical protein 16.6
FLJ10936
65 430375AW371048Hs.93758H4 histone family, member16.6
H
419607852557Hs.91579Homo Sapiens clone 2378316.6
mRNA sequence
410328BE080190Hs.62275CGI-141 protein 16.5
405426 0 16.5
432636AA340864Hs.278562claudin 7 16.5
434725AK000796Hs.4104hypothetical protein 16.5
~
414683S78296Hs.76888internexin neuronal 16.5
intermediate filament
pro
429500X78565Hs.289114hexabrachion (tenascin 16.5
C, cytotactin)
449944AF290512Hs.58215Homo Sapiens rhotekin 16.4
mRNA, partial cds
400666 0 16.4
75 421536BE250690Hs.105509CTL2gene 16.4
436032AA150797Hs.109276latexin protein 16.4
418196AI745649Hs.26549ESTs, Weakly similar 16.4
to T00066 hypothetical
p
452323Wd4356Hs.292812ESTs, Weakly similar 16.4
to C43H8.1 (C.elegans]
407699AA825974Hs.32646Homo sapiens cDNA: FLJ2190116.4
tis, clone HEP034
g0 414617AI339520Hs.20524ESTs, Moderately similar16.3
to hexokinase I [H.s
408204AA454501Hs.43666protein tyrosine phosphatase16.3
type IVA, member
452650AW270150Hs.254516ESTs 16.3
432906BE265489Hs.3123lethal giant larvae 16.3
(Drosophila) homolog
2
402408 0 16.3
1~4
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
408805H69912Hs.48269vaccinia related kinase16.3
1
447155AA100605Hs.121557ESTs, Weakly similar 16.3
to AF251041 1 SGG32445
p
405699 0 16.2
406893M22406 gb:Human intestinal 16.2
mucin mRNA, partial
cds,
418629BE247550Hs.86859growth factor receptor-bound16.2
protein 7 (GRB7)
424905NM_002497Hs.153704NIMA (never in mitosis 16.2
gene a)-related kinase
424243AI949359Hs.301837ESTs, Highly similar 16.2
to cis Golgi-localized
c
418462BE001596Hs.85266integrin, beta 4 16.1
457205AI905780Hs.198272NADH dehydrogenase (ubiquinone)16.1
1 beta subcom
428188M98447Hs.22 transglutaminase 1 (K 16.1
polypepfide epidermal
1
449845AW971183Hs.60054ESTs 16.1
406429 0 16.1
407375AA091354 gb:110815.seq.F Human 16.1
fetal heart, Lambda
ZAP
448377AI494514Hs.171380ESTs 16.1
431156NM_002220Hs.2722inositol 1,4,5-irisphosphate16.0
3-kinase A
450043AA885699Hs.24332CGI-26 protein 16.0
403121 0 16.0
400214 0 15.9
453252802436Hs.215725ESTs 15.9
451734NM_006176Hs.26944neurogranin (protein 15.9
kinase C substrate,
RC3)
416855AA188763Hs.36793Homo Sapiens cDNA: FLJ2318815.9
fis, clone LNG120
424474AA308883Hs.148680calcyon; D1 dopamine 15.9
receptor-interacting
pro
423685BE350494Hs.49753Homo Sapiens mRNA for 15.9
KIAA1561 protein, parfi
428187AI687303Hs.285529ESTs 15.9
438817A1023799Hs.163242ESTs 15.9
425692D90041Hs.155956NAT1; arylamine N-acetylUansferase15.9
421674T10707Hs.296355neuronal PAS domain 15.9
protein 2
439999AA115811Hs.6838ras homolog gene family,15.9
member E
411351W02919Hs.283476peroxisomal acyl-CoA 15.9
thioesterase
413027NM-002885Hs.75151RAP1, GTPase activating15.9
protein 1
453884AA355925Hs.36232KIAA0186 gene product 15.8
407894AJ278313Hs.41143phosphoinosifide-specific15.8
phospholipase Gbet
422748AA316266Hs.129349ESTs 15.8
414591AI888490Hs.55902ESTs 15.8
3 421877AW250380Hs.109059mitochondria) ribosomal15.8
S protein L12
404780 0 15.8
401192 0 15.8
447519U46258Hs.23448ESTs 15.8
434262AF121858Hs.12169sorting nexin 8 15.7
451253H48299Hs.26126claudin 10 15.7
435499889344Hs.14148ESTs 15.7
422424A1i86431Hs.116577prostate differenfiation15.7
factor; placental bo
424834AK001432Hs.153408Homo Sapiens cDNA FLJ1057015.7
fis, clone NT2RP20
424562AI420859Hs.150557basic transcription 15.7
element binding protein
1
45 443247BE614387Hs.47378ESTs 15.7
430696AA531276Hs.59509ESTs 15.6
437044AL035864Hs.69517ESTs, highly similar 15.6
to differentially expres
428237AF175206Hs.i83125killer celllectin-IikereceptorFl15.6
440048AA897461Hs.158469ESTs, Weakly similar 15.6
to envelope protein
(H.s -
414922D00723Hs.77631glycine cleavage system15.6
protein H (aminomethy
422030X51416Hs.110849estrogen-related receptor15.6
alpha
408716AI567839Hs.151714ESTs 15.5
410258X52638Hs.7396-phosphofructo-2-kinaselfructose-2,6-biphosp15.5
410530M25809Hs.64173ESTs, Highly similar 15.5
to VABi HUMAN VACUOLAR
A
5 447072D61594Hs.17279tyrosylprotein sulfotransferase15.5
5 1
409015BE389387Hs.49767NADH dehydrogenase (ubiquinone)15.5
Fe-S protein
447549AI871120- Hs.231265ESTs ~ 15.5
449704AK000733Hs.23900GTPase acfivafing protein15.4
427337246223Hs.176663Fc fragment of IgG, 15.4
low affinity illb,
recept
421630NM Hs.1407endothelin 2 15.4
001956
433018AI669760Hs.188881ESTs 15.4
422938NM-001809Hs.1594centromere protein A 15.3
(l7kD)
407014U38268 gb:Human cytochrome 15.2
b pseudogene, partial
cds
429311AF080157Hs.198998conserved helix-loop-helix15.2
ubiquitous kinase
65 431842NM_005764Hs.271473epithelial protein up-regulated15.2
in carcinoma,
406907225427 gb:H.sapiens protein-serinelthreonine15.2
kinase
458495AI202029Hs.148593ESTs 15.2
420551AL137692Hs.98790Homo Sapiens mRNA; cDNA15.1
DKFZp434P182 (from
c)
448443AW167128Hs.231934ESTs 15.1
70 443646A1085198Hs.298699ESTs 15.1
431538AL137547Hs.259619Homo Sapiens mRNA; cDNA15.1
DKFZp434B1120 (from
c
436687AA868643Hs.120461ESTs 15.1
420917AW135716Hs.117330ESTs 15.0
428575M19684Hs.184929serine (orcysteine) 15.0
proteinase inhibitor,
cI
75 4o34ez o 15.0
421499AI271438Hs.105022Homo Sapiens PAC clone 15.0
RP4-701016 from 7q33-q
401047 0 14.9
417749U09196Hs.82520polymerise (DNA-directed),14.9
delta 4
416693AI373204Hs.79531Homo Sapiens TTF-I interacfing1d.9
pepfide 20 mRN
80 428474A8023182Hs.184523KIAA0965 protein 14.9
428862NM Hs.2316SRY (sex-determining 14.9
000346 region Y)-box 9 (campome
430271T06199Hs.237506heatshockcognate 40 14.9
414328221666Hs.75900aconitase 2, mitochondria)14.9
415314N88802Hs.5422glycoprotein M6B 14.8
185
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
453735A1066629Hs.125073ESTs 14.8
424345AK001380Hs.145479Homo Sapiens cDNA FLJ1051814.8
fis, clone NT2RP20
423575C18863Hs.163443ESTs 14.8
438081H49546Hs.298964ESTs 14.8
403485 0 14.8
452114N22687Hs.8236ESTs 14.8
426559AB001914Hs.170414paired basic amino 14.8
acid cleaving system
4
412869AA290712Hs.82407Homo Sapiens HSPC296 14.8
mRNA, parfial cds
452101T60298 gb:yb87f12.r1 Stratagene14.7
liver (937224) Homo
420505AW967984Hs.291612ESTs 14.7
426125X87241Hs.166994FATiumorsuppressor(Drosophila)14.7
hcmolog
433336AF017986Hs.31386ESTs; Nighty similar 14.7
to FRIZZLED PROTEIN
PRE
428977AK001404Hs.194698cyclin B2 14.7
429785H82114Hs.301769ESTs 14.7
1 402424 0 14.7
~
424971AA479005Hs.154036tumor suppressing subtransferable14.7
candidate 3
433037NM Ns.279938HSPC067 protein 14.6
014158
421670BE207318Hs.106674BRCA1 associated protein-114.6
(ubiquitin carboxy
438598AI805943Hs.5723Homo Sapiens cDNA: 14.6
FLJ23439 fis, clone
HSI001
453370A1470523Hs.182356ESTs, Moderately similar14.6
to translafion inifi
410561BE540255Hs.6994Homo Sapiens cDNA: 14.6
FLJ22044 fis, clone
HEP091
402287 0 14.6
419741NM Hs.93002ubiquifin carrier protein14.6
007019 E2-C
442047AA974598Hs.150324ESTs 14.5
428582BE336699Hs.185055BENE protein 14.5
440006AK000517Hs.6844hypotheticaI protein 14.5
FLJ20510
406851AAfi09784Hs.180255major histocompatibility14.5
complex, class II,
D
457316A1123657Hs.127264ESTs 14.5
420453AL157500Hs.97840Homo Sapiens mRNA; 1d.5
cDNA DKFZp43dG015
(from c7
3 436406AW105723Hs.125346ESTs 14.5
0
420736A1263022Hs.82204ESTs 14.5
419743AW408762Hs.127478ESTs 14.5
429113D28235Hs.196384Prostaglandin-endoperoxide14.5
synthase 2(COX-2)
450256AA286887Hs.24724MFH-amplified sequences14.5
with leucine-rich
tan
3 424906AI566086Hs.153716Homo Sapiens mRNA for 14.5
S Hmob33 protein, 3'
untr
427414F11750Hs.6647Homo Sapiens cDNA FLJ1308814.4
fis, clone NT2RP30
419839U24577Hs.9330dphospholipaseA2,groupVll(platelet-activat14.4
418738AW3B8633Hs.6682solute carrier family 14.3
7, member 11
429414AI783656Hs.202095empty spiracles (Drosophila)14.3
homolog 2
424669AA417181Hs.120858Homo Sapiens cDNA FLJ1394514.3
fis, clone Y79AA10
408989AW361666Hs.49500KIAA0746 protein 14.3
406788A1911841Hs.518dTHldrosophilahomolog 14.3
417861AA334551Hs.82767sperm specific anfigen14.3
2
402104 0 14.3
45 416368888849 gb:ym96a06.r1 Soares 14.2
adult brain N2b4HB55Y
Ho
405802 0 14.2
448357N20169Hs.108923ESTs 14.2
444261AA298958Hs.10724MDS023 protein 14.2
407846AA426202Hs.40403CbpIp300-interacfing 14.2
iransactivator, with
GIu
50 425163D10040Hs.154890fatty-acid-Coenzyme 14.1
A ligase, long-chain
2
402520 0 14.1
429597NM Hs.2442a disintegrin and metalloproleinase14.1
003816 domain 9
430044AA464510Hs.152812EST cluster (not in 14.1
UniGene)
429663M68874Hs.211587Human phosphatidylcholine14.1
2-acylhydrolase (cP
5 427036AA397625Hs.163913ESTs 14.1
5
444381BE387335Hs.283713ESTs 14.1
432090AW972855Hs.292853ESTs 14.0
406778H06273Hs.101651Homo Sapiens mRNA; 14.0
cDNA DKFZp434C107
(from c7
404961AW972195Hs.284236aldo-keto reductase 1d.0
family 7, member A3
(aila
60 452313Y00486Hs.28914adenine phosphoribosyltransferase14.0
452355N54926Hs.29202G protein-coupled receptcr3414.0
429942A1338993Hs.134535ESTs 14.0
403165 0 13.9
442150A1368158Hs.128864ESTs 13.9
65 439709AW401433Hs.6649hypothetical protein 13.9
' FLJ20128
456799AC004923Hs.135187Homo sapiens clone 13.9
CDABP0025 mRNA sequence
427356AW023482Hs.97849ESTs 13.9
448982A163816dHs.225520ESTs 13.9
432025BE407132Hs.111286hypothetical protein 13.8
FLJ22512
427505AA361562Hs.17876126S proteasome-associated13.8
padl homolog
402965 0 13.8
418601AA279490Hs.86368calmegin 13.8
436954AA740151Hs.130425ESTs 13.8
405024 0 13.8
75 453976BE463830Hs.163714ESTs 13.8
431921N46466Hs.58879ESTs 13.8
401735 0 13.8
445496AB007860Hs.12802development and differenfiation13.8
enhancing fac
425007AA456483Hs.1720B1phosphodiesterase 4D, 13.7
cAMP-specific (dunce
(D
8~ 409463AI458165Hs.17296ESTs 13.7
430193A1826653Hs.102928Homo Sapiens cDNA FLJ1347913.7
fis, clone PLACE10
458869AI637934Hs.224978ESTs 13.7
426769AA075596Hs.172153glutathione peroxidase13.7
3 (plasma)
416661AA634543Hs.79440tGF-It mRNA-binding 13.7
protein 3
186
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
439901N73885Hs.124169ESTs 13.7
431374BE258532Hs.251871CTP synthase 13.7
432861AA339526Hs.279593HSPC171 protein 13.7
441172AI279652Hs.132879ESTs 13.7
410001A8041036Hs.57771kallikrein 11; serine 13.7
protease (TLSP)
430315NM Hs.239147guanine deaminase 13.6
004293
422769AA938905Hs.289112CGI-43 protein 13.6
402389 0 13.6
448977X91809Hs.22698regulator of G-protein13.6
signalling 19
1 459648 gb:IL3-CT0220-150200-070-80213.6
~ CT0220 Homo sapi
452972M31732Hs.31210B-cell CLLllymphoma 13.6
3
431441U81961Hs.2794sodium channel, nonvoltage-gated13.6
1 alpha
448585AB020676Hs.21543KIAA0869 protein 13.6
428385AF112213Hs.184062putafive Rab5-interacting13.6
protein
I 434699AA643687Hs.149425Homo Sapiens cDNA FLJ1198013.6
S fis, clone HEMBB10
447238AW451676Hs.158564ESTs 13.6
437108AA434054Hs.80624Homo Sapiens cDNA: 13.6
FLJ23442 fis, clone
HSI009
425749AW328587Hs.1594d8surfeit 2 13.5
425154NM-001851Hs.154850collagen, type IX, 13.5
alpha 1
413753U17760Hs.301103Laminin, beta 3 (nicein13.5
(125kD), kalinin (140
419034NM_002110Hs.89555hemopoieticcellkinase 13.5
448361H82028Hs.238707Homo Sapiens cDNA: 13.5
FLJ22457 fis, clone
HRC099
412754AW160375Hs.74565amyloid beta (A4) precursor-like13.5
protein 1
419081AI798863Hs.87191ESTs 13.5
407732AW138839Hs.24210ESTs 13.5
423329AF054910Hs.127111tekfin 2 (testicular) 13.5
422627BE336857Hs.118787transforming growth 13.4
factor, beta-induced,
68k
439636AF086467 gb:Homo Sapiens full 13.4
length insert cDNA
clone
417605AF006609Hs.8229dregulator of G-protein13.4
signalling 3
445861BE293423Hs.11809single Ig IL-1R-related13.4
molecule
447350AI375572Hs.172634ESTs; HER4 (c-erb-84) 13.4
451807W52854Hs.27099DKFZP564J0863 protein 13.4
421515Y11339Hs.105352GaINAc alpha-2, 6-sialyltransferase13.4
I, long f
422443NM Hs.116753histone deacetylase 13.4
014707 7B
35 412504244496Hs.26039Homo Sapiens cDNA FLJ1393713.4
fis, clone Y79AA10
453344BE349075Hs.44571ESTs 13.4
402885 0 13.4
438712AW978161Hs.169877ESTs 13.4
421774AL050374Hs.108169DKFZP586C1619 protein 13.3
425638NM-012337Hs.158450nasopharyngeal epitheliumt3.3
specific protein 1
401897 0 13.3
425601AW629485Hs.293352ESTs 13.3
450779AW204f45Hs.1560d4ESTs 13.3
444858AI199738Hs.208275ESTs, Weakly similar 13.3
to unnamed protein
produ
45 442619AA447492Hs.20183ESTs, Weakly similar 13.3
to AF1647931 protein
x
434263N34895Hs.446d8ESTs 13.3
426059BE292842Hs.166120interferon regulatory 13.3
factor 7
407467D55638 gb:Human B-cell PABL 13.3
(pseudoautosomal boundar
412560824601Hs.108300CCR4-NOT transcription13.2
complex, subunit 3
442986A1025990Hs.285520ESTs 13.2
420317AB006628Hs.96485KIAA0290 protein 13.2
443211A1128388Hs.143655ESTs 13.2
434361AF129755Hs.117772ESTs 13.2
423493AI815965Hs.129683ubiquifin-conjugafing 13.2
enzyme E2D 1 (homologou
SS 414183AW957446Hs.301711ESTs 13.2
447778BE620592Hs.71190ESTs 13.2
435106AA100847Hs.193380ESTs, Highly similar 13.1
to AF1746001 F-box
prot
439490AW249197Hs.100043ESTs, Weakly similar ~
to PSF_HUMAN PTB-ASSOCIA13.1
409606AW4d4594Hs.2387transglutaminase 4 13.1
(prostate)
421308AA687322Hs.192843ESTs 13.1
414950C15407 gb:C15407 Clontech 13.1
human aorta polyA+mRNA
(6
416783AA206186Hs.79889monocyle to macrophage13.1
differentiation-associ
415927AL120168Hs.78919Kell blood group precursor13.1
(McLeod phenotype)
422605H16646Hs.118666Human clone 23759 mRNA,13.0
partial cds
65 430427AA296701Hs.241413opficin 13.0
424620AA101043Hs.151254kallikrein 7 (chymotrypfic;13.0
stratum comeum)
421693X71490Hs.106876ATPase, H+ Uansporting,13.0
lysosomal (vacuolar
407727AW411148Hs.3804dDKFZP564M082 protein 13.0
427706AW971225Hs.293800ESTs, Weakly similar 13.0
to ALU1 HUMAN ALU
SUBFAM
70 406709AI355761Hs.242463keratin 8 13.0
405353 0 13.0
453060AW294092Hs.21594ESTs 13.0
459299BE094291Hs.155651hepatocyte nuclear 13.0
factor 3, beta
447843AW337186Hs.224891ESTs 13.0
75 446576AI659477Hs.51820ESTs, Moderately similar13.0
to ALU7_HUMAN ALU
SU
449700L02867Hs.78358ESTs 13.0
436476AA326108Hs.53631ESTs 13.0
432532AW058459Hs.162246ESTs 13.0
408405AK001332Hs.44672hypothefical protein 13.0
FLJ10470
8~ 432673AB028859Hs.278605ER associated DNAJ; 12.9
ER-associated Hsp40
co-ch
414684AW630023Hs.768933-hydroxybulyrate dehydrogenase12.9
(heart, mitoc
447210AF035269Hs.17752phosphafidylserine-specificphospholipaseAla12.9
427923AW274357Hs.268384Fzr1 protein 12.9
437395AL365408Hs.10632hypoihefical protein 12.9
DKFZp762M136
187
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
441627AA947552Hs.58086ESTs 12.9
419084AA496539Hs.179902transporter-like protein12.9
423067AA321355Hs.285401ESTs 12.9
423070855677Hs.155569ESTs 12.8
441344BE250144Hs.41514ESTs 12.8
423527A1206965Hs.105861Homo Sapiens cDNA FLJ1382412.8
fis, clone THYR010
417006AW673606Hs.80758aspartyl-tRNA synthetase12.6
453552AL041941Hs.1547293-phosphoinositide 12.8
dependent protein
kinase-1
453657W23237Hs.296162ESTs 12.8
1 434414A1798376 gbar34b07.x1 NCI CGAP 12.7
~ Ov23 Homo Sapiens
cDNA
456051T85626Hs.76239hypothetical protein 12.7
FLJ20608
451659BE379761Hs.14248ESTs, Weakly similar 12.7
to ALU8_HUMAN ALU
SUBFAM
418216AA662240Hs.283099AF15q14 protein 12.7
423281AJ271684Hs.126355Gtype (calcium dependent,12.7
carbohydrate-recog
I 424275AW673173Hs.144505DKFZP566F0546 protein 12.7
S
440062AI350518Hs.129692ESTs 12.7
444371BE540274Hs.239Forkhead box M1 12.7
412520AAd42324Hs.795H2A histone family, 12.7
member 0
413349BE086692 gb:QV1-BT0678-130400-156-g0712.7
BT0678 Homo sapi
414500W24087Hs.76285DKFZP564B167 protein 12.6
429261AW176254Hs.143475ESTs 12.6
402238 0 12.6
400280 0 12.6
421246AW582962Hs.300961ESTs, Highly similar 12.6
to AF1518051 CGI-47
pro
442029AW956698Hs.14456neural precursor cell 12.6
expressed, developments
435502L13266Hs.105glutamate receptor, 12.6
ionotropic, N-methyl
D-as
409964AW368226Hs.67928ESTs 12.6
418793AW382987Hs.88474prostaglandin-endoperoxide12.5
synthase 1 (prosta
452117AI42i760Hs.77870Homo Sapiens cDNA FLJ1275012.5
fis, clone NT2RP20
3 448074BE621355Ns.27160ESTs 12.5
0
442655AW027457Hs.30323ESTs 12.5
409928AL137163Hs.57549hypothetical protein 12.5
dJ473B4
400240 0 12.5
413048M93221Hs.75182mannose receptor, C 12.5
type 1
3 426215AW963419Hs.155223ESTs 12.5
430024A1808780Hs.227730integrin, alpha 6 12.5
445655AA873830Hs.i67746Bcelllinkerprotein 12.5
419941X98654Hs.93837phosphatidylinositol 12.5
transfer protein,
membra
425280U31519Hs.1872phosphoenolpyruvate 12.5
carboxykinase 1 (soluble)
40 427767AI879283Hs.180714cytochrome c oxidase 12.4
subunit Vla polypeptide
450243AW119084Hs.201037ESTs 12.4
408930AA146721Hs.49005hypothetical protein 12.4
418783T41368 gb:phldl 19I1TV Outward12.4
Alu-primed hncDNA
lib
452096BE394901Hs.226785ESTs 12.4
45 424513BE385864Hs.149894mitochondria) translafional12.4
inifiation factor
422306BE044325Hs.227280Homo Sapiens mRNA far 12.4
Lsm5 protein
409031AA376836Hs.76728ESTs 12.4
435515N40080Hs.6879DC13 protein 12.4
429583NM Hs.2091191-acylglycerol-3-phosphate12.3
006412 0-acyltransferase
449643805989Hs.19603ESTs 12.3
440313AL050060Hs.7158DKFZP566H073 protein 12.3
425593AA278921Hs.1908proteoglycan 1, secretary12.3
granule
447357AI375922Hs.159367ESTs 12.3
405089 0 12.3
5 414972BE263782Hs.77695KIAA0008 gene product 12.3
5
435039AW043921Hs.130526ESTs 12.3
447033A1357412Hs.157601EST-not inUniGene 12.3
427521AW973352Hs.299056ESTs 12.3
409377AA300274Hs.115659Homo Sapiens cDNA: 12.3
FLJ23461 fis, clone
HS1077
400116 0 12.3
445806AL137516Hs.13323hypothelicalprotein 12.2
FLJ22059
457817AA247751Hs.79572cathepsin D (lysosomal12.2
aspartyl protease)
442410AW996503Hs.197680ESTs 12.2
445404AI261687Hs.145541ESTs, Weakly similar 12.2
to JC4974 sodium iodide
65 403372AW249152Hs.44017SIR2 (silent mafing 12.2
type information regulati
427082AB037858Hs.173484hypothetical protein 12.2
FLJ10337
433764AW753676Hs.39982ESTs 12.2
400268 0 12.2
433190M26901Hs.3210renin 12.2
444863AW384082Hs.301323ESTs 12.2
434779AF153815Hs.50151potassium inwardly-recfifying12.2
channel, subfam
451346NM_006338Hs.26312glioma amplified on 12.2
chromosome 1 protein
(leu
430262AA218780Hs.237323N-acetylglucosamine-phosphate12.2
mutase
421071AI311238Hs.104476ESTs 12.2
75 426773NM-015556Hs.172180KIAA0440 protein 12.1
4091788E393948Hs.50915kallikrein 5 12.1
400250 0 12.1
428450NM Hs.184339KIAA0175 gene product 12.1
014791
414531T693B7Hs.76364allograft inflammatory12.1
factor 1
8~ 448210AW247775Hs.7393hypothetical protein 12.1
from EUROIMAGE 1987170
440061AA863389Hs.135643ESTs 12.1
413179N99692Hs.75227NADH dehydrogenase 12.1
(ubiquinone) 1 alpha
subco
447551BE066634Hs.929myosin, heavy polypepfide12.1
7, cardiac muscle,
400517AF242388Hs.149585lengsin 12.1
188
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
401610 0 12.0
454381AI935093Hs.193428ESTs 12.0
443997AW081465Hs.299644ESTs 12.0
402944 0 12.0
430637BE160081Hs.256290S100 calcium-binding 12.0
protein A11 (calgizzarin
415099AId92170Hs.77917ubiquifin carboxyl-terminal12.0
esterase L3 (ubiq
445422AV653731Hs.282829ESTs 12.0
416667AK000526Hs.79457hypothetical protein 12.0
FLJ20519
442611BE077155Hs.177537ESTs 12.0
1 443271BE568568Hs.195704ESTs 12.0
~
415120N64464Hs.34950ESTs 12.0
439574AI469788Hs.165190ESTs 12.0
405804 0 12.0
412519AA196241Hs.73980Uoponin T1, skeletal, 12.0
slow .
15 414135NM Hs.2128dual specificity phosphatase12.0
004419 5
447075AV662037Hs.124740ESTs 12.0
416841N33878Hs.249495heterogeneous nuclear 12.0
ribonucleoprotein A1
402943 0 11.9
416933BE561850Hs.80506small nuclear ribonucleoprotein11.9
polypeptide A
439744AL389994Hs.301272ESTs, Weakly similar 11.9
to homologue of Drosphil
405762 0 11.9
408983NM_000492Hs.663cystic fibrosis Uansmembrane11.9
conductance reg
455102BE005496 gb:CM1-BN0117-110400-183-b0911.9
BN0117 Homo sapi
402840 0 ' 11.9
25 449183AW445022Hs,196985Homo sapiens cDNA: FLJ2113511.9
fis, clone CAS072
439273AW139099 Hs.269701ESTs 11.9
450484BE220675 gb:ht98f11.x1 NCI_CGAP-Lu2411.9
Homo Sapiens cDNA
445431AF137386Hs.12701plasmolipin 11.9
401888 0 , 11.9
30 426037AW160780Hs.166071cyclin-dependent kinase11.9
5
416742838644Hs.248420ESTs 11.9
418324AW246273Hs.84131threonyl-tRNA synthetase11.8
412870N22788Hs.82407Homo Sapiens HSPC296 11.8
mRNA, partial cds
432680T47364Hs.278613interferon, alpha-inducible11.8
protein 27
3 421478AI683243Hs.97258ESTs 11.8
426635BE395109Hs.129327ESTs 11.8
420523AA262999Hs.42788ESTs 11.8
426227067058Hs.168102Human proteinase acfivated11.8
receptor-2 mRNA; 3
416658003272Hs.79432fibrillin 2 (congenital11.8
contractural arachnod
441816AI401807Hs.i49997ESTs 11.8
424596A8020639Hs.151017estrogen-relaledreceptor11.8
gamma
400640 0 11.8
448133AA723157Hs.73769folate receptor 1 (adult)11.8
401532 0 11.8
4Jr400161 0 11.8
442556AL137761Hs.8379Homo Sapiens mRNA; cDNA11.7
DKFZp586L2424 (from
c
451002AA013299Hs.8018ESTs, Weakly similar 11.7
to ALU3-HUMAN ALU SUBFAM
401879 0 11.7
415989A1267700Hs.111128ESTs 11.7
416434AW163045Hs.79334nuclear factor, interleukin11.7
3 regulated
410616AW873d01Hs.273599ESTs 11.7
449239T24653Hs.23360likely orlholog of yeast11.7
ARV1
447669AL049985Hs.19180Homo Sapiens mRNA; cDNA11.7
DKFZp56dE122 (from
c7
436877AA931484Hs.121255ESTs, Weakly similar 11.7
to cDNA EST EMBL:D67419
55 434560813052Hs.3964Homo Sapiens clone 2487711.7
mRNA sequence
448105AW591433Hs.170675ESTs, Weakly similar 11.7
to TMS2_HUMAN TRANSMEMBR
400279 0 11.6
440497AA8B7266Hs.144979ESTs 11.6
451260AW750773 gb:CMO-GN0044-260100-164-h03t
CN004d Homo sapi 1.6
429175AI953040Hs.127714ESTs, Moderately similar11.6
to SOX30 protein [H.
408209NM_004454Hs.43697ets variant gene 5 (ets-related11.6
molecule)
428856AA436735Hs.183171Homo Sapiens cDNA: FLJ2200211.6
fis, clone HEPO66
420153N22120Ns.75277hypothefical protein 11.6
FLJ13910
428760A1351459Hs.i92398ESTs 11.6
65 421401AW410478Hs.104019Uansforming, acidic 11.6
coiled-coil containing
p
404502 0 11.6
430423A1190548Hs.143479ESTs, Weakly similar 11.6
to hypothetical protein
405192 0 11.6
439092AA830149 gb:oc44f08.s1 NCI_CGAP-GCBs11.6
HomosapienscDNA
401714 0 11.5
439335AA742697Hs.62492ESTs, Weakly similar 11.5
to 559856 collagen
alpha
406082S47833Hs.82927adenosine monophosphate11.5
deaminase 2 (isoform
401010 0 i1.5
412140AA219691Hs.73625RAB6 interacting, kinesin-like11.5
(rabkinesin6)
75 409339A8020686Hs.54037ectonucleofide pyrophosphataselphosphodiester11.5
459684 gb:ao86a08,x1 Schiller 11.5
meningioma Homo sapien
451051BE254309Hs.125262DKFZP586G1624 protein 11.5
415323BE269352Hs.949neutrophil cytosolic 11.5
factor 2 (65kD, chronic
412153887934 gb:yo47b10.r1 Soares 11.5
adult brain N2b4HB55Y
Ho
8~ 427256AL042436Hs.97723ESTs 11.5
406708AI282759Hs.242463kerafin 8 11.4
457644AA770080Hs.144962ESTs, Moderately similar11.4
to 159365 ubiquitin
422848225884Hs.121483chloride channel 1, 11.4
skeletal muscle (Thomsen
424134AF070637Hs.140950, hypothetical protein 11.4
189
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
451931AK000208Hs.27267Homo Sapiens cDNA FLJ2020111.4
fis, clone COLF121
400438AF185611Hs.115352growth hormone 1 11.4
412994D32257Hs.75113general transcription 11.4
factor IIIA
408124089337Hs.42853cAMP rosponsive element11.4
binding protein-like
452249BE394412Hs.61252ESTs 11.4
424627AA344555 gb:EST50715 Gall bladder11.4
I Homo Sapiens cDNA
405626 0 11.4
436690AA373970Hs.183096ESTs 11.4
415862851034Hs.144513ESTs 11.4
406755N80129Hs.94360metallothionein 1L 11.4
433657AI244368Hs.8124PH domain containing 11.4
protein in refina
1
429612AF062649Hs.252587pituitary tumor-transforming11.4
1
423334AK000906Hs.127273hypothetical protein 11.4
FLJ10044
433053BE301909Hs.279952glutathione S-transferase11.4
subunit 13 homolog
I 428423AU076517Hs.184276solute carrier family 11.3
S 9 (sodiumlhydrogen
exch ~
442353BE379594Hs.49136ESTs 11.3
447700A1420183Hs.171077ESTs, Weakly similar 11.3
to similar to serinelthr
402077 0 11.3
409203AA780473Hs.687cytochrome P450, subfamily11.3
IVB, polypeptide 1
405145 0 11.3
428248A1126772Hs.40479ESTs 11.3
425508AA99i551Hs.97013ESTs 11.3
428340AF261088Hs.154721aconitase 1, soluble 11.3
431452A1073641Hs.152372ESTs 11.3
446651AA393907Hs.97179ESTs 11.3
443755C18397Hs.9730tachykinin 3 (neuromedin11.3
K, neurokinin beta)
436209AW850417Hs.254020ESTs, Moderately similar11.3
to unnamed protein
p
401020 0 11.3
456724AW247388Hs.301423calcium binding protein11.2
1 (calbrain)
30 d07227H94949Hs.171955trophinin associated 11.2
protein (tastin)
402066 0 11.2
442721A1015892Hs.101282Homo Sapiens mRNA; 11.2
cDNA DKFZp434B102
(from c1
401025 0 11.2
452423AA991724Hs.180535Homo sapiens cDNA: 11.2
FLJ22711 fis, clone
HS1133
3 431685AW296135Hs.267659vav 3 oncogene 11.2
S
425176AW015644Hs.301430ESTs, Moderately similar11.2
to TEFi HUMAN TRANSG
435496AW840i71Hs.265398ESTs, Weakty similar 11.2
to transformation-relate
409079W87707Hs.82065intedeukin 6 signal 11.2
transducer (gp130;
oncos
456995T89832Hs.170278ESTs 11.2
40 419223X60111Hs.1244CD9 antigen (p24) 11.2
407788BE514982Hs.38991S100 calcium-binding 11.2
protein A2
407604AW191962Hs.288061actin, beta 11.2
437929T09353Hs.106642ESTs, Weakly similar 11.1
to hypothetical protein
415789H01581 gb:yj33tO8.r1 Soares 11.1
placenta Nb2HP Homo
sapi
45 424447AL137376Hs.147368Homo sapiens mRNA; 11.1
cDNA DKFZp434J0226
(from c
436034AF282693Hs.150185infiammafion-related 11.1
G protein-coupled
recept
404931 0 11.1
445979A1695047Hs.202395ESTs 11.1
446733AA863360Hs.26040ESTs; Highly similar 11.1
to CYTOCHROME P45
IVA2
433133A8027249Hs.104741PDZ-binding kinase; 11.1
T-cell originated
protein
445258AI635931Hs.147613ESTs 11.1
417251AW015242Hs.99488ESTs; Weakly similar 11.1
to ORF YKR074w [S.cerevi
421041N36914Hs.14691ESTs 11.1
425537AB007913Hs.158291KIAA0444 protein 11.1
55 435763A1243929Hs.190419ESTs 11.1
444790A8030506Hs.1195589 protein 11.1
~
453857AL080235Hs.35861DKFZP586E1621 protein 11.1
433882090441Hs.3622procollagen-proline, 11.1
2-oxoglutarate 4-dioxyge
405358 0 11.1
60 435814AW615179Hs.152870ESTs 11.0
422809AK001379Hs.121028hypothetical protein 11.0
FLJ10549
446772AW29440dHs.144515Homo Sapiens cDNA FLJ1167211.0
fis, clone HEMBA10
456694AW016382Hs.105642Homo Sapiens cDNA: 11.0
FLJ23271 fis, clone
HEP001
441128AA570256Hs.54628ESTs 11.0
65 432677NM Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polypeptid11.0
004482
412576AA447718Hs.107057ESTs 11.0
411122F00809Hs.143696coactivator-associated11.0
arginine methyltransfe
427225AA432391Hs.258903Homo Sapiens mRNA for 11.0
KIAA1640 protein,
pare
426260NM Hs.168669oxoglutarate dehydrogenase11.0
002541 (lipoamide)
70 444652BE513613Hs.11538acfin related protein 11.0
213 complex, subunit
1A
431947AL359613Hs.49933hypotheticalprotein 11.0
DKFZp762D1011
414432BE378174Hs.26506Homo Sapiens clone 11.0
CDABP0005 mRNA sequence
458627AW088642Hs.97984ESTs; Weakly similar 10.9
to WASP-family protein
[
409142AL136877Hs.50758chromosome-associated 10.9
polypepfide C
75 447627AF090922Hs.285902CGI-113 protein 10.9
447656NM_003726Hs.19126sro kinase-associated 10.9
phosphoprolein of
55 kD
454227AW963897Hs.44743KIAA7435 protein 10.9
4o2s27 o io.s
422380AA309881Hs.136246ESTs 10.9
$0 455986BE177736 gb:RC1-HT0598-140300-021-g0610.9
HT0598 Homo sapi
410962BE273749Hs.752FK506-binding protein 10.9
1A (l2kD)
450361BE327108Hs.202512ESTs 10.9
457484H57645 gb:yr21e01.r1 Soaros 10.9
fetal liver spleen
1 NFLS
407903AI287341Hs.154029. bHLH factor Hes4 10.9
190
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
403398 0 10.9
401405 0 10.9
405570 0 10.9
421240872730Hs.29283ESTs, Weakly similar 10.9
to PLK-HUMAN PROTEOGLYCA
403649 0 10.9
447824BE6208C0 gb:601483379T1 NIH 10.9
MGC-69 Homo Sapiens
cDNA o
450935BE514743Hs.25664tumor suppressor deleted10.9
in oral cancer-relat
~
439853AL119566Hs.6721lysophospholipase-like10.9
451852851928 gb:yj71c05.r1 Soares '10.9
breast 2NbHBst Homo
sapi
1 431218NM Hs.2733homeo box B2 10.9
~ 002145
457794AA689292Hs.246850ESTs 10.9
44437dAA009841Hs.11039Homo Sapiens cDNA FLJ1279810.9
fis, clone NT2RP20
456566AW235317Hs.2592i4ESTs 10.8
405552 0 10.8
1 439436BE140845Hs.57868ESTs 10.8
435310AA705075Hs.169536Rhesus blood group-associated10.8
glycoprotein
411125AA151647Hs.68877cytochrome b-245, alpha10.8
polypeptide
415807H03139Hs.24683ESTs 10.8
409430821945Hs.166975splicing factor, argininelserine-rich10.8
5
417033H83784Hs.40532ESTs, Weakly similar 10.8
to PEBP MOUSE PHOSPHATID
418464887580 gb:ym89hOl.r1 Soares 10.8
adult brain N2b4H855Y
Ho
404567 0 10.8
418384AW149266Hs.25130ESTs 10.8
421971063127Hs.110121SEC7 homolog 10.8
25 428769AW207175Hs.106771ESTs , 10.8
459104819238Hs.282057ESTs 10.8
410896AW809637 gb:MR4-ST0124-261099-015-b0710.8
ST0124 Homo sapi
416969AI815443Hs.283404organic canontransporter10.8
408796AA688292Hs.118553ESTs 10.8
426298AW965058Hs.111583ESTs 10.8
421595AB014520Hs.105958Homo Sapiens cDNA: 10.8
FLJ22735 fis, clone
HUV001
408007AW135965Hs.246783ESTs 10.8
400167 0 10.7
445243A1217439Hs.109854ESTs, Weakly similar 10.7
to ALU1 HUMAN ALU
SUBFAM
3 421733AL119671Hs.1420fibroblastgrowth factorreceptor310.7
S (achondro
412241AW948343 gb:RCO-MT00i5-130400-031-c0110.7
MT0015 Homo sapi
425827W28316 gb:45b6 Human retina 10.7
cDNA randomly primed
sub
420255NM Hs.1298membrane metallo-endopepfidase10.7
007289 (neutral endop
430891022492Hs.248118G protein-coupled receptor10.7
8
40 402883 0 10.7
423811AW299598Hs.50895homeo box C4 10.7
447078AW885727Hs.301570ESTs 10.7
414343AL036166Hs.75914coated vesicle membrane10.7
protein
446913AA430650Hs.16529Uansmembrane 4 superfamily10.7
member (tetraspan
45 452279AA286844Hs.61260hypothetical protein 10.7
FLJ13164
401220 0 10.7
459259AJ003294 gb:AJ003294 Selected 10.7
chromosome 21 cDNA
libra
d14171AA360328Hs.865RAP1A, member of RAS 10.7
oncogene family
448449BE314567Hs.211440ESTs 10.7
429670L01087Hs.211593protein kinase C, theta10.7
446759861463Hs.i6165expressed in activated10.7
TILAKIymphocytes
400776 0 10.7
428093AW594506Hs.104830ESTs 10.7
412801AA121055 gb:zm22b01.r1 SUatagene10.6
pancreas (937208)
Ho
5 440545AW183201Hs.190559ESTs 10.6
5
434540NM-016045Hs.5184TH1 drosophila homolog10.6
414273BE269057 gb:601184231F1 NIH_MGC-810.6
Homo Sapiens cDNA
cl
401817 0 10.6
410423AW402432Hs.63489protein tyrosine phosphatase,10.6
non-receptor ly
60 430590AW383947Hs.246381CD68 antigen 10.6
426680AA320160Hs.1718i1adenylate kinase 2 10.6
445413AA151342Hs.12677CGI-147 protein 10.6
402947 0 10.6
457426AW971119 gb:EST383206 MAGE resequences,10.6
MAGL Homo sapi
65 424148BE242274Hs.1741integrin, beta? 10.6
'
404944 0 10.6
405421 0 10.6
416772A1733872Hs.79769protocadherin 1 (cadherin-like10.6
1)
414191AW250089Hs.75807PDZ and LIM domain 10.6
1 (elfin)
7~ 457588AI571225Hs.284171KIAA1535 protein 10.6
406038Y14443Hs.88219zinc finger protein 10.6
200
404790 0 10.6
418922AW956580Hs.42699Thrombospondin-1 (Hs.87409)10.6
425940A8023184Hs.163990KIAA0967 protein 10.6
75 448749AW859679Ns.21902Homo Sapiens clone 10.6
25237 mRNA sequence
418870AF147204Hs.89414CXCR4; chemokine CXG 10.5
receptor 4 (fusin)
417933X02308Hs.82962thymidylate synthetase10.5
450538AW297396Hs.227052ESTs 10.5
427928AA417662Hs.119217ESTs 10.5
432721AL121478Hs.3132steroidogenic acute 10.5
regulatory protein
429267AA299290Hs.246857ESTs, Highly similar 10.5
to S71100 protein
kinase
439190AW978693Hs.293811ESTs 10.5
d08975AW958693Hs.49391hypothetical protein 10.5
LOC54149
415130W85893Hs.249867ESTs 10.5
191
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
425738H29630Hs.159408Homo Sapiens clone 10.5
24420 mRNA sequence
440232A1766925Hs.i12554ESTs 10.5
425065AA371906Hs.294151ESTs, Moderately similar10.5
to KIAA054d protein
420829AW665612Hs.221969ESTs 10.5
430466AF052573Hs.241517polymerase (DNA directed),~
theta 10.5
407771AL138272Hs.62713ESTs 10.5
444611AK002180Hs.114d9DKFZP5640123 protein 10.5
444665BE613126Hs.47783ESTs, Weakly similar 10.5
to T12540 hypothetical
p
448030N307idHs.20161HDCME31P protein 10.5
1 438982AW97910iHs.291980ESTs 10.5
~
446224AW450551Hs.13308ESTs 10.5
405108 0 10.5
438233W52448Hs.56147ESTs 10.5
401799 0 10.5
15 454038X06374Hs.37040platelet-derived growth10.5
factor alpha polypept
414222AL135173Hs.878sorbitoldehydrogenase 10.5
421828AW891965Hs.289109dimethylarginine dimethylaminohydrolase10.5
1
422626AA344932Hs.118786metallothionein 2A 10.5
449261AI637592Hs.224958ESTs 10.4
2~ 416218821499Hs.23213ESTs 10.4
457848W26524Hs.125682ESTs; Weakly similar 10.4
to D2092.2 [C.elegans]
442577AA292998Hs.163900ESTs 10.4
406505AF016272Hs.115418cadherin 16, KSP-cadherin10.4
412258AA376768Hs.288977Homo Sapiens cDNA: 10.4
FLJ22622 fis, clone
HSI056
25 429224AI905780Hs.198272NADH dehydrogenase 10.4
(ubiquinone) 1 beta
subcom
447774BE018118Hs.19554chromosome 1 open reading10.4
frame 2
403914 0 10.4
406329 0 10.4
' 402423 0 10.4
431986AA536130Hs.149018ESTs 10.4
423145BE264548Hs.222190ESTs, Weakly similar 10.4
to secretory carrier
mem
414402BE294186 gb:601172959F1 NIH 10.4
MGC-17 Homo sapiens
cDNA c
417079065590Hs.81134interleukin 1 receptor10.4
antagonist
426095AI278023Hs.89986ESTs 10.4
3 434577837316Hs.179769Homo Sapiens cDNA: 10.4
FLJ22487 fis, clone
HRC109
442415A1005101Hs.129550ESTs 10.3
421506BE302796Hs.105097ihymidine kinase 1, 10.3
soluble
435084D17516Hs.301607adenylate cyclase activating10.3
polypeptide 1 (p
431724AA514535Hs.283704ESTs 10.3
456798AJ006422Hs.135183centaurin-alpha 10.3
41737(1T28651Ns.82030tryptophanyl-tRNA synthetase10.3
422596AF063611Hs.1186332'-5'oligoadenylate 10.3
synthetase-like
435226AI248938Hs.270106ESTs 10.3
433192AB040880Hs.225594ESTs, Moderately similar10.3
to KIAA1447 protein
45 419879217805Hs.93564Homer, neuronal immediate10.3
early gene, 2
416228AW505190Hs.79089sema domain, immunoglobulin10.3
domain (1g), Uan
453403BE466639Hs.61779Homo Sapiens cDNA FLJ1359110.3
fis, clone PLACE10
447906AL050062Hs.19999DKFZP566K023 protein 10.3
401782NM-012434Hs.117865solute cartierfamily 10.3
17 (anionisugar transpo
453927AA082465Hs.301751ESTs, Weakly similar 10.3
to /prediction
450737AW007152Hs.203330ESTs 10.3
421633AF121860Hs.106260sorting nexin 10 10.3
409881AF139799Hs.202830ESTs 10.3
432883048936Hs.3112sodium channel, nonvoltage-gated10.3
1, gamma
5 440099AL080058Hs.6909DKFZP564G202 protein 10.3
5
419024X56411Hs.1219alcohol dehydrogenase 10.3
4 (class II), pi polype
401835 0 10.3
408896A1610447Hs.d8778niban protein 10.3
443120AW402677Hs.290801ESTs 10.3
400208 0 10.2
416908AA333990Hs.80424coagulation factor 10.2
X111, A1 polypeptide
400166 0 10.2
434642W25739Hs.135287ESTs 10.2
424837BE276113Hs.153436N-acetylUansferase, 10.2
homolog of S. cerevisiae
65 435075851094Hs.12400ESTs 10.2
425912AL137629Hs.162189serinelthreonine kinase10.2
with Dbl- and pleckst
435080A1831760Hs.155111ESTs 10.2
414998NM-002543Hs.77729oxidised low density 10.2
lipoprotein (lectin-like
410020T86315Hs.728ribonuclease, RNase 10.2
A family, 2 (liver,
eosin
411410820693Hs.69954laminin, gamma 3 10.2
450294H42587Hs.238730ESTs 10.2
421154AA284333Hs.287631Nomo Sapiens cDNA FLJ1426910.2
fis, clone PLACE10
414271AK000275Hs.75871protein kinase C binding10.2
protein 1
40D812 0 10.2
75 425843BE3i3280Hs.159627death associated protein10.2
3
449392241698Hs.26039Homo Sapiens cDNA FLJ7393710.2
fis, clone Y79AA10
409089NM-014781Hs.50421KIAA0203 gene product 10.2
401383 0 10.2
456855AF035528Hs.153863MAD (mothers against 10.2
decapentaplegic, Drosoph
442912A1088060Hs.131450ESTs 10.2
400954D25969Hs.76325Homo Sapiens cDNA: 10.2
FW23125 fis, clone
LNG082
401029BE382701Hs.25960v-myc avian myelocytomatosis10.2
viral related on
416602NM-OD6159Hs.79389net (chicken)-like 10.2
2
421905AI660247Hs.32699ESTs, Weakly similar 10.2
to LIV-1 protein [H.sapi
192
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4o5os4 o io.a
450832AW970602Hs.105421ESTs 10.2
440076832052Hs.178617ESTs, Weakly similar 10.2
to AF1518401 CGI-82
pro
447563BE536115Hs.160983ESTs 10.2
421238AB033101Hs.102796KIAA1275 protein 10.2
400882 0 10.2
415738BE539367Hs.295953ESTs, Weakly similar 10.1
to AF2200491 uncharacte
445464AW172389Hs.249999ESTs 10.1
459042AW272058Hs.210338ESTs 10.1
1 414469851952Hs.32587stedod receptor RNA 10.1
~ activator 1 (complexes
w
434732A1078443 gb:oz05g05.x1 Soares 10.1
fetal liver_spleen_1NFL5
441030AW204139Hs.174424ESTs, Weakly similar 10.1
to p140mDia [M.musculus]
446855BE616767Hs.162698-cell CLLIlymphoma 10.1
7B
456785AF151074Hs.132744hypothetical protein 10.1
15 404182 0 10.1
410358AW975168Hs.13337ESTs, Weakly similar 10.1
to unnamed protein
produ
430355NM-006219Hs.239818phosphoinosifide-3-kinase,10.1
catalytic, beta po
442152839246Hs.239666Homo Sapiens cDNA FLJ1349510.1
fis, clone PLACE10
436354AI879252Hs.5151Homo Sapiens mRNA; 10.1
cDNA DKFZp564C2163
(from c
20 426711AA383471Hs.180669conserved gene amplified10.1
in osteosarcoma
450599AA460865Hs.48516ESTs 10.1
454393BE153288 gb:PMO-HT0335-180400-008-cOB10.1
HT0335 Homo sapi
403383 0 10.1
415947U04045Hs.78934mutS (E. coli) homolog10.1
2 (colon cancer, nonpo
411773NM Hs.72026protease, sg~ne, 21 10.1
006799 (lestisin)
412116AW402166Hs.784Epstein-Barrvirus induced10.1
gene 2 (lymphocyte
413808J00287Hs.182183caldesmon 1 10.0
458572A1223423Hs.292794ESTs 10.0
403295 0 10.0
3~ 403910 0 10.0
453400A1991901Hs.82590ESTs, Moderately similar10.0
to ALU7-HUMAN ALU
SU
406502 0 10.0
404743 0 10.0
412517BE271584 gb:601141065F1 NIH 10.0
MGC-9 Homo Sapiens
cDNA c1
-
35 4a2s7s o io.o
455864BE148970 gb:CMO-HT0245-031199-085-h0510.0
NT0245 Homo sapi
425734AF056209Hs.159396peptidylglycine alpha-amidaling10.0
monooxygenase
419280W07506Hs.283725Homo Sapiens cDNA FLJ1262710.0
fis, clone NT2RM40
443503AV645438Hs.282927ESTs 10.0
40 423165A1937547Hs.124915Human DNA sequence 10.0
from clone 380A1 on
chromo
450206AI796450Hs.201600ESTs 10.0
459052AA298812Hs.98539ESTs 10.0
456248AL035786Hs.82425actin related protein 10.0
2/3 complex, subunit
5
428438NM Hs.2271Endothelia i 10.0
001955
45 456525AW468397Hs.100000S100 calcium-binding 10.0
protein A8 (calgranulin
426127L36983Hs.167013dynamin 2 10.0
TABLE 138:
Pkey: Unique Eos probesetidenfifiernumber
50 CAT number: Gene cluster number
Accession: Genbank accession numbers
Pkey CAT Accession
Number
4108961226053AW809637 AW809697 AW810554 AW809707 AW809885 AW810000
1 AW810088 AW809742 AW809816 AW809749 AW809639 AW809722
_ AW809836 AW809774 AW810023 AW810013 AW809813 AW809660
5 AW809728 AW809768 AW809951 AW809657 AW809954
4121531279701_1887934 AW898205 AW896020 AW896035
4122411284681AW948343 AW948341 AW902855 AW984737
1
412517130281BE271584 AA112511
1
412801132825AA121055 AA330917
1
4133491363558_1BE086692 BE087077 BE087072
4142731431911BE269057 BE513434 BE396654
1
T
414402i443240BE294186 BE298975
1
4149501509777-1C15407 D81769 D61133
4157891555357H01581 H12850 865905 H13053
1
6 4163681591066888849 884573 H50890
5 1
4184641759038887580
-2
4187831789791T41368 T41369 T41294
1
424627241724AA344555 AA344312 AW963070
1
425827256834W28316 W26507 AA364334
1
434371- AA631362 AA631438
384839-1
43441438585_1A1798376 S46400 AW811617 AW811616 W00557 BE142245
AW858232 AW861851 AW858362 AA232351 AA218567 AA055556
AW858231
AW857541 AW814172 H66214 AW814398 AF134164 AA243093
AA173345 AA199942 AA223384 AA227092 AA227080 Ti
2379 AA092174
T61139 AA149776 AA699829 AW879188 AW813567 AW813538
AI267168 AA157718 AA157719 AA100472 AA100774 AA130756
AA157705
AA157730 AA157715 AA05352d AW849581 AW854566 C05254
AW882836 T92637 AW812621 AA206583 AA209204 BE156909
AA226824
75 AI829309 AW991957 N66951 AA527374 H66215 AA045564
AI694265 H60808 AA149726 AW195620 BE081333 BE073424
AW817662
AW817705 AW817703 AW817659 BE081531 H59570
434732392447A1078443 AA648102 AI765577 AW974381
1
439092468554AA830149 AW978407 M85983 AW503637
i
43963647467 AF086467 W81444 W81445
1
44782473861 BE620800
-1
45048483645 BE220675 AA345621 AA009992
1
451260863912-1AW750773 AI768154
451852888359851928 A1820698 848360 A1820694
1
452101898742-1T60298 A1858257 T69667 T67634T61224 T71537T68933
193
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
454163 1048369 1 AW175997 AW176000 AW175999 AW175994 AW176004 AW175989
454393 115888 1 BE153288 BE153151 BE152925AA078302
455102 1253524 1 BE005496 BE005494 AW856324 AW900199
455864 1377038_1 BE148970 BE148975 BE148957 BE148937
' 455986 1397521 1 BE177736 BE177735 BE177734
456423 187241 1 AW748920 AA487506 AA248914 AA780494
457426 336189 1 AW971119 AA574265 AA513268
457484 342113 1 H57645 T19302 AA527038 224851 H93171
457705 389383 1 AW974668 AA661959 AA649572 AA640401 AA640402
1 0 459259 966269-1 AJ003294 AJ003315 AJ003293
TABLE 13C:
Pkey: Unique number corresponding to an Eos probeset
Ref: Sequence source. The 7 digit numbers in this column are Genbank
Identifier (GI) numbers. "Dunham I. et al." refers 1o the publication entitled
"fhe DNA sequence of
15 human chromosome 22" Dunham, et al. (1999) Nature 402:489-495
Strand: Indicates DNA strand from which exons were predicted
N~posiGon: Indicates nucleotide positions of predicted exons
Pkey Ref Strand Nt~osition
400640 8117686 Plus 144324-144429
400666 8118496 Plus 17982-18115,20297-20456
400776 8131651 Plus 103576-103720
400812 8568711 Plus 71708-72153
400881 2842777 Minus 91446-91603,92123-92265
25 400882 2842777 Minus 110431-1107Q8
400965 7770576 Minus 173043-173564
401010 8117391 Minus 83967-84180
401020 8117458 Minus 59085-60227
401025 8117518 Minus 179287-179483,181044-181166,181844-182039
3 0 401047 6705887 Minus 4804-5035,5133-5314
401131 8699812 Minus 94802-94987,95804-95887,96323-96487,97596-97826
401192 9719502 Minus 69559-70101
401220 9929324 Minus 48079-48279
401383 6721135 Minus 155543-157381
35 401405 7768126 Minus 69276-69452,69548-69958
401519 6649315 Plus 157315-157950
401532 7798785 Plus 124414-124950,125050-125418
401610 7705041 Minus 18921-19505 '
401714 6715702 Plus 96484-96681
4~ 401735 3252819 Plus 217235-217356,217621-217873
401799 7331447 Plus 147802-148251
401817 7417850 Minus 4588&46535
401835 7139700 Plus 142257-142742
401879 8099914 Minus 101064-102827
45 401888 8516069 Minus 189498-190514
401897 8569218 Plus 604-767
402066 6649269 Plus 135543-136031
402077 8117414 Plus 65014-65195
402104 8119072 Plus 122409-122600
0 402238 7690126 Plus 24726-24880,26791-27021
402287 4559317 Plus 40811-42447
402389 9885999 Minus 771-972,1571-1683
402408 9796239 Minus 110326-110491
402423 9796344 Minus 62487-62664
5 5 402424 9796344 Minus 64925-65073
402496 9797769 Minus 8615-9103
402520 7596899 Minus 171761-171996
402679 8113438 Plus 132079-132216
402840 9369121 Minus 57118-57306
402883 9926562 Plus 38666-38803,38885-39019,39097-39231,39308-39445
402885 9926751 Plus 71919-72049
402926 8217647 Minus 41261-41443
402927 8217647 Minus 47247-47396
402943 6456831 Plus 38467-39068
65 402944 9368423 Plus 110411-110716,111173-111640
402947 9368458 Minus 101629-101991
402965 9581599 Minus 46865-46941,47032-47148
403022 3132351 Plus 92097-92864
403121 9180223 Plus 4059-4258
403165 9838098 Minus 90595-91848
403295 8096528 Plus 22386-22708
403381 9438267 Minus 26009-26178
403383 9438267 Minus 119837-121197
403398 6862689 Minus 13685-14699
75 403399 6684178 Plus 61841-62145,62367-62756
403482 9966050 Plus 196964-197135
403485 9966528 Plus 2888-3001,3198-3532,3655-4117
403649 8705159 Minus 27141-27247
403910 7710710 Minus 5761-6188
403912 7710730 Minus 72000-72290,72431-72700,72929-73199
403914 7417588 Minus 7431-8472
404182 4775644 Plus 18163-18444
404502 7229863 Minus 56277-56819
404567 7249169 Minus 101320-101501
194
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
4046789797204Plus115196-115448
4047438894169Minus120556-120999
4047809887810Minus175708-175871
4047907230958Plus38611-38761
4049317342203Plus44226-44382
4049446899705Plus4256-4581
4050247107727Plus88500-88697
4050898072523Plus103182-103973
d050948072579Plus135587-135758
1 4051087107890Minus135020-135472
~
4051459438278Plus37883-38052,38138-38332
4051927230070Plus115629-116071
4052246731245Minus14413-15979
4052953818412Plus56933-57099
1 4053532811095Plus118525-118892
4053582341017Minus18016-18315
4054217243869Minus97411-97687
4054267243900Minus37640-37817
4054527656638Minus93876-94275
4054845922025Plus199214-199579,199672-199920,200262-200495
4055521552506Plus45199-45647
4055702808656Plus98208-98331
'
4056264508116Minus89275-89384,92450-92629,97091-97279,98546-98666
4056994165331Plus100727-100859
4057625931935Plus160502-16111
4058025924004Minus27743-28264
4058047274891Minus122557-123551
4063296982072Minus.607903-608271
4064299256476Minus83206-83365,94051-94193
4065027711350Minus63430-63602
Table 14A lists about 695 genes up-regulated in ovarian cancer compared to
normal adult tissues. These were selected from 59680 probesets on the
Af<ymetrixlEos Hu03
GeneChip array such that the ratio of "average" ovarian cancer to "average"
normal adult tissues was greater than or equal to 4Ø The "average" ovarian
cancer level was set to
3 5 the 90th percentile amongst various ovarian cancers. The "average" normal
adult tissue level was set to the 90th percentile amongst various non-
malignant tissues. In order to
remove gene-specific background levels of non-specific hybridization, the 15th
percentile value amongst various non-malignant tissues was subtracted from
both the numerator
and the denominator before the rafio was evaluated.
TABLE
14A:
ABOUT
695
UP-REGULATED
GENES,
OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES
Pkey:
Primekey
Ex.Accn:ExempIarAccession
UG niGene
ID: ID
U
Title:
UniGene
fifie
ratio:
ratio
of
tumor
vs.
normal
tissues
45
PkeyEx. UG Tifie ratio
Accn ID
452838U65011Hs.30743Preferentially expressed70.4
antigen in melanoma
438817A1023799Hs.163242ESTs 62.8
432938T27013Hs.3132steroidogenic acute 57.8
regulatory protein
421478A1683243Hs.97258ESTs 45.7
415989A1267700Hs.111128ESTs 42.7
418179X51630Hs.1145Wilms tumor 1 36.0
449034AI624049 gbas4l a09.x1 NCI CGAP 34.0
Ut1 Homo Sapiens cDNA
clone
428579NM Hs.184942G protein-coupled receptor30.5
005756 64
55 428153AW513143Hs.98367hypothefical protein 30.1
FLJ22252 similar to
SRY-box c
436982AB018305Hs.5378spondin 1, (f-spondin) 29.4
extracellular matrix
protei
427585D31152Hs.179729collagen; type X; alpha27.0
1 (Schmid metaphyseal
chon
435094AI560129Hs.277523EST 26.2
430691C14187Hs.103538ESTs 26.2
430491AL109791Hs.241559Homo Sapiens mRNA full 26.1
length insert cDNA
clone EU
415511AI732617Hs.182362ESTs 24.8
448243AW369771Hs.77496ESTs 24.7
428187AI687303Hs.285529ESTs 23.9
408081AW451597Hs.167409ESTs 21.9
65 418007M13509Hs.83169Matrix metalloprotease 20.6
1 (interstitial collagenase
400292AA250737Hs.72472BMPR-Ib; bone morphogenetic20.6
protein receptor, iyp
422956BE545072Hs.122579ESTs 20.0
413335AI613318Hs.48442ESTs 19.9
423739AA398155Hs.97600ESTs 18.9
410929H47233Hs.30643ESTs 18.5
424086A13510i0Hs.102267lysyloxidase 17.7
424905NM Hs.153704NIMA (never in mitosis 17.4
002497 gene a)-related kinase
2
427356AW023482Hs.97849ESTs 17.4
407168845175 gb:yg40f01.s1 Soares 17.1
infant brain 1 NIB
Homo sapien
75 407638AJ404672Hs.288693EST 17.1
427469AA403084Hs.269347ESTs 17.0
438993AA828995 integdn; beta 8 16.7
428664AK001666Hs.189095similar to SALL1 (sat 16.5
(Drosophila)-like
d39820AL360204Hs.283853Homo Sapiens mRNA full 16.5
length insert cDNA
clone EU
g0 d21155H87879Hs.102267lysyloxidase 16.1
426635BE395109Hs.129327ESTs 15.9
431989AW972870Hs.291069ESTs 15.9
422805AA436989Hs.121017H2A histone family; 15.9
member A
444783AK001468Hs.62180ESTs 15.8
195
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
424581M62062Hs.150917catenin (cadhedn-associated15.7
protein), alpha 2
453197AI916269Hs.109057ESTs,WeaklysimilartoALUS_HUMANALUSUBFAMIL15.7
459325AW088369Hs.282184ESTs 15.6
428976AL037824Hs.194695ras homolog gene family,15.1
member 1
416209AA236776Hs.79078MAD2 (mitotic arrest 15.0
deficient, yeast, homology-li
408660AA525775Ns.292523ESTs 15.0
410247AF181721Hs.61345RU2S 15.0
418738AW388633Hs.6682solute carrier family 15.0
7, member 11
459583AI907673 gb:IL-BT152-080399-004 14.8
BT152 Homo sapiens
cDNA, m8
l0 413623AA825721Hs.246973ESTs 14.8
439706AW872527Hs.59761ESTs 14.7
409041A8033025Hs.50081KIAA1199 protein 14.6
451110A1955040Hs.301584ESTs 14.5
436775AA731111Hs.291891ESTs 14.3
15 443211A1128388Hs.143655ESTs 14.3
445258AI635931Hs.1d7613ESTs 14.2
447350A1375572Hs.172634ESTs; HER4 (c-erb-84) 14.2
428227AA321649Hs.2248INTERFERON-GAMMA INDUCED14.1
PROTEIN PRECURS
453392023752Hs.32964SRY (sex determining 13.9
region Y)-box 11
20 447033AI357412Hs.157601EST-not inUniGene 13.7
423811AW299598Hs.50895homeo box C4 13.7
452461N78223Hs.108106iranscdptionfactor 13.7
451106BE382701Hs.25960N-myc 13.6
416208AW291168Hs.41295ESTs 13.5
25 452249BE394412Hs.61252ESTs , 13.4
452055AI377431Hs.293772ESTs 13.2
439243AA593254Hs.191349ESTs 13.1
420149AA255920Hs.88095ESTs 12.9
429125AA446854Hs.271004ESTs 12.9
30 413597AW302885Hs.117183ESTs 12.8
416566NM-003914Ns.79378oyclin A1 12.8
442438AA995998 gb:os26b03.s1 NCI-CGAP-Kid512.7
Homo Sapiens cDNA clon
407710AW022727Hs.23616ESTs 12.6
416661AA6345d3Hs.79440iGF-ll mRNA-binding 12.6
protein 3
35 428392H10233Ns.2265secretory granule, neuroendocrine12.4
protein 1 (782 p
431725X65724Hs.2839Norrie disease (pseudoglioma)12.3
447700AI420183Hs.171077ESTs, Weakly similar 12.2
to similar to serinelthreonin
458027L49054Hs.85195ESTs, Highly similar 12.2
to t(3;5)(q25.1;p34)
fusion g
408460AA054726Hs.285574ESTs 12.2
424735031875Hs.152677short-chain alcohol 12.0
dehydrogenase family
member
415263AA948033Hs.130853ESTs 11.9
400298AA032279Hs.61635STEAP1 11.8
452096BE394901Hs.226785ESTs 11.7
421451AA291377Ns.50831ESTs 11.6
45 435496AW840171Hs.265398ESTs, Weakly similar 11.6
to transformation-related
pro
443715AI583187Hs.9700cyclin E1 11.5
402606#(NOCAT) 11.5
436954AA740151Hs.130425ESTs 11.5
413472BE242870Hs.75379solute camerfamily 1 11.5
(glial high afflnily
gluta
50 410102AW248508Hs.279727ESTs; 11.4
408562AI436323Hs.31141Homo Sapiens mRNA for 11.4
KIAA1568 protein, partial
c4
452030AL137578Hs.27607Homo sapiens mRNA; cDNA11.4
DKFZp564N2464 (from
clon
442353BE379594Hs.49136ESTs 11.3
427344NM Hs.21425-hydroxytryptamine 11.2
000869 (serotonin) receptor
3A
55 453160AI263307Hs.146228ESTs 11.2
426427M86699Hs.169840TTK protein kinase 11.1
449433AI672096Hs.9012ESTs 11.1
412723AA648459Hs.179912ESTs 11.1
400250 0 11.1
419752AA249573Hs.152618ESTs 11.1
438167828363Hs.24286ESTs 11.1
434539AW748078Hs.214410ESTs 10.9
429918AW873986Hs.119383ESTs 10.8
450375AA009647Hs.8850a disintegrin and metalloproteinase10.8
domain 12 (met
65 400289X07820Hs.2258Matrix Metalloproteinase10.8
10 (SUomofysin 2)
420900AL045633Hs.44269ESTs 10.8
428758AA433988Hs.98502Homo sapiens cDNA FLJ1430310.8
fis, clone PLACE2000132
446142AI754693Hs.145968ESTs 10.7
421285NM-000102Hs.1363cytochrome P450, subfamily10.6
XVII (stercid 17-alpha-
433496AF064254Hs.49765VERY-LONG-CHAIN ACYL-COA10.6
SYNTHETASE
418506AA084248Hs.85339G protein-coupled receptor10.5
39
433447029195Hs.3281neuronal pentraxin II 10.4
424188AW954552Hs.142634zinc finger protein 10.4
414245BE148072Hs.75850WAS protein family, 10.3
member 1
75 426462059111Hs.169993dermatan sulphate proteoglycan10.3
3
418601AA279490Hs.86368calmegin 10.3
444170AW613879Ns.102408ESTs 10.3
453616NM Hs.33846dynein, axonemal, light10.3
003462 intermediate polypeptide
407378AA299264 gb:EST11752 Uterus Homo10.2
Sapiens cDNA 5' end
simila
440901AA909358Hs.128612ESTs 10.2
407366AF026942 gb:Homo Sapiens cig33 10.2
mRNA, partial sequence.
415227AW821113Hs.72402ESTs 10.2
409269AA576953Hs.22972Homo Sapiens cDNA FLJ1335210.1
fis, clone OVARC1002165
450480X82125Hs.25040zinc finger protein 10.1
239
196
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
419088AI538323Hs.77496ESTs 10.0
453922AF053306Hs.36708budding uninhibited 9.9
by benzimidazoles 1
(yeast hom
428253AL133640Hs.183357Homo Sapiens mRNA; cDNA9.8
DKFZp586C1021 (from
clone
426471M22440Hs.170009transforming growth 9.8
factor, alpha
407881AW072003Hs.40968heparan sulfate (glucosamine)9.7
3-0-sulfotransferase
452291AF015592Hs.28853CDC7 (cell division 9.7
cycle 7, S. cerevisiae,
homolo
445537AJ245671Hs.12844EGF-like-domain; mulfiple9.7
6
442875BE623003Hs.23625Homo Sapiens clone TCCCTA001429.6
mRNA sequence
423992AW898292Hs.137206Homo Sapiens mRNA; cDNA9.6
DKFZp564H1663 (from
clon
1 412140AA219691Hs.73625RAB6 interacfing, kinesin-like9.6
~ (rabkinesin8)
407721Y12735Hs.38018dual-specificity tyrosine-(Y)-phosphorylaficn9.6
regu
438209AL120659Hs.6111KIAA0307 gene product 9.5
429782NM Hs.220689Ras-GTPase-activating 9.5
005754 protein SH3-domain-binding
p
424945A1221919Hs.173438hypotheficalprotein 9.5
FLJ10582
414972BE263782Hs.77695KIAA0008 gene product 9.4
439262AA832333Hs.124399ESTs 9.4
403381#(NOCAT) 0 9.3
424834AK001432Hs.153408Homo Sapiens cDNA FLJ105709.3
fis, clone NT2RP2003117
435509AI458679Hs.181915ESTs 9.3
ZQ 445413AA151342Hs.12677CG!-147 protein 9,2
414083AL121282Hs.257786ESTs 9.2
421373AA808229Hs.167771ESTs 9.2
430510AW162916Hs.241576hypothefical protein 9.1
PR02577
446999AA151520Hs.279525hypothefical protein 9.1
PR02605
459587AA031956 gb:zk15e04.s1 Soares~regnant_uterus-NbHPU9.1
Homo sa
414569AF109298Hs.118258Prostate cancer associated9.1
protein 1
406687M31126Hs.272620pregnancy specific beta-1-glycoprolein9.0
9
428479Y00272Hs.184572cell division cycle 9.0
2, G1 to S and G2 to
M
408908BE296227Hs.48915serine/threonine kinase9.0
15
431548AI834273Hs.9711Homo Sapiens cDNA FLJ130189.0
fis, clone NT2RP3000685
433764AW753676Hs.39982ESTs 9.0
434636AA083764Hs.241334ESTs 8.9
451807W52854Hs.27099DKFZP564J0863 protein 8.8
437872AK002015Hs.5887RNA binding motif protein8.8
7
35 443054AI745185Hs.8939yes-associated protein 8.8
65 kDa
420092AA814043Hs.88045ESTs 8.8
420159A1572490Hs.99785ESTs 8.8
447164AF026941Hs.17518Homo Sapiens cig5 mRNA,8.8
partial sequence
451254AI571016Hs.172967ESTs 8.8
432677NM Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polypeptide8.7
004482 N-a
450434AA166950Hs.18645ESTs, Weakly similar 8.7
to partial CDS [C.elegans]
400301X03635Hs.i657Estrogen receptor 1 8.7
408829NM Hs.48384heparan sulfate (glucosamine)8.7
006042 3-0-sulfotransferase
434891AA814309Hs.123583ESTs 8.7
45 436812AW298067 gb:Ul-H-BWO-ajp-g-09-0-ULs18.7
NCI-CGAP_Sub6 Homo
s
438885AI886558Hs.184987ESTs 8.7
449765N92293Hs.206832EST, Moderately similar8.7
to ALU8 HUMAN ALU SUBFAM
447342AI199268Hs.19322ESTs; Weakly similar 8.6
to Illl ALU SUBFAMILY
J WARNI
434424AI811202Hs.125365Homo sapiens cDNA: FLJ235238.6
fis, clone LNG05548
438078A1016377Hs.131693ESTs 8.6
437212A1765021Hs.210775ESTs 8.5
417728AW138437Hs.24790KIAA1573 protein 8.5
438081H49546Hs.298964ESTs 8.5
411571AA122393Hs.70811hypothetical protein 8.4
FLJ20516
55 435663A1023707Hs.134273ESTs 8.4
424717H03754Hs.152213wingless-type MMTV integration8.4
site family, member
425734AF056209Hs.159396pepfidylglycine alpha-amidafing8.4
monooxygenase COOH
450505NM Hs.25051plakophilin 2 8.4
004572
436211AK001581Hs.80961polymerase (DNA directed),8.3
gamma
436396AI683487Hs.299112Homo Sapiens cDNA FLJ114418.3
fis, clone HEMBA1001323
425695NM-005401Hs.159238protein tyrosine phosphatase,8.3
non-receptor type 14
438180AA808189Hs.272151ESTs 8.2
447268A1370413Hs.36563Homo Sapiens cDNA: FLJ224188.2
fis, clone HRC08590
433159AB035898Hs.150587kinesin-like protein 8.1
2
65 400195 0 8.1
424906A1566086Hs.153716Homo Sapiens mRNA for 8.1
Hmob33 protein, 3'
untransla
438202AW169287Hs.22588ESTs 8.1
438915AA280174Hs.23282ESTs 8.1
448776BE302464Hs.30057transporter similar 8.1
to yeast MRS2
453884AA355925Hs.36232KIAA0186 gene product 8.0
420757X78592Hs.99915androgen receptor(dihydrotestosterone8.0
receptor;t
439759AL359055Hs.67709Homo Sapiens mRNA full 8.0
length insert cDNA
clone EU
453102NM Hs.31664fizzled (Drosophila) 8.0
007197 homolog 10
424001W67883Hs.137476KIAA1051 protein 8.0
75 434415BE177494 gb:RC&HT0596-270300-011-C058.0
HT0596 Homo Sapiens
c
417576AA339449Hs.82285phosphoribosylglycinamide7.9
formyltransferase,
phosp
438966AW979074 gb:EST391184 MAGE resequences,7.9
MAGP Homo sapiens c
415245N59650Hs.27252ESTs 7.9
422352AA766296Hs.99200ESTs 7.9
425492AL021918Hs.158174zinc finger protein 7.8
184 (Kruppel-like)
442655AW027457Hs.30323ESTs 7.8
445657AW612141Hs.279575ESTs 7.8
450221AA328102Hs.24641cytoskeleton associated7.8
protein 2
426320W47595Hs.169300, transforming growth 7.8
factor, beta 2
197
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
414142AW368397Hs.150042ESTs 7.7
412170D16532Hs.73729very low density lipoprotein7.6
receptor
410011AB020641Hs.57856PFTAIRE protein kinase 7.6
1
436476AA326108Hs.53631ESTs 7.6
414132A1801235Hs.48480ESTs 7.6
437789AI581344Hs.127812ESTs, Weakly similar 7.6
to AF1413261 RNA helicase
HD
450192AA263143Hs.24596RAD51-interacting protein7.6
449328AI962493Hs.197647ESTs 7.5
440238AW451970Hs.155644paired box gene 2 7.5
1 403657#(NOCAT) 0 7.5
~
408826AF216077Hs.48376Homo Sapiens clone HB-27.5
mRNA sequence
418735N48769Hs.44609ESTs 7.5
413627BE182082Hs.246973ESTs 7.4
446293AI420213Hs.i49722ESTs 7.4
15 441627AA947552Hs.58086ESTs 7.4
425465L18964Hs.1904protein kinase C; iota 7.3
409242AL080170Hs.51692DKFZP434C091 protein 7.3
450262AW409872Hs.271166ESTs, Moderately similar7.3
to ALU7-HUMAN ALU SUBFA
440250AA876179Hs.134650ESTs 7.3
451659BE379761Hs.14248ESTs, Weakly similar 7.3
to ALUB HUMAN ALU SUBFAMIL
458861AI630223 gb:adO6g08.r1 Proliferafing7.3
Erythroid Cells (LCB:a
436032AA150797Hs.109276latexin protein 7.2
407771AL138272Hs.62713ESTs 7.2
435039AW043921Hs.130526ESTs 7.2
444342NM_014398Hs.10887similar to lysosome-associated7.2
membrane glycoprote
407829AA045084Hs.29725Homo sapiens cDNA FLJi31977.2
fis, clone NT2RP3004451
409731AA125985Hs.56145thymosin, beta, identified7.2
in neuroblasioma cells
404253#(NOCAT) 0 7.1
424120T80579Hs.290270ESTs 7.1
30 429126AW172356Hs.99083ESTs 7.1
413573AI733859Hs.149089ESTs 7.1
421464AA291553Hs.190086ESTs 7.0
430388AA356923Hs.240770nuclear cap binding 7.0
protein subunit 2,
20kD
437938A1950087 ESTs; Weakly similar 7.0
to Gag-Pol polyprotein
[M.mus
35 4203112079734Hs.97206hunfingtin interacting 7.0
protein 1
444743AA045648Hs.11817nudix (nucleoside diphosphate7.0
linked moiety X)-typ
415138C18356Hs.78045fissue factor pathway 6.9
inhibitor 2 TFPI2
410568AW162948Hs.64542pre-mRNA cleavage factor6.9
Im (68kD)
429418AI381028Hs.99283ESTs 6.9
409178BE393948Hs.50915kallikrein 5 6.9
446608N75217Hs.257846ESTs 6.9
425905AB032959Hs.161700KIAA1133 protein 6.9
428532AF157326Hs.184786TBP-interacting protein6.9
433426H69125Hs.133525ESTs 6.9
45 431322AW970622 gb:EST382704 MADE resequences,6.8
MAGK Homo Sapiens
437960AI669586Hs.222194ESTs 6.8
423244AL039379Hs.209602ESTs, Weakly similar 6.8
to ubiquitous TPR motif,
Y is
424085NtuL002914Hs.139226replication factor C 6.8
(activator 1) 2 (40kD)
448674W31178Hs.154140ESTs 6.8
438122AI620270Hs.129837ESTs 6.8
440048AA897461Hs.158469ESTs, Weakly similar 6.7
to envelope protein
[H.sapien
418478038945Hs.i cyclin-dependent kinase6.7
174 inhibitor 2A (melanoma,
p1
407162N63855Hs.142634zinc finger protein 6.7
410804064820Hs.66521Machado-Joseph disease 6.7
(spinocerebellar ataxia
3,
55 424639AI917494Hs.131329ESTs 6.7
432415T16971Hs.289014ESTs 6.7
421470827496Hs.1378annexin A3 6.7
445459AI478629Hs.158465ESTs 6.7
418203X54942Hs.83758CDC28 protein kinase 6.6
2
432809AA565509Hs.131703ESTs 6.6
409234A1879419Hs.27206ESTs 6.6
438394BE379623Hs.27693CGI-124 protein 6.6
452097AB002364Hs.27916ADAM-TS3 ; a disintegrin-like6.6
and metalloproteas
453745AA952989Hs.63908Homo Sapiens HSPC316 6.6
mRNA, partial cds
65 414136AA812434Hs.178227ESTs 6.6
423248AA380177Hs.125845ribulose-5-phosphate-3-epimerase6.6
454018AW016892Hs.241652ESTs 6.6
452281T93500Hs.28792ESTs 6.5
424620AA101043Hs.151254kallikrein 7 (chymotryptic;6.5
stratum comeum)
452594AU076405Hs.29981solute canter family 6.5
26 (sulfate transporter),
me ~
434149243829Hs.19574ESTs, Weakly similar 6.5
to katanin p80 subunit
[H.sap
425776025128Hs.159499parathyroid hormone 6.4
receptor2
418677583308Hs.87224SRY (sex determining 6.4
region Y)-box 5
409517X90780Hs.54668iroponin I, cardiac 6.4
75 432666AW204069Hs.129250ESTs, Weakly similar 6.4
to unnamed protein
product [H
448706AW291095Hs.21814class II cytokine receptorZCYTOR76.4
429163AA884766 gb:am20a10.s1 Soares 6.4
NFL-T-GBC_S1 Homo Sapiens
cDN
413582AW295647Hs.71331Homo Sapiens cDNA: FLJ219716.4
fis, clone HEP05790
419917AA320068Hs.93701Homo Sapiens mRNA; cDNA6.4
DKFZp434E232 (from
clone
8~ 424153AA451737Hs.141496MAGE-like2 6.4
434265AA846811Hs.130554Homo Sapiens cDNA: FLJ23089G.4
fis, clone LNG07061
435082AA664273Hs.186104Homo Sapiens cDNA FLJ138036.4
fis, clone THYR01000187
441081AI584019Hs.169006ESTs, Moderately similar6.4
to plakophilin 2b [H.sapi
443539A1076182Hs.134074ESTs 6.4
198
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
443830A1142095Hs.143273ESTs 6.4
452606N45202Hs.90012Homo Sapiens cDNA: FLJ234416.4
fis, clone HS100612
418384AW1d9266Hs.25130ESTs 6.3
425371D49441Hs.155981mesothelin 6.3
429441AJ224172Hs.204096lipophilin B (uteroglobin6.3
family member), prostate
449048245051Hs.22920similar to S68401 (cattle)6.3
glucose induced gene
437117AL049256Hs.122593ESTs 6.3
449579AW207260Hs.134014prostate cancer associated6.3
protein 6
453370AI470523Hs.182356ESTs, Moderately similar6.3
to Uanslafion initiation
1 426514BE616633Hs.301122bone morphogenefic protein'
~ 7 (osteogenic protein 6.3
1
415076NM Hs.77890guanylale cyclase 1, 6.3
000857 soluble, beta 3
408155AB014528Hs.43133KIAA0628 gene product 6.2
452904AL157581Hs.30957Homo Sapiens mRNA; cDNA6.2
DKFZp434E0626 (from
clone
439138AI742605Hs.193696ESTs 6.2
15 457030A1301740Hs.173381dihydropyrimidinase-like6.2
2
436281AW411194Hs.120051ESTs 6.1
407385AA610150Hs.272072ESTs, Moderately similar6.1
to ALU7_HUMAN ALU SUBFA
406815AA833930Hs.288036iRNA isopentenylpyrophosphate6.1
transferase
430437AI768801Hs.169943Homo Sapiens cDNA FLJ135696.1
fis, clone PLACE1008369
428743AL080060Hs.301549Homo Sapiens mRNA; cDNA6.1
DKFZp564H172 (from
clone
415139AW975942Hs.4852dESTs 6.1
417404NM Hs.82101-plecksUin homology-like6.1
007350 domain, family A, memt~er
433527AW235613Hs.133020ESTs 6.1
449448D60730Hs.57471ESTs 6.1
457733AW974812Hs.291971ESTs 6.1
457979AA776655Hs.270942ESTs ~ 6.1
422867L32137Hs.1584cartilage oligomeric 6.0
matrix protein
423554M90516Hs.1674glutamine-fructose-6-phosphate6.0
Uansaminase 1
421502AF111856Hs.105039solute carrier family 6.0
34 (sodium phosphate),
membe
412733AA984472Hs.74554KIAA0080 protein 6.0
422095AI868872Hs.288966ceruloplasmin (ferroxidase)6.0
449347AV649748Ns.295901ESTs 6.0
440870AI687284Hs.150539Homo Sapiens cDNA FLJ137936.0
fis, clone THYR01000085
437478AL390172Hs.118811ESTs 6.0
35 411598BE336654Hs.70937H3 histone family, member6.0
K
418134AA397769Hs.86617ESTs 6.0
418845AA852985Hs.89232chromobox homolog 5 6.0
(Drosophila NP1 alpha)
452039A1922988Hs.172510ESTs 6.0
410555092649Hs.64311a disintegrin and metalloproteinase5.9
domain 17 (tum
40 412719AW016610Hs.129911ESTs 5.9
410566AA373210Hs.43047Homo Sapiens cDNA FLJ 5,9
13585 fis, clone PLACE1009150
437099N77793Hs.48659ESTs, Highly similar 5.9
to LMA1 HUMAN LAMININ
ALPH
453431AF094754Hs.32973glycine receptor, beta 5.9
40B920AL120071Hs.48998fibroneciin leucine 5,9
rich Uansmembrane protein
2
45 417866AW067903Hs.82772"collagen, type XI, 5.9
alpha 1"
420440NM_002407Hs.97644mammagiobin 2 5.9
430291AV660345Hs.238126CGI-49 protein 5.9
405547#(NOCAT) 0 5.9
427510247542Ns.179312small nuclear RNA activafing5.9
complex, polypepiide
5O 435793A8037734Hs.4993ESTs 5.8
427975AI536065Hs.122460ESTs 5.8
428949AA442153Hs.104744ESTs, Weakly similar 5.8
to AF2088551 BM-013
[H.sapie
452693179153Hs.48589zinc finger protein 5,8
228
440138A8033023Hs.6982hypothetical protein 5.8
FLJ10201
421246AW582962Hs.300961ESTs, Highly similar 5.8
5 to AF1518051 CGI-47
protein
445424AB028945Hs.12696cortactin SH3 domain-binding5.8
protein
448186AA262105Ns.4094Homo Sapiens cDNA FLJ142085.8
fis, clone NT2RP3003264
425154NM_001851Hs.154850collagen, type IX, alpha5.7
1
419335AW960146Hs.284137Homo Sapiens cDNA FLJ128885.7
fis, clone NT2RP2004081
60 420637AW976153 gb:EST388262 MAGE resequences,5.7
MAGN Homo Sapiens
431924AK000850Hs.272203Homo Sapiens cDNA FLJ208435.7
fis, clone ADKA01954
446868AV660737Hs.135100ESTs 5.7
452971A1873878Hs.91789ESTs 5.7
428927AA441837Hs.90250ESTs 5.7
65 425282AW163518Hs.155485hunfingtin interacting 5.7
protein 2
419247S65791Hs.89764fragile X mental retardafion5.7
1
445640AW969626Hs.31704ESTs, Weakly similar 5.7
to KIAA0227 [H.sapiens]
422938NM-001809Hs.1594centromere protein A 5.6
(l7kD)
447078AW885727Hs.301570ESTs 5.6
421247BE391727Hs.102910general Uanscription 5,6
factor IIH, polypeptide
4 (5
407896D76435Hs.41154Zic family member 1 5.6
(odd-paired Drosophila
homolog
436556A1364997Hs.7572ESTs 5.6
417830AW504786Hs.132808epithelial cell transforming5.6
sequence 2 oncogene
429826N93266Hs.40747ESTs 5.6
75 432030AI908400Hs.143789ESTs 5.6
443270NM_004272Hs.9192Homer, neuronal immediate5.5
early gene,18
453900AW003582Hs.226414ESTs, Weakly similar 5.5
to ALUS-HUMAN ALU SUBFAMIL
411096080034Hs.68583mitochondrial intermediate5.5
pepfidase
419558AW953679Hs.278394ESTs 5.5
427386AW836261Hs.177486amyloid beta (A4) precursor5.5
protein (protease next
427961AW293165Hs.143134ESTs 5.5
404561#(NOCAT) 0 5.5
429682NM-006306Hs.211602SMC1 (sUuctural maintenance5.5
of chromosomes 1, yea
407216N91773Hs.102267_ lysyloxidase 5.5
199
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
410658AW105231Hs.192035ESTs 5.5
413930M86153Hs.75618RA811A, member RAS oncogene5.5
family
414315224878 gb:HSB65D052 STRATAGENE5.5
Human skeletal muscle
cD
427878005766Hs.181022CGI-07 protein 5.5
431041AA490967Hs.105276ESTs 5.5
441645A1222279Hs.201555ESTs 5.5
428071AF212848Hs.182339transcdptionfactorESE-385.4
436406AW105723Hs.125346ESTs 5.4
429181AW979104Hs.294009ESTs 5.4
410909AW898161Hs.53112ESTs, Weakly similar 5.4
to ALUB HUMAN ALU SUBFAMIL
424345AKOOi380Hs.145479Homo Sapiens cDNA FLJ105185.4
tis, clone NT2RP2000814
451996AW514021Hs.245510ESTs 5.4
449318AW236021Hs.108788ESTs, Weakly similar 5.4
to zeste [D.melanogaster)
441433AA933809Hs.42746ESTs 5.4
4454958E622641Hs.38489ESTs 5.4
410153BE311926Hs.15830Homo Sapiens cDNA FLJ126915.4
fis, clone NT2RM4002571
442611BE077155Hs.177537ESTs 5.4
452401NM Hs.29352tumor necrosis factor, 5.4
007115 alpha-induced protein
6
453161AA628608Hs.61656ESTs 5.4
419948AB041035Hs.93847NADPH oxidase 4 5.3
427718AI798680Hs.25933ESTs 5.3
453867A1929383Hs.108196HSPC037 protein 5.3
422634NM Hs.118821CGI-62 protein 5.3
016010
444478W07318Hs.240M-phase ptiosphoprotein5.3
1
428002AA418703 gb:zv98c03.;1 Soares 5.3
NhHMPu-S1 Homo Sapiens
cDNA c
443486NM Hs.9d50zinc finger protein 5.3
003428 84 (HPF2)
451177AI969716Hs.19034ESTs 5.3
408298AI745325Hs.271923ESTs; Moderately similar5.3
to 1!!! ALU SUBFAMILY
S82
435867AA954229Hs.114052ESTs 5.3
423698AA329796Hs.1098DKFZp434J1813prolein 5.3
448543AW897741Hs.21380Homo Sapiens mRNA; cDNA5.3
DKFZp586P1124 (from
clone
427660AI741320Hs.114121Homo Sapiens cDNA: FLJ232285.3
tis, clone CAE06654
430345AK000282Hs.239681hypothetical protein 5.3
FLJ20275
433222AW514472Hs.238415ESTs, Moderately similar5.3
to ALUB_HUMAN ALU SUBFA
3 449532W74653Hs.271593ESTs 5.3
S
452822X85689Hs.288617Homo Sapiens cDNA: FLJ226215.3
tis, clone HSI05658
437641AA811452Hs.291911ESTs 5.2
418379AA218940Hs.137516tidgetin-like 1 5.2
416530062801Ns.79361kallikrein 6 (neurosin,5.2
zyme)
433589AA886530Hs.188912ESTs 5.2
409143AW025980Hs.138965ESTs 5.2
410303AA32d597Hs.21851Homo Sapiens cDNA FLJ129005.2
fis, clone NT2RP2004321
413384Ntv1,000401Hs.75334exostoses (multiple) 5.2
2
424698AA16d366Hs.151973hypothetical protein 5.2
FLJ10378
45 431229AA496479 gb:zv37h05.r1 Soares 5.2
ovary tumor NbHOT Homo
sapien
433377AI752713Hs.43B45ESTs 5.2
445236AK001676Hs.12457hypothetical protein 5.2
FLJ10814
406367#(NOCAT) 0 5.2
442500AI819068Hs.209122ESTs 5.2
5 450101AV649989Hs.2d385Numan hbc647 mRNA sequence5.2
0
419140AI982647Hs.215725ESTs 5.2
411078A1222020Hs.182364ESTs, Weakly similar 5.2
to 25 kDa irypsin inhibitor
[
423020AA383092Hs.1608replication protein 5.2
A3 (l4kD)
427061A8032971Hs.173392KIAAi145 protein 5.2
S 439042AW979172 gb:EST391282 MADE resequences,5.2
5 MAGP Homo Sapiens c
452930AW195285Hs.194097ESTs 5.2
417791AW965339Hs.111471ESTs 5.1
433277W27266Hs.151010ESTs 5.1
447835AW591623Hs.t64129ESTs 5.1
60 434401A1864131Hs.71119Putative prostate cancer5.1
tumor suppresser
437496AA452378Hs.170144Homo sapiens mRNA; cDNA5.1
DKFZp547J125 (from
clone D
418849AW474547Hs.53565ESTs, Weakly similar 5.1
to 80491.1 [C.elegans]
428093AW594506Hs.104830ESTs 5.1
408621A1970672Hs.46638chromosome 11 open reading5.1
frame 8; fetal brain
(
453096AW294631Hs.11325ESTs ~ 5.1
418852BE537037Hs.273294hypothetical protein 5.1
FLJ20069
436787AA908554Hs.192756ESTs 5.1
446577A8040933Hs.15420KIAA1500 protein 5.1
437267AW511443Hs.258110ESTs 5.0
70 419423D26488Hs.90315KIAA0007 protein 5.0
404939 0 5.0
439052AF085917Hs.37921ESTs 5.0
447020T27308Hs.16986hypotheticalprotein 5.0
FLJ11046
453878AW964440Hs.19025ESTs 5.0
75 410824AW994813Hs.33264ESTs 5.0
427701AA411101Hs.221750ESTs 5.0
424602AK002055Hs.301129Homo Sapiens clone 238595.0
mRNA sequence
430044AA464510Hs.152812EST cluster (not in 5.0
UniGene)
417423AA197341Hs.111164ESTs 5.0
g0 421477A1904743Hs.104650hypothetical protein 5.0
FLJ10292
433384A1021992Hs.124244ESTs 5.0
434160BE551196Hs.114275ESTs 5.0
443555N71710Hs.21398ESTs, Moderately similar5.0
to GNPI_HUMAN GLUCOSAM
416198H27332Hs.99598ESTs 4.9
200
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
424539L02911Hs.150402acfivin A receptor, 4.9
type I
436645AW023424Hs.156520ESTs 4.9
417251AW015242Hs.99488ESTs; Weakly similar 4.9
to ORF YKR074w [S.cerevisiae]
447207AA442233Hs.17731hypothefical protein 4.9
FLJ12892
416565AW000960Hs.44970ESTs 4.9
425292NM Hs.15554537 kDa leucine-rich 4.9
005824 repeat (L88) protein
435420AI928513Hs.59203ESTs 4.9
435532AW291488Hs.117305ESTs 4.9
443268AI800271Hs.129445hypotheficalprotein 4.9
FLJ12496
446140AA356170Hs.26750Homo Sapiens cDNA: FLJ219084.9
fis, clone HEP03830
452891N75582Hs.212875ESTs, Weakly similar 4.9
to KIAA0357 [H.sapiens]
431130NM-006103Hs.2719epididymis-specific; 4.9
whey-acidic protein
type; fou
408938AA0590i3Hs.22607ESTs 4.9
432842AW674093Hs.279525hypothetical protein 4.9
PR02605
436754A1061288Hs.133437ESTs, Moderately similar4.9
to gonadotropin inducible
442573H93366Hs:7567Branched chain aminotransferase4.9
1, cytosolic, 0215
409049AI423132Hs.146343ESTs 4.9
422475AL359938Hs.117313Meis (mouse) homolog 4.9
3
447112H17800Hs.7154ESTs 4.9
458627AW088642Hs.97984ESTs; Weakly similar 4.8
to WASP-family protein
[H.sap
431689AA305688Hs.267695UDP-Gal:betaGIcNAc beta4.8
1,3-galactosylUansferase,
410530M25809Hs.64173ESTs,HighlysimilartoVAB14.8
FIUMANVACUOLARAT
429414AI783656Hs.202095empty spiracles (Drosophila)4.8
homolog 2
418882NM Hs.89433ATP-binding cassette, 4.8
004996 sub-family C (CFTRIMRP),
mem
422505AL120862Hs,124165ESTs; (HSA)PAP protein 4.8
(programmed cell death
9;
425977815138Hs.165570Homo Sapiens clone 250524.8
mRNA sequence
428555NM Hs.184908integrin, beta 8 4.8
002214
452909NM Hs.30985pannexin 1 4.8
015368
449535W15267Hs.23672low density lipoproteind.8
receptor-related protein
6
452232AW020603Hs.271698ESTs 4.8
409732NM Hs.56148NY-REN-58 antigen 4.8
016122
415115AA214228Hs.127751hypothetical protein 4.7
423161AL049227Hs.124776Homo Sapiens mRNA; cDNA4.7
DKFZp564N1116 (from
clop
441085AW136551Hs.181245Homo Sapiens cDNA FLJi25324.7
fis, clone NT2RM4000200
423575C18863Hs.i63443ESTs 4.7
415211R64730.compHs.155986ESTs; Highly similar 4.7
to SPERM SURFACE PROTEIN
SP1
418804AA809632 gb:nz17h04.s1 NC1 CGAP-GCBt4.7
Homo Sapiens cDNA clo
428405Y00762Hs.2266cholinergic receptor, 4.7
nicotinic, alpha polypeptide
432865AI753709Hs.152484ESTs 4.7
433330AW207084Hs.132816ESTs 4.7
453047AW023798Hs.286025ESTs 4.7
421308AA687322Hs.192843ESTs 4.7
456273AF154846Hs.1148zinc finger protein 4.7
443933A1091631Hs.135501Homo Sapiens two pore 4.7
potassium channel KT3.3
4S 434551BE387162Hs.280858ESTs, Highly similar 4.7
to XPB_HUMAN DNA-REPAIR
PRO
440351AF030933Hs.7179RAD1 (S. pombe) homolog4.7
426300U15979Hs.169228delta-like homolog (Drosophila)4.7
453775NM Hs.35120replication factor C 4.7
002916 (activator 1) 4 (37kD)
446102AW168067Hs.252956ESTs 4.7
420547AF155140Hs.98738gonadotropin-regulated 4.7
testicular RNA helicase
429486AF155827Hs.203963hypothetical protein 4.7
FLJ10339
429944813949Hs.226440Homo Sapiens clone 248814.7
mRNA sequence
433042AW193534Hs.281895Homo Sapiens cDNA FLJ116604.7
fis, clone HEMBA1004610
434988AI418055Hs.161160ESTs 4.6
452571W31518Hs.34665ESTs 4.6
434361AF129755Hs.117772ESTs 4.6
406400#(NOCAT) 0 4.6
410227AB009284Hs.61152exosioses (multiple)-like4.6
2 ~
419945AW290975Hs.118923ESTs 4.6
428301AW628666Hs.98440ESTs 4.6
430153AW968128 gb:EST380338 MAGE resequences,4.6
MAGJ Homo Sapiens c
431349AA503653Hs.156942ESTs, Moderately similar4.6
to ALU2 HUMAN ALU SUBFA
446254BE179829Hs.179852Homo Sapiens cDNA FLJ128324.6
fis, clone NT2RP2003137
447505AL049266Hs.18724Homo Sapiens mRNA; cDNA4.6
DKFZp564F093 (from
clone
448027AI458437Hs.177224ESTs 4.6
449611A1970394Hs.197075ESTs 4.6
459574A1741122Hs.101810Homo Sapiens cDNA FLJ 4.6
14232 fis, clone NT2RPd000035
409928AL137163Hs.57549hypothetical protein 4.6
dJ473B4
409387AW384900Hs.123526ESTs 4.6
424078A8006625Hs.139033paternally expressed 4.6
gene 3
435244N77221Hs.187824ESTs 4.6
404996#(NOCAT) 0 4.6
407905AW103655Hs.252905ESTs 4.6
411560AW851186 gb:IL3-CT0220-150200-071-H054.6
CT0220 Homo Sapiens
c
424341AA385074 gb:EST98673 Thyroid 4.6
Homo Sapiens cDNA 5'
end simil
441675AI914329Hs.5461ESTs 4.6
452172H00797Hs.133207Homo Sapiens mRNA for 4.6
KIAA1230 protein, parfial
c4
420276AA290938Hs.190561ESTs, Highly similar 4.5
to mosaic protein LR11
[H.sap
402820#(NOCAT) 0 4.5
419699AA248998Hs.31246ESTs 4.5
422529AW015128Hs.256703ESTs 4.5
438018AK001160Hs.5999hypotheficalprotein 4.5
FLJ10298
441826AW503603Hs.129915phosphotriesterase related4.5
453931AL121278Hs.25144ESTs 4.5
201
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
435538AB0115d0Hs.4930low density lipoprotein4.5
receptor-related protein
4
457465AW301344Hs.195969ESTs 4.5
418848A1820961Hs.193465ESTs 4.5
408321AW405882Hs.44205cortislafin d.5
447499AW262580Hs.14767dKIAAi621 protein 4.5
424513BE385864Hs.149894mitochondria) translalional4.5
initiation factor 2
432731831178Hs.287820fibronecfin 1 4.5
448275BE514434Ns.20830synapfic Ras GTPase 4.5
acfivating protein
1 (homolog
430371D87466Hs.2d0112KIAA0276 protein d.5
448693AW004854Hs.228320Homo sapiens cDNA: FLJ235374.5
fis, clone LNG07690
407289AA135159Hs.203349Homo Sapiens cDNA FW121494.d
fis, clone MAMMA100042
448141AI471598Hs.197531ESTs 4.4
434699AA643687Hs.149425Homo Sapiens cDNA FLJ119804.4
fis, clone HEM8B1001304
417718T86540Hs.193981ESTs 4.d
1 436464A1016176Hs.269783ESTs, Weakly similar 4.4
S to ALU1 FIUMAN ALU
SUBFAMIL
427528AU077143Hs.179565minichromosome maintenance4.4
deficient (S. cerevisia
409092AI735283Hs.172608ESTs 4.d
416241N52639Hs.32683ESTs 4.4
432005AA524190Hs.120777ESTs, Weakly similar 4.4
to ELL2_HUMAN RNA POLYMER
440234AW117264Hs.126252ESTs 4.4
448743A8032962Hs.21896KIAAii36 protein 4.4
451389N73222Hs.21738KIAA1008 protein 4.4
453331A12d0665Hs.8895ESTs 4.4
454036AA374756Hs.93560ESTs, Weakly similar 4.4
to unnamed protein
product [H
448133AA723157Hs.73769tolate receptor 1 (adult)4.4
429597NM_003816Hs.2442a disintegdn and meialloproteinase4.4
domain 9 (melt
453279AW893940Hs.59698ESTs 4.4
409459D86407Hs.54481low density lipoproteind.4
receptor-related protein
8
431708AI698136Hs.108873ESTs 4.4
3 433906A1167816Hs.43355ESTs 4.4
0
437958BE139550Hs.121668ESTs 4.4
441423A1793299Hs.126877ESTs 4.4
429876AB028977Hs.225974KIAA1054 protein 4.3
446770AV660309Hs.154986ESTs, Weakly similar 4.3
to AF1373861 plasmolipin
[H.
3 412078X69699Hs.731d9paired box gene 8 4.3
5
422093AF151852Hs.111449CGI-94 protein 4.3
423123NM-012247Hs.124027SELENOPHOSPHATE SYNTHETASE4.3
; Human selenium
448390AL035414Hs.21068hypoiheficalprotein 4.3
453628AW243307Ns.170187ESTs 4.3
40 449722BE280074Hs.23960cyclin B1 4.3
436679AI127483Hs.120451ESTs, Weakly similar 4.3
to unnamed protein
product (H
431592869016Hs.293871ESTs, Weakly similar 4.3
to ALU1 HUMAN ALU SUBFAMIL
432383AK000144Hs.274449Homo Sapiens cDNA FLJ201374.3
fis, clone COL07137
419926AW900992Hs.93796DKFZP586D2223 protein 4.3
45 452367U71207Hs.29279eyes absent (Drosophila)4.3
homolog 2
401644#(NOCAT) 0 4.3
410044BE566742Hs.58169highly expressed in 4.3
cancer, rich in leucine
heptad
413775AW409934Hs.75528nucleolar GTPase 4.3
424296AI631874Hs.169391ESTs 4.3
50 431118BE264901Hs.250502carbonic anhydrase VIII4.3
432201A1538613Hs.135657TMPRSS3a mRNA for serine4.3
protease (ECHOS1) (TADG-1
451073AI758905Hs.206063ESTs 4.3
451592A1805416Hs.213897ESTs 4.3
452453A1902519 gb:OV-BT009-10119&051 4.3
BT009 Homo Sapiens
cDNA, m
5 441020W79283Hs.35962ESTs d.2
S
439024896696Hs.35598ESTs 4.2
453619H87648Hs.33922H.sapiens novel gene 4.2
from PAC 117P20, chromosome
1
453459BE047032Hs.257789ESTs 4.2
408427AW194270Hs.177236ESTs 4.2
60 419311AA689591 gb:nv66a12.s1 NCI-CGAP_GC814.2
Homo Sapiens cDNA clo
426460D79721Hs.183702Homo Sapiens cDNA FLJ117524.2
fis, clone HEMBA1005582
444540AI693927Hs.265165ESTs 4.2
452943BE247449Hs.31082hypothetical protein 4.2
FLJ10525
453913AW004683Ns.233502ESTs 4.2
65 417847A1521558Hs.288312Homo Sapiens cDNA: FLJ223164.2
fis, clone HRC05262
428856AA436735Hs.183171Homo Sapiens cDNA: FLJ220024.2
fis, clone HEP06638
428679AA431765 gb:zw80c03.s1 Soares 4.2
tesfis NHT Homo Sapiens
cDNA
441006AW605267Hs.7627CGI-60 protein ' 4.2
436209AW850417Hs.254020ESTs, Moderately similar4.2
to unnamed protein
produc
70 446936H10207Hs.47314ESTs 4.2
406076AL390179Hs.137011Homo Sapiens mRNA; cDNA4.2
DKFZp547P134 (from
clone
428819AL135623Hs.193914KIAA0575 gene product 4.2
406671AA129547Hs.285754met proto-oncogene (hepatocyte4.2
growth factor recep
418432M14156Hs.85112insulin-like growth 4.2
factor 1 (somatomedia
C)
75 417048A1088775Hs.55498geranylgeranyldiphosphate4.2
synthase 1
431750AA514986Hs.283705ESTs 4.2
439314AA382413Hs.178144ESTs 4.2
448582A1538880Hs.94812ESTs 4.2
449554AA682382Hs.59982ESTs 4.2
g 455700BE068115 gb:CM1-BT0368-061299-060-g074.2
0 BT0368 Homo Sapiens
c
409073AA063458 gb:zt71 a07.s1 Soares~ineal~land-N3HPG4.1
Homo sapie
433929AI375499Hs.27379ESTs 4.1
415457AW081710Hs.7369ESTs, Weakly similar 4.1
to ALU1 HUMAN ALU SUBFAMIL
444381HE387335Hs.283713. ESTs 4.1
202
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
451024AA442176 gb:zw63b08.r1 Soares 4.1
total fetus Nb2HF8_9w
Homo so
415539AI733881Hs.72472BMPR-Ib; bone morphogenetic4.1
protein receptor, typ
421515Y11339 Hs.105352GaINAc alpha-2, 6-sialyltransferase4.1
I, long form
420736AI263022Hs.82204ESTs 4.1
453293AA382267Hs.10653ESTs 4.1
409564AA045857Hs.54943fracture callus 1 (rat)4.1
homolog
418378AW962081 gb:EST374154 MAGE resequences,4.1
MAGG Homo Sapiens
429628H09604 Hs.13268ESTs 4.1
439635AA477288Hs.94891Homo Sapiens cDNA: FLJ227294.1
fis, clone HSI15685
1 440452AI925136Hs.55150ESTs, Weakly similar 4.1
~ to CAYP_HUMAN GALCYPHOStN
443695AW204099Hs.112759ESTs, Weakly similar 4.1
to AF1267801 retinal
short-c
448816AB033052Hs.22151KIAA1226 protein 4.1
452795AW392555Hs.18878hypotheficalprotein 4.1
FLJ21620
443171BE281128Hs.9030TONDU 4.1
1$ 425322U63630 Hs.155637protein kinase; DNA-acfivated;4.1
catalytic polypep6
442717888362 Hs.180591ESTs, Weakly similar 4.1
to RO6F6.5b [C.elegans]
414747U30872 Hs.77204centramere protein F 4.1
(3501400kD, mitosin)
417300AI765227Hs.55610solute carrier family 4.1
30 (zinc transporter),
membe
417389BE260964Hs.82045Midkine (neurite growth-promoting4.1
factor 2)
20 448105AW591433Hs.170675ESTs, Weakly similar 4.1
to TMS2_HUMAN TRANSMEMBR
419131PA4D6293Hs.301622ESTs 4.1
406348#(NOCAT) 0 4.1
419750AL079741Hs.183114Homo Sapiens cDNA FLJ142364.1
fis, clone NT2RP4000515
419790U79250 Hs.93201glycerol-3-phosphate 4.1
dehydrogenase 2 (mitochondria
25 420908AL049974Hs.100261Homo Sapiens mRNA; cDNA4.1
DKFZp564B222 (from
clone
421039NM-003478Hs.101299cullin 5 4.t
426890AA393167Hs.41294ESTs d.1
428571NM_006531Hs.2291Probe hTg737 (polycystic4.1
kidney disease, autosomal
452834Ai638627Hs.105685ESTs 4.1
30 428771A8028992Hs.193143KIAA1069 protein 4.0
437949U78519 Hs.41654ESTs 4:0
450568AL050078Hs.25159Homo Sapiens cDNA FLJ107844.0
fis, clone NT2RP4000448
424081NM_006413Hs.139120ribonuclease P (30kD) 4.0
418375NM 003081Hs.84389synaptosomal-associated4.0
protein, 25kD
35 447204AI366881Hs.157897ESTs,ModeratelysimilartoALUC_HUMANiIIIALUCL4.0
407910AA650274Ns.41296fibronectin leucine d.0
dch transmembrane protein
3
412314AA825247Hs.250899heat shock factor binding4.0
protein 1
436291BE568452Hs.5101ESTs; Highly similar 4.0
to protein regulating
cytokin
450654AJ245587Hs.25275Kruppel-type zinc finger4.0
protein
40 426991AK001536Hs.285803Homo Sapiens cDNA FLJ128524.0
fis, clone NT2RP2DD3445
409365AA702376Hs.226440Homo Sapiens clone 248814.0
mRNA sequence
410784AW803201 gb:IL2-UM0077-070500-080-E064.0
UM0077 Homo Sapiens
c
413374NM-001034Hs.75319ribonucleotide reductase4.0
M2 polypepfide
413425F20956 gb:HSPD05390 HM3 Homo 4.0
Sapiens cDNA done 032-X4-1
45 417655AA780791Hs.14014ESTs, Weakly similar 4.0
to KIAA0973 protein
[H.sapien
424783AA913909Hs.153088TATA box binding protein4.0
(TBP)-associated factor,
425024839235 Hs.12407ESTs 4.0
445941A1267371Hs.172636ESTs 4.0
448595A8014544Hs.21572KIAA0644 gene product 4.0
50 453448AL036710Hs.209527ESTs 4.0
458944N93227 Hs.98403ESTs 4.0
400284 Estrogen receptorl 4.0
441134W29092 Hs.7678cellular refinoic acid-binding4.0
protein 1
408796AA688292Hs.118553ESTs 4.0
55 408296AL117d52Hs.44155DKFZP586G1517protein 4.0
438913AI380429Hs.172445ESTs 4.0
402408 0 4.0
411630U42349 Hs.71119Putafive prostate cancerd.0
tumor suppressor
450701H39960 Hs.288467Homo Sapiens cDNA FLJ122804.0
fis, clone MAMMA10017d
60 439780AL109688 gb:Homo Sapiens mRNA 4.0
full length insert
cDNA clone
418301AW976201Hs.187618ESTs 4.0
420077AW512260Hs.87767ESTs 4.0
426572AB037783Hs.170623hypothe6calprotein FLJ111834.0
403721 0 4.0
65 411945AL033527Hs.92137v-myc avian myelocytomatosis4.0
viral oncogene homolo
408684861377 Hs.12727hypotheticalprotein 4.0
FLJ21610 '
414869AA157291Hs.72163ESTs 4.0
437980850393 Hs.278436KIAA1474 protein 4.0
451050AW937420Hs.69662ESTs 4.0
70
TABLE
14B:
Pkey: ber
Unique
Eos
probeset
idenfifier
num
CAT
number:
Gene
cluster
number
Accession:
Genbank
accession
numbers
PkeyCAT Accession
Number
409073109851 AA063458AA063018 AI444822
1
4107841221005-1AW803201
BE079700
BE062940
4115601249443AW851186
1 AW996967
BE143456
413425136885 F20956
1 AA129374
AA13374D
AW819878
414315143512-1224878
AA494098
F13654
AA494040
AA143127
418378174656 AW962081
1 AA218925
AA354237
418804179138-1AA809632
AI917245
AI701732
AA228406
419311183793_1AA689591AW974261 AA236240 A1077451
AA631399 AW974262
203
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
420637195241AW976153 AA278945 AA747691
1
424341238294_1AA385074 AA339054 AA339115 AW956359
428002285602-1AA418703 AA418711 BE071915 BE071920 BE071912
428679294049AA431765 AA432015
1
429163300543AA884766 AW974271 AA592975AA447312
1
430153313709AW968128 AA46B102 AA468165
1
431229330060AA496479 T89859 AW020056 AW135251 A1221100 AA628705
1 A1263148 T79074
431322331543_1AW970622 AA503009 AA502998 AA502989 AA502805T92188
434415385931BE177494 AW276909 AA632849
1
436812427323AW298067 AA731645 AA810101 AW194180 AI690673 AW978773
1
43793844573-2AI950087 N70208 897040 N36809 AI308119 AW967677 N35320
AI251473 H59397 AW971573 897278 W01059 AW967671 AA908598
AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391
BE328571 T75102 834725 AA884922 BE328517 AI219788
AA884444 N92578
F13493 AA927794 AI560251 AW874068 AL134043 AW235363
AA663345 AW008282 AA488964 AA283144 AI890387 AI950344
AI741346
AI689062 AA282915 AW102898 AI872193 AI763273 AW173586
AW150329 AI653832 AI762688 AA988777 AA488892 AI35639d
AW103813
I AI539642 AA642789 AA856975 AW505512 AI961530 AW629970
S BE612881 AW276997 AW513601 AW512843 AA044209 AW856538
AA180009 AA337499 AW961101 AA251669 AA251874 AI819225
AW205862 AI683338 AI858509 AW276905 AI633006 AA972584
AA908741
AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729
H60052 T92487 A1022058 AA780419 AA551005 W80701 AW613456
AI373032 AI564269 F00531 H83488 W37181 W78802 866056
A1002839 867840 AA300207 AW959581 T63226 F04005
438966467436AW979074 AA834841 AA828650
1
438993_ AA828995 AA834879 AI926361
467651
1
439042468079AW979172 AA829595 896050
1
43978047673 AL109688 823665 826578
1
442438542469AA995998 A1916584 861781 T77332 F07756 F08149 F07647
1
449034794817_1A1624049 AW117770 A1858360
45102485565 AA442176 AA259181 -.
1
452453918300AI902519 AI902518 AI902516
1
4557001351264BE068115 BE068104 BE068102 BE068096 BE068i03 BE068154
1 BE068198
458861798085A1630223 A1630470
1
TABLE4C:
1
Pkey:
Unique
number
corresponding
to
an
Eos
probeset
Ref: The 7 digit numbers in this column are Genbank Identifier
Sequence (GI) numbers. "Dunham 1. et al." refers to the publication
source. entitled "The DNA sequence of
human
chromosome
22"
Dunham,
et
al.
(1999)
Nature
402:489-495
SUand:Indicates
DNA
strand
from
which
exons
were
predicted
Nt~osition:
Indicates
nucleotide
positions
of
predicted
exons
PkeyRef Strand Nt_position
4016448576138Plus 82655-83959
4024089796239Minus 110326-110491
4026069909429Minus 81747-82094
4028206456853Minus 82274-82443
4033819438267Minus 26009-26178
4036578843996Minus 156223-156370
4037217528046Minus 156647-157366
4042539367202Minus 55675-56055
4045619795980Minus 69039-70100
4049396862697Plus 175318-175476
4049966007890Plus 37999-38145,311652-38998,39727-39872,40557-40674,42351-42450
4055471054740Plus 124361-124520,124914-125050
5 4063489255985Minus 71754-71944
0
4063679256126Minus 58313-58489
4064009256298Plus 1553-1712,1878-2140,4252-4385,5922-6077
S 5 Table 15A lists about 499 genes up-regulated in ovarian cancer compared to
normal adult tissues that are likely to be extracellular or cell-surface
proteins. These were selected
as for Table 14A, except that the ratio was greater than or equal to 3.0, and
the predicted protein contained a structural domain that is indicative of
exUacellular localization (e.g.,
1g, fn3, egf, 7tm domains). Predicted protein domains are noted.
TABLE 15A:
A80UT 499
UP-REGULATED
GENES ENCODING
EXTRACELLULAR/CELL
SURFACE
PROTEINS,
OVARIAN
CANCER
VERSUS
NORMAL
ADULT TISSUES
Pkey: Primekey
UG ID: UniGene
ID
Title: UniGene
title
Prot. Dom.:
Predicted
protein
structural
domains
ratio: ration
tumor vs
normal
tissues
65
Pkey Ex. UG Titie Prot. Dom. ratio
Accn ID
415989 AI267700Hs.111128ESTs TM 42.7
428579 NM Hs.184942G protein-coupled TM 30.5
005756 receptor 64
428153 AW513143Hs.98367similar to SRY-boxTM 30.1
containing gene
17
70 436982 AB018305Hs.5378spondin 1, (f-spondin)SS 29.4
exUacellular matrix
427585 D31152Hs.179729collagen; type Ciq,Collagen27.0
X; alpha 1 (Schmid
metaphy
430691 C14187Hs.103538ESTs TM 26.2
418007 M13509Hs.83169Matrix metalloproteaseSS"Peptidase-M1020.6
1 (interstitial
collag
400292 AA250737Hs.72472BMPR-Ib; bone morphogeneticTM 20.6
protein rec '
75 424086 AI351010Hs.102267lysyl oxidase Lysyl-oxidase17.7
424905 NM_002497Hs.153704NIMA (never in pkise,pkinase17.4
mitosis gene a)-related
kin
427356 AW023482Hs.97849ESTs TM 17.4
407638 AJ404672Hs.288693EST TM 17.1
427469 AA403084Hs.269347ESTs TM 17.0
g0 438993 AA828995 integdn; beta 8 SS,integrin_816.7
421155 H87879Hs.102267lysyl oxidase SS 16.1
431989 AW972870Hs.291069ESTs SS 15.9
428976 AL037824Hs.194695ras homolog gene ras 15.1
family, member
I
416209 AA236776Hs.79078blAD2 (mitotic TM 15.0
. arrest deficient,
yeast, hom
204
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
413623AA825721Hs.246973ESTs TM 14.8
447350A1375572Hs.172634ESTs; HERO (c-erb-Bd)SS,TM,Furin-like,pkinase14.2
428227AA321649Hs.2248INTERFERON-GAMMA ILS 14.1
INDUCED PRO
452461N78223Hs.108106Uanscdptionfactor G9a,PHD 13.7
451106BE382701Hs.25960N-myc Myc_N term 13.6
416208AW291168Hs.41295ESTs TM 13.5
452249BE394412Hs.61252ESTs homeotwx 13.4
416566NM_003914Hs.79378cyclin A1 cyclin 12.8
416661AA634543Hs.79440IGF-II mRNA-bindingTM 12.6
protein 3
1 431725X65724Hs.2839Nome disease (pseudoglioma)SS,Cys knot12.3
~ .
458027L49054Hs.85195ESTs, Highly similarTM 12.2
to i(3;5)(q25.1;p34)
f
408460AA054726Hs.285574ESTs TM 12.2
415263AA948033Hs.130853ESTs histane 11.9
400298AA032279Hs.61635STEAP1 TM 11.8
15 421451AA291377Hs.50831ESTs TM 11.6
443715AI583187Hs.9700cyclin E1 cyclin 11.5
413472BE242870Hs.75379solute carrier TM,SDF 11.5
family 1 (glial
high affinity
g7
410102AW248508Hs.279727ESTs; SS 11.4
408562AI436323Hs.31141Homo Sapiens mRNA TM 11.4
for KIAAi 568
prote
20 442353BE379594Hs.49136ESTs TM 11.3
427344NM Hs.21425-hydroxytryptamineTM,neur-chan11.2
000869 (serotonin) receptor
3
453160AI263307Hs.146228ESTs histone 11.2
412723AA648459Hs.179912ESTs TM 11.1
400250 0 Hist_deacetyl+F10511.1
25 438167828363Hs.24286ESTs 7tm_1 11.1
434539AW748078Hs.214410ESTs ~ TM 10.9
450375AA009647Hs.8850a disintegrin and TM 10.8
metalloproteinase
domain
400289X07820Hs.2258Matrix MetalloproteinaseSS,hemopexin10.8
10 (Stromolysin
2
446142AI754693lis.145968ESTs Cadherin-C 10.7
term
3 421285NM-000102Hs.1363cylochrome P450, TM,p450 10.6
0 subfamily XVII
(steroid
433496AF064254Hs.49765VERY-LONG-CHAIN SS,TM 10.6
ACYL-COA SYNT
418506AA084248Ns.85339G protein-coupled TM 10.5
receptor 39
433447029195Hs.3281neuronal pentraxinSS 10.4
II
414245BE148072Hs.75850WAS protein family,TM 10.3
member t
35 426462059111Hs.i69993dermatan sulphate SS,LRRNT 10.3
proteoglycan 3
418601AA279490Hs.86368calmegin SS 10.3
415227AW821113Hs.72402ESTs TM 10.2
409269AA576953Hs.22972Homo Sapiens cDNA TM 10.1
FLJ13352 fis,
clone 0
426471M224d0Hs.170009transforming growthSS,EGF 9.8
factor, alpha
40 407881AW072003Hs.40968heparan sulfate SS 9.7
(glucosamine)
3-0-sulfotran
445537AJ2d5671Hs.12844EGF-like-domain; SS,EGF 9.7
multiple 6
414972BE263782Hs.77695KIAA0008 gene productTM 9.4
435509AI458679Hs.181915ESTs TM 9.3
445413AA151342Hs.12677CGI-147 protein UPF0099 9.2
4S 446999AA151520Hs.279525hypothetical proteinTM 9.1
PR02605
414569AF109298Hs.118258Prostate cancer TM 9.1
associated protein
1
406687M31126Hs.272620pregnancy specifichemopexin 9.0
beta-1-glycoprolein
9
408908BE296227Hs.48915serinelthreonine pkise,TM 9.0
kinase 15
451807W52854Hs.27099DKFZP564J0863 proteinTM 8.8
50 420159AI572490Hs.99785ESTs TM 8.8
432677NM-004482Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polyTM,Ricin-B 8.7
lectin
408829NM-006042Hs.48384heparan sulfate TM 8.7
(glucosamine)
3-0-sulfoUan
438885AI886558Hs.184987ESTs TM 8.7
447342AI199268Hs.19322ESTs; Weakly similarTM 8.6
to !!1! ALU SUBFAM
437212AI765021Hs.210775ESTs UDPGT 8.5
424717H03754Hs.152213wingless-type MMTVwnt 8.4
integration site
fami
450505NM-004572Hs.25051plakophilin 2 TM 8.4
436396AI683487Hs.299112Homo sapiens cDNA wnt 8.3
FLJ11d41 fis,
clone H
425695NM Hs.i59238protein tyrosine Y~hosphatase8.3
005401 phosphatase, non-receptor
447268AI370413Hs.36563Homo sapiens cDNA:Ribosomal-588.2
FLJ22418 fis,
clone
400195 0 TM 8.1
424906A1566086Hs.153716Homo Sapiens mRNA TM 8.1
for Hmob33 protein,
438202AW169287Hs.22588ESTs TM 8.1
439759AL359055Hs.67709Homc Sapiens mRNA TM 8.0
full length insert
cDN
65 453102NM-007197Hs.31664frizzled (Drosophila)TM,Fz,Frizzled8.0
homolog 10
424001W67883Hs.t37476KIAA1051 protein TM 8.0
442655AW027457Hs.30323ESTs TM 7.8
445657AW612141Hs.279575ESTs 7tnL1 7.8
426320W47595Hs.169300transforming growthSS,TGF-beta7.8
factor, beta 2
412170D16532Hs.73729very low density TM,IdI_recept_b,EGF7.6
lipoprotein receptor
436476AA326108Hs.53631ESTs TM 7.6
414132AI801235Hs.d8480ESTs TM 7.6
437789A1581344Hs.127812ESTs, Weakly similarTM 7.6
to AF1413261 RNA
450192AA263143Hs.24596RAD51-interacting TM 7.6
protein
75 408826AF216077Hs.d8376Homo Sapiens cloneTM 7.5
HB-2 mRNA sequence
413627BE182082Hs.246973ESTs TM 7.4
446293A1420213Hs.149722ESTs LIM,homeobox7.4
409242AL080170Hs.51692DKFZP434C091 proteinTM,7tm_7 7.3
450262AW409872Hs.271166ESTs, Moderately TM 7.3
similar to ALU7-HUMA
go 451659BE379761Hs.142d8ESTs, Weakly similarTM 7.3
to ALUB-HUMAN
A
444342NM Hs.10887similar to lysosome-associatedTM 7.2
014398 membrane g
429126AW172356Hs.99083ESTs 7trn_i 7.1
421464AA291553Hs.190086ESTs TM 7.0
420362079734Hs.97206hunfingtin interactingTM 7.0
. protein 1
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
444743AA045648Hs.11817nudix (nucleoside TM 7.0
diphosphaie linked
moiet
415138C1835fiHs.78045tissue factor pathwayKuni~ BPTI,G-gamma6.9
inhibitor 2 TFPI2
429418AI381028Hs.99283ESTs AAA 6.9
409178BE393948Hs.50915kallikrein 5 SS,trypsin 6.9
425905AB032959Hs.161700KIAA1133 protein TM 6.9
428532AF157326Hs.184786TBP-interacting TM 6.9
protein
433426H69125Hs.133525ESTs TM 6.9
448674W31178Hs.154140ESTs TM 6.8
432415T16971Hs.289014ESTs TM 6.7
418203X54942Hs.83758_ TM 6.6
CDC28 protein kinase
2
438394BE379623Hs.27693CGI-124 protein pro-isomerase6.6
452097AB002364Hs.27916ADAM-TS3 ; a disintegrin-likeReprolysin 6.6
and metal
453745AA952989Hs.63908Homo Sapiens HSPC316TGFb~propep6de6.6
mRNA, partial
c4
423248AA380177Hs.125845ribulose-5-phosphate-3-epimerasefilament 6.6
I 452281T93500Hs.28792ESTs TGF-beta 6.5
S
424620AA10i043Hs.151254kallikrein l (chymotryptic;SS,irypsin 6.5
stratum comeum
452594AU076405Hs.29981solute carver familyTM,Sulfate-Uansp6.5
26 (sulfate Uansporter)
434149243829Hs.19574ESTs, Weakly similarpkinase,fn36.5
to katanin p80
subun
425776025128Hs.159499parathyroid hormoneTM,7tm 2 6.4
receptor 2
409517X90780Hs.54668Uoponin I, cardiacY~hosphatase6.4
432666AW204069Hs.129250ESTs, Weakly similarTM 6.d
to unnamed protein
p
448706AW291095Hs.21814class II cytokine SS 6.4
receptor ZCYTOR7
413582AW295647Hs.71331Homo Sapiens cDNA:TM 6.4
FLJ21971 fis,
clone
424153AA451737Hs.141496MADE-like 2 TM 6.4
441081AI584019Hs.169006ESTs, Moderately PAX 6.4
similar to plakophilin
2b
443539A1076182Hs.134074ESTs TM 6.4
418384AW149266Hs.25130ESTs TM 6.3
425371D49441Hs.155981mesothelin SS 6.3
449048245051Hs.22920similar to S68401 SS 6.3
(cattle) glucose
induced g
437117AL049256Hs.122593ESTs TM 6.3
453370AI470523Hs.182356ESTs, Moderately ABC-tran 6.3
similar to UansIaGon
init
426514BE616633Hs.301122bone morphogeneticSS,TGF-beta6.3
protein 7 (osteogenic
p
452904AL157581Hs.30957Homo Sapiens mRNA;TM 6.2
cDNA DKFZp434E
457030AI301740Hs.173381dihydropyrimidinase-likeTM 6.2
2
436281AW411194Hs.120051ESTs TM 6.1
415139AW975942Hs.48524ESTs TM 6.1
449448D60730Hs.57471ESTs TM 6.1
457979AA776655Hs.270942ESTs TM 6.1
422867L32137Hs.1584cartilage oligomericSS,EGF,tsp_36.0
matrix protein
421502AF111856Hs.105039solute cartier TM 6.0
family 34 (sodium
phosphate)
412733AA984472Hs.74554KIAA0080 protein C2 6.0
422095A1868872Hs.288966ceruloplasmin (ferroxidase)SS 6.0
418845AA852985Hs.89232chromobox homolog Chromo shadow6.0
5 (Drosophila
HP1 alp
410555092649Hs.64311a disintegrin and TM,disintegrin,Reprolysin5.9
melalloproteinase
domain
437099N77793Hs.d8659ESTs, Highly similarlaminin_EGF5.9
to LMA1 HUMAN
L
453431AF094754Hs.32973glycine receptor, TM,neur-chan5.9
beta
417866AW067903Hs.82772~collagen, type TSPN,CoIlagen,COLFI5.9
XI, alpha 1~
430291AV660345Hs.238126CGI-49 protein TM 5.9
405547#(NOCAT) 0 TM,ABC-membrane5.9
435793AB037734Hs.4993ESTs TM 5.8
440138AB033023Hs.6982hypothetical proteinTM 5.8
FLJ10201
425154NM Hs.154850collagen, type SS,CoIlagen,TSPN5.7
001851 IX, alpha 1
419335AW960146Hs.284137Homo Sapiens cDNA TM 5.7
FLJ12888 fis,
clone N
452971AI873878Hs.91789ESTs TM 5.7
428927AA441837Hs.90250ESTs TM 5.7
419247S65791Hs.89764fragile X mental TM 5.7
retardation 1
445640AW969626Hs.31704ESTs, Weakly similarTM 5.7
to KIAA0227 [H.sap
447078AW885727Hs.301570ESTs kazal 5.6
421247BE391727Hs.102910general UanscriptionTM 5.6
factor IIH, polypeptid
432030AI908400Hs.143789ESTs SS 5.6
443270NM-004272Hs.9192Homer, neuronal TM 5.5
immediate early
gene,18
411096080034Hs.68583mitochondrialintermediatePeptidase-M35.5
peptidase
419558AW953679Hs.278394ESTs SS 5.5
427386AW836261Hs.177486amyloid beta (A4) TM 5.5
precursor protein
(protea
427961AW293165Hs.i43134ESTs TM 5.5
407216N91773Hs.102267lysyl oxidase TM 5.5
413930M86153Hs.75618RAB11A, member ras,TM 5.5
RAS oncogene family
414315224878 gb:HSB65D052 STRATAGENETM 5.5
Human sk
441645AI222279Hs.201555ESTs SS 5.5
449318AW236021Hs.108788ESTs, Weakly similarTM 5.4
to zesie [D.melanoga
441433AA933809Hs.42746ESTs TM 5.4
445495BE622641Hs.38489ESTs I LWEO,ENTH5.4
410153BE311926Hs.15830Homo Sapiens cDNA Glycos transf_25.4
FLJ12691 fis,
clone N
442611BE077155Hs.177537ESTs TM 5.4
452401NM_007115Hs.29352tumor necrosis Xlink,CUB 5.4
factor, alpha-induced
protein
419948A8041035Hs.93847NADPH oxidase 4 TM 5.3
427718AI798680Hs.25933ESTs histone 5.3
453867A1929383Hs.108196HSPC037 protein TM 5.3
408298AI745325Hs.271923ESTs; Moderately Glycos Uansf_2,DSPc5.3
similar to !!!!
ALU 50B
g 448543AW897741Hs.21380Homo Sapiens mRNA;TM 5.3
0 cDNA DKFZp586P
433222AW514472Hs.238415ESTs, Moderately TM 5.3
similar to ALU8_HUMA
449532W74653Hs.271593ESTs TM 5.3
452822X85689Hs.288617Homo Sapiens cDNA:TM,EGF,fn3 5.3
FW22621 fis, clone
418379AA218940Hs.137516fidgeGn-like 1 AAA 5.2
206
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
416530062801Hs.79361kallikrein 6 (neurosin,TM,Uypsin 5.2
zyme)
413384NM_000401Hs.75334 exostoses (multiple)TM 5.2
2
445236AK001676Hs.12457hypothetical proteinTM 5.2
FLJ10814
406367#(NDCAT) 0 proteasome,trypsin5.2
442500AI819068Hs.209122ESTs SS 5.2
450101AV649989Hs.24385Human hbc647 mRNA TM 5.2
sequence
419140AI982647Hs.215725ESTs TM 5.2
417791AW965339Hs.111471ESTs Ald Xan 5.1
dh C
437496AA452378Hs.1701d4Homo Sapiens mRNA~TSPN,Folate-carrier5.1
cDNA DKFZp547J1
418849AW474547Hs.53565ESTs, Weakly similarTM 5.1
to 80491.1 [C.elegan
428093AW594506Hs.104830ESTs TM 5.1
408621AI970672Hs.46638chromosome 11 openTM 5.1
reading frame
8; feta
418852BE537037Hs.273294hypothetical proteinTM 5.1
FLJ20069
404939 0 TM 5.0
I 447020T27308Hs.16986hypothetical proteinTM 5.0
S FLJ11046
410824AW994813Hs.33264ESTs TM 5.0
417423AA197341Hs.111164ESTs TM 5.0
421477A1904743Hs.104650hypothetical proteinTM 5.0
FLJ10292
443555N717i0Hs.21398ESTs,ModeratelysimilartoGNPIGlucosamine5.0
HUMA iso
424539L02911Hs.150402activin A receptor,SS,Activin 4.9
~ type I recp,pkinase
416565AW000960Hs.44970ESTs TM 4.9
431130NM Hs.2719epididymis-specific;SS 4.9
006103 whey-acidic protein
ty
408938AA059013Hs.22607ESTs TM 4.9
436754A1061288Hs.133437ESTs, Moderately TM 4.9
similar to gonadotropin
1
409049AI423i32Hs.146343ESTs TM 4.9
458627AW088642Hs.97984ESTs; Weakly similarTM 4.8
to WASP-family
pro
418882NM_004996Hs.89433ATP-binding cassette,TM,ABC-membrane4.8
sub-family C (CFTR
422505AL120862Hs.124165ESTs; (HSA)PAP TM 4.8
protein (programmed
ce
428555NM Hs.184908integrin, beta SS,inlegrin-B4.8
002214 8
452909NM Hs.30985pannexin 1 TM 4.8
015368
449535W15267Hs.23672low density lipoproteinSS,IdI_recepLa,EGF4.8
receptor-related
pro
452232AW020603Hs.271698ESTs TM 4.8
d23161AL049227Hs.124776Homo Sapiens mRNA;Cadherin 4.7
cDNA DKFZp564N C term
428405Y00762Hs.2266cholinergic receptor,TM,neur_chan4.7
nicotinic, alpha
polype
433330AW207084Hs.132816ESTs TM 4.7
443933A1091631Hs.135501Homo Sapiens two TM 4.7
pore potassium
channel
440351AF030933Hs.7179RAD1 (S. pombej TM 4.7
hamolog
426300015979Hs.169228delta-like homologTM,EGF 4.7
(Drosophila)
453775NM Hs.35120replicafion factorAAA,DEAD,helicase_C4.7
002916 C (activator 1)
4 (37kD)
429944813949Hs.226440Homo Sapiens cloneTM 4.7
24881 mRNA sequenc
434988AI418055Hs.161160ESTs TM 4.6
406400#(NOCAT) 0 trypsin,TM 4.6
428301AW628666Hs.98440ESTs TM 4.6
446254BE179829Hs.179852Homo Sapiens cDNA TM 4.6
FLJ12832 tis,
clone N
459574AI741122Hs.101810Homo Sapiens cDNA TM 4.6
FLJ14232 tis,
clone N
409928AL137163Hs.57549hypothetical proteinTM 4.6
dJ473B4
435244N77221Hs.187824ESTs pkinase,fn3d.6
404996#(NOCAT) 0 Peptidase 4.6
C1
407905AW103655Hs.252905ESTs SS,Ephrin 4.6
441675A1914329Hs.5461ESTs TM 4.6
420276AA290938Hs.190561ESTs, Highly similarTM,fn3,ldl_recepL4.5
to mosaic protein a
LRt
422529AW015128Hs.256703ESTs TM 4.5
438018AK001160Hs.5999hypothetical proteinTM 4.5
FLJ10298
457465AW301344Hs.195969ESTs PribosylUan4.5
418848AI820961Hs.193465ESTs TM,pkise 4.5
447499AW262580Hs.147674KIAA1621 protein TM 4.5
432731831178Hs.287820fibronectin 1 SS d.5
434699AA643687Hs.149425Homo sapiens cDNA Nucleoside-Ua24.4
FLJ11980 fis,
clone H
427528AU077143Hs.179565minichromosome TM 4.4
maintenance deficient
(S.
409092AI735283Hs.172608ESTs TM 4.d
451389N73222Hs.21738KIAA1008 protein TM 4.4
453331AI240665Ns.8895ESTs TM 4.4
448133AA723157Hs.73769folate receptor TM 4.d
1 (adult)
429597NM-003816Hs.2442a disintegrin and TM 4.4
metalloproteinase
domain
453279AW893940Hs.59698ESTs TM 4.4
409459D86407Hs.54481low density lipoproteinTM,EGF,IdI_recept4.4
receptor-related a
pro
431708AI698136Hs.108873ESTs TM d.4
433906AI167816Hs.43355ESTs TM 4.4
441423A1793299Hs.126877ESTs TM 4.4
446770AV660309Hs.154986ESTs, Weakly similarTM 4.3
to AF1373861 plasm
412078X69699Hs.73149paired box gene TM 4.3
ti
423123NM Hs.124027SELENOPHOSPHATE AIRS 4.3
012247 SYNTHETASE; H
d48390AL035414Hs.21068hypothetical proteinTM d.3
453628AW243307Hs.170187ESTs TM 4.3
452367071207Hs.29279eyes absent (Drosophila)TM 4.3
homolog 2
413775AW409934Hs.75528nucleolar GTPase MMR-HSR1 4.3
451592AI805416Hs.213897ESTs TM 4.3
419311AA689591 gb:nv66a12.s1 NCI_CGAPTM 4.2
GCB1 Homo s
452943BE247449Hs.31082hypothetical proteinTM 4.2
FLJ10525
g0 428679AA431765 gb:zw80c03.s1 SoaresTM 4.2
testis-NHT Homc
s
436209AW850417Hs.254020ESTs, Moderately TM 4.2
similar to unnamed
prate
406076AL390179Hs.137011Homo Sapiens mRNA;TM 4.2
cDNA DKFZp547P
428819AL135623Hs.193914KIAA0575 gene productTM 4.2
406671AA129547Hs.285754met prolo-oncogeneF-actin 4.2
. (hepatocyte growthcap-A
fac
207
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
431750AA514986Hs.283T05ESTs TM 4.2
449554AA682382Hs.59982ESTs TM 4.2
409073AA063d58 gb:zf71a07.s1 Soares~ineal~land-N3HPSEA 4.1
433929AI375499Hs.27379ESTs TM 4.1
415457AW081710Hs.7369ESTs, Weakly similarTM 4.1
to ALUt_HUMAN
A
44-0381BE387335Hs.283713ESTs TM 4.1
415539A1733881Hs.72472BMPR-Ib; bone morphogenetlcTM 4.1
protein rec
421515Y11339Hs.105352GaINAc alpha-2, TM d.1
6-siatyltransferase
I, long
453293AA382267Hs.10653ESTs TM 4.1
409564AA045857Hs.54943fracture callus TM 4.1
1 (rat) homolog
429628H09604Hs.13268ESTs TM 4.1
440452A1925136Hs.55150ESTs, Weakly similarTM 4.1
to CAYP-HUMAN
443695AW204099Hs.112759ESTs, Weakly similarTM 4.1
1o AF1267801 retina
425322063630Hs.155637protein kinase; TM 4.1
DNA-activated;
catalytic po
417300AI765227Hs.55610solute carrier TM 4.1
family 30 (zinc
transporter),
m
417389BE260964Hs.820d5Midkine (neurite SS,TM 4.1
growth-promoting
factor 2
452834AI638627Hs.105685ESTs kinesin 4.1
-028771AB028992Hs.193143KIAA1069 protein PI-PLGX,PI-PLGY4.0
412314AA825247Hs.250B99heat shock factor TM 4.D
binding protein
1
4362918E568452Hs.5101ESTs; Highly similarTM 4.0
to protein regulating
c
450654AJ245587Hs.25275Kruppel-type zinc KRAB 4.0
finger protein
409365AA702376Hs.226440Homo Sapiens cloneTM 4.0
24881 mRNA sequenc
413374NM Hs.75319ribonucleotide ribonuc_red4.0
001034 reductase M2 polypeptide
417655AA780791Hs.14014ESTs, Weakly similarTM 4.0
to KIAA0973 protein
-045941AI267371Hs.172636ESTs TM,lectin 4.0
c
441134W29092Hs.7678cellular re6noic lipocalin 4.0
acid-binding protein
1
411630042349Hs.71119Putative prostate TM 4.0
cancer tumor suppressor
418301AW976201Hs.187618ESTs TM 4.0
d1 AL033527Hs.92137v-myc avian myelocytomatosisTGF-beta,Myc_N4.0
1945 viral oncog term
408684861377Hs.12727hypothetical proteinTM 4.0
FLJ21610
414869AA157291Hs.72163ESTs TM 4.0
420281AI623693Hs.191533ESTs Cation_etflux3.9
416658~U03272Hs.79432fibdllin 2 (congenitalEGF,TB 3.9
contractural arachnod
411274NM Hs.69423kallikrein 10 trypsin,TM 3.9
OD2776
3 437222AL117588Hs.299963ESTs TM 3.9
S
431958X63629Hs.2877Cadherin 3, P-cadhednTM,cadherin,3.9
(placental)
430634AI860651Hs.26685ESTs TM 3.9
415716N59294Hs.301141Homo Sapiens cDNA NAP family 3.9
FLJ 11689 fis,
clone H
420179N74530Hs.21168ESTs TM 3.8
451250AA491275Hs.236940Homo sapiens cDNA TM 3.8
FLJ12542 fis,
clone N
429496AA453800Hs.192793ESTs TM 3.8
421764AI681535Hs.99342ESTs, Weakly similarTM 3.8
to KCC1 HUMAN
C
447197836075 gb:yh88b01.s1 SoaresTM,SDF 3.8
placenta Nb2HP
Hom
422939AW394055Hs.98427ESTs TM 3.8
414737AI160386Hs.125087ESTs TM 3.8
411773NM Hs.72026protease, swine, SS,trypsin 3.8
006799 21 (tesGsin)
425247NM Hs.155324matrix metalloproteinaseSS,Peplidase-M103.7
005940 11 (stromelysin
3)
424433H04607Hs.9218ESTs TM 3.7
431846BE019924Hs.271580Uroplakin 18 TM,transmembrane43.7
S 407792A1077715Hs.39384putative secreted SS 3.7
0 ligand homologous
to fjxl
417531NM Hs.1087serinelihreonine pkise,pkinase3.7
003157 kinase 2
434836AA651629Hs.118088ESTs TM 3.7
439810AL109710Hs.85568EST TM 3.7
418693AI750878Hs.87d09thromtwspondin SS,EGF,TSPN3.7
1
5 407864AF069291Hs.40539chromosome 8 open TM 3.7
5 reading frame
1
436304AA339622Hs.108887ESTs TM 3.7
452259AA317439Hs.28707signal sequence TM 3.7
receptor, gamma
(Uansloco
453468W00712Hs.32990DKFZP566F084 proteinTM 3.6
428943AW086180Hs.37636ESTs, Weakly similarTM 3.6
to KIAAi 392 protein
60 411402BE297855Hs.69855NRAS-related gene CSD,ras,CSD3.6
-025176AW0156d4Hs.301430ESTs,ModeratelysimilartoTEFiTM 3.6
HUMA
400296AA305627Hs.139336ATP-binding cassette;ABC_tran 3.6
sub-family C (CFTR
407340AA810168Hs.232119ESTs TM 3.6
418524AA300576Hs.85769acidic 82 kDa proteinTM 3.6
mRNA
65 438279AA805166Hs.165165ESTs,ModeratelysimilartoALUBTM 3.6
HUMA
439453BE264974Hs.6566thyroid hormone AAA,AAA 3.6
receptor interactor
13
441111AI806867Hs.126594ESTs TM 3.6
451806NM_003729Hs.27076RNA 3'-terminal TM 3.6
phosphate cyclase
409542AA503020Hs.36563ESTs Ribosomal_S83.6
70 425441AAd49644Hs.193063Homo Sapiens cDNA Aa traps 3.6
FLJ14201 fis,
clone N
428137AA421792Hs.170999ESTs AAA 3.6
433692A1805860Hs.208675ESTs, Weakly similarTM 3.6
to neuronal thread
pr
438689AW129261Hs.250565ESTs TM 3.6
443341AW631480Hs.8688ESTs TM 3.6
75 446261AA313893Hs.13399hypothetical proteinATP-synt-D,PH3.6
FLJ12615 similar
to m
41-0343AL036166Hs.75914coated vesicle TM 3.5
membrane protein
414812X72755Hs.77367monokine induced SS,ILS 3.5
by gamma interferon
410361BE391804Hs.62661guanylate binding TM 3.5
protein 1, interferon-indu
415786AW419196Hs.257924ESTs TM 3.5
g0 427177A8006537Hs.173880interleukin 1 receptorTM,ig 3.5
accessory protein
427687AW003867Hs.112403ESTs 7trrL1 3.5
444619BE538082Hs.8172ESTs TM 3.5
447336AW139383Hs.245437ESTs AhpGTSA 3.5
412519AA196241Hs.73980troponin T1, skeletal,TM 3.5
. slow
208
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
418792A8037805Hs.884d2KIAA1384 protein TM 3.5
408031AA081395Hs.42173Homo Sapiens cDNA TM 3.5
FLJ10366 fis,
clone N
416892L24498Hs.80409growth arrest and TM 3.5
DNA-damage-inducible,
418793AW382987Hs.88474prostaglandin-endoperoxideEGF 3.5
synthase 1 (pro
448089AI467945Hs.173696ESTs SS 3.5
422278AF072873Hs.i14218ESTs TM,Fz,Frizzled3.5
442133AW874138Hs.129017ESTs TM 3.5
410908AA121686Hs.10592ESTs GTP_EFTU 3.5
452198A1097560Hs.61210ESTs TM 3.5
1 408730AV660717Hs.47144DKFZP586N0819 proteinpkinase 3.4
0
436488BE620909Hs.261023hypotheficalproteinTM 3.4
FLJ20958
409745AA077391 gb:7B14E12 ChromosomeTM 3.4
7 Fetal Brain
cD
445870AW410053Hs.13406syntaxin 18 TM 3.4
451743AW074266Hs.23071ESTs TM 3.4
1 407846AA426202Hs.40403CbpIp300-interacfingTM 3.4
S Uansactivator,
with G
432350NM Hs.274407protease, serine,16SS 3.4
005865 (thymus)
412848AA121514Hs.70832ESTs TM 3.4
413625AW451i03Hs.71371ESTs filament 3.4
417801AA417383Hs.82582integrin, beta-likeSS 3.4
1 (with EGF-like
repeat d
20 422972N59319Hs.145404ESTs TM 3.4
429170NM-001394Hs.2359dual specificity DSPc,Rhodanese3.4
phosphatase 4;
MAP kinas
450377AB033091Hs.24936ESTs TM 3.4
443475A1066470Hs.134482. ESTs TM 3.4
419452033635Hs.90572PTK7 protein tyrosineTM,pkise,ig,SRF-TF3.4
kinase 7
25 409744AW675258Hs.56265Homo sapjens mRNA;TM 3.4
cDNA DKFZp586P
422789AK001113Hs.120842hypothetical proteinTM 3.4
FLJ10251
404440#(NOCAT) 0 TM,neur_chan3.4
417412X16896Hs.82112intedeukin 1 receptor,SS,TIR,ig 3.4
type I
411828AW161449Hs.72290wingless-type MMTVwnt 3.4
integration site
fami
30 417177NM_004458Hs.81452fatty-acid-CoenzymeSS 3.4
A ligase, long-chain
4
421013M62397Hs.1345mutated in colorectalTM 3.4
cancers
427072H38046 gb:yp58c10.r1 SoaresfetalliverspleenRibosomal-L22e3.4
1NF
433703AA210863Hs.3532nemo-like kinase pkinase 3.4
434294AJ271379Hs.21175ESTs TM 3.4
35 444188A1393i65Hs.19175ESTs TM 3.4
446109N67953Hs.145920ESTs TM 3.4
400881 0 Asparaginase-23.3
450236AW162998Hs.24684KIAA1376 protein TM 3.3
d18836AI655499Hs.i61712ESTs TM 3.3
40 437951T34530Hs.4210Homo Sapiens cDNA TM 3.3
FLJ 13069 fis,
clone N
446896T15767Hs.22452Homo Sapiens cDNA:TM 3.3
FLJ21084 fis,
clone
430687BE274217Hs.249247heterogeneous nuclearrrm 3.3
protein similar
to rat
410060NM Hs.58367glypican-4 SS 3.3
001448
419546AA244199 gb:ncO6c05.s1 NCI-CGAP_Pr1TM 3.3
Homo sapi
45 429609AF002246Hs.210863cell adhesion moleculeTM,fi3,ig 3.3
with homology
to L
413289AA128061Hs.i14992ESTs TM 3.3
440006AK000517Hs.6844hypothetical proteinTM 3.3
FLJ20510
401435#(NOCAT)- 0 TM 3.3
420072AW961196Hs.207725ESTs TM 3.3
421426AA291 Hs.33020Homo Sapiens cDNA TM 3.3
1 FLJ20434 fis,
01 clone K
425851NM-001490Hs.159642glucosaminyl (N-acetyl)SS 3.3
Uansferase 1,
core
443295A1049783Hs.241284ESTs TM 3.2
453116A1276680Hs.146086ESTs Ribosomal-L5-C3.2
456546A1690321Hs.203845ESTs, Weakly similarTM 3.2
to TWIK-related
acid
55 430016NM Hs.227656xenotropic and TM 3.2
004736 polytropic reUovirus
recepto
418281009550Hs.1154oviductal glycoproteinasp,Glyco-hydro-183.2
1,120kD (mucin
9,
433800A1034361Hs.135150lung type-I cell TM 3.2
membrane-associated
glyco
425159NtvL004341Hs.154868carbamoyl-phosphateTM 3.2
synihetase 2,
aspartat
428882AA436915Hs.131748ESTs, Modgralely carb_anhydrase3.2
similar to ALU7
HUMA
60 409533AW969543Hs.21291mitogen-acfivated TM 3.2
protein kinase
kinase kin
411248AA551538Hs.69321KIAA1359 protein TM 3.2
421379Y15221Hs.103982small inducible SS,ILB 3.2
cytokine subfamily
B (Cys-
430259BE550182Hs.127826RaIGEF-like proteinTM 3.2
3, mouse homolog
414945BE076358Hs.77667lymphocyte antigenSS 3.2
6 complex, locus
E
65 444471A8020684Hs.11217KIAA0877 protein TM 3.2
421674T10707Hs.296355neuronal PAS domainRibosomal_L3le3.2
protein 2
434163AW974720Hs.25206ESTs TM 3.2
421991NM Hs.110488KIAA0990 protein SS 3.2
014918
409589AW439900Hs.256914ESTs ' TM 3.2
70 414147BE091634 gb:IL2-8T0731-240400-069-C03TM 3.2
BT0731
414661T97401Hs.21929ESTs TM 3.2
437537AA758974Hs.121417ESTs, Weakly similarTM 3.2
to unnamed protein
p
439702AW085525Hs.i34182ESTs A2M 3.1
420552AK000492Hs.98806hypoiheficalproteinTM 3.1
441028A1333660Hs.17558ESTs ICE~20,CARD3.1
425264AA353953Hs.20369ESTs, Weakly similarTM 3.1
to gonadoiropin
indu
422109S73265Hs.1473gasUin-releasing SS,Bombesin3.1
pepfide
441859AW194364Hs.128022ESTs, Weakly similarTM 3.1
to FIGi MOUSE
FIG
415451H19415Hs.268720ESTs,ModeratelysimilartoALU1_HUMASS,Ephrin 3.1
g0 447866AWd44754Hs.211517ESTs homeobox 3.1
419978NM-001454Hs.93974forkhead box J1 Fork-head 3.1
446219A1287344Hs.149827ESTs MIP 3.1
448428AF282874Hs.21201necfin 3; DKFZP566B0846TM,ig 3.1
protein
407615AW753085 gb:PM1-CT0247-151299-005-a03TM 3.1
CT0247
209
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
410518AW976443Hs.285655ESTs RasGEF,PH,RhoGEF3.1
418396AI765805Hs.26691ESTs TM 3.1
427855861253Hs.98265ESTs TM 3.1
429272W25140Hs.110667ESTs TM 3.1
450171AL133661Hs.24583hypotheficalproteinTM 3.1
DKFZp434C0328
414774X02419Hs.77274plasminogen acfivator,SS,kdngle,trypsin3.1
urokinase
422363T55979Hs.115474replicafion factorTM 3.1
C (acfivator 1)
3 (38kD)
420062AW411096Hs.94785hypothetical proteinTM 3.1
LOC57163
428698AA852773Hs.297939ESTs; Weakly similarTM 3.1
to neogenin [H.sapie
d27051BE178110Hs.173374ESTs TM 3.1
428242H55709Hs.2250leukemia inhibitorySS 3.1
factor (cholinergic
diffe
452906BE207039Hs.75621sedne (orcysteine)TM 3.1
proteinase inhibitor,
cla
429419AB023226Hs.202276KIAA1009 protein TM 3.1
417517AF001176Hs.82238POP4 (processing TM 3.1
of precursor,
S. cerevisia
1 406137#(NOCAT) 0 TM 3.1
S
424800AL035588Hs.153203MyoD family inhibitorTM 3.1
410252AW821182Hs.61418microfibdllar-associatedTM 3.1
protein 1
420392AI242930Hs.97393KIAA0328 protein SS 3.1
423629AW021173Hs.18612Homo Sapiens cDNA:voltage_CLC,CBS3.1
FLJ21909 fis,
clone
429334D63078Hs.186180Homo sapiens cDNA:Glyco-hydro-23.1
FLJ23038 fis,
clone
449802AW901804Hs.23984hypothetical proteinTM 3.1
FLJ20147
450506NM Hs.418fibroblast activafionSS,Peptidase-S93.0
004460 protein; alpha
433849BE465884Hs.280728ESTs TM 3.0
411984NM_005419Hs.72988signal Uarisducer SH2,STAT 3.0
and acfivator
of transcript
422530AW972300Hs.118110bone marrgw stromalTM 3.0
cell antigen 2
422128AW881145 gb:OVO-0T0033-010400-182-a07TM 3.0
OT0033
409757NM_001898Hs.123114cystatin SN SS,cystatin3.0
418727AA227609Hs.94834ESTs TM 3.0
422244Y08890Hs.113503karyophedn (imporfin)TM 3.0
beta 3
456844AI264155Hs.152981CDP-diacylglycerolTM 3.0
synthase (phosphatidat
432358A109349iHs.72830ESTs SS 3.0
416896A1752862Hs.5638KIAA1572 protein BTB 3.0
447312A1434345Hs.36908activating transcriptionTM 3.0
factor 1
445021AK002025Hs.12251Homo Sapiens cDNA TM 3.0
FLJ11163 fis,
clone P
3 422611AA158177Hs.118722fucosyltransferaseSS 3.0
S B (alpha (1,6)
fucosyltran
453597BE281130Hs.33713myo-inositol 1-phosphateTM 3.0
synthase A1
401197#(NOCAT) 0 arf,Ets 3.0
d03000BE247275Hs.15i787USsnRNP-specific TM 3.0
protein,ti6kD
410008AA079552 gb:zm20h12.s1 SUatageneTM,FG-GAP 3.0
pancreas (93720
413268AL039079Hs.75256regulator of GproteinRGS 3.0
signalling 1
414080AA135257Hs.47783ESTs, Weakly similarTM 3.0
to T12540 hypotheti
426682AA393108Hs.97365ESTs TM 3.0
427651AW405731Hs.18498Homo Sapiens cDNA TM 3.0
FLJ12277 fis,
clone M
439444AI277652Hs.54578ESTs TM 3.9
433001AF217513Hs.279905clone H00310 PR00310p1TM 3.0
444895AI674383Hs.301192EST cluster (not TM,ASC 3.0
in UniGene)
441962AW972542Hs.289008Homo Sapiens cDNA:TM 3.0
FLJ21814 fis,
clone
414725AA769791Hs.120355Homo Sapiens cDNA TM,7lm_1 3.0
FLJ13148 fis,
clone N
434241AF119913Hs.283607hypothefical proteinSS 3.0
PR03077
424962NM Hs.153954TRAM-like protein TM 3.0
012288
411987AA375975Hs.183380ESTs, Moderately TM 3.0
similar to ALU7-HUMA
421977W94197Hs.110165ribosomal protein TM 3.0
L26 homolog
436481AA379597Hs.5199HSPC150 protein TM 3.0
similar to ubiquitin-conju
407872AB039723Hs.40735frizzled (Drosophila)TM,7tm_2,Fz,Frizzled3.0
homolog 3
442577AA292998Hs.163900ESTs TM 3.0
416120H46739 gb:yo14h02.s1 SoaresTM 3.0
adult brain N2b5HB5
443775AF291664Hs.204732matrix metalloproteinaseTM,Peptidase-M10,7tnL13.0
26
414664AA587775Hs.66295Homo Sapiens HSPC311TM 3.0
mRNA, partial
cd
457590AI612809Hs.5378spondin 1, (f spondin)SS 3.0
extracellular
matrix
418946AI798841Hs.132103ESTs TM 3.0
457940AL360159Hs.30445Homo Sapiens mRNA TM,SPRY,7tm-13.0
full length insert
cDN
TABLE 158:
Pkey: Unique Eos probeset identifier number
CAT number. Gene cluster number
Accession: Genbank accession numbers
Pkey CAT Accession
Number
4076151005404AW753085 AW753082 AW054744 AW753107 AW753087
1
409073109851AA063458 AA063018 A1444822
1
409745115237_1AA077391 A1347618 A1361453 A1088754 AW207491
AW960912 AA921874 AA286833 AA150722 BE152353
AW188822 BE152450
410008116812AA079552 BE142525 BE142527
1
414147142127=BE091fi34
1
414315143512224878 AA494098 F13654 AA494040 AA1d3127
1
4161201571266H46739 H51513 H19779
1
419311183793AAfi89591 AW974261 AA236240 A1077451 AA631399
1 AW974262
419546185766AA244199 AA244272 H57440
1
422128211994AW881145 AA490718 M85637 AA304575 T06067 AA331991
1
427072274884H38046 W69645 AA397968 H38047
1
g 428679294049_1AA431765 AA432015
0
438993467651AA828995 AA834879 A1926361
1
447197711623_1836075 AI366546 836167
210
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
TABLE 15C:
Pkey: Unique number corresponding to an Eos probeset
Ref: Sequence source. The 7 digit numbers in this column are Genbank
Idenfifier (GI) numbers. °Dunham I. et al." refers to the publication
entitled °The DNA sequence of
human chromosome 22" Dunham, et at. (1999) Nature 402:489-095
SUand: Indicates DNA strand from which exons were predicted
N~position: Indicates nucleofide posifions of predicted exons
Pkey Ref SfrandNt_posilion
400881 2842777Minus91446-91603,92123-92265
1 ~ 4011979719705Plus 176341-176452
401435 8217934Minus'54508-55233
404440 7528051Plus 80430-81581
404939 6862697Plus 175318-175476
404996 6007890Plus 37999-38145,38652-38998,39727-39872,40557-40674,42351-
42450
1 5 4055471054740Plus 124361-124520,124914-125050
406137 9166422Minus30487-31058
406367 9256126Minus58313-58489
406400 9256298Plus 1553-1712,1878-2140,4252-4385,5922-6077
Table 16A lists about 92 genes up-regulated in mucinous-type ovarian cancer
compared to normal adult tissues. These were selected as for Table 14A, except
that the
"average" ovarian cancer level was set to the 75th percentile amongst various
mucinous-type ovarian cancers, and the tumor/normal tissue ratio was greater
than or equal to 2.5.
TABLE
16A:
ABOUT
92
UP-REGULATED
GENES,
MUCINOUS
OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES
Pkey: s
Primekey
Ex.Accn:
ExempIarAccession
UG
ID:
UniGene
ID
Title:
UniGene
title
Prot.Predicted
Dom.:protein
domain
structure
30 ratio:tumor
ratiovs.
normal
tissues
Pkey Ex. UG Title Prot. Dom. ratio
Accn iD
430691Ci4187Hs.103538ESTs 34.9
432938T27013Hs.3132steroidogenic acuteSTART 28.0
regulatory protein
35 418007M13509Hs.83169Matrix metalloproteaseSS,Peptidase-M1022.3
1 (interstitial
collag
451181AI796330Hs.207461ESTs 10.8
452838065011Hs.30743Preferentially 10.0
expressed antigen
in melanom
407638AJ404672Hs.288693EST 9.3
450159A1702416Hs.200771ESTs, Weakly similar 9.2
to CAN2_HUMAN
40 426890AA393167Hs.41294ESTs 9.1
421155H87879Hs.102267.lysyl oxidase SS,Lysyl_oxidase8.9
437099N77793Hs.48659ESTs, Nighty similarlaminin EGF 1.6
to LMAi HUMAN
L
453866AW291498Hs.250557ESTs 7.6
435496AW840171Hs.265398ESTs, Weakly similar 7.4
to transformation-rel
4$ 418738AW388633Hs.6682solute comer family 7.2
7, member 11
431956AK002032Hs.272245Homo Sapiens cDNA RA 7.0
FLJ11170 fis,
clone P
449579AW207260Hs.134014prostate cancer 6.7
associated protein
6
424586NM Hs.150930X-ray repair complementing 6.7
003401 defecfive repa
445891AW391342Hs.199460ESTs 6.2
424717H03754Hs.152213wingless-type MMTVwnt 6.1
integration site
fami
452705H49805Hs.246005ESTs 6.1
421285NM Hs.1363cytochrome P450, TM,p450 5.5
000102 subfamily XVII
(steroid
408562AI436323Hs.31141Homo Sapiens mRNA 5.3
for KIAA1568 prote
420159AI572490Hs.99785ESTs 5.3
55 451105A1761324 gb:wi60b11.x1 NCI-CGAP-Co16 5.2
Homo s
409049AI423132Hs.146343ESTs 5.0
448674W31178Hs.154140ESTs TM 5.0
423811AW299598Hs.50895homeo box C4 4.9
427469AA403084Hs.269347ESTs 4.9
go 447033A1357412Hs.157601EST-notin UniGene PH 4.9
424433H04601Hs.9218ESTs 4.9
448811AI590371Hs.174759ESTs TM 4.8
444330A1597655Hs.49265ESTs 4.8
409041A8033025Hs.50081KIAA1199 protein 4.7
418735N48769Hs.44609ESTs 4.5
416661AA634543Hs.79440IGF-II mRNA-bindingKH-domain 4.5
protein 3
430073086136Hs.232070telomerase-associatedWD40 4.4
protein 1
407881AW072003Hs.40968heparan sulfate SS 4.4
(glucosamine)
3-0-sulfotran
422260AA315993Hs.105484ESTs; Weakly similar 4.4
to LITHOSTATHIN
70 421110AJ250717Hs.1355cathepsin E SS,asp 4.3
445676A1247763Hs.i6928ESTs 4.2
430704AW813091 gb:RC3-ST0i86-240400-111-407Epimerase 3.8
ST0186
414569AF109298Hs.118258Prostate cancer TM 3.8
associated protein
1
438078A10163T7Hs.131693ESTs 3.7
434032AW009951Hs.206892ESTs 3.7
445657AW612141Hs.279575ESTs 7tm-1 3.6
439759AL359055Hs.67709Homo Sapiens mRNA 3.5
full length insert
cDN
455666BE065813 gb:RC2-BT0318-110100-012-a08 3.5
BT0318
448844A1581519Hs.177164ESTs 3.5
449048245051Hs.22920similar to 568401 SS 3.5
(cattle) glucose
induced g
438018AK0011fi0Hs.5999hypothetical proteinTM - 3.4
FLJ10298
458123AW892676 gb:CM3-NN0004-280300-131-c12
NN0004 3.4
407385AA610150Hs.272072ESTs,ModeratelysimilartoALU7_HUMA 3.4
424894H83520Hs.153678reproduction 8 SS,UBX 3.3
211
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
424639 AI917494 ESTs 3.3
Hs.131329
414083 AL121282 ESTs 3.2
Hs.257786
426471 M22440 transforming growth SS,EGF 3.2
Hs.170009 factor, alpha
428927 AA441837 ESTs 3.1
Hs.90250
406129 #(NOCAT) 0 TM,cNMP_binding3.1
452699 AW295390 ESTs 3.1
Hs.213062
425842 A1587490 NK-2 (Drosophila) homeobox 3.1
Hs.159623 homolog B
428976 AL037824 ras homolog gene ras 3.1
Hs.194695 family, member I
436396 AI683487 Homo Sapiens cDNA wnt 3.0
Hs.299112 FLJ11d41 fis, clone
H
1 454077 AC005952 insulin-like 3 (LeydigSS,Insulin,pkinase3.0
o Hs.37062 cell)
404253 #(NOCAT) 0 hisione 2.9
452461 N78223 transcdptionfactor G9a,PHD 2.9
Hs.108106
429597 NM-003816a disintegrin and TM 2.9
Hs.2442 metalloproteinase
domain
413289 AA128061 ESTs 2.9
Hs.114992
1 429703 T93154 ESTs 2.9
Hs.28705
407829 AA045084 Homo Sapiens cDNA 2.8
Hs.29725 FLJ13197 fis, clone
N
424796 AW2982d4 ESTs 2.8
Hs.293507
424086 A1351010 lysyl oxidase Lysyl-oxidase2.8
Hs.102267
408427 AW194270 ESTs 2.7
Hs.177236
450375 AA009647 a disintegrin and 2.7
Hs.8850 metalloproteinase
domain
446999 AA151520 hypothetical protein 2.7
Hs.279525 PR02605
428819 AL135623 KIAA0575 gene product 2.7
Hs.193914
422956 BE545072 ESTs 2.7
Hs.122579
428949 AA442153 ESTs, Weakly similar 2.7
Hs.104744 to AF2088551 BM-0
25 426300 015979 delta-like homolog TM,EGF 2.6
Hs.169228 (Drosophila)
420380 AA640891 ESTs 2.6
Hs.102406
428651 AF196478 annexin A10 TM,annexin 2.6
Hs.188401
417849 AW291587 Nidogen 2 EGF,IdI_recept_b2.6
Hs.82733
453700 AB009426 apolipoprotein B TM 2.6
Hs.560 mRNA editing enzyme,
ca
417975 AA641836 Homo Sapiens cDNA: 2.6
Hs.30085 FLJ23186 fis, clone
448756 A1739241 ESTs 2.6
Hs.171480
425087 R62d2d ESTs 2.5
Hs.i26059
444153 AK001610 hypothetical proteinKetch 2.5
Hs.1041d FLJ10748
443211 A1128388 ESTs 2.5
Hs.143655
35 415263 AA948033 ESTs histone 2.5
Hs.130853
432867 AW016936 ESTs GSHPx 2.5
Hs.233364
438639 AI278360 ESTs 2.5
Hs.31409
455386 AW935875 gb:OV3-DTOOi9-120100-055-406 2.5
DT0019
419092 J05581 mucin 1, transmembraneTM,SEA 2.5
Hs.89603
452055 AI377431 ESTs 2.5
Hs.293772
TABLE 168:
Pkey: Unique
Eos probeset
identifier number
CAT number: Gene
cluster number
Accession: Genbank
accession numbers
Pkey CAT Number
Accession
430704 322217-1
AW813091 AW206655
AA484440
451105 859083
1 AI761324 AW880941
AW880937
455386 1287756
1 AW935875 BE069116
BE160251
455666 1349545-1E065788 BE065889
BE065813 B BE065832
458123 479942-1
AW892676 AA853877
D44747
TABLE 16C:
5 Pkey: Unique
5 number corresponding
to an Eos probeset
Ref: Sequence . "Dunham
source. The I. et a1."
7 digit numbers refers to
in this column the publication
are Genbank entitled
Identifier (GI) "The DNA
numbers sequence
of
human chromosome, et al. (1999) Nature
22" Dunham 402:489-495
Strand: Indicates
DNA strand from
which exons
were predicted
Nk.position:
Indicates nucleotide
posiUons of
predicted exons
6o
Pkey Ref Strand Nt~osiUon
404253 9367202 55675-56055
Minus
406129 9160131 2567-3056
Plus
65
Table 17A lists normal adult
about 183 genes tissues.
up-regulated These were
in endometrioid-type selected
ovarian cancer as for Table
compared to 14A, except
that the
"average" ovarian
cancer level
was set to the
75th percentile
amongst various
endometrioid-type
ovarian cancers,
and the tumodnormal
tissue ratio
was greater
than or equal
to
2.5.
7O TABLE 17A: ABOUT
183 UP-REGULATED
GENES, ENDOMETRIOID
OVARIAN CANCER
VERSUS NORMAL
ADULT TISSUES
Pkey: Primekey
Ex.Accn: ExempIarAccession
UG ID: UniGene
ID
Titre: UniGene
title
75 Prot. Dom.: Predicted
protein domains
ratio: ratio
tumor vs. normal
tissue
Pkey Ex. Accn Title Prot. Dom. ratio
UG ID
452838 065011 Preferentially expressed 38.9
Hs.30743 antigen in melanom
435094 AI560129 EST 28.8
Hs.277523
428153 AW513143 hypothetical protein 24.1
Hs.98367 FLJ22252 similar
to SR
428187 AI687303 ESTs 23.9
Hs.285529
449034 A1624049 gbas41a09.xi NCI-CGAP-Utt 19.9
Homosapi
453102 NM-007197frizzled (Drosophila)TM,Fz,Frizzled15.7
Hs.31664 homolog 10
212
CA 02451465 2003-12-18
WO 02/102235 PCT/US02/19297
412925A1089319Hs.179243ESTs 15.7
438817A1023799Hs.i63242ESTs 13.6
447033A1357412Hs.157601EST- not in UniGenePH 13.5
433222AW514472Hs.238415ESTs,ModeratelysimilartoALUB_HUMA 13.1
S 422956BE545072Hs.122579ESTs 12.9
450451AW591528Hs.202072ESTs 11.9
453964A1961486Hs.12744ESTs homeobox 11.5
442438AA995998 gb:os26b03.s1 NCI-CGAP-Kid5 11.d
Homo sa
431989AW972870Hs.291069ESTs SS 10.3
1 413623AA825721Hs.246973ESTs 9.7
~
440901AA909358Hs.128612ESTs 9.6
416661AA634543Hs.79440IGF-II mRNA-bindingKH-domain 9.6
protein 3
421478AI683243Hs.97258ESTs 9.3
448706AW291095Hs.21814class II cytokine SS,Tissue 9.2
receptor ZCYTOR7 fac
1 410566AA373210Hs.43047Homo Sapiens cDNA 8.7
S FLJ13585 fis,
clone P
438993AA828995 integrin; beta SS,integrin-B8.7
8
427121AI272815Hs.173656KIAA0941 protein C2, 8.4
420610AI683183Hs.99348distal-less homeo homeobox 8.1
box 5
427356AW023482Hs.97849ESTs 8.0
20 446577AB040933Hs.15420KIAA1500 protein 8.0
431118BE264901Hs.250502carbonic anhydrasecart-anhydrase7.5
VIII
448112AW245919Hs.301018ESTs, Weakly similar 6.9
to ALUB_HUMAN
451106BE382701Hs.25960N-myc HLH,Myc_N-term6.6
449433A1672096Hs.9012ESTs 6.3
2S 453922AF053306Hs.36708budding uninhibited 6.3
by benzimidazoles
1 (y
434636AA083764Hs.241334ESTs 6.1
453688AW381270Hs.194110Homo Sapiens mRNA; 5.9
cDNA DKFZp434C
422805AA436989Hs.121017H2Ahistonefamily;memberAhistone 5.8
400292AA250737Hs.72472BMPR-Ib; bone morphogenetic 5.7
protein rec
443179AI928402Hs.6933Homo Sapiens cDNA 5.6
FLJ12684 fis,
clone N
418134AA397769Hs.86617ESTs 5.5
452249BE3944i2Hs.61252ESTs homeobox 5.5
409269AA576953Hs.22972Homo Sapiens cDNA TM,UPF0016 5.5
FLJ13352 fis,
clone 0
413335AI613318Hs.48442ESTs 5.4
3 441081AI584019Hs.169006ESTs, Moderately PAX 5.4
S similar to plakophilin
2b
428029H05840Hs.293071ESTs 5.3
419183060669Hs.89663cytochrome P450, p450 5.3
subfamily XXIV
(vitami
409094AW337237 gb:xw82t01.x1 NCI 5.2
CGAP_Pan1 Homo
sa
432938T27013Hs.3132steroidogenic acuteSTART 5.1
regulatory protein
410102AW248508Hs.279727ESTs; SS 5.1
447835AW591623Hs.164129ESTs 5.1
438202AWi69287Hs.22588ESTs 5.0
423992AW898292Hs.137206Homo Sapiens mRNA; 5.0
cDNA DKFZp564H
425905AB032959Hs.161700KIAA1133 protein TM 5.0
4S 452461N78223Hs.108106transcriplionfactorG9a,PHD 4.9
430691C14187Hs.103538ESTs 4.8
441675AI914329Hs.5461ESTs 4.7
425695NM Hs.159238proteintyrosine Band 41,Y_phosphatase4.6
405401 phosphatase,non-receptor
440340AW895503Hs.125276ESTs 4.5
S 428579NM Hs.184942G protein-coupled TM 4.5
~ 005756 receptor 64
444783AK001468Hs.62180ESTs PH 4.4
451459AI797515Hs.270560ESTs, Moderately 4.4
similar to ALU7-HUMA
413395AI266507Hs.145689ESTs 4.3
415263AA948033Hs.130853ESTs histone 4.2
S 413988M81883Hs.75668glutamate decarboxylasepyridoxal_deC4.2
S t (brain, 67kD)
452030AL137578Hs.27607Homo Sapiens mRNA; 4.1
cDNA DKFZp564N
418852BE537037Hs.273294hypothefical protein 4.1
FLJ20069
446431845652Hs.153486ESTs 4.1
434891AA814309Hs.123583ESTs 4.0
415139AW975942Hs.48524ESTs G-patch 4.0
453197Ai916269Hs.109057ESTs, Weakly similar 4.0
to ALUS-HUMAN
A
447112H17800Hs.7154ESTs 3.9
420633NM_014581Hs.99526odorant-binding TM,lipocalin 3.9
protein 2B
459574A1741122Hs.101810Homc Sapiens cDNA 3.9
FLJ14232 fis,
clone N
6S d15138C18356Hs.78045fissue factor pathwayKunitz_BPTI,G-gamma3.9
inhibitor 2 TFPI2
414083AL121282Hs.257786ESTs 3.7
442006AW975183Hs.292663ESTs 3.7
409731AA125985Hs.56145thymosin, beta, Thymosin 3.7
identified in
neuroblastoma
424906AI566086Hs.153716Homo Sapiens mRNA 3.7
for Hmob33 protein,
456662NM-002448Hs.1494msh (Drosophila) homeobox 3.7
homeo box homolog
t (fo
429125AA446854Hs.271004ESTs 3.6
435538A80115d0Hs.4930low density lipoprotein 3.6
receptor-related
pro
458861AI630223 gb:adO6gO8.r1 ProliferafingPHD 3.5
Erythroid Cells
418506AA084248Hs.85339G protein-coupled 3.5
receptor 39
7S 423123NM-012247Hs.124027SELENOPHOSPHATE AIRS,AIRS 3.4
SYNTHETASE; H
437960AI669586Hs.222194ESTs 3.4
400298AA032279Hs.61635STEAP1 TM 3.4
407162N63855Hs.142634zinc finger protein 3.4
d08621AI970672Hs.46638chromosome 11 open 3.3
reading frame
8; feta
go 445829AI452457Hs.145526ESTs 3.3
450262AW409872Hs.271166ESTs, Moderately 3.3
similar to ALU7_HUMA
457979AA776655Hs.270942ESTs TM 3.3
402606#(NOCAT) 3.2
426471M22440Hs.170009transforming growthSS,EGF 3.2
factor, alpha
213
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 A 213
NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 213
NOTE: For additional volumes, please contact the Canadian Patent Office
NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:
